Patent Publication Number: US-2021179709-A1

Title: Anti-car compositions and methods

Description:
This application claims priority to U.S. Ser. No. 62/579,815, filed on Oct. 31, 2017, the entire contents of which are incorporated by reference herein. 
    
    
     FIELD OF THE INVENTION 
     The present invention relates generally to the use of immune effector cells (e.g., T cells, NK cells) engineered to express a Chimeric Antigen Receptor (CAR) to treat a disease associated with expression of a tumor antigen. 
     BACKGROUND OF THE INVENTION 
     Adoptive cell transfer (ACT) therapy with autologous T-cells, especially with T-cells transduced with Chimeric Antigen Receptors (CARs), has shown promise in hematologic cancer trials. 
     SUMMARY OF THE INVENTION 
     The present invention pertains, at least in part, to the use of immune effector cells (e.g., T cells or NK cells) engineered to express an anti-target CAR polypeptide that binds to a target CAR, as described herein, to treat cancer associated with expression of said target CAR. For instance, to treat a patient having cancer cells that express a target CAR, an anti-target CAR can be administered to specifically kill the cancer cells that express the target CAR. 
     In certain aspects, the present disclosure provides an isolated nucleic acid molecule encoding an anti-target CAR (chimeric antigen receptor) polypeptide, wherein the encoded anti-target CAR polypeptide comprises: 
     a) a ligand, e.g., an extracellular ligand, that binds to a target CAR polypeptide, 
     b) a transmembrane domain, and 
     c) an intracellular signaling domain comprising a stimulatory domain. 
     The present disclosure also provides an isolated anti-target CAR (chimeric antigen receptor) polypeptide, which comprises: 
     a) a ligand, e.g., an extracellular ligand, that binds to a target CAR polypeptide, 
     b) a transmembrane domain, and 
     c) an intracellular signaling domain comprising a stimulatory domain. 
     The present disclosure also provides a vector comprising a nucleic acid molecule encoding an anti-target CAR described herein. 
     The present disclosure also provides a cell comprising a nucleic acid described herein or a vector described herein. The present disclosure also provides a cell comprising an anti-target CAR polypeptide described herein. The present disclosure also provides a cell engineered to express an anti-target CAR polypeptide described. 
     The present disclosure also provides a method of making a cell comprising transducing a cell, e.g., an immune effector cell, e.g., T cell, with a nucleic acid described herein or a vector described herein. 
     The present disclosure also provides a method of generating a population of RNA-engineered cells comprising introducing an in vitro transcribed RNA or synthetic RNA into a cell, where the RNA comprises a nucleic acid encoding an anti-target CAR polypeptide described herein or a vector described herein. 
     In an aspect, disclosed herein is a method of treating, a subject having, or at risk of having, an unwanted effect (e.g., a disease or condition) associated with expression of a target CAR, comprising administering to the subject an effective number of cells comprising an anti-target CAR polypeptide described herein. 
     In some embodiments, the unwanted effect associated with expression of a target CAR comprises one or more of: B cell aplasia (e.g., lower number of B cells or no B cells); cytokine release syndrome (CRS); or a neurologic toxicity. 
     In some embodiments, the unwanted effect associated with expression of a target CAR is B cell aplasia. In some embodiments, administration of the anti-target CAR results in amelioration of unwanted effects associated with expression of a target CAR, e.g., reduction of B cell aplasia. 
     The present disclosure also provides, in some aspects, a method of treating a subject, e.g., mammal, having a disease or condition associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed) comprising administering to the mammal an effective number of cells comprising an anti-target CAR polypeptide described herein. Similarly, in some aspects, the disclosure provides the use of a plurality of cells comprising an anti-target CAR polypeptide described herein in the manufacture of a medicament for treating a disease, e.g., a disease or condition associated with expression of a target CAR. In related aspects, the disclosure provides a plurality of cells comprising an anti-target CAR polypeptide described herein, for use in treating a disease or condition, e.g., a disease or condition associated with expression of a target CAR. 
     The present disclosure also provides, in some aspects, a method of reducing the number of target CAR-expressing cells present in a subject, e.g., mammal, e.g., in the circulation of the subject, comprising administering to the subject an effective number of cells described herein, or an effective number of cells comprising a nucleic acid described herein, a vector described herein, or an anti-target CAR polypeptide described herein. 
     In some embodiments, the ligand comprises a cognate antigen molecule or an antibody molecule that binds to the target CAR polypeptide. In some embodiments, the ligand comprises an antibody molecule (e.g., an anti-idiotypic antibody molecule) that binds to the target CAR polypeptide, e.g., binds an extracellular domain of the target CAR polypeptide. In some embodiments, the ligand binds an antigen binding domain in the target CAR polypeptide, a hinge domain in the target CAR polypeptide, or a junction between an antigen binding domain and a hinge domain in the target CAR polypeptide. In some embodiments, the ligand comprises a cognate antigen molecule that binds the target CAR polypeptide. In some embodiments, the ligand is extracellular. In some embodiments, the anti-target CAR comprises a ligand that binds to a target CAR, a transmembrane domain, and an intracellular signaling domain, e.g., comprising a primary signaling domain and/or a costimulatory signaling domain. 
     In some embodiments, the target CAR polypeptide is a CD19CAR polypeptide and the ligand comprises an anti-idiotypic antibody that binds said CD19CAR polypeptide. In some embodiments, the target CAR polypeptide is a CD19CAR polypeptide and the ligand binds said CD19CAR polypeptide, e.g., the ligand comprises CD19 or a fragment thereof that binds said CD19CAR polypeptide. 
     In some embodiments: 
     (i) the target CAR polypeptide is a CD33CAR polypeptide and the ligand binds said CD33 CAR polypeptide, e.g., the ligand comprises CD33 or a fragment thereof that binds said CD33CAR polypeptide, or the ligand comprises an antibody molecule that binds said CD33CAR polypeptide; 
     (ii) the target CAR polypeptide is an EGFRvIIICAR polypeptide, and the ligand binds said EGFRvIIICAR polypeptide, e.g., the ligand comprises EGFRvIII or a fragment thereof that binds said EGFRvIIICAR polypeptide, or the ligand comprises an antibody molecule that binds said EGFRvIIICAR polypeptide; 
     (iii) the target CAR polypeptide is a mesothelinCAR polypeptide, and the ligand binds said mesothelin CAR polypeptide, e.g., the ligand comprises mesothelin or a fragment thereof that binds said mesothelinCAR polypeptide, or the ligand comprises an antibody molecule that binds said mesothelinCAR polypeptide; 
     (iv) the target CAR polypeptide is a BCMACAR polypeptide, and the ligand binds said BCMACAR polypeptide, e.g., the ligand comprises BCMA or a fragment thereof that binds said BCMACAR polypeptide, or the ligand comprises an antibody molecule that binds said BCMACAR polypeptide; 
     (v) the target CAR polypeptide is a CD20CAR polypeptide, and the ligand binds said CD20CAR polypeptide, e.g., the ligand comprises CD20 or a fragment thereof that binds said CD20CAR polypeptide, or the ligand comprises an antibody molecule that binds said CD20CAR polypeptide; 
     (vi) the target CAR polypeptide is a CD22CAR polypeptide, and the ligand binds said CD22CAR polypeptide, e.g., the ligand comprises CD22 or a fragment thereof that binds said CD22CAR polypeptide, or the ligand comprises an antibody molecule that binds said CD22CAR polypeptide; 
     (vii) the target CAR polypeptide is a CD123CAR polypeptide, and the ligand binds said CD123CAR polypeptide, e.g., the ligand comprises CD123 or a fragment thereof that binds said CD123CAR polypeptide, or the ligand comprises an antibody molecule that binds said CD123CAR polypeptide; or 
     (viii) the target CAR polypeptide is a CLL-1CAR polypeptide, and the ligand binds said CLL-1CAR polypeptide, e.g., the ligand comprises CLL-1 or a fragment thereof that binds said CLL-1CAR polypeptide, or the ligand comprises an antibody molecule that binds said CLL-1CAR polypeptide. 
     In some embodiments, the target CAR polypeptide comprises i) an antigen binding domain, e.g., an antigen binding domain that binds a tumor antigen described herein, e.g., an anti-CD19 binding domain, ii) a transmembrane domain, and iii) an intracellular signaling domain. 
     In some embodiments of the methods and uses described herein, the disease or condition associated with expression of a target CAR is a cancer, e.g., a cancer described herein. In some embodiments, the subject having a disease or condition associated with expression of a target CAR comprises a cell, e.g., comprises a population of cells, expressing the target CAR. In some embodiments, the cell is a cell from a cancer, e.g., a hematological cancer, e.g., a B cell cancer (e.g., ALL), a T cell cancer, or a myeloid leukemia (e.g., AML). In some embodiments, the disease associated with expression of a target CAR is a B-cell aplasia. 
     In some embodiments of the methods and uses described herein, the disease or condition associated with expression of a target CAR is a cancer, e.g., a cancer described herein. In some embodiments, the subject having a disease or condition associated with expression of a target CAR comprises a cell, e.g., comprises a population of cells, expressing the target CAR. In some embodiments, the cell, e.g., the target CAR-expressing cell, is a normal cell, e.g., a non-malignant cell, e.g., a normal or non-malignant hematopoietic cell, e.g., B cell, a myeloid cell, or an immune effector cell, e.g., a T cell, or an NK cell. 
     In some embodiments, the target CAR-expressing cell is a cancer cell, e.g., a cell from a cancer described herein. 
     In some embodiments, the subject has a cancer, e.g., a cancer described herein, or B-cell aplasia. 
     In some embodiments of the methods and uses described herein, the anti-target CAR cells are administered to the subject in about the same amount or an amount greater than the number of target CAR cells, e.g., in the subject. In some embodiments, the number of target CAR cells is estimated based on, e.g., the number of target CAR cells present in the subject e.g., at least 1 week, 2 weeks, 3 weeks, 4 weeks or more post-administration of the CAR-expressing cell therapy. In some embodiments, the number of target CAR cells is estimated based on, e.g., the number of target CAR cells present in a sample from the subject, e.g., an apheresis sample (e.g., prior to anti-target CAR transduction). In some embodiments, the number of target CAR cells is estimated based on, e.g., the number of target CAR cells that were administered to the subject, e.g., number of target CAR cells that were initially administered to the subject. In some embodiments, the anti-target CAR cells are administered at a ratio of at least 1:1, e.g., at least 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 50:1, 100:1 or 1000:1, with the target CAR cells. In some embodiments, the number of anti-target CAR cells that are administered to the subject are at least 1.5 fold, e.g., at least 1.5-100 fold, e.g., 1.5-5, 5-10, 10-15, 15-25, 25-35, 35-45, 45-55, 55-65, 65-75, 75-85, 85-95, or 95-100 fold, more than the number of target CAR cells in the subject 
     In some embodiments, any of the methods and uses described herein comprises evaluating, e.g., estimating, the number of target CAR cells in the subject, e.g., at least 1 week, 2 weeks, 3 weeks, 4 weeks or more post-administration of the CAR-expressing cell therapy. In some embodiments, the evaluating step comprises acquiring a sample, e.g., a blood sample, e.g., plasma sample, from the subject and determining:
         (i) the number of target CAR cells present in the blood sample; and/or   (ii) the number of target CAR cells present in the subject, e.g., in the circulation of the subject.       

     In some embodiments, based on the determination of the number of target CAR cells, the method comprises administering the same or greater amount of anti-target CAR cells to the subject. In some embodiments, the subject is administered the same or greater amount, e.g., at least 1.5 fold, e.g., at least 1.5-100 fold, e.g., 1.5-5, 5-10, 10-15, 15-25, 25-35, 35-45, 45-55, 55-65, 65-75, 75-85, 85-95, or 95-100 fold, more anti-target CAR cells compared to the number of target CAR cells determined in (ii). 
     In some embodiments, any of the methods and uses described herein comprises evaluating, e.g., estimating, the number of anti-target CAR cells in the subject, e.g., at least 1 week, 2 weeks, 3 weeks, 4 weeks or more post-administration of the anti-target CAR-expressing cell therapy. In some embodiments, the evaluating step comprises acquiring a sample, e.g., a blood sample, e.g., plasma sample, from the subject and determining:
         (iii) the number of anti-target CAR cells present in the blood sample; and/or   (iv) the number of anti-target CAR cells present in the subject, e.g., in the circulation of the subject.       

     In some embodiments of the methods or uses described herein, the subject is a mammal, e.g., a human. 
     In some embodiments, the subject was previously administered target CAR-expressing cells. In some embodiments, the subject experienced relapse, e.g., relapse characterized by cancer cells that are negative for the tumor antigen bound by the target CAR. In some embodiments, the subject had or has a disease associated with expression of CD19 and the relapse is a CD19-negative relapse, e.g., wherein some or all of the cancer cells in the subject are CD19-negative. 
     In some embodiments, the subject had: 
     (i) a disease associated with expression of CD33, and the relapse is a CD33-negative relapse; 
     (ii) a disease associated with expression of EGFRvIII, and the relapse is a EGFRvIII-negative relapse; 
     (iii) a disease associated with expression of mesothelin, and the relapse is a mesothelin-negative relapse; 
     (iv) a disease associated with expression of BCMA, and the relapse is a BCMA-negative relapse; 
     (v) a disease associated with expression of CD20, and the relapse is a CD20-negative relapse; 
     (vi) a disease associated with expression of CD22, and the relapse is a CD22-negative relapse; 
     (vi) a disease associated with expression of CD123, and the relapse is a CD123-negative relapse; or 
     (vii) a disease associated with expression of CLL-1, and the relapse is a CLL-1-negative relapse. 
     Anti-Target CAR-Encoding Nucleic Acids 
     In some aspects, the disclosure provides an isolated nucleic acid molecule encoding an anti-target CAR molecule. In one embodiment, the anti-target CAR comprises: i) a ligand that binds to a target CAR, ii) a transmembrane domain, and iii) an intracellular signaling domain, e.g., comprising a primary signaling domain and/or a costimulatory domain. 
     In some embodiments, the ligand of the isolated nucleic acid molecule encoding the anti-target CAR polypeptide molecule comprises a cognate antigen molecule or an antibody molecule that binds to the target CAR. In some embodiments, the ligand comprises an antibody molecule that binds to the target CAR, e.g., an anti-idiotypic antibody molecule that binds the target CAR, e.g., an anti-idiotype antibody molecule described herein. 
     In one embodiment, the isolated nucleic acid molecule comprises a sequence encoding a costimulatory domain, e.g., a costimulatory domain described herein. In embodiments, the intracellular signaling domain comprises a costimulatory domain. In embodiments, the intracellular signaling domain comprises a primary signaling domain. In embodiments, the intracellular signaling domain comprises a costimulatory domain and a primary signaling domain. 
     In some embodiments, the isolated nucleic acid molecule comprises a primary signaling domain. In certain embodiments, the encoded primary signaling domain comprises a functional signaling domain of a protein selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCER1G), FcR beta (Fc Epsilon Rib), CD79a, CD79b, Fcgamma RIIa, DAP10, and DAP12. 
     In one embodiment, the isolated nucleic acid encodes a primary signaling domain comprising a functional signaling domain of CD3 zeta. The encoded CD3 zeta primary signaling domain can comprise an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20, or a sequence with at least 95-99% identity to an amino acid sequence of SEQ ID NO:18 or SEQ ID NO: 20. In some embodiments, the encoded primary signaling domain comprises a sequence of SEQ ID NO:18 or SEQ ID NO: 20. In other embodiments, the nucleic acid sequence encoding the primary signaling domain comprises a sequence of SEQ ID NO:19 or SEQ ID NO: 21, or a sequence with at least 95-99% identity thereof. 
     In some embodiments, the intracellular signaling domain of the isolated nucleic acid molecule encoding the anti-target CAR polypeptide molecule comprises a costimulatory signaling domain. In some embodiments, the encoded costimulatory signaling domain comprises a functional signaling domain of a protein e.g., as described herein, e.g., selected from the group consisting of a MHC class I molecule, a TNF receptor protein, an Immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocytic activation molecule (SLAM protein), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83. 
     In one embodiment, the encoded costimulatory domain of 4-1BB comprises the amino acid sequence of SEQ ID NO: 14. In one embodiment, the encoded costimulatory domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO: 14, or a sequence with at least 95-99% identiy to the amino acid sequence of SEQ ID NO: 14. In one embodiment, the nucleic acid sequence encoding the costimulatory domain comprises the nucleotide sequence of SEQ ID NO: 15, or a sequence at least 95-99% identity to SEQ ID NO: 15. 
     In certain embodiments, the encoded transmembrane domain comprises an amino acid sequence of a CD8 transmembrane domain having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO: 12, or a sequence with at least 95-99% identity to an amino acid sequence of SEQ ID NO: 12. In some embodiments, the encoded transmembrane domain comprises a transmembrane domain of CD8, e.g., IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 12). In other embodiments, the nucleic acid molecule comprises a nucleotide sequence of a CD8 transmembrane domain, e.g., comprising the sequence of SEQ ID NO: 13, or a sequence with at least 95-99% identity thereof. 
     In certain embodiments, the encoded ligand that binds to a target CAR is connected to the transmembrane domain by a hinge region. In one embodiment, the encoded hinge region comprises the amino acid sequence of a CD8 hinge, e.g., SEQ ID NO: 403; or the amino acid sequence of an IgG4 hinge, e.g., SEQ ID NO: 405, or a sequence with at least 95-99% identity to SEQ ID NO:403 or 405. In other embodiments, the nucleic acid sequence encoding the hinge region comprises a sequence of SEQ ID NO: 404 or SEQ ID NO: 406, corresponding to a CD8 hinge or an IgG4 hinge, respectively, or a sequence with at least 95-99% identity to SEQ ID NO:404 or 406. 
     In certain embodiments, the anti-target CAR comprises a leader region, wherein said leader region encodes an amino acid sequence comprising SEQ ID NO: 401, or a sequence with at least 95-99% identity thereof; or said leader region comprises the nucleotide sequence of SEQ ID NO: 402, or a nucleotide sequence with at least 95-99% identity thereof. 
     Vectors 
     In another aspect, the invention pertains to a vector comprising a nucleic acid sequence encoding an anti-target CAR polypeptide described herein. In one embodiment, the vector is chosen from a DNA vector, an RNA vector, a plasmid, a lentivirus vector, adenoviral vector, or a retrovirus vector. In one embodiment, the vector is a lentivirus vector. 
     In an embodiment, the vector comprises a nucleic acid sequence that encodes an anti-target CAR, e.g., an anti-target CAR described herein, and a nucleic acid sequence that encodes an inhibitory molecule comprising: an inhKIR cytoplasmic domain; a transmembrane domain, e.g., a KIR transmembrane domain; and an inhibitor cytoplasmic domain, e.g., an ITIM domain, e.g., an inhKIR ITIM domain. In an embodiment the inhibitory molecule is a naturally occurring inhKIR, or a sequence sharing at least 50, 60, 70, 80, 85, 90, 95, or 99% homology with, or that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 residues from, a naturally occurring inhKIR. 
     In an embodiment, the nucleic acid sequence that encodes an inhibitory molecule comprises: a SLAM family cytoplasmic domain; a transmembrane domain, e.g., a SLAM family transmembrane domain; and an inhibitor cytoplasmic domain, e.g., a SLAM family domain, e.g., an SLAM family ITIM domain. In an embodiment the inhibitory molecule is a naturally occurring SLAM family member, or a sequence sharing at least 50, 60, 70, 80, 85, 90, 95, or 99% homology with, or that differs by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 residues from, a naturally occurring SLAM family member. 
     In one embodiment, the vector further comprises a promoter. In some embodiments, the promoter is chosen from an EF-1 promoter, a CMV IE gene promoter, an EF-1α promoter, an ubiquitin C promoter, or a phosphoglycerate kinase (PGK) promoter. In one embodiment, the promoter is an EF-1 promoter. In one embodiment, the EF-1 promoter comprises a sequence of SEQ ID NO: 400. 
     In one embodiment, the vector is an in vitro transcribed vector, e.g., a vector that transcribes RNA of a nucleic acid molecule described herein. In one embodiment, the nucleic acid sequence in the vector further comprises a poly(A) tail, e.g., a poly A tail described herein, e.g., comprising about 150 adenosine bases (SEQ ID NO:33). In one embodiment, the nucleic acid sequence in the vector further comprises a 3′UTR, e.g., a 3′ UTR described herein, e.g., comprising at least one repeat of a 3′UTR derived from human beta-globulin. In one embodiment, the nucleic acid sequence in the vector further comprises promoter, e.g., a T2A promoter. 
     Anti-Target CAR Polypeptides 
     In another aspect, the invention features an anti-target CAR molecule comprising: i) a ligand that binds to a target CAR, ii) a transmembrane domain, and iii) an intracellular domain that comprises a costimulatory domain 
     In some embodiments, the anti-target CAR molecule comprises a primary signaling domain. In other embodiments, the primary signaling domain of the anti-target CAR polypeptide molecule comprises a functional signaling domain of a protein selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCER1G), FcR beta (Fc Epsilon Rib), CD79a, CD79b, Fcgamma RIIa, DAP10, and DAP12. 
     In one embodiment, the primary signaling domain comprises a functional signaling domain of CD3 zeta. The CD3 zeta primary signaling domain can comprise an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20, or a sequence with at least 95-99% identity to an amino acid sequence of SEQ ID NO:18 or SEQ ID NO: 20. In some embodiments, the primary signaling domain of the CAR polypeptide molecule comprises a sequence of SEQ ID NO:18 or SEQ ID NO: 20. 
     In some embodiments, the intracellular signaling domain of the anti-target CAR polypeptide molecule comprises a costimulatory signaling domain In some embodiments, the costimulatory signaling domain comprises a functional signaling domain of a protein e.g., as described herein, e.g., selected from the group consisting of a MHC class I molecule, a TNF receptor protein, an Immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocytic activation molecule (SLAM protein), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83. 
     In some embodiments, the ligand comprises a cognate antigen molecule or an antibody molecule that binds to the target CAR. In some embodiments, the ligand comprises an antibody molecule that binds to the target CAR, e.g., an anti-idiotypic antibody molecule that binds the target CAR, e.g., an anti-idiotype antibody molecule described herein. 
     In some embodiments, the ligand of the anti-target CAR polypeptide molecule comprises an antibody, an antibody fragment, an scFv, a Fv, a Fab, a (Fab′)2, a single domain antibody (SDAB), a VH or VL domain, or a camelid VHH domain. 
     In some embodiments, the ligand of the anti-target CAR polypeptide molecule comprises a transmembrane domain of a protein chosen from an alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R α, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11 a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKp44, NKp30, NKp46, NKG2D, and/or NKG2C. 
     In some embodiments, the ligand of the anti-target CAR polypeptide molecule is connected to the transmembrane domain by a hinge region. In one embodiment, the encoded hinge region comprises the amino acid sequence of a CD8 hinge, e.g., SEQ ID NO: 403, or the amino acid sequence of an IgG4 hinge, e.g., SEQ ID NO: 405, or a sequence with at least 95-99% identity thereof. 
     In some embodiments, the anti-target CAR polypeptide molecule further comprises a leader sequence. In one embodiment, the leader sequence comprises the sequence of SEQ ID NO: 1, or an amino acid sequence with at least 95-99% identity to SEQ ID NO 401. 
     Anti-Target CAR-Expressing Cells 
     In another aspect, the invention pertains to a cell, e.g., an immune effector cell, (e.g., a population of cells, e.g., a population of immune effector cells) comprising a nucleic acid molecule, an anti-target CAR polypeptide molecule, or a vector as described herein. 
     In one embodiment, the cell is a human T cell. In one embodiment, the cell is a cell described herein, e.g., a human T cell, e.g., a human T cell described herein; or a human NK cell, e.g., a human NK cell described herein. In one embodiment, the human T cell is a CD8+ T cell. In one embodiment, the cell is a T cell and the T cell is diacylglycerol kinase (DGK) deficient. In one embodiment, the cell is a T cell and the T cell is Ikaros deficient. In one embodiment, the cell is a T cell and the T cell is both DGK and Ikaros deficient. 
     In an embodiment, the cell comprising a nucleic acid molecule, an anti-target CAR polypeptide molecule, or a vector as described herein is a cell that has not been previously engineered to express a target CAR, e.g., a target CAR described herein. 
     In another embodiment, an anti-target CAR-expressing immune effector cell described herein can further express another agent, e.g., an agent which enhances the activity of an anti-target CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Examples of inhibitory molecules include PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta, e.g., as described herein. In one embodiment, the agent that inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta, or a fragment of any of these, and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD-1 or a fragment thereof, and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28, CD27, OX40 or 4-IBB signaling domain described herein and/or a CD3 zeta signaling domain described herein). 
     Methods of Manufacturing CAR-Expressing Cells 
     In some aspects, the disclosure provides a method of making (e.g., manufacturing) a population of Chimeric Antigen Receptor (CAR)-expressing immune effector cells, comprising: 
     a) providing a population of cells comprising immune effector cells and cancer cells; 
     b) contacting the population of immune effector cells with a nucleic acid encoding a CAR polypeptide; 
     c) reducing the number or proportion of cancer cells in the population, wherein the reducing comprises one or more of:
         i) contacting the population of cells with a reagent (e.g., antibody molecule) that binds a T cell antigen other than CD3 or CD28, e.g., binds CD4 or CD8, and collecting cells that bind the reagent;   ii) contacting the population of cells with a reagent “(e.g., antibody molecule)” that binds a tumor antigen other than CD19, e.g., binds CD20, CD22, ROR1, CD10, CD34, CD123, FLT-3, CD79b, CD179b, or CD79a and collecting cells that do not bind the reagent; or   iii) contacting the population of cells with a therapeutic that preferentially reduces the number of (e.g., kills or inhibits proliferation of) cancer cells compared to noncancerous immune effector cells, wherein the therapeutic is other than a BTK inhibitor, e.g., other than ibrutinib, e.g., wherein the therapeutic comprises an antibody molecule or an antibody drug conjugate;       

     thereby making an enriched population of CAR-expressing immune effector cells. 
     In some embodiments, (b) is performed before (c), (c) is performed before (b), or (b) and (c) are performed simultaneously. 
     In some embodiments, the cancer cells are hematologic cancer cells or circulating tumor cells (e.g., circulating tumor cells from a solid tumor). 
     In some embodiments, contacting comprises contacting the population of cells with a reagent (e.g., antibody molecule) that binds a tumor antigen other than CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, e.g., comprises contacting the population of cells with a reagent (e.g., antibody molecule) that binds CD22, ROR1, CD10, CD34, FLT-3, CD79b, CD179b, or CD79a. 
     In some embodiments, the cancer cells comprise cancer cells that lack the antigen bound by the CAR, e.g., CD19-negative cancer cells. In some embodiments, the cancer cells that lack the antigen bound by the CAR comprise a portion of the protein that, in wild-type cells, comprises the antigen. In some embodiments, the protein comprises a truncation, deletion, or frameshift mutation that removes or mutates the antigen. 
     In some embodiments, the reagent (e.g., antibody molecule) of (c)(i) or (c)(ii) is bound to a solid substrate, e.g., a column or a bead, e.g., a magnetic bead or a bead suitable for optical sorting. In some embodiments, (c)(i) or (c)(ii) comprises performing MACS or FACS. In some embodiments, the therapeutic of (c)(iii) comprises an antibody molecule or an antibody drug conjugate. In some embodiments, the antibody molecule is an antiCD20 or antiCD22 antibody molecule. In some embodiments, the antibody molecule is fused to a toxin, e.g., an exotoxin A. In some embodiments, the therapeutic of (c)(iii) is bound to a solid substrate. 
     In some embodiments, the method further comprises determining the number or proportion of unwanted cells (e.g., cancer cells, e.g., cancer cells that lack the antigen bound by the CAR, e.g., CD19 negative cancer cells) in the population of cells. In some embodiments, the determining comprises performing a nucleic acid detection method, e.g., PCR, e.g., quantitative PCR, to determine the level or proportion of cancer cells in the sample, e.g., Acute Lymphocytic Leukemia (ALL) cells. In some embodiments, the determining comprises performing a deep sequencing method, e.g., DNA sequencing or RNA sequencing, e.g., nested PCR amplification and sequencing, e.g., sequencing of a tumor antigen (e.g., CD19) locus and optionally classifying the tumor antigen locus as having a mutation (e.g., deletion). In embodiments, the determining comprises performing one or more of extension assay (e.g., Wequenom), targeted PCR, digital PCR, and next generation sequencing (NGS). In embodiments, the determining comprises contacting cells with a reagent that detects a tumor antigen (e.g., wherein the tumor antigen is CD19 and the reagent comprises an anti-CD19 antibody). In embodiments, the determining comprises contacting cells with a reagent that detects a cancer cell, e.g., a reagent that detects highly proliferative cells, e.g., an antibody detecting Ki-67. 
     The present disclosure also provides, in some aspects, a method of making (e.g., manufacturing) a population of CAR (chimeric antigen receptor) expressing cells, comprising: 
     (a) providing a population of cells, wherein the population comprises immune effector cells; 
     (b) determining the number or proportion of unwanted cells (e.g., cancer cells, e.g., cancer cells that lack the antigen bound by the CAR, e.g., CD19 negative cancer cells) in the population, 
     (c)(i) if the number or proportion of (b) is less than a reference value, e.g., wherein the reference value is 10%, 5%, 4%, 3%, 2%, 1%, 0.1%, 0.01%, or 0.001% of the population, then contacting the population of cells with a nucleic acid, e.g., DNA or RNA, encoding a CAR, e.g., a CAR described herein and maintaining (e.g., culturing or expanding) the population of cells under conditions that allow expression of the CAR polypeptide from the nucleic acid, thereby making a population of CAR-expressing cells, or 
     (c)(ii) if the number or proportion of (b) is greater than the reference value, then discarding the population of cells or reducing the number or proportion of unwanted cells in the population. 
     The present disclosure also provides, in some aspects, a method of classifying a population of cells as more suitable or less suitable for CAR manufacturing, comprising: 
     (a) providing a population of cells, wherein the population comprises immune effector cells; 
     (b) determining the number or proportion of unwanted cells (e.g., cancer cells, e.g., cancer cells that lack the antigen bound by the CAR, e.g., CD19 negative cancer cells) in the population, 
     (c) if the number or proportion of (b) is greater than a reference value, then classifying the cells as less suitable (e.g., not suitable) for CAR manufacturing, or if the number or proportion of (b) is less than the reference value, then classifying the cells as more suitable for CAR manufacturing. 
     In some embodiments, if the cells are classified as more suitable for CAR manufacturing, the method further comprises contacting the cells with a nucleic acid, e.g., DNA or RNA, encoding a CAR, e.g., a CAR described herein. In some embodiments, the method further comprises maintaining (e.g., culturing or expanding) the cells under conditions that allow expression of the CAR polypeptide from the nucleic acid, thereby making a CAR-expressing cell. In embodiments, the method further comprises administering the CAR-expressing cell to a subject in need thereof. 
     In some embodiments, the cancer cells that lack the antigen bound by the CAR comprise a portion of the protein that, in wild-type cells, comprises the antigen. In some embodiments, the protein comprises a truncation, deletion, or frameshift mutation that removes or mutates the antigen. In some embodiments, the cancer cells are CD19-negative cancer cells. 
     In some embodiments, (b) comprises performing a nucleic acid detection method, e.g., PCR, e.g., quantitative PCR, to determine the level or proportion of cancer cells in the sample, e.g., Acute Lymphocytic Leukemia (ALL) cells. In some embodiments, (b) comprises performing a deep sequencing method, e.g., DNA sequencing or RNA sequencing, e.g., nested PCR amplification and sequencing, e.g., sequencing of a tumor antigen (e.g., CD19) locus and optionally classifying the tumor antigen locus as having a mutation (e.g., deletion). In embodiments, (b) comprises performing one or more of extension assay (e.g., Wequenom), targeted PCR, digital PCR, and next generation sequencing (NGS). In embodiments, (b) comprises contacting cells with a reagent that detects a tumor antigen (e.g., wherein the tumor antigen is CD19 and the reagent comprises an anti-CD19 antibody). In embodiments, (b) comprises contacting cells with a reagent that detects a cancer cell, e.g., a reagent that detects highly proliferative cells, e.g., an antibody detecting Ki-67. 
     In some embodiments, the method further comprises reducing the number or proportion of cancer cells in the population, wherein the reducing comprises one or more of:
         i) contacting the population of cells with a reagent (e.g., antibody molecule) that binds a T cell antigen other than CD3 or CD28, e.g., binds CD4 or CD8, and collecting cells that bind the reagent;   ii) contacting the population of cells with a reagent (e.g., antibody molecule) that binds a tumor antigen other than CD19, e.g., binds CD20, CD22, ROR1, CD10, CD34, CD123, FLT-3, CD79b, CD179b, or CD79a and collecting cells that do not bind the reagent; or   iii) contacting the population of cells with a therapeutic that preferentially reduces the number of (e.g., kills or inhibits proliferation of) cancer cells compared to noncancerous immune effector cells, wherein the therapeutic is other than a BTK inhibitor, e.g., other than ibrutinib, e.g., wherein the therapeutic comprises an antibody molecule or an antibody drug conjugate.
 
Methods of Treating a Patient and/or Selecting a Patient for Treatment with CAR-Expressing Cells
       

     The present disclosure provides, in some aspects, a method of treating a subject having a cancer, comprising: 
     (a) providing a population of cells from the subject, wherein the population comprises cancer cells; 
     (b) determining the number or proportion of cells (e.g., of total cells or of cancer cells) in the population that lack a first tumor antigen (e.g., CD19) or a gene encoding the first tumor antigen, wherein the first tumor antigen is bound by a plurality of CAR-expressing cells, 
     (c)(i) if the number or proportion of (b) is less than a reference value, then administering the plurality of CAR-expressing cells to the subject, or 
     (c)(ii) if the number or proportion of (b) is greater than the reference value, than administering to the subject an anti-cancer therapy other than therapy with the plurality of CAR-expressing cells. 
     The present disclosure also provides, in some aspects, a method of selecting a subject having a cancer for therapy with a plurality of CAR-expressing cells, comprising: 
     (a) providing a population of cells from the subject, wherein the population comprises cancer cells; 
     (b) determining the number or proportion of total cells or of cancer cells in the population that lack a first tumor antigen (e.g., CD19) or a gene encoding the first tumor antigen, wherein the CAR-expressing cells bind the first tumor antigen, 
     (c)(i) if the number or proportion of (b) is less than a reference value, then selecting the subject for therapy with the plurality of CAR-expressing cells, or 
     (c)(ii) if the number or proportion of (b) is greater than the reference value, than selecting the subject for an anti-cancer therapy other than therapy with the plurality of CAR-expressing cells. 
     In some embodiments, the anti-cancer therapy other than therapy with the plurality of CAR-expressing cells comprises chemotherapy, surgery, radiation, or therapy with a different plurality of CAR-expressing cells that binds a second tumor antigen. 
     In some embodiments, the plurality of CAR-expressing cells is a plurality of CD19 CAR expressing cells, e.g., cells expressing a CD19 CAR of Table 3. In some embodiments, the plurality of CAR-expressing cells is a plurality of BCMA CAR expressing cells, e.g., cells expressing a BCMA CAR of Table 5 or Table 6. 
     In some embodiments, the cancer is ALL. In some embodiments, the cancer cell is a hematologic cancer cell or a circulating tumor cell (e.g., a circulating tumor cell from a solid tumor). 
     In some embodiments, (b) comprises performing a nucleic acid detection method, e.g., PCR, e.g., quantitative PCR, to determine the level or proportion of cancer cells in the sample, e.g., ALL cells. In some embodiments, (b) comprises performing a deep sequencing method, e.g., DNA sequencing or RNA sequencing, e.g., embedded PCR amplification and sequencing, e.g., sequencing of the tumor antigen (e.g., CD19) locus and optionally classifying the tumor antigen locus as having a mutation (e.g., deletion). 
     Methods of Treatment 
     In another aspect, the present invention provides a method comprising administering to a subject (e.g., a subject who has experienced relapse from a prior administration of a target CAR therapy), an anti-target CAR molecule, e.g., as described herein, or a cell comprising one or more nucleic acids encoding an anti-target CAR molecule, e.g., as described herein. In one embodiment, the subject has a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed). In one embodiment, the subject is a human. 
     In another aspect, the invention pertains to a method of treating a subject (e.g., a subject who has experienced relapse from a prior administration of a target CAR therapy), having a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed) comprising administering to the subject an effective amount of a cell comprising an anti-target CAR molecule, e.g., as described herein. 
     In yet another aspect, the invention features a method of treating a subject (e.g., a subject who has experienced relapse from a prior administration of a target CAR therapy), having a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed), comprising administering to the subject an effective amount of a cell, e.g., an immune effector cell (e.g., a population of immune effector cells) comprising an anti-target CAR molecule, wherein the anti-target CAR molecule a ligand that binds a target CAR, a transmembrane domain, and an intracellular domain, said intracellular domain comprises a costimulatory domain and/or a primary signaling domain, wherein said ligand binds to the target CAR associated with the disease. 
     In a related aspect, the invention features a method of treating a subject (e.g., a subject who has experienced relapse from a prior administration of a target CAR therapy), having a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed). The method comprises administering to the subject an effective amount of a cell, e.g., an immune effector cell (e.g., a population of immune effector cells) comprising an anti-target CAR molecule, in combination with an agent that increases the efficacy of the immune cell, wherein: 
     the anti-target CAR molecule comprises ligand that binds to a target CAR, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and/or a primary signaling domain, wherein said ligand binds to the target CAR, e.g., binds an extracellular domain of the target CAR; and 
     the agent that increases the efficacy of the immune cell is chosen from one or more of: 
     a protein phosphatase inhibitor; 
     a kinase inhibitor; 
     a cytokine; 
     an inhibitor of an immune inhibitory molecule; or 
     an agent that decreases the level or activity of a T REG  cell. 
     In a related aspect, the invention features a method of treating a subject (e.g., a subject who has experienced relapse from a prior administration of a target CAR therapy), having a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed), comprising administering to the subject an effective amount of a cell, e.g., an immune effector cell (e.g., a population of immune effector cells) comprising an anti-target CAR molecule, wherein: 
     the anti-target CAR molecule comprises a ligand that binds to a target CAR, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and/or a primary signaling domain, wherein said ligand binds to the target CAR, e.g., binds an extracellular domain of the target CAR; and 
     the ligand of the anti-target CAR molecule comprises an antibody molecule and has a binding affinity at least 5-fold less than the antibody from which the ligand is derived. 
     In another aspect, the invention features a composition comprising an immune effector cell (e.g., a population of immune effector cells) comprising an anti-target CAR molecule, e.g., as described herein for use in the treatment of a subject having disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed). 
     In certain embodiments of any of the aforesaid methods or uses the disease associated with expression of a target CAR, is selected from a proliferative disease such as a cancer or malignancy or a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia, or is a non-cancer related indication associated with expression of a tumor antigen described herein. In one embodiment, the disease is a cancer described herein, e.g., a cancer described herein as being associated with a target CAR. In one embodiment, the disease is a hematologic cancer. In one embodiment, the hematologic cancer is leukemia. In one embodiment, the cancer is selected from the group consisting of one or more acute leukemias including but not limited to B-cell acute lymphoid leukemia (“BALL”), T-cell acute lymphoid leukemia (“TALL”), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL); additional hematologic cancers or hematologic conditions including, but not limited to B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt&#39;s lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and “preleukemia” which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and to disease associated with expression of a target CAR described herein include, but not limited to, atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases expressing a target CAR as described herein; and any combination thereof. In another embodiment, the disease associated with expression of a target CAR described herein is a solid tumor. 
     In certain embodiments of any of the aforesaid methods or uses, the disease associated with a target CAR is a disease in which any one, or more of the following tumor antigens were expressed at an earlier time point, e.g., during initial diagnosis or prior to administration of target CAR, but are altered (e.g., present at a lower level) or absent in at least a sub-population of cells when the anti-target CAR is administered: CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1 (CLECL1), CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, Mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, FAP, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, TSHR, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1/Galectin 8, MelanA/MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, legumain, HPV E6, E7, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1. 
     In other embodiments of any of the aforesaid methods or uses, the disease associated with a target CAR is a disease in which any one, or more of the following tumor antigens were expressed at an earlier time point, e.g., during initial diagnosis or prior to administration of target CAR, but are altered (e.g., present at a lower level) or absent in at least a sub-population of cells when the anti-target CAR is administered: TSHR, TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1. 
     In other embodiments of any of the aforesaid methods or uses, the disease associated with a target CAR is a disease in which any one, or more of the following tumor antigens were expressed at an earlier time point, e.g., during initial diagnosis or prior to administration of target CAR, but are altered (e.g., present at a lower level) or absent in at least a sub-population of cells when the anti-target CAR is administered: TSHR, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, CD150, 5T4, ActRIIA, B7, BMCA, CA-125, CCNA1, CD123, CD126, CD138, CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25, CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40, CD40L, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, CD74, CD8, CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII, EGP-2, EGP-4, EPHa2, ErbB2, ErbB3, ErbB4, FBP, GD2, GD3, HER1-HER2 in combination, HER2-HER3 in combination, HERV-K, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, HLA-DR, HM1.24, HMW-MAA, Her2, Her2/neu, IGF-1R, IL-11R-alpha, IL-13R-alpha2, IL-2, IL-22R-alpha, IL-6, IL-6R, Ia, Ii, L1-CAM, L1-cell adhesion molecule, Lewis Y, L1-CAM, MAGE A3, MAGE-A1, MART-1, MUC1, NKG2C ligands, NKG2D Ligands, NY-ESO-1, OEPHa2, PIGF, PSCA, PSMA, ROR1, T101, TAC, TAG72, TIM-3, TRAIL-R1, TRAIL-R1 (DR4), TRAIL-R2 (DR5), VEGF, VEGFR2, WT-1, a G-protein coupled receptor, alphafetoprotein (AFP), an angiogenesis factor, an exogenous cognate binding molecule (ExoCBM), oncogene product, anti-folate receptor, c-Met, carcinoembryonic antigen (CEA), cyclin (D1), ephrinB2, epithelial tumor antigen, estrogen receptor, fetal acethycholine e receptor, folate binding protein, gp100, hepatitis B surface antigen, kappa chain, kappa light chain, kdr, lambda chain, livin, melanoma-associated antigen, mesothelin, mouse double minute 2 homolog (MDM2), mucin 16 (MUC16), mutated p53, mutated ras, necrosis antigens, oncofetal antigen, ROR2, progesterone receptor, prostate specific antigen, tEGFR, tenascin, β2-Microglobulin, Fc Receptor-like 5 (FcRL5), or molecules expressed by HIV, HCV, HBV, or other pathogens. 
     In certain embodiments, the methods or uses are carried out in combination with an agent that increases the efficacy of the immune effector cell, e.g., an agent as described herein. 
     In any of the aforesaid methods or uses, the disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed) is selected from the group consisting of a proliferative disease, a precancerous condition, a cancer, and a non-cancer related indication, e.g., B cell aplasia, associated with expression of the target CAR. In an embodiment, the non-cancer indication is B cell aplasia. 
     The cancer can be a hematologic cancer, e.g., a cancer chosen from one or more of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt&#39;s lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin&#39;s lymphoma, Hodgkin&#39;s lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, or pre-leukemia. 
     The cancer can also be chosen from colon cancer, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine, cancer of the esophagus, melanoma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin&#39;s Disease, non-Hodgkin&#39;s lymphoma, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi&#39;s sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers, combinations of said cancers, and metastatic lesions of said cancers. 
     Methods of Making CAR-Expressing Cells 
     In another aspect, the invention pertains to a method of making a cell (e.g., an immune effector cell or population thereof) comprising introducing into (e.g., transducing) a cell, e.g., a T cell or a NK cell described herein, with a vector of comprising a nucleic acid encoding an anti-target CAR, e.g., an anti-target CAR polypeptide, e.g., as described herein; or a nucleic acid encoding an anti-target CAR molecule, e.g., as described herein. 
     The cell in the methods is an immune effector cell (e.g., a T cell or a NK cell, or a combination thereof). In some embodiments, the cell in the methods is diacylglycerol kinase (DGK) and/or Ikaros deficient. 
     In some embodiment, introducing the nucleic acid molecule encoding an anti-target CAR, e.g., as described herein, comprises transducing a vector comprising the nucleic acid molecule encoding an anti-target CAR, e.g., as described herein, or transfecting the nucleic acid molecule encoding an anti-target CAR, e.g., as described herein, wherein the nucleic acid molecule is an in vitro transcribed RNA. 
     In some embodiments, the method further comprises: 
     providing a population of immune effector cells (e.g., T cells or NK cells); and 
     removing T regulatory cells from the population, thereby providing a population of T regulatory-depleted cells; 
     wherein steps a) and b) are performed prior to introducing the nucleic acid encoding the anti-target CAR to the population. In embodiments of the methods, the T regulatory cells comprise CD25+ T cells, and are removed from the cell population using an anti-CD25 antibody, or fragment thereof. The anti-CD25 antibody, or fragment thereof, can be conjugated to a substrate, e.g., a bead. 
     In other embodiments, the population of T regulatory-depleted cells provided from step (b) contains less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells. 
     In yet other embodiments, the method further comprises: 
     removing cells from the population which express a tumor antigen that does not comprise CD25 to provide a population of T regulatory-depleted and tumor antigen depleted cells prior to introducing the nucleic acid encoding an anti-target CAR to the population. The tumor antigen can be selected from CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, or a combination thereof. 
     In other embodiments, the method further comprises 
     removing cells from the population which express a checkpoint inhibitor, to provide a population of T regulatory-depleted and inhibitory molecule depleted cells prior to introducing the nucleic acid encoding an anti-target CAR to the population. The checkpoint inhibitor can be chosen from PD-1, LAG-3, TIM3, B7-H1, CD160, P1H, 2B4, CEACAM (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5), TIGIT, CTLA-4, BTLA, and LAIR1. 
     Further embodiments disclosed herein encompass providing a population of immune effector cells. The population of immune effector cells provided can be selected based upon the expression of one or more of CD3, CD28, CD4, CD8, CD45RA, and/or CD45RO. In certain embodiments, the population of immune effector cells provided are CD3+ and/or CD28+. 
     In certain embodiments of the method, the method further comprises expanding the population of cells after the nucleic acid molecule encoding an anti-target CAR has been introduced. 
     In embodiments, the population of cells is expanded for a period of 8 days or less. 
     In certain embodiments, the population of cells is expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions. 
     In other embodiments, the population of cells is expanded in culture for 5 days show at least a one, two, three or four fold increase in cell doublings upon antigen stimulation as compared to the same cells expanded in culture for 9 days under the same culture conditions. 
     In yet other embodiments, the population of cells is expanded in culture for 5 days, and the resulting cells exhibit higher proinflammatory IFN-γ and/or GM-CSF levels, as compared to the same cells expanded in culture for 9 days under the same culture conditions. 
     In other embodiments, the population of cells is expanded by culturing the cells in the presence of an agent that stimulates a CD3/TCR complex associated signal and/or a ligand that stimulates a costimulatory molecule on the surface of the cells. The agent can be a bead conjugated with anti-CD3 antibody, or a fragment thereof, and/or anti-CD28 antibody, or a fragment thereof. 
     In other embodiments, the population of cells is expanded in an appropriate media that includes one or more interleukin that result in at least a 200-fold, 250-fold, 300-fold, or 350-fold increase in cells over a 14 day expansion period, as measured by flow cytometry. 
     In other embodiments, the population of cells is expanded in the presence IL-15 and/or IL-7. 
     In certain embodiments, the method further includes cryopreserving the population of the cells after the appropriate expansion period. 
     In yet other embodiments, the method of making disclosed herein further comprises contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT. The nucleic acid encoding the telomerase subunit can be DNA. 
     The present invention also provides a method of generating a population of RNA-engineered cells, e.g., cells described herein, e.g., immune effector cells (e.g., T cells, NK cells), transiently expressing exogenous RNA. The method comprises introducing an in vitro transcribed RNA or synthetic RNA into a cell, where the RNA comprises a nucleic acid encoding an anti-target CAR molecule, e.g., as described herein. 
     In another aspect, the invention pertains to a method of providing an anti-tumor immunity in a subject comprising administering to the subject an effective amount of a cell comprising an anti-target CAR molecule, e.g., as described herein. In one embodiment, the cell is an autologous T cell or NK cell. In one embodiment, the cell is an allogeneic T cell or NK cell. In one embodiment, the autologous or allogenic T cell or NK cell lacks expression or has low expression of a functional TCR or a functional HLA. In one embodiment, the subject is a human. 
     In one aspect, the invention includes a population of autologous cells that are transfected or transduced with a vector comprising a nucleic acid molecule encoding an anti-target CAR molecule, e.g., as described herein. In one embodiment, the vector is a retroviral vector. In one embodiment, the vector is a self-inactivating lentiviral vector as described elsewhere herein. In one embodiment, the vector is delivered (e.g., by transfecting or electroporating) to a cell, e.g., a T cell or a NK cell, wherein the vector comprises a nucleic acid molecule encoding an anti-target CAR, e.g., as described herein, which is transcribed as an mRNA molecule, and the anti-target CARs of the present invention is translated from the RNA molecule and expressed on the surface of the cell. 
     In another aspect, the present invention provides a population of cells wherein at least one cell in the population expresses an anti-target CAR having a ligand that binds a target CAR as described herein, and a second cell expressing another agent, e.g., an agent which enhances the activity of an anti-target CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Examples of inhibitory molecules include PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta. In one embodiment, the agent which inhibits an inhibitory molecule, e.g., is a molecule described herein, e.g., an agent that comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD-1, LAG-3, CTLA-4, CD160, BTLA, LAIR1, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), 2B4 and TIGIT, or a fragment of any of these, and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 4-1BB, CD27 or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD-1 or a fragment thereof, and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28, CD27, OX40 or 4-IBB signaling domain described herein and/or a CD3 zeta signaling domain described herein). 
     In one embodiment, the nucleic acid molecule encoding an anti-target CAR of the present invention molecule, e.g., as described herein, is expressed as an mRNA molecule. In one embodiment, the genetically modified anti-target CAR of the present invention-expressing cells, e.g., immune effector cells (e.g., T cells, NK cells), can be generated by transfecting or electroporating an RNA molecule encoding the desired anti-target CARs (e.g., without a vector sequence) into the cell. In one embodiment, an anti-target CAR of the present invention molecule is translated from the RNA molecule once it is incorporated and expressed on the surface of the recombinant cell. 
     Target CAR 
     In an embodiment, a target CAR as described herein, comprises: i) an antigen binding domain, ii) a transmembrane domain, and iii) an intracellular signaling domain, e.g., comprising a primary signaling domain and/or a costimulatory domain. 
     In some embodiments, the antigen binding domain of the target CAR binds a tumor antigen, e.g., a tumor antigen described herein. In some embodiments, the tumor antigen is chosen from one or more of: CD19; CD123; CD22; CD30; CD171; CS-1 (also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser/Thr)); prostate-specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-Like Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); Mesothelin; Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 21 (Testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet-derived growth factor receptor beta (PDGFR-beta); Stage-specific embryonic antigen-4 (SSEA-4); CD20; Folate receptor alpha; Receptor tyrosine-protein kinase ERBB2 (Her2/neu); Mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); Prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); Ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100 (gp100); oncogene fusion protein consisting of breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl) (bcr-abl); tyrosinase; ephrin type-A receptor 2 (EphA2); Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); transglutaminase 5 (TGS5); high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen 2 (LAGE-1a); Melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; surviving; telomerase; prostate carcinoma tumor antigen-1 (PCTA-1 or Galectin 8), melanoma antigen recognized by T cells 1 (MelanA or MART1); Rat sarcoma (Ras) mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Tyrosinase-related protein 2 (TRP-2); Cytochrome P450 1B1 (CYP1B1); CCCTC-Binding Factor (Zinc Finger Protein)—Like (BORIS or Brother of the Regulator of Imprinted Sites), Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Receptor for Advanced Glycation Endproducts (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papilloma virus E6 (HPV E6); human papilloma virus E7 (HPV E7); intestinal carboxyl esterase; heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1). 
     In some embodiments, tumor antigen bound by the target CAR is chosen from one or more of: TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1. 
     In certain embodiments, the tumor antigen bound by the target CAR is chosen from one or more of: TSHR, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, CD150, 5T4, ActRIIA, B7, BMCA, CA-125, CCNA1, CD123, CD126, CD138, CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25, CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40, CD40L, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, CD74, CD8, CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII, EGP-2, EGP-4, EPHa2, ErbB2, ErbB3, ErbB4, FBP, GD2, GD3, HER1-HER2 in combination, HER2-HER3 in combination, HERV-K, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, HLA-DR, HM1.24, HMW-MAA, Her2, Her2/neu, IGF-1R, IL-11Ralpha, IL-13R-alpha2, IL-2, IL-22R-alpha, IL-6, IL-6R, Ia, Ii, L1-CAM, L1-cell adhesion molecule, Lewis Y, L1-CAM, MAGE A3, MAGE-A1, MART-1, MUC1, NKG2C ligands, NKG2D Ligands, NY-ESO-1, OEPHa2, PIGF, PSCA, PSMA, ROR1, T101, TAC, TAG72, TIM-3, TRAIL-R1, TRAIL-R1 (DR4), TRAIL-R2 (DR5), VEGF, VEGFR2, WT-1, a G-protein coupled receptor, alphafetoprotein (AFP), an angiogenesis factor, an exogenous cognate binding molecule (ExoCBM), oncogene product, anti-folate receptor, c-Met, carcinoembryonic antigen (CEA), cyclin (D1), ephrinB2, epithelial tumor antigen, estrogen receptor, fetal acethycholine e receptor, folate binding protein, gp100, hepatitis B surface antigen, kappa chain, kappa light chain, kdr, lambda chain, livin, melanoma-associated antigen, mesothelin, mouse double minute 2 homolog (MDM2), mucin 16 (MUC16), mutated p53, mutated ras, necrosis antigens, oncofetal antigen, ROR2, progesterone receptor, prostate specific antigen, tEGFR, tenascin, β2-Microglobulin, Fc Receptor-like 5 (FcRL5), or molecules expressed by HIV, HCV, HBV, or other pathogens. 
     In some embodiments, the antigen binding domain of the target CAR molecule comprises an antibody, an antibody fragment, an scFv, a Fv, a Fab, a (Fab′)2, a single domain antibody (SDAB), a VH or VL domain, or a camelid VHH domain. 
     In some embodiments, the transmembrane domain of the target CAR molecule comprises a transmembrane domain chosen from the transmembrane domain of an alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R α, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKp44, NKp30, NKp46, NKG2D, and/or NKG2C. 
     In one embodiment, the target CAR is a CD19 CAR, a CD22 CAR, a CD123 CAR, a CD33 CAR, a mesothelin CAR, an EGFRvIII CAR, a CLL-1 CAR, or a CAR described herein. In one embodiment, the target CAR is a CD19 CAR, e.g., a CAR comprising an scFv amino acid sequence of SEQ ID NOs: 893, 898, 903, 908, 913, 918, 923, 928, 933, 938, 943, 948, or 953, or a CAR comprising the amino acid sequence of SEQ ID NOs: 2020-2022. 
     In one embodiment, the target CAR comprises an antibody or antibody fragment which includes a anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain comprising a stimulatory domain, and wherein said anti-CD19 binding domain comprises one or more of light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of any anti-CD19 light chain binding domain amino acid sequence listed in Table 3, and one or more of heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of any anti-CD19 heavy chain binding domain amino acid sequence listed in Table 3. 
     In one embodiment, the target CAR comprises an antibody or antibody fragment which includes a anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain comprising a stimulatory domain, and wherein said anti-CD19 binding domain comprises one or more of light chain complementary determining region 1 (LC CDR1), light chain complementary determining region 2 (LC CDR2), and light chain complementary determining region 3 (LC CDR3) of any anti-CD19 light chain binding domain amino acid sequence listed in Table 4B, and one or more of heavy chain complementary determining region 1 (HC CDR1), heavy chain complementary determining region 2 (HC CDR2), and heavy chain complementary determining region 3 (HC CDR3) of any anti-CD19 heavy chain binding domain amino acid sequence listed in Table 4A. 
     In one embodiment, the anti-CD19 binding domain of the target CAR comprises a sequence of SEQ ID NO: 898, or SEQ ID NO:957. 
     In one embodiment, the target CAR comprises a polypeptide having a sequence of SEQ ID NO: 902, or SEQ ID NO: 956. 
     In certain embodiments, the target CAR antigen binding domain has a binding affinity KD of 10 −4  M to 10 −8  M. 
     In one embodiment, the target CAR antigen binding domain is an antigen binding domain described herein, e.g., an antigen binding domain described herein for a target provided above. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1A  shows in vitro killing assays with NALM6 WT or NALM6 CAR19+ expressing cells. CART19 cells or CART-CAR19 cells expressing anti-idiotypic scFv in the L2H or H2L orientation were incubated with target cells Killing of NAPM6 CAR19+ cells was observed with CART-CAR19 cells in the L2H orientation and CART-CAR19 cells in the H2L orientation. 
         FIG. 1B  shows in vivo leukemia control in the CHP107R xenograft model by CART-CAR19 cells. CHP107R cells were engrafted in NOD-SCID gamma chain deficient (NSG) mice, and recipient animals were treated with the CAR19 or CART-CAR19 L2H cells, or left untreated. 
         FIGS. 2A-2D  show depletion of CART19 expressing cells by anti-CAR CART expressing cells. Cells expressing anti-CAR CART were labeled with CFSE and cells expressing CART19 or CART22 were labeled with Cell tracker violet (CTV). The CFSE labeled cells and the CTV labeled cells were then co-cultured at different ratios and the ratio of CFSE:CTV signal was assessed by flow cytometry at 24 and 48 hours. 
     
    
    
     DETAILED DESCRIPTION 
     In general, the invention features a T-cell containing an anti-target CAR which binds to a target CAR, e.g., a target CAR described herein. 
     Definitions 
     Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. 
     The term “a” and “an” refers to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element. 
     The term “about” when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or in some instances ±10%, or in some instances ±5%, or in some instances ±1%, or in some instances ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods. 
     The term “Chimeric Antigen Receptor” or alternatively a “CAR” refers to a set of polypeptides, typically two in the simplest embodiments, which when in an immune effector cell, provides the cell with specificity for a target cell, typically a cancer cell, and with intracellular signal generation. In some embodiments, a CAR comprises at least an extracellular antigen binding domain, a transmembrane domain and a cytoplasmic signaling domain (also referred to herein as “an intracellular signaling domain”) comprising a functional signaling domain derived from a stimulatory molecule and/or costimulatory molecule as defined below. In some aspects, the set of polypeptides are contiguous with each other. In some embodiments, the set of polypeptides include a dimerization switch that, upon the presence of a dimerization molecule, can couple the polypeptides to one another, e.g., can couple an antigen binding domain to an intracellular signaling domain. In one aspect, the stimulatory molecule is the zeta chain associated with the T cell receptor complex. In one aspect, the cytoplasmic signaling domain further comprises one or more functional signaling domains derived from at least one costimulatory molecule as defined below. In one aspect, the costimulatory molecule is chosen from the costimulatory molecules described herein, e.g., 4-1BB (i.e., CD137), CD27 and/or CD28. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain comprising a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain comprising a functional signaling domain derived from a costimulatory molecule and a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain comprising two functional signaling domains derived from one or more costimulatory molecule(s) and a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain comprising at least two functional signaling domains derived from one or more costimulatory molecule(s) and a functional signaling domain derived from a stimulatory molecule. In one aspect the CAR comprises an optional leader sequence at the amino-terminus (N-ter) of the CAR fusion protein. In one aspect, the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen binding domain, wherein the leader sequence is optionally cleaved from the antigen binding domain (e.g., a scFv) during cellular processing and localization of the CAR to the cellular membrane. 
     A CAR that comprises an antigen binding domain (e.g., a scFv, or TCR) that targets a specific tumor maker X, such as those described herein, is also referred to as XCAR. For example, a CAR that comprises an antigen binding domain that targets CD19 is referred to as CD19CAR. 
     As used herein, “anti-target CAR” refers to a CAR that binds a target CAR, e.g., binds the antigen binding domain of the target CAR, e.g., binds an antibody molecule portion of the target CAR. In some embodiments, an anti-target CAR comprises at least an extracellular ligand that binds to a target CAR, a transmembrane domain, and a cytoplasmic signaling domain comprising a functional signaling domain derived from a stimulatory molecule and/or costimulatory molecule, e.g., as described herein. In some embodiments, the ligand that binds to a target CAR comprises an antibody molecule (e.g., anti-idiotypic antibody molecule) that binds the target CAR, e.g., binds an extracellular domain of the target CAR, e.g., the antigen binding domain or hinge of the target CAR, e.g., binds an antibody molecule portion of the target CAR. 
     The term “ligand that binds to a target CAR” as used herein refers to a molecule that binds to a CAR polypeptide or a portion of a CAR polypeptide. The CAR polypeptide bound by the ligand that binds to a target CAR is referred to herein as a “target CAR”. In some embodiments, the ligand binds to the target CAR extracellular domain, e.g., the ligand binds to the target CAR antigen binding domain, e.g., the portion of the target CAR comprising an antibody or antibody fragment. In some embodiments, the ligand binds to the hinge of the target CAR. In some embodiments, the ligand binds the target CAR hinge and the target CAR antigen binding domain. In some embodiments, the ligand is an antigen molecule, e.g., a cognate antigen molecule, e.g., as described herein. In other embodiments, the ligand is an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an anti-antigen (e.g., CD19) idiotypic antibody molecule as described herein. 
     The term “cognate antigen molecule” refers to any antigen described herein. In some embodiments, it refers to an antigen bound, e.g., recognized or targeted, by a CAR polypeptide, e.g., any target CAR described herein. In some embodiments, it refers to a cancer associated antigen described herein. In some embodiments, the cognate antigen molecule is a recombinant molecule. 
     The term “anti-idiotypic (or idiotype) antibody molecule” or “anti-antigen idiotypic (idiotype) antibody molecule” refers to an antibody molecule that binds to an antibody, e.g., the antigen-binding site or the variable region of a target antibody (e.g., an antibody in the target CAR). In some embodiments, the anti-idiotypic antibody molecule competes for binding with the antigen recognized by the target antibody, e.g., an antigen as described herein (e.g., a cognate antigen molecule as described herein). In some embodiments, the anti-idiotypic antibody molecule binds to the CAR antigen binding domain, e.g., the portion of the CAR comprising an antibody or antibody fragment (e.g., the antigen binding portion of the CAR). 
     As used herein, “disease associated with expression of a target CAR” includes, but is not limited to, a disease associated with expression of a target CAR as described herein or condition associated with cells which express a target CAR as described herein including, e.g., proliferative diseases such as a cancer or malignancy or a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia; or a noncancer related indication associated with cells which express a target CAR as described herein. In an embodiment, the disease associated with expression of a target CAR is a cancer, e.g., a cancer wherein one or more cancer cells expresses a target CAR. In an embodiment, the disease associated with expression of a target CAR is B-cell aplasia. In an embodiment, a cancer associated with expression of a target CAR as described herein is a hematological cancer. In an embodiment, a cancer associated with expression of a target CAR as described herein is a solid cancer. In embodiments, the target CAR is expressed in cells of the disease associated with expression of a CAR. 
     As used herein, a “CD19-negative” cell refers to a cell having a loss or alteration in CD19. It shall be understood that a CD19-negative cancer need not have 100% loss of CD19, but a sufficient reduction to reduce the effectiveness of a CD19 therapy such that the cell is resistant to the CD19 therapy. In some embodiments the cells do not comprise the CD19 protein (e.g., do not comprise the CD19 protein expressed on the cell surface), and in other embodiments the cells comprise a portion of the CD19 protein that does not include the antigen. In some embodiments, the CD19-negative cells comprise a truncation, deletion, or frameshift mutation in CD19 that removes or mutates the antigen. Similarly, a “CD19-negative relapse” is a relapsed disease in which some or all of the cells, e.g., cancer cells, are CD19-negative cells, and a “CD19-negative cancer” is a cancer in which some or all of the cancer cells are CD19-negative cancer cells. Likewise, cells that are CD33-negative, EGFRvIII-negative, mesothelin-negative, BCMA-negative, CD20-negative, CD123-negative, or CLL-1 negative are cells that have a loss or alteration in the specified antigen bound by a CAR, e.g., the cells do not comprise the specified protein, or comprise a portion of the specified protein that does not comprise the specified antigen. 
     The term “signaling domain” refers to the functional portion of a protein which acts by transmitting information within the cell to regulate cellular activity via defined signaling pathways by generating second messengers or functioning as effectors by responding to such messengers. 
     The term “antibody,” as used herein, refers to a protein, or polypeptide sequence derived from an immunoglobulin molecule which specifically binds with an antigen. Antibodies can be polyclonal or monoclonal, multiple or single chain, or intact immunoglobulins, and may be derived from natural sources or from recombinant sources. Antibodies can be tetramers of immunoglobulin molecules. 
     The term “antibody fragment” refers to at least one portion of an antibody, that retains the ability to specifically interact with (e.g., by binding, steric hindrance, stabilizing/destabilizing, spatial distribution) an epitope of an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab′, F(ab′) 2 , Fv fragments, scFv antibody fragments, disulfide-linked Fvs (sdFv), a Fd fragment consisting of the VH and CH1 domains, linear antibodies, single domain antibodies such as sdAb (either VL or VH), camelid VHH domains, multi-specific antibodies formed from antibody fragments such as a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region, and an isolated CDR or other epitope binding fragments of an antibody. An antigen binding fragment can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NAR and bis-scFv (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen binding fragments can also be grafted into scaffolds based on polypeptides such as a fibronectin type III (Fn3)(see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide minibodies). 
     The term “scFv” refers to a fusion protein comprising at least one antibody fragment comprising a variable region of a light chain and at least one antibody fragment comprising a variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguously linked, e.g., via a synthetic linker, e.g., a short flexible polypeptide linker, and capable of being expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless specified, as used herein an scFv may have the VL and VH variable regions in either order, e.g., with respect to the N-terminal and C-terminal ends of the polypeptide, the scFv may comprise VL-linker-VH or may comprise VH-linker-VL. 
     The portion of the CAR of the invention comprising an antibody or antibody fragment thereof may exist in a variety of forms where the antigen binding domain is expressed as part of a contiguous polypeptide chain including, for example, a single domain antibody fragment (sdAb), a single chain antibody (scFv), a humanized antibody or bispecific antibody (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, N.Y.; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen binding domain of a CAR composition of the invention comprises an antibody fragment. In a further aspect, the CAR comprises an antibody fragment that comprises a scFv. The precise amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 (“Chothia” numbering scheme), or a combination thereof. 
     As used herein, the term “binding domain” or “antibody molecule” refers to a protein, e.g., an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain sequence. The term “binding domain” or “antibody molecule” encompasses antibodies and antibody fragments. In an embodiment, an antibody molecule is a multispecific antibody molecule, e.g., it comprises a plurality of immunoglobulin variable domain sequences, wherein a first immunoglobulin variable domain sequence of the plurality has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the plurality has binding specificity for a second epitope. In an embodiment, a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. 
     The portion of the CAR of the invention comprising an antibody or antibody fragment thereof may exist in a variety of forms where the antigen binding domain is expressed as part of a contiguous polypeptide chain including, for example, a single domain antibody fragment (sdAb), a single chain antibody (scFv), a humanized antibody, or bispecific antibody (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, N.Y.; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen binding domain of a CAR composition of the invention comprises an antibody fragment. In a further aspect, the CAR comprises an antibody fragment that comprises a scFv. 
     The term “antibody heavy chain,” refers to the larger of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations, and which normally determines the class to which the antibody belongs. 
     The term “antibody light chain,” refers to the smaller of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations. Kappa (κ) and lambda (λ) light chains refer to the two major antibody light chain isotypes. 
     The term “recombinant antibody” refers to an antibody which is generated using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage or yeast expression system. The term should also be construed to mean an antibody which has been generated by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using recombinant DNA or amino acid sequence technology which is available and well known in the art. 
     The term “antigen” or “Ag” refers to a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. The skilled artisan will understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequences or a partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an “antigen” as that term is used herein. Furthermore, one skilled in the art will understand that an antigen need not be encoded solely by a full length nucleotide sequence of a gene. It is readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to encode polypeptides that elicit the desired immune response. Moreover, a skilled artisan will understand that an antigen need not be encoded by a “gene” at all. It is readily apparent that an antigen can be generated synthesized or can be derived from a biological sample, or might be macromolecule besides a polypeptide. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a fluid with other biological components. 
     The term “anti-cancer effect” refers to a biological effect which can be manifested by various means, including but not limited to, e.g., a decrease in tumor volume, a decrease in the number of cancer cells, a decrease in the number of metastases, an increase in life expectancy, decrease in cancer cell proliferation, decrease in cancer cell survival, or amelioration of various physiological symptoms associated with the cancerous condition. An “anti-cancer effect” can also be manifested by the ability of the peptides, polynucleotides, cells and antibodies in prevention of the occurrence of cancer in the first place. The term “anti-tumor effect” refers to a biological effect which can be manifested by various means, including but not limited to, e.g., a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in tumor cell proliferation, or a decrease in tumor cell survival. 
     The term “autologous” refers to any material derived from the same individual to whom it is later to be re-introduced into the individual. 
     The term “allogeneic” refers to any material derived from a different animal of the same species as the individual to whom the material is introduced. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical. In some aspects, allogeneic material from individuals of the same species may be sufficiently unlike genetically to interact antigenically 
     The term “xenogeneic” refers to a graft derived from an animal of a different species. 
     The term “cancer” refers to a disease characterized by the uncontrolled growth of aberrant cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of various cancers are described herein and include but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, renal cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer and the like. The terms “tumor” and “cancer” are used interchangeably herein, e.g., both terms encompass solid and liquid, e.g., diffuse or circulating, tumors. As used herein, the term “cancer” or “tumor” includes premalignant, as well as malignant cancers and tumors. 
     “Derived from” as that term is used herein, indicates a relationship between a first and a second molecule. It generally refers to structural similarity between the first molecule and a second molecule and does not connotate or include a process or source limitation on a first molecule that is derived from a second molecule. For example, in the case of an intracellular signaling domain that is derived from a CD3zeta molecule, the intracellular signaling domain retains sufficient CD3zeta structure such that is has the required function, namely, the ability to generate a signal under the appropriate conditions. It does not connotate or include a limitation to a particular process of producing the intracellular signaling domain, e.g., it does not mean that, to provide the intracellular signaling domain, one must start with a CD3zeta sequence and delete unwanted sequence, or impose mutations, to arrive at the intracellular signaling domain. 
     The phrase “disease associated with expression of a tumor antigen as described herein” includes, but is not limited to, a disease associated with expression of a tumor antigen as described herein or condition associated with cells which express a tumor antigen as described herein including, e.g., proliferative diseases such as a cancer or malignancy or a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia; or a noncancer related indication associated with cells which express a tumor antigen as described herein. In one aspect, a cancer associated with expression of a tumor antigen as described herein is a hematological cancer. In one aspect, a cancer associated with expression of a tumor antigen as described herein is a solid cancer. Further diseases associated with expression of a tumor antigen described herein include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases associated with expression of a tumor antigen as described herein. Non-cancer related indications associated with expression of a tumor antigen as described herein include, but are not limited to, e.g., autoimmune disease, (e.g., lupus), inflammatory disorders (allergy and asthma) and transplantation. In some embodiments, the tumor antigen-expressing cells express, or at any time expressed, mRNA encoding the tumor antigen. In an embodiment, the tumor antigen-expressing cells produce the tumor antigen protein (e.g., wild-type or mutant), and the tumor antigen protein may be present at normal levels or reduced levels. In an embodiment, the tumor antigen-expressing cells produced detectable levels of a tumor antigen protein at one point, and subsequently produced substantially no detectable tumor antigen protein. 
     The phrase “disease associated with expression of CD19” includes, but is not limited to, a disease associated with expression of CD19 (e.g., wild-type or mutant CD19) or condition associated with cells which express, or at any time expressed, CD19 (e.g., wild-type or mutant CD19) including, e.g., proliferative diseases such as a cancer or malignancy or a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia; or a noncancer related indication associated with cells which express CD19. For the avoidance of doubt, a disease associated with expression of CD19 may include a condition associated with cells which do not presently express CD19, e.g., because CD19 expression has been downregulated, e.g., due to treatment with a molecule targeting CD19, e.g., a CD19 CAR, but which at one time expressed CD19. In one aspect, a cancer associated with expression of CD19 is a hematological cancer. In one aspect, the hematological cancer is a leukemia or a lymphoma. In one aspect, a cancer associated with expression of CD19 includes cancers and malignancies including, but not limited to, e.g., one or more acute leukemias including but not limited to, e.g., B-cell acute Lymphoid Leukemia (BALL), T-cell acute Lymphoid Leukemia (TALL), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), Chronic Lymphoid Leukemia (CLL). Additional cancers or hematologic conditions associated with expression of CD19 comprise, but are not limited to, e.g., B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt&#39;s lymphoma, diffuse large B cell lymphoma, Follicular lymphoma, Hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and “preleukemia” which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further diseases associated with expression of CD19 expression include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases associated with expression of CD19. Non-cancer related indications associated with expression of CD19 include, but are not limited to, e.g., autoimmune disease, (e.g., lupus), inflammatory disorders (allergy and asthma) and transplantation. In some embodiments, the CD19-expressing cells express, or at any time expressed, CD19 mRNA. In an embodiment, the CD19-expressing cells produce a CD19 protein (e.g., wild-type or mutant), and the CD19 protein may be present at normal levels or reduced levels. In an embodiment, the CD19-expressing cells produced detectable levels of a CD19 protein at one point, and subsequently produced substantially no detectable CD19 protein. 
     The term “disease associated with expression of a target CAR” as used herein includes but is not limited to a disease associated with expression of a target CAR, e.g., a target CAR as described herein, e.g., a CD19 CAR, or condition associated with cells which express a target CAR, e.g., a target CAR as described herein, e.g., a CD19 CAR, including, e.g., proliferative diseases such as a cancer or malignancy, a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia; or a noncancer related indication, e.g., B cell aplasia, associated with cells which express the target CAR. In one aspect, a disease associated with a target CAR, e.g., a target CAR described herein, is a solid cancer, e.g., a solid cancer described herein. In one aspect, a disease associated with a target CAR, e.g., a CD19 CAR, is a hematological cancer. In one aspect, the hematological cancer is a leukemia or a lymphoma. In one aspect, a disease associated with expression of a target CAR, e.g., a CD19 CAR, includes cancers and malignancies including, but not limited to, e.g., one or more acute leukemias including but not limited to, e.g., B-cell acute Lymphoid Leukemia (BALL), T-cell acute Lymphoid Leukemia (TALL), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), Chronic Lymphoid Leukemia (CLL). Additional cancers or hematologic conditions associated with expression of CD19 comprise, but are not limited to, e.g., B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt&#39;s lymphoma, diffuse large B cell lymphoma, Follicular lymphoma, Hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma (MCL), Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and “preleukemia” which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further diseases associated with expression of a target CAR, e.g., a CD19 CAR, include, but are not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases. Non-cancer related indications associated with expression of a target CAR, e.g., a CD19 CAR, include, but are not limited to, e.g., immune-related disorder, e.g., B cell aplasia; autoimmune disease, (e.g., lupus); inflammatory disorders (allergy and asthma) and transplantation. 
     The term “conservative sequence modifications” refers to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody or antibody fragment of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within a CAR of the invention can be replaced with other amino acid residues from the same side chain family and the altered CAR can be tested using the functional assays described herein. 
     The term “stimulation,” refers to a primary response induced by binding of a stimulatory molecule (e.g., a TCR/CD3 complex or CAR) with its cognate ligand (or tumor antigen in the case of a CAR) thereby mediating a signal transduction event, such as, but not limited to, signal transduction via the TCR/CD3 complex or signal transduction via the appropriate NK receptor or signaling domains of the CAR. Stimulation can mediate altered expression of certain molecules. 
     The term “stimulatory molecule,” refers to a molecule expressed by an immune cell (e.g., T cell, NK cell, B cell) that provides the cytoplasmic signaling sequence(s) that regulate activation of the immune cell in a stimulatory way for at least some aspect of the immune cell signaling pathway. In one aspect, the signal is a primary signal that is initiated by, for instance, binding of a TCR/CD3 complex with an MHC molecule loaded with peptide, and which leads to mediation of a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like. A primary cytoplasmic signaling sequence (also referred to as a “primary signaling domain”) that acts in a stimulatory manner may contain a signaling motif which is known as immunoreceptor tyrosine-based activation motif or ITAM. Examples of an ITAM containing cytoplasmic signaling sequence that is of particular use in the invention includes, but is not limited to, those derived from CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc Epsilon Rib), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12. In a specific CAR of the invention, the intracellular signaling domain in any one or more CARS of the invention comprises an intracellular signaling sequence, e.g., a primary signaling sequence of CD3-zeta. In a specific CAR of the invention, the primary signaling sequence of CD3-zeta is the sequence provided as SEQ ID NO:18, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. In a specific CAR of the invention, the primary signaling sequence of CD3-zeta is the sequence as provided in SEQ ID NO:20, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. 
     The term “antigen presenting cell” or “APC” refers to an immune system cell such as an accessory cell (e.g., a B-cell, a dendritic cell, and the like) that displays a foreign antigen complexed with major histocompatibility complexes (MHC&#39;s) on its surface. T-cells may recognize these complexes using their T-cell receptors (TCRs). APCs process antigens and present them to T-cells. 
     An “intracellular signaling domain,” as the term is used herein, refers to an intracellular portion of a molecule. The intracellular signaling domain generates a signal that promotes an immune effector function of the CAR containing cell, e.g., a CART cell. Examples of immune effector function, e.g., in a CART cell, include cytolytic activity and helper activity, including the secretion of cytokines. 
     In an embodiment, the intracellular signaling domain can comprise a primary intracellular signaling domain. Exemplary primary intracellular signaling domains include those derived from the molecules responsible for primary stimulation, or antigen dependent simulation. In an embodiment, the intracellular signaling domain can comprise a costimulatory intracellular domain. Exemplary costimulatory intracellular signaling domains include those derived from molecules responsible for costimulatory signals, or antigen independent stimulation. For example, in the case of a CART, a primary intracellular signaling domain can comprise a cytoplasmic sequence of a T cell receptor, and a costimulatory intracellular signaling domain can comprise cytoplasmic sequence from co-receptor or costimulatory molecule. 
     A primary intracellular signaling domain can comprise a signaling motif which is known as an immunoreceptor tyrosine-based activation motif or ITAM. Examples of ITAM containing primary cytoplasmic signaling sequences include, but are not limited to, those derived from CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc Epsilon Rib), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12. 
     The term “zeta” or alternatively “zeta chain”, “CD3-zeta” or “TCR-zeta” is defined as the protein provided as GenBank Acc. No. BAG36664.1, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like, and a “zeta stimulatory domain” or alternatively a “CD3-zeta stimulatory domain” or a “TCR-zeta stimulatory domain” is defined as the amino acid residues from the cytoplasmic domain of the zeta chain, or functional derivatives thereof, that are sufficient to functionally transmit an initial signal necessary for T cell activation. In one aspect the cytoplasmic domain of zeta comprises residues 52 through 164 of GenBank Acc. No. BAG36664.1 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like, that are functional orthologs thereof. In one aspect, the “zeta stimulatory domain” or a “CD3-zeta stimulatory domain” is the sequence provided as SEQ ID NO:18. In one aspect, the “zeta stimulatory domain” or a “CD3-zeta stimulatory domain” is the sequence provided as SEQ ID NO:20. 
     The term a “costimulatory molecule” refers to a cognate binding partner on a T cell that specifically binds with a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that are contribute to an efficient immune response. Costimulatory molecules include, but are not limited to an MHC class I molecule, BTLA and a Toll ligand receptor, as well as OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), and 4-1BB (CD137). Further examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83. 
     A costimulatory intracellular signaling domain can be the intracellular portion of a costimulatory molecule. A costimulatory molecule can be represented in the following protein families: TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), and activating NK cell receptors. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, GITR, CD30, CD40, ICOS, BAFFR, HVEM, ICAM-1, lymphocyte function-associated antigen-1 (LFA-1), CD2, CDS, CD7, CD287, LIGHT, NKG2C, NKG2D, SLAMF7, NKp80, NKp30, NKp44, NKp46, CD160, B7-H3, and a ligand that specifically binds with CD83, and the like. 
     The intracellular signaling domain can comprise the entire intracellular portion, or the entire native intracellular signaling domain, of the molecule from which it is derived, or a functional fragment or derivative thereof. 
     The term “4-1BB” refers to a member of the TNFR superfamily with an amino acid sequence provided as GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like; and a “4-1BB costimulatory domain” is defined as amino acid residues 214-255 of GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. In one aspect, the “4-1BB costimulatory domain” is the sequence provided as SEQ ID NO:14 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape and the like. 
     “Immune effector cell,” as that term is used herein, refers to a cell that is involved in an immune response, e.g., in the promotion of an immune effector response. Examples of immune effector cells include T cells, e.g., alpha/beta T cells and gamma/delta T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and myeloid-derived phagocytes. 
     “Immune effector function or immune effector response,” as that term is used herein, refers to function or response, e.g., of an immune effector cell, that enhances or promotes an immune attack of a target cell. E.g., an immune effector function or response refers a property of a T or NK cell that promotes killing or the inhibition of growth or proliferation, of a target cell. In the case of a T cell, primary stimulation and co-stimulation are examples of immune effector function or response. 
     The term “encoding” refers to the inherent property of specific sequences of nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as templates for synthesis of other polymers and macromolecules in biological processes having either a defined sequence of nucleotides (e.g., rRNA, tRNA and mRNA) or a defined sequence of amino acids and the biological properties resulting therefrom. Thus, a gene, cDNA, or RNA, encodes a protein if transcription and translation of mRNA corresponding to that gene produces the protein in a cell or other biological system. Both the coding strand, the nucleotide sequence of which is identical to the mRNA sequence and is usually provided in sequence listings, and the non-coding strand, used as the template for transcription of a gene or cDNA, can be referred to as encoding the protein or other product of that gene or cDNA. 
     Unless otherwise specified, a “nucleotide sequence encoding an amino acid sequence” includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The phrase nucleotide sequence that encodes a protein or a RNA may also include introns to the extent that the nucleotide sequence encoding the protein may in some version contain an intron(s). 
     The term “effective amount” or “therapeutically effective amount” are used interchangeably herein, and refer to an amount of a compound, formulation, material, or composition, as described herein effective to achieve a particular biological result. 
     The term “endogenous” refers to any material from or produced inside an organism, cell, tissue or system. 
     The term “exogenous” refers to any material introduced from or produced outside an organism, cell, tissue or system. 
     The term “expression” refers to the transcription and/or translation of a particular nucleotide sequence driven by a promoter. 
     The term “transfer vector” refers to a composition of matter which comprises an isolated nucleic acid and which can be used to deliver the isolated nucleic acid to the interior of a cell. Numerous vectors are known in the art including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term “transfer vector” includes an autonomously replicating plasmid or a virus. The term should also be construed to further include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells, such as, for example, a polylysine compound, liposome, and the like. Examples of viral transfer vectors include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, retroviral vectors, lentiviral vectors, and the like. 
     The term “expression vector” refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operatively linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide. 
     The term “lentivirus” refers to a genus of the Retroviridae family Lentiviruses are unique among the retroviruses in being able to infect non-dividing cells; they can deliver a significant amount of genetic information into the DNA of the host cell, so they are one of the most efficient methods of a gene delivery vector. HIV, SIV, and FIV are all examples of lentiviruses. 
     The term “lentiviral vector” refers to a vector derived from at least a portion of a lentivirus genome, including especially a self-inactivating lentiviral vector as provided in Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). Other examples of lentivirus vectors that may be used in the clinic, include but are not limited to, e.g., the LENTIVECTOR® gene delivery technology from Oxford BioMedica, the LENTIMAX™ vector system from Lentigen and the like. Nonclinical types of lentiviral vectors are also available and would be known to one skilled in the art. 
     The term “homologous” or “identity” refers to the subunit sequence identity between two polymeric molecules, e.g., between two nucleic acid molecules, such as, two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit; e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous or identical at that position. The homology between two sequences is a direct function of the number of matching or homologous positions; e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 of 10), are matched or homologous, the two sequences are 90% homologous. 
     “Humanized” forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies and antibody fragments thereof are human immunoglobulins (recipient antibody or antibody fragment) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, a humanized antibody/antibody fragment can comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications can further refine and optimize antibody or antibody fragment performance In general, the humanized antibody or antibody fragment thereof will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or a significant portion of the FR regions are those of a human immunoglobulin sequence. The humanized antibody or antibody fragment can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321: 522-525, 1986; Reichmann et al., Nature, 332: 323-329, 1988; Presta, Curr. Op. Struct. Biol., 2: 593-596, 1992. 
     “Fully human” refers to an immunoglobulin, such as an antibody or antibody fragment, where the whole molecule is of human origin or consists of an amino acid sequence identical to a human form of the antibody or immunoglobulin. 
     The term “isolated” means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not “isolated,” but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated.” An isolated nucleic acid or protein can exist in substantially purified form, or can exist in a non-native environment such as, for example, a host cell. 
     In the context of the present invention, the following abbreviations for the commonly occurring nucleic acid bases are used. “A” refers to adenosine, “C” refers to cytosine, “G” refers to guanosine, “T” refers to thymidine, and “U” refers to uridine. 
     The term “operably linked” or “transcriptional control” refers to functional linkage between a regulatory sequence and a heterologous nucleic acid sequence resulting in expression of the latter. For example, a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences can be contiguous with each other and, e.g., where necessary to join two protein coding regions, are in the same reading frame. 
     The term “parenteral” administration of an immunogenic composition includes, e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), or intrasternal injection, intratumoral, or infusion techniques. 
     The term “nucleic acid” or “polynucleotide” refers to deoxyribonucleic acids (DNA) or ribonucleic acids (RNA) and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). 
     The terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein&#39;s or peptide&#39;s sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. A polypeptide includes a natural peptide, a recombinant peptide, or a combination thereof. 
     The term “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a polynucleotide sequence. 
     The term “promoter/regulatory sequence” refers to a nucleic acid sequence which is required for expression of a gene product operably linked to the promoter/regulatory sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene product. The promoter/regulatory sequence may, for example, be one which expresses the gene product in a tissue specific manner. 
     The term “constitutive” promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell. 
     The term “inducible” promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide which encodes or specifies a gene product, causes the gene product to be produced in a cell substantially only when an inducer which corresponds to the promoter is present in the cell. 
     The term “tissue-specific” promoter refers to a nucleotide sequence which, when operably linked with a polynucleotide encodes or specified by a gene, causes the gene product to be produced in a cell substantially only if the cell is a cell of the tissue type corresponding to the promoter. 
     The terms “cancer associated antigen” or “tumor antigen” interchangeably refers to a molecule (typically a protein, carbohydrate or lipid) that is expressed on the surface of a cancer cell, either entirely or as a fragment (e.g., MHC/peptide), and which is useful for the preferential targeting of a pharmacological agent to the cancer cell. In some embodiments, a tumor antigen is a marker expressed by both normal cells and cancer cells, e.g., a lineage marker, e.g., CD19 on B cells. In some embodiments, a tumor antigen is a cell surface molecule that is overexpressed in a cancer cell in comparison to a normal cell, for instance, 1-fold over expression, 2-fold overexpression, 3-fold overexpression or more in comparison to a normal cell. In some embodiments, a tumor antigen is a cell surface molecule that is inappropriately synthesized in the cancer cell, for instance, a molecule that contains deletions, additions or mutations in comparison to the molecule expressed on a normal cell. In some embodiments, a tumor antigen will be expressed exclusively on the cell surface of a cancer cell, entirely or as a fragment (e.g., MHC/peptide), and not synthesized or expressed on the surface of a normal cell. In some embodiments, the CARs of the present invention includes CARs comprising an antigen binding domain (e.g., antibody or antibody fragment) that binds to a MHC presented peptide. Normally, peptides derived from endogenous proteins fill the pockets of Major histocompatibility complex (MHC) class I molecules, and are recognized by T cell receptors (TCRs) on CD8+T lymphocytes. The MHC class I complexes are constitutively expressed by all nucleated cells. In cancer, virus-specific and/or tumor-specific peptide/MHC complexes represent a unique class of cell surface targets for immunotherapy. TCR-like antibodies targeting peptides derived from viral or tumor antigens in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 have been described (see, e.g., Sastry et al., J Virol. 2011 85(5):1935-1942; Sergeeva et al., Blood, 2011 117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 2001 8(21):1601-1608; Dao et al., Sci Transl Med 2013 5(176):176ra33; Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example, TCR-like antibody can be identified from screening a library, such as a human scFv phage displayed library. 
     The term “tumor-supporting antigen” or “cancer-supporting antigen” interchangeably refer to a molecule (typically a protein, carbohydrate or lipid) that is expressed on the surface of a cell that is, itself, not cancerous, but supports the cancer cells, e.g., by promoting their growth or survival e.g., resistance to immune cells. Exemplary cells of this type include stromal cells and myeloid-derived suppressor cells (MDSCs). The tumor-supporting antigen itself need not play a role in supporting the tumor cells so long as the antigen is present on a cell that supports cancer cells. 
     The term “flexible polypeptide linker” or “linker” as used in the context of a scFv refers to a peptide linker that consists of amino acids such as glycine and/or serine residues used alone or in combination, to link variable heavy and variable light chain regions together. In one embodiment, the flexible polypeptide linker is a Gly/Ser linker and comprises the amino acid sequence (Gly-Gly-Gly-Ser) n , where n is a positive integer equal to or greater than 1. For example, n=1, n=2, n=3. n=4, n=5 and n=6, n=7, n=8, n=9 and n=10 (SEQ ID NO:28). In one embodiment, the flexible polypeptide linkers include, but are not limited to, (Gly 4  Ser) 4  (SEQ ID NO:29) or (Gly 4  Ser) 3  (SEQ ID NO:30). In another embodiment, the linkers include multiple repeats of (Gly 2 Ser), (GlySer) or (Gly 3 Ser) (SEQ ID NO:31). Also included within the scope of the invention are linkers described in WO2012/138475, incorporated herein by reference). 
     As used herein, a 5′ cap (also termed an RNA cap, an RNA 7-methylguanosine cap or an RNA m 7 G cap) is a modified guanine nucleotide that has been added to the “front” or 5′ end of a eukaryotic messenger RNA shortly after the start of transcription. The 5′ cap consists of a terminal group which is linked to the first transcribed nucleotide. Its presence is critical for recognition by the ribosome and protection from RNases. Cap addition is coupled to transcription, and occurs co-transcriptionally, such that each influences the other. Shortly after the start of transcription, the 5′ end of the mRNA being synthesized is bound by a cap-synthesizing complex associated with RNA polymerase. This enzymatic complex catalyzes the chemical reactions that are required for mRNA capping. Synthesis proceeds as a multi-step biochemical reaction. The capping moiety can be modified to modulate functionality of mRNA such as its stability or efficiency of translation. 
     As used herein, “in vitro transcribed RNA” refers to RNA, preferably mRNA, that has been synthesized in vitro. Generally, the in vitro transcribed RNA is generated from an in vitro transcription vector. The in vitro transcription vector comprises a template that is used to generate the in vitro transcribed RNA. 
     As used herein, a “poly(A)” is a series of adenosines attached by polyadenylation to the mRNA. In the preferred embodiment of a construct for transient expression, the polyA is between 50 and 5000 (SEQ ID NO: 34), preferably greater than 64, more preferably greater than 100, most preferably greater than 300 or 400. poly(A) sequences can be modified chemically or enzymatically to modulate mRNA functionality such as localization, stability or efficiency of translation. 
     As used herein, “polyadenylation” refers to the covalent linkage of a polyadenylyl moiety, or its modified variant, to a messenger RNA molecule. In eukaryotic organisms, most messenger RNA (mRNA) molecules are polyadenylated at the 3′ end. The 3′ poly(A) tail is a long sequence of adenine nucleotides (often several hundred) added to the pre-mRNA through the action of an enzyme, polyadenylate polymerase. In higher eukaryotes, the poly(A) tail is added onto transcripts that contain a specific sequence, the polyadenylation signal. The poly(A) tail and the protein bound to it aid in protecting mRNA from degradation by exonucleases. Polyadenylation is also important for transcription termination, export of the mRNA from the nucleus, and translation. Polyadenylation occurs in the nucleus immediately after transcription of DNA into RNA, but additionally can also occur later in the cytoplasm. After transcription has been terminated, the mRNA chain is cleaved through the action of an endonuclease complex associated with RNA polymerase. The cleavage site is usually characterized by the presence of the base sequence AAUAAA near the cleavage site. After the mRNA has been cleaved, adenosine residues are added to the free 3′ end at the cleavage site. 
     As used herein, “transient” refers to expression of a non-integrated transgene for a period of hours, days or weeks, wherein the period of time of expression is less than the period of time for expression of the gene if integrated into the genome or contained within a stable plasmid replicon in the host cell. 
     As used herein, the terms “treat”, “treatment” and “treating” refer to the reduction or amelioration of the progression, severity and/or duration of a proliferative disorder, or the amelioration of one or more symptoms (preferably, one or more discernible symptoms) of a proliferative disorder resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a CAR of the invention). In specific embodiments, the terms “treat”, “treatment” and “treating” refer to the amelioration of at least one measurable physical parameter of a proliferative disorder, such as growth of a tumor, not necessarily discernible by the patient. In other embodiments the terms “treat”, “treatment” and “treating”-refer to the inhibition of the progression of a proliferative disorder, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both. In other embodiments the terms “treat”, “treatment” and “treating” refer to the reduction or stabilization of tumor size or cancerous cell count. 
     The term “signal transduction pathway” refers to the biochemical relationship between a variety of signal transduction molecules that play a role in the transmission of a signal from one portion of a cell to another portion of a cell. The phrase “cell surface receptor” includes molecules and complexes of molecules capable of receiving a signal and transmitting signal across the membrane of a cell. 
     The term “subject” is intended to include living organisms in which an immune response can be elicited “(e.g., mammals, human)” The term, a “substantially purified” cell refers to a cell that is essentially free of other cell types. A substantially purified cell also refers to a cell which has been separated from other cell types with which it is normally associated in its naturally occurring state. In some instances, a population of substantially purified cells refers to a homogenous population of cells. In other instances, this term refers simply to cell that have been separated from the cells with which they are naturally associated in their natural state. In some aspects, the cells are cultured in vitro. In other aspects, the cells are not cultured in vitro. 
     The term “therapeutic” as used herein means a treatment. A therapeutic effect is obtained by reduction, suppression, remission, or eradication of a disease state. 
     The term “prophylaxis” as used herein means the prevention of or protective treatment for a disease or disease state. 
     In the context of the present invention, “tumor antigen” or “hyperproliferative disorder antigen” or “antigen associated with a hyperproliferative disorder” refers to antigens that are common to specific hyperproliferative disorders. In certain aspects, the hyperproliferative disorder antigens of the present invention are derived from, cancers including but not limited to primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, leukemias, uterine cancer, cervical cancer, bladder cancer, kidney cancer and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and the like. 
     The term “transfected” or “transformed” or “transduced” refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A “transfected” or “transformed” or “transduced” cell is one which has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny. 
     The term “specifically binds,” refers to an antibody, or a ligand, which recognizes and binds with a binding partner (e.g., a tumor antigen) protein present in a sample, but which antibody or ligand does not substantially recognize or bind other molecules in the sample. 
     “Regulatable chimeric antigen receptor (RCAR),” as that term is used herein, refers to a set of polypeptides, typically two in the simplest embodiments, which when in a RCARX cell, provides the RCARX cell with specificity for a target cell, typically a cancer cell, and with regulatable intracellular signal generation or proliferation, which can optimize an immune effector property of the RCARX cell. An RCARX cell relies at least in part, on an antigen binding domain to provide specificity to a target cell that comprises the antigen bound by the antigen binding domain. In an embodiment, an RCAR includes a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to the antigen binding domain. 
     “Membrane anchor” or “membrane tethering domain”, as that term is used herein, refers to a polypeptide or moiety, e.g., a myristoyl group, sufficient to anchor an extracellular or intracellular domain to the plasma membrane. 
     “Switch domain,” as that term is used herein, e.g., when referring to an RCAR, refers to an entity, typically a polypeptide-based entity, that, in the presence of a dimerization molecule, associates with another switch domain. The association results in a functional coupling of a first entity linked to, e.g., fused to, a first switch domain, and a second entity linked to, e.g., fused to, a second switch domain. A first and second switch domain are collectively referred to as a dimerization switch. In embodiments, the first and second switch domains are the same as one another, e.g., they are polypeptides having the same primary amino acid sequence, and are referred to collectively as a homodimerization switch. In embodiments, the first and second switch domains are different from one another, e.g., they are polypeptides having different primary amino acid sequences, and are referred to collectively as a heterodimerization switch. In embodiments, the switch is intracellular. In embodiments, the switch is extracellular. In embodiments, the switch domain is a polypeptide-based entity, e.g., FKBP or FRB-based, and the dimerization molecule is small molecule, e.g., a rapalogue. In embodiments, the switch domain is a polypeptide-based entity, e.g., an scFv that binds a myc peptide, and the dimerization molecule is a polypeptide, a fragment thereof, or a multimer of a polypeptide, e.g., a myc ligand or multimers of a myc ligand that bind to one or more myc scFvs. In embodiments, the switch domain is a polypeptide-based entity, e.g., myc receptor, and the dimerization molecule is an antibody or fragments thereof, e.g., myc antibody. 
     “Dimerization molecule,” as that term is used herein, e.g., when referring to an RCAR, refers to a molecule that promotes the association of a first switch domain with a second switch domain. In embodiments, the dimerization molecule does not naturally occur in the subject, or does not occur in concentrations that would result in significant dimerization. In embodiments, the dimerization molecule is a small molecule, e.g., rapamycin or a rapalogue, e.g., RAD001. 
     The term “bioequivalent” refers to an amount of an agent other than the reference compound (e.g., RAD001), required to produce an effect equivalent to the effect produced by the reference dose or reference amount of the reference compound (e.g., RAD001). In an embodiment the effect is the level of mTOR inhibition, e.g., as measured by P70 S6 kinase inhibition, e.g., as evaluated in an in vivo or in vitro assay, e.g., as measured by an assay described herein, e.g., the Boulay assay. In an embodiment, the effect is alteration of the ratio of PD-1 positive/PD-1 negative T cells, as measured by cell sorting. In an embodiment a bioequivalent amount or dose of an mTOR inhibitor is the amount or dose that achieves the same level of P70 S6 kinase inhibition as does the reference dose or reference amount of a reference compound. In an embodiment, a bioequivalent amount or dose of an mTOR inhibitor is the amount or dose that achieves the same level of alteration in the ratio of PD-1 positive/PD-1 negative T cells as does the reference dose or reference amount of a reference compound. 
     The term “low, immune enhancing, dose” when used in conjunction with an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., RAD001 or rapamycin, or a catalytic mTOR inhibitor, refers to a dose of mTOR inhibitor that partially, but not fully, inhibits mTOR activity, e.g., as measured by the inhibition of P70 S6 kinase activity. Methods for evaluating mTOR activity, e.g., by inhibition of P70 S6 kinase, are discussed herein. The dose is insufficient to result in complete immune suppression but is sufficient to enhance the immune response. In an embodiment, the low, immune enhancing, dose of mTOR inhibitor results in a decrease in the number of PD-1 positive T cells and/or an increase in the number of PD-1 negative T cells, or an increase in the ratio of PD-1 negative T cells/PD-1 positive T cells. In an embodiment, the low, immune enhancing, dose of mTOR inhibitor results in an increase in the number of naive T cells. In an embodiment, the low, immune enhancing, dose of mTOR inhibitor results in one or more of the following: 
     an increase in the expression of one or more of the following markers: CD62L high , CD127 high , CD27 + , and BCL2, e.g., on memory T cells, e.g., memory T cell precursors; 
     a decrease in the expression of KLRG1, e.g., on memory T cells, e.g., memory T cell precursors; and 
     an increase in the number of memory T cell precursors, e.g., cells with any one or combination of the following characteristics: increased CD62 high , increased CD127 high , increased CD27 + , decreased KLRG1, and increased BCL2; 
     wherein any of the changes described above occurs, e.g., at least transiently, e.g., as compared to a non-treated subject. 
     “Refractory” as used herein refers to a disease, e.g., cancer, that does not respond to a treatment. In embodiments, a refractory cancer can be resistant to a treatment before or at the beginning of the treatment. In other embodiments, the refractory cancer can become resistant during a treatment. A refractory cancer is also called a resistant cancer. 
     “Relapsed” as used herein refers to the return of a disease (e.g., cancer) or the signs and symptoms of a disease such as cancer after a period of improvement, e.g., after prior treatment of a therapy, e.g., cancer therapy 
     Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity, includes something with 95%, 96%, 97%, 98% or 99% identity, and includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98% and 98-99% identity. This applies regardless of the breadth of the range. 
     DESCRIPTION 
     Provided herein are compositions of matter and methods of use for the treatment of a disease associated with expression of a target CAR using immune effector cells (e.g., T cells, NK cells) engineered with anti-target CARs of the invention. 
     In one aspect, the invention provides a number of chimeric antigen receptors (CAR) comprising an antigen binding domain (e.g., antibody or antibody fragment, TCR or TCR fragment) engineered for specific binding to a tumor antigen, e.g., a tumor antigen described herein. In one aspect, the invention provides an immune effector cell (e.g., T cell, NK cell) engineered to express a CAR, wherein the engineered immune effector cell exhibits an anticancer property. In one aspect, a cell is transformed with the CAR and the CAR is expressed on the cell surface. In some embodiments, the cell (e.g., T cell, NK cell) is transduced with a viral vector encoding a CAR. In some embodiments, the viral vector is a retroviral vector. In some embodiments, the viral vector is a lentiviral vector. In some such embodiments, the cell may stably express the CAR. In another embodiment, the cell (e.g., T cell, NK cell) is transfected with a nucleic acid, e.g., mRNA, cDNA, DNA, encoding a CAR. In some such embodiments, the cell may transiently express the CAR. 
     In one aspect, the antigen binding domain of a CAR described herein is a scFv antibody fragment. In one aspect, such antibody fragments are functional in that they retain the equivalent binding affinity, e.g., they bind the same antigen with comparable affinity, as the IgG antibody from which it is derived. In other embodiments, the antibody fragment has a lower binding affinity, e.g., it binds the same antigen with a lower binding affinity than the antibody from which it is derived, but is functional in that it provides a biological response described herein. In one embodiment, the CAR molecule comprises an antibody fragment that has a binding affinity KD of 10 −4  M to 10 −8  M, e.g., 10 −5  M to 10 −7  M, e.g., 10 −6  M or 10 −7  M, for the target antigen. In one embodiment, the antibody fragment has a binding affinity that is at least five-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold or 1,000-fold less than a reference antibody, e.g., an antibody described herein. 
     In one aspect such antibody fragments are functional in that they provide a biological response that can include, but is not limited to, activation of an immune response, inhibition of signal-transduction origination from its target antigen, inhibition of kinase activity, and the like, as will be understood by a skilled artisan. 
     In one aspect, the antigen binding domain of the CAR is a scFv antibody fragment that is humanized compared to the murine sequence of the scFv from which it is derived. 
     In one aspect, the antigen binding domain of a CAR of the invention (e.g., a scFv) is encoded by a nucleic acid molecule whose sequence has been codon optimized for expression in a mammalian cell. In one aspect, entire CAR construct of the invention is encoded by a nucleic acid molecule whose entire sequence has been codon optimized for expression in a mammalian cell. Codon optimization refers to the discovery that the frequency of occurrence of synonymous codons (i.e., codons that code for the same amino acid) in coding DNA is biased in different species. Such codon degeneracy allows an identical polypeptide to be encoded by a variety of nucleotide sequences. A variety of codon optimization methods is known in the art, and include, e.g., methods disclosed in at least U.S. Pat. Nos. 5,786,464 and 6,114,148. 
     In one aspect, the CARs of the invention combine an antigen binding domain of a specific antibody with an intracellular signaling molecule. For example, in some aspects, the intracellular signaling molecule includes, but is not limited to, CD3-zeta chain, 4-1BB and CD28 signaling modules and combinations thereof. In one aspect, the antigen binding domain binds to a tumor antigen as described herein. 
     Furthermore, the present invention provides CARs and CAR-expressing cells and their use in medicaments or methods for treating, among other diseases, cancer or any malignancy or autoimmune diseases involving cells or tissues which express a tumor antigen as described herein. 
     In one aspect, the CAR of the invention can be used to eradicate a normal cell that express a tumor antigen as described herein, thereby applicable for use as a cellular conditioning therapy prior to cell transplantation. In one aspect, the normal cell that expresses a tumor antigen as described herein is a normal stem cell and the cell transplantation is a stem cell transplantation. 
     In one aspect, the invention provides an immune effector cell (e.g., T cell, NK cell) engineered to express a chimeric antigen receptor (CAR), wherein the engineered immune effector cell exhibits an antitumor property. A preferred antigen is a cancer associated antigen (i.e., tumor antigen) described herein. In one aspect, the antigen binding domain of the CAR comprises a partially humanized antibody fragment. In one aspect, the antigen binding domain of the CAR comprises a partially humanized scFv. Accordingly, the invention provides CARs that comprises a humanized antigen binding domain and is engineered into a cell, e.g., a T cell or a NK cell, and methods of their use for adoptive therapy. 
     In one aspect, the CARs of the invention comprise at least one intracellular domain selected from the group of a CD137 (4-1BB) signaling domain, a CD28 signaling domain, a CD27 signal domain, a CD3zeta signal domain, and any combination thereof. In one aspect, the CARs of the invention comprise at least one intracellular signaling domain is from one or more costimulatory molecule(s) other than a CD137 (4-1BB) or CD28. 
     Sequences of some examples of various components of CARs of the instant invention is listed in Table 1, where aa stands for amino acids, and na stands for nucleic acids that encode the corresponding peptide. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Sequences of various components of CAR (aa - amino acids, na - nucleic acids 
               
               
                 that encodes the corresponding protein) 
               
            
           
           
               
               
               
               
            
               
                 SEQ 
                   
                   
                 Corresp. 
               
               
                 ID 
                   
                   
                 To 
               
               
                 NO 
                 description 
                 Sequence 
                 huCD19 
               
               
                   
               
            
           
           
               
               
               
               
            
               
                 400 
                 EF-1 
                 CGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCAC 
                 100 
               
               
                   
                 promoter 
                 ATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTC 
                   
               
               
                   
                   
                 GGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGG 
                   
               
               
                   
                   
                 TAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTT 
                   
               
               
                   
                   
                 TTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAG 
                   
               
               
                   
                   
                 TAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCC 
                   
               
               
                   
                   
                 GCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCG 
                   
               
               
                   
                   
                 GGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCT 
                   
               
               
                   
                   
                 TGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGA 
                   
               
               
                   
                   
                 TCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCG 
                   
               
               
                   
                   
                 AGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTG 
                   
               
               
                   
                   
                 AGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTG 
                   
               
               
                   
                   
                 CGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTT 
                   
               
               
                   
                   
                 CGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTG 
                   
               
               
                   
                   
                 CTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAAT 
                   
               
               
                   
                   
                 GCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGG 
                   
               
               
                   
                   
                 GGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGC 
                   
               
               
                   
                   
                 ACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCAC 
                   
               
               
                   
                   
                 CGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCC 
                   
               
               
                   
                   
                 TGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCC 
                   
               
               
                   
                   
                 CGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGT 
                   
               
               
                   
                   
                 TGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTG 
                   
               
               
                   
                   
                 CAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGA 
                   
               
               
                   
                   
                 GCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCC 
                   
               
               
                   
                   
                 TTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGA 
                   
               
               
                   
                   
                 GTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGA 
                   
               
               
                   
                   
                 GCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGG 
                   
               
               
                   
                   
                 TTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGA 
                   
               
               
                   
                   
                 GACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCT 
                   
               
               
                   
                   
                 CCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCA 
                   
               
               
                   
                   
                 TTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTC 
                   
               
               
                   
                   
                 CATTTCAGGTGTCGTGA 
                   
               
               
                   
               
               
                 401 
                 Leader (aa) 
                 MALPVTALLLPLALLLHAARP 
                 13 
               
               
                   
               
               
                 402 
                 Leader (na) 
                 ATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGC 
                 54 
               
               
                   
                   
                 TCTGCTGCTGCATGCCGCTAGACCC 
                   
               
               
                   
               
               
                 403 
                 CD 8 hinge 
                 TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLD 
                 14 
               
               
                   
                 (aa) 
                 FACD 
                   
               
               
                   
               
               
                 404 
                 CD8 hinge 
                 ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGC 
                 55 
               
               
                   
                 (na) 
                 CCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAG 
                   
               
               
                   
                   
                 GCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGA 
                   
               
               
                   
                   
                 GGGGGCTGGACTTCGCCTGTGAT 
                   
               
               
                   
               
               
                 405 
                 Ig4 hinge (aa) 
                 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV 
                 102 
               
               
                   
                   
                 TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN 
                   
               
               
                   
                   
                 STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI 
                   
               
               
                   
                   
                 SKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS 
                   
               
               
                   
                   
                 DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKS 
                   
               
               
                   
                   
                 RWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKM 
                   
               
               
                   
               
               
                 406 
                 Ig4 hinge 
                 GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGC 
                 103 
               
               
                   
                 (na) 
                 CCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCC 
                   
               
               
                   
                   
                 CCCCCAAGCCCAAGGACACCCTGATGATCAGCCGGAC 
                   
               
               
                   
                   
                 CCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAGG 
                   
               
               
                   
                   
                 AGGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGG 
                   
               
               
                   
                   
                 CGTGGAGGTGCACAACGCCAAGACCAAGCCCCGGGAG 
                   
               
               
                   
                   
                 GAGCAGTTCAATAGCACCTACCGGGTGGTGTCCGTGCT 
                   
               
               
                   
                   
                 GACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAA 
                   
               
               
                   
                   
                 TACAAGTGTAAGGTGTCCAACAAGGGCCTGCCCAGCA 
                   
               
               
                   
                   
                 GCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCC 
                   
               
               
                   
                   
                 TCGGGAGCCCCAGGTGTACACCCTGCCCCCTAGCCAAG 
                   
               
               
                   
                   
                 AGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCT 
                   
               
               
                   
                   
                 GGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAG 
                   
               
               
                   
                   
                 TGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGA 
                   
               
               
                   
                   
                 CCACCCCCCCTGTGCTGGACAGCGACGGCAGCTTCTTC 
                   
               
               
                   
                   
                 CTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGC 
                   
               
               
                   
                   
                 AGGAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGA 
                   
               
               
                   
                   
                 GGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGC 
                   
               
               
                   
                   
                 CTGTCCCTGGGCAAGATG 
                   
               
               
                   
               
               
                 407 
                 IgD hinge 
                 RWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGR 
                 47 
               
               
                   
                 (aa) 
                 GGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPA 
                   
               
               
                   
                   
                 VQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTG 
                   
               
               
                   
                   
                 GVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLN 
                   
               
               
                   
                   
                 HPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASW 
                   
               
               
                   
                   
                 LLCEVSGFSPPNILLMWLEDQREVNTSGFAPARPPPQPGS 
                   
               
               
                   
                   
                 TTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASR 
                   
               
               
                   
                   
                 SLEVSYVTDH 
                   
               
               
                   
               
               
                 408 
                 IgD hinge 
                 AGGTGGCCCGAAAGTCCCAAGGCCCAGGCATCTAGTG 
                 48 
               
               
                   
                 (na) 
                 TTCCTACTGCACAGCCCCAGGCAGAAGGCAGCCTAGC 
                   
               
               
                   
                   
                 CAAAGCTACTACTGCACCTGCCACTACGCGCAATACTG 
                   
               
               
                   
                   
                 GCCGTGGCGGGGAGGAGAAGAAAAAGGAGAAAGAGA 
                   
               
               
                   
                   
                 AAGAAGAACAGGAAGAGAGGGAGACCAAGACCCCTG 
                   
               
               
                   
                   
                 AATGTCCATCCCATACCCAGCCGCTGGGCGTCTATCTC 
                   
               
               
                   
                   
                 TTGACTCCCGCAGTACAGGACTTGTGGCTTAGAGATAA 
                   
               
               
                   
                   
                 GGCCACCTTTACATGTTTCGTCGTGGGCTCTGACCTGA 
                   
               
               
                   
                   
                 AGGATGCCCATTTGACTTGGGAGGTTGCCGGAAAGGT 
                   
               
               
                   
                   
                 ACCCACAGGGGGGGTTGAGGAAGGGTTGCTGGAGCGC 
                   
               
               
                   
                   
                 CATTCCAATGGCTCTCAGAGCCAGCACTCAAGACTCAC 
                   
               
               
                   
                   
                 CCTTCCGAGATCCCTGTGGAACGCCGGGACCTCTGTCA 
                   
               
               
                   
                   
                 CATGTACTCTAAATCATCCTAGCCTGCCCCCACAGCGT 
                   
               
               
                   
                   
                 CTGATGGCCCTTAGAGAGCCAGCCGCCCAGGCACCAG 
                   
               
               
                   
                   
                 TTAAGCTTAGCCTGAATCTGCTCGCCAGTAGTGATCCC 
                   
               
               
                   
                   
                 CCAGAGGCCGCCAGCTGGCTCTTATGCGAAGTGTCCGG 
                   
               
               
                   
                   
                 CTTTAGCCCGCCCAACATCTTGCTCATGTGGCTGGAGG 
                   
               
               
                   
                   
                 ACCAGCGAGAAGTGAACACCAGCGGCTTCGCTCCAGC 
                   
               
               
                   
                   
                 CCGGCCCCCACCCCAGCCGGGTTCTACCACATTCTGGG 
                   
               
               
                   
                   
                 CCTGGAGTGTCTTAAGGGTCCCAGCACCACCTAGCCCC 
                   
               
               
                   
                   
                 CAGCCAGCCACATACACCTGTGTTGTGTCCCATGAAGA 
                   
               
               
                   
                   
                 TAGCAGGACCCTGCTAAATGCTTCTAGGAGTCTGGAGG 
                   
               
               
                   
                   
                 TTTCCTACGTGACTGACCATT 
                   
               
               
                   
               
               
                 10 
                 GS 
                 GGGGSGGGGS 
                 49 
               
               
                   
                 hinge/linker 
                   
                   
               
               
                   
                 (aa) 
                   
                   
               
               
                   
               
               
                 11 
                 GS 
                 GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC 
                 50 
               
               
                   
                 hinge/linker 
                   
                   
               
               
                   
                 (na) 
                   
                   
               
               
                   
               
               
                 12 
                 CD8TM (aa) 
                 IYIWAPLAGTCGVLLLSLVITLYC 
                 15 
               
               
                   
               
               
                 13 
                 CD8 TM (na) 
                 ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGT 
                 56 
               
               
                   
                   
                 CCTTCTCCTGTCACTGGTTATCACCCTTTACTGC 
                   
               
               
                   
               
               
                 14 
                 4-1BB 
                 KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC 
                 16 
               
               
                   
                 intracellular 
                 EL 
                   
               
               
                   
                 domain (aa) 
                   
                   
               
               
                   
               
               
                 15 
                 4-1BB 
                 AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAAC 
                 60 
               
               
                   
                 intracellular 
                 AACCATTTATGAGACCAGTACAAACTACTCAAGAGGA 
                   
               
               
                   
                 domain (na) 
                 AGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAA 
                   
               
               
                   
                   
                 GGAGGATGTGAACTG 
                   
               
               
                   
               
               
                 16 
                 CD27 (aa) 
                 QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRK 
                 51 
               
               
                   
                   
                 PEPACSP 
                   
               
               
                   
               
               
                 17 
                 CD27 (na) 
                 AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACA 
                 52 
               
               
                   
                   
                 TGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAA 
                   
               
               
                   
                   
                 GCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAG 
                   
               
               
                   
                   
                 CCTATCGCTCC 
                   
               
               
                   
               
               
                 18 
                 CD3-zeta 
                 RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKR 
                 17 
               
               
                   
                 (aa) 
                 RGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM 
                   
               
               
                   
                   
                 KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
                   
               
               
                   
               
               
                 19 
                 CD3-zeta 
                 AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGT 
                 101 
               
               
                   
                 (na) 
                 ACAAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAA 
                   
               
               
                   
                   
                 TCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAG 
                   
               
               
                   
                   
                 AGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGA 
                   
               
               
                   
                   
                 GAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACT 
                   
               
               
                   
                   
                 GCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATT 
                   
               
               
                   
                   
                 GGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCAC 
                   
               
               
                   
                   
                 GATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGG 
                   
               
               
                   
                   
                 ACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCT 
                   
               
               
                   
                   
                 CGC 
                   
               
               
                   
               
               
                 20 
                 CD3-zeta 
                 RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKR 
                 43 
               
               
                   
                 (aa) 
                 RGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM 
                   
               
               
                   
                   
                 KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
                   
               
               
                   
               
               
                 21 
                 CD3-zeta 
                 AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGT 
                 44 
               
               
                   
                 (na) 
                 ACCAGCAGGGCCAG 
                   
               
               
                   
                   
                 AACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAG 
                   
               
               
                   
                   
                 AGGAGTACGATGTTT 
                   
               
               
                   
                   
                 TGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGG 
                   
               
               
                   
                   
                 AAAGCCGAGAAGGA 
                   
               
               
                   
                   
                 AGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAA 
                   
               
               
                   
                   
                 AGATAAGATGGCGG 
                   
               
               
                   
                   
                 AGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCG 
                   
               
               
                   
                   
                 GAGGGGCAAGGGGC 
                   
               
               
                   
                   
                 ACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAG 
                   
               
               
                   
                   
                 GACACCTACGACGC 
                   
               
               
                   
                   
                 CCTTCACATGCAGGCCCTGCCCCCTCGC 
                   
               
               
                   
               
               
                 22 
                 linker 
                 GGGGS 
                 18 
               
               
                   
               
               
                 23 
                 linker 
                 GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC 
                 50 
               
               
                   
               
               
                 24 
                 PD-1 
                 Pgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfvlnwyrmspsnqtdkl 
                   
               
               
                   
                 extracellular 
                 aafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgtylcgaislapkaqikeslra 
                   
               
               
                   
                 domain (aa) 
                 elrvterraevptahpspsprpagqfqtlv 
                   
               
               
                   
               
               
                 25 
                 PD-1 
                 Cccggatggtttctggactctccggatcgcccgtggaatcccccaaccttctcaccggcac 
                   
               
               
                   
                 extracellular 
                 tcttggttgtgactgagggcgataatgcgaccttcacgtgctcgttctccaacacctccgaat 
                   
               
               
                   
                 domain (na) 
                 cattcgtgctgaactggtaccgcatgagcccgtcaaaccagaccgacaagctcgccgcgt 
                   
               
               
                   
                   
                 ttccggaagatcggtcgcaaccgggacaggattgtcggttccgcgtgactcaactgccga 
                   
               
               
                   
                   
                 atggcagagacttccacatgagcgtggtccgcgctaggcgaaacgactccgggacctac 
                   
               
               
                   
                   
                 ctgtgcggagccatctcgctggcgcctaaggcccaaatcaaagagagcttgagggccga 
                   
               
               
                   
                   
                 actgagagtgaccgagcgcagagctgaggtgccaactgcacatccatccccatcgcctc 
                   
               
               
                   
                   
                 ggcctgcggggcagtttcagaccctggtc 
                   
               
               
                   
               
               
                 26 
                 PD-1 CAR 
                 Malpvtalllplalllhaarppgwfldspdrpwnpptfspallvvtegdnatftcsfsntse 
                   
               
               
                   
                 (aa) with 
                 sfvlnwyrmspsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgt 
                   
               
               
                   
                 signal 
                 ylcgaislapkaqikeslraelrvterraevptahpspsprpagqfqtlvtttpaprpptpap 
                   
               
               
                   
                   
                 tiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkll 
                   
               
               
                   
                   
                 yifkqpfmrpvqttqeedgcscrfpeeeeggceltvkfsrsadapaykqgqnqlyneln 
                   
               
               
                   
                   
                 lgrreeydvldkttgrdpemggkprrknpqeglynelqkdkmaeayseigmkgerrr 
                   
               
               
                   
                   
                 gkghdglyqglstatkdtydalhmqalppr 
                   
               
               
                   
               
               
                 27 
                 PD-1 CAR 
                 Atggccctccctgtcactgccctgcttctccccctcgcactcctgctccacgccgctagac 
                   
               
               
                   
                 (na) 
                 cacccggatggtttctggactctccggatcgcccgtggaatcccccaaccttctcaccggc 
                   
               
               
                   
                   
                 actcttggttgtgactgagggcgataatgcgaccttcacgtgctcgttctccaacacctccga 
                   
               
               
                   
                   
                 atcattcgtgctgaactggtaccgcatgagcccgtcaaaccagaccgacaagctcgccgc 
                   
               
               
                   
                   
                 gtttccggaagatcggtcgcaaccgggacaggattgtcggttccgcgtgactcaactgcc 
                   
               
               
                   
                   
                 gaatggcagagacttccacatgagcgtggtccgcgctaggcgaaacgactccgggacct 
                   
               
               
                   
                   
                 acctgtgcggagccatctcgctggcgcctaaggcccaaatcaaagagagcttgagggcc 
                   
               
               
                   
                   
                 gaactgagagtgaccgagcgcagagctgaggtgccaactgcacatccatccccatcgcc 
                   
               
               
                   
                   
                 tcggcctgcggggcagtttcagaccctggtcacgaccactccggcgccgcgcccaccga 
                   
               
               
                   
                   
                 ctccggccccaactatcgcgagccagcccctgtcgctgaggccggaagcatgccgccct 
                   
               
               
                   
                   
                 gccgccggaggtgctgtgcatacccggggattggacttcgcatgcgacatctacatttggg 
                   
               
               
                   
                   
                 ctcctctcgccggaacttgtggcgtgctccttctgtccctggtcatcaccctgtactgcaagc 
                   
               
               
                   
                   
                 ggggtcggaaaaagcttctgtacattttcaagcagcccttcatgaggcccgtgcaaaccac 
                   
               
               
                   
                   
                 ccaggaggaggacggttgctcctgccggttccccgaagaggaagaaggaggttgcgag 
                   
               
               
                   
                   
                 ctgcgcgtgaagttctcccggagcgccgacgcccccgcctataagcagggccagaacca 
                   
               
               
                   
                   
                 gctgtacaacgaactgaacctgggacggcgggaagagtacgatgtgctggacaagcgg 
                   
               
               
                   
                   
                 cgcggccgggaccccgaaatgggcgggaagcctagaagaaagaaccctcaggaaggc 
                   
               
               
                   
                   
                 ctgtataacgagctgcagaaggacaagatggccgaggcctactccgaaattgggatgaa 
                   
               
               
                   
                   
                 gggagagcggcggaggggaaaggggcacgacggcctgtaccaaggactgtccaccg 
                   
               
               
                   
                   
                 ccaccaaggacacatacgatgccctgcacatgcaggcccttccccctcgc 
                   
               
               
                   
               
               
                 28 
                 linker 
                 (Gly-Gly-Gly-Ser) n , where  n  = 1-10 
                 105 
               
               
                   
               
               
                 29 
                 linker 
                 (Gly4 Ser)4 
                 106 
               
               
                   
               
               
                 30 
                 linker 
                 (Gly4 Ser)3 
                 107 
               
               
                   
               
               
                 31 
                 linker 
                 (Gly3Ser) 
                 108 
               
               
                   
               
               
                 32 
                 polyA 
                 (aaaaaaaaaa) n , where  n  = 200 
                 118 
               
               
                   
               
               
                 33 
                 polyA 
                 (aaaaaaaaaa) n , where  n  = 15 
                 104 
               
               
                   
               
               
                 34 
                 polyA 
                 (aaaaaaaaaa) n , where  n  = 500 
                 109 
               
               
                   
               
               
                 35 
                 polyA 
                 (tttttttttt) n , where  n  = 10 
                 110 
               
               
                   
               
               
                 36 
                 polyA 
                 (tttttttttt) n , where  n  = 500 
                 111 
               
               
                   
               
               
                 37 
                 polyA 
                 (aaaaaaaaaa) n , where  n  = 500 
                 112 
               
               
                   
               
               
                 38 
                 polyA 
                 (aaaaaaaaaa) n , where  n  = 40 
                 113 
               
               
                   
               
               
                 39 
                 PD1 CAR 
                 
                   Pgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfvlnwyrmspsnqtdkl 
                 
                   
               
               
                   
                 (aa) 
                 
                   aafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgtylcgaislapkaqikeslra 
                 
                   
               
               
                   
                   
                   elrvterraevptahpspsprpagqfqtlv tttpaprpptpaptiasqplslrpeacrpaag 
                   
               
               
                   
                   
                 gavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyitkqpfmrpvqttqee 
                   
               
               
                   
                   
                 dgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrgrd 
                   
               
               
                   
                   
                 pemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyqglstatk 
                   
               
               
                   
                   
                 dtydalhmqalppr 
               
               
                   
               
            
           
         
       
     
     Cancer Associated Antigens 
     In certain aspects, the present invention provides immune effector cells (e.g., T cells, NK cells) that are engineered to contain one or more CARs that direct the immune effector cells to cancer. This is achieved through an antigen binding domain on the CAR that is specific for a cancer associated antigen. There are two classes of cancer associated antigens (tumor antigens) that can be targeted by the CARs of the instant invention: (1) cancer associated antigens that are expressed on the surface of cancer cells; and (2) cancer associated antigens that itself is intracellar, however, a fragment of such antigen (peptide) is presented on the surface of the cancer cells by MHC (major histocompatibility complex). 
     Accordingly, the present invention provides CARs that target the following cancer associated antigens (tumor antigens): CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1 (CLECL1), CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, Mesothelin, IL-11Ra, PSCA, VEGFR2, LewisY, CD24, PDGFR-beta, PRSS21, SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, TSHR, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, legumain, HPV E6,E7, MAGE-A1, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1/Galectin 8, MelanA/MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1. 
     Anti-Target Chimeric Antigen Receptor (CAR) 
     The present invention encompasses a recombinant DNA construct comprising sequences encoding an anti-target CAR, wherein the anti-target CAR comprises a ligand that binds to a target CAR, e.g., a target CAR described herein. In an embodiment, the ligand comprises a cognate antigen molecule or an antibody molecule that binds the target CAR. In an embodiment, the antibody molecule that binds the target CAR comprises an antibody molecule that binds an extracellular domain of the target CAR, e.g., an antigen binding domain or a hinge domain of the target CAR. In an embodiment, the antibody molecule that binds the target CAR comprises an anti-idiotypic antibody molecule, e.g., an anti-idiotypic antibody molecule that binds the target CAR, e.g., binds an extracellular domain of the target CAR (e.g., an antigen binding domain or a hinge domain of the target CAR). In an embodiment, the antigen binding domain comprises a variable light (VL) domain and a variable heavy (VH) domain, optionally connected with a linker, e.g., as described herein. In an embodiment, the order of the variable domain, e.g., in which the VL and VH domains appear in the antigen binding domain, e.g., scFv, can be varied (i.e., VL-VH, or VH-VL orientation). In an embodiment, the antigen binding domain comprises a VL domain followed by a VH domain (i.e., VL-VH). In an embodiment, the antigen binding domain comprises a VH domain followed by a VL domain (i.e., VL-VH). 
     In an embodiment, the sequence of the ligand is contiguous with and in the same reading frame as a nucleic acid sequence encoding an intracellular signaling domain. The intracellular signaling domain can comprise a costimulatory signaling domain and/or a primary signaling domain, e.g., a zeta chain. The costimulatory signaling domain can be a portion of the anti-target CAR comprising at least a portion of the intracellular domain of a costimulatory molecule. 
     In specific aspects, an anti-target CAR construct of the invention comprises a scFv domain, wherein the scFv may be preceded by an optional leader sequence such as provided in SEQ ID NO: 401, and followed by an optional hinge sequence such as provided in SEQ ID NO:403 or SEQ ID NO:405 or SEQ ID NO:407 or SEQ ID NO:10, a transmembrane region such as provided in SEQ ID NO:12, an intracellular signalling domain that includes SEQ ID NO:14, and a CD3 zeta sequence that includes SEQ ID NO:18 or SEQ ID NO:20, e.g., wherein the domains are contiguous with and in the same reading frame to form a single fusion protein. 
     In one aspect, an exemplary anti-target CAR construct comprises an optional leader sequence (e.g., a leader sequence described herein), a ligand (e.g., a cognate antigen molecule or an antibody molecule that binds a target CAR), a hinge (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein), and an intracellular stimulatory domain (e.g., an intracellular stimulatory domain described herein). In one aspect, an exemplary anti-target CAR construct comprises an optional leader sequence (e.g., a leader sequence described herein), a ligand (e.g., a cognate antigen molecule or an antibody molecule that binds a target CAR), a hinge (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein), an intracellular costimulatory signaling domain (e.g., a costimulatory signaling domain described herein) and/or an intracellular primary signaling domain (e.g., a primary signaling domain described herein). 
     An exemplary leader sequence is provided as SEQ ID NO: 401. An exemplary hinge/spacer sequence is provided as SEQ ID NO: 403 or SEQ ID NO:405 or SEQ ID NO:407 or SEQ ID NO:10. An exemplary transmembrane domain sequence is provided as SEQ ID NO:12. An exemplary sequence of the intracellular signaling domain of 4-1BB is provided as SEQ ID NO: 14. An exemplary CD3zeta domain sequence is provided as SEQ ID NO: 18 or SEQ ID NO:20. 
     In one aspect, the present invention encompasses a recombinant nucleic acid construct comprising a nucleic acid molecule encoding an anti-target CAR, wherein the nucleic acid molecule comprises the nucleic acid sequence encoding a ligand, e.g., as described herein, that is contiguous with and in the same reading frame as a nucleic acid sequence encoding an intracellular signaling domain. 
     In one aspect, the present invention encompasses a recombinant nucleic acid construct comprising a nucleic acid molecule encoding an anti-target CAR, wherein the nucleic acid molecule comprises a nucleic acid sequence encoding a ligand, wherein the sequence is contiguous with and in the same reading frame as the nucleic acid sequence encoding an intracellular signaling domain. An exemplary intracellular signaling domain that can be used in the anti-target CAR includes, but is not limited to, one or more intracellular signaling domains of, e.g., CD3-zeta, CD28, CD27, 4-1BB, and the like. In some instances, the anti-target CAR can comprise any combination of CD3-zeta, CD28, 4-1BB, and the like. 
     The nucleic acid sequences coding for the desired molecules can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells expressing the nucleic acid molecule, by deriving the nucleic acid molecule from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques. Alternatively, the nucleic acid of interest can be produced synthetically, rather than cloned. 
     The present invention includes retroviral and lentiviral vector constructs expressing an anti-target CAR that can be directly transduced into a cell. 
     The present invention also includes an RNA construct that can be directly transfected into a cell. A method for generating mRNA for use in transfection involves in vitro transcription (IVT) of a template with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”) (e.g., a 3′ and/or 5′ UTR described herein), a 5′ cap (e.g., a 5′ cap described herein) and/or Internal Ribosome Entry Site (IRES) (e.g., an IRES described herein), the nucleic acid to be expressed, and a polyA tail, typically 50-2000 bases in length (SEQ ID NO:32). RNA so produced can efficiently transfect different kinds of cells. In one embodiment, the template includes sequences for the CAR. In an embodiment, an RNA CAR vector is transduced into a cell, e.g., a T cell or a NK cell, by electroporation. 
     Anti-Target CAR Ligand 
     In an embodiment, the anti-target CAR comprises a ligand that binds to a target CAR, e.g., a target CAR described herein. In an embodiment, the ligand comprises a cognate antigen molecule or an antibody molecule that binds the target CAR. In an embodiment, the antibody molecule that binds the target CAR comprises an antibody molecule that binds an extracellular domain of the target CAR, e.g., an antigen binding domain or a hinge domain of the target CAR. In an embodiment, the antibody molecule that binds the target CAR comprises an anti-idiotypic antibody molecule, e.g., an anti-idiotypic antibody molecule that binds the target CAR, e.g., binds an extracellular domain of the target CAR (e.g., an antigen binding domain or a hinge domain of the target CAR). 
     In an embodiment, the target CAR is chosen from: an CD19CAR, CD20CAR, CD22CAR, mesothelinCAR, CLL-1CAR, EGFRvIIICAR, or a CAR targeting any tumor antigen described herein. In an embodiment, the target CAR is a CD19 CAR. 
     In an embodiment, the target CAR is a target CAR described herein, and the anti-target CAR comprises a ligand that binds to the target CAR, e.g., binds an extracellular domain of the target CAR (e.g., an antigen binding domain or a hinge domain of the target CAR). In an embodiment, the ligand of the anti-target CAR binds to the target CAR antigen binding domain. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the target CAR. 
     In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the antigen binding domain on the surface of the target CAR. 
     In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a target antigen, which binds to, e.g., the target antigen binding domain on the surface of the target CAR. In some embodiments, the ligand that comprises the cognate antigen comprises the full length protein that comprises the cognate antigen. In other embodiments, the ligand that comprises the cognate antigen comprises an fragment or mutant of the protein that comprises the cognate antigen, wherein the fragment or mutant binds a target CAR. 
     In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the target antigen binding domain and/or the hinge region of the target-CAR. 
     Anti-CD19 CAR 
     In an embodiment, the target CAR is a CD19CAR and the anti-target CAR comprises a ligand that binds to a CD19CAR, e.g., binds an extracellular domain of the CD19CAR (e.g., an antigen binding domain (e.g., a CD19 antigen binding domain) or a hinge domain of the CD19CAR). In an embodiment, the ligand of the anti-target CAR binds to the CD19 antigen binding domain of the CD19CAR. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the CD19CAR. 
     In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a CD19 antigen, which binds to, e.g., the CD19 antigen binding domain on the surface of the CD19CAR. 
     In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the CD19 antigen binding domain and/or the hinge region of the CD19CAR. 
     In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the CD19 antigen binding domain on the surface of the CD19CAR. In an embodiment, the anti-idiotypic antibody molecule comprises the anti-idiotypic antibody that binds anti-CD19 of clone no. 136.20.1, as disclosed in International Application WO 2014/190273, filed on May 23, 2014, the entire contents of which are hereby incorporated by reference. 
     Exemplary anti-CAR antibodies that can be used in the methods disclosed herein are described, e.g., in WO 2014/190273 and by Jena et al., “Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T cells in Clinical Trials”, PLOS March 2013 8:3 e57838, the contents of which are incorporated by reference. 
     In one embodiment, the anti-idiotypic antibody molecule recognizes an anti-CD19 antibody molecule, e.g., an anti-CD19 scFv. For instance, the anti-idiotypic antibody molecule can compete for binding with the CD19-specific CAR mAb clone no. 136.20.1 described in Jena et al., PLOS March 2013 8:3 e57838; may have the same CDRs (e.g., one or more of, e.g., all of, VH CDR1, VH CDR2, CH CDR3, VL CDR1, VL CDR2, and VL CDR3, using the Kabat definition, the Chothia definition, or a combination of the Kabat and Chothia definitions) as the CD19-specific CAR mAb clone no. 136.20.1; may have one or more (e.g., 2) variable regions as the CD19-specific CAR mAb clone no. 136.20.1, or may comprise the CD19-specific CAR mAb clone no. 136.20.1. In some embodiments, the anti-idiotypic antibody was made according to a method described in Jena et al. In another embodiment, the anti-idiotypic antibody molecule is an anti-idiotypic antibody molecule described in WO 2014/190273. In some embodiments, the anti-idiotypic antibody molecule has the same CDRs (e.g., one or more of, e.g., all of, VH CDR1, VH CDR2, CH CDR3, VL CDR1, VL CDR2, and VL CDR3) as an antibody molecule of WO 2014/190273 such as 136.20.1; may have one or more (e.g., 2) variable regions of an antibody molecule of WO 2014/190273, or may comprise an antibody molecule of WO 2014/190273 such as 136.20.1. In other embodiments, the anti-target CAR antibody binds to a constant region of the extracellular binding domain of the target CAR molecule, e.g., as described in WO 2014/190273. In some embodiments, the anti-target CAR antibody binds to a constant region of the extracellular binding domain of the target CAR molecule, e.g., a heavy chain constant region (e.g., a CH2-CH3 hinge region) or light chain constant region. For instance, in some embodiments the anti-target CAR antibody competes for binding with the 2D3 monoclonal antibody described in WO 2014/190273, has the same CDRs (e.g., one or more of, e.g., all of, VH CDR1, VH CDR2, CH CDR3, VL CDR1, VL CDR2, and VL CDR3) as 2D3, or has one or more (e.g., 2) variable regions of 2D3, or comprises 2D3 as described in WO 2014/190273. 
     Clone 136.20.1, as disclosed in WO 2014/190273: 
     
       
         
           
               
            
               
                 HCDR1: 
               
               
                 (SEQ ID NO: 2005) 
               
               
                 GFDFSRYW 
               
               
                   
               
               
                 HCDR2: 
               
               
                 (SEQ ID NO: 2006) 
               
               
                 INLDSSTI 
               
               
                   
               
               
                 HCDR3: 
               
               
                 (SEQ ID NO: 2007) 
               
               
                 ARRYDAMDY 
               
               
                   
               
               
                 LCDR1: 
               
               
                 ((SEQ ID NO: 2008) 
               
               
                 ESVDDYGISF 
               
               
                   
               
               
                 LCDR2: 
               
               
                 (SEQ ID NO: 2009) 
               
               
                 AAP 
               
               
                   
               
               
                 LCDR3: 
               
               
                 (SEQ ID NO: 2010) 
               
               
                 QQSKD 
               
               
                   
               
               
                 VH: 
               
               
                 (SEQ ID NO: 2011) 
               
               
                 LKPREVKLVESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLE 
               
               
                   
               
               
                 WIGEINLDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYC 
               
               
                   
               
               
                 ARRYDAMDYWGQGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVK 
               
               
                   
               
               
                 ASQ 
               
               
                   
               
               
                 VL: 
               
               
                 (SEQ ID NO: 2012) 
               
               
                 ASDIVLTQSPASLAVSLGQRATISCRASESVDDYGISFMNWFQQKPGQPP 
               
               
                   
               
               
                 KLLIYAAPNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKDV 
               
               
                   
               
               
                 RWRHQAGDQTG 
               
            
           
         
       
     
     Other Anti-Target CARs 
     In an embodiment, the target CAR is a CD33CAR and the anti-target CAR comprises a ligand that binds to a CD33CAR, e.g., binds an extracellular domain of the CD33CAR (e.g., an antigen binding domain (e.g., a CD33 antigen binding domain) or a hinge domain of the CD33CAR). In an embodiment, the ligand of the anti-target CAR binds to the CD33 antigen binding domain of the CD33CAR. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the CD33CAR. In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a CD33 antigen, which binds to, e.g., the CD33 antigen binding domain on the surface of the CD33CAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the CD33 antigen binding domain and/or the hinge region of the CD33CAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the CD33 antigen binding domain on the surface of the CD33CAR. 
     In an embodiment, the target CAR is a EGFRvIIICAR and the anti-target CAR comprises a ligand that binds to a EGFRvIIICAR, e.g., binds an extracellular domain of the EGFRvIIICAR “(e.g., an antigen binding domain (e.g., a EGFRvIII antigen binding domain)” or a hinge domain of the EGFRvIIICAR). In an embodiment, the ligand of the anti-target CAR binds to the EGFRvIII antigen binding domain of the EGFRvIIICAR. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the EGFRvIII CAR. In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a EGFRvIII antigen, which binds to, e.g., the EGFRvIII antigen binding domain on the surface of the EGFRvIIICAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the EGFRvIII antigen binding domain and/or the hinge region of the EGFRvIIICAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the EGFRvIII antigen binding domain on the surface of the EGFRvIIICAR. 
     In an embodiment, the target CAR is a mesothelinCAR and the anti-target CAR comprises a ligand that binds to a mesothelinCAR, e.g., binds an extracellular domain of the mesothelinCAR (e.g., an antigen binding domain (e.g., a mesothelin antigen binding domain) or a hinge domain of the mesothelinCAR). In an embodiment, the ligand of the anti-target CAR binds to the mesothelin antigen binding domain of the mesothelinCAR. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the mesothelinCAR. In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a mesothelin antigen, which binds to, e.g., the mesothelin antigen binding domain on the surface of the mesothelinCAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the mesothelin antigen binding domain and/or the hinge region of the mesothelinCAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the mesothelin antigen binding domain on the surface of the mesothelinCAR. 
     In an embodiment, the target CAR is a BCMACAR and the anti-target CAR comprises a ligand that binds to a BCMACAR, e.g., binds an extracellular domain of the BCMACAR (e.g., an antigen binding domain (e.g., a BCMA antigen binding domain) or a hinge domain of the BCMACAR). In an embodiment, the ligand of the anti-target CAR binds to the BCMA antigen binding domain of the BCMACAR. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the BCMACAR. In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a BCMA antigen, which binds to, e.g., the BCMA antigen binding domain on the surface of the BCMACAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the BCMA antigen binding domain and/or the hinge region of the BCMACAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the BCMA antigen binding domain on the surface of the BCMACAR. 
     In an embodiment, the target CAR is a CD20CAR and the anti-target CAR comprises a ligand that binds to a CD20CAR, e.g., binds an extracellular domain of the CD20CAR (e.g., an antigen binding domain (e.g., a CD20 antigen binding domain) or a hinge domain of the CD20 CAR). In an embodiment, the ligand of the anti-target CAR binds to the CD20 antigen binding domain of the CD20CAR. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the CD20CAR. In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a CD20 antigen, which binds to, e.g., the CD20 antigen binding domain on the surface of the CD20CAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the CD20 antigen binding domain and/or the hinge region of the CD20CAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the CD20 antigen binding domain on the surface of the CD20CAR. 
     In an embodiment, the target CAR is a CD22CAR and the anti-target CAR comprises a ligand that binds to a CD22CAR, e.g., binds an extracellular domain of the CD22CAR (e.g., an antigen binding domain (e.g., a CD22 antigen binding domain) or a hinge domain of the CD22CAR). In an embodiment, the ligand of the anti-target CAR binds to the CD22 antigen binding domain of the CD22CAR. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the CD22CAR. In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a CD22 antigen, which binds to, e.g., the CD22 antigen binding domain on the surface of the CD22CAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the CD22 antigen binding domain and/or the hinge region of the CD22CAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the CD22 antigen binding domain on the surface of the CD22CAR. 
     In an embodiment, the target CAR is a CD123CAR and the anti-target CAR comprises a ligand that binds to a CD123CAR, e.g., binds an extracellular domain of the CD123CAR (e.g., an antigen binding domain (e.g., a CD22 antigen binding domain) or a hinge domain of the CD123CAR). In an embodiment, the ligand of the anti-target CAR binds to the CD123 antigen binding domain of the CD123CAR. In an embodiment, the ligand of the anti-target CAR binds to the hinge domain of the CD123CAR. In an embodiment, the anti-target CAR ligand comprises a cognate antigen, e.g., a CD123 antigen, which binds to, e.g., the CD123 antigen binding domain on the surface of the CD123CAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule that binds to the CD123 antigen binding domain and/or the hinge region of the CD123CAR. In an embodiment, the anti-target CAR ligand comprises an antibody molecule, e.g., an anti-idiotypic antibody molecule, e.g., an antibody molecule that binds to the CD123 antigen binding domain on the surface of the CD123CAR. 
     Transmembrane Domain 
     With respect to the transmembrane domain, in various embodiments, an anti-target CAR can be designed to comprise a transmembrane domain that is attached to the extracellular domain, e.g., ligand, of the anti-target CAR. A transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acid associated with the extracellular region of the protein from which the transmembrane was derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and/or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region). In one aspect, the transmembrane domain is one that is associated with one of the other domains of the anti-target CAR, e.g., in one embodiment, the transmembrane domain may be from the same protein that the signaling domain, costimulatory domain or the hinge domain is derived from. In another aspect, the transmembrane domain is not derived from the same protein that any other domain of the anti-target CAR is derived from. In some instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins, e.g., to minimize interactions with other members of the receptor complex. 
     The transmembrane domain may be derived either from a natural or from a recombinant source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. In one aspect the transmembrane domain is capable of signaling to the intracellular domain(s) whenever the anti-target CAR has bound to a target. A transmembrane domain of particular use in this invention may include at least the transmembrane region(s) of e.g., the alpha, beta or zeta chain of the T-cell receptor, CD28, CD27, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. In some embodiments, a transmembrane domain may include at least the transmembrane region(s) of, e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2R gamma, IL7R α, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKG2D, NKG2C. 
     In some instances, the transmembrane domain can be attached to the extracellular region of the anti-target CAR, e.g., the ligand of the anti-target CAR, via a hinge, e.g., a hinge from a human protein. For example, in one embodiment, the hinge can be a human Ig (immunoglobulin) hinge (e.g., an IgG4 hinge, an IgD hinge), a GS linker (e.g., a GS linker described herein), a KIR2DS2 hinge or a CD8a hinge. In one embodiment, the hinge or spacer comprises (e.g., consists of) the amino acid sequence of SEQ ID NO:403. In one aspect, the transmembrane domain comprises (e.g., consists of) a transmembrane domain of SEQ ID NO: 12. 
     In one aspect, the hinge or spacer comprises an IgG4 hinge. For example, in one embodiment, the hinge or spacer comprises a hinge of the amino acid sequence ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLS LSLGKM (SEQ ID NO:405). In some embodiments, the hinge or spacer comprises a hinge encoded by a nucleotide sequence of 
     
       
         
           
               
            
               
                 (SEQ ID NO: 406) 
               
               
                 GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCT 
               
               
                   
               
               
                 GGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGA 
               
               
                   
               
               
                 TGATCAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAG 
               
               
                   
               
               
                 GAGGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCA 
               
               
                   
               
               
                 CAACGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGG 
               
               
                   
               
               
                 TGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAA 
               
               
                   
               
               
                 TACAAGTGTAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAGAAAAC 
               
               
                   
               
               
                 CATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGC 
               
               
                   
               
               
                 CCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTG 
               
               
                   
               
               
                 GTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGG 
               
               
                   
               
               
                 CCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACG 
               
               
                   
               
               
                 GCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAG 
               
               
                   
               
               
                 GAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCA 
               
               
                   
               
               
                 CTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATG. 
               
            
           
         
       
     
     In one aspect, the hinge or spacer comprises an IgD hinge. For example, in one embodiment, the hinge or spacer comprises a hinge of the amino acid sequence RWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEE RETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAG KVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMAL REPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGF APARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYV TDH (SEQ ID NO:407). In some embodiments, the hinge or spacer comprises a hinge encoded by a nucleotide sequence of 
     
       
         
           
               
            
               
                 (SEQ ID NO: 408) 
               
               
                 AGGTGGCCCGAAAGTCCCAAGGCCCAGGCATCTAGTGTTCCTACTGCACA 
               
               
                   
               
               
                 GCCCCAGGCAGAAGGCAGCCTAGCCAAAGCTACTACTGCACCTGCCACTA 
               
               
                   
               
               
                 CGCGCAATACTGGCCGTGGCGGGGAGGAGAAGAAAAAGGAGAAAGAGAAA 
               
               
                   
               
               
                 GAAGAACAGGAAGAGAGGGAGACCAAGACCCCTGAATGTCCATCCCATAC 
               
               
                   
               
               
                 CCAGCCGCTGGGCGTCTATCTCTTGACTCCCGCAGTACAGGACTTGTGGC 
               
               
                   
               
               
                 TTAGAGATAAGGCCACCTTTACATGTTTCGTCGTGGGCTCTGACCTGAAG 
               
               
                   
               
               
                 GATGCCCATTTGACTTGGGAGGTTGCCGGAAAGGTACCCACAGGGGGGGT 
               
               
                   
               
               
                 TGAGGAAGGGTTGCTGGAGCGCCATTCCAATGGCTCTCAGAGCCAGCACT 
               
               
                   
               
               
                 CAAGACTCACCCTTCCGAGATCCCTGTGGAACGCCGGGACCTCTGTCACA 
               
               
                   
               
               
                 TGTACTCTAAATCATCCTAGCCTGCCCCCACAGCGTCTGATGGCCCTTAG 
               
               
                   
               
               
                 AGAGCCAGCCGCCCAGGCACCAGTTAAGCTTAGCCTGAATCTGCTCGCCA 
               
               
                   
               
               
                 GTAGTGATCCCCCAGAGGCCGCCAGCTGGCTCTTATGCGAAGTGTCCGGC 
               
               
                   
               
               
                 TTTAGCCCGCCCAACATCTTGCTCATGTGGCTGGAGGACCAGCGAGAAGT 
               
               
                   
               
               
                 GAACACCAGCGGCTTCGCTCCAGCCCGGCCCCCACCCCAGCCGGGTTCTA 
               
               
                   
               
               
                 CCACATTCTGGGCCTGGAGTGTCTTAAGGGTCCCAGCACCACCTAGCCCC 
               
               
                   
               
               
                 CAGCCAGCCACATACACCTGTGTTGTGTCCCATGAAGATAGCAGGACCCT 
               
               
                   
               
               
                 GCTAAATGCTTCTAGGAGTCTGGAGGTTTCCTACGTGACTGACCATT. 
               
            
           
         
       
     
     In one aspect, the transmembrane domain may be recombinant, in which case it will comprise predominantly hydrophobic residues such as leucine and valine. In one aspect a triplet of phenylalanine, tryptophan and valine can be found at each end of a recombinant transmembrane domain. 
     Optionally, a short oligo- or polypeptide linker, between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic region of the CAR. A glycine-serine doublet provides a particularly suitable linker. For example, in one aspect, the linker comprises the amino acid sequence of GGGGSGGGGS (SEQ ID NO:10). In some embodiments, the linker is encoded by a nucleotide sequence of 
     
       
         
           
               
               
            
               
                   
                 (SEQ ID NO: 11) 
               
               
                   
                 GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC. 
               
            
           
         
       
     
     In one aspect, the hinge or spacer comprises a KIR2DS2 hinge. 
     Cytoplasmic Domain 
     The cytoplasmic domain or region of the anti-target CAR includes an intracellular signaling domain. An intracellular signaling domain is generally responsible for activation of at least one of the normal effector functions of the immune cell in which the anti-target CAR has been introduced. The term “effector function” refers to a specialized function of a cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines. Thus the term “intracellular signaling domain” refers to the portion of a protein which transduces the effector function signal and directs the cell to perform a specialized function. While usually the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such truncated portion may be used in place of the intact chain as long as it transduces the effector function signal. The term intracellular signaling domain is thus meant to include any truncated portion of the intracellular signaling domain sufficient to transduce the effector function signal. 
     Examples of intracellular signaling domains for use in the anti-target CAR of the invention include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivative or variant of these sequences and any recombinant sequence that has the same functional capability. 
     It is known that signals generated through the TCR alone are insufficient for full activation of the T cell and that a secondary and/or costimulatory signal is also required. Thus, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary intracellular signaling domains) and those that act in an antigen-independent manner to provide a secondary or costimulatory signal (secondary cytoplasmic domain, e.g., a costimulatory domain). 
     A primary signaling domain regulates primary activation of the TCR complex either in a stimulatory way, or in an inhibitory way. Primary intracellular signaling domains that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs or ITAMs. 
     Examples of ITAM containing primary intracellular signaling domains that are of particular use in the invention include those of CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc Epsilon Rib), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12. In one embodiment, a CAR of the invention comprises an intracellular signaling domain, e.g., a primary signaling domain of CD3-zeta. 
     In one embodiment, a primary signaling domain comprises a modified ITAM domain, e.g., a mutated ITAM domain which has altered (e.g., increased or decreased) activity as compared to the native ITAM domain. In one embodiment, a primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and/or truncated ITAM-containing primary intracellular signaling domain. In an embodiment, a primary signaling domain comprises one, two, three, four or more ITAM motifs. 
     The intracellular signalling domain of the anti-target CAR can comprise the CD3-zeta signaling domain by itself or it can be combined with any other desired intracellular signaling domain(s) useful in the context of an anti-target CAR of the invention. For example, the intracellular signaling domain of the anti-target CAR can comprise a CD3 zeta chain portion and a costimulatory signaling domain. The costimulatory signaling domain refers to a portion of the anti-target CAR comprising the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligands that is required for an efficient response of lymphocytes to an antigen. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds with CD83, and the like. For example, CD27 costimulation has been demonstrated to enhance expansion, effector function, and survival of human CART cells in vitro and augments human T cell persistence and antitumor activity in vivo (Song et al. Blood. 2012; 119(3):696-706). Further examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), NKG2D, CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, and CD19a. 
     The intracellular signaling sequences within the cytoplasmic portion of the anti-target CAR of the invention may be linked to each other in a random or specified order. Optionally, a short oligo- or polypeptide linker, for example, between 2 and 10 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) in length may form the linkage between intracellular signaling sequence. In one embodiment, a glycine-serine doublet can be used as a suitable linker. In one embodiment, a single amino acid, e.g., an alanine, a glycine, can be used as a suitable linker. 
     In one aspect, the intracellular signaling domain is designed to comprise two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains. In an embodiment, the two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains, are separated by a linker molecule, e.g., a linker molecule described herein. In one embodiment, the intracellular signaling domain comprises two costimulatory signaling domains. In some embodiments, the linker molecule is a glycine residue. In some embodiments, the linker is an alanine residue. 
     In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta. In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta, and the signaling domain of 4-1BB. In one aspect, the signaling domain of 4-1BB is a signaling domain of SEQ ID NO: 14. In one aspect, the signaling domain of CD3-zeta is a signaling domain of SEQ ID NO: 18. 
     In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta, and the signaling domain of CD27. In one aspect, the signaling domain of CD27 comprises an amino acid sequence of 
     
       
         
           
               
            
               
                 (SEQ ID NO: 16) 
               
               
                 QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP. 
               
            
           
         
       
     
     In one aspect, the signalling domain of CD27 is encoded by a nucleic acid sequence of 
     
       
         
           
               
            
               
                 (SEQ ID NO: 17) 
               
               
                 AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCC 
               
               
                   
               
               
                 CCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCAC 
               
               
                   
               
               
                 GCGACTTCGCAGCCTATCGCTCC. 
               
            
           
         
       
     
     In one embodiment, the anti-target CAR-expressing cell further comprises an inhibitory CAR. In one embodiment, the inhibitory CAR comprises an antigen binding domain that binds an antigen found on normal cells but not cancer cells. In one embodiment, the inhibitory CAR comprises the antigen binding domain, a transmembrane domain and an intracellular domain of an inhibitory molecule. For example, the intracellular domain of the inhibitory CAR can be an intracellular domain of PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta. 
     In one embodiment, when the anti-target CAR-expressing cell comprises two or more different CARs, the extracellular domains of the different CARs can be such that the extracellular domains do not interact with one another. For example, a cell expressing a first and second CAR can have an extracellular domain of the first CAR, e.g., as a fragment, e.g., an scFv, that does not form an association with the extracellular domain of the second CAR, e.g., the antigen binding domain of the second CAR is a VHH. 
     In some embodiments, the ligand of an anti-target CAR comprises a single domain antigen binding (SDAB) molecules which includes molecules whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain variable domains, binding molecules naturally devoid of light chains, single domains derived from conventional 4-chain antibodies, engineered domains and single domain scaffolds other than those derived from antibodies. SDAB molecules may be any of the art, or any future single domain molecules. SDAB molecules may be derived from any species including, but not limited to mouse, human, camel, llama, lamprey, fish, shark, goat, rabbit, and bovine. This term also includes naturally occurring single domain antibody molecules from species other than Camelidae and sharks. 
     In one aspect, an SDAB molecule can be derived from a variable region of the immunoglobulin found in fish, such as, for example, that which is derived from the immunoglobulin isotype known as Novel Antigen Receptor (NAR) found in the serum of shark. Methods of producing single domain molecules derived from a variable region of NAR (“IgNARs”) are described in WO 03/014161 and Streltsov (2005) Protein Sci. 14:2901-2909. 
     According to another aspect, an SDAB molecule is a naturally occurring single domain antigen binding molecule known as heavy chain devoid of light chains. Such single domain molecules are disclosed in WO 9404678 and Hamers-Casterman, C. et al. (1993) Nature 363:446-448, for example. For clarity reasons, this variable domain derived from a heavy chain molecule naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain molecules naturally devoid of light chain; such VHHs are within the scope of the invention. 
     The SDAB molecules can be recombinant, CDR-grafted, humanized, camelized, de-immunized and/or in vitro generated (e.g., selected by phage display). 
     In another aspect, the anti-target CAR-expressing cell described herein can further express another agent, e.g., an agent which enhances the activity of an anti-target CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Inhibitory molecules, e.g., PD1, can, in some embodiments, decrease the ability of an anti-target CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta. In one embodiment, the agent which inhibits an inhibitory molecule, e.g., is a molecule described herein, e.g., an agent that comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta, or a fragment of any of these (e.g., at least a portion of an extracellular domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of an extracellular domain of PD1), and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and/or a CD3 zeta signaling domain described herein). PD1 is an inhibitory member of the CD28 family of receptors that also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells (Agata et al. 1996 Int Immunol 8:765-75). Two ligands for PD1, PD-L1 and PD-L2 have been shown to downregulate T cell activation upon binding to PD1 (Freeman et a. 2000 J Exp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094). Immune suppression can be reversed by inhibiting the local interaction of PD1 with PD-L1. 
     In one embodiment, the agent comprises the extracellular domain (ECD) of an inhibitory molecule, e.g., Programmed Death 1 (PD1), fused to a transmembrane domain and intracellular signaling domains such as 41BB and CD3 zeta (also referred to herein as a PD1 CAR). In one embodiment, a PD1 CAR, when used in combinations with an anti-target CAR described herein, improves the persistence of the T cell. In one embodiment, the CAR is a PD1 CAR comprising the extracellular domain of PD1 indicated as underlined in SEQ ID NO: 26. In one embodiment, the PD1 CAR comprises the amino acid sequence of SEQ ID NO:26. 
     
       
         
           
               
            
               
                 (SEQ ID NO: 26) 
               
               
                 
                   Malpvtalllplalllhaarppgwfldspdrpwnpptfspallvvtegdn 
                 
               
               
                   
               
               
                 
                   atftcsfsntsesfylnwyrmspsnqtdklaafpedrsqpgqdcrfrvtq 
                 
               
               
                   
               
               
                 
                   lpngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelrvterra 
                 
               
               
                   
               
               
                 evptahpspsprpagqfqtlvtttpaprpptpaptiasqplslrpeacrp 
               
               
                   
               
               
                 aaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyi 
               
               
                   
               
               
                 fkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqn 
               
               
                   
               
               
                 qlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkma 
               
               
                   
               
               
                 eayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr. 
               
            
           
         
       
     
     In one embodiment, the PD1 CAR comprises the amino acid sequence provided below (SEQ ID NO:39). 
     
       
         
           
               
            
               
                 (SEQ ID NO: 39) 
               
               
                 
                   pgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfylnwyrm 
                 
               
               
                   
               
               
                 
                   spsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgt 
                 
               
               
                   
               
               
                   ylcgaislapkaqikeshaelrvterraevptahpspsprpagqfqtlv t 
               
               
                   
               
               
                 ttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwap 
               
               
                   
               
               
                 lagtegvlllslvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrf 
               
               
                   
               
               
                 peeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrrg 
               
               
                   
               
               
                 rdpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdgly 
               
               
                   
               
               
                 qglstatkdtydalhmqalppr. 
               
            
           
         
       
     
     In one embodiment, the agent comprises a nucleic acid sequence encoding the PD1 CAR, e.g., the PD1 CAR described herein. In one embodiment, the nucleic acid sequence for the PD1 CAR is shown below, with the PD1 ECD underlined below in SEQ ID NO: 27 
     
       
         
           
               
            
               
                 (SEQ ID NO: 27) 
               
               
                 atggccctccctgtcactgccctgatctccccctcgcactcctgctccac 
               
               
                   
               
               
                 gccgctagaccac ccggatggtactggactctccggatcgcccgtggaat   
               
               
                   
               
               
                 
                   cccccaaccactcaccggcactcaggagtgactgagggcgataatgcgac 
                 
               
               
                   
               
               
                 
                   cacacgtgctcgttctccaacacctccgaatcattcgtgctgaactggta 
                 
               
               
                   
               
               
                 
                   ccgcatgagcccgtcaaaccagaccgacaagctcgccgcgtaccggaaga 
                 
               
               
                   
               
               
                 
                   tcggtcgcaaccgggacaggattgtcggaccgcgtgactcaactgccgaa 
                 
               
               
                   
               
               
                 
                   tggcagagacttccacatgagcgtggtccgcgctaggcgaaacgactccg 
                 
               
               
                   
               
               
                 
                   ggacctacctgtgcggagccatctcgctggcgcctaaggcccaaatcaaa 
                 
               
               
                   
               
               
                 
                   gagagcttgagggccgaactgagagtgaccgagcgcagagctgaggtgcc 
                 
               
               
                   
               
               
                 
                   aactgcacatccatccccatcgcctcggcctgcggggcagatcagaccct 
                 
               
               
                   
               
               
                   ggtc acgaccactccggcgccgcgcccaccgactccggccccaactatcg 
               
               
                   
               
               
                 cgagccagcccctgtcgctgaggccggaagcatgccgccctgccgccgga 
               
               
                   
               
               
                 ggtgctgtgcatacccggggattggacttcgcatgcgacatctacatttg 
               
               
                   
               
               
                 ggctcctctcgccggaacttgtggcgtgctccttctgtccctggtcatca 
               
               
                   
               
               
                 ccctgtactgcaagcggggtcggaaaaagcttctgtacattttcaagcag 
               
               
                   
               
               
                 cccttcatgaggcccgtgcaaaccacccaggaggaggacggttgctcctg 
               
               
                   
               
               
                 ccggttccccgaagaggaagaaggaggttgcgagctgcgcgtgaagactc 
               
               
                   
               
               
                 ccggagcgccgacgcccccgcctataagcagggccagaaccagctgtaca 
               
               
                   
               
               
                 acgaactgaacctgggacggcgggaagagtacgatgtgctggacaagcgg 
               
               
                   
               
               
                 cgcggccgggaccccgaaatgggcgggaagcctagaagaaagaaccctca 
               
               
                   
               
               
                 ggaaggcctgtataacgagctgcagaaggacaagatggccgaggcctact 
               
               
                   
               
               
                 ccgaaattgggatgaagggagagcggcggaggggaaaggggcacgacggc 
               
               
                   
               
               
                 ctgtaccaaggactgtccaccgccaccaaggacacatacgatgccctgca 
               
               
                   
               
               
                 catgcaggccatccccctcgc. 
               
            
           
         
       
     
     In one aspect, the present invention provides methods comprising administering a population of anti-target CAR-expressing cells, e.g., anti-target CAR CART cells, in combination with another agent, e.g., a kinase inhibitor, such as a kinase inhibitor described herein. In another aspect, the present invention provides methods comprising administering a population of cells wherein at least one cell in the population expresses an anti-target CAR having a ligand that binds a target CAR, and a second cell expressing another agent, e.g., an agent which enhances the activity of an anti-target CAR-expressing cell, in combination with another agent, e.g., a kinase inhibitor, such as a kinase inhibitor described herein. 
     Regulatable Anti-Target CARs 
     In some embodiments, a regulatable anti-target CAR (atRCAR) where the anti-target CAR activity can be controlled is desirable to optimize the safety and efficacy of an anti-target CAR therapy. There are many ways anti-target CAR activities can be regulated. For example, inducible apoptosis using, e.g., a caspase fused to a dimerization domain (see, e.g., Di et al., N Egnl. J. Med. 2011 Nov. 3; 365(18):1673-1683), can be used as a safety switch in the anti-target CAR therapy of the instant invention. In an aspect, an anti-target RCAR comprises a set of polypeptides, typically two in the simplest embodiments, in which the components of a standard anti-target CAR described herein, e.g., an antigen binding domain and an intracellular signaling domain, are partitioned on separate polypeptides or members. In some embodiments, the set of polypeptides include a dimerization switch that, upon the presence of a dimerization molecule, can couple the polypeptides to one another, e.g., can couple an antigen binding domain to an intracellular signaling domain. 
     In an aspect, an anti-target RCAR comprises two polypeptides or members: 1) an intracellular signaling member comprising an intracellular signaling domain, e.g., a primary intracellular signaling domain described herein, and a first switch domain; 2) a ligand that binds a target CAR wherein the ligand comprises a cognate antigen or an antibody molecule, as described herein and a second switch domain. Optionally, the anti-target RCAR comprises a transmembrane domain described herein. In an embodiment, a transmembrane domain can be disposed on the intracellular signaling member, on the antigen binding member, or on both. (Unless otherwise indicated, when members or elements of an anti-target RCAR are described herein, the order can be as provided, but other orders are included as well. In other words, in an embodiment, the order is as set out in the text, but in other embodiments, the order can be different. E.g., the order of elements on one side of a transmembrane region can be different from the example, e.g., the placement of a switch domain relative to a intracellular signaling domain can be different, e.g., reversed). 
     In an embodiment, the first and second switch domains can form an intracellular or an extracellular dimerization switch. In an embodiment, the dimerization switch can be a homodimerization switch, e.g., where the first and second switch domain are the same, or a heterodimerization switch, e.g., where the first and second switch domain are different from one another. 
     In embodiments, an anti-target RCAR can comprise a “multi switch.” A multi switch can comprise heterodimerization switch domains or homodimerization switch domains. A multi switch comprises a plurality of, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10, switch domains, independently, on a first member, e.g., a ligand member, and a second member, e.g., an intracellular signaling member. In an embodiment, the first member can comprise a plurality of first switch domains, e.g., FKBP-based switch domains, and the second member can comprise a plurality of second switch domains, e.g., FRB-based switch domains. In an embodiment, the first member can comprise a first and a second switch domain, e.g., a FKBP-based switch domain and a FRB-based switch domain, and the second member can comprise a first and a second switch domain, e.g., a FKBP-based switch domain and a FRB-based switch domain. 
     In an embodiment, the intracellular signaling member comprises one or more intracellular signaling domains, e.g., a primary intracellular signaling domain and one or more costimulatory signaling domains. 
     In an embodiment, the ligand member may comprise one or more intracellular signaling domains, e.g., one or more costimulatory signaling domains. In an embodiment, the ligand member comprises a plurality, e.g., 2 or 3 costimulatory signaling domains described herein, e.g., selected from 41BB, CD28, CD27, ICOS, and OX40, and in embodiments, no primary intracellular signaling domain. In an embodiment, the ligand member comprises the following costimulatory signaling domains, from the extracellular to intracellular direction: 41BB-CD27; 41BB-CD27; CD27-41BB; 41BB-CD28; CD28-41BB; OX40-CD28; CD28-OX40; CD28-41BB; or 41BB-CD28. In such embodiments, the intracellular binding member comprises a CD3zeta domain. In one such embodiment the anti-target RCAR comprises (1) a ligand member comprising, a ligand that binds a target CAR, a transmembrane domain, and two costimulatory domains and a first switch domain; and (2) an intracellular signaling domain comprising a transmembrane domain or membrane tethering domain and at least one primary intracellular signaling domain, and a second switch domain. 
     An embodiment provides anti-target RCARs wherein the ligand member is not tethered to the surface of the anti-target CAR cell. This allows a cell having an intracellular signaling member to be conveniently paired with one or more ligand members, without transforming the cell with a sequence that encodes the ligand member. In such embodiments, the anti-target RCAR comprises: 1) an intracellular signaling member comprising: a first switch domain, a transmembrane domain, an intracellular signaling domain, e.g., a primary intracellular signaling domain, and a first switch domain; and 2) a ligand member comprising: a ligand that binds a target CAR, and a second switch domain, wherein the ligand member does not comprise a transmembrane domain or membrane tethering domain, and, optionally, does not comprise an intracellular signaling domain. In some embodiments, the anti-target RCAR may further comprise 3) a second ligand member comprising: a ligand that binds a target CAR, e.g., a second ligand that binds a different target CAR than is bound by the ligand domain; and a second switch domain. 
     Also provided herein are anti-target RCARs wherein the ligand member comprises bispecific activation and targeting capacity. In this embodiment, the ligand member can comprise a plurality, e.g., 2, 3, 4, or 5 ligands, e.g., scFvs, wherein each ligand binds to a target CAR, e.g. different target CARs or the same target CAR, e.g., the same or different portions of the extracellular domain of the same target CAR. In an embodiment, the plurality of ligands are in tandem, and optionally, a linker or hinge region is disposed between each of the ligands. Suitable linkers and hinge regions are described herein. 
     An embodiment provides anti-target RCARs having a configuration that allows switching of proliferation. In this embodiment, the anti-target RCAR comprises: 1) an intracellular signaling member comprising: optionally, a transmembrane domain or membrane tethering domain; one or more co-stimulatory signaling domain, e.g., selected from 41BB, CD28, CD27, ICOS, and OX40, and a switch domain; and 2) a ligand member comprising ligand that binds to a target CAR, a transmembrane domain, and a primary intracellular signaling domain, e.g., a CD3zeta domain, wherein the ligand member does not comprise a switch domain, or does not comprise a switch domain that dimerizes with a switch domain on the intracellular signaling member. In an embodiment, the ligand member does not comprise a co-stimulatory signaling domain. In an embodiment, the intracellular signaling member comprises a switch domain from a homodimerization switch. In an embodiment, the intracellular signaling member comprises a first switch domain of a heterodimerization switch and the anti-target RCAR comprises a second intracellular signaling member which comprises a second switch domain of the heterodimerization switch. In such embodiments, the second intracellular signaling member comprises the same intracellular signaling domains as the intracellular signaling member. In an embodiment, the dimerization switch is intracellular. In an embodiment, the dimerization switch is extracellular. 
     In any of the anti-target RCAR configurations described here, the first and second switch domains comprise a FKBP-FRB based switch as described herein. 
     Also provided herein are cells comprising an anti-target RCAR described herein. 
     Also provided herein are nucleic acids and vectors comprising an anti-target RCAR encoding sequences. Sequence encoding various elements of an anti-target RCAR can be disposed on the same nucleic acid molecule, e.g., the same plasmid or vector, e.g., viral vector, e.g., lentiviral vector. In an embodiment, (i) sequence encoding a ligand member and (ii) sequence encoding an intracellular signaling member, can be present on the same nucleic acid, e.g., vector. Production of the corresponding proteins can be achieved, e.g., by the use of separate promoters, or by the use of a bicistronic transcription product (which can result in the production of two proteins by cleavage of a single translation product or by the translation of two separate protein products). In an embodiment, a sequence encoding a cleavable peptide, e.g., a P2A or F2A sequence, is disposed between (i) and (ii). In an embodiment, a sequence encoding an IRES, e.g., an EMCV or EV71 IRES, is disposed between (i) and (ii). In these embodiments, (i) and (ii) are transcribed as a single RNA. In an embodiment, a first promoter is operably linked to (i) and a second promoter is operably linked to (ii), such that (i) and (ii) are transcribed as separate mRNAs. 
     Alternatively, the sequence encoding various elements of an anti-target RCAR can be disposed on the different nucleic acid molecules, e.g., different plasmids or vectors, e.g., viral vector, e.g., lentiviral vector. E.g., the (i) sequence encoding a ligand member can be present on a first nucleic acid, e.g., a first vector, and the (ii) sequence encoding an intracellular signaling member can be present on the second nucleic acid, e.g., the second vector. 
     Target CAR 
     In one embodiment, methods of the invention comprise a target CAR. In an embodiment, a target CAR comprises a specific binding element otherwise referred to as an antigen binding domain. The choice of moiety depends upon the type and number of ligands that define the surface of a target cell. For example, the antigen binding domain may be chosen to recognize a cell surface marker on target cells associated with a particular disease state. Thus, examples of cell surface markers that may be bound by the antigen binding domain in a CAR described herein include those associated with viral, bacterial and parasitic infections, autoimmune disease and cancer cells. In one aspect, the portion of the target CAR comprising the antigen binding domain comprises an antigen binding domain that targets a tumor antigen, e.g., a tumor antigen described herein. 
     The antigen binding domain can be any domain that binds to the antigen including but not limited to a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, and a functional fragment thereof, including but not limited to a single-domain antibody such as a heavy chain variable domain (VH), a light chain variable domain (VL) and a variable domain (VHH) of camelid derived nanobody, and to an alternative scaffold known in the art to function as antigen binding domain, such as a recombinant fibronectin domain, a T cell receptor (TCR), or a fragment there of, e.g., single chain TCR, and the like. In some instances, it is beneficial for the antigen binding domain to be derived from the same species in which the CAR will ultimately be used in. For example, for use in humans, it may be beneficial for the antigen binding domain of the CAR to comprise human or humanized residues for the antigen binding domain of an antibody or antibody fragment. 
     In one embodiment, an antigen binding domain against CD22 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Haso et al., Blood, 121(7): 1165-1174 (2013); Wayne et al., Clin Cancer Res 16(6): 1894-1903 (2010); Kato et al., Leuk Res 37(1):83-88 (2013); Creative BioMart (creativebiomart.net): MOM-18047-S(P). 
     In one embodiment, an antigen binding domain against CS-1 is an antigen binding portion, e.g., CDRs, of Elotuzumab (BMS), see e.g., Tai et al., 2008, Blood 112(4):1329 37; Tai et al., 2007, Blood. 110(5):1656-63. 
     In one embodiment, an antigen binding domain against CLL-1 is an antigen binding portion, e.g., CDRs, of an antibody available from R&amp;D, ebiosciences, Abcam, for example, PE-CLL1-hu Cat #353604 (BioLegend); and PE-CLL1 (CLEC12A) Cat #562566 (BD). 
     In one embodiment, an antigen binding domain against CD33 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Bross et al., Clin Cancer Res 7(6):1490-1496 (2001) (Gemtuzumab Ozogamicin, hP67.6), Caron et al., Cancer Res 52(24):6761-6767 (1992) (Lintuzumab, HuM195), Lapusan et al., Invest New Drugs 30(3):1121-1131 (2012) (AVE9633), Aigner et al., Leukemia 27(5): 1107-1115 (2013) (AMG330, CD33 BiTE), Dutour et al., Adv hematol 2012:683065 (2012), and Pizzitola et al., Leukemia doi:10.1038/Lue.2014.62 (2014). 
     In one embodiment, an antigen binding domain against GD2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Mujoo et al., Cancer Res. 47(4):1098 1104 (1987); Cheung et al., Cancer Res 45(6):2642-2649 (1985), Cheung et al., J Clin Oncol 5(9):1430-1440 (1987), Cheung et al., J Clin Oncol 16(9):3053-3060 (1998), Handgretinger et al., Cancer Immunol Immunother 35(3):199-204 (1992). In some embodiments, an antigen binding domain against GD2 is an antigen binding portion of an antibody selected from mAb 14.18, 14G2a, ch14.18, hu14.18, 3F8, hu3F8, 3G6, 8B6, 60C3, 10B8, ME36.1, and 8H9, see e.g., WO2012033885, WO2013040371, WO2013192294, WO2013061273, WO2013123061, WO2013074916, and WO201385552. In some embodiments, an antigen binding domain against GD2 is an antigen binding portion of an antibody described in US Publication No.: 20100150910 or PCT Publication No.: WO 2011160119. 
     In one embodiment, an antigen binding domain against BCMA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2012163805, WO200112812, and WO2003062401. 
     In one embodiment, an antigen binding domain against Tn antigen is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 8,440,798, Brooks et al., PNAS 107(22):10056-10061 (2010), and Stone et al., OncoImmunology 1(6):863-873(2012). 
     In one embodiment, an antigen binding domain against PSMA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Parker et al., Protein Expr Purif 89(2):136-145 (2013), US 20110268656 (J591 ScFv); Frigerio et al, European J Cancer 49(9):2223-2232 (2013) (scFvD2B); WO 2006125481 (mAbs 3/A12, 3/E7 and 3/F11) and single chain antibody fragments (scFv A5 and D7). 
     In one embodiment, an antigen binding domain against ROR1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hudecek et al., Clin Cancer Res 19(12):3153-3164 (2013); WO 2011159847; and US20130101607. 
     In one embodiment, an antigen binding domain against FLT3 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2011076922, U.S. Pat. No. 5,777,084, EP0754230, US20090297529, and several commercial catalog antibodies (R&amp;D, ebiosciences, Abcam). 
     In one embodiment, an antigen binding domain against TAG72 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hombach et al., Gastroenterology 113(4):1163-1170 (1997); and Abcam ab691. 
     In one embodiment, an antigen binding domain against FAP is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Ostermann et al., Clinical Cancer Research 14:4584-4592 (2008) (FAP5), US Pat. Publication No. 2009/0304718; sibrotuzumab (see e.g., Hofheinz et al., Oncology Research and Treatment 26(1), 2003); and Tran et al., J Exp Med 210(6):1125-1135 (2013). 
     In one embodiment, an antigen binding domain against CD38 is an antigen binding portion, e.g., CDRs, of daratumumab (see, e.g., Groen et al., Blood 116(21):1261-1262 (2010); MOR202 (see, e.g., U.S. Pat. No. 8,263,746); or antibodies described in U.S. Pat. No. 8,362,211. 
     In one embodiment, an antigen binding domain against CD44v6 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Casucci et al., Blood 122(20):3461-3472 (2013). 
     In one embodiment, an antigen binding domain against CEA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Chmielewski et al., Gastoenterology 143(4):1095-1107 (2012). 
     In one embodiment, an antigen binding domain against EPCAM is an antigen binding portion, e.g., CDRS, of an antibody selected from MT110, EpCAM-CD3 bispecific Ab (see, e.g., clinicaltrials.gov/ct2/show/NCT00635596); Edrecolomab; 3622W94; ING-1; and adecatumumab (MT201). 
     In one embodiment, an antigen binding domain against PRSS21 is an antigen binding portion, e.g., CDRs, of an antibody described in U.S. Pat. No. 8,080,650. 
     In one embodiment, an antigen binding domain against B7H3 is an antigen binding portion, e.g., CDRs, of an antibody MGA271 (Macrogenics). 
     In one embodiment, an antigen binding domain against KIT is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 7,915,391, US20120288506, and several commercial catalog antibodies. 
     In one embodiment, an antigen binding domain against IL-13Ra2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2008/146911, WO2004087758, several commercial catalog antibodies, and WO2004087758. 
     In one embodiment, an antigen binding domain against CD30 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 7,090,843 B1, and EP0805871. 
     In one embodiment, an antigen binding domain against GD3 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. Nos. 7,253,263; 8,207,308; US 20120276046; EP1013761; WO2005035577; and U.S. Pat. No. 6,437,098. 
     In one embodiment, an antigen binding domain against CD171 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hong et al., J Immunother 37(2):93-104 (2014). 
     In one embodiment, an antigen binding domain against IL-11Ra is an antigen binding portion, e.g., CDRs, of an antibody available from Abcam (cat #ab55262) or Novus Biologicals (cat #EPR5446). In another embodiment, an antigen binding domain again IL-11Ra is a peptide, see, e.g., Huang et al., Cancer Res 72(1):271-281 (2012). 
     In one embodiment, an antigen binding domain against PSCA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Morgenroth et al., Prostate 67(10):1121-1131 (2007) (scFv 7F5); Nejatollahi et al., J of Oncology 2013(2013), article ID 839831 (scFv C5-II); and US Pat Publication No. 20090311181. 
     In one embodiment, an antigen binding domain against VEGFR2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Chinnasamy et al., J Clin Invest 120(11):3953-3968 (2010). 
     In one embodiment, an antigen binding domain against LewisY is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Kelly et al., Cancer Biother Radiopharm 23(4):411-423 (2008) (hu3S193 Ab (scFvs)); Dolezal et al., Protein Engineering 16(1):47-56 (2003) (NC10 scFv). 
     In one embodiment, an antigen binding domain against CD24 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Maliar et al., Gastroenterology 143(5):1375-1384 (2012). 
     In one embodiment, an antigen binding domain against PDGFR-beta is an antigen binding portion, e.g., CDRs, of an antibody Abcam ab32570. 
     In one embodiment, an antigen binding domain against SSEA-4 is an antigen binding portion, e.g., CDRs, of antibody MC813 (Cell Signaling), or other commercially available antibodies. 
     In one embodiment, an antigen binding domain against CD20 is an antigen binding portion, e.g., CDRs, of the antibody Rituximab, Ofatumumab, Ocrelizumab, Veltuzumab, or GA101. 
     In one embodiment, an antigen binding domain against Folate receptor alpha is an antigen binding portion, e.g., CDRs, of the antibody IMGN853, or an antibody described in US20120009181; U.S. Pat. No. 4,851,332, LK26: U.S. Pat. No. 5,952,484. 
     In one embodiment, an antigen binding domain against ERBB2 (Her2/neu) is an antigen binding portion, e.g., CDRs, of the antibody trastuzumab, or pertuzumab. 
     In one embodiment, an antigen binding domain against MUC1 is an antigen binding portion, e.g., CDRs, of the antibody SAR566658. 
     In one embodiment, the antigen binding domain against EGFR is antigen binding portion, e.g., CDRs, of the antibody cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab. 
     In one embodiment, an antigen binding domain against NCAM is an antigen binding portion, e.g., CDRs, of the antibody clone 2-2B: MAB5324 (EMD Millipore) In one embodiment, an antigen binding domain against Ephrin B2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Abengozar et al., Blood 119(19):4565-4576 (2012). 
     In one embodiment, an antigen binding domain against IGF-I receptor is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 8,344,112 B2; EP2322550 A1; WO 2006/138315, or PCT/US2006/022995. 
     In one embodiment, an antigen binding domain against CAIX is an antigen binding portion, e.g., CDRs, of the antibody clone 303123 (R&amp;D Systems). 
     In one embodiment, an antigen binding domain against LMP2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 7,410,640, or US20050129701. 
     In one embodiment, an antigen binding domain against gp100 is an antigen binding portion, e.g., CDRs, of the antibody HMB45, NKIbetaB, or an antibody described in WO2013165940, or US20130295007 
     In one embodiment, an antigen binding domain against tyrosinase is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 5,843,674; or U.S. Ser. No. 19/950,504048. 
     In one embodiment, an antigen binding domain against EphA2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Yu et al., Mol Ther 22(1):102-111 (2014). 
     In one embodiment, an antigen binding domain against GD3 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. Nos. 7,253,263; 8,207,308; US 20120276046; EP1013761 A3; 20120276046; WO2005035577; or U.S. Pat. No. 6,437,098. 
     In one embodiment, an antigen binding domain against fucosyl GM1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US20100297138; or WO2007/067992. 
     In one embodiment, an antigen binding domain against sLe is an antigen binding portion, e.g., CDRs, of the antibody G193 (for lewis Y), see Scott A M et al, Cancer Res 60: 3254-61 (2000), also as described in Neeson et al, J Immunol May 2013 190 (Meeting Abstract Supplement) 177.10. 
     In one embodiment, an antigen binding domain against GM3 is an antigen binding portion, e.g., CDRs, of the antibody CA 2523449 (mAb 14F7). 
     In one embodiment, an antigen binding domain against HMWMAA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Kmiecik et al., Oncoimmunology 3(1):e27185 (2014) (PMID: 24575382) (mAb9.2.27); U.S. Pat. No. 6,528,481; WO2010033866; or US 20140004124. 
     In one embodiment, an antigen binding domain against o-acetyl-GD2 is an antigen binding portion, e.g., CDRs, of the antibody 8B6. 
     In one embodiment, an antigen binding domain against TEM1/CD248 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Marty et al., Cancer Lett 235(2):298-308 (2006); Zhao et al., J Immunol Methods 363(2):221-232 (2011). 
     In one embodiment, an antigen binding domain against CLDN6 is an antigen binding portion, e.g., CDRs, of the antibody IMAB027 (Ganymed Pharmaceuticals), see e.g., clinicaltrial.gov/show/NCT02054351. 
     In one embodiment, an antigen binding domain against TSHR is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. Nos. 8,603,466; 8,501,415; or U.S. Pat. No. 8,309,693. 
     In one embodiment, an antigen binding domain against GPRC5D is an antigen binding portion, e.g., CDRs, of the antibody FAB6300A (R&amp;D Systems); or LS-A4180 (Lifespan Biosciences). 
     In one embodiment, an antigen binding domain against CD97 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 6,846,911; de Groot et al., J Immunol 183(6):4127-4134 (2009); or an antibody from R&amp;D:MAB3734. 
     In one embodiment, an antigen binding domain against ALK is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Mino-Kenudson et al., Clin Cancer Res 16(5):1561-1571 (2010). 
     In one embodiment, an antigen binding domain against polysialic acid is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Nagae et al., J Biol Chem 288(47):33784-33796 (2013). 
     In one embodiment, an antigen binding domain against PLAC1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Ghods et al., Biotechnol Appl Biochem 2013 doi:10.1002/bab.1177. 
     In one embodiment, an antigen binding domain against GloboH is an antigen binding portion of the antibody VK9; or an antibody described in, e.g., Kudryashov V et al, Glycoconj J.15(3):243-9 (1998), Lou et al., Proc Natl Acad Sci USA 111(7):2482-2487 (2014); MBr1: Bremer E-G et al. J Biol Chem 259:14773-14777 (1984). 
     In one embodiment, an antigen binding domain against NY-BR-1 is an antigen binding portion, e.g., CDRs of an antibody described in, e.g., Jager et al., Appl Immunohistochem Mol Morphol 15(1):77-83 (2007). 
     In one embodiment, an antigen binding domain against WT-1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Dao et al., Sci Transl Med 5(176):176ra33 (2013); or WO2012/135854. 
     In one embodiment, an antigen binding domain against MAGE-A1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Willemsen et al., J Immunol 174(12):7853-7858 (2005) (TCR-like scFv). 
     In one embodiment, an antigen binding domain against sperm protein 17 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Song et al., Target Oncol Aug. 14, 2013 (PMID: 23943313); Song et al., Med Oncol 29(4):2923-2931 (2012). 
     In one embodiment, an antigen binding domain against Tie 2 is an antigen binding portion, e.g., CDRs, of the antibody AB33 (Cell Signaling Technology). 
     In one embodiment, an antigen binding domain against MAD-CT-2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., PMID: 2450952; U.S. Pat. No. 7,635,753. 
     In one embodiment, an antigen binding domain against Fos-related antigen 1 is an antigen binding portion, e.g., CDRs, of the antibody 12F9 (Novus Biologicals). 
     In one embodiment, an antigen binding domain against MelanA/MART1 is an antigen binding portion, e.g., CDRs, of an antibody described in, EP2514766 A2; or U.S. Pat. No. 7,749,719. 
     In one embodiment, an antigen binding domain against sarcoma translocation breakpoints is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Luo et al, EMBO Mol. Med. 4(6):453-461 (2012). 
     In one embodiment, an antigen binding domain against TRP-2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Wang et al, J Exp Med. 184(6):2207-16 (1996). 
     In one embodiment, an antigen binding domain against CYP1B1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Maecker et al, Blood 102 (9): 3287-3294 (2003). 
     In one embodiment, an antigen binding domain against RAGE-1 is an antigen binding portion, e.g., CDRs, of the antibody MAB5328 (EMD Millipore). 
     In one embodiment, an antigen binding domain against human telomerase reverse transcriptase is an antigen binding portion, e.g., CDRs, of the antibody cat no: LS-B95-100 (Lifespan Biosciences) 
     In one embodiment, an antigen binding domain against intestinal carboxyl esterase is an antigen binding portion, e.g., CDRs, of the antibody 4F12: cat no: LS-B6190-50 (Lifespan Biosciences). 
     In one embodiment, an antigen binding domain against mut hsp70-2 is an antigen binding portion, e.g., CDRs, of the antibody Lifespan Biosciences: monoclonal: cat no: LS-C133261-100 (Lifespan Biosciences). 
     In one embodiment, an antigen binding domain against CD79a is an antigen binding portion, e.g., CDRs, of the antibody Anti-CD79a antibody [HM47/A9] (ab3121), available from Abcam; antibody CD79A Antibody #3351 available from Cell Signalling Technology; or antibody HPA017748-Anti-CD79A antibody produced in rabbit, available from Sigma Aldrich. 
     In one embodiment, an antigen binding domain against CD79b is an antigen binding portion, e.g., CDRs, of the antibody polatuzumab vedotin, anti-CD79b described in Dornan et al., “Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma” Blood. Sep. 24, 2009; 114(13):2721-9. doi: 10.1182/blood-2009-02-205500. Epub Jul. 24, 2009, or the bispecific antibody Anti-CD79b/CD3 described in “4507 Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies” Abstracts of 56 th  ASH Annual Meeting and Exposition, San Francisco, Calif. Dec. 6-9 2014. 
     In one embodiment, an antigen binding domain against CD72 is an antigen binding portion, e.g., CDRs, of the antibody J3-109 described in Myers, and Uckun, “An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.” Leuk Lymphoma. 1995 June; 18(1-2):119-22, or anti-CD72 (10D6.8.1, mIgG1) described in Poison et al., “Antibody-Drug Conjugates for the Treatment of Non-Hodgkin&#39;s Lymphoma: Target and Linker-Drug Selection” Cancer Res Mar. 15, 2009 69; 2358. 
     In one embodiment, an antigen binding domain against LAIR1 is an antigen binding portion, e.g., CDRs, of the antibody ANT-301 LAIR1 antibody, available from ProSpec; or anti-human CD305 (LAIR1) Antibody, available from BioLegend. 
     In one embodiment, an antigen binding domain against FCAR is an antigen binding portion, e.g., CDRs, of the antibody CD89/FCARAntibody (Catalog #10414-H08H), available from Sino Biological Inc. 
     In one embodiment, an antigen binding domain against LILRA2 is an antigen binding portion, e.g., CDRs, of the antibody LILRA2 monoclonal antibody (M17), clone 3C7, available from Abnova, or Mouse Anti-LILRA2 antibody, Monoclonal (2D7), available from Lifespan Biosciences. 
     In one embodiment, an antigen binding domain against CD300LF is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-CMRF35-like molecule 1 antibody, Monoclonal[UP-D2], available from BioLegend, or Rat Anti-CMRF35-like molecule 1 antibody, Monoclonal[234903], available from R&amp;D Systems. 
     In one embodiment, an antigen binding domain against CLEC12A is an antigen binding portion, e.g., CDRs, of the antibody Bispecific T cell Engager (BiTE) scFv-antibody and ADC described in Noordhuis et al., “Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody” 53 rd  ASH Annual Meeting and Exposition, Dec. 10-13, 2011, and MCLA-117 (Merus). 
     In one embodiment, an antigen binding domain against BST2 (also called CD317) is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-CD317 antibody, Monoclonal[3H4], available from Antibodies-Online or Mouse Anti-CD317 antibody, Monoclonal[696739], available from R&amp;D Systems. 
     In one embodiment, an antigen binding domain against EMR2 (also called CD312) is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-CD312 antibody, Monoclonal[LS-B8033] available from Lifespan Biosciences, or Mouse Anti-CD312 antibody, Monoclonal[494025] available from R&amp;D Systems. 
     In one embodiment, an antigen binding domain against LY75 is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-Lymphocyte antigen 75 antibody, Monoclonal[HD30] available from EMD Millipore or Mouse Anti-Lymphocyte antigen 75 antibody, Monoclonal[A15797] available from Life Technologies. 
     In one embodiment, an antigen binding domain against GPC3 is an antigen binding portion, e.g., CDRs, of the antibody hGC33 described in Nakano K, Ishiguro T, Konishi H, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs. 2010 November; 21(10):907-916, or MDX-1414, HN3, or YP7, all three of which are described in Feng et al., “Glypican-3 antibodies: a new therapeutic target for liver cancer.” FEBS Lett. Jan. 21, 2013; 588(2):377-82. 
     In one embodiment, an antigen binding domain against FCRL5 is an antigen binding portion, e.g., CDRs, of the anti-FcRL5 antibody described in Elkins et al., “FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma” Mol Cancer Ther. 2012 October; 11(10):2222-32. 
     In one embodiment, an antigen binding domain against IGLL1 is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-Immunoglobulin lambda-like polypeptide 1 antibody, Monoclonal[AT1G4] available from Lifespan Biosciences, Mouse Anti-Immunoglobulin lambda-like polypeptide 1 antibody, Monoclonal[HSL11] available from BioLegend. 
     In one embodiment, the antigen binding domain comprises one, two three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2 and HC CDR3, from an antibody listed above, and/or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2 and LC CDR3, from an antibody listed above. In one embodiment, the antigen binding domain comprises a heavy chain variable region and/or a variable light chain region of an antibody listed above. 
     In another aspect, the antigen binding domain comprises a humanized antibody or an antibody fragment. In some aspects, a non-human antibody is humanized, where specific sequences or regions of the antibody are modified to increase similarity to an antibody naturally produced in a human or fragment thereof. In one aspect, the antigen binding domain is humanized. 
     A humanized antibody can be produced using a variety of techniques known in the art, including but not limited to, CDR-grafting (see, e.g., European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089, each of which is incorporated herein in its entirety by reference), veneering or resurfacing (see, e.g., European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology, 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al., 1994, PNAS, 91:969-973, each of which is incorporated herein by its entirety by reference), chain shuffling (see, e.g., U.S. Pat. No. 5,565,332, which is incorporated herein in its entirety by reference), and techniques disclosed in, e.g., U.S. Patent Application Publication No. US2005/0042664, U.S. Patent Application Publication No. US2005/0048617, U.S. Pat. Nos. 6,407,213, 5,766,886, International Publication No. WO 9317105, Tan et al., J. Immunol., 169:1119-25 (2002), Caldas et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods, 20(3):267-79 (2000), Baca et al., J. Biol. Chem., 272(16):10678-84 (1997), Roguska et al., Protein Eng., 9(10):895-904 (1996), Couto et al., Cancer Res., 55 (23 Supp):5973s-5977s (1995), Couto et al., Cancer Res., 55(8):1717-22 (1995), Sandhu J S, Gene, 150(2):409-10 (1994), and Pedersen et al., J. Mol. Biol., 235(3):959-73 (1994), each of which is incorporated herein in its entirety by reference. Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, for example improve, antigen binding. These framework substitutions are identified by methods well-known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089; and Riechmann et al., 1988, Nature, 332:323, which are incorporated herein by reference in their entireties.) 
     A humanized antibody or antibody fragment has one or more amino acid residues remaining in it from a source which is nonhuman. These nonhuman amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain. As provided herein, humanized antibodies or antibody fragments comprise one or more CDRs from nonhuman immunoglobulin molecules and framework regions wherein the amino acid residues comprising the framework are derived completely or mostly from human germline. Multiple techniques for humanization of antibodies or antibody fragments are well-known in the art and can essentially be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody, i.e., CDR-grafting (EP 239,400; PCT Publication No. WO 91/09967; and U.S. Pat. Nos. 4,816,567; 6,331,415; 5,225,539; 5,530,101; 5,585,089; 6,548,640, the contents of which are incorporated herein by reference herein in their entirety). In such humanized antibodies and antibody fragments, substantially less than an intact human variable domain has been substituted by the corresponding sequence from a nonhuman species. Humanized antibodies are often human antibodies in which some CDR residues and possibly some framework (FR) residues are substituted by residues from analogous sites in rodent antibodies. Humanization of antibodies and antibody fragments can also be achieved by veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology, 28(4/5):489-498; Studnicka et al., Protein Engineering, 7(6):805-814 (1994); and Roguska et al., PNAS, 91:969-973 (1994)) or chain shuffling (U.S. Pat. No. 5,565,332), the contents of which are incorporated herein by reference herein in their entirety. 
     The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is to reduce antigenicity. According to the so-called “best-fit” method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., J. Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987), the contents of which are incorporated herein by reference herein in their entirety). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (see, e.g., Nicholson et al. Mol. Immun 34 (16-17): 1157-1165 (1997); Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993), the contents of which are incorporated herein by reference herein in their entirety). In some embodiments, the framework region, e.g., all four framework regions, of the heavy chain variable region are derived from a VH4_4-59 germline sequence. In one embodiment, the framework region can comprise, one, two, three, four or five modifications, e.g., substitutions, e.g., from the amino acid at the corresponding murine sequence. In one embodiment, the framework region, e.g., all four framework regions of the light chain variable region are derived from a VK3_1.25 germline sequence. In one embodiment, the framework region can comprise, one, two, three, four or five modifications, e.g., substitutions, e.g., from the amino acid at the corresponding murine sequence. 
     In some aspects, the portion of a CAR composition of the invention that comprises an antibody fragment is humanized with retention of high affinity for the target antigen and other favorable biological properties. According to one aspect of the invention, humanized antibodies and antibody fragments are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, e.g., the analysis of residues that influence the ability of the candidate immunoglobulin to bind the target antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody or antibody fragment characteristic, such as increased affinity for the target antigen, is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding. 
     A humanized antibody or antibody fragment may retain a similar antigenic specificity as the original antibody, e.g., in the present invention, the ability to bind human a cancer associated antigen as described herein. In some embodiments, a humanized antibody or antibody fragment may have improved affinity and/or specificity of binding to human a cancer associated antigen as described herein. 
     In one aspect, the antigen binding domain of the invention is characterized by particular functional features or properties of an antibody or antibody fragment. For example, in one aspect, the portion of a CAR composition of the invention that comprises an antigen binding domain specifically binds a tumor antigen as described herein. 
     In one aspect, the anti-cancer associated antigen as described herein binding domain is a fragment, e.g., a single chain variable fragment (scFv). In one aspect, the anti-cancer associated antigen as described herein binding domain is a Fv, a Fab, a (Fab′)2, or a bi-functional (e.g. bi-specific) hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)). In one aspect, the antibodies and fragments thereof of the invention binds a cancer associated antigen as described herein protein with wild-type or enhanced affinity. 
     In some instances, scFvs can be prepared according to method known in the art (see, for example, Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). ScFv molecules can be produced by linking VH and VL regions together using flexible polypeptide linkers. The scFv molecules comprise a linker (e.g., a Ser-Gly linker) with an optimized length and/or amino acid composition. The linker length can greatly affect how the variable regions of a scFv fold and interact. In fact, if a short polypeptide linker is employed (e.g., between 5-10 amino acids) intrachain folding is prevented. Interchain folding is also required to bring the two variable regions together to form a functional epitope binding site. For examples of linker orientation and size see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. U.S.A. 90:6444-6448, U.S. Patent Application Publication Nos. 2005/0100543, 2005/0175606, 2007/0014794, and PCT publication Nos. WO2006/020258 and WO2007/024715, is incorporated herein by reference. 
     An scFv can comprise a linker of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more amino acid residues between its VL and VH regions. The linker sequence may comprise any naturally occurring amino acid. In some embodiments, the linker sequence comprises amino acids glycine and serine. In another embodiment, the linker sequence comprises sets of glycine and serine repeats such as (Gly 4 Ser)n, where n is a positive integer equal to or greater than 1 (SEQ ID NO:22). In one embodiment, the linker can be (Gly 4 Ser) 4  (SEQ ID NO:29) or (Gly 4 Ser) 3 (SEQ ID NO:30). Variation in the linker length may retain or enhance activity, giving rise to superior efficacy in activity studies. 
     In another aspect, the antigen binding domain is a T cell receptor (“TCR”), or a fragment thereof, for example, a single chain TCR (scTCR). Methods to make such TCRs are known in the art. See, e.g., Willemsen R A et al, Gene Therapy 7: 1369-1377 (2000); Zhang T et al, Cancer Gene Ther 11: 487-496 (2004); Aggen et al, Gene Ther. 19(4):365-74 (2012) (references are incorporated herein by its entirety). For example, scTCR can be engineered that contains the Vα and Vβ genes from a T cell clone linked by a linker (e.g., a flexible peptide). This approach is very useful to cancer associated target that itself is intracellar, however, a fragment of such antigen (peptide) is presented on the surface of the cancer cells by MHC. 
     In one embodiment, an antigen binding domain against EGFRvIII is an antigen binding portion, e.g., CDRs, of a CAR, antibody or antigen-binding fragment thereof described in, e.g., PCT publication WO2014/130657 or US2014/0322275A1. In one embodiment, the CAR molecule comprises an EGFRvIII CAR, or an antigen binding domain according to Table 2 or SEQ ID NO:11 of WO 2014/130657, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical thereto). The amino acid and nucleotide sequences encoding the EGFRvIII CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO 2014/130657. 
     In one embodiment, an antigen binding domain against mesothelin is an antigen binding portion, e.g., CDRs, of an antibody, antigen-binding fragment or CAR described in, e.g., PCT publication WO2015/090230. In one embodiment, an antigen binding domain against mesothelin is an antigen binding portion, e.g., CDRs, of an antibody, antigen-binding fragment, or CAR described in, e.g., PCT publication WO1997/025068, WO1999/028471, WO2005/014652, WO2006/099141, WO2009/045957, WO2009/068204, WO2013/142034, WO2013/040557, or WO2013/063419. 
     In an embodiment, the CAR molecule comprises a mesothelin CAR described herein, e.g., a mesothelin CAR described in WO 2015/090230, incorporated herein by reference. In embodiments, the mesothelin CAR comprises an amino acid, or has a nucleotide sequence shown in WO 2015/090230 incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid mesothelin CAR sequences). In one embodiment, the CAR molecule comprises a mesothelin CAR, or an antigen binding domain according to Tables 2-3 of WO 2015/090230, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical thereto). The amino acid and nucleotide sequences encoding the mesothelin CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO 2015/090230. 
     In one embodiment, an antigen binding domain against CD123 is an antigen binding portion, e.g., CDRs, of an antibody, antigen-binding fragment or CAR described in, e.g., PCT publication WO2016/028896. In one embodiment, an antigen binding domain against CD123 is an antigen binding portion, e.g., CDRs, of an antibody, antigen-binding fragment or CAR described in, e.g., PCT publication WO2014/130635. In one embodiment, an antigen binding domain against CD123 is an antigen binding portion, e.g., CDRs, of an antibody, antigen-binding fragment, or CAR described in, e.g., PCT publication WO2014/138805, WO2014/138819, WO2013/173820, WO2014/144622, WO2001/66139, WO2010/126066, WO2014/144622, or US2009/0252742. 
     In one embodiment, an antigen binding domain against CD123 is an antigen binding portion, e.g., CDRs, of an antibody, antigen-binding fragment or CAR described in, e.g., US2014/0322212A1 or US2016/0068601A1, both incorporated herein by reference. In embodiments, the CD123 CAR comprises an amino acid, or has a nucleotide sequence shown in US2014/0322212A1 or US2016/0068601A1, both incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD123 CAR sequences). In one embodiment, the CAR molecule comprises a CD123 CAR (e.g., any of the CAR1-CARE), or an antigen binding domain according to Tables 1-2 of WO 2014/130635, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD123 CAR sequences). The amino acid and nucleotide sequences encoding the CD123 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO 2014/130635. 
     In other embodiments, the CAR molecule comprises a CD123 CAR comprises a CAR molecule (e.g., any of the CAR123-1 to CAR123-4 and hzCAR123-1 to hzCAR123-32), or an antigen binding domain according to Tables 2, 6, and 9 of WO2016/028896, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD123 CAR sequences). The amino acid and nucleotide sequences encoding the CD123 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/028896. 
     In one embodiment, an antigen binding domain against CD22 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Haso et al., Blood, 121(7): 1165-1174 (2013); Wayne et al., Clin Cancer Res 16(6): 1894-1903 (2010); Kato et al., Leuk Res 37(1):83-88 (2013); Creative BioMart (creativebiomart.net): MOM-18047-S(P). 
     In one embodiment, an antigen binding domain against CS-1 is an antigen binding portion, e.g., CDRs, of Elotuzumab (BMS), see e.g., Tai et al., 2008, Blood 112(4):1329-37; Tai et al., 2007, Blood. 110(5):1656-63. 
     In one embodiment, an antigen binding domain against CLL-1 is an antigen binding portion, e.g., CDRs, of an antibody available from R&amp;D, ebiosciences, Abcam, for example, PE-CLL1-hu Cat #353604 (BioLegend); and PE-CLL1 (CLEC12A) Cat #562566 (BD). 
     In other embodiments, the CLL1 CAR includes a CAR molecule, or an antigen binding domain according to Table 2 of WO2016/014535, incorporated herein by reference. The amino acid and nucleotide sequences encoding the CLL-1 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/014535. 
     In one embodiment, an antigen binding domain against CD33 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Bross et al., Clin Cancer Res 7(6):1490-1496 (2001) (Gemtuzumab Ozogamicin, hP67.6), Caron et al., Cancer Res 52(24):6761-6767 (1992) (Lintuzumab, HuM195), Lapusan et al., Invest New Drugs 30(3):1121-1131 (2012) (AVE9633), Aigner et al., Leukemia 27(5): 1107-1115 (2013) (AMG330, CD33 BiTE), Dutour et al., Adv hematol 2012:683065 (2012), and Pizzitola et al., Leukemia doi:10.1038/Lue.2014.62 (2014). 
     In one embodiment, an antigen binding domain against CD33 is an antigen binding portion, e.g., CDRs, of an antibody described in, US2016/0096892A1, incorporated herein by reference. In embodiments, the CD33 CAR comprises an amino acid, or has a nucleotide sequence shown in US2016/0096892A1, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD33 CAR sequences). In other embodiments, the CD33 CAR CAR or antigen binding domain thereof can include a CAR molecule (e.g., any of CAR33-1 to CAR-33-9), or an antigen binding domain according to Table 2 or 9 of WO2016/014576, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD33 CAR sequences). The amino acid and nucleotide sequences encoding the CD33 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/014576. 
     In one embodiment, an antigen binding domain against GD2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Mujoo et al., Cancer Res. 47(4):1098-1104 (1987); Cheung et al., Cancer Res 45(6):2642-2649 (1985), Cheung et al., J Clin Oncol 5(9):1430-1440 (1987), Cheung et al., J Clin Oncol 16(9):3053-3060 (1998), Handgretinger et al., Cancer Immunol Immunother 35(3):199-204 (1992). In some embodiments, an antigen binding domain against GD2 is an antigen binding portion of an antibody selected from mAb 14.18, 14G2a, ch14.18, hu14.18, 3F8, hu3F8, 3G6, 8B6, 60C3, 10B8, ME36.1, and 8H9, see e.g., WO2012033885, WO2013040371, WO2013192294, WO2013061273, WO2013123061, WO2013074916, and WO201385552. In some embodiments, an antigen binding domain against GD2 is an antigen binding portion of an antibody described in US Publication No.: 20100150910 or PCT Publication No.: WO 2011160119. 
     In one embodiment, an antigen binding domain against BCMA is an antigen binding portion, e.g., CDRs, of an antibody, antigen-binding fragment or CAR described in, e.g., PCT publication WO2016/014565, e.g., the antigen binding portion of CAR BCMA-10 as described in WO2016/014565. In one embodiment, an antigen binding domain against BCMA is an antigen binding portion, e.g., CDRs, of an antibody, antigen-binding fragment or CAR described in, e.g., PCT publication WO2016/014789. In one embodiment, an antigen binding domain against BCMA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2012/163805, WO2001/12812, and WO2003/062401. 
     In other embodiment, the CAR molecule comprises a BCMA CAR molecule, or an antigen binding domain against BCMA described herein, e.g., a BCMA CAR described in US-2016-0046724-A1 or WO2016/014565. In embodiments, the BCMA CAR comprises an amino acid, or has a nucleotide sequence of a CAR molecule, or an antigen binding domain according to US-2016-0046724-A1, or Table 1 or 16, SEQ ID NO: 271 or SEQ ID NO: 273 of WO2016/014565, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid BCMA CAR sequences). The amino acid and nucleotide sequences encoding the BCMA CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/014565. 
     In one embodiment, an antigen binding domain against GFR ALPHA-4 CAR antigen is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2016/025880, incorporated herein by reference. In one embodiment, the CAR molecule comprises an a GFR ALPHA-4 CAR, e.g., a CAR molecule, or an antigen binding domain according to Table 2 of WO2016/025880, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid GFR ALPHA-4 sequences). The amino acid and nucleotide sequences encoding the GFR ALPHA-4 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/025880. 
     In one embodiment, an antigen binding domain against Tn antigen is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 8,440,798; Brooks et al., PNAS 107(22):10056-10061 (2010), and Stone et al., OncoImmunology 1(61:863-873(2012). 
     In one embodiment, an antigen binding domain against PSMA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Parker et al., Protein Expr Purif 89(2):136-145 (2013), US 20110268656 (J591 ScFv); Frigerio et al, European J Cancer 49(9):2223-2232 (2013) (scFvD2B); WO 2006125481 (mAbs 3/A12, 3/E7 and 3/F11) and single chain antibody fragments (scFv A5 and D7). 
     In one embodiment, an antigen binding domain against ROR1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hudecek et al., Clin Cancer Res 19(12):3153-3164 (2013); WO 2011159847; and US20130101607. 
     In one embodiment, an antigen binding domain against FLT3 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2011076922, U.S. Pat. No. 5,777,084, EP0754230, US20090297529, and several commercial catalog antibodies (R&amp;D, ebiosciences, Abcam). 
     In one embodiment, an antigen binding domain against TAG72 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hombach et al., Gastroenterology 113(4):1163-1170 (1997); and Abcam ab691. 
     In one embodiment, an antigen binding domain against FAP is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Ostermann et al., Clinical Cancer Research 14:4584-4592 (2008) (FAP5), US Pat. Publication No. 2009/0304718; sibrotuzumab (see e.g., Hofheinz et al., Oncology Research and Treatment 26(1), 2003); and Tran et al., J Exp Med 210(6):1125-1135 (2013). 
     In one embodiment, an antigen binding domain against CD38 is an antigen binding portion, e.g., CDRs, of daratumumab (see, e.g., Groen et al., Blood 116(21):1261-1262 (2010); MOR202 (see, e.g., U.S. Pat. No. 8,263,746); or antibodies described in U.S. Pat. No. 8,362,211. 
     In one embodiment, an antigen binding domain against CD44v6 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Casucci et al., Blood 122(20):3461-3472 (2013). 
     In one embodiment, an antigen binding domain against CEA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Chmielewski et al., Gastoenterology 143(4):1095-1107 (2012). 
     In one embodiment, an antigen binding domain against EPCAM is an antigen binding portion, e.g., CDRS, of an antibody selected from MT110, EpCAM-CD3 bispecific Ab (see, e.g., clinicaltrials.gov/ct2/show/NCT00635596); Edrecolomab; 3622W94; ING-1; and adecatumumab (MT201). 
     In one embodiment, an antigen binding domain against PRSS21 is an antigen binding portion, e.g., CDRs, of an antibody described in U.S. Pat. No. 8,080,650. 
     In one embodiment, an antigen binding domain against B7H3 is an antigen binding portion, e.g., CDRs, of an antibody MGA271 (Macrogenics). 
     In one embodiment, an antigen binding domain against KIT is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 7,915,391, US20120288506, and several commercial catalog antibodies. 
     In one embodiment, an antigen binding domain against IL-13Ra2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2008/146911, WO2004087758, several commercial catalog antibodies, and WO2004087758. 
     In one embodiment, an antigen binding domain against CD30 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 7,090,843 B1, and EP0805871. 
     In one embodiment, an antigen binding domain against GD3 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. Nos. 7,253,263; 8,207,308; US 20120276046; EP1013761; WO2005035577; and U.S. Pat. No. 6,437,098. 
     In one embodiment, an antigen binding domain against CD171 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hong et al., J Immunother 37(2):93-104 (2014). 
     In one embodiment, an antigen binding domain against IL-11Ra is an antigen binding portion, e.g., CDRs, of an antibody available from Abcam (cat #ab55262) or Novus Biologicals (cat #EPR5446). In another embodiment, an antigen binding domain again IL-11Ra is a peptide, see, e.g., Huang et al., Cancer Res 72(1):271-281 (2012). 
     In one embodiment, an antigen binding domain against PSCA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Morgenroth et al., Prostate 67(10):1121-1131 (2007) (scFv 7F5); Nejatollahi et al., J of Oncology 2013(2013), article ID 839831 (scFv C5-II); and US Pat Publication No. 20090311181. 
     In one embodiment, an antigen binding domain against VEGFR2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Chinnasamy et al., J Clin Invest 120(11):3953-3968 (2010). 
     In one embodiment, an antigen binding domain against LewisY is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Kelly et al., Cancer Biother Radiopharm 23(4):411-423 (2008) (hu3S193 Ab (scFvs)); Dolezal et al., Protein Engineering 16(1):47-56 (2003) (NC10 scFv). 
     In one embodiment, an antigen binding domain against CD24 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Maliar et al., Gastroenterology 143(5):1375-1384 (2012). 
     In one embodiment, an antigen binding domain against PDGFR-beta is an antigen binding portion, e.g., CDRs, of an antibody Abcam ab32570. 
     In one embodiment, an antigen binding domain against SSEA-4 is an antigen binding portion, e.g., CDRs, of antibody MC813 (Cell Signaling), or other commercially available antibodies. 
     In one embodiment, an antigen binding domain against CD20 is an antigen binding portion, e.g., CDRs, of the antibody Rituximab, Ofatumumab, Ocrelizumab, Veltuzumab, or GA101. 
     In one embodiment, an antigen binding domain against Folate receptor alpha is an antigen binding portion, e.g., CDRs, of the antibody IMGN853, or an antibody described in US20120009181; U.S. Pat. No. 4,851,332, LK26: U.S. Pat. No. 5,952,484. 
     In one embodiment, an antigen binding domain against ERBB2 (Her2/neu) is an antigen binding portion, e.g., CDRs, of the antibody trastuzumab, or pertuzumab. 
     In one embodiment, an antigen binding domain against MUC1 is an antigen binding portion, e.g., CDRs, of the antibody SAR566658. 
     In one embodiment, the antigen binding domain against EGFR is antigen binding portion, e.g., CDRs, of the antibody cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab. 
     In one embodiment, an antigen binding domain against NCAM is an antigen binding portion, e.g., CDRs, of the antibody clone 2-2B: MAB5324 (EMD Millipore). 
     In one embodiment, an antigen binding domain against Ephrin B2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Abengozar et al., Blood 119(19):4565-4576 (2012). 
     In one embodiment, an antigen binding domain against IGF-I receptor is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 8,344,112 B2; EP2322550 A1; WO 2006/138315, or PCT/US2006/022995. 
     In one embodiment, an antigen binding domain against CAIX is an antigen binding portion, e.g., CDRs, of the antibody clone 303123 (R&amp;D Systems). 
     In one embodiment, an antigen binding domain against LMP2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 7,410,640, or US20050129701. 
     In one embodiment, an antigen binding domain against gp100 is an antigen binding portion, e.g., CDRs, of the antibody HMB45, NKIbetaB, or an antibody described in WO2013165940, or US20130295007 
     In one embodiment, an antigen binding domain against tyrosinase is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 5,843,674; or U.S. Ser. No. 19/950,504048. 
     In one embodiment, an antigen binding domain against EphA2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Yu et al., Mol Ther 22(1):102-111 (2014). 
     In one embodiment, an antigen binding domain against GD3 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. Nos. 7,253,263; 8,207,308; US 20120276046; EP1013761 A3; 20120276046; WO2005035577; or U.S. Pat. No. 6,437,098. 
     In one embodiment, an antigen binding domain against fucosyl GM1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US20100297138; or WO2007/067992. 
     In one embodiment, an antigen binding domain against sLe is an antigen binding portion, e.g., CDRs, of the antibody G193 (for lewis Y), see Scott A M et al, Cancer Res 60: 3254-61 (2000), also as described in Neeson et al, J Immunol May 2013 190 (Meeting Abstract Supplement) 177.10. 
     In one embodiment, an antigen binding domain against GM3 is an antigen binding portion, e.g., CDRs, of the antibody CA 2523449 (mAb 14F7). 
     In one embodiment, an antigen binding domain against HMWMAA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Kmiecik et al., Oncoimmunology 3(1):e27185 (2014) (PMID: 24575382) (mAb9.2.27); U.S. Pat. No. 6,528,481; WO2010033866; or US 20140004124. 
     In one embodiment, an antigen binding domain against o-acetyl-GD2 is an antigen binding portion, e.g., CDRs, of the antibody 8B6. 
     In one embodiment, an antigen binding domain against TEM1/CD248 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Marty et al., Cancer Lett 235(2):298-308 (2006); Zhao et al., J Immunol Methods 363(2):221-232 (2011). 
     In one embodiment, an antigen binding domain against CLDN6 is an antigen binding portion, e.g., CDRs, of the antibody IMAB027 (Ganymed Pharmaceuticals), see e.g., clinicaltrial.gov/show/NCT02054351. 
     In one embodiment, an antigen binding domain against TSHR is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. Nos. 8,603,466; 8,501,415; or U.S. Pat. No. 8,309,693. 
     In one embodiment, an antigen binding domain against GPRC5D is an antigen binding portion, e.g., CDRs, of the antibody FAB6300A (R&amp;D Systems); or LS-A4180 (Lifespan Biosciences). 
     In one embodiment, an antigen binding domain against CD97 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., U.S. Pat. No. 6,846,911; de Groot et al., J Immunol 183(6):4127-4134 (2009); or an antibody from R&amp;D:MAB3734. 
     In one embodiment, an antigen binding domain against ALK is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Mino-Kenudson et al., Clin Cancer Res 16(5):1561-1571 (2010). 
     In one embodiment, an antigen binding domain against polysialic acid is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Nagae et al., J Biol Chem 288(47):33784-33796 (2013). 
     In one embodiment, an antigen binding domain against PLAC1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Ghods et al., Biotechnol Appl Biochem 2013 doi:10.1002/bab.1177. 
     In one embodiment, an antigen binding domain against GloboH is an antigen binding portion of the antibody VK9; or an antibody described in, e.g., Kudryashov V et al, Glycoconj J.15(3):243-9 (1998), Lou et al., Proc Natl Acad Sci USA 111(7):2482-2487 (2014); MBr1: Bremer E-G et al. J Biol Chem 259:14773-14777 (1984). 
     In one embodiment, an antigen binding domain against NY-BR-1 is an antigen binding portion, e.g., CDRs of an antibody described in, e.g., Jager et al., Appl Immunohistochem Mol Morphol 15(1):77-83 (2007). 
     In one embodiment, an antigen binding domain against WT-1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Dao et al., Sci Transl Med 5(176):176ra33 (2013); or WO2012/135854. 
     In one embodiment, an antigen binding domain against MAGE-A1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Willemsen et al., J Immunol 174(12):7853-7858 (2005) (TCR-like scFv). 
     In one embodiment, an antigen binding domain against sperm protein 17 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Song et al., Target Oncol Aug. 14, 2013 (PMID: 23943313); Song et al., Med Oncol 29(4):2923-2931 (2012). 
     In one embodiment, an antigen binding domain against Tie 2 is an antigen binding portion, e.g., CDRs, of the antibody AB33 (Cell Signaling Technology). 
     In one embodiment, an antigen binding domain against MAD-CT-2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., PMID: 2450952; U.S. Pat. No. 7,635,753. 
     In one embodiment, an antigen binding domain against Fos-related antigen 1 is an antigen binding portion, e.g., CDRs, of the antibody 12F9 (Novus Biologicals). 
     In one embodiment, an antigen binding domain against MelanA/MART1 is an antigen binding portion, e.g., CDRs, of an antibody described in, EP2514766 A2; or U.S. Pat. No. 7,749,719. 
     In one embodiment, an antigen binding domain against sarcoma translocation breakpoints is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Luo et al, EMBO Mol. Med. 4(6):453-461 (2012). 
     In one embodiment, an antigen binding domain against TRP-2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Wang et al, J Exp Med. 184(6):2207-16 (1996). 
     In one embodiment, an antigen binding domain against CYP1B1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Maecker et al, Blood 102 (9): 3287-3294 (2003). 
     In one embodiment, an antigen binding domain against RAGE-1 is an antigen binding portion, e.g., CDRs, of the antibody MAB5328 (EMD Millipore). 
     In one embodiment, an antigen binding domain against human telomerase reverse transcriptase is an antigen binding portion, e.g., CDRs, of the antibody cat no: LS-B95-100 (Lifespan Biosciences) 
     In one embodiment, an antigen binding domain against intestinal carboxyl esterase is an antigen binding portion, e.g., CDRs, of the antibody 4F12: cat no: LS-B6190-50 (Lifespan Biosciences). 
     In one embodiment, an antigen binding domain against mut hsp70-2 is an antigen binding portion, e.g., CDRs, of the antibody Lifespan Biosciences: monoclonal: cat no: LS-C133261-100 (Lifespan Biosciences). 
     In one embodiment, an antigen binding domain against CD79a is an antigen binding portion, e.g., CDRs, of the antibody Anti-CD79a antibody [HM47/A9] (ab3121), available from Abcam; antibody CD79A Antibody #3351 available from Cell Signalling Technology; or antibody HPA017748-Anti-CD79A antibody produced in rabbit, available from Sigma Aldrich. 
     In one embodiment, an antigen binding domain against CD79b is an antigen binding portion, e.g., CDRs, of the antibody polatuzumab vedotin, anti-CD79b described in Dornan et al., “Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma” Blood. Sep. 24, 2009; 114(13):2721-9. doi: 10.1182/blood-2009-02-205500. Epub Jul. 24, 2009, or the bispecific antibody Anti-CD79b/CD3 described in “4507 Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b/CD3 As a Potential Therapy for B Cell Malignancies” Abstracts of 56 th  ASH Annual Meeting and Exposition, San Francisco, Calif. Dec. 6-9 2014. 
     In one embodiment, an antigen binding domain against CD72 is an antigen binding portion, e.g., CDRs, of the antibody J3-109 described in Myers, and Uckun, “An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.” Leuk Lymphoma. 1995 June; 18(1-2):119-22, or anti-CD72 (10D6.8.1, mIgG1) described in Poison et al., “Antibody-Drug Conjugates for the Treatment of Non-Hodgkin&#39;s Lymphoma: Target and Linker-Drug Selection” Cancer Res Mar. 15, 2009 69; 2358. 
     In one embodiment, an antigen binding domain against LAIR1 is an antigen binding portion, e.g., CDRs, of the antibody ANT-301 LAIR1 antibody, available from ProSpec; or anti-human CD305 (LAIR1) Antibody, available from BioLegend. 
     In one embodiment, an antigen binding domain against FCAR is an antigen binding portion, e.g., CDRs, of the antibody CD89/FCARAntibody (Catalog #10414-H08H), available from Sino Biological Inc. 
     In one embodiment, an antigen binding domain against LILRA2 is an antigen binding portion, e.g., CDRs, of the antibody LILRA2 monoclonal antibody (M17), clone 3C7, available from Abnova, or Mouse Anti-LILRA2 antibody, Monoclonal (2D7), available from Lifespan Biosciences. 
     In one embodiment, an antigen binding domain against CD300LF is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-CMRF35-like molecule 1 antibody, Monoclonal[UP-D2], available from BioLegend, or Rat Anti-CMRF35-like molecule 1 antibody, Monoclonal[234903], available from R&amp;D Systems. 
     In one embodiment, an antigen binding domain against CLEC12A is an antigen binding portion, e.g., CDRs, of the antibody Bispecific T cell Engager (BiTE) scFv-antibody and ADC described in Noordhuis et al., “Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1xCD3 BiTE Antibody” 53 rd  ASH Annual Meeting and Exposition, Dec. 10-13, 2011, and MCLA-117 (Merus). 
     In one embodiment, an antigen binding domain against BST2 (also called CD317) is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-CD317 antibody, Monoclonal[3H4], available from Antibodies-Online or Mouse Anti-CD317 antibody, Monoclonal[696739], available from R&amp;D Systems. 
     In one embodiment, an antigen binding domain against EMR2 (also called CD312) is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-CD312 antibody, Monoclonal[LS-B8033] available from Lifespan Biosciences, or Mouse Anti-CD312 antibody, Monoclonal[494025] available from R&amp;D Systems. 
     In one embodiment, an antigen binding domain against LY75 is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-Lymphocyte antigen 75 antibody, Monoclonal[HD30] available from EMD Millipore or Mouse Anti-Lymphocyte antigen 75 antibody, Monoclonal[A15797] available from Life Technologies. 
     In one embodiment, an antigen binding domain against GPC3 is an antigen binding portion, e.g., CDRs, of the antibody hGC33 described in Nakano K, Ishiguro T, Konishi H, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs. 2010 November; 21(10):907-916, or MDX-1414, HN3, or YP7, all three of which are described in Feng et al., “Glypican-3 antibodies: a new therapeutic target for liver cancer.” FEBS Lett. Jan. 21, 2014; 588(2):377-82. 
     In one embodiment, an antigen binding domain against FCRL5 is an antigen binding portion, e.g., CDRs, of the anti-FcRL5 antibody described in Elkins et al., “FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma” Mol Cancer Ther. 2012 October; 11(10):2222-32. 
     In one embodiment, an antigen binding domain against IGLL1 is an antigen binding portion, e.g., CDRs, of the antibody Mouse Anti-Immunoglobulin lambda-like polypeptide 1 antibody, Monoclonal[AT1G4] available from Lifespan Biosciences, Mouse Anti-Immunoglobulin lambda-like polypeptide 1 antibody, Monoclonal[HSL11] available from BioLegend. 
     In one embodiment, the antigen binding domain comprises one, two three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2 and HC CDR3, from an antibody listed above, and/or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2 and LC CDR3, from an antibody listed above. In one embodiment, the antigen binding domain comprises a heavy chain variable region and/or a variable light chain region of an antibody listed above. 
     In another aspect, the antigen binding domain comprises a humanized antibody or an antibody fragment. In some aspects, a non-human antibody is humanized, where specific sequences or regions of the antibody are modified to increase similarity to an antibody naturally produced in a human or fragment thereof. In one aspect, the antigen binding domain is humanized. 
     Bispecific CARS 
     In an embodiment a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody has specificity for no more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence which has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope. In an embodiment the first and second epitopes are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In an embodiment the first and second epitopes overlap. In an embodiment the first and second epitopes do not overlap. In an embodiment the first and second epitopes are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In an embodiment a bispecific antibody molecule comprises a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a first epitope and a heavy chain variable domain sequence and a light chain variable domain sequence which have binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In an embodiment a bispecific antibody molecule comprises a scFv, or fragment thereof, have binding specificity for a first epitope and a scFv, or fragment thereof, have binding specificity for a second epitope. 
     In certain embodiments, the antibody molecule is a multi-specific (e.g., a bispecific or a trispecific) antibody molecule. Protocols for generating bispecific or heterodimeric antibody molecules are known in the art; including but not limited to, for example, the “knob in a hole” approach described in, e.g., U.S. Pat. No. 5,731,168; the electrostatic steering Fc pairing as described in, e.g., WO 09/089004, WO 06/106905 and WO 2010/129304; Strand Exchange Engineered Domains (SEED) heterodimer formation as described in, e.g., WO 07/110205; Fab arm exchange as described in, e.g., WO 08/119353, WO 2011/131746, and WO 2013/060867; double antibody conjugate, e.g., by antibody cross-linking to generate a bi-specific structure using a heterobifunctional reagent having an amine-reactive group and a sulfhydryl reactive group as described in, e.g., U.S. Pat. No. 4,433,059; bispecific antibody determinants generated by recombining half antibodies (heavy-light chain pairs or Fabs) from different antibodies through cycle of reduction and oxidation of disulfide bonds between the two heavy chains, as described in, e.g., U.S. Pat. No. 4,444,878; trifunctional antibodies, e.g., three Fab′ fragments cross-linked through sulfhdryl reactive groups, as described in, e.g., U.S. Pat. No. 5,273,743; biosynthetic binding proteins, e.g., pair of scFvs cross-linked through C-terminal tails preferably through disulfide or amine-reactive chemical cross-linking, as described in, e.g., U.S. Pat. No. 5,534,254; bifunctional antibodies, e.g., Fab fragments with different binding specificities dimerized through leucine zippers (e.g., c-fos and c-jun) that have replaced the constant domain, as described in, e.g., U.S. Pat. No. 5,582,996; bispecific and oligospecific mono- and oligovalent receptors, e.g., VH-CH1 regions of two antibodies (two Fab fragments) linked through a polypeptide spacer between the CH1 region of one antibody and the VH region of the other antibody typically with associated light chains, as described in, e.g., U.S. Pat. No. 5,591,828; bispecific DNA-antibody conjugates, e.g., crosslinking of antibodies or Fab fragments through a double stranded piece of DNA, as described in, e.g., U.S. Pat. No. 5,635,602; bispecific fusion proteins, e.g., an expression construct containing two scFvs with a hydrophilic helical peptide linker between them and a full constant region, as described in, e.g., U.S. Pat. No. 5,637,481; multivalent and multispecific binding proteins, e.g., dimer of polypeptides having first domain with binding region of Ig heavy chain variable region, and second domain with binding region of Ig light chain variable region, generally termed diabodies (higher order structures are also encompassed creating for bispecifc, trispecific, or tetraspecific molecules, as described in, e.g., U.S. Pat. No. 5,837,242; minibody constructs with linked VL and VH chains further connected with peptide spacers to an antibody hinge region and CH3 region, which can be dimerized to form bispecific/multivalent molecules, as described in, e.g., U.S. Pat. No. 5,837,821; VH and VL domains linked with a short peptide linker (e.g., 5 or 10 amino acids) or no linker at all in either orientation, which can form dimers to form bispecific diabodies; trimers and tetramers, as described in, e.g., U.S. Pat. No. 5,844,094; String of VH domains (or VL domains in family members) connected by peptide linkages with crosslinkable groups at the C-terminus further associated with VL domains to form a series of FVs (or scFvs), as described in, e.g., U.S. Pat. No. 5,864,019; and single chain binding polypeptides with both a VH and a VL domain linked through a peptide linker are combined into multivalent structures through non-covalent or chemical crosslinking to form, e.g., homobivalent, heterobivalent, trivalent, and tetravalent structures using both scFV or diabody type format, as described in, e.g., U.S. Pat. No. 5,869,620. Additional exemplary multispecific and bispecific molecules and methods of making the same are found, for example, in U.S. Pat. Nos. 5,910,573, 5,932,448, 5,959,083, U.S. Pat. Nos. 5,989,830, 6,005,079, 6,239,259, 6,294,353, 6,333,396, 6,476,198, 6,511,663, U.S. Pat. Nos. 6,670,453, 6,743,896, 6,809,185, 6,833,441, 7,129,330, 7,183,076, 7,521,056, 7,527,787, 7,534,866, 7,612,181, US2002004587A1, US2002076406A1, US2002103345A1, US2003207346A1, US2003211078A1, US2004219643A1, US2004220388A1, US2004242847A1, US2005003403A1, US2005004352A1, US2005069552A1, US2005079170A1, US2005100543A1, US2005136049A1, US2005136051A1, US2005163782A1, US2005266425A1, US2006083747A1, US2006120960A1, US2006204493A1, US2006263367A1, US2007004909A1, US2007087381A1, US2007128150A1, US2007141049A1, US2007154901A1, US2007274985A1, US2008050370A1, US2008069820A1, US2008152645A1, US2008171855A1, US2008241884A1, US2008254512A1, US2008260738A1, US2009130106A1, US2009148905A1, US2009155275A1, US2009162359A1, US2009162360A1, US2009175851A1, US2009175867A1, US2009232811A1, US2009234105A1, US2009263392A1, US2009274649A1, EP346087A2, WO0006605A2, WO02072635A2, WO04081051A1, WO06020258A2, WO2007044887A2, WO2007095338A2, WO2007137760A2, WO2008119353A1, WO2009021754A2, WO2009068630A1, WO9103493A1, WO9323537A1, WO9409131A1, WO9412625A2, WO9509917A1, WO9637621A2, WO9964460A1. The contents of the above-referenced applications are incorporated herein by reference in their entireties. 
     Within each antibody or antibody fragment (e.g., scFv) of a bispecific antibody molecule, the VH can be upstream or downstream of the VL. In some embodiments, the upstream antibody or antibody fragment (e.g., scFv) is arranged with its VH (VH 1 ) upstream of its VL (VL 1 ) and the downstream antibody or antibody fragment (e.g., scFv) is arranged with its VL (VL 2 ) upstream of its VH (VH 2 ), such that the overall bispecific antibody molecule has the arrangement VH 1 —VL 1 -VL 2 -VH 2 . In other embodiments, the upstream antibody or antibody fragment (e.g., scFv) is arranged with its VL (VL 1 ) upstream of its VH (VH1) and the downstream antibody or antibody fragment (e.g., scFv) is arranged with its VH (VH2) upstream of its VL (VL 2 ), such that the overall bispecific antibody molecule has the arrangement VL 1 -VH 1 -VH 2 -VL 2 . Optionally, a linker is disposed between the two antibodies or antibody fragments (e.g., scFvs), e.g., between VL 1  and VL 2  if the construct is arranged as VH 1 -VL 1 -VL 2 -VH 2 , or between VH 1  and VH 2  if the construct is arranged as VL 1 -VH 1 -VH 2 -VL 2 . The linker may be a linker as described herein, e.g., a (Gly 4 -Ser)n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 4 (SEQ ID NO: 78). In general, the linker between the two scFvs should be long enough to avoid mispairing between the domains of the two scFvs. Optionally, a linker is disposed between the VL and VH of the first scFv. Optionally, a linker is disposed between the VL and VH of the second scFv. In constructs that have multiple linkers, any two or more of the linkers can be the same or different. Accordingly, in some embodiments, a bispecific CAR comprises VLs, VHs, and optionally one or more linkers in an arrangement as described herein. 
     Stability and Mutations 
     The stability of an antigen binding domain to a cancer associated antigen as described herein, e.g., scFv molecules (e.g., soluble scFv), can be evaluated in reference to the biophysical properties (e.g., thermal stability) of a conventional control scFv molecule or a full length antibody. In one embodiment, the humanized scFv has a thermal stability that is greater than about 0.1, about 0.25, about 0.5, about 0.75, about 1, about 1.25, about 1.5, about 1.75, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10 degrees, about 11 degrees, about 12 degrees, about 13 degrees, about 14 degrees, or about 15 degrees Celsius than a control binding molecule (e.g. a conventional scFv molecule) in the described assays. 
     The improved thermal stability of the antigen binding domain to a cancer associated antigen described herein, e.g., scFv is subsequently conferred to the entire CAR construct, leading to improved therapeutic properties of the CAR construct. The thermal stability of the antigen binding domain of -a cancer associated antigen described herein, e.g., scFv, can be improved by at least about 2° C. or 3° C. as compared to a conventional antibody. In one embodiment, the antigen binding domain of -a cancer associated antigen described herein, e.g., scFv, has a 1° C. improved thermal stability as compared to a conventional antibody. In another embodiment, the antigen binding domain of a cancer associated antigen described herein, e.g., scFv, has a 2° C. improved thermal stability as compared to a conventional antibody. In another embodiment, the scFv has a 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15° C. improved thermal stability as compared to a conventional antibody. Comparisons can be made, for example, between the scFv molecules disclosed herein and scFv molecules or Fab fragments of an antibody from which the scFv VH and VL were derived. Thermal stability can be measured using methods known in the art. For example, in one embodiment, Tm can be measured. Methods for measuring Tm and other methods of determining protein stability are described in more detail below. 
     Mutations in scFv (arising through humanization or direct mutagenesis of the soluble scFv) can alter the stability of the scFv and improve the overall stability of the scFv and the CAR construct. Stability of the humanized scFv is compared against the murine scFv using measurements such as Tm, temperature denaturation and temperature aggregation. 
     The binding capacity of the mutant scFvs can be determined using assays know in the art and described herein. 
     In one embodiment, the antigen binding domain of a cancer associated antigen described herein, e.g., scFv, comprises at least one mutation arising from the humanization process such that the mutated scFv confers improved stability to the CAR construct. In another embodiment, the antigen binding domain of -a cancer associated antigen described herein, e.g., scFv, comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutations arising from the humanization process such that the mutated scFv confers improved stability to the CAR construct. 
     Methods of Evaluating Protein Stability 
     The stability of an antigen binding domain may be assessed using, e.g., the methods described below. Such methods allow for the determination of multiple thermal unfolding transitions where the least stable domain either unfolds first or limits the overall stability threshold of a multidomain unit that unfolds cooperatively (e.g., a multidomain protein which exhibits a single unfolding transition). The least stable domain can be identified in a number of additional ways. Mutagenesis can be performed to probe which domain limits the overall stability. Additionally, protease resistance of a multidomain protein can be performed under conditions where the least stable domain is known to be intrinsically unfolded via DSC or other spectroscopic methods (Fontana, et al., (1997) Fold. Des., 2: R17-26; Dimasi et al. (2009) J. Mol. Biol. 393: 672-692). Once the least stable domain is identified, the sequence encoding this domain (or a portion thereof) may be employed as a test sequence in the methods. 
     Thermal Stability 
     The thermal stability of the compositions may be analyzed using a number of non-limiting biophysical or biochemical techniques known in the art. In certain embodiments, thermal stability is evaluated by analytical spectroscopy. 
     An exemplary analytical spectroscopy method is Differential Scanning Calorimetry (DSC). DSC employs a calorimeter which is sensitive to the heat absorbances that accompany the unfolding of most proteins or protein domains (see, e.g. Sanchez-Ruiz, et al., Biochemistry, 27: 1648-52, 1988). To determine the thermal stability of a protein, a sample of the protein is inserted into the calorimeter and the temperature is raised until the Fab or scFv unfolds. The temperature at which the protein unfolds is indicative of overall protein stability. 
     Another exemplary analytical spectroscopy method is Circular Dichroism (CD) spectroscopy. CD spectrometry measures the optical activity of a composition as a function of increasing temperature. Circular dichroism (CD) spectroscopy measures differences in the absorption of left-handed polarized light versus right-handed polarized light which arise due to structural asymmetry. A disordered or unfolded structure results in a CD spectrum very different from that of an ordered or folded structure. The CD spectrum reflects the sensitivity of the proteins to the denaturing effects of increasing temperature and is therefore indicative of a protein&#39;s thermal stability (see van Mierlo and Steemsma, J. Biotechnol., 79(3):281-98, 2000). 
     Another exemplary analytical spectroscopy method for measuring thermal stability is Fluorescence Emission Spectroscopy (see van Mierlo and Steemsma, supra). Yet another exemplary analytical spectroscopy method for measuring thermal stability is Nuclear Magnetic Resonance (NMR) spectroscopy (see, e.g. van Mierlo and Steemsma, supra). The thermal stability of a composition can be measured biochemically. An exemplary biochemical method for assessing thermal stability is a thermal challenge assay. In a “thermal challenge assay”, a composition is subjected to a range of elevated temperatures for a set period of time. For example, in one embodiment, test scFv molecules or molecules comprising scFv molecules are subject to a range of increasing temperatures, e.g., for 1-1.5 hours. The activity of the protein is then assayed by a relevant biochemical assay. For example, if the protein is a binding protein (e.g. an scFv or scFv-containing polypeptide) the binding activity of the binding protein may be determined by a functional or quantitative ELISA. 
     Such an assay may be done in a high-throughput format and those disclosed in the Examples using  E. coli  and high throughput screening. A library of antigen binding domains, e.g., that includes an antigen binding domain to -a cancer associated antigen described herein, e.g., scFv variants, may be created using methods known in the art. Antigen binding domain, e.g., to -a cancer associated antigen described herein, e.g., scFv, expression may be induced and the antigen binding domain, e.g., to -a cancer associated antigen described herein, e.g., scFv, may be subjected to thermal challenge. The challenged test samples may be assayed for binding and those antigen binding domains to -a cancer associated antigen described herein, e.g., scFvs, which are stable may be scaled up and further characterized. 
     Thermal stability is evaluated by measuring the melting temperature (Tm) of a composition using any of the above techniques (e.g. analytical spectroscopy techniques). The melting temperature is the temperature at the midpoint of a thermal transition curve wherein 50% of molecules of a composition are in a folded state (See e.g., Dimasi et al. (2009) J. Mol Biol. 393: 672-692). In one embodiment, Tm values for an antigen binding domain to -a cancer associated antigen described herein, e.g., scFv, are about 40° C., 41° C., 42° C., 43° C., 44° C., 45° C., 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C., 65° C., 66° C., 67° C., 68° C., 69° C., 70° C., 71° C., 72° C., 73° C., 74° C., 75° C., 76° C., 77° C., 78° C., 79° C., 80° C., 81° C., 82° C., 83° C., 84° C., 85° C., 86° C., 87° C., 88° C., 89° C., 90° C., 91° C., 92° C., 93° C., 94° C., 95° C., 96° C., 97° C., 98° C., 99° C., 100° C. In one embodiment, Tm values for an IgG is about 40° C., 41° C., 42° C., 43° C., 44° C., 45° C., 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C., 65° C., 66° C., 67° C., 68° C., 69° C., 70° C., 71° C., 72° C., 73° C., 74° C., 75° C., 76° C., 77° C., 78° C., 79° C., 80° C., 81° C., 82° C., 83° C., 84° C., 85° C., 86° C., 87° C., 88° C., 89° C., 90° C., 91° C., 92° C., 93° C., 94° C., 95° C., 96° C., 97° C., 98° C., 99° C., 100° C. In one embodiment, Tm values for an multivalent antibody is about 40° C., 41° C., 42° C., 43° C., 44° C., 45° C., 46° C., 47° C., 48° C., 49° C., 50° C., 51° C., 52° C., 53° C., 54° C., 55° C., 56° C., 57° C., 58° C., 59° C., 60° C., 61° C., 62° C., 63° C., 64° C., 65° C., 66° C., 67° C., 68° C., 69° C., 70° C., 71° C., 72° C., 73° C., 74° C., 75° C., 76° C., 77° C., 78° C., 79° C., 80° C., 81° C., 82° C., 83° C., 84° C., 85° C., 86° C., 87° C., 88° C., 89° C., 90° C., 91° C., 92° C., 93° C., 94° C., 95° C., 96° C., 97° C., 98° C., 99° C., 100° C. 
     Thermal stability is also evaluated by measuring the specific heat or heat capacity (Cp) of a composition using an analytical calorimetric technique (e.g. DSC). The specific heat of a composition is the energy (e.g. in kcal/mol) is required to rise by 1° C., the temperature of 1 mol of water. As large Cp is a hallmark of a denatured or inactive protein composition. The change in heat capacity (ΔCp) of a composition is measured by determining the specific heat of a composition before and after its thermal transition. Thermal stability may also be evaluated by measuring or determining other parameters of thermodynamic stability including Gibbs free energy of unfolding (ΔG), enthalpy of unfolding (ΔH), or entropy of unfolding (ΔS). One or more of the above biochemical assays (e.g. a thermal challenge assay) are used to determine the temperature (i.e. the Tc value) at which 50% of the composition retains its activity (e.g. binding activity). 
     In addition, mutations to the antigen binding domain of a cancer associated antigen described herein, e.g., scFv, can be made to alter the thermal stability of the antigen binding domain of a cancer associated antigen described herein, e.g., scFv, as compared with the unmutated antigen binding domain of a cancer associated antigen described herein, e.g., scFv. When the humanized antigen binding domain of a cancer associated antigen described herein, e.g., scFv, is incorporated into a CAR construct, the antigen binding domain of the cancer associated antigen described herein, e.g., humanized scFv, confers thermal stability to the overall CARs of the present invention. In one embodiment, the antigen binding domain to a cancer associated antigen described herein, e.g., scFv, comprises a single mutation that confers thermal stability to the antigen binding domain of the cancer associated antigen described herein, e.g., scFv. In another embodiment, the antigen binding domain to a cancer associated antigen described herein, e.g., scFv, comprises multiple mutations that confer thermal stability to the antigen binding domain to the cancer associated antigen described herein, e.g., scFv. In one embodiment, the multiple mutations in the antigen binding domain to a cancer associated antigen described herein, e.g., scFv, have an additive effect on thermal stability of the antigen binding domain to the cancer associated antigen described herein binding domain, e.g., scFv. 
     b) % Aggregation 
     The stability of a composition can be determined by measuring its propensity to aggregate. Aggregation can be measured by a number of non-limiting biochemical or biophysical techniques. For example, the aggregation of a composition may be evaluated using chromatography, e.g. Size-Exclusion Chromatography (SEC). SEC separates molecules on the basis of size. A column is filled with semi-solid beads of a polymeric gel that will admit ions and small molecules into their interior but not large ones. When a protein composition is applied to the top of the column, the compact folded proteins (i.e. non-aggregated proteins) are distributed through a larger volume of solvent than is available to the large protein aggregates. Consequently, the large aggregates move more rapidly through the column, and in this way the mixture can be separated or fractionated into its components. Each fraction can be separately quantified (e.g. by light scattering) as it elutes from the gel. Accordingly, the % aggregation of a composition can be determined by comparing the concentration of a fraction with the total concentration of protein applied to the gel. Stable compositions elute from the column as essentially a single fraction and appear as essentially a single peak in the elution profile or chromatogram. 
     c) Binding Affinity 
     The stability of a composition can be assessed by determining its target binding affinity. A wide variety of methods for determining binding affinity are known in the art. An exemplary method for determining binding affinity employs surface plasmon resonance. Surface plasmon resonance is an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.). For further descriptions, see Jonsson, U., et al. (1993) Ann. Biol. Clin. 51:19-26; Jonsson, U., i (1991) Biotechniques 11:620-627; Johnsson, B., et al. (1995) J. Mol. Recognit. 8:125-131; and Johnnson, B., et al. (1991) Anal. Biochem. 198:268-277. 
     In one aspect, the antigen binding domain of the CAR comprises an amino acid sequence that is homologous to an antigen binding domain amino acid sequence described herein, and the antigen binding domain retains the desired functional properties of the antigen binding domain described herein. 
     In one specific aspect, the CAR composition of the invention comprises an antibody fragment. In a further aspect, the antibody fragment comprises an scFv. 
     In various aspects, the antigen binding domain of the CAR is engineered by modifying one or more amino acids within one or both variable regions (e.g., VH and/or VL), for example within one or more CDR regions and/or within one or more framework regions. In one specific aspect, the CAR composition of the invention comprises an antibody fragment. In a further aspect, the antibody fragment comprises an scFv. 
     It will be understood by one of ordinary skill in the art that the antibody or antibody fragment of the invention may further be modified such that they vary in amino acid sequence (e.g., from wild-type), but not in desired activity. For example, additional nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues may be made to the protein For example, a nonessential amino acid residue in a molecule may be replaced with another amino acid residue from the same side chain family. In another embodiment, a string of amino acids can be replaced with a structurally similar string that differs in order and/or composition of side chain family members, e.g., a conservative substitution, in which an amino acid residue is replaced with an amino acid residue having a similar side chain, may be made. 
     Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). 
     Percent identity in the context of two or more nucleic acids or polypeptide sequences, refers to two or more sequences that are the same. Two sequences are “substantially identical” if two sequences have a specified percentage of amino acid residues or nucleotides that are the same (e.g., 60% identity, optionally 70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity over a specified region, or, when not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length. 
     For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, (1988) Proc. Nat&#39;l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology). 
     Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. 
     The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1988) Comput. Appl. Biosci. 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (1970) J. Mol. Biol. 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. 
     In one aspect, the present invention contemplates modifications of the starting antibody or fragment (e.g., scFv) amino acid sequence that generate functionally equivalent molecules. For example, the VH or VL of an antigen binding domain to -a cancer associated antigen described herein, e.g., scFv, comprised in the CAR can be modified to retain at least about 70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity of the starting VH or VL framework region of the antigen binding domain to the cancer associated antigen described herein, e.g., scFv. The present invention contemplates modifications of the entire CAR construct, e.g., modifications in one or more amino acid sequences of the various domains of the CAR construct in order to generate functionally equivalent molecules. The CAR construct can be modified to retain at least about 70%, 71%. 72%. 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity of the starting CAR construct. 
     Transmembrane Domain 
     With respect to the transmembrane domain, in various embodiments, a CAR can be designed to comprise a transmembrane domain that is attached to the extracellular domain of the CAR. A transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acid associated with the extracellular region of the protein from which the transmembrane was derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and/or one or more additional amino acids associated with the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region). In one aspect, the transmembrane domain is one that is associated with one of the other domains of the CAR e.g., in one embodiment, the transmembrane domain may be from the same protein that the signaling domain, costimulatory domain or the hinge domain is derived from. In another aspect, the transmembrane domain is not derived from the same protein that any other domain of the CAR is derived from. In some instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins, e.g., to minimize interactions with other members of the receptor complex. In one aspect, the transmembrane domain is capable of homodimerization with another CAR on the cell surface of a CAR-expressing cell. In a different aspect, the amino acid sequence of the transmembrane domain may be modified or substituted so as to minimize interactions with the binding domains of the native binding partner present in the same CAR-expressing cell. 
     The transmembrane domain may be derived either from a natural or from a recombinant source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. In one aspect the transmembrane domain is capable of signaling to the intracellular domain(s) whenever the CAR has bound to a target. A transmembrane domain of particular use in this invention may include at least the transmembrane region(s) of e.g., the alpha, beta or zeta chain of the T-cell receptor, CD28, CD27, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. In some embodiments, a transmembrane domain may include at least the transmembrane region(s) of, e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2R gamma, IL7R α, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp, NKG2D, NKG2C. 
     In some instances, the transmembrane domain can be attached to the extracellular region of the CAR, e.g., the antigen binding domain of the CAR, via a hinge, e.g., a hinge from a human protein. For example, in one embodiment, the hinge can be a human Ig (immunoglobulin) hinge (e.g., an IgG4 hinge, an IgD hinge), a GS linker (e.g., a GS linker described herein), a KIR2DS2 hinge or a CD8a hinge. In one embodiment, the hinge or spacer comprises (e.g., consists of) the amino acid sequence of SEQ ID NO:403. In one aspect, the transmembrane domain comprises (e.g., consists of) a transmembrane domain of SEQ ID NO: 12. 
     In one aspect, the hinge or spacer comprises an IgG4 hinge. For example, in one embodiment, the hinge or spacer comprises a hinge of the amino acid sequence ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFN WYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPS SIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLS LSLGKM (SEQ ID NO:405). In some embodiments, the hinge or spacer comprises a hinge encoded by a nucleotide sequence of 
     
       
         
           
               
            
               
                 (SEQ ID NO: 406) 
               
               
                 GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCT 
               
               
                   
               
               
                 GGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGA 
               
               
                   
               
               
                 TGATCAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAG 
               
               
                   
               
               
                 GAGGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCA 
               
               
                   
               
               
                 CAACGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGG 
               
               
                   
               
               
                 TGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAA 
               
               
                   
               
               
                 TACAAGTGTAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAGAAAAC 
               
               
                   
               
               
                 CATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGC 
               
               
                   
               
               
                 CCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTG 
               
               
                   
               
               
                 GTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGG 
               
               
                   
               
               
                 CCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACG 
               
               
                   
               
               
                 GCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAG 
               
               
                   
               
               
                 GAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCA 
               
               
                   
               
               
                 CTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATG. 
               
            
           
         
       
     
     In one aspect, the hinge or spacer comprises an IgD hinge. For example, in one embodiment, the hinge or spacer comprises a hinge of the amino acid sequence RWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEE RETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAG KVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMAL REPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGFSPPNILLMWLEDQREVNTSGF APARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYV TDH (SEQ ID NO:407). In some embodiments, the hinge or spacer comprises a hinge encoded by a nucleotide sequence of 
     
       
         
           
               
            
               
                 (SEQ ID NO: 408) 
               
               
                 AGGTGGCCCGAAAGTCCCAAGGCCCAGGCATCTAGTGTTCCTACTGCACA 
               
               
                   
               
               
                 GCCCCAGGCAGAAGGCAGCCTAGCCAAAGCTACTACTGCACCTGCCACTA 
               
               
                   
               
               
                 CGCGCAATACTGGCCGTGGCGGGGAGGAGAAGAAAAAGGAGAAAGAGAAA 
               
               
                   
               
               
                 GAAGAACAGGAAGAGAGGGAGACCAAGACCCCTGAATGTCCATCCCATAC 
               
               
                   
               
               
                 CCAGCCGCTGGGCGTCTATCTCTTGACTCCCGCAGTACAGGACTTGTGGC 
               
               
                   
               
               
                 TTAGAGATAAGGCCACCTTTACATGTTTCGTCGTGGGCTCTGACCTGAAG 
               
               
                   
               
               
                 GATGCCCATTTGACTTGGGAGGTTGCCGGAAAGGTACCCACAGGGGGGGT 
               
               
                   
               
               
                 TGAGGAAGGGTTGCTGGAGCGCCATTCCAATGGCTCTCAGAGCCAGCACT 
               
               
                   
               
               
                 CAAGACTCACCCTTCCGAGATCCCTGTGGAACGCCGGGACCTCTGTCACA 
               
               
                   
               
               
                 TGTACTCTAAATCATCCTAGCCTGCCCCCACAGCGTCTGATGGCCCTTAG 
               
               
                   
               
               
                 AGAGCCAGCCGCCCAGGCACCAGTTAAGCTTAGCCTGAATCTGCTCGCCA 
               
               
                   
               
               
                 GTAGTGATCCCCCAGAGGCCGCCAGCTGGCTCTTATGCGAAGTGTCCGGC 
               
               
                   
               
               
                 TTTAGCCCGCCCAACATCTTGCTCATGTGGCTGGAGGACCAGCGAGAAGT 
               
               
                   
               
               
                 GAACACCAGCGGCTTCGCTCCAGCCCGGCCCCCACCCCAGCCGGGTTCTA 
               
               
                   
               
               
                 CCACATTCTGGGCCTGGAGTGTCTTAAGGGTCCCAGCACCACCTAGCCCC 
               
               
                   
               
               
                 CAGCCAGCCACATACACCTGTGTTGTGTCCCATGAAGATAGCAGGACCCT 
               
               
                   
               
               
                 GCTAAATGCTTCTAGGAGTCTGGAGGTTTCCTACGTGACTGACCATT. 
               
            
           
         
       
     
     In one aspect, the transmembrane domain may be recombinant, in which case it will comprise predominantly hydrophobic residues such as leucine and valine. In one aspect a triplet of phenylalanine, tryptophan and valine can be found at each end of a recombinant transmembrane domain. 
     Optionally, a short oligo- or polypeptide linker, between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic region of the CAR. A glycine-serine doublet provides a particularly suitable linker. For example, in one aspect, the linker comprises the amino acid sequence of GGGGSGGGGS (SEQ ID NO:10). In some embodiments, the linker is encoded by a nucleotide sequence of 
     
       
         
           
               
               
            
               
                   
                 (SEQ ID NO: 11) 
               
               
                   
                 GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC. 
               
            
           
         
       
     
     In one aspect, the hinge or spacer comprises a KIR2DS2 hinge. 
     Cytoplasmic Domain 
     The cytoplasmic domain or region of the CAR includes an intracellular signaling domain. An intracellular signaling domain is generally responsible for activation of at least one of the normal effector functions of the immune cell in which the CAR has been introduced. The term “effector function” refers to a specialized function of a cell. Effector function of a T cell, for example, may be cytolytic activity or helper activity including the secretion of cytokines. Thus the term “intracellular signaling domain” refers to the portion of a protein which transduces the effector function signal and directs the cell to perform a specialized function. While usually the entire intracellular signaling domain can be employed, in many cases it is not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such truncated portion may be used in place of the intact chain as long as it transduces the effector function signal. The term intracellular signaling domain is thus meant to include any truncated portion of the intracellular signaling domain sufficient to transduce the effector function signal. 
     Examples of intracellular signaling domains for use in the CAR of the invention include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement, as well as any derivative or variant of these sequences and any recombinant sequence that has the same functional capability. 
     It is known that signals generated through the TCR alone are insufficient for full activation of the T cell and that a secondary and/or costimulatory signal is also required. Thus, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the TCR (primary intracellular signaling domains) and those that act in an antigen-independent manner to provide a secondary or costimulatory signal (secondary cytoplasmic domain, e.g., a costimulatory domain). 
     A primary signaling domain regulates primary activation of the TCR complex either in a stimulatory way, or in an inhibitory way. Primary intracellular signaling domains that act in a stimulatory manner may contain signaling motifs which are known as immunoreceptor tyrosine-based activation motifs or ITAMs. 
     Examples of ITAM containing primary intracellular signaling domains that are of particular use in the invention include those of CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc Epsilon Rib), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12. In one embodiment, a CAR of the invention comprises an intracellular signaling domain, e.g., a primary signaling domain of CD3-zeta. 
     In one embodiment, a primary signaling domain comprises a modified ITAM domain, e.g., a mutated ITAM domain which has altered “(e.g., increased or decreased)” activity as compared to the native ITAM domain. In one embodiment, a primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and/or truncated ITAM-containing primary intracellular signaling domain. In an embodiment, a primary signaling domain comprises one, two, three, four or more ITAM motifs. 
     The intracellular signalling domain of the CAR can comprise the CD3-zeta signaling domain by itself or it can be combined with any other desired intracellular signaling domain(s) useful in the context of a CAR of the invention. For example, the intracellular signaling domain of the CAR can comprise a CD3 zeta chain portion and a costimulatory signaling domain. The costimulatory signaling domain refers to a portion of the CAR comprising the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligands that is required for an efficient response of lymphocytes to an antigen. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds with CD83, and the like. For example, CD27 costimulation has been demonstrated to enhance expansion, effector function, and survival of human CART cells in vitro and augments human T cell persistence and antitumor activity in vivo (Song et al. Blood. 2012; 119(3):696-706). Further examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), NKG2D, CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, and CD19a. 
     The intracellular signaling sequences within the cytoplasmic portion of the CAR of the invention may be linked to each other in a random or specified order. Optionally, a short oligo- or polypeptide linker, for example, between 2 and 10 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) in length may form the linkage between intracellular signaling sequence. In one embodiment, a glycine-serine doublet can be used as a suitable linker. In one embodiment, a single amino acid, e.g., an alanine, a glycine, can be used as a suitable linker. 
     In one aspect, the intracellular signaling domain is designed to comprise two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains. In an embodiment, the two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains, are separated by a linker molecule, e.g., a linker molecule described herein. In one embodiment, the intracellular signaling domain comprises two costimulatory signaling domains. In some embodiments, the linker molecule is a glycine residue. In some embodiments, the linker is an alanine residue. 
     In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta. In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta, and the signaling domain of 4-1BB. In one aspect, the signaling domain of 4-1BB is a signaling domain of SEQ ID NO: 14. In one aspect, the signaling domain of CD3-zeta is a signaling domain of SEQ ID NO: 18. 
     In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3-zeta and the signaling domain of CD27. In one aspect, the signaling domain of CD27 comprises an amino acid sequence of 
     
       
         
           
               
            
               
                 (SEQ ID NO: 16) 
               
               
                 QRRKYRSNKGESPVEPAEPCRYSCPREEEGSTIPIQEDYRKPEPACSP. 
               
            
           
         
       
     
     In one aspect, the signalling domain of CD27 is encoded by a nucleic acid sequence of 
     
       
         
           
               
            
               
                 (SEQ ID NO: 17) 
               
               
                 AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCC 
               
               
                   
               
               
                 CCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCAC 
               
               
                   
               
               
                 GCGACTTCGCAGCCTATCGCTCC. 
               
            
           
         
       
     
     In one aspect, the CAR-expressing cell described herein can further comprise a second CAR, e.g., a second CAR that includes a different antigen binding domain, e.g., to the same target or a different target (e.g., a target other than a cancer associated antigen described herein or a different cancer associated antigen described herein). In one embodiment, the second CAR includes an antigen binding domain to a target expressed the same cancer cell type as the cancer associated antigen. In one embodiment, the CAR-expressing cell comprises a first CAR that targets a first antigen and includes an intracellular signaling domain having a costimulatory signaling domain but not a primary signaling domain, and a second CAR that targets a second, different, antigen and includes an intracellular signaling domain having a primary signaling domain but not a costimulatory signaling domain. While not wishing to be bound by theory, placement of a costimulatory signaling domain, e.g., 4-1BB, CD28, CD27 or OX-40, onto the first CAR, and the primary signaling domain, e.g., CD3 zeta, on the second CAR can limit the CAR activity to cells where both targets are expressed. In one embodiment, the CAR expressing cell comprises a first cancer associated antigen CAR that includes an antigen binding domain that binds a target antigen described herein, a transmembrane domain and a costimulatory domain and a second CAR that targets a different target antigen (e.g., an antigen expressed on that same cancer cell type as the first target antigen) and includes an antigen binding domain, a transmembrane domain and a primary signaling domain. In another embodiment, the CAR expressing cell comprises a first CAR that includes an antigen binding domain that binds a target antigen described herein, a transmembrane domain and a primary signaling domain and a second CAR that targets an antigen other than the first target antigen (e.g., an antigen expressed on the same cancer cell type as the first target antigen) and includes an antigen binding domain to the antigen, a transmembrane domain and a costimulatory signaling domain. 
     In one embodiment, the CAR-expressing cell comprises an XCAR described herein and an inhibitory CAR. In one embodiment, the inhibitory CAR comprises an antigen binding domain that binds an antigen found on normal cells but not cancer cells. In one embodiment, the inhibitory CAR comprises the antigen binding domain, a transmembrane domain and an intracellular domain of an inhibitory molecule. For example, the intracellular domain of the inhibitory CAR can be an intracellular domain of PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta. 
     In one embodiment, when the CAR-expressing cell comprises two or more different CARs, the antigen binding domains of the different CARs can be such that the antigen binding domains do not interact with one another. For example, a cell expressing a first and second CAR can have an antigen binding domain of the first CAR, e.g., as a fragment, e.g., an scFv, that does not form an association with the antigen binding domain of the second CAR, e.g., the antigen binding domain of the second CAR is a VHH. 
     In some embodiments, the antigen binding domain comprises a single domain antigen binding (SDAB) molecules include molecules whose complementary determining regions are part of a single domain polypeptide. Examples include, but are not limited to, heavy chain variable domains, binding molecules naturally devoid of light chains, single domains derived from conventional 4-chain antibodies, engineered domains and single domain scaffolds other than those derived from antibodies. SDAB molecules may be any of the art, or any future single domain molecules. SDAB molecules may be derived from any species including, but not limited to mouse, human, camel, llama, lamprey, fish, shark, goat, rabbit, and bovine. This term also includes naturally occurring single domain antibody molecules from species other than Camelidae and sharks. 
     In one aspect, an SDAB molecule can be derived from a variable region of the immunoglobulin found in fish, such as, for example, that which is derived from the immunoglobulin isotype known as Novel Antigen Receptor (NAR) found in the serum of shark. Methods of producing single domain molecules derived from a variable region of NAR (“IgNARs”) are described in WO 03/014161 and Streltsov (2005) Protein Sci. 14:2901-2909. 
     According to another aspect, an SDAB molecule is a naturally occurring single domain antigen binding molecule known as heavy chain devoid of light chains. Such single domain molecules are disclosed in WO 9404678 and Hamers-Casterman, C. et al. (1993) Nature 363:446-448, for example. For clarity reasons, this variable domain derived from a heavy chain molecule naturally devoid of light chain is known herein as a VHH or nanobody to distinguish it from the conventional VH of four chain immunoglobulins. Such a VHH molecule can be derived from Camelidae species, for example in camel, llama, dromedary, alpaca and guanaco. Other species besides Camelidae may produce heavy chain molecules naturally devoid of light chain; such VHHs are within the scope of the invention. 
     The SDAB molecules can be recombinant, CDR-grafted, humanized, camelized, de-immunized and/or in vitro generated (e.g., selected by phage display). 
     It has also been discovered, that cells having a plurality of chimeric membrane embedded receptors comprising an antigen binding domain that interactions between the antigen binding domain of the receptors can be undesirable, e.g., because it inhibits the ability of one or more of the antigen binding domains to bind its cognate antigen. Accordingly, disclosed herein are cells having a first and a second non-naturally occurring chimeric membrane embedded receptor comprising antigen binding domains that minimize such interactions. Also disclosed herein are nucleic acids encoding a first and a second non-naturally occurring chimeric membrane embedded receptor comprising antigen binding domains that minimize such interactions, as well as methods of making and using such cells and nucleic acids. In an embodiment the antigen binding domain of one of said first said second non-naturally occurring chimeric membrane embedded receptor, comprises an scFv, and the other comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. 
     In some embodiments, the claimed invention comprises a first and second CAR, wherein the antigen binding domain of one of said first CAR said second CAR does not comprise a variable light domain and a variable heavy domain. In some embodiments, the antigen binding domain of one of said first CAR said second CAR is an scFv, and the other is not an scFv. In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises a nanobody. In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises a camelid VHH domain. 
     In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises an scFv, and the other comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises an scFv, and the other comprises a nanobody. In some embodiments, the antigen binding domain of one of said first CAR said second CAR comprises an scFv, and the other comprises a camelid VHH domain. 
     In some embodiments, when present on the surface of a cell, binding of the antigen binding domain of said first CAR to its cognate antigen is not substantially reduced by the presence of said second CAR. In some embodiments, binding of the antigen binding domain of said first CAR to its cognate antigen in the presence of said second CAR is 85%, 90%, 95%, 96%, 97%, 98% or 99% of binding of the antigen binding domain of said first CAR to its cognate antigen in the absence of said second CAR. 
     In some embodiments, when present on the surface of a cell, the antigen binding domains of said first CAR said second CAR, associate with one another less than if both were scFv antigen binding domains. In some embodiments, the antigen binding domains of said first CAR said second CAR, associate with one another 85%, 90%, 95%, 96%, 97%, 98% or 99% less than if both were scFv antigen binding domains. 
     In another aspect, the CAR-expressing cell described herein can further express another agent, e.g., an agent which enhances the activity of a CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Inhibitory molecules, e.g., PD1, can, in some embodiments, decrease the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta. In one embodiment, the agent which inhibits an inhibitory molecule, e.g., is a molecule described herein, e.g., an agent that comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta, or a fragment of any of these (e.g., at least a portion of an extracellular domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of an extracellular domain of PD1), and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and/or a CD3 zeta signaling domain described herein). PD1 is an inhibitory member of the CD28 family of receptors that also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells (Agata et al. 1996 Int. Immunol 8:765-75). Two ligands for PD1, PD-L1 and PD-L2 have been shown to downregulate T cell activation upon binding to PD1 (Freeman et a. 2000 J Exp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094) Immune suppression can be reversed by inhibiting the local interaction of PD1 with PD-L1. 
     In one embodiment, the agent comprises the extracellular domain (ECD) of an inhibitory molecule, e.g., Programmed Death 1 (PD1), fused to a transmembrane domain and intracellular signaling domains such as 41BB and CD3 zeta (also referred to herein as a PD1 CAR). In one embodiment, the PD1 CAR, when used in combinations with a XCAR described herein, improves the persistence of the T cell. In one embodiment, the CAR is a PD1 CAR comprising the extracellular domain of PD1 indicated as underlined in SEQ ID NO: 26. In one embodiment, the PD1 CAR comprises the amino acid sequence of SEQ ID NO:26. 
     
       
         
           
               
            
               
                 (SEQ ID NO: 26) 
               
               
                 Malpvtalllplalllhaarp pgwfldspdrpwnpptfspallvvtegdn   
               
               
                   
               
               
                 
                   atftcsfsntsesfylnwyrmspsnqtdklaafpedrsqpgqdcrfrvtq 
                 
               
               
                   
               
               
                 
                   lpngrdfhmsvvrarrndsgtylcgaislapkaqikeslraelrvterra 
                 
               
               
                   
               
               
                   evptahpspsprpagqfqtlv tttpaprpptpaptiasqplslrpeacrp 
               
               
                   
               
               
                 aaggavhtrgldfacdiyiwaplagtcgvlllslvitlyclugrkkllyi 
               
               
                   
               
               
                 fkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadapaykqgqn 
               
               
                   
               
               
                 qlynelnlgrreeydvldlurgrdpemggkprrknpqeglynelqkdkma 
               
               
                   
               
               
                 eayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr. 
               
            
           
         
       
     
     In one embodiment, the PD1 CAR comprises the amino acid sequence provided below (SEQ ID NO:39). 
     
       
         
           
               
            
               
                 (SEQ ID NO: 39) 
               
               
                 
                   pgwfldspdrpwnpptfspallvvtegdnatftcsfsntsesfylnwyrm 
                 
               
               
                   
               
               
                 
                   spsnqtdklaafpedrsqpgqdcrfrvtqlpngrdfhmsvvrarrndsgt 
                 
               
               
                   
               
               
                   ylcgaislapkaqikeshaelivterraevptahpspsprpagqfqtlv t 
               
               
                   
               
               
                 ttpaprpptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwap 
               
               
                   
               
               
                 lagtegvlllslvidyckrgrkkllyifkqpfmrpvqttqeedgcscrfp 
               
               
                   
               
               
                 eeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldlargr 
               
               
                   
               
               
                 dpemggkprrknpqeglynelqkdkmaeayseigmkgerrrgkghdglyq 
               
               
                   
               
               
                 glstatkdtydalhmqalppr. 
               
            
           
         
       
     
     In one embodiment, the agent comprises a nucleic acid sequence encoding the PD1 CAR, e.g., the PD1 CAR described herein. In one embodiment, the nucleic acid sequence for the PD1 CAR is shown below, with the PD1 ECD underlined below in SEQ ID NO: 27 
     
       
         
           
               
            
               
                 (SEQ ID NO: 27) 
               
               
                 atggccctccctgtcactgccctgcactccccctcgcactcctgctccac 
               
               
                   
               
               
                 gccgctagacca cccggatggtttctggactctccggatcgcccgtggaa   
               
               
                   
               
               
                 
                   tcccccaaccactcaccggcactcaggagtgactgagggcgataatgcga 
                 
               
               
                   
               
               
                 
                   ccacacgtgctcgttctccaacacctccgaatcattcgtgctgaactggt 
                 
               
               
                   
               
               
                 
                   accgcatgagcccgtcaaaccagaccgacaagctcgccgcgtaccggaag 
                 
               
               
                   
               
               
                 
                   atcggtcgcaaccgggacaggattgtcggaccgcgtgactcaactgccga 
                 
               
               
                   
               
               
                 
                   atggcagagacttccacatgagcgtggtccgcgctaggcgaaacgactcc 
                 
               
               
                   
               
               
                 
                   gggacctacctgtgcggagccatctcgctggcgcctaaggcccaaatcaa 
                 
               
               
                   
               
               
                 
                   agagagcttgagggccgaactgagagtgaccgagcgcagagctgaggtgc 
                 
               
               
                   
               
               
                 
                   caactgcacatccatccccatcgcctcggcctgcggggcagatcagaccc 
                 
               
               
                   
               
               
                   tggtc acgaccactccggcgccgcgcccaccgactccggccccaactatc 
               
               
                   
               
               
                 gcgagccagcccctgtcgctgaggccggaagcatgccgccctgccgccgg 
               
               
                   
               
               
                 aggtgctgtgcatacccggggattggacttcgcatgcgacatctacattt 
               
               
                   
               
               
                 gggctcctctcgccggaacttgtggcgtgctccttctgtccctggtcatc 
               
               
                   
               
               
                 accctgtactgcaagcggggtcggaaaaagcttctgtacattttcaagca 
               
               
                   
               
               
                 gcccttcatgaggcccgtgcaaaccacccaggaggaggacggttgctcct 
               
               
                   
               
               
                 gccggttccccgaagaggaagaaggaggttgcgagctgcgcgtgaagact 
               
               
                   
               
               
                 cccggagcgccgacgcccccgcctataagcagggccagaaccagctgtac 
               
               
                   
               
               
                 aacgaactgaacctgggacggcgggaagagtacgatgtgctggacaagcg 
               
               
                   
               
               
                 gcgcggccgggaccccgaaatgggcgggaagcctagaagaaagaaccctc 
               
               
                   
               
               
                 aggaaggcctgtataacgagctgcagaaggacaagatggccgaggcctac 
               
               
                   
               
               
                 tccgaaattgggatgaagggagagcggcggaggggaaaggggcacgacgg 
               
               
                   
               
               
                 cctgtaccaaggactgtccaccgccaccaaggacacatacgatgccctgc 
               
               
                   
               
               
                 acatgcaggccatccccctcgc. 
               
            
           
         
       
     
     In another aspect, the present invention provides a population of CAR-expressing cells, e.g., CART cells. In some embodiments, the population of CAR-expressing cells comprises a mixture of cells expressing different CARs. For example, in one embodiment, the population of CART cells can include a first cell expressing a CAR having an antigen binding domain to a cancer associated antigen described herein, and a second cell expressing a CAR having a different antigen binding domain, e.g., an antigen binding domain to a different a cancer associated antigen described herein, e.g., an antigen binding domain to a cancer associated antigen described herein that differs from the cancer associated antigen bound by the antigen binding domain of the CAR expressed by the first cell. As another example, the population of CAR-expressing cells can include a first cell expressing a CAR that includes an antigen binding domain to a cancer associated antigen described herein, and a second cell expressing a CAR that includes an antigen binding domain to a target other than a cancer associated antigen as described herein. In one embodiment, the population of CAR-expressing cells includes, e.g., a first cell expressing a CAR that includes a primary intracellular signaling domain, and a second cell expressing a CAR that includes a secondary signaling domain. 
     In another aspect, the present invention provides a population of cells wherein at least one cell in the population expresses a CAR having an antigen binding domain to a cancer associated antigen described herein, and a second cell expressing another agent, e.g., an agent which enhances the activity of a CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Inhibitory molecules, e.g., PD-1, can, in some embodiments, decrease the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD-1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta. In one embodiment, the agent which inhibits an inhibitory molecule, e.g., is a molecule described herein, e.g., an agent that comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD-1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta, or a fragment of any of these, and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27, OX40 or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD-1 or a fragment thereof, and a second polypeptide of an intracellular signaling domain described herein (e.g., a 4-1BB signaling domain described herein and/or a CD3 zeta signaling domain described herein). 
     In one aspect, the present invention provides methods comprising administering a population of CAR-expressing cells, e.g., CART cells, e.g., a mixture of cells expressing different CARs, in combination with another agent, e.g., a kinase inhibitor, such as a kinase inhibitor described herein. In another aspect, the present invention provides methods comprising administering a population of cells wherein at least one cell in the population expresses a CAR having an antigen binding domain of a cancer associated antigen described herein, and a second cell expressing another agent, e.g., an agent which enhances the activity of a CAR-expressing cell, in combination with another agent, e.g., a kinase inhibitor, such as a kinase inhibitor described herein. 
     Regulatable Chimeric Antigen Receptors 
     In some embodiments, a regulatable CAR (RCAR) where the CAR activity can be controlled is desirable to optimize the safety and efficacy of a CAR therapy. In embodiments, a target CAR is an RCAR. There are many ways CAR activities can be regulated. For example, inducible apoptosis using, e.g., a caspase fused to a dimerization domain (see, e.g., Di et al., N Egnl. J. Med. 2011 Nov. 3; 365(18):1673-1683), can be used as a safety switch in the CAR therapy of the instant invention. In an aspect, a RCAR comprises a set of polypeptides, typically two in the simplest embodiments, in which the components of a standard CAR described herein, e.g., an antigen binding domain and an intracellular signaling domain, are partitioned on separate polypeptides or members. In some embodiments, the set of polypeptides include a dimerization switch that, upon the presence of a dimerization molecule, can couple the polypeptides to one another, e.g., can couple an antigen binding domain to an intracellular signaling domain. 
     In an aspect, an RCAR comprises two polypeptides or members: 1) an intracellular signaling member comprising an intracellular signaling domain, e.g., a primary intracellular signaling domain described herein, and a first switch domain; 2) an antigen binding member comprising an antigen binding domain, e.g., that targets a tumor antigen described herein, as described herein and a second switch domain Optionally, the RCAR comprises a transmembrane domain described herein. In an embodiment, a transmembrane domain can be disposed on the intracellular signaling member, on the antigen binding member, or on both. (Unless otherwise indicated, when members or elements of an RCAR are described herein, the order can be as provided, but other orders are included as well. In other words, in an embodiment, the order is as set out in the text, but in other embodiments, the order can be different. E.g., the order of elements on one side of a transmembrane region can be different from the example, e.g., the placement of a switch domain relative to a intracellular signaling domain can be different, e.g., reversed). 
     In an embodiment, the first and second switch domains can form an intracellular or an extracellular dimerization switch. In an embodiment, the dimerization switch can be a homodimerization switch, e.g., where the first and second switch domain are the same, or a heterodimerization switch, e.g., where the first and second switch domain are different from one another. 
     In embodiments, an RCAR can comprise a “multi switch.” A multi switch can comprise heterodimerization switch domains or homodimerization switch domains. A multi switch comprises a plurality of, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10, switch domains, independently, on a first member, e.g., an antigen binding member, and a second member, e.g., an intracellular signaling member. In an embodiment, the first member can comprise a plurality of first switch domains, e.g., FKBP-based switch domains, and the second member can comprise a plurality of second switch domains, e.g., FRB-based switch domains. In an embodiment, the first member can comprise a first and a second switch domain, e.g., a FKBP-based switch domain and a FRB-based switch domain, and the second member can comprise a first and a second switch domain, e.g., a FKBP-based switch domain and a FRB-based switch domain. 
     In an embodiment, the intracellular signaling member comprises one or more intracellular signaling domains, e.g., a primary intracellular signaling domain and one or more costimulatory signaling domains. 
     In an embodiment, the antigen binding member may comprise one or more intracellular signaling domains, e.g., one or more costimulatory signaling domains. In an embodiment, the antigen binding member comprises a plurality, e.g., 2 or 3 costimulatory signaling domains described herein, e.g., selected from 41BB, CD28, CD27, ICOS, and OX40, and in embodiments, no primary intracellular signaling domain. In an embodiment, the antigen binding member comprises the following costimulatory signaling domains, from the extracellular to intracellular direction: 41BB-CD27; 41BB-CD27; CD27-41BB; 41BB-CD28; CD28-41BB; OX40-CD28; CD28-OX40; CD28-41BB; or 41BB-CD28. In such embodiments, the intracellular binding member comprises a CD3zeta domain. In one such embodiment the RCAR comprises (1) an antigen binding member comprising, an antigen binding domain, a transmembrane domain, and two costimulatory domains and a first switch domain; and (2) an intracellular signaling domain comprising a transmembrane domain or membrane tethering domain and at least one primary intracellular signaling domain, and a second switch domain. 
     An embodiment provides RCARs wherein the antigen binding member is not tethered to the surface of the CAR cell. This allows a cell having an intracellular signaling member to be conveniently paired with one or more antigen binding domains, without transforming the cell with a sequence that encodes the antigen binding member. In such embodiments, the RCAR comprises: 1) an intracellular signaling member comprising: a first switch domain, a transmembrane domain, an intracellular signaling domain, e.g., a primary intracellular signaling domain, and a first switch domain; and 2) an antigen binding member comprising: an antigen binding domain, and a second switch domain, wherein the antigen binding member does not comprise a transmembrane domain or membrane tethering domain, and, optionally, does not comprise an intracellular signaling domain. In some embodiments, the RCAR may further comprise 3) a second antigen binding member comprising: a second antigen binding domain, e.g., a second antigen binding domain that binds a different antigen than is bound by the antigen binding domain; and a second switch domain. 
     Also provided herein are RCARs wherein the antigen binding member comprises bispecific activation and targeting capacity. In this embodiment, the antigen binding member can comprise a plurality, e.g., 2, 3, 4, or 5 antigen binding domains, e.g., scFvs, wherein each antigen binding domain binds to a target antigen, e.g. different antigens or the same antigen, e.g., the same or different epitopes on the same antigen. In an embodiment, the plurality of antigen binding domains are in tandem, and optionally, a linker or hinge region is disposed between each of the antigen binding domains. Suitable linkers and hinge regions are described herein. 
     An embodiment provides RCARs having a configuration that allows switching of proliferation. In this embodiment, the RCAR comprises: 1) an intracellular signaling member comprising: optionally, a transmembrane domain or membrane tethering domain; one or more co-stimulatory signaling domain, e.g., selected from 41BB, CD28, CD27, ICOS, and OX40, and a switch domain; and 2) an antigen binding member comprising: an antigen binding domain, a transmembrane domain, and a primary intracellular signaling domain, e.g., a CD3zeta domain, wherein the antigen binding member does not comprise a switch domain, or does not comprise a switch domain that dimerizes with a switch domain on the intracellular signaling member. In an embodiment, the antigen binding member does not comprise a co-stimulatory signaling domain. In an embodiment, the intracellular signaling member comprises a switch domain from a homodimerization switch. In an embodiment, the intracellular signaling member comprises a first switch domain of a heterodimerization switch and the RCAR comprises a second intracellular signaling member which comprises a second switch domain of the heterodimerization switch. In such embodiments, the second intracellular signaling member comprises the same intracellular signaling domains as the intracellular signaling member. In an embodiment, the dimerization switch is intracellular. In an embodiment, the dimerization switch is extracellular. 
     In any of the RCAR configurations described here, the first and second switch domains comprise a FKBP-FRB based switch as described herein. 
     Also provided herein are cells comprising an RCAR described herein. Any cell that is engineered to express a RCAR can be used as a RCARX cell. In an embodiment the RCARX cell is a T cell, and is referred to as a RCART cell. In an embodiment the RCARX cell is an NK cell, and is referred to as a RCARN cell. 
     Also provided herein are nucleic acids and vectors comprising RCAR encoding sequences. Sequence encoding various elements of an RCAR can be disposed on the same nucleic acid molecule, e.g., the same plasmid or vector, e.g., viral vector, e.g., lentiviral vector. In an embodiment, (i) sequence encoding an antigen binding member and (ii) sequence encoding an intracellular signaling member, can be present on the same nucleic acid, e.g., vector. Production of the corresponding proteins can be achieved, e.g., by the use of separate promoters, or by the use of a bicistronic transcription product (which can result in the production of two proteins by cleavage of a single translation product or by the translation of two separate protein products). In an embodiment, a sequence encoding a cleavable peptide, e.g., a P2A or F2A sequence, is disposed between (i) and (ii). In an embodiment, a sequence encoding an IRES, e.g., an EMCV or EV71 IRES, is disposed between (i) and (ii). In these embodiments, (i) and (ii) are transcribed as a single RNA. In an embodiment, a first promoter is operably linked to (i) and a second promoter is operably linked to (ii), such that (i) and (ii) are transcribed as separate mRNAs. 
     Alternatively, the sequence encoding various elements of an RCAR can be disposed on the different nucleic acid molecules, e.g., different plasmids or vectors, e.g., viral vector, e.g., lentiviral vector. E.g., the (i) sequence encoding an antigen binding member can be present on a first nucleic acid, e.g., a first vector, and the (ii) sequence encoding an intracellular signaling member can be present on the second nucleic acid, e.g., the second vector. 
     Dimerization Switches 
     Dimerization switches can be non-covalent or covalent. In a non-covalent dimerization switch, the dimerization molecule promotes a non-covalent interaction between the switch domains. In a covalent dimerization switch, the dimerization molecule promotes a covalent interaction between the switch domains. 
     In an embodiment, the RCAR comprises a FKBP/FRAP, or FKBP/FRB,-based dimerization switch. FKBP12 (FKBP, or FK506 binding protein) is an abundant cytoplasmic protein that serves as the initial intracellular target for the natural product immunosuppressive drug, rapamycin. Rapamycin binds to FKBP and to the large PI3K homolog FRAP (RAFT, mTOR). FRB is a 93 amino acid portion of FRAP, that is sufficient for binding the FKBP-rapamycin complex (Chen, J., Zheng, X. F., Brown, E. J. &amp; Schreiber, S. L. (1995) Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 92: 4947-51.) 
     In embodiments, an FKBP/FRAP, e.g., an FKBP/FRB, based switch can use a dimerization molecule, e.g., rapamycin or a rapamycin analog. 
     The amino acid sequence of FKBP is as follows: 
     
       
         
           
               
            
               
                 (SEQ ID NO: 52) 
               
               
                 D V P D Y A S L G G P S S P K K K R K V S R G V Q 
               
               
                   
               
               
                 V E T I S P G D G R T F P K R G Q T C V V H Y T G 
               
               
                   
               
               
                 M L E D G K K F D S S R D R N K P F K F M L G K Q 
               
               
                   
               
               
                 E V I R G W E E G V A Q M S V G Q R A K L T I S P 
               
               
                   
               
               
                 D Y A Y G A T G H P G I I P P H A T L V F D V E L 
               
               
                   
               
               
                 L K L E T S Y 
               
            
           
         
       
     
     In embodiments, an FKBP switch domain can comprise a fragment of FKBP having the ability to bind with FRB, or a fragment or analog thereof, in the presence of rapamycin or a rapalog, e.g., the underlined portion of SEQ ID NO: 52, which is: 
     
       
         
           
               
            
               
                 (SEQ ID NO: 53) 
               
               
                 V Q V E T I S P G D G R T F P K R G Q T C V V H Y 
               
               
                   
               
               
                 T G M L E D G K K F D S S R D R N K P F K F M L G 
               
               
                   
               
               
                 K Q E V I R G W E E G V A Q M S V G Q R A K L T I 
               
               
                   
               
               
                 S P D Y A Y G A T G H P G I I P P H A T L V F D V 
               
               
                   
               
               
                 E L L K L E T S 
               
            
           
         
       
     
     The amino acid sequence of FRB is as follows: 
     
       
         
           
               
               
            
               
                   
                 (SEQ ID NO: 54) 
               
               
                   
                 ILWHEMWHEG LEEASRLYFG ERNVKGMFEV LEPLHAMMER 
               
               
                   
                   
               
               
                   
                 GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA 
               
               
                   
                   
               
               
                   
                 WDLYYHVFRR ISK 
               
            
           
         
       
     
     “FKBP/FRAP, e.g., an FKBP/FRB, based switch” as that term is used herein, refers to a dimerization switch comprising: a first switch domain, which comprises an FKBP fragment or analog thereof having the ability to bind with FRB, or a fragment or analog thereof, in the presence of rapamycin or a rapalog, e.g., RAD001, and has at least 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identity with, or differs by no more than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 amino acid residues from, the FKBP sequence of SEQ ID NO: 52 or 53; and a second switch domain, which comprises an FRB fragment or analog thereof having the ability to bind with FRB, or a fragment or analog thereof, in the presence of rapamycin or a rapalog, and has at least 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identity with, or differs by no more than 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1 amino acid residues from, the FRB sequence of SEQ ID NO: 54. In an embodiment, a RCAR described herein comprises one switch domain comprises amino acid residues disclosed in SEQ ID NO: 52 (or SEQ ID NO: 53), and one switch domain comprises amino acid residues disclosed in SEQ ID NO: 54. 
     In embodiments, the FKBP/FRB dimerization switch comprises a modified FRB switch domain that exhibits altered, e.g., enhanced, complex formation between an FRB-based switch domain, e.g., the modified FRB switch domain, a FKBP-based switch domain, and the dimerization molecule, e.g., rapamycin or a rapalogue, e.g., RAD001. In an embodiment, the modified FRB switch domain comprises one or more mutations, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, selected from mutations at amino acid position(s) L2031, E2032, 52035, R2036, F2039, G2040, T2098, W2101, D2102, Y2105, and F2108, where the wild-type amino acid is mutated to any other naturally-occurring amino acid. In an embodiment, a mutant FRB comprises a mutation at E2032, where E2032 is mutated to phenylalanine (E2032F), methionine (E2032M), arginine (E2032R), valine (E2032V), tyrosine (E2032Y), isoleucine (E2032I), e.g., SEQ ID NO: 55, or leucine (E2032L), e.g., SEQ ID NO: 56. In an embodiment, a mutant FRB comprises a mutation at T2098, where T2098 is mutated to phenylalanine (T2098F) or leucine (T2098L), e.g., SEQ ID NO: 57. In an embodiment, a mutant FRB comprises a mutation at E2032 and at T2098, where E2032 is mutated to any amino acid, and where T2098 is mutated to any amino acid, e.g., SEQ ID NO: 58. In an embodiment, a mutant FRB comprises an E2032I and a T2098L mutation, e.g., SEQ ID NO: 59. In an embodiment, a mutant FRB comprises an E2032L and a T2098L mutation, e.g., SEQ ID NO: 60. 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Exemplary mutant FRB having increased 
               
               
                 affinity for a dimerization molecule. 
               
            
           
           
               
               
               
               
            
               
                   
                   
                   
                 SEQ  
               
               
                   
                 FRB 
                   
                 ID  
               
               
                   
                 mutant 
                 Amino Acid Sequence 
                 NO:  
               
               
                   
                   
               
               
                   
                 E2032I 
                 ILWHEMWHEGLIEASRLYFGERNVKG 
                 55  
               
               
                   
                 mutant 
                 MFEVLEPLHAMMERGPQTLKETSFNQ 
                   
               
               
                   
                   
                 AYGRDLMEAQEWCRKYMKSGNVKDLT 
                   
               
               
                   
                   
                 QAWDLYYHVFRRISKTS 
                   
               
               
                   
                   
               
               
                   
                 E2032L 
                 ILWHEMWHEGLLEASRLYFGERNVKG 
                 56  
               
               
                   
                 mutant 
                 MFEVLEPLHAMMERGPQTLKETSFNQ 
                   
               
               
                   
                   
                 AYGRDLMEAQEWCRKYMKSGNVKDLT 
                   
               
               
                   
                   
                 QAWDLYYHVFRRISKTS 
                   
               
               
                   
                   
               
               
                   
                 T2098L 
                 ILWHEMWHEGLEEASRLYFGERNVKG 
                 57  
               
               
                   
                 mutant 
                 MFEVLEPLHAMMERGPQTLKETSFNQ 
                   
               
               
                   
                   
                 AYGRDLMEAQEWCRKYMKSGNVKDLL 
                   
               
               
                   
                   
                 QAWDLYYHVFRRISKTS 
                   
               
               
                   
                   
               
               
                   
                 E2032, 
                 ILWHEMWHEGL   X   EASRLYFGERNVKG 
                 58  
               
               
                   
                 T2098 
                 MFEVLEPLHAMMERGPQTLKETSFNQ 
                   
               
               
                   
                 mutant 
                 AYGRDLMEAQEWCRKYMKSGNVKDL   X     
                   
               
               
                   
                   
                 QAWDLYYHVFRRISKTS 
                   
               
               
                   
                   
               
               
                   
                 E20321, 
                 ILWHEMWHEGLIEASRLYFGERNVKG 
                 59  
               
               
                   
                 T2098L 
                 MFEVLEPLHAMMERGPQTLKETSFNQ 
                   
               
               
                   
                 mutant 
                 AYGRDLMEAQEWCRKYMKSGNVKDLL 
                   
               
               
                   
                   
                 QAWDLYYHVFRRISKTS 
                   
               
               
                   
                   
               
               
                   
                 E2032L, 
                 ILWHEMWHEGLLEASRLYFGERNVKG 
                 60  
               
               
                   
                 T2098L 
                 MFEVLEPLHAMMERGPQTLKETSFNQ 
                   
               
               
                   
                 mutant 
                 AYGRDLMEAQEWCRKYMKSGNVKDLL 
                   
               
               
                   
                   
                 QAWDLYYHVFRRISKTS 
               
               
                   
                   
               
            
           
         
       
     
     Other suitable dimerization switches include a GyrB-GyrB based dimerization switch, a Gibberellin-based dimerization switch, a tag/binder dimerization switch, and a halo-tag/snap-tag dimerization switch. Following the guidance provided herein, such switches and relevant dimerization molecules will be apparent to one of ordinary skill. 
     Dimerization Molecule 
     Association between the switch domains is promoted by the dimerization molecule. In the presence of dimerization molecule interaction or association between switch domains allows for signal transduction between a polypeptide associated with, e.g., fused to, a first switch domain, and a polypeptide associated with, e.g., fused to, a second switch domain. In the presence of non-limiting levels of dimerization molecule signal transduction is increased by 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 5, 10, 50, 100 fold, e.g., as measured in a system described herein. 
     Rapamycin and rapamycin analogs (sometimes referred to as rapalogues), e.g., RAD001, can be used as dimerization molecules in a FKBP/FRB-based dimerization switch described herein. In an embodiment the dimerization molecule can be selected from rapamycin (sirolimus), RAD001 (everolimus), zotarolimus, temsirolimus, AP-23573 (ridaforolimus), biolimus and AP21967. Additional rapamycin analogs suitable for use with FKBP/FRB-based dimerization switches are further described in the section entitled “Combination Therapies”, or in the subsection entitled “Exemplary mTOR inhibitors”. 
     Split CAR 
     In some embodiments, the CAR-expressing cell (e.g., target CAR or anti-target CAR) uses a split CAR. The split CAR approach is described in more detail in publications WO2014/055442 and WO2014/055657. Briefly, a split CAR system comprises a cell expressing a first CAR having a first antigen binding domain and a costimulatory domain (e.g., 41BB), and the cell also expresses a second CAR having a second antigen binding domain and an intracellular signaling domain (e.g., CD3 zeta). When the cell encounters the first antigen, the costimulatory domain is activated, and the cell proliferates. When the cell encounters the second antigen, the intracellular signaling domain is activated and cell-killing activity begins. Thus, the CAR-expressing cell is only fully activated in the presence of both antigens. 
     Exemplary CAR Molecules 
     The CAR molecules disclosed herein can comprise a binding domain that binds to a target, e.g., a target as described herein; a transmembrane domain, e.g., a transmembrane domain as described herein; and an intracellular signaling domain, e.g., an intracellular domain as described herein. In embodiments, the binding domain comprises a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of a heavy chain binding domain described herein, and/or a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of a light chain binding domain described herein. 
     CD19 CAR 
     In other embodiments, the CAR molecule comprises a CD19 CAR molecule described herein, e.g., a CD19 CAR molecule described in US-2015-0283178-A1, e.g., CTL019. In embodiments, the CD19 CAR comprises an amino acid, or has a nucleotide sequence shown in US-2015-0283178-A1, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical thereto). 
     In one embodiment, the CAR T cell that specifically binds to CD19 has the USAN designation TISAGENLECLEUCEL-T. CTL019 is made by a gene modification of T cells is mediated by stable insertion via transduction with a self-inactivating, replication deficient Lentiviral (LV) vector containing the CTL019 transgene under the control of the EF-1 alpha promoter. CTL019 can be a mixture of transgene positive and negative T cells that are delivered to the subject on the basis of percent transgene positive T cells. 
     In other embodiments, the CD19 CAR includes a CAR molecule, or an antigen binding domain (e.g., a humanized antigen binding domain) according to Table 3 of WO2014/153270, incorporated herein by reference. The amino acid and nucleotide sequences encoding the CD19 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2014/153270. In embodiments, the CD19 CAR comprises an amino acid, or has a nucleotide sequence shown in WO2014/153270 incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD19 CAR sequences). 
     In one embodiment, the parental murine scFv sequence is the CAR19 construct provided in PCT publication WO2012/079000 (incorporated herein by reference) and provided herein in Table 3. In one embodiment, the anti-CD19 binding domain is a scFv described in WO2012/079000 and provided herein in Table 3. 
     In one embodiment, the CD19 CAR comprises an amino acid sequence provided as SEQ ID NO: 12 in PCT publication WO2012/079000. In embodiment, the amino acid sequence is: 
     MALPVTALLLPLALLLHAARPdigmtgttsslsaslgdrvtiscrasgdiskylnwyqqkpdgtvklli yhtsrlhsgvpsrfsgsgsgtdysltisnlegediatyfcgggntlpytfgggtkleitggggsggggsggggsevklqesgpglva psgslsvtctvsgvslpdygvswirgpprkglewlgviwgsettyynsalksrltiikdnsksgvflkmnslqtddtaiyycakh yyyggsyamdywgggtsvtvsstttpaprpptpaptiasgplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllsly itlyckrgrkkllyifkgpfmrpvgttgeedgcscrfpeeeeggcelrvkfsrsadapaykqgqnqlynelnlgrreeydvldkrr grdpemggkprrknpgeglynelgkdkmaeayseigmkgerrrgkghdglygglstatkdtydalhmqalppr (SEQ ID NO: 891), or a sequence substantially identical thereto (e.g., at least 85%, 90% or 95% or higher identical thereto), with or without the signal peptide sequence indicated in capital letters. 
     In embodiment, the amino acid sequence is: 
     digmtgttsslsaslgdrvtiscrasgdiskylnwyqqkpdgtvklliyhtsrlhsgvpsrfsgsgsgtdysltisnleqe diatyfcgggntlpytfgggtkleitggggsggggsggggsevklgesgpglvapsqslsvtctvsgvslpdygvswirqpprkg lewlgviwgsettyynsalksrltiikdnsksgvflkmnslgtddtaiyycakhyyyggsyamdywgggtsvtvsstttpaprp ptpaptiasgplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitlyckrgrkkllyifkgpfmrpvgttqeedg cscrfpeeeeggcelrvkfsrsadapaykgggnglynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdkm aeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr (SEQ ID NO: 892), or a sequence substantially homologous thereto (e.g., at least 85%, 90% or 95% or higher identical thereto). 
     In embodiments, the CAR molecule is a CD19 CAR molecule described herein, e.g., a humanized CAR molecule described herein, e.g., a humanized CD19 CAR molecule of Table 3 or having CDRs as set out in Tables 4A and 4B. 
     In embodiments, the CAR molecule is a CD19 CAR molecule described herein, e.g., a murine CAR molecule described herein, e.g., a murine CD19 CAR molecule of Table 3 or having CDRs as set out in Tables 4A and 4B. 
     In some embodiments, the CAR molecule comprises one, two, and/or three CDRs from the heavy chain variable region and/or one, two, and/or three CDRs from the light chain variable region of the murine or humanized CD19 CAR of Tables 4A and 4B. 
     In one embodiment, the antigen binding domain comprises one, two three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2 and HC CDR3, from an antibody listed herein, and/or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2 and LC CDR3, from an antibody listed herein. In one embodiment, the antigen binding domain comprises a heavy chain variable region and/or a variable light chain region of an antibody listed or described herein. 
     Exemplary CD19 CARs include any of the CD19 CARs or anti-CD19 binding domains described herein, e.g., in one or more tables (e.g., Table 3) described herein (e.g., or an anti-CD19 CAR described in Xu et al. Blood 123.24(2014):3750-9; Kochenderfer et al. Blood 122.25(2013):4129-39, Cruz et al. Blood 122.17(2013):2965-73, NCT00586391, NCT01087294, NCT02456350, NCT00840853, NCT02659943, NCT02650999, NCT02640209, NCT01747486, NCT02546739, NCT02656147, NCT02772198, NCT00709033, NCT02081937, NCT00924326, NCT02735083, NCT02794246, NCT02746952, NCT01593696, NCT02134262, NCT01853631, NCT02443831, NCT02277522, NCT02348216, NCT02614066, NCT02030834, NCT02624258, NCT02625480, NCT02030847, NCT02644655, NCT02349698, NCT02813837, NCT02050347, NCT01683279, NCT02529813, NCT02537977, NCT02799550, NCT02672501, NCT02819583, NCT02028455, NCT01840566, NCT01318317, NCT01864889, NCT02706405, NCT01475058, NCT01430390, NCT02146924, NCT02051257, NCT02431988, NCT01815749, NCT02153580, NCT01865617, NCT02208362, NCT02685670, NCT02535364, NCT02631044, NCT02728882, NCT02735291, NCT01860937, NCT02822326, NCT02737085, NCT02465983, NCT02132624, NCT02782351, NCT01493453, NCT02652910, NCT02247609, NCT01029366, NCT01626495, NCT02721407, NCT01044069, NCT00422383, NCT01680991, NCT02794961, or NCT02456207, each of which is incorporated herein by reference in its entirety. 
     Exemplary CD19 CAR and antigen binding domain constructs that can be used in the methods described herein are shown in Table 3. The light and heavy chain CDR sequences according to Kabat are shown by the bold and underlined text, and are also summarized in Tables 3 and 4A-4B below. The location of the signal sequence and histidine tag are also underlined. In embodiments, the CD19 CAR sequences and antigen binding fragments thereof do not include the signal sequence and/or histidine tag sequences. 
     In embodiments, the CD19 CAR comprises an anti-CD19 binding domain (e.g., murine or humanized anti-CD19 binding domain), a transmembrane domain, and an intracellular signaling domain, and wherein said anti-CD19 binding domain comprises a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of any anti-CD19 heavy chain binding domain amino acid sequences listed in Table 3 and 4A-4B, or a sequence at least 85%, 90%, 95% or more identical thereto (e.g., having less than 5, 4, 3, 2 or 1 amino acid substitutions, e.g., conservative substitutions). 
     In one embodiment, the anti-CD19 binding domain comprises a light chain variable region described herein (e.g., in Table 3) and/or a heavy chain variable region described herein (e.g., in Table 3), or a sequence at least 85%, 90%, 95% or more identical thereto. 
     In one embodiment, the encoded anti-CD19 binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence of Tables 3, or a sequence at least 85%, 90%, 95% or more identical thereto. 
     In an embodiment, the human or humanized anti-CD19 binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in Table 3, or a sequence at least 85%, 90%, 95% or more identical thereto; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain variable region provided in Table 3, or a sequence at least 85%, 90%, 95% or more identical thereto. 
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 CD19 CAR Constructs 
               
            
           
           
               
               
               
            
               
                   
                 SEQ ID 
                   
               
               
                 Name 
                 NO: 
                 Sequence 
               
               
                   
               
            
           
           
               
            
               
                 CAR 1 
               
            
           
           
               
               
               
            
               
                 CAR 1 scFv 
                 893 
                 EIVMTQSPATLSLSPGERATLSCRASQDISKYLNWYQQKPGQAPRLLIYHTSRLH 
               
               
                 domain 
                   
                 SGIPARFSGSGSGTDYTLTISSLQPEDFAVYFCQQGNTLPYTFGQGTKLEIKGGG 
               
               
                   
                   
                 GSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTCTVSGVSLPDYGVSWIRQPPGK 
               
               
                   
                   
                 GLEWIGVIWGSETTYYSSSLKSRVTISKDNSKNQVSLKLSSVTAADTAVYYCAKH 
               
               
                   
                   
                 YYYGGSYAMDYWGQGTLVTVSS 
               
               
                   
               
               
                 103101 
                 894 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 1 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Soluble 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                 scFv - nt 
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaact 
               
               
                   
                   
                 ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgt 
               
               
                   
                   
                 actgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccac 
               
               
                   
                   
                 cggggaagggtctggaatggattggagtgatttggggctctgagactacttacta 
               
               
                   
                   
                 ctcttcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcag 
               
               
                   
                   
                 gtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg 
               
               
                   
                   
                 ctaagcattactattatggcgggagctacgcaatggattactggggacagggtac 
               
               
                   
                   
                 tctggtcaccgtgtccagccaccaccatcatcaccatcaccat 
               
               
                   
               
               
                 103101 
                 895 
                     MALPVTALLLPLALLLHAARP   eivmtqspatlslspgeratlscrasgdiskyln 
               
               
                 CAR 1 
                   
                 wyggkpggaprlliyhtsrlhsgiparfsgsgsgtdytltisslgpedfavyfcq 
               
               
                 Soluble 
                   
                 qgntlpytfgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltc 
               
               
                 scFv - aa 
                   
                 tvsgyslpdygvswirqppgkglewigviwgsettyyssslksrvtiskdnsknq 
               
               
                   
                   
                 vslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss   hhhhhhhh     
               
               
                   
               
               
                 104875 
                 896 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 1 - 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Full - nt 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                   
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaact 
               
               
                   
                   
                 ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgt 
               
               
                   
                   
                 actgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccac 
               
               
                   
                   
                 cggggaagggtctggaatggattggagtgatttggggctctgagactacttacta 
               
               
                   
                   
                 ctcttcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcag 
               
               
                   
                   
                 gtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg 
               
               
                   
                   
                 ctaagcattactattatggcgggagctacgcaatggattactggggacagggtac 
               
               
                   
                   
                 tctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggct 
               
               
                   
                   
                 cctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcag 
               
               
                   
                   
                 ctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttg 
               
               
                   
                   
                 ggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctt 
               
               
                   
                   
                 tactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatga 
               
               
                   
                   
                 ggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagagga 
               
               
                   
                   
                 ggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca 
               
               
                   
                   
                 gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagag 
               
               
                   
                   
                 aggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaa 
               
               
                   
                   
                 gccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataag 
               
               
                   
                   
                 atggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaag 
               
               
                   
                   
                 gccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc 
               
               
                   
                   
                 tcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 104875 
                 897 
                 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc   rasqdiskyln     
               
               
                 CAR 1 - 
                   
                 wyqqkpgqaprlliy   htsrlhs   giparfsgsgsgtdytltisslqpedfavyfc   q     
               
               
                 Full - aa 
                   
                     qgntlpyt   fgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltc 
               
               
                   
                   
                 tvsgvslp   dyg   v   s   wirqppgkglewig   viwgsettyyssslks   rvtiskdnsknq 
               
               
                   
                   
                 vslklssvtaadtavyycak   hyyyggsyamdy   wgqgtlvtvsstttpaprpptpa 
               
               
                   
                   
                 ptiasgplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitl 
               
               
                   
                   
                 yckrgrkkllyifkgpfmrpvgttqeedgcscrfpeeeeggcelrvkfsrsadap 
               
               
                   
                   
                 aykgggnglynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdk 
               
               
                   
                   
                 maeayseigmkgerrrgkghdglygglstatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 2 
               
            
           
           
               
               
               
            
               
                 CAR 2 scFv 
                 898 
                 eivmtqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlh 
               
               
                 domain 
                   
                 sgiparfsgsgsgtdytltisslgpedfavyfcqqgntlpytfgqgtkleikggg 
               
               
                   
                   
                 gsggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygyswirgppgk 
               
               
                   
                   
                 giewigviwgsettyygsslksrvtiskdnsknqvslklssvtaadtavyycakh 
               
               
                   
                   
                 yyyggsyamdywgggtlvtvss 
               
               
                   
               
               
                 103102 
                 899 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 2 - 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Soluble 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                 scFv - nt 
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaact 
               
               
                   
                   
                 ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgt 
               
               
                   
                   
                 actgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccac 
               
               
                   
                   
                 cggggaagggtctggaatggattggagtgatttggggctctgagactacttacta 
               
               
                   
                   
                 ccaatcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcag 
               
               
                   
                   
                 gtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg 
               
               
                   
                   
                 ctaagcattactattatggcgggagctacgcaatggattactggggacagggtac 
               
               
                   
                   
                 tctggtcaccgtgtccagccaccaccatcatcaccatcaccat 
               
               
                   
               
               
                 103102 
                 900 
                     MALPVTALLLPLALLLHAARP   eivmtqspatlslspgeratlscrasqdiskyln 
               
               
                 CAR 2 - 
                   
                 wyggkpggaprlliyhtsrlhsgiparfsgsgsgtdytltisslgpedfavyfcq 
               
               
                 Soluble 
                   
                 ggntlpytfgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltc 
               
               
                 scFv - aa 
                   
                 tvsgvslpdygvswirqppgkglewigviwgsettyygsslksrvtiskdnsknq 
               
               
                   
                   
                 vslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss   hhhhhhhh     
               
               
                   
               
               
                 104876 
                 901 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 2 - 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Full - nt 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                   
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaact 
               
               
                   
                   
                 ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgt 
               
               
                   
                   
                 actgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccac 
               
               
                   
                   
                 cggggaagggtctggaatggattggagtgatttggggctctgagactacttacta 
               
               
                   
                   
                 ccaatcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcag 
               
               
                   
                   
                 gtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg 
               
               
                   
                   
                 ctaagcattactattatggcgggagctacgcaatggattactggggacagggtac 
               
               
                   
                   
                 tctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggct 
               
               
                   
                   
                 cctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcag 
               
               
                   
                   
                 ctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttg 
               
               
                   
                   
                 ggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctt 
               
               
                   
                   
                 tactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatga 
               
               
                   
                   
                 ggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagagga 
               
               
                   
                   
                 ggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca 
               
               
                   
                   
                 gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagag 
               
               
                   
                   
                 aggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaa 
               
               
                   
                   
                 gccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataag 
               
               
                   
                   
                 atggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaag 
               
               
                   
                   
                 gccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc 
               
               
                   
                   
                 tcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 104876 
                 902 
                 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc   rasqdiskyln     
               
               
                 CAR 2 - 
                   
                 wyqqkpgqaprlliy   htsrlhs   giparfsgsgsgtdytltisslqpedfavyfc   q     
               
               
                 Full - aa 
                   
                     qgntlpyt   fgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltc 
               
               
                   
                   
                 tvsgvslp   dygvs   wirqppgkglewig   viwgsettyyqsslks   rvtiskdnsknq 
               
               
                   
                   
                 vslklssvtaadtavyycak   hyyyggsyamdy   wgqgtlvtvsstttpaprpptpa 
               
               
                   
                   
                 ptiasqplslrpeacrpaaggavhtrgldfacdiylwaplagtcgvlllslvitl 
               
               
                   
                   
                 yckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrykfsrsadap 
               
               
                   
                   
                 aykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelqkdk 
               
               
                   
                   
                 maeayseigmkgerrrgkghdglyqglstatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 3 
               
            
           
           
               
               
               
            
               
                 CAR 3 scFV 
                 903 
                 qvqlqesgpglvkpsetlsltctvsgvslpdygyswirqppgkglewigviwgse 
               
               
                 domain 
                   
                 ttyyssslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdyw 
               
               
                   
                   
                 gqgtlvtvssggggsggggsggggseivmtqspatlslspgeratlscrasqdis 
               
               
                   
                   
                 kylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfav 
               
               
                   
                   
                 yfcqqgntlpytfgqgtkleik 
               
               
                   
               
               
                 103104 
                 904 
                 atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccg 
               
               
                 CAR 3 - 
                   
                 ctcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctga 
               
               
                 Soluble 
                   
                 gactctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtg 
               
               
                 scFv - nt 
                   
                 agctggattagacagcctcccggaaagggactggagtggatcggagtgatttggg 
               
               
                   
                   
                 gtagcgaaaccacttactattcatcttccctgaagtcacgggtcaccatttcaaa 
               
               
                   
                   
                 ggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgac 
               
               
                   
                   
                 accgccgtgtattactgtgccaagcattactactatggagggtcctacgccatgg 
               
               
                   
                   
                 actactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcgg 
               
               
                   
                   
                 aggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgca 
               
               
                   
                   
                 accctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaag 
               
               
                   
                   
                 atatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggct 
               
               
                   
                   
                 tcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcggg 
               
               
                   
                   
                 tctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggact 
               
               
                   
                   
                 tcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccaggg 
               
               
                   
                   
                 caccaagcttgagatcaaacatcaccaccatcatcaccatcac 
               
               
                   
               
               
                 103104 
                 905 
                     MALPVTALLLPLALLLHAARP   qvqlqesgpglvkpsetlsltctvsgvslpdygv 
               
               
                 CAR 3 - 
                   
                 swirgppgkglewigviwgsettyyssslksrvtiskdnsknqvslklssvtaad 
               
               
                 Soluble 
                   
                 tavyycakhyyyggsyamdywgggtlvtvssggggsggggsggggseivmtgspa 
               
               
                 scFv - aa 
                   
                 tlslspgeratlscrasgdiskylnwyggkpggaprlliyhtsrlhsgiparfsg 
               
               
                   
                   
                 sgsgtdytltissigpedfavyfcqqgntlpytfgqgtkleik   hhhhhhhh     
               
               
                   
               
               
                 104877 
                 906 
                 atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccg 
               
               
                 CAR 3 - 
                   
                 ctcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctga 
               
               
                 Full - nt 
                   
                 gactctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtg 
               
               
                   
                   
                 agctggattagacagcctcccggaaagggactggagtggatcggagtgatttggg 
               
               
                   
                   
                 gtagcgaaaccacttactattcatcttccctgaagtcacgggtcaccatttcaaa 
               
               
                   
                   
                 ggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgac 
               
               
                   
                   
                 accgccgtgtattactgtgccaagcattactactatggagggtcctacgccatgg 
               
               
                   
                   
                 actactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcgg 
               
               
                   
                   
                 aggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgca 
               
               
                   
                   
                 accctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaag 
               
               
                   
                   
                 atatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggct 
               
               
                   
                   
                 tcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcggg 
               
               
                   
                   
                 tctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggact 
               
               
                   
                   
                 tcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccaggg 
               
               
                   
                   
                 caccaagcttgagatcaaaaccactactcccgctccaaggccacccacccctgcc 
               
               
                   
                   
                 ccgaccatcgcctctcagccgctttccctgcgtccggaggcatgtagacccgcag 
               
               
                   
                   
                 ctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttg 
               
               
                   
                   
                 ggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctt 
               
               
                   
                   
                 tactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatga 
               
               
                   
                   
                 ggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagagga 
               
               
                   
                   
                 ggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca 
               
               
                   
                   
                 gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagag 
               
               
                   
                   
                 aggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaa 
               
               
                   
                   
                 gccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataag 
               
               
                   
                   
                 atggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaag 
               
               
                   
                   
                 gccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc 
               
               
                   
                   
                 tcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 104877 
                 907 
                 MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp   dygv     
               
               
                 CAR 3 
                   
                     s   wirgppgkglewig   viwgsettyyssslks   rvtiskdnsknqvslklssvtaad 
               
               
                 Full - aa 
                   
                 tavyycak   hyyyggsyamdy   wgqgtlvtvssggggsggggsggggseivmtgspa 
               
               
                   
                   
                 tisispgeratlsc   rasqdiskyln   wyggkpgqaprlliy   htsrlhs   giparfsg 
               
               
                   
                   
                 sgsgtdytltisslqpedfavyfcq   qgntlpyt   fgqgtkleiktttpaprpptpa 
               
               
                   
                   
                 ptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllsivitl 
               
               
                   
                   
                 yckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrykfsrsadap 
               
               
                   
                   
                 aykqgqnqlynelnlgrreeydvidkrrgrdpemggkprrknpqeglynelqkdk 
               
               
                   
                   
                 maeayseigmkgerrrgkghdglyggistatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 4 
               
            
           
           
               
               
               
            
               
                 CAR 4 scFv 
                 908 
                 qvqlgesgpglvkpsetlsltctvsgvslpdygvswirgppgkglewigviwgse 
               
               
                 domain 
                   
                 ttyyqsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdyw 
               
               
                   
                   
                 gqgtlvtvssggggsggggsggggseivmtqspatlslspgeratlscrasqdis 
               
               
                   
                   
                 kylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfav 
               
               
                   
                   
                 yfcqqgntlpytfgqgtkleik 
               
               
                   
               
               
                 103106 
                 909 
                 atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccg 
               
               
                 CAR 4 - 
                   
                 ctcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctga 
               
               
                 Soluble 
                   
                 gactctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtg 
               
               
                 scFv - nt 
                   
                 agctggattagacagcctcccggaaagggactggagtggatcggagtgatttggg 
               
               
                   
                   
                 gtagcgaaaccacttactatcaatcttccctgaagtcacgggtcaccatttcaaa 
               
               
                   
                   
                 ggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgac 
               
               
                   
                   
                 accgccgtgtattactgtgccaagcattactactatggagggtcctacgccatgg 
               
               
                   
                   
                 actactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcgg 
               
               
                   
                   
                 aggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgca 
               
               
                   
                   
                 accctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaag 
               
               
                   
                   
                 atatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggct 
               
               
                   
                   
                 tcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcggg 
               
               
                   
                   
                 tctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggact 
               
               
                   
                   
                 tcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccaggg 
               
               
                   
                   
                 caccaagcttgagatcaaacatcaccaccatcatcaccatcac 
               
               
                   
               
               
                 103106 
                 910 
                     MALPVTALLLPLALLLHAARP   qvqlqesgpglvkpsetlsltctvsgvslpdygv 
               
               
                 CAR 4 - 
                   
                 swirqppgkglewigviwgsettyyqsslksrvtiskdnsknqvslklssvtaad 
               
               
                 Soluble 
                   
                 tavyycakhyyyggsyamdywgqgtlvtvssggggsggggsggggseivmtqspa 
               
               
                 scFv -aa 
                   
                 tlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsg 
               
               
                   
                   
                 sgsgtdytltisslqpedfavyfcqqgntlpytfgpgtkleik   hhhhhhhh     
               
               
                   
               
               
                 104878 
                 911 
                 atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccg 
               
               
                 CAR 4 - 
                   
                 ctcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctga 
               
               
                 Full - nt 
                   
                 gactctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtg 
               
               
                   
                   
                 agctggattagacagcctcccggaaagggactggagtggatcggagtgatttggg 
               
               
                   
                   
                 gtagcgaaaccacttactatcaatcttccctgaagtcacgggtcaccatttcaaa 
               
               
                   
                   
                 ggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgac 
               
               
                   
                   
                 accgccgtgtattactgtgccaagcattactactatggagggtcctacgccatgg 
               
               
                   
                   
                 actactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcgg 
               
               
                   
                   
                 aggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgca 
               
               
                   
                   
                 accctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaag 
               
               
                   
                   
                 atatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggct 
               
               
                   
                   
                 tcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcggg 
               
               
                   
                   
                 tctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggact 
               
               
                   
                   
                 tcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccaggg 
               
               
                   
                   
                 caccaagcttgagatcaaaaccactactcccgctccaaggccacccacccctgcc 
               
               
                   
                   
                 ccgaccatcgcctctcagccgctttccctgcgtccggaggcatgtagacccgcag 
               
               
                   
                   
                 ctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttg 
               
               
                   
                   
                 ggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctt 
               
               
                   
                   
                 tactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatga 
               
               
                   
                   
                 ggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagagga 
               
               
                   
                   
                 ggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca 
               
               
                   
                   
                 gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagag 
               
               
                   
                   
                 aggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaa 
               
               
                   
                   
                 gccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataag 
               
               
                   
                   
                 atggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaag 
               
               
                   
                   
                 gccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc 
               
               
                   
                   
                 tcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 104878 
                 912 
                 MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp   dygv     
               
               
                 CAR 4 - 
                   
                     s   wirgppgkglewig   viwgsettyyqsslks   rvtiskdnsknqvslklssvtaad 
               
               
                 Full - aa 
                   
                 tavyycak   hyyyggsyamdy   wgqgtlvtvssggggsggggsggggseivmtgspa 
               
               
                   
                   
                 tlslspgeratlsc   rasqdiskyln   wyqqkpgqaprlliy   htsrlhs   giparfsg 
               
               
                   
                   
                 sgsgtdytltisslgpedfavyfc   qqgntlpyt   fgqgtkleiktttpaprpptpa 
               
               
                   
                   
                 ptiasgplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllslvitl 
               
               
                   
                   
                 yckrgrkkllyifkgpfmrpvgttqeedgcscrfpeeeeggcelrvkfsrsadap 
               
               
                   
                   
                 aykgggnglynelnlgrreeydvldkrrgrdpemggkprrknpqeglynelgkdk 
               
               
                   
                   
                 maeayseigmkgerrrgkghdglygglstatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 5 
               
            
           
           
               
               
               
            
               
                 CAR5 scFv 
                 913 
                 eivmtqspatlslspgeratlscrasqdiskylnwyggkpgqaprlliyhtsrlh 
               
               
                 domain 
                   
                 sgiparfsgsgsgtdytltisslgpedfavyfcqqgntlpytfgqgtkleikggg 
               
               
                   
                   
                 gsggggsggggsggggsqvqlgesgpglvkpsetlsltctvsgvslpdygvswir 
               
               
                   
                   
                 gppgkglewigviwgsettyyssslksrvtiskdnsknqvslklssvtaadtavy 
               
               
                   
                   
                 ycakhyyyggsyamdywgggtlvtvss 
               
               
                   
               
               
                 99789 
                 914 
                 atggccctcccagtgaccgctctgctgctgcctctcgcacttcttctccatgccg 
               
               
                 CAR 5 - 
                   
                 ctcggcctgagatcgtcatgacccaaagccccgctaccctgtccctgtcacccgg 
               
               
                 Soluble 
                   
                 cgagagggcaaccctttcatgcagggccagccaggacatttctaagtacctcaac 
               
               
                 scFv - nt 
                   
                 tggtatcagcagaagccagggcaggctcctcgcctgctgatctaccacaccagcc 
               
               
                   
                   
                 gcctccacagcggtatccccgccagattttccgggagcgggtctggaaccgacta 
               
               
                   
                   
                 caccctcaccatctcttctctgcagcccgaggatttcgccgtctatttctgccag 
               
               
                   
                   
                 caggggaatactctgccgtacaccttcggtcaaggtaccaagctggaaatcaagg 
               
               
                   
                   
                 gaggcggaggatcaggcggtggcggaagcggaggaggtggctccggaggaggagg 
               
               
                   
                   
                 ttcccaagtgcagcttcaagaatcaggacccggacttgtgaagccatcagaaacc 
               
               
                   
                   
                 ctctccctgacttgtaccgtgtccggtgtgagcctccccgactacggagtctctt 
               
               
                   
                   
                 ggattcgccagcctccggggaagggtcttgaatggattggggtgatttggggatc 
               
               
                   
                   
                 agagactacttactactcttcatcacttaagtcacgggtcaccatcagcaaagat 
               
               
                   
                   
                 aatagcaagaaccaagtgtcacttaagctgtcatctgtgaccgccgctgacaccg 
               
               
                   
                   
                 ccgtgtactattgtgccaaacattactattacggagggtcttatgctatggacta 
               
               
                   
                   
                 ctggggacaggggaccctggtgactgtctctagccatcaccatcaccaccatcat 
               
               
                   
                   
                 cac 
               
               
                   
               
               
                 99789 
                 915 
                     MALPVTALLLPLALLLHAARP   eivmtqspatlslspgeratlscrasgdiskyln 
               
               
                 CAR 5 - 
                   
                 wyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslgpedfavyfcq 
               
               
                 Soluble 
                   
                 qgntlpytfgqgtkleikggggsggggsggggsggggsqvqlgesgpglvkpset 
               
               
                 scFv - aa 
                   
                 lsltctvsgvslpdygyswirqppgkglewigviwgsettyyssslksrvtiskd 
               
               
                   
                   
                 nskngvslklssvtaadtavyycakhyyyggsyamdywgggtlvtvss   hhhhhhh     
               
               
                   
                   
                 
                   
                     h 
                   
                 
               
               
                   
               
               
                 104879 
                 916 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 5 - 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Full - nt 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                   
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagcggcggaggcgg 
               
               
                   
                   
                 gagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaact 
               
               
                   
                   
                 ctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtctt 
               
               
                   
                   
                 ggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctc 
               
               
                   
                   
                 tgagactacttactactcttcatccctcaagtcacgcgtcaccatctcaaaggac 
               
               
                   
                   
                 aactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccg 
               
               
                   
                   
                 ccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggatta 
               
               
                   
                   
                 ctggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgagg 
               
               
                   
                   
                 ccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggagg 
               
               
                   
                   
                 catgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctg 
               
               
                   
                   
                 cgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttca 
               
               
                   
                   
                 ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatcttta 
               
               
                   
                   
                 agcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatg 
               
               
                   
                   
                 ccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgc 
               
               
                   
                   
                 agcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactca 
               
               
                   
                   
                 atcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggaccc 
               
               
                   
                   
                 agaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgag 
               
               
                   
                   
                 ctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaac 
               
               
                   
                   
                 gcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa 
               
               
                   
                   
                 ggacacctatgacgctcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 104879 
                 917 
                 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc   rasqdiskyln     
               
               
                 CAR 5 - 
                   
                 wyggkpggaprlliy   htsrlhs   giparfsgsgsgtdytltissigpedfavyfc   q     
               
               
                 Full - aa 
                   
                     qgntlpyt   fgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpset 
               
               
                   
                   
                 lsltctvsgvslp   dygvs   wirqppgkglewig   viwgsettyyssslks   rvtiskd 
               
               
                   
                   
                 nsknqvslklssvtaadtavyycak   hyyyggsyamdy   wgqgtlvtvsstttpapr 
               
               
                   
                   
                 pptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvllls 
               
               
                   
                   
                 lvitlyckrgrkkllyifkgpfmrpvgttqeedgcscrfpeeeeggcelrykfsr 
               
               
                   
                   
                 sadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglyne 
               
               
                   
                   
                 lgkdkmaeayseigmkgerrrgkghdglygglstatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 6 
               
            
           
           
               
               
               
            
               
                 CAR 6 
                 918 
                 eivmtqspatlslspgeratlscrasgdiskylnwyggkpgqaprlliyhtsrlh 
               
               
                 scFv 
                   
                 sgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleikggg 
               
               
                 domain 
                   
                 gsggggsggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygvswir 
               
               
                   
                   
                 qppgkglewigviwgsettyygsslksrvtiskdnsknqvslklssvtaadtavy 
               
               
                   
                   
                 ycakhyyyggsyamdywgqgtlvtvss 
               
               
                   
               
               
                 99790 
                 919 
                 atggccctcccagtgaccgctctgctgctgcctctcgcacttcttctccatgccg 
               
               
                 CAR 6 - 
                   
                 ctcggcctgagatcgtcatgacccaaagccccgctaccctgtccctgtcacccgg 
               
               
                 Soluble 
                   
                 cgagagggcaaccctttcatgcagggccagccaggacatttctaagtacctcaac 
               
               
                 scFv - nt 
                   
                 tggtatcagcagaagccagggcaggctcctcgcctgctgatctaccacaccagcc 
               
               
                   
                   
                 gcctccacagcggtatccccgccagattttccgggagcgggtctggaaccgacta 
               
               
                   
                   
                 caccctcaccatctcttctctgcagcccgaggatttcgccgtctatttctgccag 
               
               
                   
                   
                 caggggaatactctgccgtacaccttcggtcaaggtaccaagctggaaatcaagg 
               
               
                   
                   
                 gaggcggaggatcaggcggtggcggaagcggaggaggtggctccggaggaggagg 
               
               
                   
                   
                 ttcccaagtgcagcttcaagaatcaggacccggacttgtgaagccatcagaaacc 
               
               
                   
                   
                 ctctccctgacttgtaccgtgtccggtgtgagcctccccgactacggagtctctt 
               
               
                   
                   
                 ggattcgccagcctccggggaagggtcttgaatggattggggtgatttggggatc 
               
               
                   
                   
                 agagactacttactaccagtcatcacttaagtcacgggtcaccatcagcaaagat 
               
               
                   
                   
                 aatagcaagaaccaagtgtcacttaagctgtcatctgtgaccgccgctgacaccg 
               
               
                   
                   
                 ccgtgtactattgtgccaaacattactattacggagggtcttatgctatggacta 
               
               
                   
                   
                 ctggggacaggggaccctggtgactgtctctagccatcaccatcaccaccatcat 
               
               
                   
                   
                 cac 
               
               
                   
               
               
                 99790 
                 920 
                     MALPVTALLLPLALLLHAARP   eivmtqspatlslspgeratlscrasqdiskyln 
               
               
                 CAR 6 - 
                   
                 wyggkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltissigpedfavyfcq 
               
               
                 Soluble 
                   
                 qgntlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpset 
               
               
                 scFv - aa 
                   
                 lsltctvsgyslpdygyswirqppgkglewigviwgsettyygsslksrvtiskd 
               
               
                   
                   
                 nsknqvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss   hhhhhhh     
               
               
                   
                   
                 
                   
                     h 
                   
                 
               
               
                   
               
               
                 104880 
                 921 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 6 - 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Full - nt 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                   
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagcggaggcggagg 
               
               
                   
                   
                 gagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaact 
               
               
                   
                   
                 ctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtctt 
               
               
                   
                   
                 ggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctc 
               
               
                   
                   
                 tgagactacttactaccaatcatccctcaagtcacgcgtcaccatctcaaaggac 
               
               
                   
                   
                 aactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccg 
               
               
                   
                   
                 ccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggatta 
               
               
                   
                   
                 ctggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgagg 
               
               
                   
                   
                 ccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggagg 
               
               
                   
                   
                 catgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctg 
               
               
                   
                   
                 cgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttca 
               
               
                   
                   
                 ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatcttta 
               
               
                   
                   
                 agcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatg 
               
               
                   
                   
                 ccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgc 
               
               
                   
                   
                 agcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactca 
               
               
                   
                   
                 atcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggaccc 
               
               
                   
                   
                 agaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgag 
               
               
                   
                   
                 ctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaac 
               
               
                   
                   
                 gcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa 
               
               
                   
                   
                 ggacacctatgacgctcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 104880 
                 922 
                 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc   rasqdiskyln     
               
               
                 CAR 6 - 
                   
                 wyqqkpgqaprlliy   htsrlhs   giparfsgsgsgtdytltisslqpedfavyfc   q     
               
               
                 Full - aa 
                   
                     qgntlpyt   fgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpset 
               
               
                   
                   
                 lsltctvsgvslp   dygvs   wirqppgkglewig   viwgsettyygsslks   rvtiskd 
               
               
                   
                   
                 nsknqvslklssvtaadtavyycak   hyyyggsyamdy   wgqgtlvtvsstttpapr 
               
               
                   
                   
                 pptpaptiasgplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvllls 
               
               
                   
                   
                 lvitlyckrgrkkllyifkgpfmrpvgttqeedgcscrfpeeeeggcelrvkfsr 
               
               
                   
                   
                 sadapaykgggnglynelnlgrreeydvldkrrgrdpemggkprrknpqeglyne 
               
               
                   
                   
                 lgkdkmaeayseigmkgerrrgkghdglygglstatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 7 
               
            
           
           
               
               
               
            
               
                 CAR 7 scFv 
                 923 
                 qvqlqesgpglvkpsetlsltctvsgvslpdygvswirgppgkglewigviwgse 
               
               
                 domain 
                   
                 ttyyssslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdyw 
               
               
                   
                   
                 gqgtlvtvssggggsggggsggggsggggseivmtqspatlslspgeratlscra 
               
               
                   
                   
                 sqdiskylnwyqqkpgqaprlliyhtsrinsgiparfsgsgsgtdytltisslqp 
               
               
                   
                   
                 edfavyfcqqgntlpytfgqgtkleik 
               
               
                   
               
               
                 100796 
                 924 
                 atggcactgcctgtcactgccctcctgctgcctctggccctccttctgcatgccg 
               
               
                 CAR 7 - 
                   
                 ccaggccccaagtccagctgcaagagtcaggacccggactggtgaagccgtctga 
               
               
                 Soluble 
                   
                 gactctctcactgacttgtaccgtcagcggcgtgtccctccccgactacggagtg 
               
               
                 scFv - nt 
                   
                 tcatggatccgccaacctcccgggaaagggcttgaatggattggtgtcatctggg 
               
               
                   
                   
                 gttctgaaaccacctactactcatcttccctgaagtccagggtgaccatcagcaa 
               
               
                   
                   
                 ggataattccaagaaccaggtcagccttaagctgtcatctgtgaccgctgctgac 
               
               
                   
                   
                 accgccgtgtattactgcgccaagcactactattacggaggaagctacgctatgg 
               
               
                   
                   
                 actattggggacagggcactctcgtgactgtgagcagcggcggtggagggtctgg 
               
               
                   
                   
                 aggtggaggatccggtggtggtgggtcaggcggaggagggagcgagattgtgatg 
               
               
                   
                   
                 actcagtcaccagccaccctttctctttcacccggcgagagagcaaccctgagct 
               
               
                   
                   
                 gtagagccagccaggacatttctaagtacctcaactggtatcagcaaaaaccggg 
               
               
                   
                   
                 gcaggcccctcgcctcctgatctaccatacctcacgccttcactctggtatcccc 
               
               
                   
                   
                 gctcggtttagcggatcaggatctggtaccgactacactctgaccatttccagcc 
               
               
                   
                   
                 tgcagccagaagatttcgcagtgtatttctgccagcagggcaatacccttcctta 
               
               
                   
                   
                 caccttcggtcagggaaccaagctcgaaatcaagcaccatcaccatcatcaccac 
               
               
                   
                   
                 cat 
               
               
                   
               
               
                 100796 
                 925 
                     MALPVTALLLPLALLLHAARP   qvqlqesgpglvkpsetlsltctvsgvslpdygv 
               
               
                 CAR 7 - 
                   
                 swirqppgkglewigviwgsettyyssslksrvtiskdnsknqvslklssvtaad 
               
               
                 Soluble 
                   
                 tavyycaknyyyggsyamdywgqgtlvtvssggggsggggsggggsggggseivm 
               
               
                 scFv - aa 
                   
                 tqspatlslspgeratlscrasqdiskylnwyqqkpgqaprlliyhtsrinsgip 
               
               
                   
                   
                 arfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik   hhhhhhh     
               
               
                   
                   
                 
                   
                     h 
                   
                 
               
               
                   
               
               
                 104881 
                 926 
                 atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccg 
               
               
                 CAR 7 
                   
                 ctcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctga 
               
               
                 Full - nt 
                   
                 gactctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtg 
               
               
                   
                   
                 agctggattagacagcctcccggaaagggactggagtggatcggagtgatttggg 
               
               
                   
                   
                 gtagcgaaaccacttactattcatcttccctgaagtcacgggtcaccatttcaaa 
               
               
                   
                   
                 ggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgac 
               
               
                   
                   
                 accgccgtgtattactgtgccaagcattactactatggagggtcctacgccatgg 
               
               
                   
                   
                 actactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcgg 
               
               
                   
                   
                 aggaggcgggagcggtggaggtggctccggaggtggcggaagcgaaatcgtgatg 
               
               
                   
                   
                 acccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttctt 
               
               
                   
                   
                 gtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccggg 
               
               
                   
                   
                 acaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattccc 
               
               
                   
                   
                 gcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctc 
               
               
                   
                   
                 tccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgta 
               
               
                   
                   
                 caccttcggccagggcaccaagcttgagatcaaaaccactactcccgctccaagg 
               
               
                   
                   
                 ccacccacccctgccccgaccatcgcctctcagccgctttccctgcgtccggagg 
               
               
                   
                   
                 catgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctg 
               
               
                   
                   
                 cgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttca 
               
               
                   
                   
                 ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatcttta 
               
               
                   
                   
                 agcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatg 
               
               
                   
                   
                 ccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgc 
               
               
                   
                   
                 agcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactca 
               
               
                   
                   
                 atcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggaccc 
               
               
                   
                   
                 agaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgag 
               
               
                   
                   
                 ctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaac 
               
               
                   
                   
                 gcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa 
               
               
                   
                   
                 ggacacctatgacgctcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 104881 
                 927 
                 MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp   dygv     
               
               
                 CAR 7 
                   
                     s   wirqppgkglewig   viwgsettyyssslks   rvtiskdnsknqvslklssvtaad 
               
               
                 Full - aa 
                   
                 tavyycak   hyyyggsyamdy   wgqgtlvtvssggggsggggsggggsggggseivm 
               
               
                   
                   
                 tqspatlslspgeratlsc   rasqdiskyln   wyqqkpgqaprlliy   htsrlhs   gip 
               
               
                   
                   
                 arfsgsgsgtdytltisslqpedfavyfc   qqgntlpyt   fgqgtkleiktttpapr 
               
               
                   
                   
                 pptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvllls 
               
               
                   
                   
                 lvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsr 
               
               
                   
                   
                 sadapaykqgqnqlynelnlgrreeydvldkrrgrdpemggkprrknpqeglyne 
               
               
                   
                   
                 lqkdkmaeayseigmkgerrrgkghdglyggistatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 8 
               
            
           
           
               
               
               
            
               
                 CAR 8 scFv 
                 928 
                 qvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgse 
               
               
                 domain 
                   
                 ttyyqsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdyw 
               
               
                   
                   
                 gqgtlvtvssggggsggggsggggsggggseivmtqspatlslspgeratlscra 
               
               
                   
                   
                 sqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqp 
               
               
                   
                   
                 edfavyfcqqgntlpytfgqgtkleik 
               
               
                   
               
               
                 100798 
                 929 
                 atggcactgcctgtcactgccctcctgctgcctctggccctccttctgcatgccg 
               
               
                 CAR 8 - 
                   
                 ccaggccccaagtccagctgcaagagtcaggacccggactggtgaagccgtctga 
               
               
                 Soluble 
                   
                 gactctctcactgacttgtaccgtcagcggcgtgtccctccccgactacggagtg 
               
               
                 scFV - nt 
                   
                 tcatggatccgccaacctcccgggaaagggcttgaatggattggtgtcatctggg 
               
               
                   
                   
                 gttctgaaaccacctactaccagtcttccctgaagtccagggtgaccatcagcaa 
               
               
                   
                   
                 ggataattccaagaaccaggtcagccttaagctgtcatctgtgaccgctgctgac 
               
               
                   
                   
                 accgccgtgtattactgcgccaagcactactattacggaggaagctacgctatgg 
               
               
                   
                   
                 actattggggacagggcactctcgtgactgtgagcagcggcggtggagggtctgg 
               
               
                   
                   
                 aggtggaggatccggtggtggtgggtcaggcggaggagggagcgagattgtgatg 
               
               
                   
                   
                 actcagtcaccagccaccctttctctttcacccggcgagagagcaaccctgagct 
               
               
                   
                   
                 gtagagccagccaggacatttctaagtacctcaactggtatcagcaaaaaccggg 
               
               
                   
                   
                 gcaggcccctcgcctcctgatctaccatacctcacgccttcactctggtatcccc 
               
               
                   
                   
                 gctcggtttagcggatcaggatctggtaccgactacactctgaccatttccagcc 
               
               
                   
                   
                 tgcagccagaagatttcgcagtgtatttctgccagcagggcaatacccttcctta 
               
               
                   
                   
                 caccttcggtcagggaaccaagctcgaaatcaagcaccatcaccatcatcatcac 
               
               
                   
                   
                 cac 
               
               
                   
               
               
                 100798 
                 930 
                     MALPVTALLLPLALLLHAARP   qvqlqesgpglvkpsetlsltctvsgvslpdygv 
               
               
                 CAR 8 - 
                   
                 swirgppgkglewigviwgsettyygsslksrvtiskdnsknqvslklssvtaad 
               
               
                 Soluble 
                   
                 tavyycakhyyyggsyamdywgggtlvtvssggggsggggsggggsggggseivm 
               
               
                 scFv - aa 
                   
                 tgspatlslspgeratlscrasgdiskylnwyggkpgqaprlliyhtsrlhsgip 
               
               
                   
                   
                 arfsgsgsgtdytltisslgpedfavyfcqqgntlpytfgqgtkleik   hhhhhhh     
               
               
                   
                   
                 
                   
                     h 
                   
                 
               
               
                   
               
               
                 104882 
                 931 
                 atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccg 
               
               
                 CAR 8 - 
                   
                 ctcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctga 
               
               
                 Full - nt 
                   
                 gactctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtg 
               
               
                   
                   
                 agctggattagacagcctcccggaaagggactggagtggatcggagtgatttggg 
               
               
                   
                   
                 gtagcgaaaccacttactatcaatcttccctgaagtcacgggtcaccatttcaaa 
               
               
                   
                   
                 ggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgac 
               
               
                   
                   
                 accgccgtgtattactgtgccaagcattactactatggagggtcctacgccatgg 
               
               
                   
                   
                 actactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcgg 
               
               
                   
                   
                 aggaggcgggagcggtggaggtggctccggaggcggtgggtcagaaatcgtgatg 
               
               
                   
                   
                 acccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttctt 
               
               
                   
                   
                 gtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccggg 
               
               
                   
                   
                 acaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattccc 
               
               
                   
                   
                 gcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctc 
               
               
                   
                   
                 tccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgta 
               
               
                   
                   
                 caccttcggccagggcaccaagcttgagatcaaaaccactactcccgctccaagg 
               
               
                   
                   
                 ccacccacccctgccccgaccatcgcctctcagccgctttccctgcgtccggagg 
               
               
                   
                   
                 catgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctg 
               
               
                   
                   
                 cgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttca 
               
               
                   
                   
                 ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatcttta 
               
               
                   
                   
                 agcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatg 
               
               
                   
                   
                 ccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgc 
               
               
                   
                   
                 agcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactca 
               
               
                   
                   
                 atcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggaccc 
               
               
                   
                   
                 agaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgag 
               
               
                   
                   
                 ctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaac 
               
               
                   
                   
                 gcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa 
               
               
                   
                   
                 ggacacctatgacgctcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 104882 
                 932 
                 MALPVTALLLPLALLLHAARPqvqlqesgpglvkpsetlsltctvsgvslp   dygv     
               
               
                 CAR 8 - 
                   
                     s   wirqppgkglewig   viwgsettyyqsslks   rvtiskdnsknqvslklssvtaad 
               
               
                 Full - aa 
                   
                 tavyycak   hyyyggsyamdy   wgqgtlvtvssggggsggggsggggsggggseivm 
               
               
                   
                   
                 tqspatlslspgeratlsc   rasqdiskyln   wyqqkpgqaprlliy   htsrlhs   gip 
               
               
                   
                   
                 arfsgsgsgtdytltisslqpedfavyfc   qqgntlpyt   fgqgtkleiktttpapr 
               
               
                   
                   
                 pptpaptiasgplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvllls 
               
               
                   
                   
                 lvitlyckrgrkkllyifkgpfmrpvgttqeedgcscrfpeeeeggcelrykfsr 
               
               
                   
                   
                 sadapaykgggnglynelnlgrreeydvidkrrgrdpemggkprrknpqeglyne 
               
               
                   
                   
                 lgkdkmaeayseigmkgerrrgkghdglyggistatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 9 
               
            
           
           
               
               
               
            
               
                 CAR 9 scFv 
                 933 
                 eivmtqspatlslspgeratlscrasgdiskylnwyggkpgqaprlliyhtsrlh 
               
               
                 domain 
                   
                 sgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleikggg 
               
               
                   
                   
                 gsggggsggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygvswir 
               
               
                   
                   
                 qppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaadtavy 
               
               
                   
                   
                 ycakhyyyggsyamdywgqgtlvtvss 
               
               
                   
               
               
                 99789 
                 934 
                 atggccctcccagtgaccgctctgctgctgcctctcgcacttcttctccatgccg 
               
               
                 CAR 9 - 
                   
                 ctcggcctgagatcgtcatgacccaaagccccgctaccctgtccctgtcacccgg 
               
               
                 Soluble 
                   
                 cgagagggcaaccctttcatgcagggccagccaggacatttctaagtacctcaac 
               
               
                 scFv - nt 
                   
                 tggtatcagcagaagccagggcaggctcctcgcctgctgatctaccacaccagcc 
               
               
                   
                   
                 gcctccacagcggtatccccgccagattttccgggagcgggtctggaaccgacta 
               
               
                   
                   
                 caccctcaccatctcttctctgcagcccgaggatttcgccgtctatttctgccag 
               
               
                   
                   
                 caggggaatactctgccgtacaccttcggtcaaggtaccaagctggaaatcaagg 
               
               
                   
                   
                 gaggcggaggatcaggcggtggcggaagcggaggaggtggctccggaggaggagg 
               
               
                   
                   
                 ttcccaagtgcagcttcaagaatcaggacccggacttgtgaagccatcagaaacc 
               
               
                   
                   
                 ctctccctgacttgtaccgtgtccggtgtgagcctccccgactacggagtctctt 
               
               
                   
                   
                 ggattcgccagcctccggggaagggtcttgaatggattggggtgatttggggatc 
               
               
                   
                   
                 agagactacttactacaattcatcacttaagtcacgggtcaccatcagcaaagat 
               
               
                   
                   
                 aatagcaagaaccaagtgtcacttaagctgtcatctgtgaccgccgctgacaccg 
               
               
                   
                   
                 ccgtgtactattgtgccaaacattactattacggagggtcttatgctatggacta 
               
               
                   
                   
                 ctggggacaggggaccctggtgactgtctctagccatcaccatcaccaccatcat 
               
               
                   
                   
                 cac 
               
               
                   
               
               
                 99789 
                 935 
                     MALPVTALLLPLALLLHAARP   eivmtqspatlslspgeratlscrasgdiskyln 
               
               
                 CAR 9 - 
                   
                 wyggkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltissigpedfavyfcq 
               
               
                 Soluble 
                   
                 qgntlpytfgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpset 
               
               
                 scFv - aa 
                   
                 lsltctvsgyslpdygyswirqppgkglewigviwgsettyynsslksrvtiskd 
               
               
                   
                   
                 nskngvslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss   hhhhhhh     
               
               
                   
                   
                 
                   
                     h 
                   
                 
               
               
                   
               
               
                 105974 
                 936 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 9 - 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Full - nt 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                   
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagcggaggcggtgg 
               
               
                   
                   
                 gagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaact 
               
               
                   
                   
                 ctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtctt 
               
               
                   
                   
                 ggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctc 
               
               
                   
                   
                 tgagactacttactacaactcatccctcaagtcacgcgtcaccatctcaaaggac 
               
               
                   
                   
                 aactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccg 
               
               
                   
                   
                 ccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggatta 
               
               
                   
                   
                 ctggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgagg 
               
               
                   
                   
                 ccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggagg 
               
               
                   
                   
                 catgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctg 
               
               
                   
                   
                 cgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttca 
               
               
                   
                   
                 ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatcttta 
               
               
                   
                   
                 agcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatg 
               
               
                   
                   
                 ccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgc 
               
               
                   
                   
                 agcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactca 
               
               
                   
                   
                 atcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggaccc 
               
               
                   
                   
                 agaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgag 
               
               
                   
                   
                 ctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaac 
               
               
                   
                   
                 gcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa 
               
               
                   
                   
                 ggacacctatgacgctcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 105974 
                 937 
                 MALPVTALLLPLALLLHAARPeivmtqspatlslspgeratlsc   rasqdiskyln     
               
               
                 CAR 9 - 
                   
                 wyqqkpgqaprlliy   htsrlhs   giparfsgsgsgtdytltisslqpedfavyfc   q     
               
               
                 Full - aa 
                   
                     qgntlpyt   fgqgtkleikggggsggggsggggsggggsqvqlqesgpglvkpset 
               
               
                   
                   
                 lsltctvsgvslp   dygvs   wirqppgkglewig   viwgsettyynsslks   rvtiskd 
               
               
                   
                   
                 nsknqvslklssvtaadtavyycak   hyyyggsyamdy   wgqgtlvtvsstttpapr 
               
               
                   
                   
                 pptpaptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvllls 
               
               
                   
                   
                 lvitlyckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsr 
               
               
                   
                   
                 sadapaykqgqnqlynelnlgrreeydvidkrrgrdpemggkprrknpqeglyne 
               
               
                   
                   
                 lqkdkmaeayseigmkgerrrgkghdglyggistatkdtydalhmqalppr 
               
               
                   
               
            
           
           
               
            
               
                 CAR 10 
               
            
           
           
               
               
               
            
               
                 CAR 10 
                 938 
                 qvqlqesgpglvkpsetlsltctvsgvslpdygvswirqppgkglewigviwgse 
               
               
                 scFv 
                   
                 ttyynsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdyw 
               
               
                 domain 
                   
                 gqgtlvtvssggggsggggsggggsggggseivmtqspatlslspgeratlscra 
               
               
                   
                   
                 sqdiskylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqp 
               
               
                   
                   
                 edfavyfcqqgntlpytfgqgtkleik 
               
               
                   
               
               
                 100796 
                 939 
                 atggcactgcctgtcactgccctcctgctgcctctggccctccttctgcatgccg 
               
               
                 CAR 10 - 
                   
                 ccaggccccaagtccagctgcaagagtcaggacccggactggtgaagccgtctga 
               
               
                 Soluble 
                   
                 gactctctcactgacttgtaccgtcagcggcgtgtccctccccgactacggagtg 
               
               
                 scFV - nt 
                   
                 tcatggatccgccaacctcccgggaaagggcttgaatggattggtgtcatctggg 
               
               
                   
                   
                 gttctgaaaccacctactacaactcttccctgaagtccagggtgaccatcagcaa 
               
               
                   
                   
                 ggataattccaagaaccaggtcagccttaagctgtcatctgtgaccgctgctgac 
               
               
                   
                   
                 accgccgtgtattactgcgccaagcactactattacggaggaagctacgctatgg 
               
               
                   
                   
                 actattggggacagggcactctcgtgactgtgagcagcggcggtggagggtctgg 
               
               
                   
                   
                 aggtggaggatccggtggtggtgggtcaggcggaggagggagcgagattgtgatg 
               
               
                   
                   
                 actcagtcaccagccaccctttctctttcacccggcgagagagcaaccctgagct 
               
               
                   
                   
                 gtagagccagccaggacatttctaagtacctcaactggtatcagcaaaaaccggg 
               
               
                   
                   
                 gcaggcccctcgcctcctgatctaccatacctcacgccttcactctggtatcccc 
               
               
                   
                   
                 gctcggtttagcggatcaggatctggtaccgactacactctgaccatttccagcc 
               
               
                   
                   
                 tgcagccagaagatttcgcagtgtatttctgccagcagggcaatacccttcctta 
               
               
                   
                   
                 caccttcggtcagggaaccaagctcgaaatcaagcaccatcaccatcatcaccac 
               
               
                   
                   
                 cat 
               
               
                   
               
               
                 100796 
                 940 
                     MALPVTALLLPLALLLHAARP   qvqlqesgpglvkpsetlsltctvsgvslpdygv 
               
               
                 CAR 10 - 
                   
                 swirgppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaad 
               
               
                 Soluble 
                   
                 tavyycakhyyyggsyamdywgggtlvtvssggggsggggsggggsggggseivm 
               
               
                 scFv - aa 
                   
                 tgspatlslspgeratlscrasgdiskylnwyggkpgqaprlliyhtsrlhsgip 
               
               
                   
                   
                 arfsgsgsgtdytltisslgpedfavyfcqqgntlpytfgqgtkleik   hhhhhhh     
               
               
                   
                   
                 
                   
                     h 
                   
                 
               
               
                   
               
               
                 105975 
                 941 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 10 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Full - nt 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                   
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagcggaggcggtgg 
               
               
                   
                   
                 gagccaggtccaactccaagaaagcggaccgggtcttgtgaagccatcagaaact 
               
               
                   
                   
                 ctttcactgacttgtactgtgagcggagtgtctctccccgattacggggtgtctt 
               
               
                   
                   
                 ggatcagacagccaccggggaagggtctggaatggattggagtgatttggggctc 
               
               
                   
                   
                 tgagactacttactacaactcatccctcaagtcacgcgtcaccatctcaaaggac 
               
               
                   
                   
                 aactctaagaatcaggtgtcactgaaactgtcatctgtgaccgcagccgacaccg 
               
               
                   
                   
                 ccgtgtactattgcgctaagcattactattatggcgggagctacgcaatggatta 
               
               
                   
                   
                 ctggggacagggtactctggtcaccgtgtccagcaccactaccccagcaccgagg 
               
               
                   
                   
                 ccacccaccccggctcctaccatcgcctcccagcctctgtccctgcgtccggagg 
               
               
                   
                   
                 catgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctg 
               
               
                   
                   
                 cgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttca 
               
               
                   
                   
                 ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatcttta 
               
               
                   
                   
                 agcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatg 
               
               
                   
                   
                 ccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgc 
               
               
                   
                   
                 agcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactca 
               
               
                   
                   
                 atcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggaccc 
               
               
                   
                   
                 agaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgag 
               
               
                   
                   
                 ctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaac 
               
               
                   
                   
                 gcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa 
               
               
                   
                   
                 ggacacctatgacgctcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 105975 
                 942 
                 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSC   RASQDISKYLN     
               
               
                 CAR 10 
                   
                 WYQQKPGQAPRLLIY   HTSRLHS   GIPARFSGSGSGTDYTLTISSLQPEDFAVYFC   Q     
               
               
                 Full - aa 
                   
                     QGNTLPYT   FGQGTKLEIKGGGGSGGGGSGGGGSGGGGSQVQLQESGPGLVKPSET 
               
               
                   
                   
                 LSLTCTVSGVSLP   DYGVS   WIRQPPGKGLEWIG   VIWGSETTYYNSSLKS   RVTISKD 
               
               
                   
                   
                 NSKNQVSLKLSSVTAADTAVYYCAK   HYYYGGSYAMDY   WGQGTLVTVSSTTTPAPR 
               
               
                   
                   
                 PPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLS 
               
               
                   
                   
                 LVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR 
               
               
                   
                   
                 SADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE 
               
               
                   
                   
                 LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
               
               
                   
               
            
           
           
               
            
               
                 CAR 11 
               
            
           
           
               
               
               
            
               
                 CAR 11 
                 943 
                 eivmtqspatlslspgeratlscrasgdiskylnwyggkpgqaprlliyhtsrlh 
               
               
                 scFv 
                   
                 sgiparfsgsgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleikggg 
               
               
                 domain 
                   
                 gsggggsggggsqvqlqesgpglvkpsetlsltctvsgvslpdygyswirgppgk 
               
               
                   
                   
                 glewigviwgsettyynsslksrvtiskdnsknqvslklssvtaadtavyycakh 
               
               
                   
                   
                 yyyggsyamdywgqgtlvtvss 
               
               
                   
               
               
                 103101 
                 944 
                 Atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 11 - 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Soluble 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                 scFv - nt 
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaact 
               
               
                   
                   
                 ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgt 
               
               
                   
                   
                 actgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccac 
               
               
                   
                   
                 cggggaagggtctggaatggattggagtgatttggggctctgagactacttacta 
               
               
                   
                   
                 caattcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcag 
               
               
                   
                   
                 gtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg 
               
               
                   
                   
                 ctaagcattactattatggcgggagctacgcaatggattactggggacagggtac 
               
               
                   
                   
                 tctggtcaccgtgtccagccaccaccatcatcaccatcaccat 
               
               
                   
               
               
                 103101 
                 945 
                     MALPVTALLLPLALLLHAARP   eivmtqspatlslspgeratlscrasgdiskyln 
               
               
                 CAR 11 - 
                   
                 wyggkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltissigpedfavyfcq 
               
               
                 Soluble 
                   
                 qgntlpytfgqgtkleikggggsggggsggggsqvqlqesgpglvkpsetlsltc 
               
               
                 scFv-aa 
                   
                 tvsgysipdygvswirqppgkglewigviwgsettyynsslksrvtiskdnsknq 
               
               
                   
                   
                 vslklssvtaadtavyycakhyyyggsyamdywgqgtlvtvss   hhhhhhhh     
               
               
                   
               
               
                 105976 
                 946 
                 atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccg 
               
               
                 CAR 11 
                   
                 ctcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctga 
               
               
                 Full - nt 
                   
                 gactctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtg 
               
               
                   
                   
                 agctggattagacagcctcccggaaagggactggagtggatcggagtgatttggg 
               
               
                   
                   
                 gtagcgaaaccacttactataactcttccctgaagtcacgggtcaccatttcaaa 
               
               
                   
                   
                 ggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgac 
               
               
                   
                   
                 accgccgtgtattactgtgccaagcattactactatggagggtcctacgccatgg 
               
               
                   
                   
                 actactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcgg 
               
               
                   
                   
                 aggaggcgggagcggtggaggtggctccggaggtggcggaagcgaaatcgtgatg 
               
               
                   
                   
                 acccagagccctgcaaccctgtccctttctcccggggaacgggctaccctttctt 
               
               
                   
                   
                 gtcgggcatcacaagatatctcaaaatacctcaattggtatcaacagaagccggg 
               
               
                   
                   
                 acaggcccctaggcttcttatctaccacacctctcgcctgcatagcgggattccc 
               
               
                   
                   
                 gcacgctttagcgggtctggaagcgggaccgactacactctgaccatctcatctc 
               
               
                   
                   
                 tccagcccgaggacttcgccgtctacttctgccagcagggtaacaccctgccgta 
               
               
                   
                   
                 caccttcggccagggcaccaagcttgagatcaaaaccactactcccgctccaagg 
               
               
                   
                   
                 ccacccacccctgccccgaccatcgcctctcagccgctttccctgcgtccggagg 
               
               
                   
                   
                 catgtagacccgcagctggtggggccgtgcatacccggggtcttgacttcgcctg 
               
               
                   
                   
                 cgatatctacatttgggcccctctggctggtacttgcggggtcctgctgctttca 
               
               
                   
                   
                 ctcgtgatcactctttactgtaagcgcggtcggaagaagctgctgtacatcttta 
               
               
                   
                   
                 agcaacccttcatgaggcctgtgcagactactcaagaggaggacggctgttcatg 
               
               
                   
                   
                 ccggttcccagaggaggaggaaggcggctgcgaactgcgcgtgaaattcagccgc 
               
               
                   
                   
                 agcgcagatgctccagcctacaagcaggggcagaaccagctctacaacgaactca 
               
               
                   
                   
                 atcttggtcggagagaggagtacgacgtgctggacaagcggagaggacgggaccc 
               
               
                   
                   
                 agaaatgggcgggaagccgcgcagaaagaatccccaagagggcctgtacaacgag 
               
               
                   
                   
                 ctccaaaaggataagatggcagaagcctatagcgagattggtatgaaaggggaac 
               
               
                   
                   
                 gcagaagaggcaaaggccacgacggactgtaccagggactcagcaccgccaccaa 
               
               
                   
                   
                 ggacacctatgacgctcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 105976 
                 947 
                 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGVSLP   DYGV     
               
               
                 CAR 11 
                   
                     S   WIRQPPGKGLEWIG   VIWGSETTYYNSSLKS   RVTISKDNSKNQVSLKLSSVTAAD 
               
               
                 Full - aa 
                   
                 TAVYYCAK   HYYYGGSYAMDY   WGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVM 
               
               
                   
                   
                 TQSPATLSLSPGERATLSC   RASQDISKYLN   WYQQKPGQAPRLLIY   HTSRLHS   GIP 
               
               
                   
                   
                 ARFSGSGSGTDYTLTISSLQPEDFAVYFC   QQGNTLPYT   FGQGTKLEIKTTTPAPR 
               
               
                   
                   
                 PPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLS 
               
               
                   
                   
                 LVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSR 
               
               
                   
                   
                 SADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNE 
               
               
                   
                   
                 LQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
               
               
                   
               
            
           
           
               
            
               
                 CAR 12 
               
            
           
           
               
               
               
            
               
                 CAR 12 
                 948 
                 qvqlqesgpglvkpsetlsltctvsgvslpdygyswirqppgkglewigviwgse 
               
               
                 scFv 
                   
                 ttyynsslksrvtiskdnsknqvslklssvtaadtavyycakhyyyggsyamdyw 
               
               
                 domain 
                   
                 gqgtlvtvssggggsggggsggggseivmtqspatlslspgeratlscrasqdis 
               
               
                   
                   
                 kylnwyqqkpgqaprlliyhtsrlhsgiparfsgsgsgtdytltisslqpedfav 
               
               
                   
                   
                 yfcqqgntlpytfgqgtkleik 
               
               
                   
               
               
                 103104 
                 949 
                 atggctctgcccgtgaccgcactcctcctgccactggctctgctgcttcacgccg 
               
               
                 CAR 12 - 
                   
                 ctcgcccacaagtccagcttcaagaatcagggcctggtctggtgaagccatctga 
               
               
                 Soluble 
                   
                 gactctgtccctcacttgcaccgtgagcggagtgtccctcccagactacggagtg 
               
               
                 scFv - nt 
                   
                 agctggattagacagcctcccggaaagggactggagtggatcggagtgatttggg 
               
               
                   
                   
                 gtagcgaaaccacttactataactcttccctgaagtcacgggtcaccatttcaaa 
               
               
                   
                   
                 ggataactcaaagaatcaagtgagcctcaagctctcatcagtcaccgccgctgac 
               
               
                   
                   
                 accgccgtgtattactgtgccaagcattactactatggagggtcctacgccatgg 
               
               
                   
                   
                 actactggggccagggaactctggtcactgtgtcatctggtggaggaggtagcgg 
               
               
                   
                   
                 aggaggcgggagcggtggaggtggctccgaaatcgtgatgacccagagccctgca 
               
               
                   
                   
                 accctgtccctttctcccggggaacgggctaccctttcttgtcgggcatcacaag 
               
               
                   
                   
                 atatctcaaaatacctcaattggtatcaacagaagccgggacaggcccctaggct 
               
               
                   
                   
                 tcttatctaccacacctctcgcctgcatagcgggattcccgcacgctttagcggg 
               
               
                   
                   
                 tctggaagcgggaccgactacactctgaccatctcatctctccagcccgaggact 
               
               
                   
                   
                 tcgccgtctacttctgccagcagggtaacaccctgccgtacaccttcggccaggg 
               
               
                   
                   
                 caccaagcttgagatcaaacatcaccaccatcatcaccatcac 
               
               
                   
               
               
                 103104 
                 950 
                     MALPVTALLLPLALLLHAARP   qvqlqesgpglvkpsetlsltctvsgvslpdygv 
               
               
                 CAR 12 - 
                   
                 swirgppgkglewigviwgsettyynsslksrvtiskdnsknqvslklssvtaad 
               
               
                 Soluble 
                   
                 tavyycakhyyyggsyamdywgggtlvtvssggggsggggsggggseivmtgspa 
               
               
                 scFv -aa 
                   
                 tlslspgeratlscrasgdiskylnwyggkpgqaprlliyhtsrlhsgiparfsg 
               
               
                   
                   
                 sgsgtdytltisslqpedfavyfcqqgntlpytfgqgtkleik   hhhhhhhh     
               
               
                   
               
               
                 105977 
                 951 
                 atggccctccctgtcaccgccctgctgcttccgctggctcttctgctccacgccg 
               
               
                 CAR 12 - 
                   
                 ctcggcccgaaattgtgatgacccagtcacccgccactcttagcctttcacccgg 
               
               
                 Full - nt 
                   
                 tgagcgcgcaaccctgtcttgcagagcctcccaagacatctcaaaataccttaat 
               
               
                   
                   
                 tggtatcaacagaagcccggacaggctcctcgccttctgatctaccacaccagcc 
               
               
                   
                   
                 ggctccattctggaatccctgccaggttcagcggtagcggatctgggaccgacta 
               
               
                   
                   
                 caccctcactatcagctcactgcagccagaggacttcgctgtctatttctgtcag 
               
               
                   
                   
                 caagggaacaccctgccctacacctttggacagggcaccaagctcgagattaaag 
               
               
                   
                   
                 gtggaggtggcagcggaggaggtgggtccggcggtggaggaagccaggtccaact 
               
               
                   
                   
                 ccaagaaagcggaccgggtcttgtgaagccatcagaaactctttcactgacttgt 
               
               
                   
                   
                 actgtgagcggagtgtctctccccgattacggggtgtcttggatcagacagccac 
               
               
                   
                   
                 cggggaagggtctggaatggattggagtgatttggggctctgagactacttacta 
               
               
                   
                   
                 caactcatccctcaagtcacgcgtcaccatctcaaaggacaactctaagaatcag 
               
               
                   
                   
                 gtgtcactgaaactgtcatctgtgaccgcagccgacaccgccgtgtactattgcg 
               
               
                   
                   
                 ctaagcattactattatggcgggagctacgcaatggattactggggacagggtac 
               
               
                   
                   
                 tctggtcaccgtgtccagcaccactaccccagcaccgaggccacccaccccggct 
               
               
                   
                   
                 cctaccatcgcctcccagcctctgtccctgcgtccggaggcatgtagacccgcag 
               
               
                   
                   
                 ctggtggggccgtgcatacccggggtcttgacttcgcctgcgatatctacatttg 
               
               
                   
                   
                 ggcccctctggctggtacttgcggggtcctgctgctttcactcgtgatcactctt 
               
               
                   
                   
                 tactgtaagcgcggtcggaagaagctgctgtacatctttaagcaacccttcatga 
               
               
                   
                   
                 ggcctgtgcagactactcaagaggaggacggctgttcatgccggttcccagagga 
               
               
                   
                   
                 ggaggaaggcggctgcgaactgcgcgtgaaattcagccgcagcgcagatgctcca 
               
               
                   
                   
                 gcctacaagcaggggcagaaccagctctacaacgaactcaatcttggtcggagag 
               
               
                   
                   
                 aggagtacgacgtgctggacaagcggagaggacgggacccagaaatgggcgggaa 
               
               
                   
                   
                 gccgcgcagaaagaatccccaagagggcctgtacaacgagctccaaaaggataag 
               
               
                   
                   
                 atggcagaagcctatagcgagattggtatgaaaggggaacgcagaagaggcaaag 
               
               
                   
                   
                 gccacgacggactgtaccagggactcagcaccgccaccaaggacacctatgacgc 
               
               
                   
                   
                 tcttcacatgcaggccctgccgcctcgg 
               
               
                   
               
               
                 105977 
                 952 
                 MALPVTALLLPLALLLHAARPEIVMTQSPATLSLSPGERATLSC   RASQDISKYLN     
               
               
                 CAR 12 - 
                   
                 WYQQKPGQAPRLLIY   HTSRLHS   GIPARFSGSGSGTDYTLTISSLQPEDFAVYFC   Q     
               
               
                 Full - aa 
                   
                     QGNTLPYT   FGQGTKLEIKGGGGSGGGGSGGGGSQVQLQESGPGLVKPSETLSLTC 
               
               
                   
                   
                 TVSGVSLP   DYGVS   WIRQPPGKGLEWIG   VIWGSETTYYNSSLKS   RVTISKDNSKNQ 
               
               
                   
                   
                 VSLKLSSVTAADTAVYYCAK   HYYYGGSYAMDY   WGQGTLVTVSSTTTPAPRPPTPA 
               
               
                   
                   
                 PTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITL 
               
               
                   
                   
                 YCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAP 
               
               
                   
                   
                 AYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK 
               
               
                   
                   
                 MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
               
               
                   
               
            
           
           
               
            
               
                 CTL019 
               
            
           
           
               
               
               
            
               
                 CTL019 - 
                 953 
                 atggccctgcccgtcaccgctctgctgctgccccttgctctgcttcttcatgcag 
               
               
                 Soluble 
                   
                 caaggccggacatccagatgacccaaaccacctcatccctctctgcctctcttgg 
               
               
                 scFv- 
                   
                 agacagggtgaccatttcttgtcgcgccagccaggacatcagcaagtatctgaac 
               
               
                 Histag - 
                   
                 tggtatcagcagaagccggacggaaccgtgaagctcctgatctaccatacctctc 
               
               
                 nt 
                   
                 gcctgcatagcggcgtgccctcacgcttctctggaagcggatcaggaaccgatta 
               
               
                   
                   
                 ttctctcactatttcaaatcttgagcaggaagatattgccacctatttctgccag 
               
               
                   
                   
                 cagggtaataccctgccctacaccttcggaggagggaccaagctcgaaatcaccg 
               
               
                   
                   
                 gtggaggaggcagcggcggtggagggtctggtggaggtggttctgaggtgaagct 
               
               
                   
                   
                 gcaagaatcaggccctggacttgtggccccttcacagtccctgagcgtgacttgc 
               
               
                   
                   
                 accgtgtccggagtctccctgcccgactacggagtgtcatggatcagacaacctc 
               
               
                   
                   
                 cacggaaaggactggaatggctcggtgtcatctggggtagcgaaactacttacta 
               
               
                   
                   
                 caattcagccctcaaaagcaggctgactattatcaaggacaacagcaagtcccaa 
               
               
                   
                   
                 gtctttcttaagatgaactcactccagactgacgacaccgcaatctactattgtg 
               
               
                   
                   
                 ctaagcactactactacggaggatcctacgctatggattactggggacaaggtac 
               
               
                   
                   
                 ttccgtcactgtctcttcacaccatcatcaccatcaccatcac 
               
               
                   
               
               
                 CTL019 - 
                 954 
                     MALPVTALLLPLALLLHAARP   diqmtqttssisasigdrytiscrasqdiskyln 
               
               
                 Soluble 
                   
                 wyggkpdgtvklliyhtsrlhsgvpsrfsgsgsgtdysltisnlegediatyfcg 
               
               
                 scFv- 
                   
                 qgntlpytfgqgtkleitggggsggggsggggsevklgesgpglvapsgslsvtc 
               
               
                 Histag - 
                   
                 tvsgyslpdygvswirgpprkglewlgviwgsettyynsalksrltiikdnsksq 
               
               
                 aa 
                   
                 vfikmnslgtddtaiyycakhyyyggsyamdywgggtsvtvss   hhhhhhhh     
               
               
                   
               
               
                 CTL019 
                 955 
                 atggccttaccagtgaccgccttgctcctgccgctggccttgctgctccacgccg 
               
               
                 Full - nt 
                   
                 ccaggccggacatccagatgacacagactacatcctccctgtctgcctctctggg 
               
               
                   
                   
                 agacagagtcaccatcagttgcagggcaagtcaggacattagtaaatatttaaat 
               
               
                   
                   
                 tggtatcagcagaaaccagatggaactgttaaactcctgatctaccatacatcaa 
               
               
                   
                   
                 gattacactcaggagtcccatcaaggttcagtggcagtgggtctggaacagatta 
               
               
                   
                   
                 ttctctcaccattagcaacctggagcaagaagatattgccacttacttttgccaa 
               
               
                   
                   
                 cagggtaatacgcttccgtacacgttcggaggggggaccaagctggagatcacag 
               
               
                   
                   
                 gtggcggtggctcgggcggtggtgggtcgggtggcggcggatctgaggtgaaact 
               
               
                   
                   
                 gcaggagtcaggacctggcctggtggcgccctcacagagcctgtccgtcacatgc 
               
               
                   
                   
                 actgtctcaggggtctcattacccgactatggtgtaagctggattcgccagcctc 
               
               
                   
                   
                 cacgaaagggtctggagtggctgggagtaatatggggtagtgaaaccacatacta 
               
               
                   
                   
                 taattcagctctcaaatccagactgaccatcatcaaggacaactccaagagccaa 
               
               
                   
                   
                 gttttcttaaaaatgaacagtctgcaaactgatgacacagccatttactactgtg 
               
               
                   
                   
                 ccaaacattattactacggtggtagctatgctatggactactggggccaaggaac 
               
               
                   
                   
                 ctcagtcaccgtctcctcaaccacgacgccagcgccgcgaccaccaacaccggcg 
               
               
                   
                   
                 cccaccatcgcgtcgcagcccctgtccctgcgcccagaggcgtgccggccagcgg 
               
               
                   
                   
                 cggggggcgcagtgcacacgagggggctggacttcgcctgtgatatctacatctg 
               
               
                   
                   
                 ggcgcccttggccgggacttgtggggtccttctcctgtcactggttatcaccctt 
               
               
                   
                   
                 tactgcaaacggggcagaaagaaactcctgtatatattcaaacaaccatttatga 
               
               
                   
                   
                 gaccagtacaaactactcaagaggaagatggctgtagctgccgatttccagaaga 
               
               
                   
                   
                 agaagaaggaggatgtgaactgagagtgaagttcagcaggagcgcagacgccccc 
               
               
                   
                   
                 gcgtacaagcagggccagaaccagctctataacgagctcaatctaggacgaagag 
               
               
                   
                   
                 aggagtacgatgttttggacaagagacgtggccgggaccctgagatggggggaaa 
               
               
                   
                   
                 gccgagaaggaagaaccctcaggaaggcctgtacaatgaactgcagaaagataag 
               
               
                   
                   
                 atggcggaggcctacagtgagattgggatgaaaggcgagcgccggaggggcaagg 
               
               
                   
                   
                 ggcacgatggcctttaccagggtctcagtacagccaccaaggacacctacgacgc 
               
               
                   
                   
                 ccttcacatgcaggccctgccccctcgc 
               
               
                   
               
               
                 CTL019 
                 956 
                 MALPVTALLLPLALLLHAARPdiqmtqttssisasigdrvtiscrasqdiskyln 
               
               
                 Full - aa 
                   
                 wyqqkpdgtvklliyhtsrlhsgvpsrfsgsgsgtdysltisnleqediatyfcq 
               
               
                   
                   
                 qgntlpytfgqgtkleitggggsggggsggggsevklqesgpglvapsqslsvtc 
               
               
                   
                   
                 tvsgvslpdygvswirqpprkglewlgviwgsettyynsalksrltiikdnsksq 
               
               
                   
                   
                 vflkmnslqtddtaiyycakhyyyggsyamdywgqgtsvtvsstttpaprpptpa 
               
               
                   
                   
                 ptiasqplslrpeacrpaaggavhtrgldfacdiyiwaplagtcgvlllsivitl 
               
               
                   
                   
                 yckrgrkkllyifkqpfmrpvqttqeedgcscrfpeeeeggcelrvkfsrsadap 
               
               
                   
                   
                 aykqgqnqlynelnlgrreeydvidkrrgrdpemggkprrknpqeglynelqkdk 
               
               
                   
                   
                 maeayseigmkgerrrgkghdglyggistatkdtydalhmqalppr 
               
               
                   
               
               
                 CTL019 
                 957 
                 diqmtqttsslsaslgdrvtiscrasqdiskylnwyqqkpdgtvklliyhtsrlh 
               
               
                 scFv 
                   
                 sgvpsrfsgsgsgtdysltisnleqediatyfcqqgntlpytfgqgtkleitggg 
               
               
                 domain 
                   
                 gsggggsggggsevklqesgpglvapsqslsvtctvsgvslpdygvswirqpprk 
               
               
                   
                   
                 glewlgviwgsettyynsalksrltiikdnsksqvflkmnslqtddtaiyycakh 
               
               
                   
                   
                 yyyggsyamdywgqgtsvtvss 
               
               
                   
               
               
                 mCAR 1 
                 2020 
                 QVQLLESGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGD 
               
               
                 scFv 
                   
                 GDTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISSVVDFYFD 
               
               
                   
                   
                 YWGQGTTVTGGGSGGGSGGGSGGGSELVLTQSPKFMSTSVGDRVSVTCKASQNVG 
               
               
                   
                   
                 TNVAWYQQKPGQSPKPLIYSATYRNSGVPDRFTGSGSGTDFTLTITNVQSKDLAD 
               
               
                   
                   
                 YFCQYNRYPYTSFFFTKLEIKRRS 
               
               
                   
               
               
                 mCAR 1 
                   
                 QVQLLESGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGD 
               
               
                 Full - aa 
                   
                 GDTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISSVVDFYFD 
               
               
                   
                   
                 YWGQGTTVTGGGSGGGSGGGSGGGSELVLTQSPKFMSTSVGDRVSVTCKASQNVG 
               
               
                   
                   
                 TNVAWYQQKPGQSPKPLIYSATYRNSGVPDRFTGSGSGTDFTLTITNVQSKDLAD 
               
               
                   
                   
                 YFCQYNRYPYTSFFFTKLEIKRRSKIEVMYPPPYLDNEKSNGTIIHVKGKHLCPS 
               
               
                   
                   
                 PLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRR 
               
               
                   
                   
                 PGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYD 
               
               
                   
                   
                 VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDG 
               
               
                   
                   
                 LYQGLSTATKDTYDALHMQALPPR 
               
               
                   
               
               
                 mCAR 2 
                 2021 
                 DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLH 
               
               
                 scFv 
                   
                 SGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGQGTKLEITGST 
               
               
                   
                   
                 SGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQP 
               
               
                   
                   
                 PRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYC 
               
               
                   
                   
                 AKHYYYGGSYAMDYWGQGTSVTVSSE 
               
               
                   
               
               
                 mCAR 2 
                   
                 DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLH 
               
               
                 CAR - aa 
                   
                 SGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGQGTKLEITGST 
               
               
                   
                   
                 SGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQP 
               
               
                   
                   
                 PRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYC 
               
               
                   
                   
                 AKHYYYGGSYAMDYWGQGTSVTVSSESKYGPPCPPCPMFWVLVVVGGVLACYSLL 
               
               
                   
                   
                 VTVAFIIFWVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFEEEEGGCELRVKF 
               
               
                   
                   
                 SRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY 
               
               
                   
                   
                 NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRL 
               
               
                   
               
               
                 mCAR 2 
                   
                 DIQMTQTT   SSLSASLGDR VTISCRASQD ISKYLNWYQQ KPDGTVKLLI 
               
               
                 Full - aa 
                   
                 YHTSRLHSGV PSRFSGSGSG TDYSLTISNL EQEDIATYFC QQGNTLPYTF 
               
               
                   
                   
                 GGGTKLEITG STSGSGKPGS GEGSTKGEVK LQESGPGLVA PSQSLSVTCT 
               
               
                   
                   
                 VSGVSLPDYG VSWIRQPPRK GLEWLGVIWG SETTYYNSAL KSRLTIIKDN 
               
               
                   
                   
                 SKSQVFLKMN SLQTDDTAIY YCAKHYYYGG SYAMDYWGQG TSVTVSSESK 
               
               
                   
                   
                 YGPPCPPCPM            FWVLVVVGGV            LACYSLLVTV 
               
               
                   
                   
                 AFIIFWVKRG RKKLLYIFKQ PFMRPVQTTQ EEDGCSCRFE EEEGGCELRV 
               
               
                   
                   
                 KFSRSADAPA YQQGQNQLYN ELNLGRREEY DVLDKRRGRD PEMGGKPRRK 
               
               
                   
                   
                 NPQEGLYNEL QKDKMAEAYS EIGMKGERRR GKGHDGLYQG LSTATKDTYD 
               
               
                   
                   
                 ALHMQALPPR LEGGGEGRGS LLTCGDVEEN PGPRMLLLVT SLLLCELPHP 
               
               
                   
                   
                 AFLLIPRKVC NGIGIGEFKD SLSINATNIK HFKNCTSISG DLHILPVAFR 
               
               
                   
                   
                 GDSFTHTPPL DPQELDILKT VKEITGFLLI QAWPENRTDL HAFENLEIIR 
               
               
                   
                   
                 GRTKQHGQFS LAVVSLNITS LGLRSLKEIS DGDVIISGNK NLCYANTINW 
               
               
                   
                   
                 KKLFGTSGQK TKIISNRGEN SCKATGQVCH ALCSPEGCWG PEPRDCVSCR 
               
               
                   
                   
                 NVSRGRECVD KCNLLEGEPR EFVENSECIQ CHPECLPQAM NITCTGRGPD 
               
               
                   
                   
                 NCIQCAHYID GPHCVKTCPA GVMGENNTLV WKYADAGHVC HLCHPNCTYG 
               
               
                   
                   
                 CTGPGLEGCP TNGPKIPSIA TGMVGALLLL LVVALGIGLF M 
               
               
                   
               
               
                 mCAR 3 
                 2022 
                 DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLH 
               
               
                 scFv 
                   
                 SGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGST 
               
               
                   
                   
                 SGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQP 
               
               
                   
                   
                 PRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYC 
               
               
                   
                   
                 AKHYYYGGSYAMDYWGQGTSVTVSS 
               
               
                   
               
               
                 mCAR 3 
                   
                 DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLH 
               
               
                 Full - aa 
                   
                 SGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEITGST 
               
               
                   
                   
                 SGSGKPGSGEGSTKGEVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQP 
               
               
                   
                   
                 PRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYC 
               
               
                   
                   
                 AKHYYYGGSYAMDYWGQGTSVTVSSAAAIEVMYPPPYLDNEKSNGTIIHVKGKHL 
               
               
                   
                   
                 CPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMT 
               
               
                   
                   
                 PRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRRE 
               
               
                   
                   
                 EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG 
               
               
                   
                   
                 HDGLYQGLSTATKDTYDALHMQALPPR 
               
               
                   
               
               
                 SSJ25-C1 
                   
                 QVQLLESGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIYPGD 
               
               
                 VH 
                   
                 GDTNYNGKFKGQATLTADKSSSTAYMQLSGLTSEDSAVYSCARKTISSVVDFYFD 
               
               
                 sequence 
                   
                 YWGQGTTVT 
               
               
                   
               
               
                 SSJ25-C1 
                   
                 ELVLTQSPKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKPLIYSATYRN 
               
               
                 VL 
                   
                 SGVPDRFTGSGSGTDFTLTITNVQSKDLADYFYFCQYNRYPYTSGGGTKLEIKRR 
               
               
                 sequence 
                   
                 S 
               
               
                   
               
            
           
         
       
     
     In some embodiments, the CD19 CAR or binding domain includes the amino acid sequence of CTL019, or is encoded by the nucleotide sequence of CTL019 according to Table 3 with or without the leader sequence or the his tag, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or higher identity). 
     In some embodiments, the CDRs are defined according to the Kabat numbering scheme, the Chothia numbering scheme, or a combination thereof. 
     The sequences of humanized CDR sequences of the scFv domains are shown in Table 4A for the heavy chain variable domains and in Table 4B for the light chain variable domains. “ID” stands for the respective SEQ ID NO for each CDR. 
     
       
         
           
               
             
               
                 TABLE 4A 
               
             
            
               
                   
               
               
                 Heavy Chain Variable Domain CDRs (according to Kabat) 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 SEQ 
                   
                 SEQ 
                   
                 SEQ 
               
               
                 Candidate 
                 FW 
                 HCDR1 
                 ID 
                 HCDR2 
                 ID 
                 HCDR3 
                 ID 
               
               
                   
               
               
                 murine_CART19 
                   
                 DYGVS 
                 958 
                 VIWGSETTYYNSALKS 
                 959 
                 HYYYGGSYAMDY 
                 960 
               
               
                   
               
               
                 humanized_CART19 a 
                 VH4 
                 DYGVS 
                 958 
                 VIWGSETTYY  S  LKS 
                 961 
                 HYYYGGSYAMDY 
                 960 
               
               
                   
               
               
                 humanized_CART19 b 
                 VH4 
                 DYGVS 
                 958 
                 VIWGSETTYY  S  LKS 
                 962 
                 HYYYGGSYAMDY 
                 960 
               
               
                   
               
               
                 humanized_CART19 c 
                 VH4 
                 DYGVS 
                 958 
                 VIWGSETTYYNS  KKS 
                 963 
                 HYYYGGSYAMDY 
                 960 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 4B 
               
             
            
               
                   
               
               
                 Light Chain Variable Domain CDRs (according to Kabat) 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                   
                   
                   
                 SEQ 
                   
                 SEQ 
                   
                 SEQ 
               
               
                 Candidate 
                 FW 
                 LCDR1 
                 ID 
                 LCDR2 
                 ID 
                 LCDR3 
                 ID 
               
               
                   
               
               
                 murine_CART19 
                   
                 RASQDISKYLN 
                 964 
                 HTSRLHS 
                 965 
                 QQGNTLPYT 
                 966 
               
               
                   
               
               
                 humanized_CART19 a 
                 VK3 
                 RASQDISKYLN 
                 964 
                 HTSRLHS 
                 965 
                 QQGNTLPYT 
                 966 
               
               
                   
               
               
                 humanized_CART19 b 
                 VK3 
                 RASQDISKYLN 
                 964 
                 HTSRLHS 
                 965 
                 QQGNTLPYT 
                 966 
               
               
                   
               
               
                 humanized_CART19 c 
                 VK3 
                 RASQDISKYLN 
                 964 
                 HTSRLHS 
                 965 
                 QQGNTLPYT 
                 966 
               
               
                   
               
            
           
         
       
     
     In one embodiment, the CAR molecule comprises a BCMA CAR molecule described herein, e.g., a BCMA CAR described in US-2016-0046724-A1 or WO2016/014565. In embodiments, the BCMA CAR comprises an amino acid, or has a nucleotide sequence of a CAR molecule, or an antigen binding domain according to US-2016-0046724-A1, or Table 1 or 16, SEQ ID NO: 271 or SEQ ID NO: 273 of WO2016/014565, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid BCMA CAR sequences). The amino acid and nucleotide sequences encoding the BCMA CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/014565. 
     BCMA CAR 
     In embodiments, the BCMA CAR comprises an anti-BCMA binding domain (e.g., human or humanized anti-BCMA binding domain), a transmembrane domain, and an intracellular signaling domain, and wherein said anti-BCMA binding domain comprises a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of any anti-BMCA heavy chain binding domain amino acid sequences listed in Table 5 or 6, or a sequence at least 85%, 90%, 95% or more identical thereto (e.g., having less than 5, 4, 3, 2 or 1 amino acid substitutions, e.g., conservative substitutions). 
     In one embodiment, the anti-BCMA binding domain comprises a light chain variable region described herein (e.g., in Table 5 or 6) and/or a heavy chain variable region described herein (e.g., in Table 5 or 6), or a sequence at least 85%, 90%, 95% or more identical thereto. 
     In one embodiment, the encoded anti-BCMA binding domain is a scFv comprising a light chain and a heavy chain of an amino acid sequence of Table 5 or 6. 
     In an embodiment, the human or humanized anti-BCMA binding domain (e.g., an scFv) comprises: a light chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a light chain variable region provided in Table 5 or 6, or a sequence at least 85%, 90%, 95% or more identical thereto; and/or a heavy chain variable region comprising an amino acid sequence having at least one, two or three modifications (e.g., substitutions, e.g., conservative substitutions) but not more than 30, 20 or 10 modifications (e.g., substitutions, e.g., conservative substitutions) of an amino acid sequence of a heavy chain variable region provided in Table 5 or 6, or a sequence at least 85%, 90%, 95% or more identical thereto. 
     
       
         
           
               
             
               
                 TABLE 5 
               
             
            
               
                   
               
               
                 Amino Acid and Nucleic Acid Sequences of exemplary anti-BCMA scFv domains 
               
               
                 and BCMA CAR molecules 
               
            
           
           
               
               
               
            
               
                   
                 SEQ 
                   
               
               
                 Name/ 
                 ID 
                   
               
               
                 Description 
                 NO: 
                 Sequence 
               
               
                   
               
            
           
           
               
            
               
                 139109 
               
            
           
           
               
               
               
            
               
                 139109- aa 
                 967 
                 EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 ScFv domain 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSSASGGGGSGGRASGGGGSDIQLTQSPSSLSASVGDRVTITCRASQ 
               
               
                   
                   
                 SISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP 
               
               
                   
                   
                 EDFATYYCQQSYSTPYTFGQGTKVEIK 
               
               
                 139109- nt 
                 968 
                 GAAGTGCAATTGGTGGAATCAGGGGGAGGACTTGTGCAGCCTGGAGGATCGCT 
               
               
                 ScFv domain 
                   
                 GAGACTGTCATGTGCCGTGTCCGGCTTTGCCCTGTCCAACCACGGGATGTCCT 
               
               
                   
                   
                 GGGTCCGCCGCGCGCCTGGAAAGGGCCTCGAATGGGTGTCGGGTATTGTGTAC 
               
               
                   
                   
                 AGCGGTAGCACCTACTATGCCGCATCCGTGAAGGGGAGATTCACCATCAGCCG 
               
               
                   
                   
                 GGACAACTCCAGGAACACTCTGTACCTCCAAATGAATTCGCTGAGGCCAGAGG 
               
               
                   
                   
                 ACACTGCCATCTACTACTGCTCCGCGCATGGCGGAGAGTCCGACGTCTGGGGA 
               
               
                   
                   
                 CAGGGGACCACCGTGACCGTGTCTAGCGCGTCCGGCGGAGGCGGCAGCGGGGG 
               
               
                   
                   
                 TCGGGCATCAGGGGGCGGCGGATCGGACATCCAGCTCACCCAGTCCCCGAGCT 
               
               
                   
                   
                 CGCTGTCCGCCTCCGTGGGAGATCGGGTCACCATCACGTGCCGCGCCAGCCAG 
               
               
                   
                   
                 TCGATTTCCTCCTACCTGAACTGGTACCAACAGAAGCCCGGAAAAGCCCCGAA 
               
               
                   
                   
                 GCTTCTCATCTACGCCGCCTCGAGCCTGCAGTCAGGAGTGCCCTCACGGTTCT 
               
               
                   
                   
                 CCGGCTCCGGTTCCGGTACTGATTTCACCCTGACCATTTCCTCCCTGCAACCG 
               
               
                   
                   
                 GAGGACTTCGCTACTTACTACTGCCAGCAGTCGTACTCCACCCCCTACACTTT 
               
               
                   
                   
                 CGGACAAGGCACCAAGGTCGAAATCAAG 
               
               
                 139109- aa 
                 969 
                 EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 VH 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSS 
               
               
                 139109- aa 
                 970 
                 DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASS 
               
               
                 VL 
                   
                 LQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEI 
               
               
                   
                   
                 K 
               
               
                 139109- aa 
                 971 
                 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAVSGFALSNH 
               
               
                 Full CAR 
                   
                 GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSL 
               
               
                   
                   
                 RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIQLTQ 
               
               
                   
                   
                 SPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVP 
               
               
                   
                   
                 SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYTFGQGTKVEIKTTTPA 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV 
               
               
                   
                   
                 LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL 
               
               
                   
                   
                 RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN 
               
               
                   
                   
                 PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM 
               
               
                   
                   
                 QALPPR 
               
               
                 139109- nt 
                 972 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAATTGGTGGAATCAGGGGGAGGACTTGTGCAGCCTG 
               
               
                   
                   
                 GAGGATCGCTGAGACTGTCATGTGCCGTGTCCGGCTTTGCCCTGTCCAACCAC 
               
               
                   
                   
                 GGGATGTCCTGGGTCCGCCGCGCGCCTGGAAAGGGCCTCGAATGGGTGTCGGG 
               
               
                   
                   
                 TATTGTGTACAGCGGTAGCACCTACTATGCCGCATCCGTGAAGGGGAGATTCA 
               
               
                   
                   
                 CCATCAGCCGGGACAACTCCAGGAACACTCTGTACCTCCAAATGAATTCGCTG 
               
               
                   
                   
                 AGGCCAGAGGACACTGCCATCTACTACTGCTCCGCGCATGGCGGAGAGTCCGA 
               
               
                   
                   
                 CGTCTGGGGACAGGGGACCACCGTGACCGTGTCTAGCGCGTCCGGCGGAGGCG 
               
               
                   
                   
                 GCAGCGGGGGTCGGGCATCAGGGGGCGGCGGATCGGACATCCAGCTCACCCAG 
               
               
                   
                   
                 TCCCCGAGCTCGCTGTCCGCCTCCGTGGGAGATCGGGTCACCATCACGTGCCG 
               
               
                   
                   
                 CGCCAGCCAGTCGATTTCCTCCTACCTGAACTGGTACCAACAGAAGCCCGGAA 
               
               
                   
                   
                 AAGCCCCGAAGCTTCTCATCTACGCCGCCTCGAGCCTGCAGTCAGGAGTGCCC 
               
               
                   
                   
                 TCACGGTTCTCCGGCTCCGGTTCCGGTACTGATTTCACCCTGACCATTTCCTC 
               
               
                   
                   
                 CCTGCAACCGGAGGACTTCGCTACTTACTACTGCCAGCAGTCGTACTCCACCC 
               
               
                   
                   
                 CCTACACTTTCGGACAAGGCACCAAGGTCGAAATCAAGACCACTACCCCAGCA 
               
               
                   
                   
                 CCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG 
               
               
                   
                   
                 TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG 
               
               
                   
                   
                 ACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTC 
               
               
                   
                   
                 CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCT 
               
               
                   
                   
                 GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG 
               
               
                   
                   
                 AGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTG 
               
               
                   
                   
                 CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA 
               
               
                   
                   
                 CCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG 
               
               
                   
                   
                 ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT 
               
               
                   
                   
                 CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA 
               
               
                   
                   
                 TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGAC 
               
               
                   
                   
                 TGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG 
               
               
                   
                   
                 CAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139103 
               
            
           
           
               
               
               
            
               
                 139103- aa 
                 973 
                 QVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMSWVRQAPGKGLGWVSGISR 
               
               
                 ScFv domain 
                   
                 SGENTYYADSVKGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARSPAHYYGG 
               
               
                   
                   
                 MDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIVLTQSPGTLSLSPGERATLS 
               
               
                   
                   
                 CRASQSISSSFLAWYQQKPGQAPRLLIYGASRRATGIPDRFSGSGSGTDFTLT 
               
               
                   
                   
                 ISRLEPEDSAVYYCQQYHSSPSWTFGQGTKLEIK 
               
               
                 139103- nt 
                 974 
                 CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCGGAAGATCGCT 
               
               
                 ScFv domain 
                   
                 TAGACTGTCGTGTGCCGCCAGCGGGTTCACTTTCTCGAACTACGCGATGTCCT 
               
               
                   
                   
                 GGGTCCGCCAGGCACCCGGAAAGGGACTCGGTTGGGTGTCCGGCATTTCCCGG 
               
               
                   
                   
                 TCCGGCGAAAATACCTACTACGCCGACTCCGTGAAGGGCCGCTTCACCATCTC 
               
               
                   
                   
                 AAGGGACAACAGCAAAAACACCCTGTACTTGCAAATGAACTCCCTGCGGGATG 
               
               
                   
                   
                 AAGATACAGCCGTGTACTATTGCGCCCGGTCGCCTGCCCATTACTACGGCGGA 
               
               
                   
                   
                 ATGGACGTCTGGGGACAGGGAACCACTGTGACTGTCAGCAGCGCGTCGGGTGG 
               
               
                   
                   
                 CGGCGGCTCAGGGGGTCGGGCCTCCGGGGGGGGAGGGTCCGACATCGTGCTGA 
               
               
                   
                   
                 CCCAGTCCCCGGGAACCCTGAGCCTGAGCCCGGGAGAGCGCGCGACCCTGTCA 
               
               
                   
                   
                 TGCCGGGCATCCCAGAGCATTAGCTCCTCCTTTCTCGCCTGGTATCAGCAGAA 
               
               
                   
                   
                 GCCCGGACAGGCCCCGAGGCTGCTGATCTACGGCGCTAGCAGAAGGGCTACCG 
               
               
                   
                   
                 GAATCCCAGACCGGTTCTCCGGCTCCGGTTCCGGGACCGATTTCACCCTTACT 
               
               
                   
                   
                 ATCTCGCGCCTGGAACCTGAGGACTCCGCCGTCTACTACTGCCAGCAGTACCA 
               
               
                   
                   
                 CTCATCCCCGTCGTGGACGTTCGGACAGGGCACCAAGCTGGAGATTAAG 
               
               
                 139103- aa 
                 975 
                 QVQLVESGGGLVQPGRSLRLSCAASGFTFSNYAMSWVRQAPGKGLGWVSGISR 
               
               
                 VH 
                   
                 SGENTYYADSVKGRFTISRDNSKNTLYLQMNSLRDEDTAVYYCARSPAHYYGG 
               
               
                   
                   
                 MDVWGQGTTVTVSS 
               
               
                 139103- aa 
                 976 
                 DIVLTQSPGTLSLSPGERATLSCRASQSISSSFLAWYQQKPGQAPRLLIYGAS 
               
               
                 VL 
                   
                 RRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTKL 
               
               
                   
                   
                 EIK 
               
               
                 139103- aa 
                 977 
                 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGRSLRLSCAASGFTFSNY 
               
               
                 Full CAR 
                   
                 AMSWVRQAPGKGLGWVSGISRSGENTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                   
                   
                 LRDEDTAVYYCARSPAHYYGGMDVWGQGTTVTVSSASGGGGSGGRASGGGGSD 
               
               
                   
                   
                 IVLTQSPGTLSLSPGERATLSCRASQSISSSFLAWYQQKPGQAPRLLIYGASR 
               
               
                   
                   
                 RATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTKLE 
               
               
                   
                   
                 IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP 
               
               
                   
                   
                 LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE 
               
               
                   
                   
                 EEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG 
               
               
                   
                   
                 GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD 
               
               
                   
                   
                 TYDALHMQALPPR 
               
               
                 139103- nt 
                 978 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCG 
               
               
                   
                   
                 GAAGATCGCTTAGACTGTCGTGTGCCGCCAGCGGGTTCACTTTCTCGAACTAC 
               
               
                   
                   
                 GCGATGTCCTGGGTCCGCCAGGCACCCGGAAAGGGACTCGGTTGGGTGTCCGG 
               
               
                   
                   
                 CATTTCCCGGTCCGGCGAAAATACCTACTACGCCGACTCCGTGAAGGGCCGCT 
               
               
                   
                   
                 TCACCATCTCAAGGGACAACAGCAAAAACACCCTGTACTTGCAAATGAACTCC 
               
               
                   
                   
                 CTGCGGGATGAAGATACAGCCGTGTACTATTGCGCCCGGTCGCCTGCCCATTA 
               
               
                   
                   
                 CTACGGCGGAATGGACGTCTGGGGACAGGGAACCACTGTGACTGTCAGCAGCG 
               
               
                   
                   
                 CGTCGGGTGGCGGCGGCTCAGGGGGTCGGGCCTCCGGGGGGGGAGGGTCCGAC 
               
               
                   
                   
                 ATCGTGCTGACCCAGTCCCCGGGAACCCTGAGCCTGAGCCCGGGAGAGCGCGC 
               
               
                   
                   
                 GACCCTGTCATGCCGGGCATCCCAGAGCATTAGCTCCTCCTTTCTCGCCTGGT 
               
               
                   
                   
                 ATCAGCAGAAGCCCGGACAGGCCCCGAGGCTGCTGATCTACGGCGCTAGCAGA 
               
               
                   
                   
                 AGGGCTACCGGAATCCCAGACCGGTTCTCCGGCTCCGGTTCCGGGACCGATTT 
               
               
                   
                   
                 CACCCTTACTATCTCGCGCCTGGAACCTGAGGACTCCGCCGTCTACTACTGCC 
               
               
                   
                   
                 AGCAGTACCACTCATCCCCGTCGTGGACGTTCGGACAGGGCACCAAGCTGGAG 
               
               
                   
                   
                 ATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC 
               
               
                   
                   
                 CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG 
               
               
                   
                   
                 CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCT 
               
               
                   
                   
                 CTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTG 
               
               
                   
                   
                 TAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC 
               
               
                   
                   
                 CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAG 
               
               
                   
                   
                 GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC 
               
               
                   
                   
                 AGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGA 
               
               
                   
                   
                 GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC 
               
               
                   
                   
                 GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA 
               
               
                   
                   
                 GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA 
               
               
                   
                   
                 GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC 
               
               
                   
                   
                 ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139105 
               
            
           
           
               
               
               
            
               
                 139105- aa 
                 979 
                 QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW 
               
               
                 ScFv domain 
                   
                 NSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCSVHSFLAYWG 
               
               
                   
                   
                 QGTLVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLPVTPGEPASISCRSSQ 
               
               
                   
                   
                 SLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKI 
               
               
                   
                   
                 SRVEAEDVGVYYCMQALQTPYTFGQGTKVE1K 
               
               
                 139105- nt 
                 980 
                 CAAGTGCAACTCGTCGAATCCGGTGGAGGTCTGGTCCAACCTGGTAGAAGCCT 
               
               
                 ScFv domain 
                   
                 GAGACTGTCGTGTGCGGCCAGCGGATTCACCTTTGATGACTATGCTATGCACT 
               
               
                   
                   
                 GGGTGCGGCAGGCCCCAGGAAAGGGCCTGGAATGGGTGTCGGGAATTAGCTGG 
               
               
                   
                   
                 AACTCCGGGTCCATTGGCTACGCCGACTCCGTGAAGGGCCGCTTCACCATCTC 
               
               
                   
                   
                 CCGCGACAACGCAAAGAACTCCCTGTACTTGCAAATGAACTCGCTCAGGGCTG 
               
               
                   
                   
                 AGGATACCGCGCTGTACTACTGCTCCGTGCATTCCTTCCTGGCCTACTGGGGA 
               
               
                   
                   
                 CAGGGAACTCTGGTCACCGTGTCGAGCGCCTCCGGCGGCGGGGGCTCGGGTGG 
               
               
                   
                   
                 ACGGGCCTCGGGCGGAGGGGGGTCCGACATCGTGATGACCCAGACCCCGCTGA 
               
               
                   
                   
                 GCTTGCCCGTGACTCCCGGAGAGCCTGCATCCATCTCCTGCCGGTCATCCCAG 
               
               
                   
                   
                 TCCCTTCTCCACTCCAACGGATACAACTACCTCGACTGGTACCTCCAGAAGCC 
               
               
                   
                   
                 GGGACAGAGCCCTCAGCTTCTGATCTACCTGGGGTCAAATAGAGCCTCAGGAG 
               
               
                   
                   
                 TGCCGGATCGGTTCAGCGGATCTGGTTCGGGAACTGATTTCACTCTGAAGATT 
               
               
                   
                   
                 TCCCGCGTGGAAGCCGAGGACGTGGGCGTCTACTACTGTATGCAGGCGCTGCA 
               
               
                   
                   
                 GACCCCCTATACCTTCGGCCAAGGGACGAAAGTGGAGATCAAG 
               
               
                 139105- aa 
                 981 
                 QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW 
               
               
                 VH 
                   
                 NSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCSVHSFLAYWG 
               
               
                   
                   
                 QGTLVTVSS 
               
               
                 139105- aa 
                 982 
                 DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLI 
               
               
                 VL 
                   
                 YLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQG 
               
               
                   
                   
                 TKVEIK 
               
               
                 139105- aa 
                 983 
                 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGRSLRLSCAASGFTFDDY 
               
               
                 Full CAR 
                   
                 AMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNS 
               
               
                   
                   
                 LRAEDTALYYCSVHSFLAYWGQGTLVTVSSASGGGGSGGRASGGGGSDIVMTQ 
               
               
                   
                   
                 TPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNR 
               
               
                   
                   
                 ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKVEIK 
               
               
                   
                   
                 TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA 
               
               
                   
                   
                 GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE 
               
               
                   
                   
                 GGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK 
               
               
                   
                   
                 PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY 
               
               
                   
                   
                 DALHMQALPPR 
               
               
                 139105- nt 
                 984 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAACTCGTCGAATCCGGTGGAGGTCTGGTCCAACCTG 
               
               
                   
                   
                 GTAGAAGCCTGAGACTGTCGTGTGCGGCCAGCGGATTCACCTTTGATGACTAT 
               
               
                   
                   
                 GCTATGCACTGGGTGCGGCAGGCCCCAGGAAAGGGCCTGGAATGGGTGTCGGG 
               
               
                   
                   
                 AATTAGCTGGAACTCCGGGTCCATTGGCTACGCCGACTCCGTGAAGGGCCGCT 
               
               
                   
                   
                 TCACCATCTCCCGCGACAACGCAAAGAACTCCCTGTACTTGCAAATGAACTCG 
               
               
                   
                   
                 CTCAGGGCTGAGGATACCGCGCTGTACTACTGCTCCGTGCATTCCTTCCTGGC 
               
               
                   
                   
                 CTACTGGGGACAGGGAACTCTGGTCACCGTGTCGAGCGCCTCCGGCGGCGGGG 
               
               
                   
                   
                 GCTCGGGTGGACGGGCCTCGGGCGGAGGGGGGTCCGACATCGTGATGACCCAG 
               
               
                   
                   
                 ACCCCGCTGAGCTTGCCCGTGACTCCCGGAGAGCCTGCATCCATCTCCTGCCG 
               
               
                   
                   
                 GTCATCCCAGTCCCTTCTCCACTCCAACGGATACAACTACCTCGACTGGTACC 
               
               
                   
                   
                 TCCAGAAGCCGGGACAGAGCCCTCAGCTTCTGATCTACCTGGGGTCAAATAGA 
               
               
                   
                   
                 GCCTCAGGAGTGCCGGATCGGTTCAGCGGATCTGGTTCGGGAACTGATTTCAC 
               
               
                   
                   
                 TCTGAAGATTTCCCGCGTGGAAGCCGAGGACGTGGGCGTCTACTACTGTATGC 
               
               
                   
                   
                 AGGCGCTGCAGACCCCCTATACCTTCGGCCAAGGGACGAAAGTGGAGATCAAG 
               
               
                   
                   
                 ACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCA 
               
               
                   
                   
                 GCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGC 
               
               
                   
                   
                 ATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCT 
               
               
                   
                   
                 GGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCG 
               
               
                   
                   
                 CGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGC 
               
               
                   
                   
                 AGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAA 
               
               
                   
                   
                 GGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTA 
               
               
                   
                   
                 CAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGG 
               
               
                   
                   
                 AGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAG 
               
               
                   
                   
                 CCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAA 
               
               
                   
                   
                 GATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCA 
               
               
                   
                   
                 AAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTAT 
               
               
                   
                   
                 GACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139111 
               
            
           
           
               
               
               
            
               
                 139111- aa 
                 985 
                 EVQLLESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 ScFv domain 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLSVTPGQPASISCKSSQ 
               
               
                   
                   
                 SLLRNDGKTPLYWYLQKAGQPPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKI 
               
               
                   
                   
                 SRVEAEDVGAYYCMQNIQFPSFGGGTKLEIK 
               
               
                 139111- nt 
                 986 
                 GAAGTGCAATTGTTGGAATCTGGAGGAGGACTTGTGCAGCCTGGAGGATCACT 
               
               
                 ScFv domain 
                   
                 GAGACTTTCGTGTGCGGTGTCAGGCTTCGCCCTGAGCAACCACGGCATGAGCT 
               
               
                   
                   
                 GGGTGCGGAGAGCCCCGGGGAAGGGTCTGGAATGGGTGTCCGGGATCGTCTAC 
               
               
                   
                   
                 TCCGGTTCAACTTACTACGCCGCAAGCGTGAAGGGTCGCTTCACCATTTCCCG 
               
               
                   
                   
                 CGATAACTCCCGGAACACCCTGTACCTCCAAATGAACTCCCTGCGGCCCGAGG 
               
               
                   
                   
                 ACACCGCCATCTACTACTGTTCCGCGCATGGAGGAGAGTCCGATGTCTGGGGA 
               
               
                   
                   
                 CAGGGCACTACCGTGACCGTGTCGAGCGCCTCGGGGGGAGGAGGCTCCGGCGG 
               
               
                   
                   
                 TCGCGCCTCCGGGGGGGGTGGCAGCGACATTGTGATGACGCAGACTCCACTCT 
               
               
                   
                   
                 CGCTGTCCGTGACCCCGGGACAGCCCGCGTCCATCTCGTGCAAGAGCTCCCAG 
               
               
                   
                   
                 AGCCTGCTGAGGAACGACGGAAAGACTCCTCTGTATTGGTACCTCCAGAAGGC 
               
               
                   
                   
                 TGGACAGCCCCCGCAACTGCTCATCTACGAAGTGTCAAATCGCTTCTCCGGGG 
               
               
                   
                   
                 TGCCGGATCGGTTTTCCGGCTCGGGATCGGGCACCGACTTCACCCTGAAAATC 
               
               
                   
                   
                 TCCAGGGTCGAGGCCGAGGACGTGGGAGCCTACTACTGCATGCAAAACATCCA 
               
               
                   
                   
                 GTTCCCTTCCTTCGGCGGCGGCACAAAGCTGGAGATTAAG 
               
               
                 139111- aa 
                 987 
                 EVQLLESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 VH 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSS 
               
               
                 139111- aa 
                 988 
                 DIVMTQTPLSLSVTPGQPASISCKSSQSLLRNDGKTPLYWYLQKAGQPPQLLI 
               
               
                 VL 
                   
                 YEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGAYYCMQNIQFPSFGGGT 
               
               
                   
                   
                 KLEIK 
               
               
                 139111- aa 
                 989 
                 MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAVSGFALSNH 
               
               
                 Full CAR 
                   
                 GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSL 
               
               
                   
                   
                 RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIVMTQ 
               
               
                   
                   
                 TPLSLSVTPGQPASISCKSSQSLLRNDGKTPLYWYLQKAGQPPQLLIYEVSNR 
               
               
                   
                   
                 FSGVPDRFSGSGSGTDFTLKISRVEAEDVGAYYCMQNIQFPSFGGGTKLEIKT 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAG 
               
               
                   
                   
                 TCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 
               
               
                   
                   
                 GCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP 
               
               
                   
                   
                 RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD 
               
               
                   
                   
                 ALHMQALPPR 
               
               
                 139111- nt 
                 990 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAATTGTTGGAATCTGGAGGAGGACTTGTGCAGCCTG 
               
               
                   
                   
                 GAGGATCACTGAGACTTTCGTGTGCGGTGTCAGGCTTCGCCCTGAGCAACCAC 
               
               
                   
                   
                 GGCATGAGCTGGGTGCGGAGAGCCCCGGGGAAGGGTCTGGAATGGGTGTCCGG 
               
               
                   
                   
                 GATCGTCTACTCCGGTTCAACTTACTACGCCGCAAGCGTGAAGGGTCGCTTCA 
               
               
                   
                   
                 CCATTTCCCGCGATAACTCCCGGAACACCCTGTACCTCCAAATGAACTCCCTG 
               
               
                   
                   
                 CGGCCCGAGGACACCGCCATCTACTACTGTTCCGCGCATGGAGGAGAGTCCGA 
               
               
                   
                   
                 TGTCTGGGGACAGGGCACTACCGTGACCGTGTCGAGCGCCTCGGGGGGAGGAG 
               
               
                   
                   
                 GCTCCGGCGGTCGCGCCTCCGGGGGGGGTGGCAGCGACATTGTGATGACGCAG 
               
               
                   
                   
                 ACTCCACTCTCGCTGTCCGTGACCCCGGGACAGCCCGCGTCCATCTCGTGCAA 
               
               
                   
                   
                 GAGCTCCCAGAGCCTGCTGAGGAACGACGGAAAGACTCCTCTGTATTGGTACC 
               
               
                   
                   
                 TCCAGAAGGCTGGACAGCCCCCGCAACTGCTCATCTACGAAGTGTCAAATCGC 
               
               
                   
                   
                 TTCTCCGGGGTGCCGGATCGGTTTTCCGGCTCGGGATCGGGCACCGACTTCAC 
               
               
                   
                   
                 CCTGAAAATCTCCAGGGTCGAGGCCGAGGACGTGGGAGCCTACTACTGCATGC 
               
               
                   
                   
                 AAAACATCCAGTTCCCTTCCTTCGGCGGCGGCACAAAGCTGGAGATTAAGACC 
               
               
                   
                   
                 ACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCC 
               
               
                   
                   
                 TCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATA 
               
               
                   
                   
                 CCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGT 
               
               
                   
                   
                 ACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGG 
               
               
                   
                   
                 TCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA 
               
               
                   
                   
                 CTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGC 
               
               
                   
                   
                 GGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAA 
               
               
                   
                   
                 GCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGT 
               
               
                   
                   
                 ACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCG 
               
               
                   
                   
                 CGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGAT 
               
               
                   
                   
                 GGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAG 
               
               
                   
                   
                 GCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGAC 
               
               
                   
                   
                 GCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139100 
               
            
           
           
               
               
               
            
               
                 139100- aa 
                 991 
                 QVQLVQSGAEVRKTGASVKVSCKASGYIFDNFGINWVRQAPGQGLEWMGWINP 
               
               
                 ScFv domain 
                   
                 KNNNTNYAQKFQGRVTITADESTNTAYMEVSSLRSEDTAVYYCARGPYYYQSY 
               
               
                   
                   
                 MDVWGQGTMVTVSSASGGGGSGGRASGGGGSDIVMTQTPLSLPVTPGEPASIS 
               
               
                   
                   
                 CRSSQSLLHSNGYNYLNWYLQKPGQSPQLLIYLGSKRASGVPDRFSGSGSGTD 
               
               
                   
                   
                 FTLHITRVGAEDVGVYYCMQALQTPYTFGQGTKLEIK 
               
               
                 139100- nt 
                 992 
                 CAAGTCCAACTCGTCCAGTCCGGCGCAGAAGTCAGAAAAACCGGTGCTAGCGT 
               
               
                 ScFv domain 
                   
                 GAAAGTGTCCTGCAAGGCCTCCGGCTACATTTTCGATAACTTCGGAATCAACT 
               
               
                   
                   
                 GGGTCAGACAGGCCCCGGGCCAGGGGCTGGAATGGATGGGATGGATCAACCCC 
               
               
                   
                   
                 AAGAACAACAACACCAACTACGCACAGAAGTTCCAGGGCCGCGTGACTATCAC 
               
               
                   
                   
                 CGCCGATGAATCGACCAATACCGCCTACATGGAGGTGTCCTCCCTGCGGTCGG 
               
               
                   
                   
                 AGGACACTGCCGTGTATTACTGCGCGAGGGGCCCATACTACTACCAAAGCTAC 
               
               
                   
                   
                 ATGGACGTCTGGGGACAGGGAACCATGGTGACCGTGTCATCCGCCTCCGGTGG 
               
               
                   
                   
                 TGGAGGCTCCGGGGGGCGGGCTTCAGGAGGCGGAGGAAGCGATATTGTGATGA 
               
               
                   
                   
                 CCCAGACTCCGCTTAGCCTGCCCGTGACTCCTGGAGAACCGGCCTCCATTTCC 
               
               
                   
                   
                 TGCCGGTCCTCGCAATCACTCCTGCATTCCAACGGTTACAACTACCTGAATTG 
               
               
                   
                   
                 GTACCTCCAGAAGCCTGGCCAGTCGCCCCAGTTGCTGATCTATCTGGGCTCGA 
               
               
                   
                   
                 AGCGCGCCTCCGGGGTGCCTGACCGGTTTAGCGGATCTGGGAGCGGCACGGAC 
               
               
                   
                   
                 TTCACTCTCCACATCACCCGCGTGGGAGCGGAGGACGTGGGAGTGTACTACTG 
               
               
                   
                   
                 TATGCAGGCGCTGCAGACTCCGTACACATTCGGACAGGGCACCAAGCTGGAGA 
               
               
                   
                   
                 TCAAG 
               
               
                 139100- aa 
                 993 
                 QVQLVQSGAEVRKTGASVKVSCKASGYIFDNFGINWVRQAPGQGLEWMGWINP 
               
               
                 VH 
                   
                 KNNNTNYAQKFQGRVTITADESTNTAYMEVSSLRSEDTAVYYCARGPYYYQSY 
               
               
                   
                   
                 MDVWGQGTMVTVSS 
               
               
                 139100- aa 
                 994 
                 DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLNWYLQKPGQSPQLLI 
               
               
                 VL 
                   
                 YLGSKRASGVPDRFSGSGSGTDFTLHITRVGAEDVGVYYCMQALQTPYTFGQG 
               
               
                   
                   
                 TKLEIK 
               
               
                 139100- aa 
                 995 
                 MALPVTALLLPLALLLHAARPQVQLVQSGAEVRKTGASVKVSCKASGYIFDNF 
               
               
                 Full CAR 
                   
                 GINWVRQAPGQGLEWMGWINPKNNNTNYAQKFQGRVTITADESTNTAYMEVSS 
               
               
                   
                   
                 LRSEDTAVYYCARGPYYYQSYMDVWGQGTMVTVSSASGGGGSGGRASGGGGSD 
               
               
                   
                   
                 IVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLNWYLQKPGQSPQLLIY 
               
               
                   
                   
                 LGSKRASGVPDRFSGSGSGTDFTLHITRVGAEDVGVYYCMQALQTPYTFGQGT 
               
               
                   
                   
                 KLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI 
               
               
                   
                   
                 WAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF 
               
               
                   
                   
                 PEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDP 
               
               
                   
                   
                 EMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTA 
               
               
                   
                   
                 TKDTYDALHMQALPPR 
               
               
                 139100- nt 
                 996 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTCCAACTCGTCCAGTCCGGCGCAGAAGTCAGAAAAACCG 
               
               
                   
                   
                 GTGCTAGCGTGAAAGTGTCCTGCAAGGCCTCCGGCTACATTTTCGATAACTTC 
               
               
                   
                   
                 GGAATCAACTGGGTCAGACAGGCCCCGGGCCAGGGGCTGGAATGGATGGGATG 
               
               
                   
                   
                 GATCAACCCCAAGAACAACAACACCAACTACGCACAGAAGTTCCAGGGCCGCG 
               
               
                   
                   
                 TGACTATCACCGCCGATGAATCGACCAATACCGCCTACATGGAGGTGTCCTCC 
               
               
                   
                   
                 CTGCGGTCGGAGGACACTGCCGTGTATTACTGCGCGAGGGGCCCATACTACTA 
               
               
                   
                   
                 CCAAAGCTACATGGACGTCTGGGGACAGGGAACCATGGTGACCGTGTCATCCG 
               
               
                   
                   
                 CCTCCGGTGGTGGAGGCTCCGGGGGGCGGGCTTCAGGAGGCGGAGGAAGCGAT 
               
               
                   
                   
                 ATTGTGATGACCCAGACTCCGCTTAGCCTGCCCGTGACTCCTGGAGAACCGGC 
               
               
                   
                   
                 CTCCATTTCCTGCCGGTCCTCGCAATCACTCCTGCATTCCAACGGTTACAACT 
               
               
                   
                   
                 ACCTGAATTGGTACCTCCAGAAGCCTGGCCAGTCGCCCCAGTTGCTGATCTAT 
               
               
                   
                   
                 CTGGGCTCGAAGCGCGCCTCCGGGGTGCCTGACCGGTTTAGCGGATCTGGGAG 
               
               
                   
                   
                 CGGCACGGACTTCACTCTCCACATCACCCGCGTGGGAGCGGAGGACGTGGGAG 
               
               
                   
                   
                 TGTACTACTGTATGCAGGCGCTGCAGACTCCGTACACATTCGGACAGGGCACC 
               
               
                   
                   
                 AAGCTGGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCC 
               
               
                   
                   
                 TACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAG 
               
               
                   
                   
                 CTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATT 
               
               
                   
                   
                 TGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCAC 
               
               
                   
                   
                 TCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCT 
               
               
                   
                   
                 TCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTC 
               
               
                   
                   
                 CCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGC 
               
               
                   
                   
                 AGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATC 
               
               
                   
                   
                 TTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCA 
               
               
                   
                   
                 GAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGA 
               
               
                   
                   
                 GCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGG 
               
               
                   
                   
                 AACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCC 
               
               
                   
                   
                 ACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139101 
               
            
           
           
               
               
               
            
               
                 139101- aa 
                 997 
                 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSDAMTWVRQAPGKGLEWVSVISG 
               
               
                 ScFv domain 
                   
                 SGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLDSSGYYY 
               
               
                   
                   
                 ARGPRYWGQGTLVTVSSASGGGGSGGRASGGGGSDIQLTQSPSSLSASVGDRV 
               
               
                   
                   
                 TITCRASQSISSYLNWYQQKPGKAPKLLIYGASTLASGVPARFSGSGSGTHFT 
               
               
                   
                   
                 LTINSLQSEDSATYYCQQSYKRASFGQGTKVEIK 
               
               
                 139101- nt 
                 998 
                 CAAGTGCAACTTCAAGAATCAGGCGGAGGACTCGTGCAGCCCGGAGGATCATT 
               
               
                 ScFv domain 
                   
                 GCGGCTCTCGTGCGCCGCCTCGGGCTTCACCTTCTCGAGCGACGCCATGACCT 
               
               
                   
                   
                 GGGTCCGCCAGGCCCCGGGGAAGGGGCTGGAATGGGTGTCTGTGATTTCCGGC 
               
               
                   
                   
                 TCCGGGGGAACTACGTACTACGCCGATTCCGTGAAAGGTCGCTTCACTATCTC 
               
               
                   
                   
                 CCGGGACAACAGCAAGAACACCCTTTATCTGCAAATGAATTCCCTCCGCGCCG 
               
               
                   
                   
                 AGGACACCGCCGTGTACTACTGCGCCAAGCTGGACTCCTCGGGCTACTACTAT 
               
               
                   
                   
                 GCCCGGGGTCCGAGATACTGGGGACAGGGAACCCTCGTGACCGTGTCCTCCGC 
               
               
                   
                   
                 GTCCGGCGGAGGAGGGTCGGGAGGGCGGGCCTCCGGCGGCGGCGGTTCGGACA 
               
               
                   
                   
                 TCCAGCTGACCCAGTCCCCATCCTCACTGAGCGCAAGCGTGGGCGACAGAGTC 
               
               
                   
                   
                 ACCATTACATGCAGGGCGTCCCAGAGCATCAGCTCCTACCTGAACTGGTACCA 
               
               
                   
                   
                 ACAGAAGCCTGGAAAGGCTCCTAAGCTGTTGATCTACGGGGCTTCGACCCTGG 
               
               
                   
                   
                 CATCCGGGGTGCCCGCGAGGTTTAGCGGAAGCGGTAGCGGCACTCACTTCACT 
               
               
                   
                   
                 CTGACCATTAACAGCCTCCAGTCCGAGGATTCAGCCACTTACTACTGTCAGCA 
               
               
                   
                   
                 GTCCTACAAGCGGGCCAGCTTCGGACAGGGCACTAAGGTCGAGATCAAG 
               
               
                 139101- aa 
                 999 
                 QVQLQESGGGLVQPGGSLRLSCAASGFTFSSDAMTWVRQAPGKGLEWVSVISG 
               
               
                 VH 
                   
                 SGGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLDSSGYYY 
               
               
                   
                   
                 ARGPRYWGQGTLVTVSS 
               
               
                 139101- aa 
                 1000 
                 DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGAST 
               
               
                 VL 
                   
                 LASGVPARFSGSGSGTHFTLTINSLQSEDSATYYCQQSYKRASFGQGTKVEIK 
               
               
                 139101- aa 
                 1001 
                 MALPVTALLLPLALLLHAARPQVQLQESGGGLVQPGGSLRLSCAASGFTFSSD 
               
               
                 Full CAR 
                   
                 AMTWVRQAPGKGLEWVSVISGSGGTTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                   
                   
                 LRAEDTAVYYCAKLDSSGYYYARGPRYWGQGTLVTVSSASGGGGSGGRASGGG 
               
               
                   
                   
                 GSDIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGA 
               
               
                   
                   
                 STLASGVPARFSGSGSGTHFTLTINSLQSEDSATYYCQQSYKRASFGQGTKVE 
               
               
                   
                   
                 IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP 
               
               
                   
                   
                 LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE 
               
               
                   
                   
                 EEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG 
               
               
                   
                   
                 GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD 
               
               
                   
                   
                 TYDALHMQALPPR 
               
               
                 139101- nt 
                 1002 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAACTTCAAGAATCAGGCGGAGGACTCGTGCAGCCCG 
               
               
                   
                   
                 GAGGATCATTGCGGCTCTCGTGCGCCGCCTCGGGCTTCACCTTCTCGAGCGAC 
               
               
                   
                   
                 GCCATGACCTGGGTCCGCCAGGCCCCGGGGAAGGGGCTGGAATGGGTGTCTGT 
               
               
                   
                   
                 GATTTCCGGCTCCGGGGGAACTACGTACTACGCCGATTCCGTGAAAGGTCGCT 
               
               
                   
                   
                 TCACTATCTCCCGGGACAACAGCAAGAACACCCTTTATCTGCAAATGAATTCC 
               
               
                   
                   
                 CTCCGCGCCGAGGACACCGCCGTGTACTACTGCGCCAAGCTGGACTCCTCGGG 
               
               
                   
                   
                 CTACTACTATGCCCGGGGTCCGAGATACTGGGGACAGGGAACCCTCGTGACCG 
               
               
                   
                   
                 TGTCCTCCGCGTCCGGCGGAGGAGGGTCGGGAGGGCGGGCCTCCGGCGGCGGC 
               
               
                   
                   
                 GGTTCGGACATCCAGCTGACCCAGTCCCCATCCTCACTGAGCGCAAGCGTGGG 
               
               
                   
                   
                 CGACAGAGTCACCATTACATGCAGGGCGTCCCAGAGCATCAGCTCCTACCTGA 
               
               
                   
                   
                 ACTGGTACCAACAGAAGCCTGGAAAGGCTCCTAAGCTGTTGATCTACGGGGCT 
               
               
                   
                   
                 TCGACCCTGGCATCCGGGGTGCCCGCGAGGTTTAGCGGAAGCGGTAGCGGCAC 
               
               
                   
                   
                 TCACTTCACTCTGACCATTAACAGCCTCCAGTCCGAGGATTCAGCCACTTACT 
               
               
                   
                   
                 ACTGTCAGCAGTCCTACAAGCGGGCCAGCTTCGGACAGGGCACTAAGGTCGAG 
               
               
                   
                   
                 ATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC 
               
               
                   
                   
                 CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG 
               
               
                   
                   
                 CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCT 
               
               
                   
                   
                 CTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTG 
               
               
                   
                   
                 TAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC 
               
               
                   
                   
                 CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAG 
               
               
                   
                   
                 GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC 
               
               
                   
                   
                 AGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGA 
               
               
                   
                   
                 GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC 
               
               
                   
                   
                 GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA 
               
               
                   
                   
                 GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA 
               
               
                   
                   
                 GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC 
               
               
                   
                   
                 ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139102 
               
            
           
           
               
               
               
            
               
                 139102- aa 
                 1003 
                 QVQLVQSGAEVKKPGASVKVSCKASGYTFSNYGITWVRQAPGQGLEWMGWISA 
               
               
                 ScFv domain 
                   
                 YNGNTNYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGPYYYYMD 
               
               
                   
                   
                 VWGKGTMVTVSSASGGGGSGGRASGGGGSEIVMTQSPLSLPVTPGEPASISCR 
               
               
                   
                   
                 SSQSLLYSNGYNYVDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFK 
               
               
                   
                   
                 LQISRVEAEDVGIYYCMQGRQFPYSFGQGTKVEIK 
               
               
                 139102- nt 
                 1004 
                 CAAGTCCAACTGGTCCAGAGCGGTGCAGAAGTGAAGAAGCCCGGAGCGAGCGT 
               
               
                 ScFv domain 
                   
                 GAAAGTGTCCTGCAAGGCTTCCGGGTACACCTTCTCCAACTACGGCATCACTT 
               
               
                   
                   
                 GGGTGCGCCAGGCCCCGGGACAGGGCCTGGAATGGATGGGGTGGATTTCCGCG 
               
               
                   
                   
                 TACAACGGCAATACGAACTACGCTCAGAAGTTCCAGGGTAGAGTGACCATGAC 
               
               
                   
                   
                 TAGGAACACCTCCATTTCCACCGCCTACATGGAACTGTCCTCCCTGCGGAGCG 
               
               
                   
                   
                 AGGACACCGCCGTGTACTATTGCGCCCGGGGACCATACTACTACTACATGGAT 
               
               
                   
                   
                 GTCTGGGGGAAGGGGACTATGGTCACCGTGTCATCCGCCTCGGGAGGCGGCGG 
               
               
                   
                   
                 ATCAGGAGGACGCGCCTCTGGTGGTGGAGGATCGGAGATCGTGATGACCCAGA 
               
               
                   
                   
                 GCCCTCTCTCCTTGCCCGTGACTCCTGGGGAGCCCGCATCCATTTCATGCCGG 
               
               
                   
                   
                 AGCTCCCAGTCACTTCTCTACTCCAACGGCTATAACTACGTGGATTGGTACCT 
               
               
                   
                   
                 CCAAAAGCCGGGCCAGAGCCCGCAGCTGCTGATCTACCTGGGCTCGAACAGGG 
               
               
                   
                   
                 CCAGCGGAGTGCCTGACCGGTTCTCCGGGTCGGGAAGCGGGACCGACTTCAAG 
               
               
                   
                   
                 CTGCAAATCTCGAGAGTGGAGGCCGAGGACGTGGGAATCTACTACTGTATGCA 
               
               
                   
                   
                 GGGCCGCCAGTTTCCGTACTCGTTCGGACAGGGCACCAAAGTGGAAATCAAG 
               
               
                 139102- aa 
                 1005 
                 QVQLVQSGAEVKKPGASVKVSCKASGYTFSNYGITWVRQAPGQGLEWMGWISA 
               
               
                 VH 
                   
                 YNGNTNYAQKFQGRVTMTRNTSISTAYMELSSLRSEDTAVYYCARGPYYYYMD 
               
               
                   
                   
                 VWGKGTMVTVSS 
               
               
                 139102- aa 
                 1006 
                 EIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYVDWYLQKPGQSPQLLI 
               
               
                 VL 
                   
                 YLGSNRASGVPDRFSGSGSGTDFKLQISRVEAEDVGIYYCMQGRQFPYSFGQG 
               
               
                   
                   
                 TKVEIK 
               
               
                 139102- aa 
                 1007 
                 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFSNY 
               
               
                 Full CAR 
                   
                 GITWVRQAPGQGLEWMGWISAYNGNTNYAQKFQGRVTMTRNTSISTAYMELSS 
               
               
                   
                   
                 LRSEDTAVYYCARGPYYYYMDVWGKGTMVTVSSASGGGGSGGRASGGGGSEIV 
               
               
                   
                   
                 MTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYVDWYLQKPGQSPQLLIYLG 
               
               
                   
                   
                 SNRASGVPDRFSGSGSGTDFKLQISRVEAEDVGIYYCMQGRQFPYSFGQGTKV 
               
               
                   
                   
                 EIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWA 
               
               
                   
                   
                 PLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPE 
               
               
                   
                   
                 EEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEM 
               
               
                   
                   
                 GGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATK 
               
               
                   
                   
                 DTYDALHMQALPPR 
               
               
                 139102- nt 
                 1008 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTCCAACTGGTCCAGAGCGGTGCAGAAGTGAAGAAGCCCG 
               
               
                   
                   
                 GAGCGAGCGTGAAAGTGTCCTGCAAGGCTTCCGGGTACACCTTCTCCAACTAC 
               
               
                   
                   
                 GGCATCACTTGGGTGCGCCAGGCCCCGGGACAGGGCCTGGAATGGATGGGGTG 
               
               
                   
                   
                 GATTTCCGCGTACAACGGCAATACGAACTACGCTCAGAAGTTCCAGGGTAGAG 
               
               
                   
                   
                 TGACCATGACTAGGAACACCTCCATTTCCACCGCCTACATGGAACTGTCCTCC 
               
               
                   
                   
                 CTGCGGAGCGAGGACACCGCCGTGTACTATTGCGCCCGGGGACCATACTACTA 
               
               
                   
                   
                 CTACATGGATGTCTGGGGGAAGGGGACTATGGTCACCGTGTCATCCGCCTCGG 
               
               
                   
                   
                 GAGGCGGCGGATCAGGAGGACGCGCCTCTGGTGGTGGAGGATCGGAGATCGTG 
               
               
                   
                   
                 ATGACCCAGAGCCCTCTCTCCTTGCCCGTGACTCCTGGGGAGCCCGCATCCAT 
               
               
                   
                   
                 TTCATGCCGGAGCTCCCAGTCACTTCTCTACTCCAACGGCTATAACTACGTGG 
               
               
                   
                   
                 ATTGGTACCTCCAAAAGCCGGGCCAGAGCCCGCAGCTGCTGATCTACCTGGGC 
               
               
                   
                   
                 TCGAACAGGGCCAGCGGAGTGCCTGACCGGTTCTCCGGGTCGGGAAGCGGGAC 
               
               
                   
                   
                 CGACTTCAAGCTGCAAATCTCGAGAGTGGAGGCCGAGGACGTGGGAATCTACT 
               
               
                   
                   
                 ACTGTATGCAGGGCCGCCAGTTTCCGTACTCGTTCGGACAGGGCACCAAAGTG 
               
               
                   
                   
                 GAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCAT 
               
               
                   
                   
                 CGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTG 
               
               
                   
                   
                 GGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCC 
               
               
                   
                   
                 CCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTA 
               
               
                   
                   
                 CTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGA 
               
               
                   
                   
                 GGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAG 
               
               
                   
                   
                 GAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGC 
               
               
                   
                   
                 TCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTC 
               
               
                   
                   
                 GGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATG 
               
               
                   
                   
                 GGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCA 
               
               
                   
                   
                 AAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCA 
               
               
                   
                   
                 GAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAG 
               
               
                   
                   
                 GACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139104 
               
            
           
           
               
               
               
            
               
                 139104- aa 
                 1009 
                 EVQLLETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 ScFv domain 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPATLSVSPGESATLSCRASQ 
               
               
                   
                   
                 SVSSNLAWYQQKPGQAPRLLIYGASTRASGIPDRFSGSGSGTDFTLTISSLQA 
               
               
                   
                   
                 EDVAVYYCQQYGSSLTFGGGTKVEIK 
               
               
                 139104- nt 
                 1010 
                 GAAGTGCAATTGCTCGAAACTGGAGGAGGTCTGGTGCAACCTGGAGGATCACT 
               
               
                 ScFv domain 
                   
                 TCGCCTGTCCTGCGCCGTGTCGGGCTTTGCCCTGTCCAACCATGGAATGAGCT 
               
               
                   
                   
                 GGGTCCGCCGCGCGCCGGGGAAGGGCCTCGAATGGGTGTCCGGCATCGTCTAC 
               
               
                   
                   
                 TCCGGCTCCACCTACTACGCCGCGTCCGTGAAGGGCCGGTTCACGATTTCACG 
               
               
                   
                   
                 GGACAACTCGCGGAACACCCTGTACCTCCAAATGAATTCCCTTCGGCCGGAGG 
               
               
                   
                   
                 ATACTGCCATCTACTACTGCTCCGCCCACGGTGGCGAATCCGACGTCTGGGGC 
               
               
                   
                   
                 CAGGGAACCACCGTGACCGTGTCCAGCGCGTCCGGGGGAGGAGGAAGCGGGGG 
               
               
                   
                   
                 TAGAGCATCGGGTGGAGGCGGATCAGAGATCGTGCTGACCCAGTCCCCCGCCA 
               
               
                   
                   
                 CCTTGAGCGTGTCACCAGGAGAGTCCGCCACCCTGTCATGCCGCGCCAGCCAG 
               
               
                   
                   
                 TCCGTGTCCTCCAACCTGGCTTGGTACCAGCAGAAGCCGGGGCAGGCCCCTAG 
               
               
                   
                   
                 ACTCCTGATCTATGGGGCGTCGACCCGGGCATCTGGAATTCCCGATAGGTTCA 
               
               
                   
                   
                 GCGGATCGGGCTCGGGCACTGACTTCACTCTGACCATCTCCTCGCTGCAAGCC 
               
               
                   
                   
                 GAGGACGTGGCTGTGTACTACTGTCAGCAGTACGGAAGCTCCCTGACTTTCGG 
               
               
                   
                   
                 TGGCGGGACCAAAGTCGAGATTAAG 
               
               
                 139104- aa 
                 1011 
                 EVQLLETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 VH 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSS 
               
               
                 139104- aa 
                 1012 
                 EIVLTQSPATLSVSPGESATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGAST 
               
               
                 VL 
                   
                 RASGIPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYGSSLTFGGGTKVEIK 
               
               
                 139104- aa 
                 1013 
                 MALPVTALLLPLALLLHAARPEVQLLETGGGLVQPGGSLRLSCAVSGFALSNH 
               
               
                 Full CAR 
                   
                 GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSL 
               
               
                   
                   
                 RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQ 
               
               
                   
                   
                 SPATLSVSPGESATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRASGIP 
               
               
                   
                   
                 DRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYGSSLTFGGGTKVEIKTTTPAP 
               
               
                   
                   
                 RPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVL 
               
               
                   
                   
                 LLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELR 
               
               
                   
                   
                 VKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP 
               
               
                   
                   
                 QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ 
               
               
                   
                   
                 ALPPR 
               
               
                 139104- nt 
                 1014 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAATTGCTCGAAACTGGAGGAGGTCTGGTGCAACCTG 
               
               
                   
                   
                 GAGGATCACTTCGCCTGTCCTGCGCCGTGTCGGGCTTTGCCCTGTCCAACCAT 
               
               
                   
                   
                 GGAATGAGCTGGGTCCGCCGCGCGCCGGGGAAGGGCCTCGAATGGGTGTCCGG 
               
               
                   
                   
                 CATCGTCTACTCCGGCTCCACCTACTACGCCGCGTCCGTGAAGGGCCGGTTCA 
               
               
                   
                   
                 CGATTTCACGGGACAACTCGCGGAACACCCTGTACCTCCAAATGAATTCCCTT 
               
               
                   
                   
                 CGGCCGGAGGATACTGCCATCTACTACTGCTCCGCCCACGGTGGCGAATCCGA 
               
               
                   
                   
                 CGTCTGGGGCCAGGGAACCACCGTGACCGTGTCCAGCGCGTCCGGGGGAGGAG 
               
               
                   
                   
                 GAAGCGGGGGTAGAGCATCGGGTGGAGGCGGATCAGAGATCGTGCTGACCCAG 
               
               
                   
                   
                 TCCCCCGCCACCTTGAGCGTGTCACCAGGAGAGTCCGCCACCCTGTCATGCCG 
               
               
                   
                   
                 CGCCAGCCAGTCCGTGTCCTCCAACCTGGCTTGGTACCAGCAGAAGCCGGGGC 
               
               
                   
                   
                 AGGCCCCTAGACTCCTGATCTATGGGGCGTCGACCCGGGCATCTGGAATTCCC 
               
               
                   
                   
                 GATAGGTTCAGCGGATCGGGCTCGGGCACTGACTTCACTCTGACCATCTCCTC 
               
               
                   
                   
                 GCTGCAAGCCGAGGACGTGGCTGTGTACTACTGTCAGCAGTACGGAAGCTCCC 
               
               
                   
                   
                 TGACTTTCGGTGGCGGGACCAAAGTCGAGATTAAGACCACTACCCCAGCACCG 
               
               
                   
                   
                 AGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCC 
               
               
                   
                   
                 GGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACT 
               
               
                   
                   
                 TCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTG 
               
               
                   
                   
                 CTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCT 
               
               
                   
                   
                 GTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGG 
               
               
                   
                   
                 ACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGC 
               
               
                   
                   
                 GTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCA 
               
               
                   
                   
                 GCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACA 
               
               
                   
                   
                 AGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCC 
               
               
                   
                   
                 CAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAG 
               
               
                   
                   
                 CGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGT 
               
               
                   
                   
                 ACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAG 
               
               
                   
                   
                 GCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139106 
               
            
           
           
               
               
               
            
               
                 139106- aa 
                 1015 
                 EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 ScFv domain 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSSASGGGGSGGRASGGGGSEIVMTQSPATLSVSPGERATLSCRASQ 
               
               
                   
                   
                 SVSSKLAWYQQKPGQAPRLLMYGASIRATGIPDRFSGSGSGTEFTLTISSLEP 
               
               
                   
                   
                 EDFAVYYCQQYGSSSWTFGQGTKVEIK 
               
               
                 139106- nt 
                 1016 
                 GAAGTGCAATTGGTGGAAACTGGAGGAGGACTTGTGCAACCTGGAGGATCATT 
               
               
                 ScFv domain 
                   
                 GAGACTGAGCTGCGCAGTGTCGGGATTCGCCCTGAGCAACCATGGAATGTCCT 
               
               
                   
                   
                 GGGTCAGAAGGGCCCCTGGAAAAGGCCTCGAATGGGTGTCAGGGATCGTGTAC 
               
               
                   
                   
                 TCCGGTTCCACTTACTACGCCGCCTCCGTGAAGGGGCGCTTCACTATCTCACG 
               
               
                   
                   
                 GGATAACTCCCGCAATACCCTGTACCTCCAAATGAACAGCCTGCGGCCGGAGG 
               
               
                   
                   
                 ATACCGCCATCTACTACTGTTCCGCCCACGGTGGAGAGTCTGACGTCTGGGGC 
               
               
                   
                   
                 CAGGGAACTACCGTGACCGTGTCCTCCGCGTCCGGCGGTGGAGGGAGCGGCGG 
               
               
                   
                   
                 CCGCGCCAGCGGCGGCGGAGGCTCCGAGATCGTGATGACCCAGAGCCCCGCTA 
               
               
                   
                   
                 CTCTGTCGGTGTCGCCCGGAGAAAGGGCGACCCTGTCCTGCCGGGCGTCGCAG 
               
               
                   
                   
                 TCCGTGAGCAGCAAGCTGGCTTGGTACCAGCAGAAGCCGGGCCAGGCACCACG 
               
               
                   
                   
                 CCTGCTTATGTACGGTGCCTCCATTCGGGCCACCGGAATCCCGGACCGGTTCT 
               
               
                   
                   
                 CGGGGTCGGGGTCCGGTACCGAGTTCACACTGACCATTTCCTCGCTCGAGCCC 
               
               
                   
                   
                 GAGGACTTTGCCGTCTATTACTGCCAGCAGTACGGCTCCTCCTCATGGACGTT 
               
               
                   
                   
                 CGGCCAGGGGACCAAGGTCGAAATCAAG 
               
               
                 139106- aa 
                 1017 
                 EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 VH 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSS 
               
               
                 139106- aa 
                 1018 
                 EIVMTQSPATLSVSPGERATLSCRASQSVSSKLAWYQQKPGQAPRLLMYGASI 
               
               
                 VL 
                   
                 RATGIPDRFSGSGSGTEFTLTISSLEPEDFAVYYCQQYGSSSWTFGQGTKVEI 
               
               
                   
                   
                 K 
               
               
                 139106- aa 
                 1019 
                 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAVSGFALSNH 
               
               
                 Full CAR 
                   
                 GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSL 
               
               
                   
                   
                 RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVMTQ 
               
               
                   
                   
                 SPATLSVSPGERATLSCRASQSVSSKLAWYQQKPGQAPRLLMYGASIRATGIP 
               
               
                   
                   
                 DRFSGSGSGTEFTLTISSLEPEDFAVYYCQQYGSSSWTFGQGTKVEIKTTTPA 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV 
               
               
                   
                   
                 LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL 
               
               
                   
                   
                 RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN 
               
               
                   
                   
                 PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM 
               
               
                   
                   
                 QALPPR 
               
               
                 139106- nt 
                 1020 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAATTGGTGGAAACTGGAGGAGGACTTGTGCAACCTG 
               
               
                   
                   
                 GAGGATCATTGAGACTGAGCTGCGCAGTGTCGGGATTCGCCCTGAGCAACCAT 
               
               
                   
                   
                 GGAATGTCCTGGGTCAGAAGGGCCCCTGGAAAAGGCCTCGAATGGGTGTCAGG 
               
               
                   
                   
                 GATCGTGTACTCCGGTTCCACTTACTACGCCGCCTCCGTGAAGGGGCGCTTCA 
               
               
                   
                   
                 CTATCTCACGGGATAACTCCCGCAATACCCTGTACCTCCAAATGAACAGCCTG 
               
               
                   
                   
                 CGGCCGGAGGATACCGCCATCTACTACTGTTCCGCCCACGGTGGAGAGTCTGA 
               
               
                   
                   
                 CGTCTGGGGCCAGGGAACTACCGTGACCGTGTCCTCCGCGTCCGGCGGTGGAG 
               
               
                   
                   
                 GGAGCGGCGGCCGCGCCAGCGGCGGCGGAGGCTCCGAGATCGTGATGACCCAG 
               
               
                   
                   
                 AGCCCCGCTACTCTGTCGGTGTCGCCCGGAGAAAGGGCGACCCTGTCCTGCCG 
               
               
                   
                   
                 GGCGTCGCAGTCCGTGAGCAGCAAGCTGGCTTGGTACCAGCAGAAGCCGGGCC 
               
               
                   
                   
                 AGGCACCACGCCTGCTTATGTACGGTGCCTCCATTCGGGCCACCGGAATCCCG 
               
               
                   
                   
                 GACCGGTTCTCGGGGTCGGGGTCCGGTACCGAGTTCACACTGACCATTTCCTC 
               
               
                   
                   
                 GCTCGAGCCCGAGGACTTTGCCGTCTATTACTGCCAGCAGTACGGCTCCTCCT 
               
               
                   
                   
                 CATGGACGTTCGGCCAGGGGACCAAGGTCGAAATCAAGACCACTACCCCAGCA 
               
               
                   
                   
                 CCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG 
               
               
                   
                   
                 TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG 
               
               
                   
                   
                 ACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTC 
               
               
                   
                   
                 CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCT 
               
               
                   
                   
                 GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG 
               
               
                   
                   
                 AGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTG 
               
               
                   
                   
                 CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA 
               
               
                   
                   
                 CCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG 
               
               
                   
                   
                 ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT 
               
               
                   
                   
                 CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA 
               
               
                   
                   
                 TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGAC 
               
               
                   
                   
                 TGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG 
               
               
                   
                   
                 CAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139107 
               
            
           
           
               
               
               
            
               
                 139107- aa 
                 1021 
                 EVQLVETGGGVVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 ScFv domain 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPGTLSLSPGERATLSCRASQ 
               
               
                   
                   
                 SVGSTNLAWYQQKPGQAPRLLIYDASNRATGIPDRFSGGGSGTDFTLTISRLE 
               
               
                   
                   
                 PEDFAVYYCQQYGSSPPWTFGQGTKVEIK 
               
               
                 139107- nt 
                 1022 
                 GAAGTGCAATTGGTGGAGACTGGAGGAGGAGTGGTGCAACCTGGAGGAAGCCT 
               
               
                 ScFv domain 
                   
                 GAGACTGTCATGCGCGGTGTCGGGCTTCGCCCTCTCCAACCACGGAATGTCCT 
               
               
                   
                   
                 GGGTCCGCCGGGCCCCTGGGAAAGGACTTGAATGGGTGTCCGGCATCGTGTAC 
               
               
                   
                   
                 TCGGGTTCCACCTACTACGCGGCCTCAGTGAAGGGCCGGTTTACTATTAGCCG 
               
               
                   
                   
                 CGACAACTCCAGAAACACACTGTACCTCCAAATGAACTCGCTGCGGCCGGAAG 
               
               
                   
                   
                 ATACCGCTATCTACTACTGCTCCGCCCATGGGGGAGAGTCGGACGTCTGGGGA 
               
               
                   
                   
                 CAGGGCACCACTGTCACTGTGTCCAGCGCTTCCGGCGGTGGTGGAAGCGGGGG 
               
               
                   
                   
                 ACGGGCCTCAGGAGGCGGTGGCAGCGAGATTGTGCTGACCCAGTCCCCCGGGA 
               
               
                   
                   
                 CCCTGAGCCTGTCCCCGGGAGAAAGGGCCACCCTCTCCTGTCGGGCATCCCAG 
               
               
                   
                   
                 TCCGTGGGGTCTACTAACCTTGCATGGTACCAGCAGAAGCCCGGCCAGGCCCC 
               
               
                   
                   
                 TCGCCTGCTGATCTACGACGCGTCCAATAGAGCCACCGGCATCCCGGATCGCT 
               
               
                   
                   
                 TCAGCGGAGGCGGATCGGGCACCGACTTCACCCTCACCATTTCAAGGCTGGAA 
               
               
                   
                   
                 CCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTATGGTTCGTCCCCACCCTG 
               
               
                   
                   
                 GACGTTCGGCCAGGGGACTAAGGTCGAGATCAAG 
               
               
                 139107- aa 
                 1023 
                 EVQLVETGGGVVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 VH 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSS 
               
               
                 139107- aa 
                 1024 
                 EIVLTQSPGTLSLSPGERATLSCRASQSVGSTNLAWYQQKPGQAPRLLIYDAS 
               
               
                 VL 
                   
                 NRATGIPDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKV 
               
               
                   
                   
                 EIK 
               
               
                 139107- aa 
                 1025 
                 MALPVTALLLPLALLLHAARPEVQLVETGGGVVQPGGSLRLSCAVSGFALSNH 
               
               
                 Full CAR 
                   
                 GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSL 
               
               
                   
                   
                 RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQ 
               
               
                   
                   
                 SPGTLSLSPGERATLSCRASQSVGSTNLAWYQQKPGQAPRLLIYDASNRATGI 
               
               
                   
                   
                 PDRFSGGGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPWTFGQGTKVEIKTTT 
               
               
                   
                   
                 PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC 
               
               
                   
                   
                 GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC 
               
               
                   
                   
                 ELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR 
               
               
                   
                   
                 KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL 
               
               
                   
                   
                 HMQALPPR 
               
               
                 139107- nt 
                 1026 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAATTGGTGGAGACTGGAGGAGGAGTGGTGCAACCTG 
               
               
                   
                   
                 GAGGAAGCCTGAGACTGTCATGCGCGGTGTCGGGCTTCGCCCTCTCCAACCAC 
               
               
                   
                   
                 GGAATGTCCTGGGTCCGCCGGGCCCCTGGGAAAGGACTTGAATGGGTGTCCGG 
               
               
                   
                   
                 CATCGTGTACTCGGGTTCCACCTACTACGCGGCCTCAGTGAAGGGCCGGTTTA 
               
               
                   
                   
                 CTATTAGCCGCGACAACTCCAGAAACACACTGTACCTCCAAATGAACTCGCTG 
               
               
                   
                   
                 CGGCCGGAAGATACCGCTATCTACTACTGCTCCGCCCATGGGGGAGAGTCGGA 
               
               
                   
                   
                 CGTCTGGGGACAGGGCACCACTGTCACTGTGTCCAGCGCTTCCGGCGGTGGTG 
               
               
                   
                   
                 GAAGCGGGGGACGGGCCTCAGGAGGCGGTGGCAGCGAGATTGTGCTGACCCAG 
               
               
                   
                   
                 TCCCCCGGGACCCTGAGCCTGTCCCCGGGAGAAAGGGCCACCCTCTCCTGTCG 
               
               
                   
                   
                 GGCATCCCAGTCCGTGGGGTCTACTAACCTTGCATGGTACCAGCAGAAGCCCG 
               
               
                   
                   
                 GCCAGGCCCCTCGCCTGCTGATCTACGACGCGTCCAATAGAGCCACCGGCATC 
               
               
                   
                   
                 CCGGATCGCTTCAGCGGAGGCGGATCGGGCACCGACTTCACCCTCACCATTTC 
               
               
                   
                   
                 AAGGCTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTATGGTTCGT 
               
               
                   
                   
                 CCCCACCCTGGACGTTCGGCCAGGGGACTAAGGTCGAGATCAAGACCACTACC 
               
               
                   
                   
                 CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTC 
               
               
                   
                   
                 CCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGG 
               
               
                   
                   
                 GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGC 
               
               
                   
                   
                 GGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAA 
               
               
                   
                   
                 GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC 
               
               
                   
                   
                 AAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGC 
               
               
                   
                   
                 GAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGG 
               
               
                   
                   
                 GCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACG 
               
               
                   
                   
                 TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA 
               
               
                   
                   
                 AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA 
               
               
                   
                   
                 AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG 
               
               
                   
                   
                 ACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT 
               
               
                   
                   
                 CACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139108 
               
            
           
           
               
               
               
            
               
                 139108- aa 
                 1027 
                 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISS 
               
               
                 ScFv domain 
                   
                 SGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARESGDGMDV 
               
               
                   
                   
                 WGQGTTVTVSSASGGGGSGGRASGGGGSDIQMTQSPSSLSASVGDRVTITCRA 
               
               
                   
                   
                 SQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL 
               
               
                   
                   
                 QPEDFATYYCQQSYTLAFGQGTKVDIK 
               
               
                 139108- nt 
                 1028 
                 CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGAAACCTGGAGGATCATT 
               
               
                 ScFv domain 
                   
                 GAGACTGTCATGCGCGGCCTCGGGATTCACGTTCTCCGATTACTACATGAGCT 
               
               
                   
                   
                 GGATTCGCCAGGCTCCGGGGAAGGGACTGGAATGGGTGTCCTACATTTCCTCA 
               
               
                   
                   
                 TCCGGCTCCACCATCTACTACGCGGACTCCGTGAAGGGGAGATTCACCATTAG 
               
               
                   
                   
                 CCGCGATAACGCCAAGAACAGCCTGTACCTTCAGATGAACTCCCTGCGGGCTG 
               
               
                   
                   
                 AAGATACTGCCGTCTACTACTGCGCAAGGGAGAGCGGAGATGGGATGGACGTC 
               
               
                   
                   
                 TGGGGACAGGGTACCACTGTGACCGTGTCGTCGGCCTCCGGCGGAGGGGGTTC 
               
               
                   
                   
                 GGGTGGAAGGGCCAGCGGCGGCGGAGGCAGCGACATCCAGATGACCCAGTCCC 
               
               
                   
                   
                 CCTCATCGCTGTCCGCCTCCGTGGGCGACCGCGTCACCATCACATGCCGGGCC 
               
               
                   
                   
                 TCACAGTCGATCTCCTCCTACCTCAATTGGTATCAGCAGAAGCCCGGAAAGGC 
               
               
                   
                   
                 CCCTAAGCTTCTGATCTACGCAGCGTCCTCCCTGCAATCCGGGGTCCCATCTC 
               
               
                   
                   
                 GGTTCTCCGGCTCGGGCAGCGGTACCGACTTCACTCTGACCATCTCGAGCCTG 
               
               
                   
                   
                 CAGCCGGAGGACTTCGCCACTTACTACTGTCAGCAAAGCTACACCCTCGCGTT 
               
               
                   
                   
                 TGGCCAGGGCACCAAAGTGGACATCAAG 
               
               
                 139108- aa 
                 1029 
                 QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISS 
               
               
                 VH 
                   
                 SGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARESGDGMDV 
               
               
                   
                   
                 WGQGTTVTVSS 
               
               
                 139108- aa 
                 1030 
                 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASS 
               
               
                 VL 
                   
                 LQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTLAFGQGTKVDIK 
               
               
                 139108- aa 
                 1031 
                 MALPVTALLLPLALLLHAARPQVQLVESGGGLVKPGGSLRLSCAASGFTFSDY 
               
               
                 Full CAR 
                   
                 YMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNS 
               
               
                   
                   
                 LRAEDTAVYYCARESGDGMDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIQM 
               
               
                   
                   
                 TQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSG 
               
               
                   
                   
                 VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYTLAFGQGTKVDIKTTTPA 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV 
               
               
                   
                   
                 LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL 
               
               
                   
                   
                 RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN 
               
               
                   
                   
                 PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM 
               
               
                   
                   
                 QALPPR 
               
               
                 139108- nt 
                 1032 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGAAACCTG 
               
               
                   
                   
                 GAGGATCATTGAGACTGTCATGCGCGGCCTCGGGATTCACGTTCTCCGATTAC 
               
               
                   
                   
                 TACATGAGCTGGATTCGCCAGGCTCCGGGGAAGGGACTGGAATGGGTGTCCTA 
               
               
                   
                   
                 CATTTCCTCATCCGGCTCCACCATCTACTACGCGGACTCCGTGAAGGGGAGAT 
               
               
                   
                   
                 TCACCATTAGCCGCGATAACGCCAAGAACAGCCTGTACCTTCAGATGAACTCC 
               
               
                   
                   
                 CTGCGGGCTGAAGATACTGCCGTCTACTACTGCGCAAGGGAGAGCGGAGATGG 
               
               
                   
                   
                 GATGGACGTCTGGGGACAGGGTACCACTGTGACCGTGTCGTCGGCCTCCGGCG 
               
               
                   
                   
                 GAGGGGGTTCGGGTGGAAGGGCCAGCGGCGGCGGAGGCAGCGACATCCAGATG 
               
               
                   
                   
                 ACCCAGTCCCCCTCATCGCTGTCCGCCTCCGTGGGCGACCGCGTCACCATCAC 
               
               
                   
                   
                 ATGCCGGGCCTCACAGTCGATCTCCTCCTACCTCAATTGGTATCAGCAGAAGC 
               
               
                   
                   
                 CCGGAAAGGCCCCTAAGCTTCTGATCTACGCAGCGTCCTCCCTGCAATCCGGG 
               
               
                   
                   
                 GTCCCATCTCGGTTCTCCGGCTCGGGCAGCGGTACCGACTTCACTCTGACCAT 
               
               
                   
                   
                 CTCGAGCCTGCAGCCGGAGGACTTCGCCACTTACTACTGTCAGCAAAGCTACA 
               
               
                   
                   
                 CCCTCGCGTTTGGCCAGGGCACCAAAGTGGACATCAAGACCACTACCCCAGCA 
               
               
                   
                   
                 CCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG 
               
               
                   
                   
                 TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG 
               
               
                   
                   
                 ACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTC 
               
               
                   
                   
                 CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCT 
               
               
                   
                   
                 GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG 
               
               
                   
                   
                 AGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTG 
               
               
                   
                   
                 CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA 
               
               
                   
                   
                 CCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG 
               
               
                   
                   
                 ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT 
               
               
                   
                   
                 CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA 
               
               
                   
                   
                 TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGAC 
               
               
                   
                   
                 TGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG 
               
               
                   
                   
                 CAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139110 
               
            
           
           
               
               
               
            
               
                 139110- aa 
                 1033 
                 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISS 
               
               
                 ScFv domain 
                   
                 SGNTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSTMVREDY 
               
               
                   
                   
                 WGQGTLVTVSSASGGGGSGGRASGGGGSDIVLTQSPLSLPVTLGQPASISCKS 
               
               
                   
                   
                 SESLVHNSGKTYLNWFHQRPGQSPRRLIYEVSNRDSGVPDRFTGSGSGTDFTL 
               
               
                   
                   
                 KISRVEAEDVGVYYCMQGTHWPGTFGQGTKLEIK 
               
               
                 139110- nt 
                 1034 
                 CAAGTGCAACTGGTGCAAAGCGGAGGAGGATTGGTCAAACCCGGAGGAAGCCT 
               
               
                 ScFv domain 
                   
                 GAGACTGTCATGCGCGGCCTCTGGATTCACCTTCTCCGATTACTACATGTCAT 
               
               
                   
                   
                 GGATCAGACAGGCCCCGGGGAAGGGCCTCGAATGGGTGTCCTACATCTCGTCC 
               
               
                   
                   
                 TCCGGGAACACCATCTACTACGCCGACAGCGTGAAGGGCCGCTTTACCATTTC 
               
               
                   
                   
                 CCGCGACAACGCAAAGAACTCGCTGTACCTTCAGATGAATTCCCTGCGGGCTG 
               
               
                   
                   
                 AAGATACCGCGGTGTACTATTGCGCCCGGTCCACTATGGTCCGGGAGGACTAC 
               
               
                   
                   
                 TGGGGACAGGGCACACTCGTGACCGTGTCCAGCGCGAGCGGGGGTGGAGGCAG 
               
               
                   
                   
                 CGGTGGACGCGCCTCCGGCGGCGGCGGTTCAGACATCGTGCTGACTCAGTCGC 
               
               
                   
                   
                 CCCTGTCGCTGCCGGTCACCCTGGGCCAACCGGCCTCAATTAGCTGCAAGTCC 
               
               
                   
                   
                 TCGGAGAGCCTGGTGCACAACTCAGGAAAGACTTACCTGAACTGGTTCCATCA 
               
               
                   
                   
                 GCGGCCTGGACAGTCCCCACGGAGGCTCATCTATGAAGTGTCCAACAGGGATT 
               
               
                   
                   
                 CGGGGGTGCCCGACCGCTTCACTGGCTCCGGGTCCGGCACCGACTTCACCTTG 
               
               
                   
                   
                 AAAATCTCCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACTGTATGCAGGG 
               
               
                   
                   
                 TACCCACTGGCCTGGAACCTTTGGACAAGGAACTAAGCTCGAGATTAAG 
               
               
                 139110- aa 
                 1035 
                 QVQLVQSGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISS 
               
               
                 VH 
                   
                 SGNTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARSTMVREDY 
               
               
                   
                   
                 WGQGTLVTVSS 
               
               
                 139110- aa 
                 1036 
                 DIVLTQSPLSLPVTLGQPASISCKSSESLVHNSGKTYLNWFHQRPGQSPRRLI 
               
               
                 VL 
                   
                 YEVSNRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPGTFGQG 
               
               
                   
                   
                 TKLEIK 
               
               
                 139110- aa 
                 1037 
                 MALPVTALLLPLALLLHAARPQVQLVQSGGGLVKPGGSLRLSCAASGFTFSDY 
               
               
                 Full CAR 
                   
                 YMSWIRQAPGKGLEWVSYISSSGNTIYYADSVKGRFTISRDNAKNSLYLQMNS 
               
               
                   
                   
                 LRAEDTAVYYCARSTMVREDYWGQGTLVTVSSASGGGGSGGRASGGGGSDIVL 
               
               
                   
                   
                 TQSPLSLPVTLGQPASISCKSSESLVHNSGKTYLNWFHQRPGQSPRRLIYEVS 
               
               
                   
                   
                 NRDSGVPDRFTGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPGTFGQGTKLE 
               
               
                   
                   
                 IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP 
               
               
                   
                   
                 LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE 
               
               
                   
                   
                 EEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG 
               
               
                   
                   
                 GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD 
               
               
                   
                   
                 TYDALHMQALPPR 
               
               
                 139110- nt 
                 1038 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAACTGGTGCAAAGCGGAGGAGGATTGGTCAAACCCG 
               
               
                   
                   
                 GAGGAAGCCTGAGACTGTCATGCGCGGCCTCTGGATTCACCTTCTCCGATTAC 
               
               
                   
                   
                 TACATGTCATGGATCAGACAGGCCCCGGGGAAGGGCCTCGAATGGGTGTCCTA 
               
               
                   
                   
                 CATCTCGTCCTCCGGGAACACCATCTACTACGCCGACAGCGTGAAGGGCCGCT 
               
               
                   
                   
                 TTACCATTTCCCGCGACAACGCAAAGAACTCGCTGTACCTTCAGATGAATTCC 
               
               
                   
                   
                 CTGCGGGCTGAAGATACCGCGGTGTACTATTGCGCCCGGTCCACTATGGTCCG 
               
               
                   
                   
                 GGAGGACTACTGGGGACAGGGCACACTCGTGACCGTGTCCAGCGCGAGCGGGG 
               
               
                   
                   
                 GTGGAGGCAGCGGTGGACGCGCCTCCGGCGGCGGCGGTTCAGACATCGTGCTG 
               
               
                   
                   
                 ACTCAGTCGCCCCTGTCGCTGCCGGTCACCCTGGGCCAACCGGCCTCAATTAG 
               
               
                   
                   
                 CTGCAAGTCCTCGGAGAGCCTGGTGCACAACTCAGGAAAGACTTACCTGAACT 
               
               
                   
                   
                 GGTTCCATCAGCGGCCTGGACAGTCCCCACGGAGGCTCATCTATGAAGTGTCC 
               
               
                   
                   
                 AACAGGGATTCGGGGGTGCCCGACCGCTTCACTGGCTCCGGGTCCGGCACCGA 
               
               
                   
                   
                 CTTCACCTTGAAAATCTCCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACT 
               
               
                   
                   
                 GTATGCAGGGTACCCACTGGCCTGGAACCTTTGGACAAGGAACTAAGCTCGAG 
               
               
                   
                   
                 ATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC 
               
               
                   
                   
                 CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG 
               
               
                   
                   
                 CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCT 
               
               
                   
                   
                 CTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTG 
               
               
                   
                   
                 TAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC 
               
               
                   
                   
                 CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAG 
               
               
                   
                   
                 GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC 
               
               
                   
                   
                 AGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGA 
               
               
                   
                   
                 GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC 
               
               
                   
                   
                 GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA 
               
               
                   
                   
                 GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA 
               
               
                   
                   
                 GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC 
               
               
                   
                   
                 ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139112 
               
            
           
           
               
               
               
            
               
                 139112- aa 
                 1039 
                 QVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 ScFv domain 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSSASGGGGSGGRASGGGGSDIRLTQSPSPLSASVGDRVTITCQASE 
               
               
                   
                   
                 DINKFLNWYHQTPGKAPKLLIYDASTLQTGVPSRFSGSGSGTDFTLTINSLQP 
               
               
                   
                   
                 EDIGTYYCQQYESLPLTFGGGTKVEIK 
               
               
                 139112- nt 
                 1040 
                 CAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCGGTGGAAGCCT 
               
               
                 ScFv domain 
                   
                 TAGGCTGTCGTGCGCCGTCAGCGGGTTTGCTCTGAGCAACCATGGAATGTCCT 
               
               
                   
                   
                 GGGTCCGCCGGGCACCGGGAAAAGGGCTGGAATGGGTGTCCGGCATCGTGTAC 
               
               
                   
                   
                 AGCGGGTCAACCTATTACGCCGCGTCCGTGAAGGGCAGATTCACTATCTCAAG 
               
               
                   
                   
                 AGACAACAGCCGGAACACCCTGTACTTGCAAATGAATTCCCTGCGCCCCGAGG 
               
               
                   
                   
                 ACACCGCCATCTACTACTGCTCCGCCCACGGAGGAGAGTCGGACGTGTGGGGC 
               
               
                   
                   
                 CAGGGAACGACTGTGACTGTGTCCAGCGCATCAGGAGGGGGTGGTTCGGGCGG 
               
               
                   
                   
                 CCGGGCCTCGGGGGGAGGAGGTTCCGACATTCGGCTGACCCAGTCCCCGTCCC 
               
               
                   
                   
                 CACTGTCGGCCTCCGTCGGCGACCGCGTGACCATCACTTGTCAGGCGTCCGAG 
               
               
                   
                   
                 GACATTAACAAGTTCCTGAACTGGTACCACCAGACCCCTGGAAAGGCCCCCAA 
               
               
                   
                   
                 GCTGCTGATCTACGATGCCTCGACCCTTCAAACTGGAGTGCCTAGCCGGTTCT 
               
               
                   
                   
                 CCGGGTCCGGCTCCGGCACTGATTTCACTCTGACCATCAACTCATTGCAGCCG 
               
               
                   
                   
                 GAAGATATCGGGACCTACTATTGCCAGCAGTACGAATCCCTCCCGCTCACATT 
               
               
                   
                   
                 CGGCGGGGGAACCAAGGTCGAGATTAAG 
               
               
                 139112- aa 
                 1041 
                 QVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 VH 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSS 
               
               
                 139112- aa 
                 1042 
                 DIRLTQSPSPLSASVGDRVTITCQASEDINKFLNWYHQTPGKAPKLLIYDAST 
               
               
                 VL 
                   
                 LQTGVPSRFSGSGSGTDFTLTINSLQPEDIGTYYCQQYESLPLTFGGGTKVEI 
               
               
                   
                   
                 K 
               
               
                 139112- aa 
                 1043 
                 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAVSGFALSNH 
               
               
                 Full CAR 
                   
                 GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSL 
               
               
                   
                   
                 RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSDIRLTQ 
               
               
                   
                   
                 SPSPLSASVGDRVTITCQASEDINKFLNWYHQTPGKAPKLLIYDASTLQTGVP 
               
               
                   
                   
                 SRFSGSGSGTDFTLTINSLQPEDIGTYYCQQYESLPLTFGGGTKVEIKTTTPA 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV 
               
               
                   
                   
                 LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL 
               
               
                   
                   
                 RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN 
               
               
                   
                   
                 PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM 
               
               
                   
                   
                 QALPPR 
               
               
                 139112- nt 
                 1044 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAACTCGTGGAATCTGGTGGAGGACTCGTGCAACCCG 
               
               
                   
                   
                 GTGGAAGCCTTAGGCTGTCGTGCGCCGTCAGCGGGTTTGCTCTGAGCAACCAT 
               
               
                   
                   
                 GGAATGTCCTGGGTCCGCCGGGCACCGGGAAAAGGGCTGGAATGGGTGTCCGG 
               
               
                   
                   
                 CATCGTGTACAGCGGGTCAACCTATTACGCCGCGTCCGTGAAGGGCAGATTCA 
               
               
                   
                   
                 CTATCTCAAGAGACAACAGCCGGAACACCCTGTACTTGCAAATGAATTCCCTG 
               
               
                   
                   
                 CGCCCCGAGGACACCGCCATCTACTACTGCTCCGCCCACGGAGGAGAGTCGGA 
               
               
                   
                   
                 CGTGTGGGGCCAGGGAACGACTGTGACTGTGTCCAGCGCATCAGGAGGGGGTG 
               
               
                   
                   
                 GTTCGGGCGGCCGGGCCTCGGGGGGAGGAGGTTCCGACATTCGGCTGACCCAG 
               
               
                   
                   
                 TCCCCGTCCCCACTGTCGGCCTCCGTCGGCGACCGCGTGACCATCACTTGTCA 
               
               
                   
                   
                 GGCGTCCGAGGACATTAACAAGTTCCTGAACTGGTACCACCAGACCCCTGGAA 
               
               
                   
                   
                 AGGCCCCCAAGCTGCTGATCTACGATGCCTCGACCCTTCAAACTGGAGTGCCT 
               
               
                   
                   
                 AGCCGGTTCTCCGGGTCCGGCTCCGGCACTGATTTCACTCTGACCATCAACTC 
               
               
                   
                   
                 ATTGCAGCCGGAAGATATCGGGACCTACTATTGCCAGCAGTACGAATCCCTCC 
               
               
                   
                   
                 CGCTCACATTCGGCGGGGGAACCAAGGTCGAGATTAAGACCACTACCCCAGCA 
               
               
                   
                   
                 CCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG 
               
               
                   
                   
                 TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG 
               
               
                   
                   
                 ACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTC 
               
               
                   
                   
                 CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCT 
               
               
                   
                   
                 GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG 
               
               
                   
                   
                 AGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTG 
               
               
                   
                   
                 CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA 
               
               
                   
                   
                 CCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG 
               
               
                   
                   
                 ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT 
               
               
                   
                   
                 CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA 
               
               
                   
                   
                 TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGAC 
               
               
                   
                   
                 TGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG 
               
               
                   
                   
                 CAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139113 
               
            
           
           
               
               
               
            
               
                 139113- aa 
                 1045 
                 EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 ScFv domain 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSSASGGGGSGGRASGGGGSETTLTQSPATLSVSPGERATLSCRASQ 
               
               
                   
                   
                 SVGSNLAWYQQKPGQGPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQP 
               
               
                   
                   
                 EDFAVYYCQQYNDWLPVTFGQGTKVEIK 
               
               
                 139113- nt 
                 1046 
                 GAAGTGCAATTGGTGGAAACTGGAGGAGGACTTGTGCAACCTGGAGGATCATT 
               
               
                 ScFv domain 
                   
                 GCGGCTCTCATGCGCTGTCTCCGGCTTCGCCCTGTCAAATCACGGGATGTCGT 
               
               
                   
                   
                 GGGTCAGACGGGCCCCGGGAAAGGGTCTGGAATGGGTGTCGGGGATTGTGTAC 
               
               
                   
                   
                 AGCGGCTCCACCTACTACGCCGCTTCGGTCAAGGGCCGCTTCACTATTTCACG 
               
               
                   
                   
                 GGACAACAGCCGCAACACCCTCTATCTGCAAATGAACTCTCTCCGCCCGGAGG 
               
               
                   
                   
                 ATACCGCCATCTACTACTGCTCCGCACACGGCGGCGAATCCGACGTGTGGGGA 
               
               
                   
                   
                 CAGGGAACCACTGTCACCGTGTCGTCCGCATCCGGTGGCGGAGGATCGGGTGG 
               
               
                   
                   
                 CCGGGCCTCCGGGGGCGGCGGCAGCGAGACTACCCTGACCCAGTCCCCTGCCA 
               
               
                   
                   
                 CTCTGTCCGTGAGCCCGGGAGAGAGAGCCACCCTTAGCTGCCGGGCCAGCCAG 
               
               
                   
                   
                 AGCGTGGGCTCCAACCTGGCCTGGTACCAGCAGAAGCCAGGACAGGGTCCCAG 
               
               
                   
                   
                 GCTGCTGATCTACGGAGCCTCCACTCGCGCGACCGGCATCCCCGCGAGGTTCT 
               
               
                   
                   
                 CCGGGTCGGGTTCCGGGACCGAGTTCACCCTGACCATCTCCTCCCTCCAACCG 
               
               
                   
                   
                 GAGGACTTCGCGGTGTACTACTGTCAGCAGTACAACGATTGGCTGCCCGTGAC 
               
               
                   
                   
                 ATTTGGACAGGGGACGAAGGTGGAAATCAAA 
               
               
                 139113- aa 
                 1047 
                 EVQLVETGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 VH 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSS 
               
               
                 139113- aa 
                 1048 
                 ETTLTQSPATLSVSPGERATLSCRASQSVGSNLAWYQQKPGQGPRLLIYGAST 
               
               
                 VL 
                   
                 RATGIPARFSGSGSGTEFTLTISSLQPEDFAVYYCQQYNDWLPVTFGQGTKVE 
               
               
                   
                   
                 IK 
               
               
                 139113- aa 
                 1049 
                 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAVSGFALSNH 
               
               
                 Full CAR 
                   
                 GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSL 
               
               
                   
                   
                 RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSETTLTQ 
               
               
                   
                   
                 SPATLSVSPGERATLSCRASQSVGSNLAWYQQKPGQGPRLLIYGASTRATGIP 
               
               
                   
                   
                 ARFSGSGSGTEFTLTISSLQPEDFAVYYCQQYNDWLPVTFGQGTKVEIKTTTP 
               
               
                   
                   
                 APRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCG 
               
               
                   
                   
                 VLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCE 
               
               
                   
                   
                 LRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK 
               
               
                   
                   
                 NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH 
               
               
                   
                   
                 MQALPPR 
               
               
                 139113- nt 
                 1050 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAATTGGTGGAAACTGGAGGAGGACTTGTGCAACCTG 
               
               
                   
                   
                 GAGGATCATTGCGGCTCTCATGCGCTGTCTCCGGCTTCGCCCTGTCAAATCAC 
               
               
                   
                   
                 GGGATGTCGTGGGTCAGACGGGCCCCGGGAAAGGGTCTGGAATGGGTGTCGGG 
               
               
                   
                   
                 GATTGTGTACAGCGGCTCCACCTACTACGCCGCTTCGGTCAAGGGCCGCTTCA 
               
               
                   
                   
                 CTATTTCACGGGACAACAGCCGCAACACCCTCTATCTGCAAATGAACTCTCTC 
               
               
                   
                   
                 CGCCCGGAGGATACCGCCATCTACTACTGCTCCGCACACGGCGGCGAATCCGA 
               
               
                   
                   
                 CGTGTGGGGACAGGGAACCACTGTCACCGTGTCGTCCGCATCCGGTGGCGGAG 
               
               
                   
                   
                 GATCGGGTGGCCGGGCCTCCGGGGGCGGCGGCAGCGAGACTACCCTGACCCAG 
               
               
                   
                   
                 TCCCCTGCCACTCTGTCCGTGAGCCCGGGAGAGAGAGCCACCCTTAGCTGCCG 
               
               
                   
                   
                 GGCCAGCCAGAGCGTGGGCTCCAACCTGGCCTGGTACCAGCAGAAGCCAGGAC 
               
               
                   
                   
                 AGGGTCCCAGGCTGCTGATCTACGGAGCCTCCACTCGCGCGACCGGCATCCCC 
               
               
                   
                   
                 GCGAGGTTCTCCGGGTCGGGTTCCGGGACCGAGTTCACCCTGACCATCTCCTC 
               
               
                   
                   
                 CCTCCAACCGGAGGACTTCGCGGTGTACTACTGTCAGCAGTACAACGATTGGC 
               
               
                   
                   
                 TGCCCGTGACATTTGGACAGGGGACGAAGGTGGAAATCAAAACCACTACCCCA 
               
               
                   
                   
                 GCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCT 
               
               
                   
                   
                 GCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTC 
               
               
                   
                   
                 TTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGG 
               
               
                   
                   
                 GTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAA 
               
               
                   
                   
                 GCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAG 
               
               
                   
                   
                 AGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAA 
               
               
                   
                   
                 CTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCA 
               
               
                   
                   
                 GAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGC 
               
               
                   
                   
                 TGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAG 
               
               
                   
                   
                 AATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGC 
               
               
                   
                   
                 CTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACG 
               
               
                   
                   
                 GACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCAC 
               
               
                   
                   
                 ATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 139114 
               
            
           
           
               
               
               
            
               
                 139114- aa 
                 1051 
                 EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 ScFv domain 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSSASGGGGSGGRASGGGGSEIVLTQSPGTLSLSPGERATLSCRASQ 
               
               
                   
                   
                 SIGSSSLAWYQQKPGQAPRLLMYGASSRASGIPDRFSGSGSGTDFTLTISRLE 
               
               
                   
                   
                 PEDFAVYYCQQYAGSPPFTFGQGTKVEIK 
               
               
                 139114- nt 
                 1052 
                 GAAGTGCAATTGGTGGAATCTGGTGGAGGACTTGTGCAACCTGGAGGATCACT 
               
               
                 ScFv domain 
                   
                 GAGACTGTCATGCGCGGTGTCCGGTTTTGCCCTGAGCAATCATGGGATGTCGT 
               
               
                   
                   
                 GGGTCCGGCGCGCCCCCGGAAAGGGTCTGGAATGGGTGTCGGGTATCGTCTAC 
               
               
                   
                   
                 TCCGGGAGCACTTACTACGCCGCGAGCGTGAAGGGCCGCTTCACCATTTCCCG 
               
               
                   
                   
                 CGATAACTCCCGCAACACCCTGTACTTGCAAATGAACTCGCTCCGGCCTGAGG 
               
               
                   
                   
                 ACACTGCCATCTACTACTGCTCCGCACACGGAGGAGAATCCGACGTGTGGGGC 
               
               
                   
                   
                 CAGGGAACTACCGTGACCGTCAGCAGCGCCTCCGGCGGCGGGGGCTCAGGCGG 
               
               
                   
                   
                 ACGGGCTAGCGGCGGCGGTGGCTCCGAGATCGTGCTGACCCAGTCGCCTGGCA 
               
               
                   
                   
                 CTCTCTCGCTGAGCCCCGGGGAAAGGGCAACCCTGTCCTGTCGGGCCAGCCAG 
               
               
                   
                   
                 TCCATTGGATCATCCTCCCTCGCCTGGTATCAGCAGAAACCGGGACAGGCTCC 
               
               
                   
                   
                 GCGGCTGCTTATGTATGGGGCCAGCTCAAGAGCCTCCGGCATTCCCGACCGGT 
               
               
                   
                   
                 TCTCCGGGTCCGGTTCCGGCACCGATTTCACCCTGACTATCTCGAGGCTGGAG 
               
               
                   
                   
                 CCAGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGCGGGGTCCCCGCCGTT 
               
               
                   
                   
                 CACGTTCGGACAGGGAACCAAGGTCGAGATCAAG 
               
               
                 139114- aa 
                 1053 
                 EVQLVESGGGLVQPGGSLRLSCAVSGFALSNHGMSWVRRAPGKGLEWVSGIVY 
               
               
                 VH 
                   
                 SGSTYYAASVKGRFTISRDNSRNTLYLQMNSLRPEDTAIYYCSAHGGESDVWG 
               
               
                   
                   
                 QGTTVTVSS 
               
               
                 139114- aa 
                 1054 
                 EIVLTQSPGTLSLSPGERATLSCRASQSIGSSSLAWYQQKPGQAPRLLMYGAS 
               
               
                 VL 
                   
                 SRASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSPPFTFGQGTKV 
               
               
                   
                   
                 EIK 
               
               
                 139114- aa 
                 1055 
                 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAVSGFALSNH 
               
               
                 Full CAR 
                   
                 GMSWVRRAPGKGLEWVSGIVYSGSTYYAASVKGRFTISRDNSRNTLYLQMNSL 
               
               
                   
                   
                 RPEDTAIYYCSAHGGESDVWGQGTTVTVSSASGGGGSGGRASGGGGSEIVLTQ 
               
               
                   
                   
                 SPGTLSLSPGERATLSCRASQSIGSSSLAWYQQKPGQAPRLLMYGASSRASGI 
               
               
                   
                   
                 PDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYAGSPPFTFGQGTKVEIKTTT 
               
               
                   
                   
                 PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC 
               
               
                   
                   
                 GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC 
               
               
                   
                   
                 ELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR 
               
               
                   
                   
                 KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL 
               
               
                   
                   
                 HMQALPPR 
               
               
                 139114- nt 
                 1056 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAATTGGTGGAATCTGGTGGAGGACTTGTGCAACCTG 
               
               
                   
                   
                 GAGGATCACTGAGACTGTCATGCGCGGTGTCCGGTTTTGCCCTGAGCAATCAT 
               
               
                   
                   
                 GGGATGTCGTGGGTCCGGCGCGCCCCCGGAAAGGGTCTGGAATGGGTGTCGGG 
               
               
                   
                   
                 TATCGTCTACTCCGGGAGCACTTACTACGCCGCGAGCGTGAAGGGCCGCTTCA 
               
               
                   
                   
                 CCATTTCCCGCGATAACTCCCGCAACACCCTGTACTTGCAAATGAACTCGCTC 
               
               
                   
                   
                 CGGCCTGAGGACACTGCCATCTACTACTGCTCCGCACACGGAGGAGAATCCGA 
               
               
                   
                   
                 CGTGTGGGGCCAGGGAACTACCGTGACCGTCAGCAGCGCCTCCGGCGGCGGGG 
               
               
                   
                   
                 GCTCAGGCGGACGGGCTAGCGGCGGCGGTGGCTCCGAGATCGTGCTGACCCAG 
               
               
                   
                   
                 TCGCCTGGCACTCTCTCGCTGAGCCCCGGGGAAAGGGCAACCCTGTCCTGTCG 
               
               
                   
                   
                 GGCCAGCCAGTCCATTGGATCATCCTCCCTCGCCTGGTATCAGCAGAAACCGG 
               
               
                   
                   
                 GACAGGCTCCGCGGCTGCTTATGTATGGGGCCAGCTCAAGAGCCTCCGGCATT 
               
               
                   
                   
                 CCCGACCGGTTCTCCGGGTCCGGTTCCGGCACCGATTTCACCCTGACTATCTC 
               
               
                   
                   
                 GAGGCTGGAGCCAGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGCGGGGT 
               
               
                   
                   
                 CCCCGCCGTTCACGTTCGGACAGGGAACCAAGGTCGAGATCAAGACCACTACC 
               
               
                   
                   
                 CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTC 
               
               
                   
                   
                 CCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGG 
               
               
                   
                   
                 GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGC 
               
               
                   
                   
                 GGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAA 
               
               
                   
                   
                 GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC 
               
               
                   
                   
                 AAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGC 
               
               
                   
                   
                 GAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGG 
               
               
                   
                   
                 GCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACG 
               
               
                   
                   
                 TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA 
               
               
                   
                   
                 AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA 
               
               
                   
                   
                 AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG 
               
               
                   
                   
                 ACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT 
               
               
                   
                   
                 CACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 149362 
               
            
           
           
               
               
               
            
               
                 149362-aa 
                 1057 
                 QVQLQESGPGLVKPSETLSLTCTVSGGSISSSYYYWGWIRQPPGKGLEWIGSI 
               
               
                 ScFv domain 
                   
                 YYSGSAYYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCARHWQEWPD 
               
               
                   
                   
                 AFDIWGQGTMVTVSSGGGGSGGGGSGGGGSETTLTQSPAFMSATPGDKVIISC 
               
               
                   
                   
                 KASQDIDDAMNWYQQKPGEAPLFIIQSATSPVPGIPPRFSGSGFGTDFSLTIN 
               
               
                   
                   
                 NIESEDAAYYFCLQHDNFPLTFGQGTKLEIK 
               
               
                 149362-nt ScFv 
                 1058 
                 CAAGTGCAGCTTCAGGAAAGCGGACCGGGCCTGGTCAAGCCATCCGAAACTCT 
               
               
                 domain 
                   
                 CTCCCTGACTTGCACTGTGTCTGGCGGTTCCATCTCATCGTCGTACTACTACT 
               
               
                   
                   
                 GGGGCTGGATTAGGCAGCCGCCCGGAAAGGGACTGGAGTGGATCGGAAGCATC 
               
               
                   
                   
                 TACTATTCCGGCTCGGCGTACTACAACCCTAGCCTCAAGTCGAGAGTGACCAT 
               
               
                   
                   
                 CTCCGTGGATACCTCCAAGAACCAGTTTTCCCTGCGCCTGAGCTCCGTGACCG 
               
               
                   
                   
                 CCGCTGACACCGCCGTGTACTACTGTGCTCGGCATTGGCAGGAATGGCCCGAT 
               
               
                   
                   
                 GCCTTCGACATTTGGGGCCAGGGCACTATGGTCACTGTGTCATCCGGGGGTGG 
               
               
                   
                   
                 AGGCAGCGGGGGAGGAGGGTCCGGGGGGGGAGGTTCAGAGACAACCTTGACCC 
               
               
                   
                   
                 AGTCACCCGCATTCATGTCCGCCACTCCGGGAGACAAGGTCATCATCTCGTGC 
               
               
                   
                   
                 AAAGCGTCCCAGGATATCGACGATGCCATGAATTGGTACCAGCAGAAGCCTGG 
               
               
                   
                   
                 CGAAGCGCCGCTGTTCATTATCCAATCCGCAACCTCGCCCGTGCCTGGAATCC 
               
               
                   
                   
                 CACCGCGGTTCAGCGGCAGCGGTTTCGGAACCGACTTTTCCCTGACCATTAAC 
               
               
                   
                   
                 AACATTGAGTCCGAGGACGCCGCCTACTACTTCTGCCTGCAACACGACAACTT 
               
               
                   
                   
                 CCCTCTCACGTTCGGCCAGGGAACCAAGCTGGAAATCAAG 
               
               
                 149362-aa VH 
                 1059 
                 QVQLQESGPGLVKPSETLSLTCTVSGGSISSSYYYWGWIRQPPGKGLEWIGSI 
               
               
                   
                   
                 YYSGSAYYNPSLKSRVTISVDTSKNQFSLRLSSVTAADTAVYYCARHWQEWPD 
               
               
                   
                   
                 AFDIWGQGTMVTVSS 
               
               
                 149362-aa VL 
                 1060 
                 ETTLTQSPAFMSATPGDKVIISCKASQDIDDAMNWYQQKPGEAPLFIIQSATS 
               
               
                   
                   
                 PVPGIPPRFSGSGFGTDFSLTINNIESEDAAYYFCLQHDNFPLTFGQGTKLEI 
               
               
                   
                   
                 K 
               
               
                 149362-aa Full 
                 1061 
                 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSETLSLTCTVSGGSISSS 
               
               
                 CAR 
                   
                 YYYWGWIRQPPGKGLEWIGSIYYSGSAYYNPSLKSRVTISVDTSKNQFSLRLS 
               
               
                   
                   
                 SVTAADTAVYYCARHWQEWPDAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSET 
               
               
                   
                   
                 TLTQSPAFMSATPGDKVIISCKASQDIDDAMNWYQQKPGEAPLFIIQSATSPV 
               
               
                   
                   
                 PGIPPRFSGSGFGTDFSLTINNIESEDAAYYFCLQHDNFPLTFGQGTKLEIKT 
               
               
                   
                   
                 TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAG 
               
               
                   
                   
                 TCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEG 
               
               
                   
                   
                 GCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP 
               
               
                   
                   
                 RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD 
               
               
                   
                   
                 ALHMQALPPR 
               
               
                 149362-nt 
                 1062 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAGCTTCAGGAAAGCGGACCGGGCCTGGTCAAGCCAT 
               
               
                   
                   
                 CCGAAACTCTCTCCCTGACTTGCACTGTGTCTGGCGGTTCCATCTCATCGTCG 
               
               
                   
                   
                 TACTACTACTGGGGCTGGATTAGGCAGCCGCCCGGAAAGGGACTGGAGTGGAT 
               
               
                   
                   
                 CGGAAGCATCTACTATTCCGGCTCGGCGTACTACAACCCTAGCCTCAAGTCGA 
               
               
                   
                   
                 GAGTGACCATCTCCGTGGATACCTCCAAGAACCAGTTTTCCCTGCGCCTGAGC 
               
               
                   
                   
                 TCCGTGACCGCCGCTGACACCGCCGTGTACTACTGTGCTCGGCATTGGCAGGA 
               
               
                   
                   
                 ATGGCCCGATGCCTTCGACATTTGGGGCCAGGGCACTATGGTCACTGTGTCAT 
               
               
                   
                   
                 CCGGGGGTGGAGGCAGCGGGGGAGGAGGGTCCGGGGGGGGAGGTTCAGAGACA 
               
               
                   
                   
                 ACCTTGACCCAGTCACCCGCATTCATGTCCGCCACTCCGGGAGACAAGGTCAT 
               
               
                   
                   
                 CATCTCGTGCAAAGCGTCCCAGGATATCGACGATGCCATGAATTGGTACCAGC 
               
               
                   
                   
                 AGAAGCCTGGCGAAGCGCCGCTGTTCATTATCCAATCCGCAACCTCGCCCGTG 
               
               
                   
                   
                 CCTGGAATCCCACCGCGGTTCAGCGGCAGCGGTTTCGGAACCGACTTTTCCCT 
               
               
                   
                   
                 GACCATTAACAACATTGAGTCCGAGGACGCCGCCTACTACTTCTGCCTGCAAC 
               
               
                   
                   
                 ACGACAACTTCCCTCTCACGTTCGGCCAGGGAACCAAGCTGGAAATCAAGACC 
               
               
                   
                   
                 ACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCC 
               
               
                   
                   
                 TCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATA 
               
               
                   
                   
                 CCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGT 
               
               
                   
                   
                 ACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGG 
               
               
                   
                   
                 TCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGA 
               
               
                   
                   
                 CTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGC 
               
               
                   
                   
                 GGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAA 
               
               
                   
                   
                 GCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGT 
               
               
                   
                   
                 ACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCG 
               
               
                   
                   
                 CGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGAT 
               
               
                   
                   
                 GGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAG 
               
               
                   
                   
                 GCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGAC 
               
               
                   
                   
                 GCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 149363 
               
            
           
           
               
               
               
            
               
                 149363-aa 
                 1063 
                 VNLRESGPALVKPTQTLTLTCTFSGFSLRTSGMCVSWIRQPPGKALEWLARID 
               
               
                 ScFv domain 
                   
                 WDEDKFYSTSLKTRLTISKDTSDNQVVLRMTNMDPADTATYYCARSGAGGTSA 
               
               
                   
                   
                 TAFDIWGPGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTIT 
               
               
                   
                   
                 CRASQDIYNNLAWFQLKPGSAPRSLMYAANKSQSGVPSRFSGSASGTDFTLTI 
               
               
                   
                   
                 SSLQPEDFATYYCQHYYRFPYSFGQGTKLEIK 
               
               
                 149363-nt ScFv 
                 1064 
                 CAAGTCAATCTGCGCGAATCCGGCCCCGCCTTGGTCAAGCCTACCCAGACCCT 
               
               
                 domain 
                   
                 CACTCTGACCTGTACTTTCTCCGGCTTCTCCCTGCGGACTTCCGGGATGTGCG 
               
               
                   
                   
                 TGTCCTGGATCAGACAGCCTCCGGGAAAGGCCCTGGAGTGGCTCGCTCGCATT 
               
               
                   
                   
                 GACTGGGATGAGGACAAGTTCTACTCCACCTCACTCAAGACCAGGCTGACCAT 
               
               
                   
                   
                 CAGCAAAGATACCTCTGACAACCAAGTGGTGCTCCGCATGACCAACATGGACC 
               
               
                   
                   
                 CAGCCGACACTGCCACTTACTACTGCGCGAGGAGCGGAGCGGGCGGAACCTCC 
               
               
                   
                   
                 GCCACCGCCTTCGATATTTGGGGCCCGGGTACCATGGTCACCGTGTCAAGCGG 
               
               
                   
                   
                 AGGAGGGGGGTCCGGGGGCGGCGGTTCCGGGGGAGGCGGATCGGACATTCAGA 
               
               
                   
                   
                 TGACTCAGTCACCATCGTCCCTGAGCGCTAGCGTGGGCGACAGAGTGACAATC 
               
               
                   
                   
                 ACTTGCCGGGCATCCCAGGACATCTATAACAACCTTGCGTGGTTCCAGCTGAA 
               
               
                   
                   
                 GCCTGGTTCCGCACCGCGGTCACTTATGTACGCCGCCAACAAGAGCCAGTCGG 
               
               
                   
                   
                 GAGTGCCGTCCCGGTTTTCCGGTTCGGCCTCGGGAACTGACTTCACCCTGACG 
               
               
                   
                   
                 ATCTCCAGCCTGCAACCCGAGGATTTCGCCACCTACTACTGCCAGCACTACTA 
               
               
                   
                   
                 CCGCTTTCCCTACTCGTTCGGACAGGGAACCAAGCTGGAAATCAAG 
               
               
                 149363-aa VH 
                 1065 
                 QVNLRESGPALVKPTQTLTLTCTFSGFSLRTSGMCVSWIRQPPGKALEWLARI 
               
               
                   
                   
                 DWDEDKFYSTSLKTRLTISKDTSDNQVVLRMTNMDPADTATYYCARSGAGGTS 
               
               
                   
                   
                 ATAFDIWGPGTMVTVSS 
               
               
                 149363-aa VL 
                 1066 
                 DIQMTQSPSSLSASVGDRVTITCRASQDIYNNLAWFQLKPGSAPRSLMYAANK 
               
               
                   
                   
                 SQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQHYYRFPYSFGQGTKLEI 
               
               
                   
                   
                 K 
               
               
                 149363-aa Full 
                 1067 
                 MALPVTALLLPLALLLHAARPQVNLRESGPALVKPTQTLTLTCTFSGFSLRTS 
               
               
                 CAR 
                   
                 GMCVSWIRQPPGKALEWLARIDWDEDKFYSTSLKTRLTISKDTSDNQVVLRMT 
               
               
                   
                   
                 NMDPADTATYYCARSGAGGTSATAFDIWGPGTMVTVSSGGGGSGGGGSGGGGS 
               
               
                   
                   
                 DIQMTQSPSSLSASVGDRVTITCRASQDIYNNLAWFQLKPGSAPRSLMYAANK 
               
               
                   
                   
                 SQSGVPSRFSGSASGTDFTLTISSLQPEDFATYYCQHYYRFPYSFGQGTKLEI 
               
               
                   
                   
                 KTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL 
               
               
                   
                   
                 AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEE 
               
               
                   
                   
                 EGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGG 
               
               
                   
                   
                 KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT 
               
               
                   
                   
                 YDALHMQALPPR 
               
               
                 149363-nt 
                 1068 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTCAATCTGCGCGAATCCGGCCCCGCCTTGGTCAAGCCTA 
               
               
                   
                   
                 CCCAGACCCTCACTCTGACCTGTACTTTCTCCGGCTTCTCCCTGCGGACTTCC 
               
               
                   
                   
                 GGGATGTGCGTGTCCTGGATCAGACAGCCTCCGGGAAAGGCCCTGGAGTGGCT 
               
               
                   
                   
                 CGCTCGCATTGACTGGGATGAGGACAAGTTCTACTCCACCTCACTCAAGACCA 
               
               
                   
                   
                 GGCTGACCATCAGCAAAGATACCTCTGACAACCAAGTGGTGCTCCGCATGACC 
               
               
                   
                   
                 AACATGGACCCAGCCGACACTGCCACTTACTACTGCGCGAGGAGCGGAGCGGG 
               
               
                   
                   
                 CGGAACCTCCGCCACCGCCTTCGATATTTGGGGCCCGGGTACCATGGTCACCG 
               
               
                   
                   
                 TGTCAAGCGGAGGAGGGGGGTCCGGGGGCGGCGGTTCCGGGGGAGGCGGATCG 
               
               
                   
                   
                 GACATTCAGATGACTCAGTCACCATCGTCCCTGAGCGCTAGCGTGGGCGACAG 
               
               
                   
                   
                 AGTGACAATCACTTGCCGGGCATCCCAGGACATCTATAACAACCTTGCGTGGT 
               
               
                   
                   
                 TCCAGCTGAAGCCTGGTTCCGCACCGCGGTCACTTATGTACGCCGCCAACAAG 
               
               
                   
                   
                 AGCCAGTCGGGAGTGCCGTCCCGGTTTTCCGGTTCGGCCTCGGGAACTGACTT 
               
               
                   
                   
                 CACCCTGACGATCTCCAGCCTGCAACCCGAGGATTTCGCCACCTACTACTGCC 
               
               
                   
                   
                 AGCACTACTACCGCTTTCCCTACTCGTTCGGACAGGGAACCAAGCTGGAAATC 
               
               
                   
                   
                 AAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTC 
               
               
                   
                   
                 CCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCG 
               
               
                   
                   
                 TGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTG 
               
               
                   
                   
                 GCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAA 
               
               
                   
                   
                 GCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTG 
               
               
                   
                   
                 TGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAG 
               
               
                   
                   
                 GAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGC 
               
               
                   
                   
                 CTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAG 
               
               
                   
                   
                 AGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGG 
               
               
                   
                   
                 AAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGA 
               
               
                   
                   
                 TAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAG 
               
               
                   
                   
                 GCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACC 
               
               
                   
                   
                 TATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 149364 
               
            
           
           
               
               
               
            
               
                 149364-aa 
                 1069 
                 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISS 
               
               
                 ScFv domain 
                   
                 SSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKTIAAVYAF 
               
               
                   
                   
                 DIWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPLSLPVTPEEPASISCRS 
               
               
                   
                   
                 SQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTL 
               
               
                   
                   
                 KISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIK 
               
               
                 149364-nt ScFv 
                 1070 
                 GAAGTGCAGCTTGTCGAATCCGGGGGGGGACTGGTCAAGCCGGGCGGATCACT 
               
               
                 domain 
                   
                 GAGACTGTCCTGCGCCGCGAGCGGCTTCACGTTCTCCTCCTACTCCATGAACT 
               
               
                   
                   
                 GGGTCCGCCAAGCCCCCGGGAAGGGACTGGAATGGGTGTCCTCTATCTCCTCG 
               
               
                   
                   
                 TCGTCGTCCTACATCTACTACGCCGACTCCGTGAAGGGAAGATTCACCATTTC 
               
               
                   
                   
                 CCGCGACAACGCAAAGAACTCACTGTACTTGCAAATGAACTCACTCCGGGCCG 
               
               
                   
                   
                 AAGATACTGCTGTGTACTATTGCGCCAAGACTATTGCCGCCGTCTACGCTTTC 
               
               
                   
                   
                 GACATCTGGGGCCAGGGAACCACCGTGACTGTGTCGTCCGGTGGTGGTGGCTC 
               
               
                   
                   
                 GGGCGGAGGAGGAAGCGGCGGCGGGGGGTCCGAGATTGTGCTGACCCAGTCGC 
               
               
                   
                   
                 CACTGAGCCTCCCTGTGACCCCCGAGGAACCCGCCAGCATCAGCTGCCGGTCC 
               
               
                   
                   
                 AGCCAGTCCCTGCTCCACTCCAACGGATACAATTACCTCGATTGGTACCTTCA 
               
               
                   
                   
                 GAAGCCTGGACAAAGCCCGCAGCTGCTCATCTACTTGGGATCAAACCGCGCGT 
               
               
                   
                   
                 CAGGAGTGCCTGACCGGTTCTCCGGCTCGGGCAGCGGTACCGATTTCACCCTG 
               
               
                   
                   
                 AAAATCTCCAGGGTGGAGGCAGAGGACGTGGGAGTGTATTACTGTATGCAGGC 
               
               
                   
                   
                 GCTGCAGACTCCGTACACATTTGGGCAGGGCACCAAGCTGGAGATCAAG 
               
               
                 149364-aa VH 
                 1071 
                 EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISS 
               
               
                   
                   
                 SSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKTIAAVYAF 
               
               
                   
                   
                 DIWGQGTTVTVSS 
               
               
                 149364-aa VL 
                 1072 
                 EIVLTQSPLSLPVTPEEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLI 
               
               
                   
                   
                 YLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQG 
               
               
                   
                   
                 TKLEIK 
               
               
                 149364-aa Full 
                 1073 
                 MALPVTALLLPLALLLHAARPEVQLVESGGGLVKPGGSLRLSCAASGFTFSSY 
               
               
                 CAR 
                   
                 SMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNS 
               
               
                   
                   
                 LRAEDTAVYYCAKTIAAVYAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSEIVL 
               
               
                   
                   
                 TQSPLSLPVTPEEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGS 
               
               
                   
                   
                 NRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLE 
               
               
                   
                   
                 IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP 
               
               
                   
                   
                 LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE 
               
               
                   
                   
                 EEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG 
               
               
                   
                   
                 GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD 
               
               
                   
                   
                 TYDALHMQALPPR 
               
               
                 149364-nt 
                 1074 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAGCTTGTCGAATCCGGGGGGGGACTGGTCAAGCCGG 
               
               
                   
                   
                 GCGGATCACTGAGACTGTCCTGCGCCGCGAGCGGCTTCACGTTCTCCTCCTAC 
               
               
                   
                   
                 TCCATGAACTGGGTCCGCCAAGCCCCCGGGAAGGGACTGGAATGGGTGTCCTC 
               
               
                   
                   
                 TATCTCCTCGTCGTCGTCCTACATCTACTACGCCGACTCCGTGAAGGGAAGAT 
               
               
                   
                   
                 TCACCATTTCCCGCGACAACGCAAAGAACTCACTGTACTTGCAAATGAACTCA 
               
               
                   
                   
                 CTCCGGGCCGAAGATACTGCTGTGTACTATTGCGCCAAGACTATTGCCGCCGT 
               
               
                   
                   
                 CTACGCTTTCGACATCTGGGGCCAGGGAACCACCGTGACTGTGTCGTCCGGTG 
               
               
                   
                   
                 GTGGTGGCTCGGGCGGAGGAGGAAGCGGCGGCGGGGGGTCCGAGATTGTGCTG 
               
               
                   
                   
                 ACCCAGTCGCCACTGAGCCTCCCTGTGACCCCCGAGGAACCCGCCAGCATCAG 
               
               
                   
                   
                 CTGCCGGTCCAGCCAGTCCCTGCTCCACTCCAACGGATACAATTACCTCGATT 
               
               
                   
                   
                 GGTACCTTCAGAAGCCTGGACAAAGCCCGCAGCTGCTCATCTACTTGGGATCA 
               
               
                   
                   
                 AACCGCGCGTCAGGAGTGCCTGACCGGTTCTCCGGCTCGGGCAGCGGTACCGA 
               
               
                   
                   
                 TTTCACCCTGAAAATCTCCAGGGTGGAGGCAGAGGACGTGGGAGTGTATTACT 
               
               
                   
                   
                 GTATGCAGGCGCTGCAGACTCCGTACACATTTGGGCAGGGCACCAAGCTGGAG 
               
               
                   
                   
                 ATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC 
               
               
                   
                   
                 CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG 
               
               
                   
                   
                 CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCT 
               
               
                   
                   
                 CTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTG 
               
               
                   
                   
                 TAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC 
               
               
                   
                   
                 CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAG 
               
               
                   
                   
                 GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC 
               
               
                   
                   
                 AGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGA 
               
               
                   
                   
                 GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC 
               
               
                   
                   
                 GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA 
               
               
                   
                   
                 GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA 
               
               
                   
                   
                 GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC 
               
               
                   
                   
                 ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 149365 
               
            
           
           
               
               
               
            
               
                 149365-aa 
                 1075 
                 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISS 
               
               
                 ScFv domain 
                   
                 SGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLRGAFDI 
               
               
                   
                   
                 WGQGTMVTVSSGGGGSGGGGSGGGGSSYVLTQSPSVSAAPGYTATISCGGNNI 
               
               
                   
                   
                 GTKSVHWYQQKPGQAPLLVIRDDSVRPSKIPGRFSGSNSGNMATLTISGVQAG 
               
               
                   
                   
                 DEADFYCQVWDSDSEHVVFGGGTKLTVL 
               
               
                 149365-nt ScFv 
                 1076 
                 GAAGTCCAGCTCGTGGAGTCCGGCGGAGGCCTTGTGAAGCCTGGAGGTTCGCT 
               
               
                 domain 
                   
                 GAGACTGTCCTGCGCCGCCTCCGGCTTCACCTTCTCCGACTACTACATGTCCT 
               
               
                   
                   
                 GGATCAGACAGGCCCCGGGAAAGGGCCTGGAATGGGTGTCCTACATCTCGTCA 
               
               
                   
                   
                 TCGGGCAGCACTATCTACTACGCGGACTCAGTGAAGGGGCGGTTCACCATTTC 
               
               
                   
                   
                 CCGGGATAACGCGAAGAACTCGCTGTATCTGCAAATGAACTCACTGAGGGCCG 
               
               
                   
                   
                 AGGACACCGCCGTGTACTACTGCGCCCGCGATCTCCGCGGGGCATTTGACATC 
               
               
                   
                   
                 TGGGGACAGGGAACCATGGTCACAGTGTCCAGCGGAGGGGGAGGATCGGGTGG 
               
               
                   
                   
                 CGGAGGTTCCGGGGGTGGAGGCTCCTCCTACGTGCTGACTCAGAGCCCAAGCG 
               
               
                   
                   
                 TCAGCGCTGCGCCCGGTTACACGGCAACCATCTCCTGTGGCGGAAACAACATT 
               
               
                   
                   
                 GGGACCAAGTCTGTGCACTGGTATCAGCAGAAGCCGGGCCAAGCTCCCCTGTT 
               
               
                   
                   
                 GGTGATCCGCGATGACTCCGTGCGGCCTAGCAAAATTCCGGGACGGTTCTCCG 
               
               
                   
                   
                 GCTCCAACAGCGGCAATATGGCCACTCTCACCATCTCGGGAGTGCAGGCCGGA 
               
               
                   
                   
                 GATGAAGCCGACTTCTACTGCCAAGTCTGGGACTCAGACTCCGAGCATGTGGT 
               
               
                   
                   
                 GTTCGGGGGCGGAACCAAGCTGACTGTGCTC 
               
               
                 149365-aa VH 
                 1077 
                 EVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISS 
               
               
                   
                   
                 SGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDLRGAFDI 
               
               
                   
                   
                 WGQGTMVTVSS 
               
               
                 149365-aa VL 
                 1078 
                 SYVLTQSPSVSAAPGYTATISCGGNNIGTKSVHWYQQKPGQAPLLVIRDDSVR 
               
               
                   
                   
                 PSKIPGRFSGSNSGNMATLTISGVQAGDEADFYCQVWDSDSEHVVFGGGTKLT 
               
               
                   
                   
                 VL 
               
               
                 149365-aa Full 
                 1079 
                 MALPVTALLLPLALLLHAARPEVQLVESGGGLVKPGGSLRLSCAASGFTFSDY 
               
               
                 CAR 
                   
                 YMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNS 
               
               
                   
                   
                 LRAEDTAVYYCARDLRGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSSYVLTQ 
               
               
                   
                   
                 SPSVSAAPGYTATISCGGNNIGTKSVHWYQQKPGQAPLLVIRDDSVRPSKIPG 
               
               
                   
                   
                 RFSGSNSGNMATLTISGVQAGDEADFYCQVWDSDSEHVVFGGGTKLTVLTTTP 
               
               
                   
                   
                 APRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCG 
               
               
                   
                   
                 VLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCE 
               
               
                   
                   
                 LRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK 
               
               
                   
                   
                 NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALH 
               
               
                   
                   
                 MQALPPR 
               
               
                 149365-nt 
                 1080 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTCCAGCTCGTGGAGTCCGGCGGAGGCCTTGTGAAGCCTG 
               
               
                   
                   
                 GAGGTTCGCTGAGACTGTCCTGCGCCGCCTCCGGCTTCACCTTCTCCGACTAC 
               
               
                   
                   
                 TACATGTCCTGGATCAGACAGGCCCCGGGAAAGGGCCTGGAATGGGTGTCCTA 
               
               
                   
                   
                 CATCTCGTCATCGGGCAGCACTATCTACTACGCGGACTCAGTGAAGGGGCGGT 
               
               
                   
                   
                 TCACCATTTCCCGGGATAACGCGAAGAACTCGCTGTATCTGCAAATGAACTCA 
               
               
                   
                   
                 CTGAGGGCCGAGGACACCGCCGTGTACTACTGCGCCCGCGATCTCCGCGGGGC 
               
               
                   
                   
                 ATTTGACATCTGGGGACAGGGAACCATGGTCACAGTGTCCAGCGGAGGGGGAG 
               
               
                   
                   
                 GATCGGGTGGCGGAGGTTCCGGGGGTGGAGGCTCCTCCTACGTGCTGACTCAG 
               
               
                   
                   
                 AGCCCAAGCGTCAGCGCTGCGCCCGGTTACACGGCAACCATCTCCTGTGGCGG 
               
               
                   
                   
                 AAACAACATTGGGACCAAGTCTGTGCACTGGTATCAGCAGAAGCCGGGCCAAG 
               
               
                   
                   
                 CTCCCCTGTTGGTGATCCGCGATGACTCCGTGCGGCCTAGCAAAATTCCGGGA 
               
               
                   
                   
                 CGGTTCTCCGGCTCCAACAGCGGCAATATGGCCACTCTCACCATCTCGGGAGT 
               
               
                   
                   
                 GCAGGCCGGAGATGAAGCCGACTTCTACTGCCAAGTCTGGGACTCAGACTCCG 
               
               
                   
                   
                 AGCATGTGGTGTTCGGGGGCGGAACCAAGCTGACTGTGCTCACCACTACCCCA 
               
               
                   
                   
                 GCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCT 
               
               
                   
                   
                 GCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTC 
               
               
                   
                   
                 TTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGG 
               
               
                   
                   
                 GTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAA 
               
               
                   
                   
                 GCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAG 
               
               
                   
                   
                 AGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAA 
               
               
                   
                   
                 CTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCA 
               
               
                   
                   
                 GAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGC 
               
               
                   
                   
                 TGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAG 
               
               
                   
                   
                 AATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGC 
               
               
                   
                   
                 CTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACG 
               
               
                   
                   
                 GACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCAC 
               
               
                   
                   
                 ATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 149366 
               
            
           
           
               
               
               
            
               
                 149366-aa 
                 1081 
                 QVQLVQSGAEVKKPGASVKVSCKPSGYTVTSHYIHWVRRAPGQGLEWMGMINP 
               
               
                 ScFv domain 
                   
                 SGGVTAYSQTLQGRVTMTSDTSSSTVYMELSSLRSEDTAMYYCAREGSGSGWY 
               
               
                   
                   
                 FDFWGRGTLVTVSSGGGGSGGGGSGGGGSSYVLTQPPSVSVSPGQTASITCSG 
               
               
                   
                   
                 DGLSKKYVSWYQQKAGQSPVVLISRDKERPSGIPDRFSGSNSADTATLTISGT 
               
               
                   
                   
                 QAMDEADYYCQAWDDTTVVFGGGTKLTVL 
               
               
                 149366-nt ScFv 
                 1082 
                 CAAGTGCAGCTGGTGCAGAGCGGGGCCGAAGTCAAGAAGCCGGGAGCCTCCGT 
               
               
                 domain 
                   
                 GAAAGTGTCCTGCAAGCCTTCGGGATACACCGTGACCTCCCACTACATTCATT 
               
               
                   
                   
                 GGGTCCGCCGCGCCCCCGGCCAAGGACTCGAGTGGATGGGCATGATCAACCCT 
               
               
                   
                   
                 AGCGGCGGAGTGACCGCGTACAGCCAGACGCTGCAGGGACGCGTGACTATGAC 
               
               
                   
                   
                 CTCGGATACCTCCTCCTCCACCGTCTATATGGAACTGTCCAGCCTGCGGTCCG 
               
               
                   
                   
                 AGGATACCGCCATGTACTACTGCGCCCGGGAAGGATCAGGCTCCGGGTGGTAT 
               
               
                   
                   
                 TTCGACTTCTGGGGAAGAGGCACCCTCGTGACTGTGTCATCTGGGGGAGGGGG 
               
               
                   
                   
                 TTCCGGTGGTGGCGGATCGGGAGGAGGCGGTTCATCCTACGTGCTGACCCAGC 
               
               
                   
                   
                 CACCCTCCGTGTCCGTGAGCCCCGGCCAGACTGCATCGATTACATGTAGCGGC 
               
               
                   
                   
                 GACGGCCTCTCCAAGAAATACGTGTCGTGGTACCAGCAGAAGGCCGGACAGAG 
               
               
                   
                   
                 CCCGGTGGTGCTGATCTCAAGAGATAAGGAGCGGCCTAGCGGAATCCCGGACA 
               
               
                   
                   
                 GGTTCTCGGGTTCCAACTCCGCGGACACTGCTACTCTGACCATCTCGGGGACC 
               
               
                   
                   
                 CAGGCTATGGACGAAGCCGATTACTACTGCCAAGCCTGGGACGACACTACTGT 
               
               
                   
                   
                 CGTGTTTGGAGGGGGCACCAAGTTGACCGTCCTT 
               
               
                 149366-aa VH 
                 1083 
                 QVQLVQSGAEVKKPGASVKVSCKPSGYTVTSHYIHWVRRAPGQGLEWMGMINP 
               
               
                   
                   
                 SGGVTAYSQTLQGRVTMTSDTSSSTVYMELSSLRSEDTAMYYCAREGSGSGWY 
               
               
                   
                   
                 FDFWGRGTLVTVSS 
               
               
                 149366-aa VL 
                 1084 
                 SYVLTQPPSVSVSPGQTASITCSGDGLSKKYVSWYQQKAGQSPVVLISRDKER 
               
               
                   
                   
                 PSGIPDRFSGSNSADTATLTISGTQAMDEADYYCQAWDDTTVVFGGGTKLTVL 
               
               
                 149366-aa Full 
                 1085 
                 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKPSGYTVTSH 
               
               
                 CAR 
                   
                 YIHWVRRAPGQGLEWMGMINPSGGVTAYSQTLQGRVTMTSDTSSSTVYMELSS 
               
               
                   
                   
                 LRSEDTAMYYCAREGSGSGWYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSSYV 
               
               
                   
                   
                 LTQPPSVSVSPGQTASITCSGDGLSKKYVSWYQQKAGQSPVVLISRDKERPSG 
               
               
                   
                   
                 IPDRFSGSNSADTATLTISGTQAMDEADYYCQAWDDTTVVFGGGTKLTVLTTT 
               
               
                   
                   
                 PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC 
               
               
                   
                   
                 GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC 
               
               
                   
                   
                 ELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR 
               
               
                   
                   
                 KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL 
               
               
                   
                   
                 HMQALPPR 
               
               
                 149366-nt 
                 1086 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAGCTGGTGCAGAGCGGGGCCGAAGTCAAGAAGCCGG 
               
               
                   
                   
                 GAGCCTCCGTGAAAGTGTCCTGCAAGCCTTCGGGATACACCGTGACCTCCCAC 
               
               
                   
                   
                 TACATTCATTGGGTCCGCCGCGCCCCCGGCCAAGGACTCGAGTGGATGGGCAT 
               
               
                   
                   
                 GATCAACCCTAGCGGCGGAGTGACCGCGTACAGCCAGACGCTGCAGGGACGCG 
               
               
                   
                   
                 TGACTATGACCTCGGATACCTCCTCCTCCACCGTCTATATGGAACTGTCCAGC 
               
               
                   
                   
                 CTGCGGTCCGAGGATACCGCCATGTACTACTGCGCCCGGGAAGGATCAGGCTC 
               
               
                   
                   
                 CGGGTGGTATTTCGACTTCTGGGGAAGAGGCACCCTCGTGACTGTGTCATCTG 
               
               
                   
                   
                 GGGGAGGGGGTTCCGGTGGTGGCGGATCGGGAGGAGGCGGTTCATCCTACGTG 
               
               
                   
                   
                 CTGACCCAGCCACCCTCCGTGTCCGTGAGCCCCGGCCAGACTGCATCGATTAC 
               
               
                   
                   
                 ATGTAGCGGCGACGGCCTCTCCAAGAAATACGTGTCGTGGTACCAGCAGAAGG 
               
               
                   
                   
                 CCGGACAGAGCCCGGTGGTGCTGATCTCAAGAGATAAGGAGCGGCCTAGCGGA 
               
               
                   
                   
                 ATCCCGGACAGGTTCTCGGGTTCCAACTCCGCGGACACTGCTACTCTGACCAT 
               
               
                   
                   
                 CTCGGGGACCCAGGCTATGGACGAAGCCGATTACTACTGCCAAGCCTGGGACG 
               
               
                   
                   
                 ACACTACTGTCGTGTTTGGAGGGGGCACCAAGTTGACCGTCCTTACCACTACC 
               
               
                   
                   
                 CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTC 
               
               
                   
                   
                 CCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGG 
               
               
                   
                   
                 GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGC 
               
               
                   
                   
                 GGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAA 
               
               
                   
                   
                 GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC 
               
               
                   
                   
                 AAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGC 
               
               
                   
                   
                 GAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGG 
               
               
                   
                   
                 GCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACG 
               
               
                   
                   
                 TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA 
               
               
                   
                   
                 AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA 
               
               
                   
                   
                 AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG 
               
               
                   
                   
                 ACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT 
               
               
                   
                   
                 CACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 149367 
               
            
           
           
               
               
               
            
               
                 149367-aa 
                 1087 
                 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYI 
               
               
                 ScFv domain 
                   
                 YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAGIAARL 
               
               
                   
                   
                 RGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIVMTQSPSSVSASVGDRVII 
               
               
                   
                   
                 TCRASQGIRNWLAWYQQKPGKAPNLLIYAASNLQSGVPSRFSGSGSGADFTLT 
               
               
                   
                   
                 ISSLQPEDVATYYCQKYNSAPFTFGPGTKVDIK 
               
               
                 149367-nt ScFv 
                 1088 
                 CAAGTGCAGCTTCAGGAGAGCGGCCCGGGACTCGTGAAGCCGTCCCAGACCCT 
               
               
                 domain 
                   
                 GTCCCTGACTTGCACCGTGTCGGGAGGAAGCATCTCGAGCGGAGGCTACTATT 
               
               
                   
                   
                 GGTCGTGGATTCGGCAGCACCCTGGAAAGGGCCTGGAATGGATCGGCTACATC 
               
               
                   
                   
                 TACTACTCCGGCTCGACCTACTACAACCCATCGCTGAAGTCCAGAGTGACAAT 
               
               
                   
                   
                 CTCAGTGGACACGTCCAAGAATCAGTTCAGCCTGAAGCTCTCTTCCGTGACTG 
               
               
                   
                   
                 CGGCCGACACCGCCGTGTACTACTGCGCACGCGCTGGAATTGCCGCCCGGCTG 
               
               
                   
                   
                 AGGGGTGCCTTCGACATTTGGGGACAGGGCACCATGGTCACCGTGTCCTCCGG 
               
               
                   
                   
                 CGGCGGAGGTTCCGGGGGTGGAGGCTCAGGAGGAGGGGGGTCCGACATCGTCA 
               
               
                   
                   
                 TGACTCAGTCGCCCTCAAGCGTCAGCGCGTCCGTCGGGGACAGAGTGATCATC 
               
               
                   
                   
                 ACCTGTCGGGCGTCCCAGGGAATTCGCAACTGGCTGGCCTGGTATCAGCAGAA 
               
               
                   
                   
                 GCCCGGAAAGGCCCCCAACCTGTTGATCTACGCCGCCTCAAACCTCCAATCCG 
               
               
                   
                   
                 GGGTGCCGAGCCGCTTCAGCGGCTCCGGTTCGGGTGCCGATTTCACTCTGACC 
               
               
                   
                   
                 ATCTCCTCCCTGCAACCTGAAGATGTGGCTACCTACTACTGCCAAAAGTACAA 
               
               
                   
                   
                 CTCCGCACCTTTTACTTTCGGACCGGGGACCAAAGTGGACATTAAG 
               
               
                 149367-aa VH 
                 1089 
                 QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGGYYWSWIRQHPGKGLEWIGYI 
               
               
                   
                   
                 YYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARAGIAARL 
               
               
                   
                   
                 RGAFDIWGQGTMVTVSS 
               
               
                 149367-aa VL 
                 1090 
                 DIVMTQSPSSVSASVGDRVIITCRASQGIRNWLAWYQQKPGKAPNLLIYAASN 
               
               
                   
                   
                 LQSGVPSRFSGSGSGADFTLTISSLQPEDVATYYCQKYNSAPFTFGPGTKVDI 
               
               
                   
                   
                 K 
               
               
                 149367-aa Full 
                 1091 
                 MALPVTALLLPLALLLHAARPQVQLQESGPGLVKPSQTLSLTCTVSGGSISSG 
               
               
                 CAR 
                   
                 GYYWSWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLS 
               
               
                   
                   
                 SVTAADTAVYYCARAGIAARLRGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGS 
               
               
                   
                   
                 DIVMTQSPSSVSASVGDRVIITCRASQGIRNWLAWYQQKPGKAPNLLIYAASN 
               
               
                   
                   
                 LQSGVPSRFSGSGSGADFTLTISSLQPEDVATYYCQKYNSAPFTFGPGTKVDI 
               
               
                   
                   
                 KTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL 
               
               
                   
                   
                 AGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEE 
               
               
                   
                   
                 EGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGG 
               
               
                   
                   
                 KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT 
               
               
                   
                   
                 YDALHMQALPPR 
               
               
                 149367-nt 
                 1092 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAGCTTCAGGAGAGCGGCCCGGGACTCGTGAAGCCGT 
               
               
                   
                   
                 CCCAGACCCTGTCCCTGACTTGCACCGTGTCGGGAGGAAGCATCTCGAGCGGA 
               
               
                   
                   
                 GGCTACTATTGGTCGTGGATTCGGCAGCACCCTGGAAAGGGCCTGGAATGGAT 
               
               
                   
                   
                 CGGCTACATCTACTACTCCGGCTCGACCTACTACAACCCATCGCTGAAGTCCA 
               
               
                   
                   
                 GAGTGACAATCTCAGTGGACACGTCCAAGAATCAGTTCAGCCTGAAGCTCTCT 
               
               
                   
                   
                 TCCGTGACTGCGGCCGACACCGCCGTGTACTACTGCGCACGCGCTGGAATTGC 
               
               
                   
                   
                 CGCCCGGCTGAGGGGTGCCTTCGACATTTGGGGACAGGGCACCATGGTCACCG 
               
               
                   
                   
                 TGTCCTCCGGCGGCGGAGGTTCCGGGGGTGGAGGCTCAGGAGGAGGGGGGTCC 
               
               
                   
                   
                 GACATCGTCATGACTCAGTCGCCCTCAAGCGTCAGCGCGTCCGTCGGGGACAG 
               
               
                   
                   
                 AGTGATCATCACCTGTCGGGCGTCCCAGGGAATTCGCAACTGGCTGGCCTGGT 
               
               
                   
                   
                 ATCAGCAGAAGCCCGGAAAGGCCCCCAACCTGTTGATCTACGCCGCCTCAAAC 
               
               
                   
                   
                 CTCCAATCCGGGGTGCCGAGCCGCTTCAGCGGCTCCGGTTCGGGTGCCGATTT 
               
               
                   
                   
                 CACTCTGACCATCTCCTCCCTGCAACCTGAAGATGTGGCTACCTACTACTGCC 
               
               
                   
                   
                 AAAAGTACAACTCCGCACCTTTTACTTTCGGACCGGGGACCAAAGTGGACATT 
               
               
                   
                   
                 AAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTC 
               
               
                   
                   
                 CCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCG 
               
               
                   
                   
                 TGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTG 
               
               
                   
                   
                 GCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAA 
               
               
                   
                   
                 GCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTG 
               
               
                   
                   
                 TGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAG 
               
               
                   
                   
                 GAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGC 
               
               
                   
                   
                 CTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAG 
               
               
                   
                   
                 AGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGG 
               
               
                   
                   
                 AAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGA 
               
               
                   
                   
                 TAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAG 
               
               
                   
                   
                 GCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACC 
               
               
                   
                   
                 TATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 149368 
               
            
           
           
               
               
               
            
               
                 149368-aa 
                 1093 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIP 
               
               
                 ScFv domain 
                   
                 IFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRGGYQLLR 
               
               
                   
                   
                 WDVGLLRSAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSSYVLTQPPSVSVAPG 
               
               
                   
                   
                 QTARITCGGNNIGSKSVHWYQQKPGQAPVLVLYGKNNRPSGVPDRFSGSRSGT 
               
               
                   
                   
                 TASLTITGAQAEDEADYYCSSRDSSGDHLRVFGTGTKVTVL 
               
               
                 149368-nt ScFv 
                 1094 
                 CAAGTGCAGCTGGTCCAGTCGGGCGCCGAGGTCAAGAAGCCCGGGAGCTCTGT 
               
               
                 domain 
                   
                 GAAAGTGTCCTGCAAGGCCTCCGGGGGCACCTTTAGCTCCTACGCCATCTCCT 
               
               
                   
                   
                 GGGTCCGCCAAGCACCGGGTCAAGGCCTGGAGTGGATGGGGGGAATTATCCCT 
               
               
                   
                   
                 ATCTTCGGCACTGCCAACTACGCCCAGAAGTTCCAGGGACGCGTGACCATTAC 
               
               
                   
                   
                 CGCGGACGAATCCACCTCCACCGCTTATATGGAGCTGTCCAGCTTGCGCTCGG 
               
               
                   
                   
                 AAGATACCGCCGTGTACTACTGCGCCCGGAGGGGTGGATACCAGCTGCTGAGA 
               
               
                   
                   
                 TGGGACGTGGGCCTCCTGCGGTCGGCGTTCGACATCTGGGGCCAGGGCACTAT 
               
               
                   
                   
                 GGTCACTGTGTCCAGCGGAGGAGGCGGATCGGGAGGCGGCGGATCAGGGGGAG 
               
               
                   
                   
                 GCGGTTCCAGCTACGTGCTTACTCAACCCCCTTCGGTGTCCGTGGCCCCGGGA 
               
               
                   
                   
                 CAGACCGCCAGAATCACTTGCGGAGGAAACAACATTGGGTCCAAGAGCGTGCA 
               
               
                   
                   
                 TTGGTACCAGCAGAAGCCAGGACAGGCCCCTGTGCTGGTGCTCTACGGGAAGA 
               
               
                   
                   
                 ACAATCGGCCCAGCGGAGTGCCGGACAGGTTCTCGGGTTCACGCTCCGGTACA 
               
               
                   
                   
                 ACCGCTTCACTGACTATCACCGGGGCCCAGGCAGAGGATGAAGCGGACTACTA 
               
               
                   
                   
                 CTGTTCCTCCCGGGATTCATCCGGCGACCACCTCCGGGTGTTCGGAACCGGAA 
               
               
                   
                   
                 CGAAGGTCACCGTGCTG 
               
               
                 149368-aa VH 
                 1095 
                 QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIP 
               
               
                   
                   
                 IFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARRGGYQLLR 
               
               
                   
                   
                 WDVGLLRSAFDIWGQGTMVTVSS 
               
               
                 149368-aa VL 
                 1096 
                 SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVLYGKNNR 
               
               
                   
                   
                 PSGVPDRFSGSRSGTTASLTITGAQAEDEADYYCSSRDSSGDHLRVFGTGTKV 
               
               
                   
                   
                 TVL 
               
               
                 149368-aa Full 
                 1097 
                 MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGSSVKVSCKASGGTFSSY 
               
               
                 CAR 
                   
                 AISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSS 
               
               
                   
                   
                 LRSEDTAVYYCARRGGYQLLRWDVGLLRSAFDIWGQGTMVTVSSGGGGSGGGG 
               
               
                   
                   
                 SGGGGSSYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVL 
               
               
                   
                   
                 YGKNNRPSGVPDRFSGSRSGTTASLTITGAQAEDEADYYCSSRDSSGDHLRVF 
               
               
                   
                   
                 GTGTKVTVLTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFAC 
               
               
                   
                   
                 DIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGC 
               
               
                   
                   
                 SCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRR 
               
               
                   
                   
                 GRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQG 
               
               
                   
                   
                 LSTATKDTYDALHMQALPPR 
               
               
                 149368-nt 
                 1098 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCCAAGTGCAGCTGGTCCAGTCGGGCGCCGAGGTCAAGAAGCCCG 
               
               
                   
                   
                 GGAGCTCTGTGAAAGTGTCCTGCAAGGCCTCCGGGGGCACCTTTAGCTCCTAC 
               
               
                   
                   
                 GCCATCTCCTGGGTCCGCCAAGCACCGGGTCAAGGCCTGGAGTGGATGGGGGG 
               
               
                   
                   
                 AATTATCCCTATCTTCGGCACTGCCAACTACGCCCAGAAGTTCCAGGGACGCG 
               
               
                   
                   
                 TGACCATTACCGCGGACGAATCCACCTCCACCGCTTATATGGAGCTGTCCAGC 
               
               
                   
                   
                 TTGCGCTCGGAAGATACCGCCGTGTACTACTGCGCCCGGAGGGGTGGATACCA 
               
               
                   
                   
                 GCTGCTGAGATGGGACGTGGGCCTCCTGCGGTCGGCGTTCGACATCTGGGGCC 
               
               
                   
                   
                 AGGGCACTATGGTCACTGTGTCCAGCGGAGGAGGCGGATCGGGAGGCGGCGGA 
               
               
                   
                   
                 TCAGGGGGAGGCGGTTCCAGCTACGTGCTTACTCAACCCCCTTCGGTGTCCGT 
               
               
                   
                   
                 GGCCCCGGGACAGACCGCCAGAATCACTTGCGGAGGAAACAACATTGGGTCCA 
               
               
                   
                   
                 AGAGCGTGCATTGGTACCAGCAGAAGCCAGGACAGGCCCCTGTGCTGGTGCTC 
               
               
                   
                   
                 TACGGGAAGAACAATCGGCCCAGCGGAGTGCCGGACAGGTTCTCGGGTTCACG 
               
               
                   
                   
                 CTCCGGTACAACCGCTTCACTGACTATCACCGGGGCCCAGGCAGAGGATGAAG 
               
               
                   
                   
                 CGGACTACTACTGTTCCTCCCGGGATTCATCCGGCGACCACCTCCGGGTGTTC 
               
               
                   
                   
                 GGAACCGGAACGAAGGTCACCGTGCTGACCACTACCCCAGCACCGAGGCCACC 
               
               
                   
                   
                 CACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCAT 
               
               
                   
                   
                 GTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGC 
               
               
                   
                   
                 GATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTC 
               
               
                   
                   
                 ACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCT 
               
               
                   
                   
                 TTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGT 
               
               
                   
                   
                 TCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATT 
               
               
                   
                   
                 CAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACA 
               
               
                   
                   
                 ACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGA 
               
               
                   
                   
                 GGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGG 
               
               
                   
                   
                 CCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTG 
               
               
                   
                   
                 GTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGA 
               
               
                   
                   
                 CTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCC 
               
               
                   
                   
                 GCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 149369 
               
            
           
           
               
               
               
            
               
                 149369-aa 
                 1099 
                 EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRT 
               
               
                 ScFv domain 
                   
                 YYRSKWYSFYAISLKSRIIINPDTSKNQFSLQLKSVTPEDTAVYYCARSSPEG 
               
               
                   
                   
                 LFLYWFDPWGQGTLVTVSSGGDGSGGGGSGGGGSSSELTQDPAVSVALGQTIR 
               
               
                   
                   
                 ITCQGDSLGNYYATWYQQKPGQAPVLVIYGTNNRPSGIPDRFSASSSGNTASL 
               
               
                   
                   
                 TITGAQAEDEADYYCNSRDSSGHHLLFGTGTKVTVL 
               
               
                 149369-nt ScFv 
                 1100 
                 GAAGTGCAGCTCCAACAGTCAGGACCGGGGCTCGTGAAGCCATCCCAGACCCT 
               
               
                 domain 
                   
                 GTCCCTGACTTGTGCCATCTCGGGAGATAGCGTGTCATCGAACTCCGCCGCCT 
               
               
                   
                   
                 GGAACTGGATTCGGCAGAGCCCGTCCCGCGGACTGGAGTGGCTTGGAAGGACC 
               
               
                   
                   
                 TACTACCGGTCCAAGTGGTACTCTTTCTACGCGATCTCGCTGAAGTCCCGCAT 
               
               
                   
                   
                 TATCATTAACCCTGATACCTCCAAGAATCAGTTCTCCCTCCAACTGAAATCCG 
               
               
                   
                   
                 TCACCCCCGAGGACACAGCAGTGTATTACTGCGCACGGAGCAGCCCCGAAGGA 
               
               
                   
                   
                 CTGTTCCTGTATTGGTTTGACCCCTGGGGCCAGGGGACTCTTGTGACCGTGTC 
               
               
                   
                   
                 GAGCGGCGGAGATGGGTCCGGTGGCGGTGGTTCGGGGGGCGGCGGATCATCAT 
               
               
                   
                   
                 CCGAACTGACCCAGGACCCGGCTGTGTCCGTGGCGCTGGGACAAACCATCCGC 
               
               
                   
                   
                 ATTACGTGCCAGGGAGACTCCCTGGGCAACTACTACGCCACTTGGTACCAGCA 
               
               
                   
                   
                 GAAGCCGGGCCAAGCCCCTGTGTTGGTCATCTACGGGACCAACAACAGACCTT 
               
               
                   
                   
                 CCGGCATCCCCGACCGGTTCAGCGCTTCGTCCTCCGGCAACACTGCCAGCCTG 
               
               
                   
                   
                 ACCATCACTGGAGCGCAGGCCGAAGATGAGGCCGACTACTACTGCAACAGCAG 
               
               
                   
                   
                 AGACTCCTCGGGTCATCACCTCTTGTTCGGAACTGGAACCAAGGTCACCGTGC 
               
               
                   
                   
                 TG 
               
               
                 149369-aa VH 
                 1101 
                 EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRT 
               
               
                   
                   
                 YYRSKWYSFYAISLKSRIIINPDTSKNQFSLQLKSVTPEDTAVYYCARSSPEG 
               
               
                   
                   
                 LFLYWFDPWGQGTLVTVSS 
               
               
                 149369-aa VL 
                 1102 
                 SSELTQDPAVSVALGQTIRITCQGDSLGNYYATWYQQKPGQAPVLVIYGTNNR 
               
               
                   
                   
                 PSGIPDRFSASSSGNTASLTITGAQAEDEADYYCNSRDSSGHHLLFGTGTKVT 
               
               
                   
                   
                 VL 
               
               
                 149369-aa Full 
                 1103 
                 MALPVTALLLPLALLLHAARPEVQLQQSGPGLVKPSQTLSLTCAISGDSVSSN 
               
               
                 CAR 
                   
                 SAAWNWIRQSPSRGLEWLGRTYYRSKWYSFYAISLKSRIIINPDTSKNQFSLQ 
               
               
                   
                   
                 LKSVTPEDTAVYYCARSSPEGLFLYWFDPWGQGTLVTVSSGGDGSGGGGSGGG 
               
               
                   
                   
                 GSSSELTQDPAVSVALGQTIRITCQGDSLGNYYATWYQQKPGQAPVLVIYGTN 
               
               
                   
                   
                 NRPSGIPDRFSASSSGNTASLTITGAQAEDEADYYCNSRDSSGHHLLFGTGTK 
               
               
                   
                   
                 VTVLTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW 
               
               
                   
                   
                 APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP 
               
               
                   
                   
                 EEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPE 
               
               
                   
                   
                 MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT 
               
               
                   
                   
                 KDTYDALHMQALPPR 
               
               
                 149369-nt 
                 1104 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 Full CAR 
                   
                 CGCTCGGCCCGAAGTGCAGCTCCAACAGTCAGGACCGGGGCTCGTGAAGCCAT 
               
               
                   
                   
                 CCCAGACCCTGTCCCTGACTTGTGCCATCTCGGGAGATAGCGTGTCATCGAAC 
               
               
                   
                   
                 TCCGCCGCCTGGAACTGGATTCGGCAGAGCCCGTCCCGCGGACTGGAGTGGCT 
               
               
                   
                   
                 TGGAAGGACCTACTACCGGTCCAAGTGGTACTCTTTCTACGCGATCTCGCTGA 
               
               
                   
                   
                 AGTCCCGCATTATCATTAACCCTGATACCTCCAAGAATCAGTTCTCCCTCCAA 
               
               
                   
                   
                 CTGAAATCCGTCACCCCCGAGGACACAGCAGTGTATTACTGCGCACGGAGCAG 
               
               
                   
                   
                 CCCCGAAGGACTGTTCCTGTATTGGTTTGACCCCTGGGGCCAGGGGACTCTTG 
               
               
                   
                   
                 TGACCGTGTCGAGCGGCGGAGATGGGTCCGGTGGCGGTGGTTCGGGGGGCGGC 
               
               
                   
                   
                 GGATCATCATCCGAACTGACCCAGGACCCGGCTGTGTCCGTGGCGCTGGGACA 
               
               
                   
                   
                 AACCATCCGCATTACGTGCCAGGGAGACTCCCTGGGCAACTACTACGCCACTT 
               
               
                   
                   
                 GGTACCAGCAGAAGCCGGGCCAAGCCCCTGTGTTGGTCATCTACGGGACCAAC 
               
               
                   
                   
                 AACAGACCTTCCGGCATCCCCGACCGGTTCAGCGCTTCGTCCTCCGGCAACAC 
               
               
                   
                   
                 TGCCAGCCTGACCATCACTGGAGCGCAGGCCGAAGATGAGGCCGACTACTACT 
               
               
                   
                   
                 GCAACAGCAGAGACTCCTCGGGTCATCACCTCTTGTTCGGAACTGGAACCAAG 
               
               
                   
                   
                 GTCACCGTGCTGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTAC 
               
               
                   
                   
                 CATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTG 
               
               
                   
                   
                 GTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGG 
               
               
                   
                   
                 GCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCT 
               
               
                   
                   
                 TTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCA 
               
               
                   
                   
                 TGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCA 
               
               
                   
                   
                 GAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGA 
               
               
                   
                   
                 TGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTG 
               
               
                   
                   
                 GTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAA 
               
               
                   
                   
                 ATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCT 
               
               
                   
                   
                 CCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAAC 
               
               
                   
                   
                 GCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACC 
               
               
                   
                   
                 AAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1978-A4 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1105 
                 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-A4 - aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVEGSGSLD 
               
               
                 ScFv domain 
                   
                 YWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGERATLSCRAS 
               
               
                   
                   
                 QSVSSAYLAWYQQKPGQPPRLLISGASTRATGIPDRFGGSGSGTDFTLTISRL 
               
               
                   
                   
                 EPEDFAVYYCQHYGSSFNGSSLFTFGQGTRLEIK 
               
               
                 BCMA_EBB- 
                 1106 
                 GAAGTGCAGCTCGTGGAGTCAGGAGGCGGCCTGGTCCAGCCGGGAGGGTCCCT 
               
               
                 C1978-A4 - nt 
                   
                 TAGACTGTCATGCGCCGCAAGCGGATTCACTTTCTCCTCCTATGCCATGAGCT 
               
               
                 ScFv domain 
                   
                 GGGTCCGCCAAGCCCCCGGAAAGGGACTGGAATGGGTGTCCGCCATCTCGGGG 
               
               
                   
                   
                 TCTGGAGGCTCAACTTACTACGCTGACTCCGTGAAGGGACGGTTCACCATTAG 
               
               
                   
                   
                 CCGCGACAACTCCAAGAACACCCTCTACCTCCAAATGAACTCCCTGCGGGCCG 
               
               
                   
                   
                 AGGATACCGCCGTCTACTACTGCGCCAAAGTGGAAGGTTCAGGATCGCTGGAC 
               
               
                   
                   
                 TACTGGGGACAGGGTACTCTCGTGACCGTGTCATCGGGCGGAGGAGGTTCCGG 
               
               
                   
                   
                 CGGTGGCGGCTCCGGCGGCGGAGGGTCGGAGATCGTGATGACCCAGAGCCCTG 
               
               
                   
                   
                 GTACTCTGAGCCTTTCGCCGGGAGAAAGGGCCACCCTGTCCTGCCGCGCTTCC 
               
               
                   
                   
                 CAATCCGTGTCCTCCGCGTACTTGGCGTGGTACCAGCAGAAGCCGGGACAGCC 
               
               
                   
                   
                 CCCTCGGCTGCTGATCAGCGGGGCCAGCACCCGGGCAACCGGAATCCCAGACA 
               
               
                   
                   
                 GATTCGGGGGTTCCGGCAGCGGCACAGATTTCACCCTGACTATTTCGAGGTTG 
               
               
                   
                   
                 GAGCCCGAGGACTTTGCGGTGTATTACTGTCAGCACTACGGGTCGTCCTTTAA 
               
               
                   
                   
                 TGGCTCCAGCCTGTTCACGTTCGGACAGGGGACCCGCCTGGAAATCAAG 
               
               
                 BCMA_EBB- 
                 1107 
                 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-A4 - aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVEGSGSLD 
               
               
                 VH 
                   
                 YWGQGTLVTVSS 
               
               
                 BCMA_EBB- 
                 1108 
                 EIVMTQSPGTLSLSPGERATLSCRASQSVSSAYLAWYQQKPGQPPRLLISGAS 
               
               
                 C1978-A4 - aa 
                   
                 TRATGIPDRFGGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSFNGSSLFTFGQ 
               
               
                 VL 
                   
                 GTRLEIK 
               
               
                 BCMA_EBB- 
                 1109 
                 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1978-A4 - aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                 Full CART 
                   
                 LRAEDTAVYYCAKVEGSGSLDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMT 
               
               
                   
                   
                 QSPGTLSLSPGERATLSCRASQSVSSAYLAWYQQKPGQPPRLLISGASTRATG 
               
               
                   
                   
                 IPDRFGGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSFNGSSLFTFGQGTRLE 
               
               
                   
                   
                 IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP 
               
               
                   
                   
                 LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE 
               
               
                   
                   
                 EEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG 
               
               
                   
                   
                 GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD 
               
               
                   
                   
                 TYDALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1110 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1978-A4 - nt 
                   
                 CGCTCGGCCCGAAGTGCAGCTCGTGGAGTCAGGAGGCGGCCTGGTCCAGCCGG 
               
               
                 Full CART 
                   
                 GAGGGTCCCTTAGACTGTCATGCGCCGCAAGCGGATTCACTTTCTCCTCCTAT 
               
               
                   
                   
                 GCCATGAGCTGGGTCCGCCAAGCCCCCGGAAAGGGACTGGAATGGGTGTCCGC 
               
               
                   
                   
                 CATCTCGGGGTCTGGAGGCTCAACTTACTACGCTGACTCCGTGAAGGGACGGT 
               
               
                   
                   
                 TCACCATTAGCCGCGACAACTCCAAGAACACCCTCTACCTCCAAATGAACTCC 
               
               
                   
                   
                 CTGCGGGCCGAGGATACCGCCGTCTACTACTGCGCCAAAGTGGAAGGTTCAGG 
               
               
                   
                   
                 ATCGCTGGACTACTGGGGACAGGGTACTCTCGTGACCGTGTCATCGGGCGGAG 
               
               
                   
                   
                 GAGGTTCCGGCGGTGGCGGCTCCGGCGGCGGAGGGTCGGAGATCGTGATGACC 
               
               
                   
                   
                 CAGAGCCCTGGTACTCTGAGCCTTTCGCCGGGAGAAAGGGCCACCCTGTCCTG 
               
               
                   
                   
                 CCGCGCTTCCCAATCCGTGTCCTCCGCGTACTTGGCGTGGTACCAGCAGAAGC 
               
               
                   
                   
                 CGGGACAGCCCCCTCGGCTGCTGATCAGCGGGGCCAGCACCCGGGCAACCGGA 
               
               
                   
                   
                 ATCCCAGACAGATTCGGGGGTTCCGGCAGCGGCACAGATTTCACCCTGACTAT 
               
               
                   
                   
                 TTCGAGGTTGGAGCCCGAGGACTTTGCGGTGTATTACTGTCAGCACTACGGGT 
               
               
                   
                   
                 CGTCCTTTAATGGCTCCAGCCTGTTCACGTTCGGACAGGGGACCCGCCTGGAA 
               
               
                   
                   
                 ATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC 
               
               
                   
                   
                 CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG 
               
               
                   
                   
                 CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCT 
               
               
                   
                   
                 CTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTG 
               
               
                   
                   
                 TAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC 
               
               
                   
                   
                 CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAG 
               
               
                   
                   
                 GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC 
               
               
                   
                   
                 AGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGA 
               
               
                   
                   
                 GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC 
               
               
                   
                   
                 GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA 
               
               
                   
                   
                 GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA 
               
               
                   
                   
                 GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC 
               
               
                   
                   
                 ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1978-G1 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1111 
                 EVQLVETGGGLVQPGGSLRLSCAASGITFSRYPMSWVRQAPGKGLEWV 
               
               
                 C1978-G1 - aa 
                   
                 SGISDSGVSTYYADSAKGRFTISRDNSKNTLFLQMSSLRDEDTAVYYCV 
               
               
                 ScFv domain 
                   
                 TRAGSEASDIWGQGTMVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSL 
               
               
                   
                   
                 SPGERATLSCRASQSVSNSLAWYQQKPGQAPRLLIYDASSRATGIPDRFS 
               
               
                   
                   
                 GSGSGTDFTLTISRLEPEDFAIYYCQQFGTSSGLTFGGGTKLEIK 
               
               
                 BCMA_EBB- 
                 1112 
                 GAAGTGCAACTGGTGGAAACCGGTGGCGGCCTGGTGCAGCCTGGAGGATCATT 
               
               
                 C1978-G1 - nt 
                   
                 GAGGCTGTCATGCGCGGCCAGCGGTATTACCTTCTCCCGGTACCCCATGTCCT 
               
               
                 ScFv domain 
                   
                 GGGTCAGACAGGCCCCGGGGAAAGGGCTTGAATGGGTGTCCGGGATCTCGGAC 
               
               
                   
                   
                 TCCGGTGTCAGCACTTACTACGCCGACTCCGCCAAGGGACGCTTCACCATTTC 
               
               
                   
                   
                 CCGGGACAACTCGAAGAACACCCTGTTCCTCCAAATGAGCTCCCTCCGGGACG 
               
               
                   
                   
                 AGGATACTGCAGTGTACTACTGCGTGACCCGCGCCGGGTCCGAGGCGTCTGAC 
               
               
                   
                   
                 ATTTGGGGACAGGGCACTATGGTCACCGTGTCGTCCGGCGGAGGGGGCTCGGG 
               
               
                   
                   
                 AGGCGGTGGCAGCGGAGGAGGAGGGTCCGAGATCGTGCTGACCCAATCCCCGG 
               
               
                   
                   
                 CCACCCTCTCGCTGAGCCCTGGAGAAAGGGCAACCTTGTCCTGTCGCGCGAGC 
               
               
                   
                   
                 CAGTCCGTGAGCAACTCCCTGGCCTGGTACCAGCAGAAGCCCGGACAGGCTCC 
               
               
                   
                   
                 GAGACTTCTGATCTACGACGCTTCGAGCCGGGCCACTGGAATCCCCGACCGCT 
               
               
                   
                   
                 TTTCGGGGTCCGGCTCAGGAACCGATTTCACCCTGACAATCTCACGGCTGGAG 
               
               
                   
                   
                 CCAGAGGATTTCGCCATCTATTACTGCCAGCAGTTCGGTACTTCCTCCGGCCT 
               
               
                   
                   
                 GACTTTCGGAGGCGGCACGAAGCTCGAAATCAAG 
               
               
                 BCMA_EBB- 
                 1113 
                 EVQLVETGGGLVQPGGSLRLSCAASGITFSRYPMSWVRQAPGKGLEWVSGISD 
               
               
                 C1978-G1 - aa 
                   
                 SGVSTYYADSAKGRFTISRDNSKNTLFLQMSSLRDEDTAVYYCVTRAGSEASD 
               
               
                 VH 
                   
                 IWGQGTMVTVSS 
               
               
                 BCMA_EBB- 
                 1114 
                 EIVLTQSPATLSLSPGERATLSCRASQSVSNSLAWYQQKPGQAPRLLIYDASS 
               
               
                 C1978-G1 - aa 
                   
                 RATGIPDRFSGSGSGTDFTLTISRLEPEDFAIYYCQQFGTSSGLTFGGGTKLE 
               
               
                 VL 
                   
                 IK 
               
               
                 BCMA_EBB- 
                 1115 
                 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAASGIT 
               
               
                 C1978-G1 - aa 
                   
                 FSRYPMSWVRQAPGKGLEWVSGISDSGVSTYYADSAKGRFTISRDNSK 
               
               
                 Full CART 
                   
                 NTLFLQMSSLRDEDTAVYYCVTRAGSEASDIVVGQGTMVTVSSGGGGS 
               
               
                   
                   
                 GGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQSVSNSLAWYQQK 
               
               
                   
                   
                 PGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAIYYCQQ 
               
               
                   
                   
                 FGTSSGLTFGGGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGG 
               
               
                   
                   
                 AVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQ 
               
               
                   
                   
                 PFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQ 
               
               
                   
                   
                 LYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK 
               
               
                   
                   
                 MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1116 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1978-G1 - nt 
                   
                 CGCTCGGCCCGAAGTGCAACTGGTGGAAACCGGTGGCGGCCTGGTGCAGCCTG 
               
               
                 Full CART 
                   
                 GAGGATCATTGAGGCTGTCATGCGCGGCCAGCGGTATTACCTTCTCCCGGTAC 
               
               
                   
                   
                 CCCATGTCCTGGGTCAGACAGGCCCCGGGGAAAGGGCTTGAATGGGTGTCCGG 
               
               
                   
                   
                 GATCTCGGACTCCGGTGTCAGCACTTACTACGCCGACTCCGCCAAGGGACGCT 
               
               
                   
                   
                 TCACCATTTCCCGGGACAACTCGAAGAACACCCTGTTCCTCCAAATGAGCTCC 
               
               
                   
                   
                 CTCCGGGACGAGGATACTGCAGTGTACTACTGCGTGACCCGCGCCGGGTCCGA 
               
               
                   
                   
                 GGCGTCTGACATTTGGGGACAGGGCACTATGGTCACCGTGTCGTCCGGCGGAG 
               
               
                   
                   
                 GGGGCTCGGGAGGCGGTGGCAGCGGAGGAGGAGGGTCCGAGATCGTGCTGACC 
               
               
                   
                   
                 CAATCCCCGGCCACCCTCTCGCTGAGCCCTGGAGAAAGGGCAACCTTGTCCTG 
               
               
                   
                   
                 TCGCGCGAGCCAGTCCGTGAGCAACTCCCTGGCCTGGTACCAGCAGAAGCCCG 
               
               
                   
                   
                 GACAGGCTCCGAGACTTCTGATCTACGACGCTTCGAGCCGGGCCACTGGAATC 
               
               
                   
                   
                 CCCGACCGCTTTTCGGGGTCCGGCTCAGGAACCGATTTCACCCTGACAATCTC 
               
               
                   
                   
                 ACGGCTGGAGCCAGAGGATTTCGCCATCTATTACTGCCAGCAGTTCGGTACTT 
               
               
                   
                   
                 CCTCCGGCCTGACTTTCGGAGGCGGCACGAAGCTCGAAATCAAGACCACTACC 
               
               
                   
                   
                 CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTC 
               
               
                   
                   
                 CCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGG 
               
               
                   
                   
                 GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGC 
               
               
                   
                   
                 GGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAA 
               
               
                   
                   
                 GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC 
               
               
                   
                   
                 AAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGC 
               
               
                   
                   
                 GAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGG 
               
               
                   
                   
                 GCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACG 
               
               
                   
                   
                 TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA 
               
               
                   
                   
                 AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA 
               
               
                   
                   
                 AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG 
               
               
                   
                   
                 ACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT 
               
               
                   
                   
                 CACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1979-C1 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1117 
                 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1979-C1 - aa 
                   
                 SGGSTYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAIYYCARATYKRELR 
               
               
                 ScFv domain 
                   
                 YYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTVSLSPGERAT 
               
               
                   
                   
                 LSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFT 
               
               
                   
                   
                 LTISRLEPEDSAVYYCQQYHSSPSWTFGQGTRLEIK 
               
               
                 BCMA_EBB- 
                 1118 
                 CAAGTGCAGCTCGTGGAATCGGGTGGCGGACTGGTGCAGCCGGGGGGCTCACT 
               
               
                 C1979-C1 - nt 
                   
                 TAGACTGTCCTGCGCGGCCAGCGGATTCACTTTCTCCTCCTACGCCATGTCCT 
               
               
                 ScFv domain 
                   
                 GGGTCAGACAGGCCCCTGGAAAGGGCCTGGAATGGGTGTCCGCAATCAGCGGC 
               
               
                   
                   
                 AGCGGCGGCTCGACCTATTACGCGGATTCAGTGAAGGGCAGATTCACCATTTC 
               
               
                   
                   
                 CCGGGACAACGCCAAGAACTCCTTGTACCTTCAAATGAACTCCCTCCGCGCGG 
               
               
                   
                   
                 AAGATACCGCAATCTACTACTGCGCTCGGGCCACTTACAAGAGGGAACTGCGC 
               
               
                   
                   
                 TACTACTACGGGATGGACGTCTGGGGCCAGGGAACCATGGTCACCGTGTCCAG 
               
               
                   
                   
                 CGGAGGAGGAGGATCGGGAGGAGGCGGTAGCGGGGGTGGAGGGTCGGAGATCG 
               
               
                   
                   
                 TGATGACCCAGTCCCCCGGCACTGTGTCGCTGTCCCCCGGCGAACGGGCCACC 
               
               
                   
                   
                 CTGTCATGTCGGGCCAGCCAGTCAGTGTCGTCAAGCTTCCTCGCCTGGTACCA 
               
               
                   
                   
                 GCAGAAACCGGGACAAGCTCCCCGCCTGCTGATCTACGGAGCCAGCAGCCGGG 
               
               
                   
                   
                 CCACCGGTATTCCTGACCGGTTCTCCGGTTCGGGGTCCGGGACCGACTTTACT 
               
               
                   
                   
                 CTGACTATCTCTCGCCTCGAGCCAGAGGACTCCGCCGTGTATTACTGCCAGCA 
               
               
                   
                   
                 GTACCACTCCTCCCCGTCCTGGACGTTCGGACAGGGCACAAGGCTGGAGATTA 
               
               
                   
                   
                 AG 
               
               
                 BCMA_EBB- 
                 1119 
                 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1979-C1 - aa 
                   
                 SGGSTYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAIYYCARATYKRELR 
               
               
                 VH 
                   
                 YYYGMDVWGQGTMVTVSS 
               
               
                 BCMA_EBB- 
                 1120 
                 EIVMTQSPGTVSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGAS 
               
               
                 C1979-C1 - aa 
                   
                 SRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTRL 
               
               
                 VL 
                   
                 EIK 
               
               
                 BCMA_EBB- 
                 1121 
                 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1979-C1 - aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNAKNSLYLQMNS 
               
               
                 Full CART 
                   
                 LRAEDTAIYYCARATYKRELRYYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGG 
               
               
                   
                   
                 SEIVMTQSPGTVSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGA 
               
               
                   
                   
                 SSRATGIPDRFSGSGSGTDFTLTISRLEPEDSAVYYCQQYHSSPSWTFGQGTR 
               
               
                   
                   
                 LEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW 
               
               
                   
                   
                 APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP 
               
               
                   
                   
                 EEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPE 
               
               
                   
                   
                 MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT 
               
               
                   
                   
                 KDTYDALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1122 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1979-C1 - nt 
                   
                 CGCTCGGCCCCAAGTGCAGCTCGTGGAATCGGGTGGCGGACTGGTGCAGCCGG 
               
               
                 Full CART 
                   
                 GGGGCTCACTTAGACTGTCCTGCGCGGCCAGCGGATTCACTTTCTCCTCCTAC 
               
               
                   
                   
                 GCCATGTCCTGGGTCAGACAGGCCCCTGGAAAGGGCCTGGAATGGGTGTCCGC 
               
               
                   
                   
                 AATCAGCGGCAGCGGCGGCTCGACCTATTACGCGGATTCAGTGAAGGGCAGAT 
               
               
                   
                   
                 TCACCATTTCCCGGGACAACGCCAAGAACTCCTTGTACCTTCAAATGAACTCC 
               
               
                   
                   
                 CTCCGCGCGGAAGATACCGCAATCTACTACTGCGCTCGGGCCACTTACAAGAG 
               
               
                   
                   
                 GGAACTGCGCTACTACTACGGGATGGACGTCTGGGGCCAGGGAACCATGGTCA 
               
               
                   
                   
                 CCGTGTCCAGCGGAGGAGGAGGATCGGGAGGAGGCGGTAGCGGGGGTGGAGGG 
               
               
                   
                   
                 TCGGAGATCGTGATGACCCAGTCCCCCGGCACTGTGTCGCTGTCCCCCGGCGA 
               
               
                   
                   
                 ACGGGCCACCCTGTCATGTCGGGCCAGCCAGTCAGTGTCGTCAAGCTTCCTCG 
               
               
                   
                   
                 CCTGGTACCAGCAGAAACCGGGACAAGCTCCCCGCCTGCTGATCTACGGAGCC 
               
               
                   
                   
                 AGCAGCCGGGCCACCGGTATTCCTGACCGGTTCTCCGGTTCGGGGTCCGGGAC 
               
               
                   
                   
                 CGACTTTACTCTGACTATCTCTCGCCTCGAGCCAGAGGACTCCGCCGTGTATT 
               
               
                   
                   
                 ACTGCCAGCAGTACCACTCCTCCCCGTCCTGGACGTTCGGACAGGGCACAAGG 
               
               
                   
                   
                 CTGGAGATTAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTAC 
               
               
                   
                   
                 CATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTG 
               
               
                   
                   
                 GTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGG 
               
               
                   
                   
                 GCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCT 
               
               
                   
                   
                 TTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCA 
               
               
                   
                   
                 TGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCA 
               
               
                   
                   
                 GAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGA 
               
               
                   
                   
                 TGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTG 
               
               
                   
                   
                 GTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAA 
               
               
                   
                   
                 ATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCT 
               
               
                   
                   
                 CCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAAC 
               
               
                   
                   
                 GCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACC 
               
               
                   
                   
                 AAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1978-C7 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1123 
                 EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-C7 - aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNTLKAEDTAVYYCARATYKRELR 
               
               
                 ScFv domain 
                   
                 YYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPSTLSLSPGESAT 
               
               
                   
                   
                 LSCRASQSVSTTFLAWYQQKPGQAPRLLIYGSSNRATGIPDRFSGSGSGTDFT 
               
               
                   
                   
                 LTIRRLEPEDFAVYYCQQYHSSPSWTFGQGTKVEIK 
               
               
                 BCMA_EBB- 
                 1124 
                 GAGGTGCAGCTTGTGGAAACCGGTGGCGGACTGGTGCAGCCCGGAGGAAGCCT 
               
               
                 C1978-C7 - nt 
                   
                 CAGGCTGTCCTGCGCCGCGTCCGGCTTCACCTTCTCCTCGTACGCCATGTCCT 
               
               
                 ScFv domain 
                   
                 GGGTCCGCCAGGCCCCCGGAAAGGGCCTGGAATGGGTGTCCGCCATCTCTGGA 
               
               
                   
                   
                 AGCGGAGGTTCCACGTACTACGCGGACAGCGTCAAGGGAAGGTTCACAATCTC 
               
               
                   
                   
                 CCGCGATAATTCGAAGAACACTCTGTACCTTCAAATGAACACCCTGAAGGCCG 
               
               
                   
                   
                 AGGACACTGCTGTGTACTACTGCGCACGGGCCACCTACAAGAGAGAGCTCCGG 
               
               
                   
                   
                 TACTACTACGGAATGGACGTCTGGGGCCAGGGAACTACTGTGACCGTGTCCTC 
               
               
                   
                   
                 GGGAGGGGGTGGCTCCGGGGGGGGCGGCTCCGGCGGAGGCGGTTCCGAGATTG 
               
               
                   
                   
                 TGCTGACCCAGTCACCTTCAACTCTGTCGCTGTCCCCGGGAGAGAGCGCTACT 
               
               
                   
                   
                 CTGAGCTGCCGGGCCAGCCAGTCCGTGTCCACCACCTTCCTCGCCTGGTATCA 
               
               
                   
                   
                 GCAGAAGCCGGGGCAGGCACCACGGCTCTTGATCTACGGGTCAAGCAACAGAG 
               
               
                   
                   
                 CGACCGGAATTCCTGACCGCTTCTCGGGGAGCGGTTCAGGCACCGACTTCACC 
               
               
                   
                   
                 CTGACTATCCGGCGCCTGGAACCCGAAGATTTCGCCGTGTATTACTGTCAACA 
               
               
                   
                   
                 GTACCACTCCTCGCCGTCCTGGACCTTTGGCCAAGGAACCAAAGTGGAAATCA 
               
               
                   
                   
                 AG 
               
               
                 BCMA_EBB- 
                 1125 
                 EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-C7 - aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNTLKAEDTAVYYCARATYKRELR 
               
               
                 VH 
                   
                 YYYGMDVWGQGTTVTVSS 
               
               
                 BCMA_EBB- 
                 1126 
                 EIVLTQSPSTLSLSPGESATLSCRASQSVSTTFLAWYQQKPGQAPRLLIYGSS 
               
               
                 C1978-C7 - aa 
                   
                 NRATGIPDRFSGSGSGTDFTLTIRRLEPEDFAVYYCQQYHSSPSWTFGQGTKV 
               
               
                 VL 
                   
                 EIK 
               
               
                 BCMA_EBB- 
                 1127 
                 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1978-C7 - aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNT 
               
               
                 Full CART 
                   
                 LKAEDTAVYYCARATYKRELRYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGG 
               
               
                   
                   
                 SEIVLTQSPSTLSLSPGESATLSCRASQSVSTTFLAWYQQKPGQAPRLLIYGS 
               
               
                   
                   
                 SNRATGIPDRFSGSGSGTDFTLTIRRLEPEDFAVYYCQQYHSSPSWTFGQGTK 
               
               
                   
                   
                 VEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW 
               
               
                   
                   
                 APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP 
               
               
                   
                   
                 EEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPE 
               
               
                   
                   
                 MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT 
               
               
                   
                   
                 KDTYDALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1128 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1978-C7 - nt 
                   
                 CGCTCGGCCCGAGGTGCAGCTTGTGGAAACCGGTGGCGGACTGGTGCAGCCCG 
               
               
                 Full CART 
                   
                 GAGGAAGCCTCAGGCTGTCCTGCGCCGCGTCCGGCTTCACCTTCTCCTCGTAC 
               
               
                   
                   
                 GCCATGTCCTGGGTCCGCCAGGCCCCCGGAAAGGGCCTGGAATGGGTGTCCGC 
               
               
                   
                   
                 CATCTCTGGAAGCGGAGGTTCCACGTACTACGCGGACAGCGTCAAGGGAAGGT 
               
               
                   
                   
                 TCACAATCTCCCGCGATAATTCGAAGAACACTCTGTACCTTCAAATGAACACC 
               
               
                   
                   
                 CTGAAGGCCGAGGACACTGCTGTGTACTACTGCGCACGGGCCACCTACAAGAG 
               
               
                   
                   
                 AGAGCTCCGGTACTACTACGGAATGGACGTCTGGGGCCAGGGAACTACTGTGA 
               
               
                   
                   
                 CCGTGTCCTCGGGAGGGGGTGGCTCCGGGGGGGGCGGCTCCGGCGGAGGCGGT 
               
               
                   
                   
                 TCCGAGATTGTGCTGACCCAGTCACCTTCAACTCTGTCGCTGTCCCCGGGAGA 
               
               
                   
                   
                 GAGCGCTACTCTGAGCTGCCGGGCCAGCCAGTCCGTGTCCACCACCTTCCTCG 
               
               
                   
                   
                 CCTGGTATCAGCAGAAGCCGGGGCAGGCACCACGGCTCTTGATCTACGGGTCA 
               
               
                   
                   
                 AGCAACAGAGCGACCGGAATTCCTGACCGCTTCTCGGGGAGCGGTTCAGGCAC 
               
               
                   
                   
                 CGACTTCACCCTGACTATCCGGCGCCTGGAACCCGAAGATTTCGCCGTGTATT 
               
               
                   
                   
                 ACTGTCAACAGTACCACTCCTCGCCGTCCTGGACCTTTGGCCAAGGAACCAAA 
               
               
                   
                   
                 GTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTAC 
               
               
                   
                   
                 CATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTG 
               
               
                   
                   
                 GTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGG 
               
               
                   
                   
                 GCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCT 
               
               
                   
                   
                 TTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCA 
               
               
                   
                   
                 TGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCA 
               
               
                   
                   
                 GAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGA 
               
               
                   
                   
                 TGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTG 
               
               
                   
                   
                 GTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAA 
               
               
                   
                   
                 ATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCT 
               
               
                   
                   
                 CCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAAC 
               
               
                   
                   
                 GCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACC 
               
               
                   
                   
                 AAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1978-D10 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1129 
                 EVQLVETGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW 
               
               
                 C1978-D10 - aa 
                   
                 NSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARVGKAVPDV 
               
               
                 ScFv domain 
                   
                 WGQGTTVTVSSGGGGSGGGGSGGGGSDIVMTQTPSSLSASVGDRVTITCRASQ 
               
               
                   
                   
                 SISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP 
               
               
                   
                   
                 EDFATYYCQQSYSTPYSFGQGTRLEIK 
               
               
                 BCMA_EBB- 
                 1130 
                 GAAGTGCAGCTCGTGGAAACTGGAGGTGGACTCGTGCAGCCTGGACGGTCGCT 
               
               
                 C1978-D10- nt 
                   
                 GCGGCTGAGCTGCGCTGCATCCGGCTTCACCTTCGACGATTATGCCATGCACT 
               
               
                 ScFv domain 
                   
                 GGGTCAGACAGGCGCCAGGGAAGGGACTTGAGTGGGTGTCCGGTATCAGCTGG 
               
               
                   
                   
                 AATAGCGGCTCAATCGGATACGCGGACTCCGTGAAGGGAAGGTTCACCATTTC 
               
               
                   
                   
                 CCGCGACAACGCCAAGAACTCCCTGTACTTGCAAATGAACAGCCTCCGGGATG 
               
               
                   
                   
                 AGGACACTGCCGTGTACTACTGCGCCCGCGTCGGAAAAGCTGTGCCCGACGTC 
               
               
                   
                   
                 TGGGGCCAGGGAACCACTGTGACCGTGTCCAGCGGCGGGGGTGGATCGGGCGG 
               
               
                   
                   
                 TGGAGGGTCCGGTGGAGGGGGCTCAGATATTGTGATGACCCAGACCCCCTCGT 
               
               
                   
                   
                 CCCTGTCCGCCTCGGTCGGCGACCGCGTGACTATCACATGTAGAGCCTCGCAG 
               
               
                   
                   
                 AGCATCTCCAGCTACCTGAACTGGTATCAGCAGAAGCCGGGGAAGGCCCCGAA 
               
               
                   
                   
                 GCTCCTGATCTACGCGGCATCATCACTGCAATCGGGAGTGCCGAGCCGGTTTT 
               
               
                   
                   
                 CCGGGTCCGGCTCCGGCACCGACTTCACGCTGACCATTTCTTCCCTGCAACCC 
               
               
                   
                   
                 GAGGACTTCGCCACTTACTACTGCCAGCAGTCCTACTCCACCCCTTACTCCTT 
               
               
                   
                   
                 CGGCCAAGGAACCAGGCTGGAAATCAAG 
               
               
                 BCMA_EBB- 
                 1131 
                 EVQLVETGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGISW 
               
               
                 C1978-D10 - aa 
                   
                 NSGSIGYADSVKGRFTISRDNAKNSLYLQMNSLRDEDTAVYYCARVGKAVPDV 
               
               
                 VH 
                   
                 WGQGTTVTVSS 
               
               
                 BCMA_EBB- 
                 1132 
                 DIVMTQTPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASS 
               
               
                 C1978-D10- aa 
                   
                 LQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYSFGQGTRLEI 
               
               
                 VL 
                   
                 K 
               
               
                 BCMA_EBB- 
                 1133 
                 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGRSLRLSCAASGFTFDDY 
               
               
                 C1978-D10 - aa 
                   
                 AMHWVRQAPGKGLEWVSGISWNSGSIGYADSVKGRFTISRDNAKNSLYLQMNS 
               
               
                 Full CART 
                   
                 LRDEDTAVYYCARVGKAVPDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIVMTQ 
               
               
                   
                   
                 TPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVP 
               
               
                   
                   
                 SRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPYSFGQGTRLEIKTTTPA 
               
               
                   
                   
                 PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGV 
               
               
                   
                   
                 LLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL 
               
               
                   
                   
                 RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN 
               
               
                   
                   
                 PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHM 
               
               
                   
                   
                 QALPPR 
               
               
                 BCMA_EBB- 
                 1134 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1978-D10 - nt 
                   
                 CGCTCGGCCCGAAGTGCAGCTCGTGGAAACTGGAGGTGGACTCGTGCAGCCTG 
               
               
                 Full CART 
                   
                 GACGGTCGCTGCGGCTGAGCTGCGCTGCATCCGGCTTCACCTTCGACGATTAT 
               
               
                   
                   
                 GCCATGCACTGGGTCAGACAGGCGCCAGGGAAGGGACTTGAGTGGGTGTCCGG 
               
               
                   
                   
                 TATCAGCTGGAATAGCGGCTCAATCGGATACGCGGACTCCGTGAAGGGAAGGT 
               
               
                   
                   
                 TCACCATTTCCCGCGACAACGCCAAGAACTCCCTGTACTTGCAAATGAACAGC 
               
               
                   
                   
                 CTCCGGGATGAGGACACTGCCGTGTACTACTGCGCCCGCGTCGGAAAAGCTGT 
               
               
                   
                   
                 GCCCGACGTCTGGGGCCAGGGAACCACTGTGACCGTGTCCAGCGGCGGGGGTG 
               
               
                   
                   
                 GATCGGGCGGTGGAGGGTCCGGTGGAGGGGGCTCAGATATTGTGATGACCCAG 
               
               
                   
                   
                 ACCCCCTCGTCCCTGTCCGCCTCGGTCGGCGACCGCGTGACTATCACATGTAG 
               
               
                   
                   
                 AGCCTCGCAGAGCATCTCCAGCTACCTGAACTGGTATCAGCAGAAGCCGGGGA 
               
               
                   
                   
                 AGGCCCCGAAGCTCCTGATCTACGCGGCATCATCACTGCAATCGGGAGTGCCG 
               
               
                   
                   
                 AGCCGGTTTTCCGGGTCCGGCTCCGGCACCGACTTCACGCTGACCATTTCTTC 
               
               
                   
                   
                 CCTGCAACCCGAGGACTTCGCCACTTACTACTGCCAGCAGTCCTACTCCACCC 
               
               
                   
                   
                 CTTACTCCTTCGGCCAAGGAACCAGGCTGGAAATCAAGACCACTACCCCAGCA 
               
               
                   
                   
                 CCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCG 
               
               
                   
                   
                 TCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTG 
               
               
                   
                   
                 ACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTC 
               
               
                   
                   
                 CTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCT 
               
               
                   
                   
                 GCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGG 
               
               
                   
                   
                 AGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTG 
               
               
                   
                   
                 CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAA 
               
               
                   
                   
                 CCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGG 
               
               
                   
                   
                 ACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAAT 
               
               
                   
                   
                 CCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTA 
               
               
                   
                   
                 TAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGAC 
               
               
                   
                   
                 TGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATG 
               
               
                   
                   
                 CAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1979-C12 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1135 
                 EVQLVESGGGLVQPGRSLRLSCTASGFTFDDYAMHWVRQRPGKGLEWVASINW 
               
               
                 C1979-C12- aa 
                   
                 KGNSLAYGDSVKGRFAISRDNAKNTVFLQMNSLRTEDTAVYYCASHQGVAYYN 
               
               
                 ScFv domain 
                   
                 YAMDVWGRGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLS 
               
               
                   
                   
                 CRATQSIGSSFLAWYQQRPGQAPRLLIYGASQRATGIPDRFSGRGSGTDFTLT 
               
               
                   
                   
                 ISRVEPEDSAVYYCQHYESSPSWTFGQGTKVEIK 
               
               
                 BCMA_EBB- 
                 1136 
                 GAAGTGCAGCTCGTGGAGAGCGGGGGAGGATTGGTGCAGCCCGGAAGGTCCCT 
               
               
                 C1979-C12 - nt 
                   
                 GCGGCTCTCCTGCACTGCGTCTGGCTTCACCTTCGACGACTACGCGATGCACT 
               
               
                 ScFv domain 
                   
                 GGGTCAGACAGCGCCCGGGAAAGGGCCTGGAATGGGTCGCCTCAATCAACTGG 
               
               
                   
                   
                 AAGGGAAACTCCCTGGCCTATGGCGACAGCGTGAAGGGCCGCTTCGCCATTTC 
               
               
                   
                   
                 GCGCGACAACGCCAAGAACACCGTGTTTCTGCAAATGAATTCCCTGCGGACCG 
               
               
                   
                   
                 AGGATACCGCTGTGTACTACTGCGCCAGCCACCAGGGCGTGGCATACTATAAC 
               
               
                   
                   
                 TACGCCATGGACGTGTGGGGAAGAGGGACGCTCGTCACCGTGTCCTCCGGGGG 
               
               
                   
                   
                 CGGTGGATCGGGTGGAGGAGGAAGCGGTGGCGGGGGCAGCGAAATCGTGCTGA 
               
               
                   
                   
                 CTCAGAGCCCGGGAACTCTTTCACTGTCCCCGGGAGAACGGGCCACTCTCTCG 
               
               
                   
                   
                 TGCCGGGCCACCCAGTCCATCGGCTCCTCCTTCCTTGCCTGGTACCAGCAGAG 
               
               
                   
                   
                 GCCAGGACAGGCGCCCCGCCTGCTGATCTACGGTGCTTCCCAACGCGCCACTG 
               
               
                   
                   
                 GCATTCCTGACCGGTTCAGCGGCAGAGGGTCGGGAACCGATTTCACACTGACC 
               
               
                   
                   
                 ATTTCCCGGGTGGAGCCCGAAGATTCGGCAGTCTACTACTGTCAGCATTACGA 
               
               
                   
                   
                 GTCCTCCCCTTCATGGACCTTCGGTCAAGGGACCAAAGTGGAGATCAAG 
               
               
                 BCMA_EBB- 
                 1137 
                 EVQLVESGGGLVQPGRSLRLSCTASGFTFDDYAMHWVRQRPGKGLEWVASINW 
               
               
                 C1979-C12 - aa 
                   
                 KGNSLAYGDSVKGRFAISRDNAKNTVFLQMNSLRTEDTAVYYCASHQGVAYYN 
               
               
                 VH 
                   
                 YAMDVWGRGTLVTVSS 
               
               
                 BCMA_EBB- 
                 1138 
                 EIVLTQSPGTLSLSPGERATLSCRATQSIGSSFLAWYQQRPGQAPRLLIYGAS 
               
               
                 C1979-C12 - aa 
                   
                 QRATGIPDRFSGRGSGTDFTLTISRVEPEDSAVYYCQHYESSPSWTFGQGTKV 
               
               
                 VL 
                   
                 EIK 
               
               
                 BCMA_EBB- 
                 1139 
                 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGRSLRLSCTASGFTFDDY 
               
               
                 C1979-C12 - aa 
                   
                 AMHWVRQRPGKGLEWVASINWKGNSLAYGDSVKGRFAISRDNAKNTVFLQMNS 
               
               
                 Full CART 
                   
                 LRTEDTAVYYCASHQGVAYYNYAMDVWGRGTLVTVSSGGGGSGGGGSGGGGSE 
               
               
                   
                   
                 IVLTQSPGTLSLSPGERATLSCRATQSIGSSFLAWYQQRPGQAPRLLIYGASQ 
               
               
                   
                   
                 RATGIPDRFSGRGSGTDFTLTISRVEPEDSAVYYCQHYESSPSWTFGQGTKVE 
               
               
                   
                   
                 IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP 
               
               
                   
                   
                 LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE 
               
               
                   
                   
                 EEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG 
               
               
                   
                   
                 GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD 
               
               
                   
                   
                 TYDALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1140 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1979-C12 - nt 
                   
                 CGCTCGGCCCGAAGTGCAGCTCGTGGAGAGCGGGGGAGGATTGGTGCAGCCCG 
               
               
                 Full CART 
                   
                 GAAGGTCCCTGCGGCTCTCCTGCACTGCGTCTGGCTTCACCTTCGACGACTAC 
               
               
                   
                   
                 GCGATGCACTGGGTCAGACAGCGCCCGGGAAAGGGCCTGGAATGGGTCGCCTC 
               
               
                   
                   
                 AATCAACTGGAAGGGAAACTCCCTGGCCTATGGCGACAGCGTGAAGGGCCGCT 
               
               
                   
                   
                 TCGCCATTTCGCGCGACAACGCCAAGAACACCGTGTTTCTGCAAATGAATTCC 
               
               
                   
                   
                 CTGCGGACCGAGGATACCGCTGTGTACTACTGCGCCAGCCACCAGGGCGTGGC 
               
               
                   
                   
                 ATACTATAACTACGCCATGGACGTGTGGGGAAGAGGGACGCTCGTCACCGTGT 
               
               
                   
                   
                 CCTCCGGGGGCGGTGGATCGGGTGGAGGAGGAAGCGGTGGCGGGGGCAGCGAA 
               
               
                   
                   
                 ATCGTGCTGACTCAGAGCCCGGGAACTCTTTCACTGTCCCCGGGAGAACGGGC 
               
               
                   
                   
                 CACTCTCTCGTGCCGGGCCACCCAGTCCATCGGCTCCTCCTTCCTTGCCTGGT 
               
               
                   
                   
                 ACCAGCAGAGGCCAGGACAGGCGCCCCGCCTGCTGATCTACGGTGCTTCCCAA 
               
               
                   
                   
                 CGCGCCACTGGCATTCCTGACCGGTTCAGCGGCAGAGGGTCGGGAACCGATTT 
               
               
                   
                   
                 CACACTGACCATTTCCCGGGTGGAGCCCGAAGATTCGGCAGTCTACTACTGTC 
               
               
                   
                   
                 AGCATTACGAGTCCTCCCCTTCATGGACCTTCGGTCAAGGGACCAAAGTGGAG 
               
               
                   
                   
                 ATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC 
               
               
                   
                   
                 CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG 
               
               
                   
                   
                 CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCT 
               
               
                   
                   
                 CTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTG 
               
               
                   
                   
                 TAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC 
               
               
                   
                   
                 CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAG 
               
               
                   
                   
                 GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC 
               
               
                   
                   
                 AGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGA 
               
               
                   
                   
                 GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC 
               
               
                   
                   
                 GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA 
               
               
                   
                   
                 GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA 
               
               
                   
                   
                 GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC 
               
               
                   
                   
                 ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1980-G4 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1141 
                 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1980-G4- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVVRDGMDV 
               
               
                 ScFv domain 
                   
                 WGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASQ 
               
               
                   
                   
                 SVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGNGSGTDFTLTISRLE 
               
               
                   
                   
                 PEDFAVYYCQQYGSPPRFTFGPGTKVDIK 
               
               
                 BCMA_EBB- 
                 1142 
                 GAGGTGCAGTTGGTCGAAAGCGGGGGCGGGCTTGTGCAGCCTGGCGGATCACT 
               
               
                 C1980-G4- nt 
                   
                 GCGGCTGTCCTGCGCGGCATCAGGCTTCACGTTTTCTTCCTACGCCATGTCCT 
               
               
                 ScFv domain 
                   
                 GGGTGCGCCAGGCCCCTGGAAAGGGACTGGAATGGGTGTCCGCGATTTCGGGG 
               
               
                   
                   
                 TCCGGCGGGAGCACCTACTACGCCGATTCCGTGAAGGGCCGCTTCACTATCTC 
               
               
                   
                   
                 GCGGGACAACTCCAAGAACACCCTCTACCTCCAAATGAATAGCCTGCGGGCCG 
               
               
                   
                   
                 AGGATACCGCCGTCTACTATTGCGCTAAGGTCGTGCGCGACGGAATGGACGTG 
               
               
                   
                   
                 TGGGGACAGGGTACCACCGTGACAGTGTCCTCGGGGGGAGGCGGTAGCGGCGG 
               
               
                   
                   
                 AGGAGGAAGCGGTGGTGGAGGTTCCGAGATTGTGCTGACTCAATCACCCGCGA 
               
               
                   
                   
                 CCCTGAGCCTGTCCCCCGGCGAAAGGGCCACTCTGTCCTGTCGGGCCAGCCAA 
               
               
                   
                   
                 TCAGTCTCCTCCTCGTACCTGGCCTGGTACCAGCAGAAGCCAGGACAGGCTCC 
               
               
                   
                   
                 GAGACTCCTTATCTATGGCGCATCCTCCCGCGCCACCGGAATCCCGGATAGGT 
               
               
                   
                   
                 TCTCGGGAAACGGATCGGGGACCGACTTCACTCTCACCATCTCCCGGCTGGAA 
               
               
                   
                   
                 CCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCCCGCCTAGATT 
               
               
                   
                   
                 CACTTTCGGCCCCGGCACCAAAGTGGACATCAAG 
               
               
                 BCMA_EBB- 
                 1143 
                 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1980-G4- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVVRDGMDV 
               
               
                 VH 
                   
                 WGQGTTVTVSS 
               
               
                 BCMA_EBB- 
                 1144 
                 EIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGAS 
               
               
                 C1980-G4- aa 
                   
                 SRATGIPDRFSGNGSGTDFTLTISRLEPEDFAVYYCQQYGSPPRFTFGPGTKV 
               
               
                 VL 
                   
                 DIK 
               
               
                 BCMA_EBB- 
                 1145 
                 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1980-G4- aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                 Full CART 
                   
                 LRAEDTAVYYCAKVVRDGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQ 
               
               
                   
                   
                 SPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGI 
               
               
                   
                   
                 PDRFSGNGSGTDFTLTISRLEPEDFAVYYCQQYGSPPRFTFGPGTKVDIKTTT 
               
               
                   
                   
                 PAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC 
               
               
                   
                   
                 GVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGC 
               
               
                   
                   
                 ELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR 
               
               
                   
                   
                 KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDAL 
               
               
                   
                   
                 HMQALPPR 
               
               
                 BCMA_EBB- 
                 1146 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1980-G4- nt 
                   
                 CGCTCGGCCCGAGGTGCAGTTGGTCGAAAGCGGGGGCGGGCTTGTGCAGCCTG 
               
               
                 Full CART 
                   
                 GCGGATCACTGCGGCTGTCCTGCGCGGCATCAGGCTTCACGTTTTCTTCCTAC 
               
               
                   
                   
                 GCCATGTCCTGGGTGCGCCAGGCCCCTGGAAAGGGACTGGAATGGGTGTCCGC 
               
               
                   
                   
                 GATTTCGGGGTCCGGCGGGAGCACCTACTACGCCGATTCCGTGAAGGGCCGCT 
               
               
                   
                   
                 TCACTATCTCGCGGGACAACTCCAAGAACACCCTCTACCTCCAAATGAATAGC 
               
               
                   
                   
                 CTGCGGGCCGAGGATACCGCCGTCTACTATTGCGCTAAGGTCGTGCGCGACGG 
               
               
                   
                   
                 AATGGACGTGTGGGGACAGGGTACCACCGTGACAGTGTCCTCGGGGGGAGGCG 
               
               
                   
                   
                 GTAGCGGCGGAGGAGGAAGCGGTGGTGGAGGTTCCGAGATTGTGCTGACTCAA 
               
               
                   
                   
                 TCACCCGCGACCCTGAGCCTGTCCCCCGGCGAAAGGGCCACTCTGTCCTGTCG 
               
               
                   
                   
                 GGCCAGCCAATCAGTCTCCTCCTCGTACCTGGCCTGGTACCAGCAGAAGCCAG 
               
               
                   
                   
                 GACAGGCTCCGAGACTCCTTATCTATGGCGCATCCTCCCGCGCCACCGGAATC 
               
               
                   
                   
                 CCGGATAGGTTCTCGGGAAACGGATCGGGGACCGACTTCACTCTCACCATCTC 
               
               
                   
                   
                 CCGGCTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGCAGTACGGCAGCC 
               
               
                   
                   
                 CGCCTAGATTCACTTTCGGCCCCGGCACCAAAGTGGACATCAAGACCACTACC 
               
               
                   
                   
                 CCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCTGTC 
               
               
                   
                   
                 CCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCCGGG 
               
               
                   
                   
                 GTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACTTGC 
               
               
                   
                   
                 GGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCGGAA 
               
               
                   
                   
                 GAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTACTC 
               
               
                   
                   
                 AAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGCTGC 
               
               
                   
                   
                 GAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGG 
               
               
                   
                   
                 GCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACG 
               
               
                   
                   
                 TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGA 
               
               
                   
                   
                 AAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGA 
               
               
                   
                   
                 AGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACG 
               
               
                   
                   
                 ACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTT 
               
               
                   
                   
                 CACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1980-D2 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1147 
                 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1980-D2- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIPQTGTFD 
               
               
                 ScFv domain 
                   
                 YWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAS 
               
               
                   
                   
                 QSVSSSYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRL 
               
               
                   
                   
                 EPEDFAVYYCQHYGSSPSWTFGQGTRLEIK 
               
               
                 BCMA_EBB- 
                 1148 
                 GAAGTGCAGCTGCTGGAGTCCGGCGGTGGATTGGTGCAACCGGGGGGATCGCT 
               
               
                 C1980-D2- nt 
                   
                 CAGACTGTCCTGTGCGGCGTCAGGCTTCACCTTCTCGAGCTACGCCATGTCAT 
               
               
                 ScFv domain 
                   
                 GGGTCAGACAGGCCCCTGGAAAGGGTCTGGAATGGGTGTCCGCCATTTCCGGG 
               
               
                   
                   
                 AGCGGGGGATCTACATACTACGCCGATAGCGTGAAGGGCCGCTTCACCATTTC 
               
               
                   
                   
                 CCGGGACAACTCCAAGAACACTCTCTATCTGCAAATGAACTCCCTCCGCGCTG 
               
               
                   
                   
                 AGGACACTGCCGTGTACTACTGCGCCAAAATCCCTCAGACCGGCACCTTCGAC 
               
               
                   
                   
                 TACTGGGGACAGGGGACTCTGGTCACCGTCAGCAGCGGTGGCGGAGGTTCGGG 
               
               
                   
                   
                 GGGAGGAGGAAGCGGCGGCGGAGGGTCCGAGATTGTGCTGACCCAGTCACCCG 
               
               
                   
                   
                 GCACTTTGTCCCTGTCGCCTGGAGAAAGGGCCACCCTTTCCTGCCGGGCATCC 
               
               
                   
                   
                 CAATCCGTGTCCTCCTCGTACCTGGCCTGGTACCAGCAGAGGCCCGGACAGGC 
               
               
                   
                   
                 CCCACGGCTTCTGATCTACGGAGCAAGCAGCCGCGCGACCGGTATCCCGGACC 
               
               
                   
                   
                 GGTTTTCGGGCTCGGGCTCAGGAACTGACTTCACCCTCACCATCTCCCGCCTG 
               
               
                   
                   
                 GAACCCGAAGATTTCGCTGTGTATTACTGCCAGCACTACGGCAGCTCCCCGTC 
               
               
                   
                   
                 CTGGACGTTCGGCCAGGGAACTCGGCTGGAGATCAAG 
               
               
                 BCMA_EBB- 
                 1149 
                 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1980-D2- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKIPQTGTFD 
               
               
                 VH 
                   
                 YWGQGTLVTVSS 
               
               
                 BCMA_EBB- 
                 1150 
                 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIYGAS 
               
               
                 C1980-D2- aa 
                   
                 SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPSWTFGQGTRL 
               
               
                 VL 
                   
                 EIK 
               
               
                 BCMA_EBB- 
                 1151 
                 MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1980-D2- aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                 Full CART 
                   
                 LRAEDTAVYYCAKIPQTGTFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLT 
               
               
                   
                   
                 QSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQRPGQAPRLLIYGASSRATG 
               
               
                   
                   
                 IPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPSWTFGQGTRLEIKTT 
               
               
                   
                   
                 TPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGT 
               
               
                   
                   
                 CGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG 
               
               
                   
                   
                 CELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR 
               
               
                   
                   
                 RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDA 
               
               
                   
                   
                 LHMQALPPR 
               
               
                 BCMA_EBB- 
                 1152 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1980-D2- nt 
                   
                 CGCTCGGCCCGAAGTGCAGCTGCTGGAGTCCGGCGGTGGATTGGTGCAACCGG 
               
               
                 Full CART 
                   
                 GGGGATCGCTCAGACTGTCCTGTGCGGCGTCAGGCTTCACCTTCTCGAGCTAC 
               
               
                   
                   
                 GCCATGTCATGGGTCAGACAGGCCCCTGGAAAGGGTCTGGAATGGGTGTCCGC 
               
               
                   
                   
                 CATTTCCGGGAGCGGGGGATCTACATACTACGCCGATAGCGTGAAGGGCCGCT 
               
               
                   
                   
                 TCACCATTTCCCGGGACAACTCCAAGAACACTCTCTATCTGCAAATGAACTCC 
               
               
                   
                   
                 CTCCGCGCTGAGGACACTGCCGTGTACTACTGCGCCAAAATCCCTCAGACCGG 
               
               
                   
                   
                 CACCTTCGACTACTGGGGACAGGGGACTCTGGTCACCGTCAGCAGCGGTGGCG 
               
               
                   
                   
                 GAGGTTCGGGGGGAGGAGGAAGCGGCGGCGGAGGGTCCGAGATTGTGCTGACC 
               
               
                   
                   
                 CAGTCACCCGGCACTTTGTCCCTGTCGCCTGGAGAAAGGGCCACCCTTTCCTG 
               
               
                   
                   
                 CCGGGCATCCCAATCCGTGTCCTCCTCGTACCTGGCCTGGTACCAGCAGAGGC 
               
               
                   
                   
                 CCGGACAGGCCCCACGGCTTCTGATCTACGGAGCAAGCAGCCGCGCGACCGGT 
               
               
                   
                   
                 ATCCCGGACCGGTTTTCGGGCTCGGGCTCAGGAACTGACTTCACCCTCACCAT 
               
               
                   
                   
                 CTCCCGCCTGGAACCCGAAGATTTCGCTGTGTATTACTGCCAGCACTACGGCA 
               
               
                   
                   
                 GCTCCCCGTCCTGGACGTTCGGCCAGGGAACTCGGCTGGAGATCAAGACCACT 
               
               
                   
                   
                 ACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCAGCCTCT 
               
               
                   
                   
                 GTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGCATACCC 
               
               
                   
                   
                 GGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCTGGTACT 
               
               
                   
                   
                 TGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCGCGGTCG 
               
               
                   
                   
                 GAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGCAGACTA 
               
               
                   
                   
                 CTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAAGGCGGC 
               
               
                   
                   
                 TGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCA 
               
               
                   
                   
                 GGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACG 
               
               
                   
                   
                 ACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGC 
               
               
                   
                   
                 AGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGC 
               
               
                   
                   
                 AGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCC 
               
               
                   
                   
                 ACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCT 
               
               
                   
                   
                 CTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1978-A10 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1153 
                 EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-A10- aa 
                   
                 SGGSTYYADSVKGRFTMSRENDKNSVFLQMNSLRVEDTGVYYCARANYKRELR 
               
               
                 ScFv domain 
                   
                 YYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGESAT 
               
               
                   
                   
                 LSCRASQRVASNYLAWYQHKPGQAPSLLISGASSRATGVPDRFSGSGSGTDFT 
               
               
                   
                   
                 LAISRLEPEDSAVYYCQHYDSSPSWTFGQGTKVEIK 
               
               
                 BCMA_EBB- 
                 1154 
                 GAAGTGCAACTGGTGGAAACCGGTGGAGGACTCGTGCAGCCTGGCGGCAGCCT 
               
               
                 C1978-A10- nt 
                   
                 CCGGCTGAGCTGCGCCGCTTCGGGATTCACCTTTTCCTCCTACGCGATGTCTT 
               
               
                 ScFv domain 
                   
                 GGGTCAGACAGGCCCCCGGAAAGGGGCTGGAATGGGTGTCAGCCATCTCCGGC 
               
               
                   
                   
                 TCCGGCGGATCAACGTACTACGCCGACTCCGTGAAAGGCCGGTTCACCATGTC 
               
               
                   
                   
                 GCGCGAGAATGACAAGAACTCCGTGTTCCTGCAAATGAACTCCCTGAGGGTGG 
               
               
                   
                   
                 AGGACACCGGAGTGTACTATTGTGCGCGCGCCAACTACAAGAGAGAGCTGCGG 
               
               
                   
                   
                 TACTACTACGGAATGGACGTCTGGGGACAGGGAACTATGGTGACCGTGTCATC 
               
               
                   
                   
                 CGGTGGAGGGGGAAGCGGCGGTGGAGGCAGCGGGGGCGGGGGTTCAGAAATTG 
               
               
                   
                   
                 TCATGACCCAGTCCCCGGGAACTCTTTCCCTCTCCCCCGGGGAATCCGCGACT 
               
               
                   
                   
                 TTGTCCTGCCGGGCCAGCCAGCGCGTGGCCTCGAACTACCTCGCATGGTACCA 
               
               
                   
                   
                 GCATAAGCCAGGCCAAGCCCCTTCCCTGCTGATTTCCGGGGCTAGCAGCCGCG 
               
               
                   
                   
                 CCACTGGCGTGCCGGATAGGTTCTCGGGAAGCGGCTCGGGTACCGATTTCACC 
               
               
                   
                   
                 CTGGCAATCTCGCGGCTGGAACCGGAGGATTCGGCCGTGTACTACTGCCAGCA 
               
               
                   
                   
                 CTATGACTCATCCCCCTCCTGGACATTCGGACAGGGCACCAAGGTCGAGATCA 
               
               
                   
                   
                 AG 
               
               
                 BCMA_EBB- 
                 1155 
                 EVQLVETGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-A10- aa 
                   
                 SGGSTYYADSVKGRFTMSRENDKNSVFLQMNSLRVEDTGVYYCARANYKRELR 
               
               
                 VH 
                   
                 YYYGMDVWGQGTMVTVSS 
               
               
                 BCMA_EBB- 
                 1156 
                 EIVMTQSPGTLSLSPGESATLSCRASQRVASNYLAWYQHKPGQAPSLLISGAS 
               
               
                 C1978-A10- aa 
                   
                 SRATGVPDRFSGSGSGTDFTLAISRLEPEDSAVYYCQHYDSSPSWTFGQGTKV 
               
               
                 VL 
                   
                 EIK 
               
               
                 BCMA_EBB- 
                 1157 
                 MALPVTALLLPLALLLHAARPEVQLVETGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1978-A10- aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTMSRENDKNSVFLQMNS 
               
               
                 Full 
                 CART 
                 LRVEDTGVYYCARANYKRELRYYYGMDVWGQGTMVTVSSGGGGSGGGGSGGGG 
               
               
                   
                   
                 SEIVMTQSPGTLSLSPGESATLSCRASQRVASNYLAWYQHKPGQAPSLLISGA 
               
               
                   
                   
                 SSRATGVPDRFSGSGSGTDFTLAISRLEPEDSAVYYCQHYDSSPSWTFGQGTK 
               
               
                   
                   
                 VEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIW 
               
               
                   
                   
                 APLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFP 
               
               
                   
                   
                 EEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPE 
               
               
                   
                   
                 MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT 
               
               
                   
                   
                 KDTYDALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1158 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1978-A10- nt 
                   
                 CGCTCGGCCCGAAGTGCAACTGGTGGAAACCGGTGGAGGACTCGTGCAGCCTG 
               
               
                 Full CART 
                   
                 GCGGCAGCCTCCGGCTGAGCTGCGCCGCTTCGGGATTCACCTTTTCCTCCTAC 
               
               
                   
                   
                 GCGATGTCTTGGGTCAGACAGGCCCCCGGAAAGGGGCTGGAATGGGTGTCAGC 
               
               
                   
                   
                 CATCTCCGGCTCCGGCGGATCAACGTACTACGCCGACTCCGTGAAAGGCCGGT 
               
               
                   
                   
                 TCACCATGTCGCGCGAGAATGACAAGAACTCCGTGTTCCTGCAAATGAACTCC 
               
               
                   
                   
                 CTGAGGGTGGAGGACACCGGAGTGTACTATTGTGCGCGCGCCAACTACAAGAG 
               
               
                   
                   
                 AGAGCTGCGGTACTACTACGGAATGGACGTCTGGGGACAGGGAACTATGGTGA 
               
               
                   
                   
                 CCGTGTCATCCGGTGGAGGGGGAAGCGGCGGTGGAGGCAGCGGGGGCGGGGGT 
               
               
                   
                   
                 TCAGAAATTGTCATGACCCAGTCCCCGGGAACTCTTTCCCTCTCCCCCGGGGA 
               
               
                   
                   
                 ATCCGCGACTTTGTCCTGCCGGGCCAGCCAGCGCGTGGCCTCGAACTACCTCG 
               
               
                   
                   
                 CATGGTACCAGCATAAGCCAGGCCAAGCCCCTTCCCTGCTGATTTCCGGGGCT 
               
               
                   
                   
                 AGCAGCCGCGCCACTGGCGTGCCGGATAGGTTCTCGGGAAGCGGCTCGGGTAC 
               
               
                   
                   
                 CGATTTCACCCTGGCAATCTCGCGGCTGGAACCGGAGGATTCGGCCGTGTACT 
               
               
                   
                   
                 ACTGCCAGCACTATGACTCATCCCCCTCCTGGACATTCGGACAGGGCACCAAG 
               
               
                   
                   
                 GTCGAGATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTAC 
               
               
                   
                   
                 CATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTG 
               
               
                   
                   
                 GTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGG 
               
               
                   
                   
                 GCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCT 
               
               
                   
                   
                 TTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCA 
               
               
                   
                   
                 TGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCA 
               
               
                   
                   
                 GAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGA 
               
               
                   
                   
                 TGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTG 
               
               
                   
                   
                 GTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAA 
               
               
                   
                   
                 ATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCT 
               
               
                   
                   
                 CCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAAC 
               
               
                   
                   
                 GCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACC 
               
               
                   
                   
                 AAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1978-D4 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1159 
                 EVQLLETGGGLVQPGGSLRLSCAASGFSFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-D4- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKALVGATGA 
               
               
                 ScFv domain 
                   
                 FDIWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCR 
               
               
                   
                   
                 ASQSLSSNFLAWYQQKPGQAPGLLIYGASNWATGTPDRFSGSGSGTDFTLTIT 
               
               
                   
                   
                 RLEPEDFAVYYCQYYGTSPMYTFGQGTKVEIK 
               
               
                 BCMA_EBB- 
                 1160 
                 GAAGTGCAGCTGCTCGAAACCGGTGGAGGGCTGGTGCAGCCAGGGGGCTCCCT 
               
               
                 C1978-D4- nt 
                   
                 GAGGCTTTCATGCGCCGCTAGCGGATTCTCCTTCTCCTCTTACGCCATGTCGT 
               
               
                 ScFv domain 
                   
                 GGGTCCGCCAAGCCCCTGGAAAAGGCCTGGAATGGGTGTCCGCGATTTCCGGG 
               
               
                   
                   
                 AGCGGAGGTTCGACCTATTACGCCGACTCCGTGAAGGGCCGCTTTACCATCTC 
               
               
                   
                   
                 CCGGGATAACTCCAAGAACACTCTGTACCTCCAAATGAACTCGCTGAGAGCCG 
               
               
                   
                   
                 AGGACACCGCCGTGTATTACTGCGCGAAGGCGCTGGTCGGCGCGACTGGGGCA 
               
               
                   
                   
                 TTCGACATCTGGGGACAGGGAACTCTTGTGACCGTGTCGAGCGGAGGCGGCGG 
               
               
                   
                   
                 CTCCGGCGGAGGAGGGAGCGGGGGCGGTGGTTCCGAAATCGTGTTGACTCAGT 
               
               
                   
                   
                 CCCCGGGAACCCTGAGCTTGTCACCCGGGGAGCGGGCCACTCTCTCCTGTCGC 
               
               
                   
                   
                 GCCTCCCAATCGCTCTCATCCAATTTCCTGGCCTGGTACCAGCAGAAGCCCGG 
               
               
                   
                   
                 ACAGGCCCCGGGCCTGCTCATCTACGGCGCTTCAAACTGGGCAACGGGAACCC 
               
               
                   
                   
                 CTGATCGGTTCAGCGGAAGCGGATCGGGTACTGACTTTACCCTGACCATCACC 
               
               
                   
                   
                 AGACTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGTACTACGGCACCTC 
               
               
                   
                   
                 CCCCATGTACACATTCGGACAGGGTACCAAGGTCGAGATTAAG 
               
               
                 BCMA_EBB- 
                 1161 
                 EVQLLETGGGLVQPGGSLRLSCAASGFSFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-D4- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKALVGATGA 
               
               
                 VH 
                   
                 FDIWGQGTLVTVSS 
               
               
                 BCMA_EBB- 
                 1162 
                 EIVLTQSPGTLSLSPGERATLSCRASQSLSSNFLAWYQQKPGQAPGLLIYGAS 
               
               
                 C1978-D4- aa 
                   
                 NWATGTPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQYYGTSPMYTFGQGTKV 
               
               
                 VL 
                   
                 EIK 
               
               
                 BCMA_EBB- 
                 1163 
                 MALPVTALLLPLALLLHAARPEVQLLETGGGLVQPGGSLRLSCAASGFSFSSY 
               
               
                 C1978-D4- aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                 Full CART 
                   
                 LRAEDTAVYYCAKALVGATGAFDIWGQGTLVTVSSGGGGSGGGGSGGGGSEIV 
               
               
                   
                   
                 LTQSPGTLSLSPGERATLSCRASQSLSSNFLAWYQQKPGQAPGLLIYGASNWA 
               
               
                   
                   
                 TGTPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQYYGTSPMYTFGQGTKVEIK 
               
               
                   
                   
                 TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA 
               
               
                   
                   
                 GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE 
               
               
                   
                   
                 GGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK 
               
               
                   
                   
                 PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY 
               
               
                   
                   
                 DALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1164 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1978-D4- nt 
                   
                 CGCTCGGCCCGAAGTGCAGCTGCTCGAAACCGGTGGAGGGCTGGTGCAGCCAG 
               
               
                 Full CART 
                   
                 GGGGCTCCCTGAGGCTTTCATGCGCCGCTAGCGGATTCTCCTTCTCCTCTTAC 
               
               
                   
                   
                 GCCATGTCGTGGGTCCGCCAAGCCCCTGGAAAAGGCCTGGAATGGGTGTCCGC 
               
               
                   
                   
                 GATTTCCGGGAGCGGAGGTTCGACCTATTACGCCGACTCCGTGAAGGGCCGCT 
               
               
                   
                   
                 TTACCATCTCCCGGGATAACTCCAAGAACACTCTGTACCTCCAAATGAACTCG 
               
               
                   
                   
                 CTGAGAGCCGAGGACACCGCCGTGTATTACTGCGCGAAGGCGCTGGTCGGCGC 
               
               
                   
                   
                 GACTGGGGCATTCGACATCTGGGGACAGGGAACTCTTGTGACCGTGTCGAGCG 
               
               
                   
                   
                 GAGGCGGCGGCTCCGGCGGAGGAGGGAGCGGGGGCGGTGGTTCCGAAATCGTG 
               
               
                   
                   
                 TTGACTCAGTCCCCGGGAACCCTGAGCTTGTCACCCGGGGAGCGGGCCACTCT 
               
               
                   
                   
                 CTCCTGTCGCGCCTCCCAATCGCTCTCATCCAATTTCCTGGCCTGGTACCAGC 
               
               
                   
                   
                 AGAAGCCCGGACAGGCCCCGGGCCTGCTCATCTACGGCGCTTCAAACTGGGCA 
               
               
                   
                   
                 ACGGGAACCCCTGATCGGTTCAGCGGAAGCGGATCGGGTACTGACTTTACCCT 
               
               
                   
                   
                 GACCATCACCAGACTGGAACCGGAGGACTTCGCCGTGTACTACTGCCAGTACT 
               
               
                   
                   
                 ACGGCACCTCCCCCATGTACACATTCGGACAGGGTACCAAGGTCGAGATTAAG 
               
               
                   
                   
                 ACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCA 
               
               
                   
                   
                 GCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGC 
               
               
                   
                   
                 ATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCT 
               
               
                   
                   
                 GGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCG 
               
               
                   
                   
                 CGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGC 
               
               
                   
                   
                 AGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAA 
               
               
                   
                   
                 GGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTA 
               
               
                   
                   
                 CAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGG 
               
               
                   
                   
                 AGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAG 
               
               
                   
                   
                 CCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAA 
               
               
                   
                   
                 GATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCA 
               
               
                   
                   
                 AAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTAT 
               
               
                   
                   
                 GACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1980-A2 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1165 
                 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1980-A2- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLWFGEGFDP 
               
               
                 ScFv domain 
                   
                 WGQGTLVTVSSGGGGSGGGGSGGGGSDIVLTQSPLSLPVTPGEPASISCRSSQ 
               
               
                   
                   
                 SLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKI 
               
               
                   
                   
                 SRVEAEDVGVYYCMQALQTPLTFGGGTKVD1K 
               
               
                 BCMA_EBB- 
                 1166 
                 GAAGTGCAGCTGCTTGAGAGCGGTGGAGGTCTGGTGCAGCCCGGGGGATCACT 
               
               
                 C1980-A2- nt 
                   
                 GCGCCTGTCCTGTGCCGCGTCCGGTTTCACTTTCTCCTCGTACGCCATGTCGT 
               
               
                 ScFv domain 
                   
                 GGGTCAGACAGGCACCGGGAAAGGGACTGGAATGGGTGTCAGCCATTTCGGGT 
               
               
                   
                   
                 TCGGGGGGCAGCACCTACTACGCTGACTCCGTGAAGGGCCGGTTCACCATTTC 
               
               
                   
                   
                 CCGCGACAACTCCAAGAACACCTTGTACCTCCAAATGAACTCCCTGCGGGCCG 
               
               
                   
                   
                 AAGATACCGCCGTGTATTACTGCGTGCTGTGGTTCGGAGAGGGATTCGACCCG 
               
               
                   
                   
                 TGGGGACAAGGAACACTCGTGACTGTGTCATCCGGCGGAGGCGGCAGCGGTGG 
               
               
                   
                   
                 CGGCGGTTCCGGCGGCGGCGGATCTGACATCGTGTTGACCCAGTCCCCTCTGA 
               
               
                   
                   
                 GCCTGCCGGTCACTCCTGGCGAACCAGCCAGCATCTCCTGCCGGTCGAGCCAG 
               
               
                   
                   
                 TCCCTCCTGCACTCCAATGGGTACAACTACCTCGATTGGTATCTGCAAAAGCC 
               
               
                   
                   
                 GGGCCAGAGCCCCCAGCTGCTGATCTACCTTGGGTCAAACCGCGCTTCCGGGG 
               
               
                   
                   
                 TGCCTGATAGATTCTCCGGGTCCGGGAGCGGAACCGACTTTACCCTGAAAATC 
               
               
                   
                   
                 TCGAGGGTGGAGGCCGAGGACGTCGGAGTGTACTACTGCATGCAGGCGCTCCA 
               
               
                   
                   
                 GACTCCCCTGACCTTCGGAGGAGGAACGAAGGTCGACATCAAGA 
               
               
                 BCMA_EBB- 
                 1167 
                 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1980-A2- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVLWFGEGFDP 
               
               
                 VH 
                   
                 WGQGTLVTVSS 
               
               
                 BCMA_EBB- 
                 1168 
                 DIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLI 
               
               
                 C1980-A2- aa 
                   
                 YLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGG 
               
               
                 VL 
                   
                 TKVDIK 
               
               
                 BCMA_EBB- 
                 1169 
                 MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1980-A2- aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                 Full CART 
                   
                 LRAEDTAVYYCVLWFGEGFDPWGQGTLVTVSSGGGGSGGGGSGGGGSDIVLTQ 
               
               
                   
                   
                 SPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNR 
               
               
                   
                   
                 ASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVDIK 
               
               
                   
                   
                 TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLA 
               
               
                   
                   
                 GTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE 
               
               
                   
                   
                 GGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK 
               
               
                   
                   
                 PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY 
               
               
                   
                   
                 DALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1170 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1980-A2- nt 
                   
                 CGCTCGGCCCGAAGTGCAGCTGCTTGAGAGCGGTGGAGGTCTGGTGCAGCCCG 
               
               
                 Full CART 
                   
                 GGGGATCACTGCGCCTGTCCTGTGCCGCGTCCGGTTTCACTTTCTCCTCGTAC 
               
               
                   
                   
                 GCCATGTCGTGGGTCAGACAGGCACCGGGAAAGGGACTGGAATGGGTGTCAGC 
               
               
                   
                   
                 CATTTCGGGTTCGGGGGGCAGCACCTACTACGCTGACTCCGTGAAGGGCCGGT 
               
               
                   
                   
                 TCACCATTTCCCGCGACAACTCCAAGAACACCTTGTACCTCCAAATGAACTCC 
               
               
                   
                   
                 CTGCGGGCCGAAGATACCGCCGTGTATTACTGCGTGCTGTGGTTCGGAGAGGG 
               
               
                   
                   
                 ATTCGACCCGTGGGGACAAGGAACACTCGTGACTGTGTCATCCGGCGGAGGCG 
               
               
                   
                   
                 GCAGCGGTGGCGGCGGTTCCGGCGGCGGCGGATCTGACATCGTGTTGACCCAG 
               
               
                   
                   
                 TCCCCTCTGAGCCTGCCGGTCACTCCTGGCGAACCAGCCAGCATCTCCTGCCG 
               
               
                   
                   
                 GTCGAGCCAGTCCCTCCTGCACTCCAATGGGTACAACTACCTCGATTGGTATC 
               
               
                   
                   
                 TGCAAAAGCCGGGCCAGAGCCCCCAGCTGCTGATCTACCTTGGGTCAAACCGC 
               
               
                   
                   
                 GCTTCCGGGGTGCCTGATAGATTCTCCGGGTCCGGGAGCGGAACCGACTTTAC 
               
               
                   
                   
                 CCTGAAAATCTCGAGGGTGGAGGCCGAGGACGTCGGAGTGTACTACTGCATGC 
               
               
                   
                   
                 AGGCGCTCCAGACTCCCCTGACCTTCGGAGGAGGAACGAAGGTCGACATCAAG 
               
               
                   
                   
                 ACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGCCTCCCA 
               
               
                   
                   
                 GCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGGCCGTGC 
               
               
                   
                   
                 ATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCTCTGGCT 
               
               
                   
                   
                 GGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTGTAAGCG 
               
               
                   
                   
                 CGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGCCTGTGC 
               
               
                   
                   
                 AGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAGGAGGAA 
               
               
                   
                   
                 GGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTA 
               
               
                   
                   
                 CAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGG 
               
               
                   
                   
                 AGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAG 
               
               
                   
                   
                 CCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAA 
               
               
                   
                   
                 GATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCA 
               
               
                   
                   
                 AAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTAT 
               
               
                   
                   
                 GACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1981-C3 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1171 
                 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1981-C3- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGYDSSGY 
               
               
                 ScFv domain 
                   
                 YRDYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGER 
               
               
                   
                   
                 ATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGISDRFSGSGSGTD 
               
               
                   
                   
                 FTLTISRLEPEDFAVYYCQHYGNSPPKFTFGPGTKLEIK 
               
               
                 BCMA_EBB- 
                 1172 
                 CAAGTGCAGCTCGTGGAGTCAGGCGGAGGACTGGTGCAGCCCGGGGGCTCCCT 
               
               
                 C1981-C3- nt 
                   
                 GAGACTTTCCTGCGCGGCATCGGGTTTTACCTTCTCCTCCTATGCTATGTCCT 
               
               
                 ScFv domain 
                   
                 GGGTGCGCCAGGCCCCGGGAAAGGGACTGGAATGGGTGTCCGCAATCAGCGGT 
               
               
                   
                   
                 AGCGGGGGCTCAACATACTACGCCGACTCCGTCAAGGGTCGCTTCACTATTTC 
               
               
                   
                   
                 CCGGGACAACTCCAAGAATACCCTGTACCTCCAAATGAACAGCCTCAGGGCCG 
               
               
                   
                   
                 AGGATACTGCCGTGTACTACTGCGCCAAAGTCGGATACGATAGCTCCGGTTAC 
               
               
                   
                   
                 TACCGGGACTACTACGGAATGGACGTGTGGGGACAGGGCACCACCGTGACCGT 
               
               
                   
                   
                 GTCAAGCGGCGGAGGCGGTTCAGGAGGGGGAGGCTCCGGCGGTGGAGGGTCCG 
               
               
                   
                   
                 AAATCGTCCTGACTCAGTCGCCTGGCACTCTGTCGTTGTCCCCGGGGGAGCGC 
               
               
                   
                   
                 GCTACCCTGTCGTGTCGGGCGTCGCAGTCCGTGTCGAGCTCCTACCTCGCGTG 
               
               
                   
                   
                 GTACCAGCAGAAGCCCGGACAGGCCCCTAGACTTCTGATCTACGGCACTTCTT 
               
               
                   
                   
                 CACGCGCCACCGGGATCAGCGACAGGTTCAGCGGCTCCGGCTCCGGGACCGAC 
               
               
                   
                   
                 TTCACCCTGACCATTAGCCGGCTGGAGCCTGAAGATTTCGCCGTGTATTACTG 
               
               
                   
                   
                 CCAACACTACGGAAACTCGCCGCCAAAGTTCACGTTCGGACCCGGAACCAAGC 
               
               
                   
                   
                 TGGAAATCAAG 
               
               
                 BCMA_EBB- 
                 1173 
                 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1981-C3- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVGYDSSGY 
               
               
                 VH 
                   
                 YRDYYGMDVWGQGTTVTVSS 
               
               
                 BCMA_EBB- 
                 1174 
                 EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTS 
               
               
                 C1981-C3- aa 
                   
                 SRATGISDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGNSPPKFTFGPGTK 
               
               
                 VL 
                   
                 LEIK 
               
               
                 BCMA_EBB- 
                 1175 
                 MALPVTALLLPLALLLHAARPQVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1981-C3- aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                 Full CART 
                   
                 LRAEDTAVYYCAKVGYDSSGYYRDYYGMDVWGQGTTVTVSSGGGGSGGGGSGG 
               
               
                   
                   
                 GGSEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIY 
               
               
                   
                   
                 GTSSRATGISDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGNSPPKFTFGP 
               
               
                   
                   
                 GTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDI 
               
               
                   
                   
                 YIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSC 
               
               
                   
                   
                 RFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGR 
               
               
                   
                   
                 DPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLS 
               
               
                   
                   
                 TATKDTYDALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1176 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1981-C3- nt 
                   
                 CGCTCGGCCCCAAGTGCAGCTCGTGGAGTCAGGCGGAGGACTGGTGCAGCCCG 
               
               
                 Full CART 
                   
                 GGGGCTCCCTGAGACTTTCCTGCGCGGCATCGGGTTTTACCTTCTCCTCCTAT 
               
               
                   
                   
                 GCTATGTCCTGGGTGCGCCAGGCCCCGGGAAAGGGACTGGAATGGGTGTCCGC 
               
               
                   
                   
                 AATCAGCGGTAGCGGGGGCTCAACATACTACGCCGACTCCGTCAAGGGTCGCT 
               
               
                   
                   
                 TCACTATTTCCCGGGACAACTCCAAGAATACCCTGTACCTCCAAATGAACAGC 
               
               
                   
                   
                 CTCAGGGCCGAGGATACTGCCGTGTACTACTGCGCCAAAGTCGGATACGATAG 
               
               
                   
                   
                 CTCCGGTTACTACCGGGACTACTACGGAATGGACGTGTGGGGACAGGGCACCA 
               
               
                   
                   
                 CCGTGACCGTGTCAAGCGGCGGAGGCGGTTCAGGAGGGGGAGGCTCCGGCGGT 
               
               
                   
                   
                 GGAGGGTCCGAAATCGTCCTGACTCAGTCGCCTGGCACTCTGTCGTTGTCCCC 
               
               
                   
                   
                 GGGGGAGCGCGCTACCCTGTCGTGTCGGGCGTCGCAGTCCGTGTCGAGCTCCT 
               
               
                   
                   
                 ACCTCGCGTGGTACCAGCAGAAGCCCGGACAGGCCCCTAGACTTCTGATCTAC 
               
               
                   
                   
                 GGCACTTCTTCACGCGCCACCGGGATCAGCGACAGGTTCAGCGGCTCCGGCTC 
               
               
                   
                   
                 CGGGACCGACTTCACCCTGACCATTAGCCGGCTGGAGCCTGAAGATTTCGCCG 
               
               
                   
                   
                 TGTATTACTGCCAACACTACGGAAACTCGCCGCCAAAGTTCACGTTCGGACCC 
               
               
                   
                   
                 GGAACCAAGCTGGAAATCAAGACCACTACCCCAGCACCGAGGCCACCCACCCC 
               
               
                   
                   
                 GGCTCCTACCATCGCCTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGAC 
               
               
                   
                   
                 CCGCAGCTGGTGGGGCCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATC 
               
               
                   
                   
                 TACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGT 
               
               
                   
                   
                 GATCACTCTTTACTGTAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGC 
               
               
                   
                   
                 AACCCTTCATGAGGCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGC 
               
               
                   
                   
                 CGGTTCCCAGAGGAGGAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCG 
               
               
                   
                   
                 CAGCGCAGATGCTCCAGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAAC 
               
               
                   
                   
                 TCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGG 
               
               
                   
                   
                 GACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTA 
               
               
                   
                   
                 CAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGA 
               
               
                   
                   
                 AAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGC 
               
               
                   
                   
                 ACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCG 
               
               
                   
                   
                 G 
               
               
                   
               
            
           
           
               
            
               
                 BCMA_EBB-C1978-G4 
               
            
           
           
               
               
               
            
               
                 BCMA_EBB- 
                 1177 
                 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-G4- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMGWSSGYL 
               
               
                 ScFv domain 
                   
                 GAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLS 
               
               
                   
                   
                 CRASQSVASSFLAWYQQKPGQAPRLLIYGASGRATGIPDRFSGSGSGTDFTLT 
               
               
                   
                   
                 ISRLEPEDFAVYYCQHYGGSPRLTFGGGTKVDIK 
               
               
                 BCMA_EBB- 
                 1178 
                 GAAGTCCAACTGGTGGAGTCCGGGGGAGGGCTCGTGCAGCCCGGAGGCAGCCT 
               
               
                 C1978-G4- nt 
                   
                 TCGGCTGTCGTGCGCCGCCTCCGGGTTCACGTTCTCATCCTACGCGATGTCGT 
               
               
                 ScFv domain 
                   
                 GGGTCAGACAGGCACCAGGAAAGGGACTGGAATGGGTGTCCGCCATTAGCGGC 
               
               
                   
                   
                 TCCGGCGGTAGCACCTACTATGCCGACTCAGTGAAGGGAAGGTTCACTATCTC 
               
               
                   
                   
                 CCGCGACAACAGCAAGAACACCCTGTACCTCCAAATGAACTCTCTGCGGGCCG 
               
               
                   
                   
                 AGGATACCGCGGTGTACTATTGCGCCAAGATGGGTTGGTCCAGCGGATACTTG 
               
               
                   
                   
                 GGAGCCTTCGACATTTGGGGACAGGGCACTACTGTGACCGTGTCCTCCGGGGG 
               
               
                   
                   
                 TGGCGGATCGGGAGGCGGCGGCTCGGGTGGAGGGGGTTCCGAAATCGTGTTGA 
               
               
                   
                   
                 CCCAGTCACCGGGAACCCTCTCGCTGTCCCCGGGAGAACGGGCTACACTGTCA 
               
               
                   
                   
                 TGTAGAGCGTCCCAGTCCGTGGCTTCCTCGTTCCTGGCCTGGTACCAGCAGAA 
               
               
                   
                   
                 GCCGGGACAGGCACCCCGCCTGCTCATCTACGGAGCCAGCGGCCGGGCGACCG 
               
               
                   
                   
                 GCATCCCTGACCGCTTCTCCGGTTCCGGCTCGGGCACCGACTTTACTCTGACC 
               
               
                   
                   
                 ATTAGCAGGCTTGAGCCCGAGGATTTTGCCGTGTACTACTGCCAACACTACGG 
               
               
                   
                   
                 GGGGAGCCCTCGCCTGACCTTCGGAGGCGGAACTAAGGTCGATATCAAAA 
               
               
                 BCMA_EBB- 
                 1179 
                 EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISG 
               
               
                 C1978-G4- aa 
                   
                 SGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKMGWSSGYL 
               
               
                 VH 
                   
                 GAFDIWGQGTTVTVSS 
               
               
                 BCMA_EBB- 
                 1180 
                 EIVLTQSPGTLSLSPGERATLSCRASQSVASSFLAWYQQKPGQAPRLLIYGAS 
               
               
                 C1978-G4- aa 
                   
                 GRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGGSPRLTFGGGTKV 
               
               
                 VL 
                   
                 DIK 
               
               
                 BCMA_EBB- 
                 1181 
                 MALPVTALLLPLALLLHAARPEVQLVESGGGLVQPGGSLRLSCAASGFTFSSY 
               
               
                 C1978-G4- aa 
                   
                 AMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNS 
               
               
                 Full CART 
                   
                 LRAEDTAVYYCAKMGWSSGYLGAFDIWGQGTTVTVSSGGGGSGGGGSGGGGSE 
               
               
                   
                   
                 IVLTQSPGTLSLSPGERATLSCRASQSVASSFLAWYQQKPGQAPRLLIYGASG 
               
               
                   
                   
                 RATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQHYGGSPRLTFGGGTKVD 
               
               
                   
                   
                 IKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAP 
               
               
                   
                   
                 LAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEE 
               
               
                   
                   
                 EEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMG 
               
               
                   
                   
                 GKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD 
               
               
                   
                   
                 TYDALHMQALPPR 
               
               
                 BCMA_EBB- 
                 1182 
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCACGC 
               
               
                 C1978-G4- nt 
                   
                 CGCTCGGCCCGAAGTCCAACTGGTGGAGTCCGGGGGAGGGCTCGTGCAGCCCG 
               
               
                 Full CART 
                   
                 GAGGCAGCCTTCGGCTGTCGTGCGCCGCCTCCGGGTTCACGTTCTCATCCTAC 
               
               
                   
                   
                 GCGATGTCGTGGGTCAGACAGGCACCAGGAAAGGGACTGGAATGGGTGTCCGC 
               
               
                   
                   
                 CATTAGCGGCTCCGGCGGTAGCACCTACTATGCCGACTCAGTGAAGGGAAGGT 
               
               
                   
                   
                 TCACTATCTCCCGCGACAACAGCAAGAACACCCTGTACCTCCAAATGAACTCT 
               
               
                   
                   
                 CTGCGGGCCGAGGATACCGCGGTGTACTATTGCGCCAAGATGGGTTGGTCCAG 
               
               
                   
                   
                 CGGATACTTGGGAGCCTTCGACATTTGGGGACAGGGCACTACTGTGACCGTGT 
               
               
                   
                   
                 CCTCCGGGGGTGGCGGATCGGGAGGCGGCGGCTCGGGTGGAGGGGGTTCCGAA 
               
               
                   
                   
                 ATCGTGTTGACCCAGTCACCGGGAACCCTCTCGCTGTCCCCGGGAGAACGGGC 
               
               
                   
                   
                 TACACTGTCATGTAGAGCGTCCCAGTCCGTGGCTTCCTCGTTCCTGGCCTGGT 
               
               
                   
                   
                 ACCAGCAGAAGCCGGGACAGGCACCCCGCCTGCTCATCTACGGAGCCAGCGGC 
               
               
                   
                   
                 CGGGCGACCGGCATCCCTGACCGCTTCTCCGGTTCCGGCTCGGGCACCGACTT 
               
               
                   
                   
                 TACTCTGACCATTAGCAGGCTTGAGCCCGAGGATTTTGCCGTGTACTACTGCC 
               
               
                   
                   
                 AACACTACGGGGGGAGCCCTCGCCTGACCTTCGGAGGCGGAACTAAGGTCGAT 
               
               
                   
                   
                 ATCAAAACCACTACCCCAGCACCGAGGCCACCCACCCCGGCTCCTACCATCGC 
               
               
                   
                   
                 CTCCCAGCCTCTGTCCCTGCGTCCGGAGGCATGTAGACCCGCAGCTGGTGGGG 
               
               
                   
                   
                 CCGTGCATACCCGGGGTCTTGACTTCGCCTGCGATATCTACATTTGGGCCCCT 
               
               
                   
                   
                 CTGGCTGGTACTTGCGGGGTCCTGCTGCTTTCACTCGTGATCACTCTTTACTG 
               
               
                   
                   
                 TAAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAGGC 
               
               
                   
                   
                 CTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAGAGGAG 
               
               
                   
                   
                 GAGGAAGGCGGCTGCGAACTGCGCGTGAAATTCAGCCGCAGCGCAGATGCTCC 
               
               
                   
                   
                 AGCCTACAAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGA 
               
               
                   
                   
                 GAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGC 
               
               
                   
                   
                 GGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAA 
               
               
                   
                   
                 GGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAA 
               
               
                   
                   
                 GAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGAC 
               
               
                   
                   
                 ACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                 Additional exemplary BCMA CAR sequences 
               
            
           
           
               
               
               
            
               
                   
                   
                 SEQ 
               
               
                   
                   
                 ID 
               
               
                 Name 
                 Sequence 
                 NO: 
               
               
                   
               
               
                 A7D12.2 
                 QIQLVQSGPDLKKPGETVKLSCKASGYTFTNFGMNWVKQAPGKGFKWMAWINTYTGE 
                 1183 
               
               
                 VH 
                 SYFADDFKGRFAFSVETSATTAYLQINNLKTEDTATYFCARGEIYYGYDGGFAYWGQ 
                   
               
               
                   
                 GTLVTVSA 
                   
               
               
                   
               
               
                 A7D12.2 
                 DVVMTQSHRFMSTSVGDRVSITCRASQDVNTAVSWYQQKPGQSPKLLIFSASYRYTG 
                 1184 
               
               
                 VL 
                 VPDRFTGSGSGADFTLTISSVQAEDLAVYYCQQHYSTPWTFGGGTKLDIK 
                   
               
               
                   
               
               
                 A7D12.2 
                 QIQLVQSGPDLKKPGETVKLSCKASGYTFTNFGMNWVKQAPGKGFKWMAWINTYTGE 
                 1185 
               
               
                 scFv 
                 SYFADDFKGRFAFSVETSATTAYLQINNLKTEDTATYFCARGEIYYGYDGGFAYWGQ 
                   
               
               
                 domain 
                 GTLVTVSAGGGGSGGGGSGGGGSDVVMTQSHRFMSTSVGDRVSITCRASQDVNTAVS 
                   
               
               
                   
                 WYQQKPGQSPKLLIFSASYRYTGVPDRFTGSGSGADFTLTISSVQAEDLAVYYCQQH 
                   
               
               
                   
                 YSTPWTFGGGTKLDIK 
                   
               
               
                   
               
               
                 A7D12.2 
                 QIQLVQSGPDLKKPGETVKLSCKASGYTFTNFGMNWVKQAPGKGFKWMAWINTYTGE 
                 1186 
               
               
                 Full 
                 SYFADDFKGRFAFSVETSATTAYLQINNLKTEDTATYFCARGEIYYGYDGGFAYWGQ 
                   
               
               
                 CART 
                 GTLVTVSAGGGGSGGGGSGGGGSDVVMTQSHRFMSTSVGDRVSITCRASQDVNTAVS 
                   
               
               
                   
                 WYQQKPGQSPKLLIFSASYRYTGVPDRFTGSGSGADFTLTISSVQAEDLAVYYCQQH 
                   
               
               
                   
                 YSTPWTFGGGTKLDIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLD 
                   
               
               
                   
                 FACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCS 
                   
               
               
                   
                 CRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPE 
                   
               
               
                   
                 MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY 
                   
               
               
                   
                 DALHMQALPPR 
                   
               
               
                   
               
               
                 C11D5.3 
                 QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETRE 
                 1187 
               
               
                 VH 
                 PAYAYDFRGRFAFSLETSASTAYLQINNLKYEDTATYFCALDYSYAMDYWGQGTSVT 
                   
               
               
                   
                 VSS 
                   
               
               
                   
               
               
                 C11D5.3 
                 DIVLTQSPASLAMSLGKRATISCRASESVSVIGAHLIHWYQQKPGQPPKLLIYLASN 
                 1188 
               
               
                 VL 
                 LETGVPARFSGSGSGTDFTLTIDPVEEDDVAIYSCLQSRIFPRTFGGGTKLEIK 
                   
               
               
                   
               
               
                 C11D5.3 
                 QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETRE 
                 1189 
               
               
                 scFv 
                 PAYAYDFRGRFAFSLETSASTAYLQINNLKYEDTATYFCALDYSYAMDYWGQGTSVT 
                   
               
               
                 domain 
                 VSSGGGGSGGGGSGGGGSQIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKR 
                   
               
               
                   
                 APGKGLKWMGWINTETREPAYAYDFRGRFAFSLETSASTAYLQINNLKYEDTATYFC 
                   
               
               
                   
                 ALDYSYAMDYWGQGTSVTVSS 
                   
               
               
                   
               
               
                 C11D5.3 
                 QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKRAPGKGLKWMGWINTETRE 
                 1190 
               
               
                 Full 
                 PAYAYDFRGRFAFSLETSASTAYLQINNLKYEDTATYFCALDYSYAMDYWGQGTSVT 
                   
               
               
                 CART 
                 VSSGGGGSGGGGSGGGGSQIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKR 
                   
               
               
                   
                 APGKGLKWMGWINTETREPAYAYDFRGRFAFSLETSASTAYLQINNLKYEDTATYFC 
                   
               
               
                   
                 ALDYSYAMDYWGQGTSVTVSSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVH 
                   
               
               
                   
                 TRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQE 
                   
               
               
                   
                 EDGCSCRFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRR 
                   
               
               
                   
                 GRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTA 
                   
               
               
                   
                 TKDTYDALHMQALPPR 
                   
               
               
                   
               
               
                 C12A3.2 
                 QIQLVQSGPELKKPGETVKISCKASGYTFRHYSMNWVKQAPGKGLKWMGRINTESGV 
                 1191 
               
               
                 VH 
                 PIYADDFKGRFAFSVETSASTAYLVINNLKDEDTASYFCSNDYLYSLDFWGQGTALT 
                   
               
               
                   
                 VSS 
                   
               
               
                   
               
               
                 C12A3.2 
                 DIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLLIQLASN 
                 1192 
               
               
                 VL 
                 VQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK 
                   
               
               
                   
               
               
                 C12A3.2 
                 QIQLVQSGPELKKPGETVKISCKASGYTFRHYSMNWVKQAPGKGLKWMGRINTESGV 
                 1193 
               
               
                 scFv 
                 PIYADDFKGRFAFSVETSASTAYLVINNLKDEDTASYFCSNDYLYSLDFWGQGTALT 
                   
               
               
                 domain 
                 VSSGGGGSGGGGSGGGGSDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYW 
                   
               
               
                   
                 YQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSR 
                   
               
               
                   
                 TIPRTFGGGTKLEIK 
                   
               
               
                   
               
               
                 C12A3.2 
                 QIQLVQSGPELKKPGETVKISCKASGYTFRHYSMNWVKQAPGKGLKWMGRINTESGV 
                 1194 
               
               
                 Full 
                 PIYADDFKGRFAFSVETSASTAYLVINNLKDEDTASYFCSNDYLYSLDFWGQGTALT 
                   
               
               
                 CART 
                 VSSGGGGSGGGGSGGGGSDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYW 
                   
               
               
                   
                 YQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSR 
                   
               
               
                   
                 TIPRTFGGGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF 
                   
               
               
                   
                 ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSC 
                   
               
               
                   
                 RFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEM 
                   
               
               
                   
                 GGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD 
                   
               
               
                   
                 ALHMQALPPR 
                   
               
               
                   
               
               
                 C13F12.1 
                 QIQLVQSGPELKKPGETVKISCKASGYTFTHYSMNWVKQAPGKGLKWMGRINTETGE 
                 1195 
               
               
                 VH 
                 PLYADDFKGRFAFSLETSASTAYLVINNLKNEDTATFFCSNDYLYSCDYWGQGTTLT 
                   
               
               
                   
                 VSS 
                   
               
               
                   
               
               
                 C13F12.1 
                 DIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYWYQQKPGQPPTLLIQLASN 
                 1196 
               
               
                 VL 
                 VQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK 
                   
               
               
                   
               
               
                 C13F12.1 
                 QIQLVQSGPELKKPGETVKISCKASGYTFTHYSMNWVKQAPGKGLKWMGRINTETGE 
                 1197 
               
               
                 scFv 
                 PLYADDFKGRFAFSLETSASTAYLVINNLKNEDTATFFCSNDYLYSCDYWGQGTTLT 
                   
               
               
                 domain 
                 VSSGGGGSGGGGSGGGGSDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYW 
                   
               
               
                   
                 YQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSR 
                   
               
               
                   
                 TIPRTFGGGTKLEIK 
                   
               
               
                   
               
               
                 C13F12.1 
                 QIQLVQSGPELKKPGETVKISCKASGYTFTHYSMNWVKQAPGKGLKWMGRINTETGE 
                 1198 
               
               
                 Full 
                 PLYADDFKGRFAFSLETSASTAYLVINNLKNEDTATFFCSNDYLYSCDYWGQGTTLT 
                   
               
               
                 CART 
                 VSSGGGGSGGGGSGGGGSDIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIYW 
                   
               
               
                   
                 YQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTIDPVEEDDVAVYYCLQSR 
                   
               
               
                   
                 TIPRTFGGGTKLEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF 
                   
               
               
                   
                 ACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSC 
                   
               
               
                   
                 RFPEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEM 
                   
               
               
                   
                 GGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD 
                   
               
               
                   
                 ALHMQALPPR 
               
               
                   
               
            
           
         
       
     
     Exemplary BCMA CAR constructs disclose herein comprise an scFv (e.g., a scFv as disclosed in Table 5 or 6, optionally preceded with an optional leader sequence (e.g., SEQ ID NO: 2 and SEQ ID NO: 3 or 1938 for exemplary leader amino acid and nucleotide sequences, respectively). The sequences of the scFv fragments (e.g., an ScFv from any of SEQ ID NOs: 967-1182, e.g., SEQ ID NOs: 967, 973, 979, 985, 991, 997, 1003, 1009, 1015, 1021, 1027, 1033, 1039, 1045, 1051, 1057, 1063, 1069, 1075, 1081, 1087, 1093, 1099, 1105, 1111, 1117, 1123, 1129, 1135, 1141, 1147, 1153, 1159, 1165, 1171, 1177, not including the optional leader sequence) are provided herein in Tables 5 or 6. The BCMA CAR construct can further include an optional hinge domain, e.g., a CD8 hinge domain (e.g., including the amino acid sequence of SEQ ID NO: 403 or encoded by a nucleic acid sequence of SEQ ID NO: 404); a transmembrane domain, e.g., a CD8 transmembrane domain (e.g., including the amino acid sequence of SEQ ID NO: 12 or encoded by the nucleotide sequence of SEQ ID NO: 13 or 1939); an intracellular domain, e.g., a 4-1BB intracellular domain (e.g., including the amino acid sequence of SEQ ID NO: 14 or encoded by the nucleotide sequence of SEQ ID NO: 15 or 1940; and a functional signaling domain, e.g., a CD3 zeta domain (e.g., including amino acid sequence of SEQ ID NO: 18 or 20, or encoded by the nucleotide sequence of SEQ ID NO: 19, 1941, or 21). In certain embodiments, the domains are contiguous with and in the same reading frame to form a single fusion protein. In other embodiments, the domain are in separate polypeptides, e.g., as in an RCAR molecule as described herein. 
     In certain embodiments, the full length BCMA CAR molecule includes the amino acid sequence of, or is encoded by the nucleotide sequence of, BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1 provided in Table 5 or 6, or a sequence substantially (e.g., 85%, 95-99% or higher) identical thereto. 
     In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes the scFv amino acid sequence of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1 provided in Table 5 or 6 (with or without the leader sequence), or a sequence substantially identical (e.g., 85%, 95-99% or higher identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences. 
     In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes the heavy chain variable region and/or the light chain variable region of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1 provided in Table 5 or 6, or a sequence substantially identical (e.g., 85%, 95-99% or higher identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences. 
     In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes one, two or three CDRs from the heavy chain variable region (e.g., HCDR1, HCDR2 and/or HCDR3), provided in Table 7; and/or one, two or three CDRs from the light chain variable region (e.g., LCDR1, LCDR2 and/or LCDR3) of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1, provided in Table 8; or a sequence substantially identical (e.g., 85%, 95-99% or higher identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences. 
     In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes one, two or three CDRs from the heavy chain variable region (e.g., HCDR1, HCDR2 and/or HCDR3), provided in Table 9; and/or one, two or three CDRs from the light chain variable region (e.g., LCDR1, LCDR2 and/or LCDR3) of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1, provided in Table 10; or a sequence substantially identical (e.g., 85%, 95-99% or higher identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences. 
     In certain embodiments, the BCMA CAR molecule, or the anti-BCMA antigen binding domain, includes one, two or three CDRs from the heavy chain variable region (e.g., HCDR1, HCDR2 and/or HCDR3), provided in Table 11; and/or one, two or three CDRs from the light chain variable region (e.g., LCDR1, LCDR2 and/or LCDR3) of BCMA-1, BCMA-2, BCMA-3, BCMA-4, BCMA-5, BCMA-6, BCMA-7, BCMA-8, BCMA-9, BCMA-10, BCMA-11, BCMA-12, BCMA-13, BCMA-14, BCMA-15, 149362, 149363, 149364, 149365, 149366, 149367, 149368, 149369, BCMA_EBB-C1978-A4, BCMA_EBB-C1978-G1, BCMA_EBB-C1979-C1, BCMA_EBB-C1978-C7, BCMA_EBB-C1978-D10, BCMA_EBB-C1979-C12, BCMA_EBB-C1980-G4, BCMA_EBB-C1980-D2, BCMA_EBB-C1978-A10, BCMA_EBB-C1978-D4, BCMA_EBB-C1980-A2, BCMA_EBB-C1981-C3, BCMA_EBB-C1978-G4, A7D12.2, C11D5.3, C12A3.2, or C13F12.1, provided in Table 12; or a sequence substantially identical (e.g., 85%, 95-99% or higher identical, or up to 20, 15, 10, 8, 6, 5, 4, 3, 2, or 1 amino acid changes, e.g., substitutions (e.g., conservative substitutions)) to any of the aforesaid sequences. 
     The sequences of human CDR sequences of the scFv domains are shown in Tables 7, 9, and 11 for the heavy chain variable domains and in Tables 8, 10, and 12 for the light chain variable domains. “ID” stands for the respective SEQ ID NO for each CDR. 
     
       
         
           
               
             
               
                 TABLE 7 
               
             
            
               
                   
               
               
                 Heavy Chain Variable Domain CDRs according to the 
               
               
                 Kabat numbering scheme (Rabat et al. (1991), 
               
               
                 “Sequences of Proteins of Immunological Interest,” 
               
               
                 5th Ed. Public Health Service, National Institutes of 
               
               
                 Health, Bethesda, MD) 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Candidate 
                 HCDR1 
                 ID 
                 HCDR2 
                 ID 
                 HCDR3 
                 ID 
               
               
                   
               
               
                 139109 
                 NHGMS 
                 1199 
                 GIVYSGSTYYAASVKG 
                 1239 
                 HGGESDV 
                 1279 
               
               
                   
               
               
                 139103 
                 NYAMS 
                 1200 
                 GISRSGENTYYADSVKG 
                 1240 
                 SPAHYYGGMDV 
                 1280 
               
               
                   
               
               
                 139105 
                 DYAMH 
                 1201 
                 GISWNSGSIGYADSVKG 
                 1241 
                 HSFLAY 
                 1281 
               
               
                   
               
               
                 139111 
                 NHGMS 
                 1202 
                 GIVYSGSTYYAASVKG 
                 1242 
                 HGGESDV 
                 1282 
               
               
                   
               
               
                 139100 
                 NFGIN 
                 1203 
                 WINPKNNNTNYAQKFQG 
                 1243 
                 GPYYYQSYMDV 
                 1283 
               
               
                   
               
               
                 139101 
                 SDAMT 
                 1204 
                 VISGSGGTTYYADSVKG 
                 1244 
                 LDSSGYYYARGPR 
                 1284 
               
               
                   
                   
                   
                   
                   
                 Y 
                   
               
               
                   
               
               
                 139102 
                 NYGIT 
                 1205 
                 WISAYNGNTNYAQKFOG 
                 1245 
                 GPYYYYMDV 
                 1285 
               
               
                   
               
               
                 139104 
                 NHGMS 
                 1206 
                 GIVYSGSTYYAASVKG 
                 1246 
                 HGGESDV 
                 1286 
               
               
                   
               
               
                 139106 
                 NHGMS 
                 1207 
                 GIVYSGSTYYAASVKG 
                 1247 
                 HGGESDV 
                 1287 
               
               
                   
               
               
                 139107 
                 NHGMS 
                 1208 
                 GIVYSGSTYYAASVKG 
                 1248 
                 HGGESDV 
                 1288 
               
               
                   
               
               
                 139108 
                 DYYMS 
                 1209 
                 YISSSGSTIYYADSVKG 
                 1249 
                 ESGDGMDV 
                 1289 
               
               
                   
               
               
                 139110 
                 DYYMS 
                 1210 
                 YISSSGNTIYYADSVKG 
                 1250 
                 STMVREDY 
                 1290 
               
               
                   
               
               
                 139112 
                 NHGMS 
                 1211 
                 GIVYSGSTYYAASVKG 
                 1251 
                 HGGESDV 
                 1291 
               
               
                   
               
               
                 139113 
                 NHGMS 
                 1212 
                 GIVYSGSTYYAASVKG 
                 1252 
                 HGGESDV 
                 1292 
               
               
                   
               
               
                 139114 
                 NHGMS 
                 1213 
                 GIVYSGSTYYAASVKG 
                 1253 
                 HGGESDV 
                 1293 
               
               
                   
               
               
                 149362 
                 SSYYYWG 
                 1214 
                 SIYYSGSAYYNPSLKS 
                 1254 
                 HWQEWPDAFDI 
                 1294 
               
               
                   
               
               
                 149363 
                 TSGMCVS 
                 1215 
                 RIDWDEDKEYSTSLKT 
                 1255 
                 SGAGGTSATAFDI 
                 1295 
               
               
                   
               
               
                 149364 
                 SYSMN 
                 1216 
                 SISSSSSYIYYADSVKG 
                 1256 
                 TIAAVYAFDI 
                 1296 
               
               
                   
               
               
                 149365 
                 DYYMS 
                 1217 
                 YISSSGSTIYYADSVKG 
                 1257 
                 DLRGAFDI 
                 1297 
               
               
                   
               
               
                 149366 
                 SHYIH 
                 1218 
                 MINPSGGVTAYSQTLQG 
                 1258 
                 EGSGSGWYFDF 
                 1298 
               
               
                   
               
               
                 149367 
                 SGGYYWS 
                 1219 
                 YIYYSGSTYYNPSLKS 
                 1259 
                 AGIAARLRGAFDI 
                 1299 
               
               
                   
               
               
                 149368 
                 SYAIS 
                 1220 
                 GIIPIFGTANYAQKFQG 
                 1260 
                 RGGYQLLRWDVGL 
                 1300 
               
               
                   
                   
                   
                   
                   
                 LRSAFDI 
                   
               
               
                   
               
               
                 149369 
                 SNSAAWN 
                 1221 
                 RTYYRSKWYSFYAISLK 
                 1261 
                 SSPEGLFLYWFDP 
                 1301 
               
               
                   
                   
                   
                 S 
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1222 
                 AISGSGGSTYYADSVKG 
                 1262 
                 VEGSGSLDY 
                 1302 
               
               
                 C1978-A4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RYFMS 
                 1223 
                 GISDSGVSTYYADSAKG 
                 1263 
                 RAGSEASDl 
                 1303 
               
               
                 C1978-G1 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1224 
                 AISGSGGSTYYADSVKG 
                 1264 
                 ATYKRELRYYYGM 
                 1304 
               
               
                 C1979-C1 
                   
                   
                   
                   
                 DV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1225 
                 AISGSGGSTYYADSVKG 
                 1265 
                 ATYKRELRYYYGM 
                 1305 
               
               
                 C1978-C7 
                   
                   
                   
                   
                 DV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 DYAMH 
                 1226 
                 GISWNSGSIGYADSVKG 
                 1266 
                 VGKAVPDV 
                 1306 
               
               
                 C1978-D10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 DYAMH 
                 1227 
                 SINWKGNSLAYGDSVKG 
                 1267 
                 HQGVAYYNYAMDV 
                 1307 
               
               
                 C1979-C12 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1228 
                 AISGSGGSTYYADSVKG 
                 1268 
                 VVRDGMDV 
                 1308 
               
               
                 C1980-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1229 
                 AISGSGGSTYYADSVKG 
                 1269 
                 IPQTGTFDY 
                 1309 
               
               
                 C1980-D2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1230 
                 AISGSGGSTYYADSVKG 
                 1270 
                 ANYKRELRYYYGM 
                 1310 
               
               
                 C1978-A10 
                   
                   
                   
                   
                 DV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1231 
                 AISGSGGSTYYADSVKG 
                 1271 
                 ALVGATGAFDI 
                 1311 
               
               
                 C1978-D4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1232 
                 AISGSGGSTYYADSVKG 
                 1272 
                 WFGEGFDP 
                 1312 
               
               
                 C1980-A2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1233 
                 AISGSGGSTYYADSVKG 
                 1273 
                 VGYDSSGYYRDYY 
                 1313 
               
               
                 C1981-C3 
                   
                   
                   
                   
                 GMDV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SYAMS 
                 1234 
                 AISGSGGSTYYADSVKG 
                 1274 
                 MGWSSGYLGAFDI 
                 1314 
               
               
                 C1978-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 A7D12.2 
                 NFGMN 
                 1235 
                 WINTYTGESYFADDFKG 
                 1275 
                 GEIYYGYDGGFAY 
                 1315 
               
               
                   
               
               
                 C11D5.3 
                 DYSIN 
                 1236 
                 WINTETREPAYAYDFRG 
                 1276 
                 DYSYAMDY 
                 1316 
               
               
                   
               
               
                 C12A3.2 
                 HYSMN 
                 1237 
                 RINTESGVPIYADDFKG 
                 1277 
                 DYLYSLDF 
                 1317 
               
               
                   
               
               
                 C13F12.1 
                 HYSMN 
                 1238 
                 RINTETGEPLYADDFKG 
                 1278 
                 DYLYSCDY 
                 1318 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 8 
               
             
            
               
                   
               
               
                 Light Chain Variable Domain CDRs according to the 
               
               
                 Kabat numbering scheme (Kabat et al. (1991), 
               
               
                 “Sequences of Proteins of Immunological Interest,” 
               
               
                 5th Ed. Public Health Service, National Institutes 
               
               
                 of Health, Bethesda, MD) 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Candidate 
                 LCDR1 
                 ID 
                 LCDR2 
                 ID 
                 LCDR3 
                 ID 
               
               
                   
               
               
                 139109 
                 RASQSISSYLN 
                 1319 
                 AASSLQS 
                 1359 
                 QQSYSTPYT 
                 1399 
               
               
                   
               
               
                 139103 
                 RASQSISSSFLA 
                 1320 
                 GASRRAT 
                 1360 
                 QQYHSSPSWT 
                 1400 
               
               
                   
               
               
                 139105 
                 RSSQSLLHSNGYNYLD 
                 1321 
                 LGSNRAS 
                 1361 
                 MQALQTPYT 
                 1401 
               
               
                   
               
               
                 139111 
                 KSSQSLLRNDGKTPLY 
                 1322 
                 EVSNRFS 
                 1362 
                 MQNIQFPS 
                 1402 
               
               
                   
               
               
                 139100 
                 RSSQSLLHSNGYNYLN 
                 1323 
                 LGSKRAS 
                 1363 
                 MQALQTPYT 
                 1403 
               
               
                   
               
               
                 139101 
                 RASQSISSYLN 
                 1324 
                 GASTLAS 
                 1364 
                 QQSYKRAS 
                 1404 
               
               
                   
               
               
                 139102 
                 RSSQSLLYSNGYNYVD 
                 1325 
                 LGSNRAS 
                 1365 
                 MQGRQFPYS 
                 1405 
               
               
                   
               
               
                 139104 
                 RASQSVSSNLA 
                 1326 
                 GASTRAS 
                 1366 
                 QQYGSSLT 
                 1406 
               
               
                   
               
               
                 139106 
                 RASQSVSSKLA 
                 1327 
                 GASIRAT 
                 1367 
                 QQYGSSSWT 
                 1407 
               
               
                   
               
               
                 139107 
                 RASQSVGSTNLA 
                 1328 
                 DASNRAT 
                 1368 
                 QQYGSSPPWT 
                 1408 
               
               
                   
               
               
                 139108 
                 RASQSISSYLN 
                 1329 
                 AASSLQS 
                 1369 
                 QQSYTLA 
                 1409 
               
               
                   
               
               
                 139110 
                 KSSESLVHNSGKTYLN 
                 1330 
                 EVSNRDS 
                 1370 
                 MQGTHWPGT 
                 1410 
               
               
                   
               
               
                 139112 
                 QASEDINKFLN 
                 1331 
                 DASTLQT 
                 1371 
                 QQYESLPLT 
                 1411 
               
               
                   
               
               
                 139113 
                 RASQSVGSNLA 
                 1332 
                 GASTRAT 
                 1372 
                 QQYNDWLPVT 
                 1412 
               
               
                   
               
               
                 139114 
                 RASQSIGSSSLA 
                 1333 
                 GASSRAS 
                 1373 
                 QQYAGSPPFT 
                 1413 
               
               
                   
               
               
                 149362 
                 KASQDIDDAMN 
                 1334 
                 SATSPVP 
                 1374 
                 LQHDNFPLT 
                 1414 
               
               
                   
               
               
                 149363 
                 RASQDIYNNLA 
                 1335 
                 AANKSQS 
                 1375 
                 QHYYRFPYS 
                 1415 
               
               
                   
               
               
                 149364 
                 RSSQSLLHSNGYNYLD 
                 1336 
                 LGSNRAS 
                 1376 
                 MQALQTPYT 
                 1416 
               
               
                   
               
               
                 149365 
                 GGNNIGTKSVH 
                 1337 
                 DDSVRPS 
                 1377 
                 QVWDSDSEHV 
                 1417 
               
               
                   
                   
                   
                   
                   
                 V 
                   
               
               
                   
               
               
                 149366 
                 SGDGLSKKYVS 
                 1338 
                 RDKERPS 
                 1378 
                 QAWDDTTVV 
                 1418 
               
               
                   
               
               
                 149367 
                 RASQGIRNWLA 
                 1339 
                 AASNLQS 
                 1379 
                 QKYNSAPFT 
                 1419 
               
               
                   
               
               
                 149368 
                 GGNNIGSKSVH 
                 1340 
                 GKNNRPS 
                 1380 
                 SSRDSSGDHLR 
                 1420 
               
               
                   
                   
                   
                   
                   
                 V 
                   
               
               
                   
               
               
                 149369 
                 QGDSLGNYYAT 
                 1341 
                 GTNNRPS 
                 1381 
                 NSRDSSGHHLL 
                 1421 
               
               
                   
               
               
                 BCMA_EB 
                 RASQSVSSAYLA 
                 1342 
                 GASTRAT 
                 1382 
                 QHYGSSFNGSS 
                 1422 
               
               
                 B-C1978- 
                   
                   
                   
                   
                 LFT 
                   
               
               
                 A4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSVSNSLA 
                 1343 
                 DASSRAT 
                 1383 
                 QQFGTSSGLT 
                 1423 
               
               
                 B-C1978- 
                   
                   
                   
                   
                   
                   
               
               
                 G1 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSVSSSFLA 
                 1344 
                 GASSRAT 
                 1384 
                 QQYHSSPSWT 
                 1424 
               
               
                 B-C1979- 
                   
                   
                   
                   
                   
                   
               
               
                 C1 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSVSTTFLA 
                 1345 
                 GSSNRAT 
                 1385 
                 QQYHSSPSWT 
                 1425 
               
               
                 B-C1978- 
                   
                   
                   
                   
                   
                   
               
               
                 C7 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSISSYLN 
                 1346 
                 AASSLQS 
                 1386 
                 QQSYSTPYS 
                 1426 
               
               
                 B-C1978- 
                   
                   
                   
                   
                   
                   
               
               
                 D10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RATQSIGSSFLA 
                 1347 
                 GASQRAT 
                 1387 
                 QHYESSPSWT 
                 1427 
               
               
                 B-C1979- 
                   
                   
                   
                   
                   
                   
               
               
                 C12 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSVSSSYLA 
                 1348 
                 GASSRAT 
                 1388 
                 QQYGSPPRFT 
                 1428 
               
               
                 B-C1980- 
                   
                   
                   
                   
                   
                   
               
               
                 G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSVSSSYLA 
                 1349 
                 GASSRAT 
                 1389 
                 QHYGSSPSWT 
                 1429 
               
               
                 B-C1980- 
                   
                   
                   
                   
                   
                   
               
               
                 D2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQRVASNYLA 
                 1350 
                 GASSRAT 
                 1390 
                 QHYDSSPSWT 
                 1430 
               
               
                 B-C1978- 
                   
                   
                   
                   
                   
                   
               
               
                 A10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSLSSNFLA 
                 1351 
                 GASNVVAT 
                 1391 
                 QYYGTSPMYT 
                 1431 
               
               
                 B-C1978- 
                   
                   
                   
                   
                   
                   
               
               
                 D4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RSSQSLLHSNGYNYLD 
                 1352 
                 LGSNRAS 
                 1392 
                 MQALQTPLT 
                 1432 
               
               
                 B-C1980- 
                   
                   
                   
                   
                   
                   
               
               
                 A2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSVSSSYLA 
                 1353 
                 GTSSRAT 
                 1393 
                 QHYGNSPPKFT 
                 1433 
               
               
                 B-C1981- 
                   
                   
                   
                   
                   
                   
               
               
                 C3 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EB 
                 RASQSVASSFLA 
                 1354 
                 GASGRAT 
                 1394 
                 QHYGGSPRLT 
                 1434 
               
               
                 B-C1978- 
                   
                   
                   
                   
                   
                   
               
               
                 G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 A7D12.2 
                 RASQDVNTAVS 
                 1355 
                 SASYRYT 
                 1395 
                 QQHYSTPWT 
                 1435 
               
               
                   
               
               
                 C11D5.3 
                 RASESVSVIGAHLIH 
                 1356 
                 LASNLET 
                 1396 
                 LQSRIFPRT 
                 1436 
               
               
                   
               
               
                 C12A3.2 
                 RASESVTILGSHLIY 
                 1357 
                 LASNVQT 
                 1397 
                 LQSRTIPRT 
                 1437 
               
               
                   
               
               
                 C13F12.1 
                 RASESVTILGSHLIY 
                 1358 
                 LASNVQT 
                 1398 
                 LQSRTIPRT 
                 1438 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 9 
               
             
            
               
                   
               
               
                 Heavy Chain Variable Domain CDRs according 
               
               
                 to the Chothia numbering scheme 
               
               
                 (A1-Lazikani et al., (1997) JMB 273,927-948)  
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Candidate 
                 HCDR1 
                 ID 
                 HCDR2 
                 ID 
                 HCDR3 
                 ID 
               
               
                   
               
               
                 139109 
                 GFALSNH 
                 1439 
                 VYSGS 
                 1479 
                 HGGESDV 
                 1519 
               
               
                   
               
               
                 139103 
                 GFTFSNY 
                 1440 
                 SRSGEN 
                 1480 
                 SPAHYYG 
                 1520 
               
               
                   
                   
                   
                   
                   
                 GMDV 
                   
               
               
                   
               
               
                 139105 
                 GFTFDDY 
                 1441 
                 SWNSGS 
                 1481 
                 HSFLAY 
                 1521 
               
               
                   
               
               
                 139111 
                 GFALSNH 
                 1442 
                 VYSGS 
                 1482 
                 HGGESDV 
                 1522 
               
               
                   
               
               
                 139100 
                 GYIFDNF 
                 1443 
                 NPKNNN 
                 1483 
                 GPYYYQS 
                 1523 
               
               
                   
                   
                   
                   
                   
                 YMDV 
                   
               
               
                   
               
               
                 139101 
                 GFTFSSD 
                 1444 
                 SGSGGT 
                 1484 
                 LDSSGYY 
                 1524 
               
               
                   
                   
                   
                   
                   
                 YARGPRY 
                   
               
               
                   
               
               
                 139102 
                 GYTFSNY 
                 1445 
                 SAYNGN 
                 1485 
                 GPYYYYM 
                 1525 
               
               
                   
                   
                   
                   
                   
                 DV 
                   
               
               
                   
               
               
                 139104 
                 GFALSNH 
                 1446 
                 VYSGS 
                 1486 
                 HGGESDV 
                 1526 
               
               
                   
               
               
                 139106 
                 GFALSNH 
                 1447 
                 VYSGS 
                 1487 
                 HGGESDV 
                 1527 
               
               
                   
               
               
                 139107 
                 GFALSNH 
                 1448 
                 VYSGS 
                 1488 
                 HGGESDV 
                 1528 
               
               
                   
               
               
                 139108 
                 GFTFSDY 
                 1449 
                 SSSGST 
                 1489 
                 ESGDGMDV 
                 1529 
               
               
                   
               
               
                 139110 
                 GFTFSDY 
                 1450 
                 SSSGNT 
                 1490 
                 STMVREDY 
                 1530 
               
               
                   
               
               
                 139112 
                 GFALSNH 
                 1451 
                 VYSGS 
                 1491 
                 HGGESDV 
                 1531 
               
               
                   
               
               
                 139113 
                 GFALSNH 
                 1452 
                 VYSGS 
                 1492 
                 HGGESDV 
                 1532 
               
               
                   
               
               
                 139114 
                 GFALSNH 
                 1453 
                 VYSGS 
                 1493 
                 HGGESDV 
                 1533 
               
               
                   
               
               
                 149362 
                 GGSISSSYY 
                 1454 
                 YYSGS 
                 1494 
                 HWQEWPDA 
                 1534 
               
               
                   
                   
                   
                   
                   
                 FDI 
                   
               
               
                   
               
               
                 149363 
                 GFSLRTSGM 
                 1455 
                 DWDED 
                 1495 
                 SGAGGTSA 
                 1535 
               
               
                   
                   
                   
                   
                   
                 TAFDI 
                   
               
               
                   
               
               
                 149364 
                 GFTFSSY 
                 1456 
                 SSSSSY 
                 1496 
                 TIAAVYAF 
                 1536 
               
               
                   
                   
                   
                   
                   
                 DI 
                   
               
               
                   
               
               
                 149365 
                 GFTFSDY 
                 1457 
                 SSSGST 
                 1497 
                 DLRGAFDI 
                 1537 
               
               
                   
               
               
                 149366 
                 GYTVTSH 
                 1458 
                 NPSGGV 
                 1498 
                 EGSGSGWY 
                 1538 
               
               
                   
                   
                   
                   
                   
                 FDF 
                   
               
               
                   
               
               
                 149367 
                 GGSISSGGY 
                 1459 
                 YYSGS 
                 1499 
                 AGIAARLR 
                 1539 
               
               
                   
                   
                   
                   
                   
                 GAFDI 
                   
               
               
                   
               
               
                 149368 
                 GGTFSSY 
                 1460 
                 IPIFGT 
                 1500 
                 RGGYQLLR 
                 1540 
               
               
                   
                   
                   
                   
                   
                 WDVGLLRS 
                   
               
               
                   
                   
                   
                   
                   
                 AFDI 
                   
               
               
                   
               
               
                 149369 
                 GDSVSSNSA 
                 1461 
                 YYRSKWY 
                 1501 
                 SSPEGLFL 
                 1541 
               
               
                   
                   
                   
                   
                   
                 YWFDP 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1462 
                 SGSGGS 
                 1502 
                 VEGSGSLD 
                 1542 
               
               
                 C1978-A4 
                   
                   
                   
                   
                 Y 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 G1TFSRY 
                 1463 
                 SDSGVS 
                 1503 
                 RAGSEASD 
                 1543 
               
               
                 C1978-G1 
                   
                   
                   
                   
                 I 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1464 
                 SGSGGS 
                 1504 
                 ATYKRELR 
                 1544 
               
               
                 C1979-C1 
                   
                   
                   
                   
                 YYYGMDV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1465 
                 SGSGGS 
                 1505 
                 ATYKRELR 
                 1545 
               
               
                 C1978-C7 
                   
                   
                   
                   
                 YYYGMDV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFDDY 
                 1466 
                 SWNSGS 
                 1506 
                 VGKAVPDV 
                 1546 
               
               
                 C1978-D10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFDDY 
                 1467 
                 NWKGNS 
                 1507 
                 HQGVAYYN 
                 1547 
               
               
                 C1979-C12 
                   
                   
                   
                   
                 YAMDV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1468 
                 SGSGGS 
                 1508 
                 VVRDGMDV 
                 1548 
               
               
                 C1980-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1469 
                 SGSGGS 
                 1509 
                 IPQTGTFD 
                 1549 
               
               
                 C1980-D2 
                   
                   
                   
                   
                 Y 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1470 
                 SGSGGS 
                 1510 
                 ANYKRELR 
                 1550 
               
               
                 C1978-A10 
                   
                   
                   
                   
                 YYYGMDV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFSFSSY 
                 1471 
                 SGSGGS 
                 1511 
                 ALVGATGA 
                 1551 
               
               
                 C1978-D4 
                   
                   
                   
                   
                 FDI 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1472 
                 SGSGGS 
                 1512 
                 WFGEGFDP 
                 1552 
               
               
                 C1980-A2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1473 
                 SGSGGS 
                 1513 
                 VGYDSSGY 
                 1553 
               
               
                 C1981-C3 
                   
                   
                   
                   
                 YRDYYGMD 
                   
               
               
                   
                   
                   
                   
                   
                 V 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSY 
                 1474 
                 SGSGGS 
                 1514 
                 MGWSSGYL 
                 1554 
               
               
                 C1978-G4 
                   
                   
                   
                   
                 GAFDI 
                   
               
               
                   
               
               
                 A7D12.2 
                 GYTFTNF 
                 1475 
                 NTYTGE 
                 1515 
                 GEIYYGYD 
                 1555 
               
               
                   
                   
                   
                   
                   
                 GGFAY 
                   
               
               
                   
               
               
                 C11D5.3 
                 GYTFTDY 
                 1476 
                 NTETRE 
                 1516 
                 DYSYAMDY 
                 1556 
               
               
                   
               
               
                 C12A3.2 
                 GYTFRHY 
                 1477 
                 NTESGV 
                 1517 
                 DYLYSLDF 
                 1557 
               
               
                   
               
               
                 C13F12.1 
                 GYTFTHY 
                 1478 
                 NTETGE 
                 1518 
                 DYLYSCDY 
                 1558 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 10 
               
             
            
               
                   
               
               
                 Light Chain Variable Domain CDRs according 
               
               
                 to the Chothia numbering scheme 
               
               
                 (A1-Lazikani et al., (1997) JMB 273,927-948)  
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Candidate 
                 LCDR1 
                 ID 
                 LCDR2 
                 ID 
                 LCDR3 
                 ID 
               
               
                   
               
               
                 139109 
                 SQSISSY 
                 1559 
                 AAS 
                 1599 
                 SYSTPY 
                 1639 
               
               
                   
               
               
                 139103 
                 SQSISSSF 
                 1560 
                 GAS 
                 1600 
                 YHSSPSW 
                 1640 
               
               
                   
               
               
                 139105 
                 SQSLLHSNGYNY 
                 1561 
                 LGS 
                 1601 
                 ALQTPY 
                 1641 
               
               
                   
               
               
                 139111 
                 SQSLLRNDGKTP 
                 1562 
                 EVS 
                 1602 
                 NIQFP 
                 1642 
               
               
                   
               
               
                 139100 
                 SQSLLHSNGYNY 
                 1563 
                 LGS 
                 1603 
                 ALQTPY 
                 1643 
               
               
                   
               
               
                 139101 
                 SQSISSY 
                 1564 
                 GAS 
                 1604 
                 SYKRA 
                 1644 
               
               
                   
               
               
                 139102 
                 SQSLLYSNGYNY 
                 1565 
                 LGS 
                 1605 
                 GRQFPY 
                 1645 
               
               
                   
               
               
                 139104 
                 SQSVSSN 
                 1566 
                 GAS 
                 1606 
                 YGSSL 
                 1646 
               
               
                   
               
               
                 139106 
                 SQSVSSK 
                 1567 
                 GAS 
                 1607 
                 YGSSSW 
                 1647 
               
               
                   
               
               
                 139107 
                 SQSVGSTN 
                 1568 
                 DAS 
                 1608 
                 YGSSPPW 
                 1648 
               
               
                   
               
               
                 139108 
                 SQSISSY 
                 1569 
                 AAS 
                 1609 
                 SYTL 
                 1649 
               
               
                   
               
               
                 139110 
                 SESLVHNSGKTY 
                 1570 
                 EVS 
                 1610 
                 GTHWPG 
                 1650 
               
               
                   
               
               
                 139112 
                 SEDINKF 
                 1571 
                 DAS 
                 1611 
                 YESLPL 
                 1651 
               
               
                   
               
               
                 139113 
                 SQSVGSN 
                 1572 
                 GAS 
                 1612 
                 YNDWLPV 
                 1652 
               
               
                   
               
               
                 139114 
                 SQSIGSSS 
                 1573 
                 GAS 
                 1613 
                 YAGSPPF 
                 1653 
               
               
                   
               
               
                 149362 
                 SQDIDDA 
                 1574 
                 SAT 
                 1614 
                 HDNFPL 
                 1654 
               
               
                   
               
               
                 149363 
                 SQDIYNN 
                 1575 
                 AAN 
                 1615 
                 yyRFpy 
                 1655 
               
               
                   
               
               
                 149364 
                 SQSLLHSNGYNY 
                 1576 
                 LGS 
                 1616 
                 ALQTPY 
                 1656 
               
               
                   
               
               
                 149365 
                 NNIGTKS 
                 1577 
                 DDS 
                 1617 
                 WDSDSEHV 
                 1657 
               
               
                   
               
               
                 149366 
                 DGLSKKY 
                 1578 
                 RDK 
                 1618 
                 WDDTTV 
                 1658 
               
               
                   
               
               
                 149367 
                 SQGIRNW 
                 1579 
                 AAS 
                 1619 
                 YNSAPF 
                 1659 
               
               
                   
               
               
                 149368 
                 NNIGSKS 
                 1580 
                 GKN 
                 1620 
                 RDSSGDHLR 
                 1660 
               
               
                   
               
               
                 149369 
                 DSLGNYY 
                 1581 
                 GTN 
                 1621 
                 RDSSGHHL 
                 1661 
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSVSSAY 
                 1582 
                 GAS 
                 1622 
                 YGSSFNGSS 
                 1662 
               
               
                 C1978-A4 
                   
                   
                   
                   
                 LF 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSVSNS 
                 1583 
                 DAS 
                 1623 
                 FGTSSGL 
                 1663 
               
               
                 C1978-G1 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSVSSSF 
                 1584 
                 GAS 
                 1624 
                 YHSSPSW 
                 1664 
               
               
                 C1979-C1 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSVSTTF 
                 1585 
                 GSS 
                 1625 
                 YHSSPSW 
                 1665 
               
               
                 C1978-C7 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSISSY 
                 1586 
                 AAS 
                 1626 
                 SYSTPY 
                 1666 
               
               
                 C1978-D10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 TQSIGSSF 
                 1587 
                 GAS 
                 1627 
                 YESSPSW 
                 1667 
               
               
                 C1979-C12 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSVSSSY 
                 1588 
                 GAS 
                 1628 
                 YGSPPRF 
                 1668 
               
               
                 C1980-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSVSSSY 
                 1589 
                 GAS 
                 1629 
                 YGSSPSW 
                 1669 
               
               
                 C1980-D2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQRVASNY 
                 1590 
                 GAS 
                 1630 
                 YDSSPSW 
                 1670 
               
               
                 C1978-A10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSLSSNF 
                 1591 
                 GAS 
                 1631 
                 YGTSPMY 
                 1671 
               
               
                 C1978-D4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSLLHSNGYNY 
                 1592 
                 LGS 
                 1632 
                 ALQTPL 
                 1672 
               
               
                 C1980-A2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSVSSSY 
                 1593 
                 GTS 
                 1633 
                 YGNSPPKF 
                 1673 
               
               
                 C1981-C3 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 SQSVASSF 
                 1594 
                 GAS 
                 1634 
                 YGGSPRL 
                 1674 
               
               
                 C1978-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 A7D12.2 
                 SQDVNTA 
                 1595 
                 SAS 
                 1635 
                 HYSTPW 
                 1675 
               
               
                   
               
               
                 C11D5.3 
                 SESVSVIGAHL 
                 1596 
                 LAS 
                 1636 
                 SRIFPR 
                 1676 
               
               
                   
               
               
                 C12A3.2 
                 SESVTILGSHL 
                 1597 
                 LAS 
                 1637 
                 SRTIPR 
                 1677 
               
               
                   
               
               
                 C13F12.1 
                 SESVTILGSHL 
                 1598 
                 LAS 
                 1638 
                 SRTIPR 
                 1678 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 11 
               
             
            
               
                   
               
               
                 Heavy Chain Variable Domain CDRs according to a combination of 
               
               
                 the Kabat numbering scheme (Kabat et al. (1991), “Sequences of 
               
               
                 Proteins of Immunological Interest,” 5th Ed. Public Health 
               
               
                 Service, National Institutes of Health, Bethesda, MD) and the 
               
               
                 Chothia numbering scheme (A1-Lazikani et al., (1997) JMB 
               
               
                 273,927-948). 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Candidate 
                 HCDR1 
                 ID 
                 HCDR2 
                 ID 
                 HCDR3 
                 ID 
               
               
                   
               
               
                 139109 
                 GFALSNHGMS 
                 1679 
                 GIVYSGSTYYAASVKG 
                 1719 
                 HGGESDV 
                 1759 
               
               
                   
               
               
                 139103 
                 GFTFSNYAMS 
                 1680 
                 GISRSGENTYYADSVKG 
                 1720 
                 SPAHYYGGMDV 
                 1760 
               
               
                   
               
               
                 139105 
                 GFTFDDYAMH 
                 1681 
                 GISWNSGSIGYADSVKG 
                 1721 
                 HSFLAY 
                 1761 
               
               
                   
               
               
                 139111 
                 GFALSNHGMS 
                 1682 
                 GIVYSGSTYYAASVKG 
                 1722 
                 HGGESDV 
                 1762 
               
               
                   
               
               
                 139100 
                 GYIFDNFGIN 
                 1683 
                 WINPKNNNTNYAQKFQG 
                 1723 
                 GPYYYQSYMDV 
                 1763 
               
               
                   
               
               
                 139101 
                 GFTFSSDAMT 
                 1684 
                 VISGSGGTTYYADSVKG 
                 1724 
                 LDSSGYYYARGPRY 
                 1764 
               
               
                   
               
               
                 139102 
                 GYTESNYGIT 
                 1685 
                 WISAYNGNTNYAOKFQG 
                 1725 
                 GPYYYYMDV 
                 1765 
               
               
                   
               
               
                 139104 
                 GFALSNHGMS 
                 1686 
                 GIVYSGSTYYAASVKG 
                 1726 
                 HGGESDV 
                 1766 
               
               
                   
               
               
                 139106 
                 GFALSNHGMS 
                 1687 
                 GIVYSGSTYYAASVKG 
                 1727 
                 HGGESDV 
                 1767 
               
               
                   
               
               
                 139107 
                 GFALSNHGMS 
                 1688 
                 GIVYSGSTYYAASVKG 
                 1728 
                 HGGESDV 
                 1768 
               
               
                   
               
               
                 139108 
                 GFTFSDYYMS 
                 1689 
                 YISSSGSTIYYADSVKG 
                 1729 
                 ESGDGMDV 
                 1769 
               
               
                   
               
               
                 139110 
                 GFTFSDYYMS 
                 1690 
                 YISSSGNTIYYADSVKG 
                 1730 
                 STMVREDY 
                 1770 
               
               
                   
               
               
                 139112 
                 GFALSNHGMS 
                 1691 
                 GIVYSGSTYYAASVKG 
                 1731 
                 HGGESDV 
                 1771 
               
               
                   
               
               
                 139113 
                 GFALSNHGMS 
                 1692 
                 GIVYSGSTYYAASVKG 
                 1732 
                 HGGESDV 
                 1772 
               
               
                   
               
               
                 139114 
                 GFALSNHGMS 
                 1693 
                 GIVYSGSTYYAASVKG 
                 1733 
                 HGGESDV 
                 1773 
               
               
                   
               
               
                 149362 
                 GGSISSSYYY 
                 1694 
                 SIVYSGSAYYNPSLKS 
                 1734 
                 HWQEWPDAFDI 
                 1774 
               
               
                   
                 WG 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 149363 
                 GFSLRTSGMC 
                 1695 
                 RIDWDEDKFYSTSLKT 
                 1735 
                 SGAGGTSATAFDI 
                 1775 
               
               
                   
                 VS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 149364 
                 GFTFSSYSMN 
                 1696 
                 SISSSSSYIYYADSVKG 
                 1736 
                 TIAAVYAFDI 
                 1776 
               
               
                   
               
               
                 149365 
                 GFTFSDYYMS 
                 1697 
                 YISSSGSTIYYADSVKG 
                 1737 
                 DLRGAFDI 
                 1777 
               
               
                   
               
               
                 149366 
                 GYTVTSHYIH 
                 1698 
                 MINPSGGVTAYSQTLQG 
                 1738 
                 EGSGSGWYFDF 
                 1778 
               
               
                   
               
               
                 149367 
                 GGSISSGGYY 
                 1699 
                 YIYYSGSTYYNPSLKS 
                 1739 
                 AGIAARLRGAFDI 
                 1779 
               
               
                   
                 WS 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 149368 
                 GGTFSSYAIS 
                 1700 
                 GIIPIFGTANYAQKFQG 
                 1740 
                 RGGYQLLRWDVGLL 
                 1780 
               
               
                   
                   
                   
                   
                   
                 RSAFDI 
                   
               
               
                   
               
               
                 149369 
                 GDSVSSNSAA 
                 1701 
                 RTYYRSKWYSFYAISLKS 
                 1741 
                 SSPEGLFLYWFDP 
                 1781 
               
               
                   
                 WN 
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMAJEBB- 
                 GFTFSSYAMS 
                 1702 
                 AISGSGGSTYYADSVKG 
                 1742 
                 VEGSGSLDY 
                 1782 
               
               
                 C1978-A4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GITFSRYPMS 
                 1703 
                 GISDSGVSTYYADSAKG 
                 1743 
                 RAGSEASDI 
                 1783 
               
               
                 C1978-G1 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSYAMS 
                 1704 
                 AISGSGGSTYYADSVKG 
                 1744 
                 ATYKRELRYYYGMD 
                 1784 
               
               
                 C1979-C1 
                   
                   
                   
                   
                 V 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSYAMS 
                 1705 
                 AISGSGGSTYYADSVKG 
                 1745 
                 ATYKRELRYYYGMD 
                 1785 
               
               
                 C1978-C7 
                   
                   
                   
                   
                 V 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFDDYAMH 
                 1706 
                 GISWNSGSIGYADSVKG 
                 1746 
                 VGKAVPDV 
                 1786 
               
               
                 C1978-D10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFDDYAMH 
                 1707 
                 SIMVKGNSLAYGDSVKG 
                 1747 
                 HQGVAYYNYAMDV 
                 1787 
               
               
                 C1979-C12 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSYAMS 
                 1708 
                 AISGSGGSTYYADSVKG 
                 1748 
                 VVRDGMDV 
                 1788 
               
               
                 C1980-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSYAMS 
                 1709 
                 AISGSGGSTYYADSVKG 
                 1749 
                 IPQTGTFDY 
                 1789 
               
               
                 C1980-D2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSYAMS 
                 1710 
                 AISGSGGSTYYADSVKG 
                 1750 
                 ANYKRELRYYYGMD 
                 1790 
               
               
                 C1978-A10 
                   
                   
                   
                   
                 V 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFSFSSYAMS 
                 1711 
                 AISGSGGSTYYADSVKG 
                 1751 
                 ALVGATGAFDI 
                 1791 
               
               
                 C1978-D4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSYAMS 
                 1712 
                 AISGSGGSTYYADSVKG 
                 1752 
                 WFGEGFDP 
                 1792 
               
               
                 C1980-A2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSYAMS 
                 1713 
                 AISGSGGSTYYADSVKG 
                 1753 
                 VGYDSSGYYRDYYG 
                 1793 
               
               
                 C1981-C3 
                   
                   
                   
                   
                 MDV 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 GFTFSSYAMS 
                 1714 
                 AISGSGGSTYYADSVKG 
                 1754 
                 MGWSSGYLGAFDI 
                 1794 
               
               
                 C1978-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 A7D12.2 
                 GYTFTNFGMN 
                 1715 
                 WINTYTGESYFADDFKG 
                 1755 
                 GEIYYGYDGGFAY 
                 1795 
               
               
                   
               
               
                 C11D5.3 
                 GYTFTDYSIN 
                 1716 
                 WINTETREPAYAYDFRG 
                 1756 
                 DYSYAMDY 
                 1796 
               
               
                   
               
               
                 C12A3.2 
                 GYTFRHYSMN 
                 1717 
                 RINTESGVPIYADDFKG 
                 1757 
                 DYLYSLDF 
                 1797 
               
               
                   
               
               
                 C13F12.1 
                 GYTFTHYSMN 
                 1718 
                 RINTETGEPLYADDFKG 
                 1758 
                 DYLYSCDY 
                 1798 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 12 
               
             
            
               
                   
               
               
                 Light Chain Variable Domain CDRs according to a combination of 
               
               
                 the Kabat numbering scheme (Kabat et al. (1991), “Sequences of 
               
               
                 Proteins of Immunological Interest,” 5th Ed. Public Health 
               
               
                 Service, National Institutes of Health, Bethesda, MD) and the 
               
               
                 Chothia numbering scheme (A1-Lazikani et al., (1997) JMB 
               
               
                 273,927-948). 
               
            
           
           
               
               
               
               
               
               
               
            
               
                 Candidate 
                 LCDR1 
                 ID 
                 LCDR2 
                 ID 
                 LCDR3 
                 ID 
               
               
                   
               
               
                 139109 
                 RASQSISSYLN 
                 1799 
                 AASSLQS 
                 1839 
                 QQSYSTPYT 
                 1879 
               
               
                   
               
               
                 139103 
                 RASQSISSSFLA 
                 1800 
                 GASRRAT 
                 1840 
                 QQYHSSPSWT 
                 1880 
               
               
                   
               
               
                 139105 
                 RSSQSLLHSNGYNYLD 
                 1801 
                 LGSNRAS 
                 1841 
                 MQALQTPYT 
                 1881 
               
               
                   
               
               
                 139111 
                 KSSQSLLRNDGKTPLY 
                 1802 
                 EVSNRFS 
                 1842 
                 MQNIQFPS 
                 1882 
               
               
                   
               
               
                 139100 
                 RSSQSLLHSNGYNYLN 
                 1803 
                 LGSKRAS 
                 1843 
                 MQALQTPYT 
                 1883 
               
               
                   
               
               
                 139101 
                 RASQSISSYLN 
                 1804 
                 GASTLAS 
                 1844 
                 QQSYKRAS 
                 1884 
               
               
                   
               
               
                 139102 
                 RSSQSLLYSNGYNYVD 
                 1805 
                 LGSNRAS 
                 1845 
                 MQGRQFPYS 
                 1885 
               
               
                   
               
               
                 139104 
                 RASQSVSSNLA 
                 1806 
                 GASTRAS 
                 1846 
                 QQYGSSLT 
                 1886 
               
               
                   
               
               
                 139106 
                 RASQSVSSKLA 
                 1807 
                 GASIRAT 
                 1847 
                 QQYGSSSWT 
                 1887 
               
               
                   
               
               
                 139107 
                 RASQSVGSTNLA 
                 1808 
                 DASNRAT 
                 1848 
                 QQYGSSPPWT 
                 1888 
               
               
                   
               
               
                 139108 
                 RASQSISSYLN 
                 1809 
                 AASSLQS 
                 1849 
                 QQSYTLA 
                 1889 
               
               
                   
               
               
                 139110 
                 KSSESLVHNSGKTYLN 
                 1810 
                 EVSNRDS 
                 1850 
                 MQGTHWPGT 
                 1890 
               
               
                   
               
               
                 139112 
                 QASEDINKFLN 
                 1811 
                 DASTLQT 
                 1851 
                 QQYESLPLT 
                 1891 
               
               
                   
               
               
                 139113 
                 RASQSVGSNLA 
                 1812 
                 GASTRAT 
                 1852 
                 QQYNDWLPVT 
                 1892 
               
               
                   
               
               
                 139114 
                 RASQSIGSSSLA 
                 1813 
                 GASSRAS 
                 1853 
                 QQYAGSPPFT 
                 1893 
               
               
                   
               
               
                 149362 
                 KASQDIDDAMN 
                 1814 
                 SATSPVP 
                 1854 
                 LQHDNFPLT 
                 1894 
               
               
                   
               
               
                 149363 
                 RASQDIYNNLA 
                 1815 
                 AANKSQS 
                 1855 
                 QHYYRFPYS 
                 1895 
               
               
                   
               
               
                 149364 
                 RSSQSLLHSNGYNYLD 
                 1816 
                 LGSNRAS 
                 1856 
                 MQALQTPYT 
                 1896 
               
               
                   
               
               
                 149365 
                 GGNNIGTKSVH 
                 1817 
                 DDSVRPS 
                 1857 
                 QVWDSDSEHV 
                 1897 
               
               
                   
                   
                   
                   
                   
                 V 
                   
               
               
                   
               
               
                 149366 
                 SGDGLSKKYVS 
                 1818 
                 RDKERPS 
                 1858 
                 QAWDDTTVV 
                 1898 
               
               
                   
               
               
                 149367 
                 RASQGIRNWLA 
                 1819 
                 AASNLQS 
                 1859 
                 QKYNSAPFT 
                 1899 
               
               
                   
               
               
                 149368 
                 GGNNIGSKSVH 
                 1820 
                 GKNNRPS 
                 1860 
                 SSRDSSGDHL 
                 1900 
               
               
                   
                   
                   
                   
                   
                 RV 
                   
               
               
                   
               
               
                 149369 
                 QGDSLGNYYAT 
                 1821 
                 GTNNRPS 
                 1861 
                 NSRDSSGHHL 
                 1901 
               
               
                   
                   
                   
                   
                   
                 L 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSVSSAYLA 
                 1822 
                 GASTRAT 
                 1862 
                 QHYGSSFNGS 
                 1902 
               
               
                 C1978-A4 
                   
                   
                   
                   
                 SLFT 
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSVSNSLA 
                 1823 
                 DASSRAT 
                 1863 
                 QQFGTSSGLT 
                 1903 
               
               
                 C1978-G1 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSVSSSFLA 
                 1824 
                 GASSRAT 
                 1864 
                 QQYHSSPSWT 
                 1904 
               
               
                 C1979-C1 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSVSTTFLA 
                 1825 
                 GSSNRAT 
                 1865 
                 QQYHSSPSWT 
                 1905 
               
               
                 C1978-C7 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSISSYLN 
                 1826 
                 AASSLQS 
                 1866 
                 QQSYSTPYS 
                 1906 
               
               
                 C1978-D10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RATQSIGSSFLA 
                 1827 
                 GASQRAT 
                 1867 
                 QHYESSPSWT 
                 1907 
               
               
                 C1979-C12 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BGMAJEBB- 
                 RASQSVSSSYLA 
                 1828 
                 GASSRAT 
                 1868 
                 QQYGSPPRFT 
                 1908 
               
               
                 C1980-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSVSSSYLA 
                 1829 
                 GASSRAT 
                 1869 
                 QHYGSSPSWT 
                 1909 
               
               
                 C1980-D2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQRVASNYLA 
                 1830 
                 GASSRAT 
                 1870 
                 QHYDSSPSWT 
                 1910 
               
               
                 C1978-A10 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSLSSNFLA 
                 1831 
                 GASNWAT 
                 1871 
                 QYYGTSPMYT 
                 1911 
               
               
                 C1978-D4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RSSQSLLHSNGYNYLD 
                 1832 
                 LGSNRAS 
                 1872 
                 MQALQTPLT 
                 1912 
               
               
                 C1980-A2 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSVSSSYLA 
                 1833 
                 GTSSRAT 
                 1873 
                 QHYGNSPPKFT 
                 1913 
               
               
                 C1981-C3 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 BCMA_EBB- 
                 RASQSVASSFLA 
                 1834 
                 GASGRAT 
                 1874 
                 QHYGGSPRLT 
                 1914 
               
               
                 C1978-G4 
                   
                   
                   
                   
                   
                   
               
               
                   
               
               
                 A7D12.2 
                 RASQDVNTAVS 
                 1835 
                 SASYRYT 
                 1875 
                 QQHYSTPWT 
                 1915 
               
               
                   
               
               
                 C11D5.3 
                 RASESVSVIGAHLIH 
                 1836 
                 LASNLET 
                 1876 
                 LQSRIFPRT 
                 1916 
               
               
                   
               
               
                 C12A3.2 
                 RASESVTILGSHLIY 
                 1837 
                 LASNVQT 
                 1877 
                 LQSRTIPRT 
                 1917 
               
               
                   
               
               
                 C13F12.1 
                 RASESVTILGSHLIY 
                 1838 
                 LASNVQT 
                 1878 
                 LQSRTIPRT 
                 1918 
               
               
                   
               
            
           
         
       
     
     In certain embodiments, the CAR molecule described herein (e.g., the CAR nucleic acid or the CAR polypeptide) or a BCMA binding domain includes: 
     (1) one, two, or three light chain (LC) CDRs chosen from one of the following: 
     (i) a LC CDR1 of SEQ ID NO: 1320, LC CDR2 of SEQ ID NO: 1360 and LC CDR3 of SEQ ID NO: 1400 of BCMA-4 CAR (139103); 
     (ii) a LC CDR1 of SEQ ID NO: 1319, LC CDR2 of SEQ ID NO: 1359 and LC CDR3 of SEQ ID NO: 1399 of BCMA-10 CAR (139109); 
     (iii) a LC CDR1 of SEQ ID NO: 1331, LC CDR2 of SEQ ID NO: 1371 and LC CDR3 of SEQ ID NO: 1411 of BCMA-13 CAR (139112); or 
     (iv) a LC CDR1 of SEQ ID NO: 1333, LC CDR2 of SEQ ID NO: 1373 and LC CDR3 of SEQ ID NO: 1413 of BCMA-15 CAR (139114), and/or 
     (2) one, two, or three heavy chain (HC) CDRs from one of the following: 
     (i) a HC CDR1 of SEQ ID NO: 1200, HC CDR2 of SEQ ID NO: 1240 and HC CDR3 of SEQ ID NO: 1280 of BCMA-4 CAR (139103); 
     (ii) a HC CDR1 of SEQ ID NO: 1199, HC CDR2 of SEQ ID NO: 1239 and HC CDR3 of SEQ ID NO: 1279 of BCMA-10 CAR (139109); 
     (iii) a HC CDR1 of SEQ ID NO: 1121, HC CDR2 of SEQ ID NO: 1251 and HC CDR3 of SEQ ID NO: 1291 of BCMA-13 CAR (139112); or 
     (iv) a HC CDR1 of SEQ ID NO: 1213, HC CDR2 of SEQ ID NO: 1253 and HC CDR3 of SEQ ID NO: 1293 of BCMA-15 (139114). 
     In certain embodiments, the CAR molecule described herein (e.g., the CAR nucleic acid or the CAR polypeptide) includes: 
     (1) one, two, or three light chain (LC) CDRs chosen from one of the following: 
     (i) a LC CDR1 of SEQ ID NO: 1560, LC CDR2 of SEQ ID NO: 1600 and LC CDR3 of SEQ ID NO: 1640 of BCMA-4 CAR (139103); 
     (ii) a LC CDR1 of SEQ ID NO: 1559, LC CDR2 of SEQ ID NO: 1599 and LC CDR3 of SEQ ID NO: 1639 of BCMA-10 CAR (139109); 
     (iii) a LC CDR1 of SEQ ID NO: 1571, LC CDR2 of SEQ ID NO: 1611 and LC CDR3 of SEQ ID NO: 1651 of BCMA-13 CAR (139112); or 
     (iv) a LC CDR1 of SEQ ID NO: 1573, LC CDR2 of SEQ ID NO: 1613 and LC CDR3 of SEQ ID NO: 1653 of BCMA-15 CAR (139114); and/or 
     (2) one, two, or three heavy chain (HC) CDRs chosen from one of the following: 
     (i) a HC CDR1 of SEQ ID NO: 1440, HC CDR2 of SEQ ID NO: 1480 and HC CDR3 of SEQ ID NO: 1520 of BCMA-4 CAR (139103); 
     (ii) a HC CDR1 of SEQ ID NO: 1439, HC CDR2 of SEQ ID NO: 1479 and HC CDR3 of SEQ ID NO: 1519 of BCMA-10 CAR (139109); 
     (iii) a HC CDR1 of SEQ ID NO: 1451, HC CDR2 of SEQ ID NO: 1491 and HC CDR3 of SEQ ID NO: 1531 of BCMA-13 CAR (139112); or 
     (iv) a HC CDR1 of SEQ ID NO: 1453, HC CDR2 of SEQ ID NO: 1493 and HC CDR3 of SEQ ID NO: 1533 of BCMA-15 CAR (139114). 
     In certain embodiments, the CAR molecule described herein (e.g., the CAR nucleic acid or the CAR polypeptide) includes: 
     (1) one, two, or three light chain (LC) CDRs chosen from one of the following: 
     (i) a LC CDR1 of SEQ ID NO: 1800 LC CDR2 of SEQ ID NO: 1840 and LC CDR3 of SEQ ID NO: 1880 of BCMA-4 CAR (139103); 
     (ii) a LC CDR1 of SEQ ID NO: 1799, LC CDR2 of SEQ ID NO: 1839 and LC CDR3 of SEQ ID NO: 1879 of BCMA-10 CAR (139109); 
     (iii) a LC CDR1 of SEQ ID NO: 1811, LC CDR2 of SEQ ID NO: 1851 and LC CDR3 of SEQ ID NO: 1891 of BCMA-13 CAR (139112); or 
     (iv) a LC CDR1 of SEQ ID NO: 1813, LC CDR2 of SEQ ID NO: 1853 and LC CDR3 of SEQ ID NO: 1893 of BCMA-15 CAR (139114); and/or 
     (2) one, two, or three heavy chain (HC) CDRs chosen from one of the following: 
     (i) a HC CDR1 of SEQ ID NO: 1680, HC CDR2 of SEQ ID NO: 1720 and HC CDR3 of SEQ ID NO: 1760 of BCMA-4 CAR (139103); 
     (ii) a HC CDR1 of SEQ ID NO: 1679, HC CDR2 of SEQ ID NO: 1719 and HC CDR3 of SEQ ID NO: 1759 of BCMA-10 CAR (139109); 
     (iii) a HC CDR1 of SEQ ID NO: 1691, HC CDR2 of SEQ ID NO: 1731 and HC CDR3 of SEQ ID NO: 1771 of BCMA-13 CAR (139112); 
     (iv) a HC CDR1 of SEQ ID NO: 1693, HC CDR2 of SEQ ID NO: 1733 and HC CDR3 of SEQ ID NO: 1773 of BCMA-15 CAR (139114). 
     Exemplary Components of the CAR Molecules: 
       
     
       
         
           
               
            
               
                 Leader (amino acid sequence) 
               
               
                 (SEQ ID NO: 1919) 
               
               
                 MALPVTALLLPLALLLHAARP  
               
               
                   
               
               
                 leader (nucleic acid sequence) 
               
               
                 (SEQ ID NO: 1920) 
               
               
                 ATGGCCCTGCCTGTGACAGCCCTGCTGCTGCCTCTGGCTCTGCTGCTGCA 
               
               
                   
               
               
                 TGCCGCTAGACCC 
               
               
                   
               
               
                 leader (nucleic acid sequence) 
               
               
                 (SEQ ID NO: 2000) 
               
               
                 ATGGCCCTCCCTGTCACCGCCCTGCTGCTTCCGCTGGCTCTTCTGCTCCA 
               
               
                   
               
               
                 CGCCGCTCGGCCC 
               
               
                   
               
               
                 CD8 hinge (amino acid sequence) 
               
               
                 (SEQ ID NO: 1921) 
               
               
                 TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD 
               
               
                   
               
               
                 CD8 hinge (nucleic acid sequence) 
               
               
                 (SEQ ID NO: 1922) 
               
               
                 ACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTC 
               
               
                   
               
               
                 GCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCG 
               
               
                   
               
               
                 CAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT  
               
               
                   
               
               
                 CD8 transmembrane (amino acid sequence) 
               
               
                 (SEQ ID NO: 1923) 
               
               
                 IYIWAPLAGTCGVLLLSLVITLYC 
               
               
                   
               
               
                 CD8 transmembrane (nucleic acid sequence) 
               
               
                 (SEQ ID NO: 1924) 
               
               
                 ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTC 
               
               
                   
               
               
                 ACTGGTTATCACCCTTTACTGC 
               
               
                   
               
               
                 CD8 transmembrane (nucleic acid sequence) 
               
               
                 (SEQ ID NO: 2001) 
               
               
                 ATCTACATTTGGGCCCCTCTGGCTGGTACTTGCGGGGTCCTGCTGCTTTC 
               
               
                   
               
               
                 ACTCGTGATCACTCTTTACTGT 
               
               
                   
               
               
                 4-1BB Intracellular domain (amino acid 
               
               
                 sequence) 
               
               
                 (SEQ ID NO: 1925) 
               
               
                 KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL 
               
               
                   
               
               
                 4-1BB Intracellular domain (nucleic acid 
               
               
                 sequence) 
               
               
                 (SEQ ID NO: 1926) 
               
               
                 AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAG 
               
               
                   
               
               
                 ACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAG 
               
               
                   
               
               
                 AAGAAGAAGAAGGAGGATGTGAACTG 
               
               
                   
               
               
                 4-1BB Intracellular domain (nucleic acid 
               
               
                 sequence) 
               
               
                 (SEQ ID NO: 2002) 
               
               
                 AAGCGCGGTCGGAAGAAGCTGCTGTACATCTTTAAGCAACCCTTCATGAG 
               
               
                   
               
               
                 GCCTGTGCAGACTACTCAAGAGGAGGACGGCTGTTCATGCCGGTTCCCAG 
               
               
                   
               
               
                 AGGAGGAGGAAGGCGGCTGCGAACTG 
               
               
                   
               
               
                 CD28 Intracellular domain (amino acid 
               
               
                 sequence) 
               
               
                 (SEQ ID NO: 1927) 
               
               
                 RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID 
               
               
                   
               
               
                 NO: 1927) 
               
               
                   
               
               
                 CD28 Intracellular domain (nucleotide 
               
               
                 sequence) 
               
               
                 (SEQ ID NO: 1928) 
               
               
                 AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCC 
               
               
                   
               
               
                 CCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCAC 
               
               
                   
               
               
                 GCGACTTCGCAGCCTATCGCTCC (SEQ ID NO: 1928) 
               
               
                   
               
               
                 ICOS Intracellular domain (amino acid 
               
               
                 sequence) 
               
               
                 (SEQ ID NO: 1929) 
               
               
                 T K K K Y S S S V H D P N G E Y M F M R A V N T A 
               
               
                   
               
               
                 K K S R L T D V T L (SEQ ID NO: 1929) 
               
               
                   
               
               
                 ICOS Intracellular domain (nucleotide 
               
               
                 sequence) 
               
               
                 (SEQ ID NO: 1930) 
               
               
                 ACAAAAAAGAAGTATTCATCCAGTGTGCACGACCCTAACGGTGAATACAT 
               
               
                   
               
               
                 GTTCATGAGAGCAGTGAACACAGCCAAAAAATCCAGACTCACAGATGTGA 
               
               
                   
               
               
                 CCCTA (SEQ ID NO: 1930) 
               
               
                   
               
               
                 CD3 zeta domain (amino acid sequence) 
               
               
                 (SEQ ID NO: 1931) 
               
               
                 RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR 
               
               
                   
               
               
                 RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT 
               
               
                   
               
               
                 YDALHMQALPPR 
               
               
                   
               
               
                 CD3 zeta (nucleic acid sequence) 
               
               
                 (SEQ ID NO: 1932) 
               
               
                 AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACAAGCAGGGCCA 
               
               
                   
               
               
                 GAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATG 
               
               
                   
               
               
                 TTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGA 
               
               
                   
               
               
                 AGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGAT 
               
               
                   
               
               
                 GGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCA 
               
               
                   
               
               
                 AGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACC 
               
               
                   
               
               
                 TACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC 
               
               
                   
               
               
                 CD3 zeta (nucleic acid sequence) 
               
               
                 (SEQ ID NO: 2003) 
               
               
                 CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACAAGCAGGGGCA 
               
               
                   
               
               
                 GAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACG 
               
               
                   
               
               
                 TGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGC 
               
               
                   
               
               
                 AGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGAT 
               
               
                   
               
               
                 GGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCA 
               
               
                   
               
               
                 AAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACC 
               
               
                   
               
               
                 TATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGG 
               
               
                   
               
               
                 CD3 zeta domain (amino acid sequence; NCBI 
               
               
                 Reference NM_000734.3) 
               
               
                 (SEQ ID NO: 1933) 
               
               
                 RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR 
               
               
                   
               
               
                 RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDT 
               
               
                   
               
               
                 YDALHMQALPPR 
               
               
                   
               
               
                 CD3 zeta (nucleic acid sequence; NCBI 
               
               
                 Reference Sequence NM_000734.3);  
               
               
                 (SEQ ID NO: 1934) 
               
               
                 AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCA 
               
               
                   
               
               
                 GAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATG 
               
               
                   
               
               
                 TTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGA 
               
               
                   
               
               
                 AGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGAT 
               
               
                   
               
               
                 GGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCA 
               
               
                   
               
               
                 AGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACC 
               
               
                   
               
               
                 TACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC 
               
               
                   
               
               
                 IgG4 Hinge (amino acid sequence) 
               
               
                 (SEQ ID NO: 1935) 
               
               
                 ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQ 
               
               
                   
               
               
                 EDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE 
               
               
                   
               
               
                 YKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCL 
               
               
                   
               
               
                 VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQ 
               
               
                   
               
               
                 EGNVFSCSVMHEALHNHYTQKSLSLSLGKM 
               
               
                   
               
               
                 IgG4 Hinge (nucleotide sequence) 
               
               
                 (SEQ ID NO: 1936) 
               
               
                 GAGAGCAAGTACGGCCCTCCCTGCCCCCCTTGCCCTGCCCCCGAGTTCCT 
               
               
                   
               
               
                 GGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAGGACACCCTGA 
               
               
                   
               
               
                 TGATCAGCCGGACCCCCGAGGTGACCTGTGTGGTGGTGGACGTGTCCCAG 
               
               
                   
               
               
                 GAGGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCA 
               
               
                   
               
               
                 CAACGCCAAGACCAAGCCCCGGGAGGAGCAGTTCAATAGCACCTACCGGG 
               
               
                   
               
               
                 TGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAGGAA 
               
               
                   
               
               
                 TACAAGTGTAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAGAAAAC 
               
               
                   
               
               
                 CATCAGCAAGGCCAAGGGCCAGCCTCGGGAGCCCCAGGTGTACACCCTGC 
               
               
                   
               
               
                 CCCCTAGCCAAGAGGAGATGACCAAGAACCAGGTGTCCCTGACCTGCCTG 
               
               
                   
               
               
                 GTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAACGG 
               
               
                   
               
               
                 CCAGCCCGAGAACAACTACAAGACCACCCCCCCTGTGCTGGACAGCGACG 
               
               
                   
               
               
                 GCAGCTTCTTCCTGTACAGCCGGCTGACCGTGGACAAGAGCCGGTGGCAG 
               
               
                   
               
               
                 GAGGGCAACGTCTTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCA 
               
               
                   
               
               
                 CTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAGATG 
               
            
           
         
       
     
     Mesothelin CAR 
     In an embodiment, the CAR molecule comprises a mesothelin CAR described herein, e.g., a mesothelin CAR described in WO 2015/090230, incorporated herein by reference. In embodiments, the mesothelin CAR comprises an amino acid, or has a nucleotide sequence shown in WO 2015/090230 incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid mesothelin CAR sequences). In one embodiment, the CAR molecule comprises a mesothelin CAR, or an antigen binding domain according to Tables 2-3 of WO 2015/090230, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical thereto). The amino acid and nucleotide sequences encoding the mesothelin CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO 2015/090230. 
     CLL-1 CAR 
     In an embodiment, the CAR molecule comprises a CLL1 CAR described herein, e.g., a CLL1 CAR described in US2016/0051651A1, incorporated herein by reference. In embodiments, the CLL1 CAR comprises an amino acid, or has a nucleotide sequence shown in US2016/0051651A1, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CLL1 CAR sequences). 
     In other embodiments, the CLL1 CAR includes a CAR molecule, or an antigen binding domain according to Table 2 of WO2016/014535, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CLL1 CAR sequences). The amino acid and nucleotide sequences encoding the CLL-1 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/014535. 
     CD33 CAR 
     In an embodiment, the CAR molecule comprises a CD33 CAR described herein, e.g., a CD33 CAR described in US2016/0096892A1, incorporated herein by reference. In embodiments, the CD33 CAR comprises an amino acid, or has a nucleotide sequence shown in US2016/0096892A1, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD33 CAR sequences). In other embodiments, the CD33 CAR CAR or antigen binding domain thereof can include a CAR molecule (e.g., any of CAR33-1 to CAR-33-9), or an antigen binding domain according to Table 2 or 9 of WO2016/014576, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD33 CAR sequences). The amino acid and nucleotide sequences encoding the CD33 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/014576. 
     CD123 CAR 
     In embodiments, the CAR molecule comprises a CD123 CAR described herein, e.g., a CD123 CAR described in US2014/0322212A1 or US2016/0068601A1, both incorporated herein by reference. In embodiments, the CD123 CAR comprises an amino acid, or has a nucleotide sequence shown in US2014/0322212A1 or US2016/0068601A1, both incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD123 CAR sequences). In one embodiment, the CAR molecule comprises a CD123 CAR (e.g., any of the CAR1-CAR8), or an antigen binding domain according to Tables 1-2 of WO 2014/130635, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD123 CAR sequences). The amino acid and nucleotide sequences encoding the CD123 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO 2014/130635. 
     In other embodiments, the CAR molecule comprises a CD123 CAR comprises a CAR molecule (e.g., any of the CAR123-1 to CAR123-4 and hzCAR123-1 to hzCAR123-32), or an antigen binding domain according to Tables 2, 6, and 9 of WO2016/028896, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid CD123 CAR sequences). The amino acid and nucleotide sequences encoding the CD123 CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO2016/028896. 
     EGFRvIII CAR 
     In an embodiment, the CAR molecule comprises an EGFRvIII CAR molecule described herein, e.g., an EGFRvIII CAR described US2014/0322275A1, incorporated herein by reference. In embodiments, the EGFRvIII CAR comprises an amino acid, or has a nucleotide sequence shown in US2014/0322275A1, incorporated herein by reference, or a sequence substantially identical to any of the aforesaid sequences (e.g., at least 85%, 90%, 95% or more identical to any of the aforesaid EGFRvIII CAR sequences). In one embodiment, the CAR molecule comprises an EGFRvIII CAR, or an antigen binding domain according to Table 2 or SEQ ID NO:11 of WO 2014/130657, incorporated herein by reference, or a sequence substantially identical thereto (e.g., at least 85%, 90%, 95% or more identical thereto). The amino acid and nucleotide sequences encoding the EGFRvIII CAR molecules and antigen binding domains (e.g., including one, two, three VH CDRs; and one, two, three VL CDRs according to Kabat or Chothia), are specified in WO 2014/130657. 
     RNA Transfection 
     Disclosed herein are methods for producing an in vitro transcribed RNA anti-target CAR. The present invention also includes an anti-target CAR encoding RNA construct that can be directly transfected into a cell. A method for generating mRNA for use in transfection can involve in vitro transcription (IVT) of a template with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”), a 5′ cap and/or Internal Ribosome Entry Site (IRES), the nucleic acid to be expressed, and a polyA tail, typically 50-2000 bases in length (SEQ ID NO:32). RNA so produced can efficiently transfect different kinds of cells. In one aspect, the template includes sequences for the CAR. 
     In one aspect, an anti-target CAR of the present invention is encoded by a messenger RNA (mRNA). In one aspect, the mRNA encoding an anti-target CAR described herein is introduced into an immune effector cell, e.g., a T cell or a NK cell, for production of an anti-target CAR-expressing cell, e.g., a CART cell or a CAR NK cell. 
     In one embodiment, the in vitro transcribed RNA anti-target CAR can be introduced to a cell as a form of transient transfection. The RNA is produced by in vitro transcription using a polymerase chain reaction (PCR)-generated template. DNA of interest from any source can be directly converted by PCR into a template for in vitro mRNA synthesis using appropriate primers and RNA polymerase. The source of the DNA can be, for example, genomic DNA, plasmid DNA, phage DNA, cDNA, synthetic DNA sequence or any other appropriate source of DNA. The desired temple for in vitro transcription is an anti-target CAR described herein. For example, the template for the RNA anti-target CAR comprises an extracellular region comprising a single chain variable domain of an antibody to a tumor associated antigen described herein; a hinge region (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein); and a cytoplasmic region that includes an intracellular signaling domain, e.g., an intracellular signaling domain described herein, e.g., comprising the signaling domain of CD3-zeta and the signaling domain of 4-1BB. 
     In one embodiment, the DNA to be used for PCR contains an open reading frame. The DNA can be from a naturally occurring DNA sequence from the genome of an organism. In one embodiment, the nucleic acid can include some or all of the 5′ and/or 3′ untranslated regions (UTRs). The nucleic acid can include exons and introns. In one embodiment, the DNA to be used for PCR is a human nucleic acid sequence. In another embodiment, the DNA to be used for PCR is a human nucleic acid sequence including the 5′ and 3′ UTRs. The DNA can alternatively be an artificial DNA sequence that is not normally expressed in a naturally occurring organism. An exemplary artificial DNA sequence is one that contains portions of genes that are ligated together to form an open reading frame that encodes a fusion protein. The portions of DNA that are ligated together can be from a single organism or from more than one organism. 
     PCR is used to generate a template for in vitro transcription of mRNA which is used for transfection. Methods for performing PCR are well known in the art. Primers for use in PCR are designed to have regions that are substantially complementary to regions of the DNA to be used as a template for the PCR. “Substantially complementary,” as used herein, refers to sequences of nucleotides where a majority or all of the bases in the primer sequence are complementary, or one or more bases are non-complementary, or mismatched. Substantially complementary sequences are able to anneal or hybridize with the intended DNA target under annealing conditions used for PCR. The primers can be designed to be substantially complementary to any portion of the DNA template. For example, the primers can be designed to amplify the portion of a nucleic acid that is normally transcribed in cells (the open reading frame), including 5′ and 3′ UTRs. The primers can also be designed to amplify a portion of a nucleic acid that encodes a particular domain of interest. In one embodiment, the primers are designed to amplify the coding region of a human cDNA, including all or portions of the 5′ and 3′ UTRs. Primers useful for PCR can be generated by synthetic methods that are well known in the art. “Forward primers” are primers that contain a region of nucleotides that are substantially complementary to nucleotides on the DNA template that are upstream of the DNA sequence that is to be amplified. “Upstream” is used herein to refer to a location 5, to the DNA sequence to be amplified relative to the coding strand. “Reverse primers” are primers that contain a region of nucleotides that are substantially complementary to a double-stranded DNA template that are downstream of the DNA sequence that is to be amplified. “Downstream” is used herein to refer to a location 3′ to the DNA sequence to be amplified relative to the coding strand. 
     Any DNA polymerase useful for PCR can be used in the methods disclosed herein. The reagents and polymerase are commercially available from a number of sources. 
     Chemical structures with the ability to promote stability and/or translation efficiency may also be used. The RNA preferably has 5′ and 3′ UTRs. In one embodiment, the 5′ UTR is between one and 3000 nucleotides in length. The length of 5′ and 3′ UTR sequences to be added to the coding region can be altered by different methods, including, but not limited to, designing primers for PCR that anneal to different regions of the UTRs. Using this approach, one of ordinary skill in the art can modify the 5′ and 3′ UTR lengths required to achieve optimal translation efficiency following transfection of the transcribed RNA. 
     The 5′ and 3′ UTRs can be the naturally occurring, endogenous 5′ and 3′ UTRs for the nucleic acid of interest. Alternatively, UTR sequences that are not endogenous to the nucleic acid of interest can be added by incorporating the UTR sequences into the forward and reverse primers or by any other modifications of the template. The use of UTR sequences that are not endogenous to the nucleic acid of interest can be useful for modifying the stability and/or translation efficiency of the RNA. For example, it is known that AU-rich elements in 3′ UTR sequences can decrease the stability of mRNA. Therefore, 3′ UTRs can be selected or designed to increase the stability of the transcribed RNA based on properties of UTRs that are well known in the art. 
     In one embodiment, the 5′ UTR can contain the Kozak sequence of the endogenous nucleic acid. Alternatively, when a 5′ UTR that is not endogenous to the nucleic acid of interest is being added by PCR as described above, a consensus Kozak sequence can be redesigned by adding the 5′ UTR sequence. Kozak sequences can increase the efficiency of translation of some RNA transcripts, but does not appear to be required for all RNAs to enable efficient translation. The requirement for Kozak sequences for many mRNAs is known in the art. In other embodiments the 5′ UTR can be 5′UTR of an RNA virus whose RNA genome is stable in cells. In other embodiments various nucleotide analogues can be used in the 3′ or 5′ UTR to impede exonuclease degradation of the mRNA. 
     To enable synthesis of RNA from a DNA template without the need for gene cloning, a promoter of transcription should be attached to the DNA template upstream of the sequence to be transcribed. When a sequence that functions as a promoter for an RNA polymerase is added to the 5′ end of the forward primer, the RNA polymerase promoter becomes incorporated into the PCR product upstream of the open reading frame that is to be transcribed. In one preferred embodiment, the promoter is a T7 polymerase promoter, as described elsewhere herein. Other useful promoters include, but are not limited to, T3 and SP6 RNA polymerase promoters. Consensus nucleotide sequences for T7, T3 and SP6 promoters are known in the art. 
     In a preferred embodiment, the mRNA has both a cap on the 5′ end and a 3′ poly (A) tail which determine ribosome binding, initiation of translation and stability mRNA in the cell. On a circular DNA template, for instance, plasmid DNA, RNA polymerase produces a long concatameric product which is not suitable for expression in eukaryotic cells. The transcription of plasmid DNA linearized at the end of the 3′ UTR results in normal sized mRNA which is not effective in eukaryotic transfection even if it is polyadenylated after transcription. 
     On a linear DNA template, phage T7 RNA polymerase can extend the 3′ end of the transcript beyond the last base of the template (Schenborn and Mierendorf, Nuc Acids Res., 13:6223-36 (1985); Nacheva and Berzal-Herranz, Eur. J. Biochem., 270:1485-65 (2003). 
     The conventional method of integration of polyA/T stretches into a DNA template is molecular cloning. However polyA/T sequence integrated into plasmid DNA can cause plasmid instability, which is why plasmid DNA templates obtained from bacterial cells are often highly contaminated with deletions and other aberrations. This makes cloning procedures not only laborious and time consuming but often not reliable. That is why a method which allows construction of DNA templates with polyA/T 3′ stretch without cloning highly desirable. 
     The polyA/T segment of the transcriptional DNA template can be produced during PCR by using a reverse primer containing a polyA/T tail, such as 100T tail (SEQ ID NO: 35) (size can be 50-5000 T (SEQ ID NO: 36)), or after PCR by any other method, including, but not limited to, DNA ligation or in vitro recombination. Poly(A) tails also provide stability to RNAs and reduce their degradation. Generally, the length of a poly(A) tail positively correlates with the stability of the transcribed RNA. In one embodiment, the poly(A) tail is between 100 and 5000 adenosines (SEQ ID NO: 37). 
     Poly(A) tails of RNAs can be further extended following in vitro transcription with the use of a poly(A) polymerase, such as  E. coli  polyA polymerase (E-PAP). In one embodiment, increasing the length of a poly(A) tail from 100 nucleotides to between 300 and 400 nucleotides (SEQ ID NO: 38) results in about a two-fold increase in the translation efficiency of the RNA. Additionally, the attachment of different chemical groups to the 3′ end can increase mRNA stability. Such attachment can contain modified/artificial nucleotides, aptamers and other compounds. For example, ATP analogs can be incorporated into the poly(A) tail using poly(A) polymerase. ATP analogs can further increase the stability of the RNA. 
     5′ caps on also provide stability to RNA molecules. In a preferred embodiment, RNAs produced by the methods disclosed herein include a 5′ cap. The 5′ cap is provided using techniques known in the art and described herein (Cougot, et al., Trends in Biochem. Sci., 29:436-444 (2001); Stepinski, et al., RNA, 7:1468-95 (2001); Elango, et al., Biochim. Biophys. Res. Commun., 330:958-966 (2005)). 
     The RNAs produced by the methods disclosed herein can also contain an internal ribosome entry site (IRES) sequence. The IRES sequence may be any viral, chromosomal or artificially designed sequence which initiates cap-independent ribosome binding to mRNA and facilitates the initiation of translation. Any solutes suitable for cell electroporation, which can contain factors facilitating cellular permeability and viability such as sugars, peptides, lipids, proteins, antioxidants, and surfactants can be included. 
     RNA can be introduced into target cells using any of a number of different methods, for instance, commercially available methods which include, but are not limited to, electroporation (Amaxa Nucleofector-II (Amaxa Biosystems, Cologne, Germany)), (ECM 830 (BTX) (Harvard Instruments, Boston, Mass.) or the Gene Pulser II (BioRad, Denver, Colo.), Multiporator (Eppendort, Hamburg Germany), cationic liposome mediated transfection using lipofection, polymer encapsulation, peptide mediated transfection, or biolistic particle delivery systems such as “gene guns” (see, for example, Nishikawa, et al. Hum Gene Ther., 12(8):861-70 (2001). 
     Non-Viral Delivery Methods 
     In some aspects, non-viral methods can be used to deliver a nucleic acid encoding an anti-target CAR described herein into a cell or tissue or a subject. 
     In some embodiments, the non-viral method includes the use of a transposon (also called a transposable element). In some embodiments, a transposon is a piece of DNA that can insert itself at a location in a genome, for example, a piece of DNA that is capable of self-replicating and inserting its copy into a genome, or a piece of DNA that can be spliced out of a longer nucleic acid and inserted into another place in a genome. For example, a transposon comprises a DNA sequence made up of inverted repeats flanking genes for transposition. 
     Exemplary methods of nucleic acid delivery using a transposon include a Sleeping Beauty transposon system (SBTS) and a piggyBac (PB) transposon system. See, e.g., Aronovich et al. Hum. Mol. Genet. 20.R1(2011):R14-20; Singh et al. Cancer Res. 15(2008):2961-2971; Huang et al. Mol. Ther. 16(2008):580-589; Grabundzija et al. Mol. Ther. 18(2010):1200-1209; Kebriaei et al. Blood. 122.21(2013):166; Williams. Molecular Therapy 16.9(2008):1515-16; Bell et al. Nat. Protoc. 2.12(2007):3153-65; and Ding et al. Cell. 122.3(2005):473-83, all of which are incorporated herein by reference. 
     The SBTS includes two components: 1) a transposon containing a transgene and 2) a source of transposase enzyme. The transposase can transpose the transposon from a carrier plasmid (or other donor DNA) to a target DNA, such as a host cell chromosome/genome. For example, the transposase binds to the carrier plasmid/donor DNA, cuts the transposon (including transgene(s)) out of the plasmid, and inserts it into the genome of the host cell. See, e.g., Aronovich et al. supra. 
     Exemplary transposons include a pT2-based transposon. See, e.g., Grabundzija et al. Nucleic Acids Res. 41.3(2013):1829-47; and Singh et al. Cancer Res. 68.8(2008): 2961-2971, all of which are incorporated herein by reference. Exemplary transposases include a Tc1/mariner-type transposase, e.g., the SB10 transposase or the SB11 transposase (a hyperactive transposase which can be expressed, e.g., from a cytomegalovirus promoter). See, e.g., Aronovich et al.; Kebriaei et al.; and Grabundzija et al., all of which are incorporated herein by reference. 
     Use of the SBTS permits efficient integration and expression of a transgene, e.g., a nucleic acid encoding an anti-target CAR described herein. Provided herein are methods of generating a cell, e.g., T cell or NK cell, that stably expresses an anti-target CAR described herein, e.g., using a transposon system such as SBTS. 
     In accordance with methods described herein, in some embodiments, one or more nucleic acids, e.g., plasmids, containing the SBTS components are delivered to a cell (e.g., T or NK cell). For example, the nucleic acid(s) are delivered by standard methods of nucleic acid (e.g., plasmid DNA) delivery, e.g., methods described herein, e.g., electroporation, transfection, or lipofection. In some embodiments, the nucleic acid contains a transposon comprising a transgene, e.g., a nucleic acid encoding an anti-target CAR described herein. In some embodiments, the nucleic acid contains a transposon comprising a transgene (e.g., a nucleic acid encoding an anti-target CAR described herein) as well as a nucleic acid sequence encoding a transposase enzyme. In other embodiments, a system with two nucleic acids is provided, e.g., a dual-plasmid system, e.g., where a first plasmid contains a transposon comprising a transgene, and a second plasmid contains a nucleic acid sequence encoding a transposase enzyme. For example, the first and the second nucleic acids are co-delivered into a host cell. 
     In some embodiments, cells, e.g., T or NK cells, are generated that express an anti-target CAR described herein by using a combination of gene insertion using the SBTS and genetic editing using a nuclease (e.g., Zinc finger nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), the CRISPR/Cas system, or engineered meganuclease re-engineered homing endonucleases). 
     In some embodiments, use of a non-viral method of delivery permits reprogramming of cells, e.g., T or NK cells, and direct infusion of the cells into a subject. Advantages of non-viral vectors include but are not limited to the ease and relatively low cost of producing sufficient amounts required to meet a patient population, stability during storage, and lack of immunogenicity. 
     Nucleic Acid Constructs Encoding an Anti-Target CAR 
     The present invention also provides nucleic acid molecules encoding one or more anti-target CAR constructs described herein. In one aspect, the nucleic acid molecule is provided as a messenger RNA transcript. In one aspect, the nucleic acid molecule is provided as a DNA construct. 
     Accordingly, in one aspect, the invention pertains to a nucleic acid molecule encoding an anti-target (CAR), wherein the anti-target CAR comprises a ligand that binds to a target CAR described herein, a transmembrane domain (e.g., a transmembrane domain described herein), and an intracellular signaling domain (e.g., an intracellular signaling domain described herein) comprising a stimulatory domain, e.g., a costimulatory signaling domain (e.g., a costimulatory signaling domain described herein) and/or a primary signaling domain (e.g., a primary signaling domain described herein, e.g., a zeta chain described herein). In one embodiment, the transmembrane domain is transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CDS, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In some embodiments, a transmembrane domain may include at least the transmembrane region(s) of, e.g., KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2R gamma, IL7R α, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG/Cbp. 
     In one embodiment, the transmembrane domain comprises a sequence of SEQ ID NO: 12, or a sequence with 95-99% identity thereof. In one embodiment, the antigen binding domain is connected to the transmembrane domain by a hinge region, e.g., a hinge described herein. In one embodiment, the hinge region comprises SEQ ID NO:403 or SEQ ID NO:405 or SEQ ID NO:407 or SEQ ID NO:10, or a sequence with 95-99% identity thereof. In one embodiment, the isolated nucleic acid molecule further comprises a sequence encoding a costimulatory domain. In one embodiment, the costimulatory domain is a functional signaling domain of a protein selected from the group consisting of OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), and 4-1BB (CD137). Further examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, and PAG/Cbp. In one embodiment, the costimulatory domain comprises a sequence of SEQ ID NOs:14, or a sequence with 95-99% identity thereof. In one embodiment, the intracellular signaling domain comprises a functional signaling domain of 4-1BB and a functional signaling domain of CD3 zeta. In one embodiment, the intracellular signaling domain comprises the sequence of any one of SEQ ID NOs: 14, or a sequence with 95-99% identity thereof, and the sequence of SEQ ID NO: 18 or SEQ ID NO:20, or a sequence with 95-99% identity thereof, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain. 
     In another aspect, the invention pertains to an isolated nucleic acid molecule encoding an anti-target CAR construct comprising a leader sequence of SEQ ID NO: 401, a ligand as described herein, a hinge region of SEQ ID NO:403 or SEQ ID NO:405 or SEQ ID NO:407 or SEQ ID NO:10 (or a sequence with 95-99% identity thereof), a transmembrane domain having a sequence of SEQ ID NO: 12 (or a sequence with 95-99% identity thereof), a 4-1BB costimulatory domain having a sequence of SEQ ID NOs:14 (or a sequence with 95-99% identity thereof), and a CD3 zeta stimulatory domain having a sequence of SEQ ID NO:18 or SEQ ID NO:20 (or a sequence with 95-99% identity thereof). 
     In another aspect, the invention pertains to a nucleic acid molecule encoding an anti-target CAR molecule that comprises a ligand that binds to a target CAR, e.g., a ligand comprising a cognate antigen or antibody molecule, e.g., an anti-idiotypic antibody molecule that binds to a target CAR. In an embodiment, the anti-idiotypic antibody comprises the antibody of clone 136.20.1, as disclosed herein and in International Application WO 2014/190273, the entire contents of which are hereby incorporated by reference. 
     In one embodiment, the encoded anti-target CAR molecule further comprises a sequence encoding a costimulatory domain. In one embodiment, the costimulatory domain is a functional signaling domain of a protein selected from the group consisting of OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a/CD18) and 4-1BB (CD137). In one embodiment, the costimulatory domain comprises a sequence of SEQ ID NO: 14. In one embodiment, the transmembrane domain is a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In one embodiment, the transmembrane domain comprises a sequence of SEQ ID NO:12. In one embodiment, the intracellular signaling domain comprises a functional signaling domain of 4-1BB and a functional signaling domain of zeta. In one embodiment, the intracellular signaling domain comprises a sequence of SEQ ID NO: 14 and the sequence of SEQ ID NO: 18, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain. In one embodiment, the anti-target CAR ligand as described herein is connected to the transmembrane domain by a hinge region. In one embodiment, the hinge region comprises SEQ ID NO:403. In one embodiment, the hinge region comprises SEQ ID NO:405 or SEQ ID NO:407 or SEQ ID NO:10. 
     The nucleic acid sequences coding for the desired molecules can be obtained using recombinant methods known in the art, such as, for example by screening libraries from cells expressing the gene, by deriving the gene from a vector known to include the same, or by isolating directly from cells and tissues containing the same, using standard techniques. Alternatively, the gene of interest can be produced synthetically, rather than cloned. 
     The present invention also provides vectors in which a DNA of the present invention is inserted. Vectors derived from retroviruses such as the lentivirus are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells. Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses such as murine leukemia viruses in that they can transduce non-proliferating cells, such as hepatocytes. They also have the added advantage of low immunogenicity. A retroviral vector may also be, e.g., a gammaretroviral vector. A gammaretroviral vector may include, e.g., a promoter, a packaging signal (ψ), a primer binding site (PBS), one or more (e.g., two) long terminal repeats (LTR), and a transgene of interest, e.g., a gene encoding an anti-target CAR. A gammaretroviral vector may lack viral structural gens such as gag, pol, and env. Exemplary gammaretroviral vectors include Murine Leukemia Virus (MLV), Spleen-Focus Forming Virus (SFFV), and Myeloproliferative Sarcoma Virus (MPSV), and vectors derived therefrom. Other gammaretroviral vectors are described, e.g., in Tobias Maetzig et al., “Gammaretroviral Vectors: Biology, Technology and Application” Viruses. 2011 June; 3(6): 677-713. 
     In another embodiment, the vector comprising the nucleic acid encoding the desired anti-target CAR of the invention is an adenoviral vector (A5/35). In another embodiment, the expression of nucleic acids encoding anti-target CARs can be accomplished using of transposons such as sleeping beauty, crisper, CAS9, and zinc finger nucleases. See below June et al. 2009 Nature Reviews Immunology  9.10: 704-716, is incorporated herein by reference. 
     In brief summary, the expression of natural or synthetic nucleic acids encoding anti-target CARs is typically achieved by operably linking a nucleic acid encoding the anti-target CAR polypeptide or portions thereof to a promoter, and incorporating the construct into an expression vector. The vectors can be suitable for replication and integration eukaryotes. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the desired nucleic acid sequence. 
     The expression constructs of the present invention may also be used for nucleic acid immunization and gene therapy, using standard gene delivery protocols. Methods for gene delivery are known in the art. See, e.g., U.S. Pat. Nos. 5,399,346, 5,580,859, 5,589,466, incorporated by reference herein in their entireties. In another embodiment, the invention provides a gene therapy vector. 
     The nucleic acid can be cloned into a number of types of vectors. For example, the nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus, and a cosmid. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors. 
     Further, the expression vector may be provided to a cell in the form of a viral vector. Viral vector technology is well known in the art and is described, for example, in Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. In general, a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers, (e.g., WO 01/96584; WO 01/29058; and U.S. Pat. No. 6,326,193). 
     A number of viral based systems have been developed for gene transfer into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. A selected gene can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells of the subject either in vivo or ex vivo. A number of retroviral systems are known in the art. In some embodiments, adenovirus vectors are used. A number of adenovirus vectors are known in the art. In one embodiment, lentivirus vectors are used. 
     Additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well. The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription. Exemplary promoters include the CMV IE gene, EF-1α, ubiquitin C, or phosphoglycerokinase (PGK) promoters. 
     An example of a promoter that is capable of expressing an anti-target CAR encoding nucleic acid molecule in a mammalian T cell is the EF1a promoter. The native EF1a promoter drives expression of the alpha subunit of the elongation factor-1 complex, which is responsible for the enzymatic delivery of aminoacyl tRNAs to the ribosome. The EF1a promoter has been extensively used in mammalian expression plasmids and has been shown to be effective in driving anti-target CAR expression from nucleic acid molecules cloned into a lentiviral vector. See, e.g., Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). In one aspect, the EF1a promoter comprises the sequence provided as SEQ ID NO:400. 
     Another example of a promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto. However, other constitutive promoter sequences may also be used, including, but not limited to the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, as well as human gene promoters such as, but not limited to, the actin promoter, the myosin promoter, the elongation factor-1a promoter, the hemoglobin promoter, and the creatine kinase promoter. Further, the invention should not be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the invention. The use of an inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Examples of inducible promoters include, but are not limited to a metallothionine promoter, a glucocorticoid promoter, a progesterone promoter, and a tetracycline promoter. 
     A vector may also include, e.g., a signal sequence to facilitate secretion, a polyadenylation signal and transcription terminator (e.g., from Bovine Growth Hormone (BGH) gene), an element allowing episomal replication and replication in prokaryotes (e.g. SV40 origin and ColE1 or others known in the art) and/or elements to allow selection (e.g., ampicillin resistance gene and/or zeocin marker). 
     In order to assess the expression of an anti-target CAR polypeptide or portions thereof, the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors. In other aspects, the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure. Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells. Useful selectable markers include, for example, antibiotic-resistance genes, such as neo and the like. 
     Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences. In general, a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Expression of the reporter gene is assayed at a suitable time after the DNA has been introduced into the recipient cells. Suitable reporter genes may include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene (e.g., Ui-Tei et al., 2000 FEBS Letters 479: 79-82). Suitable expression systems are well known and may be prepared using known techniques or obtained commercially. In general, the construct with the minimal 5′ flanking region showing the highest level of expression of reporter gene is identified as the promoter. Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter-driven transcription. 
     Methods of introducing and expressing genes into a cell are known in the art. In the context of an expression vector, the vector can be readily introduced into a host cell, e.g., mammalian, bacterial, yeast, or insect cell by any method in the art. For example, the expression vector can be transferred into a host cell by physical, chemical, or biological means. 
     Physical methods for introducing a polynucleotide into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells comprising vectors and/or exogenous nucleic acids are well-known in the art. See, for example, Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1-4, Cold Spring Harbor Press, NY). A preferred method for the introduction of a polynucleotide into a host cell is calcium phosphate transfection 
     Biological methods for introducing a polynucleotide of interest into a host cell include the use of DNA and RNA vectors. Viral vectors, and especially retroviral vectors, have become the most widely used method for inserting genes into mammalian, e.g., human cells. Other viral vectors can be derived from lentivirus, poxviruses, herpes simplex virus I, adenoviruses and adeno-associated viruses, and the like. See, for example, U.S. Pat. Nos. 5,350,674 and 5,585,362. 
     Chemical means for introducing a polynucleotide into a host cell include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle). Other methods of state-of-the-art targeted delivery of nucleic acids are available, such as delivery of polynucleotides with targeted nanoparticles or other suitable sub-micron sized delivery system. 
     In the case where a non-viral delivery system is utilized, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of the nucleic acids into a host cell (in vitro, ex vivo or in vivo). In another aspect, the nucleic acid may be associated with a lipid. The nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. Lipid, lipid/DNA or lipid/expression vector associated compositions are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles, or with a “collapsed” structure. They may also simply be interspersed in a solution, possibly forming aggregates that are not uniform in size or shape. Lipids are fatty substances which may be naturally occurring or synthetic lipids. For example, lipids include the fatty droplets that naturally occur in the cytoplasm as well as the class of compounds which contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, amino alcohols, and aldehydes. 
     Lipids suitable for use can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine (“DMPC”) can be obtained from Sigma, St. Louis, Mo.; dicetyl phosphate (“DCP”) can be obtained from K &amp; K Laboratories (Plainview, N.Y.); cholesterol (“Choi”) can be obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol (“DMPG”) and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, Ala.). Stock solutions of lipids in chloroform or chloroform/methanol can be stored at about −20° C. Chloroform is used as the only solvent since it is more readily evaporated than methanol. “Liposome” is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes can be characterized as having vesicular structures with a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh et al., 1991 Glycobiology 5: 505-10). However, compositions that have different structures in solution than the normal vesicular structure are also encompassed. For example, the lipids may assume a micellar structure or merely exist as nonuniform aggregates of lipid molecules. Also contemplated are lipofectamine-nucleic acid complexes. 
     Regardless of the method used to introduce exogenous nucleic acids into a host cell or otherwise expose a cell to the inhibitor of the present invention, in order to confirm the presence of the recombinant DNA sequence in the host cell, a variety of assays may be performed. Such assays include, for example, “molecular biological” assays well known to those of skill in the art, such as Southern and Northern blotting, RT-PCR and PCR; “biochemical” assays, such as detecting the presence or absence of a particular peptide, e.g., by immunological means (ELISAs and Western blots) or by assays described herein to identify agents falling within the scope of the invention. 
     The present invention further provides a vector comprising an anti-target CAR encoding nucleic acid molecule. In one aspect, an anti-target CAR vector can be directly transduced into a cell, e.g., a T cell or a NK cell. In one aspect, the vector is a cloning or expression vector, e.g., a vector including, but not limited to, one or more plasmids (e.g., expression plasmids, cloning vectors, minicircles, minivectors, double minute chromosomes), retroviral and lentiviral vector constructs. In one aspect, the vector is capable of expressing the anti-target CAR construct in mammalian immune effector cells (e.g., T cells, NK cells). In one aspect, the mammalian T cell is a human T cell. In one aspect, the mammalian NK cell is a human NK cell. 
     Sources of Cells 
     Prior to expansion and genetic modification or other modification, a source of cells, e.g., T cells or natural killer (NK) cells, can be obtained from a subject. The term “subject” is intended to include living organisms in which an immune response can be elicited (e.g., mammals). Examples of subjects include humans, monkeys, chimpanzees, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. 
     In certain aspects of the present disclosure, immune effector cells, e.g., T cells, can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as Ficoll™ separation. In one preferred aspect, cells from the circulating blood of an individual are obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one aspect, the cells collected by apheresis may be washed to remove the plasma fraction and, optionally, to place the cells in an appropriate buffer or media for subsequent processing steps. In one embodiment, the cells are washed with phosphate buffered saline (PBS). In an alternative embodiment, the wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations. 
     Initial activation steps in the absence of calcium can lead to magnified activation. As those of ordinary skill in the art would readily appreciate a washing step may be accomplished by methods known to those in the art, such as by using a semi-automated “flow-through” centrifuge (for example, the Cobe 2991 cell processor, the Baxter CytoMate, or the Haemonetics Cell Saver 5) according to the manufacturer&#39;s instructions. After washing, the cells may be resuspended in a variety of biocompatible buffers, such as, for example, Ca-free, Mg-free PBS, PlasmaLyte A, or other saline solution with or without buffer. Alternatively, the undesirable components of the apheresis sample may be removed and the cells directly resuspended in culture media. 
     It is recognized that the methods of the application can utilize culture media conditions comprising 5% or less, for example 2%, human AB serum, and employ known culture media conditions and compositions, for example those described in Smith et al., “Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement”  Clinical  &amp;  Translational Immunology  (2015) 4, e31; doi:10.1038/cti.2014.31. 
     In one aspect, T cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLL™ gradient or by counterflow centrifugal elutriation. 
     The methods described herein can include, e.g., selection of a specific subpopulation of immune effector cells, e.g., T cells, that are a T regulatory cell-depleted population, CD25+ depleted cells, using, e.g., a negative selection technique, e.g., described herein. Preferably, the population of T regulatory depleted cells contains less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% of CD25+ cells. 
     In one embodiment, T regulatory cells, e.g., CD25+ T cells, are removed from the population using an anti-CD25 antibody, or fragment thereof, or a CD25-binding ligand, IL-2. In one embodiment, the anti-CD25 antibody, or fragment thereof, or CD25-binding ligand is conjugated to a substrate, e.g., a bead, or is otherwise coated on a substrate, e.g., a bead. In one embodiment, the anti-CD25 antibody, or fragment thereof, is conjugated to a substrate as described herein. 
     In one embodiment, the T regulatory cells, e.g., CD25+ T cells, are removed from the population using CD25 depletion reagent from Miltenyi™. In one embodiment, the ratio of cells to CD25 depletion reagent is 1e7 cells to 20 uL, or 1e7 cells to 15 uL, or 1e7 cells to 10 uL, or 1e7 cells to 5 uL, or 1e7 cells to 2.5 uL, or 1e7 cells to 1.25 uL. In one embodiment, e.g., for T regulatory cells, e.g., CD25+ depletion, greater than 500 million cells/ml is used. In a further aspect, a concentration of cells of 600, 700, 800, or 900 million cells/ml is used. 
     In one embodiment, the population of immune effector cells to be depleted includes about 6×10 9  CD25+ T cells. In other aspects, the population of immune effector cells to be depleted include about 1×10 9  to 1×10 10  CD25+ T cell, and any integer value in between. In one embodiment, the resulting population T regulatory depleted cells has 2×10 9  T regulatory cells, e.g., CD25+ cells, or less (e.g., 1×10 9 , 5×10 8 , 1×10 8 , 5×10 7 , 1×10 7 , or less CD25+ cells). 
     In one embodiment, the T regulatory cells, e.g., CD25+ cells, are removed from the population using the CliniMAC system with a depletion tubing set, such as, e.g., tubing 162-01. In one embodiment, the CliniMAC system is run on a depletion setting such as, e.g., DEPLETION2.1. 
     Without wishing to be bound by a particular theory, decreasing the level of negative regulators of immune cells (e.g., decreasing the number of unwanted immune cells, e.g., T REG  cells), in a subject prior to apheresis or during manufacturing of a CAR-expressing cell product can reduce the risk of subject relapse. For example, methods of depleting T REG  cells are known in the art. Methods of decreasing T REG  cells include, but are not limited to, cyclophosphamide, anti-GITR antibody (an anti-GITR antibody described herein), CD25-depletion, and combinations thereof. 
     In some embodiments, the manufacturing methods comprise reducing the number of (e.g., depleting) T REG  cells prior to manufacturing of the anti-target CAR-expressing cell. For example, manufacturing methods comprise contacting the sample, e.g., the apheresis sample, with an anti-GITR antibody and/or an anti-CD25 antibody (or fragment thereof, or a CD25-binding ligand), e.g., to deplete T REG  cells prior to manufacturing of the anti-target CAR-expressing cell (e.g., T cell, NK cell) product. 
     In an embodiment, a subject is pre-treated with one or more therapies that reduce T REG  cells prior to collection of cells for anti-target CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to anti-target CAR-expressing cell treatment. In an embodiment, methods of decreasing T REG  cells include, but are not limited to, administration to the subject of one or more of cyclophosphamide, anti-GITR antibody, CD25-depletion, or a combination thereof. Administration of one or more of cyclophosphamide, anti-GITR antibody, CD25-depletion, or a combination thereof, can occur before, during or after an infusion of the anti-target CAR-expressing cell product. 
     In an embodiment, a subject is pre-treated with cyclophosphamide prior to collection of cells for anti-target CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to CAR-expressing cell treatment. In an embodiment, a subject is pre treated with an anti-GITR antibody prior to collection of cells for anti-target CAR-expressing cell product manufacturing, thereby reducing the risk of subject relapse to anti-target CAR-expressing cell treatment. 
     In one embodiment, the population of cells to be removed are neither the regulatory T cells or tumor cells, but cells that otherwise negatively affect the expansion and/or function of CART cells, e.g. cells expressing CD14, CD11b, CD33, CD15, or other markers expressed by potentially immune suppressive cells. In one embodiment, such cells are envisioned to be removed concurrently with regulatory T cells and/or tumor cells, or following said depletion, or in another order. 
     The methods described herein can include more than one selection step, e.g., more than one depletion step. Enrichment of a T cell population by negative selection can be accomplished, e.g., with a combination of antibodies directed to surface markers unique to the negatively selected cells. One method is cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4+ cells by negative selection, a monoclonal antibody cocktail can include antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8. 
     The methods described herein can further include removing cells from the population which express a tumor antigen, e.g., a tumor antigen that does not comprise CD25, e.g., CD19, CD30, CD38, CD123, CD20, CD14 or CD11b, to thereby provide a population of T regulatory depleted, e.g., CD25+ depleted, and tumor antigen depleted cells that are suitable for expression of a CAR, e.g., a CAR described herein. In one embodiment, tumor antigen expressing cells are removed simultaneously with the T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, or fragment thereof, and an anti-tumor antigen antibody, or fragment thereof, can be attached to the same substrate, e.g., bead, which can be used to remove the cells or an anti-CD25 antibody, or fragment thereof, or the anti-tumor antigen antibody, or fragment thereof, can be attached to separate beads, a mixture of which can be used to remove the cells. In other embodiments, the removal of T regulatory cells, e.g., CD25+ cells, and the removal of the tumor antigen expressing cells is sequential, and can occur, e.g., in either order. 
     Also provided are methods that include removing cells from the population which express a check point inhibitor, e.g., a check point inhibitor described herein, e.g., one or more of PD1+ cells, LAG3+ cells, and TIM3+ cells, to thereby provide a population of T regulatory depleted, e.g., CD25+ depleted cells, and check point inhibitor depleted cells, e.g., PD1+, LAG3+ and/or TIM3+ depleted cells. Exemplary check point inhibitors include B7-H1, B7-1, CD160, P1H, 2B4, PD1, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, TIGIT, CTLA-4, BTLA and LAIR1. In one embodiment, check point inhibitor expressing cells are removed simultaneously with the T regulatory, e.g., CD25+ cells. For example, an anti-CD25 antibody, or fragment thereof, and an anti-check point inhibitor antibody, or fragment thereof, can be attached to the same bead which can be used to remove the cells, or an anti-CD25 antibody, or fragment thereof, and the anti-check point inhibitor antibody, or fragment there, can be attached to separate beads, a mixture of which can be used to remove the cells. In other embodiments, the removal of T regulatory cells, e.g., CD25+ cells, and the removal of the check point inhibitor expressing cells is sequential, and can occur, e.g., in either order. 
     Methods described herein can include a positive selection step. For example, T cells can isolated by incubation with anti-CD3/anti-CD28 (e.g., 3×28)-conjugated beads, such as DYNABEADS® M-450 CD3/CD28 T, for a time period sufficient for positive selection of the desired T cells. In one embodiment, the time period is about 30 minutes. In a further embodiment, the time period ranges from 30 minutes to 36 hours or longer and all integer values there between. In a further embodiment, the time period is at least 1, 2, 3, 4, 5, or 6 hours. In yet another embodiment, the time period is 10 to 24 hours, e.g., 24 hours. Longer incubation times may be used to isolate T cells in any situation where there are few T cells as compared to other cell types, such in isolating tumor infiltrating lymphocytes (TIL) from tumor tissue or from immunocompromised individuals. Further, use of longer incubation times can increase the efficiency of capture of CD8+ T cells. Thus, by simply shortening or lengthening the time T cells are allowed to bind to the CD3/CD28 beads and/or by increasing or decreasing the ratio of beads to T cells (as described further herein), subpopulations of T cells can be preferentially selected for or against at culture initiation or at other time points during the process. Additionally, by increasing or decreasing the ratio of anti-CD3 and/or anti-CD28 antibodies on the beads or other surface, subpopulations of T cells can be preferentially selected for or against at culture initiation or at other desired time points. 
     In one embodiment, a T cell population can be selected that expresses one or more of IFN-γ, TNFα, IL-17A, IL-2, IL-3, IL-4, GM-CSF, IL-10, IL-13, granzyme B, and perforin, or other appropriate molecules, e.g., other cytokines. Methods for screening for cell expression can be determined, e.g., by the methods described in PCT Publication No.: WO 2013/126712. 
     For isolation of a desired population of cells by positive or negative selection, the concentration of cells and surface (e.g., particles such as beads) can be varied. In certain aspects, it may be desirable to significantly decrease the volume in which beads and cells are mixed together (e.g., increase the concentration of cells), to ensure maximum contact of cells and beads. For example, in one aspect, a concentration of 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml, 6 billion/ml, or 5 billion/ml is used. In one aspect, a concentration of 1 billion cells/ml is used. In yet one aspect, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further aspects, concentrations of 125 or 150 million cells/ml can be used. 
     Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells, or from samples where there are many tumor cells present (e.g., leukemic blood, tumor tissue, etc.). Such populations of cells may have therapeutic value and would be desirable to obtain. For example, using high concentration of cells allows more efficient selection of CD8+ T cells that normally have weaker CD28 expression. 
     In a related aspect, it may be desirable to use lower concentrations of cells. By significantly diluting the mixture of T cells and surface (e.g., particles such as beads), interactions between the particles and cells is minimized. This selects for cells that express high amounts of desired antigens to be bound to the particles. For example, CD4+ T cells express higher levels of CD28 and are more efficiently captured than CD8+ T cells in dilute concentrations. In one aspect, the concentration of cells used is 5×10 6 /ml. In other aspects, the concentration used can be from about 1×10 5 /ml to 1×10 6 /ml, and any integer value in between. 
     In other aspects, the cells may be incubated on a rotator for varying lengths of time at varying speeds at either 2-10° C. or at room temperature. 
     T cells for stimulation can also be frozen after a washing step. Wishing not to be bound by theory, the freeze and subsequent thaw step provides a more uniform product by removing granulocytes and to some extent monocytes in the cell population. After the washing step that removes plasma and platelets, the cells may be suspended in a freezing solution. While many freezing solutions and parameters are known in the art and will be useful in this context, one method involves using PBS containing 20% DMSO and 8% human serum albumin, or culture media containing 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin and 7.5% DMSO, or 31.25% Plasmalyte-A, 31.25% Dextrose 5%, 0.45% NaCl, 10% Dextran 40 and 5% Dextrose, 20% Human Serum Albumin, and 7.5% DMSO or other suitable cell freezing media containing for example, Hespan and PlasmaLyte A, the cells then are frozen to −80° C. at a rate of 1° per minute and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing may be used as well as uncontrolled freezing immediately at −20° C. or in liquid nitrogen. 
     In certain aspects, cryopreserved cells are thawed and washed as described herein and allowed to rest for one hour at room temperature prior to activation using the methods of the present invention. 
     Also contemplated in the context of the invention is the collection of blood samples or apheresis product from a subject at a time period prior to when the expanded cells as described herein might be needed. As such, the source of the cells to be expanded can be collected at any time point necessary, and desired cells, such as T cells, isolated and frozen for later use in immune effector cell therapy for any number of diseases or conditions that would benefit from immune effector cell therapy, such as those described herein. In one aspect a blood sample or an apheresis is taken from a generally healthy subject. In certain aspects, a blood sample or an apheresis is taken from a generally healthy subject who is at risk of developing a disease, but who has not yet developed a disease, and the cells of interest are isolated and frozen for later use. In certain aspects, the T cells may be expanded, frozen, and used at a later time. In certain aspects, samples are collected from a patient shortly after diagnosis of a particular disease as described herein but prior to any treatments. In a further aspect, the cells are isolated from a blood sample or an apheresis from a subject prior to any number of relevant treatment modalities, including but not limited to treatment with agents such as natalizumab, efalizumab, antiviral agents, chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies, cytoxan, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, and irradiation. 
     In a further aspect of the present invention, T cells are obtained from a patient directly following treatment that leaves the subject with functional T cells. In this regard, it has been observed that following certain cancer treatments, in particular treatments with drugs that damage the immune system, shortly after treatment during the period when patients would normally be recovering from the treatment, the quality of T cells obtained may be optimal or improved for their ability to expand ex vivo. Likewise, following ex vivo manipulation using the methods described herein, these cells may be in a preferred state for enhanced engraftment and in vivo expansion. Thus, it is contemplated within the context of the present invention to collect blood cells, including T cells, dendritic cells, or other cells of the hematopoietic lineage, during this recovery phase. Further, in certain aspects, mobilization (for example, mobilization with GM-CSF) and conditioning regimens can be used to create a condition in a subject wherein repopulation, recirculation, regeneration, and/or expansion of particular cell types is favored, especially during a defined window of time following therapy. Illustrative cell types include T cells, B cells, dendritic cells, and other cells of the immune system. 
     In one embodiment, the immune effector cells expressing an anti-target CAR molecule, e.g., an anti-target CAR molecule described herein, are obtained from a subject that has received a low, immune enhancing dose of an mTOR inhibitor. In an embodiment, the population of immune effector cells, e.g., T cells, to be engineered to express an anti-target CAR, are harvested after a sufficient time, or after sufficient dosing of the low, immune enhancing, dose of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g., T cells/PD1 positive immune effector cells, e.g., T cells, in the subject or harvested from the subject has been, at least transiently, increased. 
     In other embodiments, population of immune effector cells, e.g., T cells, which have, or will be engineered to express an anti-target CAR, can be treated ex vivo by contact with an amount of an mTOR inhibitor that increases the number of PD1 negative immune effector cells, e.g., T cells or increases the ratio of PD1 negative immune effector cells, e.g., T cells/PD1 positive immune effector cells, e.g., T cells. 
     In one embodiment, a T cell population is diacylglycerol kinase (DGK)-deficient. DGK-deficient cells include cells that do not express DGK RNA or protein, or have reduced or inhibited DGK activity. DGK-deficient cells can be generated by genetic approaches, e.g., administering RNA-interfering agents, e.g., siRNA, shRNA, miRNA, to reduce or prevent DGK expression. Alternatively, DGK-deficient cells can be generated by treatment with DGK inhibitors described herein. 
     In one embodiment, a T cell population is Ikaros-deficient. Ikaros-deficient cells include cells that do not express Ikaros RNA or protein, or have reduced or inhibited Ikaros activity, Ikaros-deficient cells can be generated by genetic approaches, e.g., administering RNA-interfering agents, e.g., siRNA, shRNA, miRNA, to reduce or prevent Ikaros expression. Alternatively, Ikaros-deficient cells can be generated by treatment with Ikaros inhibitors, e.g., lenalidomide. 
     In embodiments, a T cell population is DGK-deficient and Ikaros-deficient, e.g., does not express DGK and Ikaros, or has reduced or inhibited DGK and Ikaros activity. Such DGK and Ikaros-deficient cells can be generated by any of the methods described herein. 
     In an embodiment, the NK cells are obtained from the subject. In another embodiment, the NK cells are an NK cell line, e.g., NK-92 cell line (Conkwest). 
     Allogeneic CAR 
     In embodiments described herein, the immune effector cell can be an allogeneic immune effector cell, e.g., T cell or NK cell. For example, the cell can be an allogeneic T cell, e.g., an allogeneic T cell lacking expression of a functional T cell receptor (TCR) and/or human leukocyte antigen (HLA), e.g., HLA class I and/or HLA class II. 
     A T cell lacking a functional TCR can be, e.g., engineered such that it does not express any functional TCR on its surface, engineered such that it does not express one or more subunits that comprise a functional TCR or engineered such that it produces very little functional TCR on its surface. Alternatively, the T cell can express a substantially impaired TCR, e.g., by expression of mutated or truncated forms of one or more of the subunits of the TCR. The term “substantially impaired TCR” means that this TCR will not elicit an adverse immune reaction in a host. 
     A T cell described herein can be, e.g., engineered such that it does not express a functional HLA on its surface. For example, a T cell described herein, can be engineered such that cell surface expression HLA, e.g., HLA class 1 and/or HLA class II, is downregulated. 
     In some embodiments, the T cell can lack a functional TCR and a functional HLA, e.g., HLA class I and/or HLA class II. 
     Modified T cells that lack expression of a functional TCR and/or HLA can be obtained by any suitable means, including a knock out or knock down of one or more subunit of TCR or HLA. For example, the T cell can include a knock down of TCR and/or HLA using siRNA, shRNA, clustered regularly interspaced short palindromic repeats (CRISPR) transcription-activator like effector nuclease (TALEN), or zinc finger endonuclease (ZFN). 
     In some embodiments, the allogeneic cell can be a cell which does not express or expresses at low levels an inhibitory molecule, e.g. by any method described herein. For example, the cell can be a cell that does not express or expresses at low levels an inhibitory molecule, e.g., that can decrease the ability of an anti-target CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta. Inhibition of an inhibitory molecule, e.g., by inhibition at the DNA, RNA or protein level, can optimize a CAR-expressing cell performance. In embodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN), e.g., as described herein, can be used. 
     siRNA and shRNA to Inhibit TCR or HLA 
     In some embodiments, TCR expression and/or HLA expression can be inhibited using siRNA or shRNA that targets a nucleic acid encoding a TCR and/or HLA in a T cell. 
     Expression of siRNA and shRNAs in T cells can be achieved using any conventional expression system, e.g., such as a lentiviral expression system. 
     Exemplary shRNAs that downregulate expression of components of the TCR are described, e.g., in US Publication No.: 2012/0321667. Exemplary siRNA and shRNA that downregulate expression of HLA class I and/or HLA class II genes are described, e.g., in U.S. publication No.: US 2007/0036773. 
     CRISPR to inhibit TCR or HLA 
     “CRISPR” or “CRISPR to TCR and/or HLA” or “CRISPR to inhibit TCR and/or HLA” as used herein refers to a set of clustered regularly interspaced short palindromic repeats, or a system comprising such a set of repeats. “Cas”, as used herein, refers to a CRISPR-associated protein. A “CRISPR/Cas” system refers to a system derived from CRISPR and Cas which can be used to silence or mutate a TCR and/or HLA gene. 
     Naturally-occurring CRISPR/Cas systems are found in approximately 40% of sequenced eubacteria genomes and 90% of sequenced archaea. Grissa et al. (2007)  BMC Bioinformatics  8: 172. This system is a type of prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages and provides a form of acquired immunity. Barrangou et al. (2007)  Science  315: 1709-1712; Marragini et al. (2008)  Science  322: 1843-1845. 
     The CRISPR/Cas system has been modified for use in gene editing (silencing, enhancing or changing specific genes) in eukaryotes such as mice or primates. Wiedenheft et al. (2012)  Nature  482: 331-8. This is accomplished by introducing into the eukaryotic cell a plasmid containing a specifically designed CRISPR and one or more appropriate Cas. 
     The CRISPR sequence, sometimes called a CRISPR locus, comprises alternating repeats and spacers. In a naturally-occurring CRISPR, the spacers usually comprise sequences foreign to the bacterium such as a plasmid or phage sequence; in the TCR and/or HLA CRISPR/Cas system, the spacers are derived from the TCR or HLA gene sequence. 
     RNA from the CRISPR locus is constitutively expressed and processed by Cas proteins into small RNAs. These comprise a spacer flanked by a repeat sequence. The RNAs guide other Cas proteins to silence exogenous genetic elements at the RNA or DNA level. Horvath et al. (2010)  Science  327: 167-170; Makarova et al. (2006)  Biology Direct  1: 7. The spacers thus serve as templates for RNA molecules, analogously to siRNAs. Pennisi (2013)  Science  341: 833-836. 
     As these naturally occur in many different types of bacteria, the exact arrangements of the CRISPR and structure, function and number of Cas genes and their product differ somewhat from species to species. Haft et al. (2005)  PLoS Comput. Biol.  1: e60; Kunin et al. (2007)  Genome Biol.  8: R61; Mojica et al. (2005)  J. Mol. Evol.  60: 174-182; Bolotin et al. (2005)  Microbiol.  151: 2551-2561; Pourcel et al. (2005)  Microbiol.  151: 653-663; and Stern et al. (2010)  Trends. Genet.  28: 335-340. For example, the Cse (Cas subtype,  E. coli ) proteins (e.g., CasA) form a functional complex, Cascade, that processes CRISPR RNA transcripts into spacer-repeat units that Cascade retains. Brouns et al. (2008)  Science  321: 960-964. In other prokaryotes, Cas6 processes the CRISPR transcript. The CRISPR-based phage inactivation in  E. coli  requires Cascade and Cas3, but not Cas1 or Cas2. The Cmr (Cas RAMP module) proteins in  Pyrococcus furiosus  and other prokaryotes form a functional complex with small CRISPR RNAs that recognizes and cleaves complementary target RNAs. A simpler CRISPR system relies on the protein Cas9, which is a nuclease with two active cutting sites, one for each strand of the double helix. Combining Cas9 and modified CRISPR locus RNA can be used in a system for gene editing. Pennisi (2013) Science 341: 833-836. 
     The CRISPR/Cas system can thus be used to edit a TCR and/or HLA gene (adding or deleting a basepair), or introducing a premature stop which thus decreases expression of a TCR and/or HLA. The CRISPR/Cas system can alternatively be used like RNA interference, turning off TCR and/or HLA gene in a reversible fashion. In a mammalian cell, for example, the RNA can guide the Cas protein to a TCR and/or HLA promoter, sterically blocking RNA polymerases. 
     Artificial CRISPR/Cas systems can be generated which inhibit TCR and/or HLA, using technology known in the art, e.g., that described in U.S. Publication No. 20140068797, and Cong (2013) Science 339: 819-823. Other artificial CRISPR/Cas systems that are known in the art may also be generated which inhibit TCR and/or HLA, e.g., that described in Tsai (2014) Nature Biotechnol., 32:6 569-576, U.S. Pat. Nos. 8,871,445; 8,865,406; 8,795,965; 8,771,945; and U.S. Pat. No. 8,697,359. 
     TALEN to Inhibit TCR and/or HLA 
     “TALEN” or “TALEN to HLA and/or TCR” or “TALEN to inhibit HLA and/or TCR” refers to a transcription activator-like effector nuclease, an artificial nuclease which can be used to edit the HLA and/or TCR gene. 
     TALENs are produced artificially by fusing a TAL effector DNA binding domain to a DNA cleavage domain. Transcription activator-like effects (TALEs) can be engineered to bind any desired DNA sequence, including a portion of the HLA or TCR gene. By combining an engineered TALE with a DNA cleavage domain, a restriction enzyme can be produced which is specific to any desired DNA sequence, including a HLA or TCR sequence. These can then be introduced into a cell, wherein they can be used for genome editing. Boch (2011)  Nature Biotech.  29: 135-6; and Boch et al. (2009)  Science  326: 1509-12; Moscou et al. (2009)  Science  326: 3501. 
     TALEs are proteins secreted by  Xanthomonas  bacteria. The DNA binding domain contains a repeated, highly conserved 33-34 amino acid sequence, with the exception of the 12th and 13th amino acids. These two positions are highly variable, showing a strong correlation with specific nucleotide recognition. They can thus be engineered to bind to a desired DNA sequence. 
     To produce a TALEN, a TALE protein is fused to a nuclease (N), which is a wild-type or mutated Fold endonuclease. Several mutations to FokI have been made for its use in TALENs; these, for example, improve cleavage specificity or activity. Cermak et al. (2011)  Nucl. Acids Res.  39: e82; Miller et al. (2011)  Nature Biotech.  29: 143-8; Hockemeyer et al. (2011)  Nature Biotech.  29: 731-734; Wood et al. (2011)  Science  333: 307; Doyon et al. (2010)  Nature Methods  8: 74-79; Szczepek et al. (2007)  Nature Biotech.  25: 786-793; and Guo et al. (2010)  J. Mol. Biol.  200: 96. 
     The FokI domain functions as a dimer, requiring two constructs with unique DNA binding domains for sites in the target genome with proper orientation and spacing. Both the number of amino acid residues between the TALE DNA binding domain and the FokI cleavage domain and the number of bases between the two individual TALEN binding sites appear to be important parameters for achieving high levels of activity. Miller et al. (2011)  Nature Biotech.  29: 143-8. 
     A HLA or TCR TALEN can be used inside a cell to produce a double-stranded break (DSB). A mutation can be introduced at the break site if the repair mechanisms improperly repair the break via non-homologous end joining. For example, improper repair may introduce a frame shift mutation. Alternatively, foreign DNA can be introduced into the cell along with the TALEN; depending on the sequences of the foreign DNA and chromosomal sequence, this process can be used to correct a defect in the HLA or TCR gene or introduce such a defect into a wt HLA or TCR gene, thus decreasing expression of HLA or TCR. 
     TALENs specific to sequences in HLA or TCR can be constructed using any method known in the art, including various schemes using modular components. Zhang et al. (2011)  Nature Biotech.  29: 149-53; Geibler et al. (2011)  PLoS ONE  6: e19509. 
     Zinc Finger Nuclease to Inhibit HLA and/or TCR 
     “ZFN” or “Zinc Finger Nuclease” or “ZFN to HLA and/or TCR” or “ZFN to inhibit HLA and/or TCR” refer to a zinc finger nuclease, an artificial nuclease which can be used to edit the HLA and/or TCR gene. 
     Like a TALEN, a ZFN comprises a Fold nuclease domain (or derivative thereof) fused to a DNA-binding domain. In the case of a ZFN, the DNA-binding domain comprises one or more zinc fingers. Carroll et al. (2011)  Genetics Society of America  188: 773-782; and Kim et al. (1996)  Proc. Natl. Acad. Sci. USA  93: 1156-1160. 
     A zinc finger is a small protein structural motif stabilized by one or more zinc ions. A zinc finger can comprise, for example, Cys2His2, and can recognize an approximately 3-bp sequence. Various zinc fingers of known specificity can be combined to produce multi-finger polypeptides which recognize about 6, 9, 12, 15 or 18-bp sequences. Various selection and modular assembly techniques are available to generate zinc fingers (and combinations thereof) recognizing specific sequences, including phage display, yeast one-hybrid systems, bacterial one-hybrid and two-hybrid systems, and mammalian cells. 
     Like a TALEN, a ZFN must dimerize to cleave DNA. Thus, a pair of ZFNs are required to target non-palindromic DNA sites. The two individual ZFNs must bind opposite strands of the DNA with their nucleases properly spaced apart. Bitinaite et al. (1998)  Proc. Natl. Acad. Sci. USA  95: 10570-5. 
     Also like a TALEN, a ZFN can create a double-stranded break in the DNA, which can create a frame-shift mutation if improperly repaired, leading to a decrease in the expression and amount of HLA and/or TCR in a cell. ZFNs can also be used with homologous recombination to mutate in the HLA or TCR gene. 
     ZFNs specific to sequences in HLA AND/OR TCR can be constructed using any method known in the art. See, e.g., Provasi (2011) Nature Med. 18: 807-815; Torikai (2013) Blood 122: 1341-1349; Cathomen et al. (2008)  Mol. Ther.  16: 1200-7; Guo et al. (2010)  J. Mol. Biol.  400: 96; U.S. Patent Publication 2011/0158957; and U.S. Patent Publication 2012/0060230. 
     Telomerase Expression 
     While not wishing to be bound by any particular theory, in some embodiments, a therapeutic T cell has short term persistence in a patient, due to shortened telomeres in the T cell; accordingly, transfection with a telomerase gene can lengthen the telomeres of the T cell and improve persistence of the T cell in the patient. See Carl June, “Adoptive T cell therapy for cancer in the clinic”, Journal of Clinical Investigation, 117:1466-1476 (2007). Thus, in an embodiment, an immune effector cell, e.g., a T cell, ectopically expresses a telomerase subunit, e.g., the catalytic subunit of telomerase, e.g., TERT, e.g., hTERT. In some aspects, this disclosure provides a method of producing an anti-target CAR-expressing cell, comprising contacting a cell with a nucleic acid encoding a telomerase subunit, e.g., the catalytic subunit of telomerase, e.g., TERT, e.g., hTERT. The cell may be contacted with the nucleic acid before, simultaneous with, or after being contacted with a construct encoding an anti-target CAR. 
     In one aspect, the disclosure features a method of making a population of immune effector cells (e.g., T cells, NK cells). In an embodiment, the method comprises: providing a population of immune effector cells (e.g., T cells or NK cells), contacting the population of immune effector cells with a nucleic acid encoding a CAR; and contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT, under conditions that allow for anti-target CAR and telomerase expression. 
     In an embodiment, the nucleic acid encoding the telomerase subunit is DNA. In an embodiment, the nucleic acid encoding the telomerase subunit comprises a promoter capable of driving expression of the telomerase subunit. 
     In an embodiment, hTERT has the amino acid sequence of GenBank Protein ID AAC51724.1 (Meyerson et al., “hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization” Cell Volume 90, Issue 4, Aug. 22, 1997, Pages 785-795) as follows: 
     
       
         
           
               
            
               
                 (SEQ ID NO: 61) 
               
               
                 MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRAL 
               
               
                   
               
               
                 VAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFG 
               
               
                   
               
               
                 FALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLV 
               
               
                   
               
               
                 HLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCE 
               
               
                   
               
               
                 RAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTP 
               
               
                   
               
               
                 VGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVG 
               
               
                   
               
               
                 RQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSL 
               
               
                   
               
               
                 RPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNH 
               
               
                   
               
               
                 AQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQ 
               
               
                   
               
               
                 LLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKH 
               
               
                   
               
               
                 AKLSLQELTWKMSVRGCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMS 
               
               
                   
               
               
                 VYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRE 
               
               
                   
               
               
                 LSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKR 
               
               
                   
               
               
                 AERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQ 
               
               
                   
               
               
                 DPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKA 
               
               
                   
               
               
                 AHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNE 
               
               
                   
               
               
                 ASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDME 
               
               
                   
               
               
                 NKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNL 
               
               
                   
               
               
                 RKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYA 
               
               
                   
               
               
                 RTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTN 
               
               
                   
               
               
                 IYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAK 
               
               
                   
               
               
                 NAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQ 
               
               
                   
               
               
                 TQLSRKLPGTTLTALEAAANPALPSDFKTILD 
               
            
           
         
       
     
     In an embodiment, the hTERT has a sequence at least 80%, 85%, 90%, 95%, 96{circumflex over ( )}, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 61. In an embodiment, the hTERT has a sequence of SEQ ID NO: 61. In an embodiment, the hTERT comprises a deletion (e.g., of no more than 5, 10, 15, 20, or 30 amino acids) at the N-terminus, the C-terminus, or both. In an embodiment, the hTERT comprises a transgenic amino acid sequence (e.g., of no more than 5, 10, 15, 20, or 30 amino acids) at the N-terminus, the C-terminus, or both. 
     In an embodiment, the hTERT is encoded by the nucleic acid sequence of GenBank Accession No. AF018167 (Meyerson et al., “hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization” Cell Volume 90, Issue 4, Aug. 22, 1997, Pages 785-795): 
     
       
         
           
               
            
               
                 (SEQ ID NO: 62) 
               
            
           
           
               
               
            
               
                 1 
                 caggcagcgt ggtcctgctg cgcacgtggg aagccctggc 
               
               
                   
               
               
                   
                 cccggccacc cccgcgatgc  
               
               
                   
               
               
                 61 
                 cgcgcgctcc ccgctgccga gccgtgcgct ccctgctgcg 
               
               
                   
               
               
                   
                 cagccactac cgcgaggtgc  
               
               
                   
               
               
                 121 
                 tgccgctggc cacgttcgtg cggcgcctgg ggccccaggg 
               
               
                   
               
               
                   
                 ctggcggctg gtgcagcgcg  
               
               
                   
               
               
                 181 
                 gggacccggc ggctttccgc gcgctggtgg cccagtgcct 
               
               
                   
               
               
                   
                 ggtgtgcgtg ccctgggacg  
               
               
                   
               
               
                 241 
                 cacggccgcc ccccgccgcc ccctccttcc gccaggtgtc 
               
               
                   
               
               
                   
                 ctgcctgaag gagctggtgg  
               
               
                   
               
               
                 301 
                 cccgagtgct gcagaggctg tgcgagcgcg gcgcgaagaa 
               
               
                   
               
               
                   
                 cgtgctggcc ttcggcttcg  
               
               
                   
               
               
                 361 
                 cgctgctgga cggggcccgc gggggccccc ccgaggcctt 
               
               
                   
               
               
                   
                 caccaccagc gtgcgcagct  
               
               
                   
               
               
                 421 
                 acctgcccaa cacggtgacc gacgcactgc gggggagcgg 
               
               
                   
               
               
                   
                 ggcgtggggg ctgctgttgc  
               
               
                   
               
               
                 481 
                 gccgcgtggg cgacgacgtg ctggttcacc tgctggcacg 
               
               
                   
               
               
                   
                 ctgcgcgctc tttgtgctgg  
               
               
                   
               
               
                 541 
                 tggctcccag ctgcgcctac caggtgtgcg ggccgccgct 
               
               
                   
               
               
                   
                 gtaccagctc ggcgctgcca  
               
               
                   
               
               
                 601 
                 ctcaggcccg gcccccgcca cacgctagtg gaccccgaag 
               
               
                   
               
               
                   
                 gcgtctggga tgcgaacggg  
               
               
                   
               
               
                 661 
                 cctggaacca tagcgtcagg gaggccgggg tccccctggg 
               
               
                   
               
               
                   
                 cctgccagcc ccgggtgcga  
               
               
                   
               
               
                 721 
                 ggaggcgcgg gggcagtgcc agccgaagtc tgccgttgcc 
               
               
                   
               
               
                   
                 caagaggccc aggcgtggcg  
               
               
                   
               
               
                 781 
                 ctgcccctga gccggagcgg acgcccgttg ggcaggggtc 
               
               
                   
               
               
                   
                 ctgggcccac ccgggcagga  
               
               
                   
               
               
                 841 
                 cgcgtggacc gagtgaccgt ggtttctgtg tggtgtcacc 
               
               
                   
               
               
                   
                 tgccagaccc gccgaagaag  
               
               
                   
               
               
                 901 
                 ccacctcttt ggagggtgcg ctctctggca cgcgccactc 
               
               
                   
               
               
                   
                 ccacccatcc gtgggccgcc  
               
               
                   
               
               
                 961 
                 agcaccacgc gggcccccca tccacatcgc ggccaccacg 
               
               
                   
               
               
                   
                 tccctgggac acgccttgtc  
               
               
                   
               
               
                 1021 
                 ccccggtgta cgccgagacc aagcacttcc tctactcctc 
               
               
                   
               
               
                   
                 aggcgacaag gagcagctgc  
               
               
                   
               
               
                 1081 
                 ggccctcctt cctactcagc tctctgaggc ccagcctgac 
               
               
                   
               
               
                   
                 tggcgctcgg aggctcgtgg  
               
               
                   
               
               
                 1141 
                 agaccatctt tctgggttcc aggccctgga tgccagggac 
               
               
                   
               
               
                   
                 tccccgcagg ttgccccgcc  
               
               
                   
               
               
                 1201 
                 tgccccagcg ctactggcaa atgcggcccc tgtttctgga 
               
               
                   
               
               
                   
                 gctgcttggg aaccacgcgc  
               
               
                   
               
               
                 1261 
                 agtgccccta cggggtgctc ctcaagacgc actgcccgct 
               
               
                   
               
               
                   
                 gcgagctgcg gtcaccccag  
               
               
                   
               
               
                 1321 
                 cagccggtgt ctgtgcccgg gagaagcccc agggctctgt 
               
               
                   
               
               
                   
                 ggcggccccc gaggaggagg  
               
               
                   
               
               
                 1381 
                 acacagaccc ccgtcgcctg gtgcagctgc tccgccagca 
               
               
                   
               
               
                   
                 cagcagcccc tggcaggtgt  
               
               
                   
               
               
                 1441 
                 acggcttcgt gcgggcctgc ctgcgccggc tggtgccccc 
               
               
                   
               
               
                   
                 aggcctctgg ggctccaggc  
               
               
                   
               
               
                 1501 
                 acaacgaacg ccgcttcctc aggaacacca agaagttcat 
               
               
                   
               
               
                   
                 ctccctgggg aagcatgcca  
               
               
                   
               
               
                 1561 
                 agctctcgct gcaggagctg acgtggaaga tgagcgtgcg 
               
               
                   
               
               
                   
                 gggctgcgct tggctgcgca  
               
               
                   
               
               
                 1621 
                 ggagcccagg ggttggctgt gttccggccg cagagcaccg 
               
               
                   
               
               
                   
                 tctgcgtgag gagatcctgg  
               
               
                   
               
               
                 1681 
                 ccaagttcct gcactggctg atgagtgtgt acgtcgtcga 
               
               
                   
               
               
                   
                 gctgctcagg tctttctttt  
               
               
                   
               
               
                 1741 
                 atgtcacgga gaccacgttt caaaagaaca ggctcttttt 
               
               
                   
               
               
                   
                 ctaccggaag agtgtctgga  
               
               
                   
               
               
                 1801 
                 gcaagttgca aagcattgga atcagacagc acttgaagag 
               
               
                   
               
               
                   
                 ggtgcagctg cgggagctgt  
               
               
                   
               
               
                 1861 
                 cggaagcaga ggtcaggcag catcgggaag ccaggcccgc 
               
               
                   
               
               
                   
                 cctgctgacg tccagactcc  
               
               
                   
               
               
                 1921 
                 gcttcatccc caagcctgac gggctgcggc cgattgtgaa 
               
               
                   
               
               
                   
                 catggactac gtcgtgggag  
               
               
                   
               
               
                 1981 
                 ccagaacgtt ccgcagagaa aagagggccg agcgtctcac 
               
               
                   
               
               
                   
                 ctcgagggtg aaggcactgt  
               
               
                   
               
               
                 2041 
                 tcagcgtgct caactacgag cgggcgcggc gccccggcct 
               
               
                   
               
               
                   
                 cctgggcgcc tctgtgctgg  
               
               
                   
               
               
                 2101 
                 gcctggacga tatccacagg gcctggcgca ccttcgtgct 
               
               
                   
               
               
                   
                 gcgtgtgcgg gcccaggacc  
               
               
                   
               
               
                 2161 
                 cgccgcctga gctgtacttt gtcaaggtgg atgtgacggg 
               
               
                   
               
               
                   
                 cgcgtacgac accatccccc  
               
               
                   
               
               
                 2221 
                 aggacaggct cacggaggtc atcgccagca tcatcaaacc 
               
               
                   
               
               
                   
                 ccagaacacg tactgcgtgc  
               
               
                   
               
               
                 2281 
                 gtcggtatgc cgtggtccag aaggccgccc atgggcacgt 
               
               
                   
               
               
                   
                 ccgcaaggcc ttcaagagcc  
               
               
                   
               
               
                 2341 
                 acgtctctac cttgacagac ctccagccgt acatgcgaca 
               
               
                   
               
               
                   
                 gttcgtggct cacctgcagg  
               
               
                   
               
               
                 2401 
                 agaccagccc gctgagggat gccgtcgtca tcgagcagag 
               
               
                   
               
               
                   
                 ctcctccctg aatgaggcca  
               
               
                   
               
               
                 2461 
                 gcagtggcct cttcgacgtc ttcctacgct tcatgtgcca 
               
               
                   
               
               
                   
                 ccacgccgtg cgcatcaggg  
               
               
                   
               
               
                 2521 
                 gcaagtccta cgtccagtgc caggggatcc cgcagggctc 
               
               
                   
               
               
                   
                 catcctctcc acgctgctct  
               
               
                   
               
               
                 2581 
                 gcagcctgtg ctacggcgac atggagaaca agctgtttgc 
               
               
                   
               
               
                   
                 ggggattcgg cgggacgggc  
               
               
                   
               
               
                 2641 
                 tgctcctgcg tttggtggat gatttcttgt tggtgacacc 
               
               
                   
               
               
                   
                 tcacctcacc cacgcgaaaa  
               
               
                   
               
               
                 2701 
                 ccttcctcag gaccctggtc cgaggtgtcc ctgagtatgg 
               
               
                   
               
               
                   
                 ctgcgtggtg aacttgcgga  
               
               
                   
               
               
                 2761 
                 agacagtggt gaacttccct gtagaagacg aggccctggg 
               
               
                   
               
               
                   
                 tggcacggct tttgttcaga  
               
               
                   
               
               
                 2821 
                 tgccggccca cggcctattc ccctggtgcg gcctgctgct 
               
               
                   
               
               
                   
                 ggatacccgg accctggagg  
               
               
                   
               
               
                 2881 
                 tgcagagcga ctactccagc tatgcccgga cctccatcag 
               
               
                   
               
               
                   
                 agccagtctc accttcaacc  
               
               
                   
               
               
                 2941 
                 gcggcttcaa ggctgggagg aacatgcgtc gcaaactctt 
               
               
                   
               
               
                   
                 tggggtcttg cggctgaagt  
               
               
                   
               
               
                 3001 
                 gtcacagcct gtttctggat ttgcaggtga acagcctcca 
               
               
                   
               
               
                   
                 gacggtgtgc accaacatct  
               
               
                   
               
               
                 3061 
                 acaagatcct cctgctgcag gcgtacaggt ttcacgcatg 
               
               
                   
               
               
                   
                 tgtgctgcag ctcccatttc  
               
               
                   
               
               
                 3121 
                 atcagcaagt ttggaagaac cccacatttt tcctgcgcgt 
               
               
                   
               
               
                   
                 catctctgac acggcctccc  
               
               
                   
               
               
                 3181 
                 tctgctactc catcctgaaa gccaagaacg cagggatgtc 
               
               
                   
               
               
                   
                 gctgggggcc aagggcgccg  
               
               
                   
               
               
                 3241 
                 ccggccctct gccctccgag gccgtgcagt ggctgtgcca 
               
               
                   
               
               
                   
                 ccaagcattc ctgctcaagc  
               
               
                   
               
               
                 3301 
                 tgactcgaca ccgtgtcacc tacgtgccac tcctggggtc 
               
               
                   
               
               
                   
                 actcaggaca gcccagacgc  
               
               
                   
               
               
                 3361 
                 agctgagtcg gaagctcccg gggacgacgc tgactgccct 
               
               
                   
               
               
                   
                 ggaggccgca gccaacccgg  
               
               
                   
               
               
                 3421 
                 cactgccctc agacttcaag accatcctgg actgatggcc 
               
               
                   
               
               
                   
                 acccgcccac agccaggccg  
               
               
                   
               
               
                 3481 
                 agagcagaca ccagcagccc tgtcacgccg ggctctacgt 
               
               
                   
               
               
                   
                 cccagggagg gaggggcggc  
               
               
                   
               
               
                 3541 
                 ccacacccag gcccgcaccg ctgggagtct gaggcctgag 
               
               
                   
               
               
                   
                 tgagtgtttg gccgaggcct  
               
               
                   
               
               
                 3601 
                 gcatgtccgg ctgaaggctg agtgtccggc tgaggcctga 
               
               
                   
               
               
                   
                 gcgagtgtcc agccaagggc  
               
               
                   
               
               
                 3661 
                 tgagtgtcca gcacacctgc cgtcttcact tccccacagg 
               
               
                   
               
               
                   
                 ctggcgctcg gctccacccc  
               
               
                   
               
               
                 3721 
                 agggccagct tttcctcacc aggagcccgg cttccactcc 
               
               
                   
               
               
                   
                 ccacatagga atagtccatc  
               
               
                   
               
               
                 3781 
                 cccagattcg ccattgttca cccctcgccc tgccctcctt 
               
               
                   
               
               
                   
                 tgccttccac ccccaccatc  
               
               
                   
               
               
                 3841 
                 caggtggaga ccctgagaag gaccctggga gctctgggaa 
               
               
                   
               
               
                   
                 tttggagtga ccaaaggtgt  
               
               
                   
               
               
                 3901 
                 gccctgtaca caggcgagga ccctgcacct ggatgggggt 
               
               
                   
               
               
                   
                 ccctgtgggt caaattgggg  
               
               
                   
               
               
                 3961 
                 ggaggtgctg tgggagtaaa atactgaata tatgagtttt 
               
               
                   
               
               
                   
                 tcagttttga aaaaaaaaaa  
               
               
                   
               
               
                 4021 
                 aaaaaaa  
               
            
           
         
       
     
     In an embodiment, the hTERT is encoded by a nucleic acid having a sequence at least 80%, 85%, 90%, 95%, 96, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 62. In an embodiment, the hTERT is encoded by a nucleic acid of SEQ ID NO: 62. 
     Activation and Expansion of Immune Effector Cells (e.g., T Cells) 
     Immune effector cells such as T cells may be activated and expanded generally using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005. 
     As demonstrated by the data disclosed herein, expanding the T cells by the methods disclosed herein can multiply the cells by about 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, 100 fold, 200 fold, 300 fold, 400 fold, 500 fold, 600 fold, 700 fold, 800 fold, 900 fold, 1000 fold, 2000 fold, 3000 fold, 4000 fold, 5000 fold, 6000 fold, 7000 fold, 8000 fold, 9000 fold, 10,000 fold, 100,000 fold, 1,000,000 fold, 10,000,000 fold, or greater, and any and all whole or partial intergers therebetween. In one embodiment, the T cells expand in the range of about 20 fold to about 50 fold. 
     Generally, a population of immune effector cells e.g., T regulatory cell depleted cells, may be expanded by contact with a surface having attached thereto an agent that stimulates a CD3/TCR complex associated signal and a ligand that stimulates a costimulatory molecule on the surface of the T cells. In particular, T cell populations may be stimulated as described herein, such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a ligand that binds the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. To stimulate proliferation of either CD4+ T cells or CD8+ T cells, an anti-CD3 antibody and an anti-CD28 antibody can be used. Examples of an anti-CD28 antibody include 9.3, B-T3, XR-CD28 (Diaclone, Besançon, France) can be used as can other methods commonly known in the art (Berg et al., Transplant Proc. 30(8):3975-3977, 1998; Haanen et al., J. Exp. Med. 190(9):13191328, 1999; Garland et al., J. Immunol Meth. 227(1-2):53-63, 1999). 
     In certain aspects, the primary stimulatory signal and the costimulatory signal for the T cell may be provided by different protocols. For example, the agents providing each signal may be in solution or coupled to a surface. When coupled to a surface, the agents may be coupled to the same surface (i.e., in “cis” formation) or to separate surfaces (i.e., in “trans” formation). Alternatively, one agent may be coupled to a surface and the other agent in solution. In one aspect, the agent providing the costimulatory signal is bound to a cell surface and the agent providing the primary activation signal is in solution or coupled to a surface. In certain aspects, both agents can be in solution. In one aspect, the agents may be in soluble form, and then cross-linked to a surface, such as a cell expressing Fc receptors or an antibody or other binding agent which will bind to the agents. In this regard, see for example, U.S. Patent Application Publication Nos. 20040101519 and 20060034810 for artificial antigen presenting cells (aAPCs) that are contemplated for use in activating and expanding T cells in the present invention. 
     In one aspect, the two agents are immobilized on beads, either on the same bead, i.e., “cis,” or to separate beads, i.e., “trans.” By way of example, the agent providing the primary activation signal is an anti-CD3 antibody or an antigen-binding fragment thereof and the agent providing the costimulatory signal is an anti-CD28 antibody or antigen-binding fragment thereof; and both agents are co-immobilized to the same bead in equivalent molecular amounts. In one aspect, a 1:1 ratio of each antibody bound to the beads for CD4+ T cell expansion and T cell growth is used. In certain aspects of the present invention, a ratio of anti CD3:CD28 antibodies bound to the beads is used such that an increase in T cell expansion is observed as compared to the expansion observed using a ratio of 1:1. In one particular aspect an increase of from about 1 to about 3 fold is observed as compared to the expansion observed using a ratio of 1:1. In one aspect, the ratio of CD3:CD28 antibody bound to the beads ranges from 100:1 to 1:100 and all integer values there between. In one aspect, more anti-CD28 antibody is bound to the particles than anti-CD3 antibody, i.e., the ratio of CD3:CD28 is less than one. In certain aspects, the ratio of anti CD28 antibody to anti CD3 antibody bound to the beads is greater than 2:1. In one particular aspect, a 1:100 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:75 CD3:CD28 ratio of antibody bound to beads is used. In a further aspect, a 1:50 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:30 CD3:CD28 ratio of antibody bound to beads is used. In one preferred aspect, a 1:10 CD3:CD28 ratio of antibody bound to beads is used. In one aspect, a 1:3 CD3:CD28 ratio of antibody bound to the beads is used. In yet one aspect, a 3:1 CD3:CD28 ratio of antibody bound to the beads is used. 
     Ratios of particles to cells from 1:500 to 500:1 and any integer values in between may be used to stimulate T cells or other target cells. As those of ordinary skill in the art can readily appreciate, the ratio of particles to cells may depend on particle size relative to the target cell. For example, small sized beads could only bind a few cells, while larger beads could bind many. In certain aspects the ratio of cells to particles ranges from 1:100 to 100:1 and any integer values in-between and in further aspects the ratio comprises 1:9 to 9:1 and any integer values in between, can also be used to stimulate T cells. The ratio of anti-CD3- and anti-CD28-coupled particles to T cells that result in T cell stimulation can vary as noted above, however certain preferred values include 1:100, 1:50, 1:40, 1:30, 1:20, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, and 15:1 with one preferred ratio being at least 1:1 particles per T cell. In one aspect, a ratio of particles to cells of 1:1 or less is used. In one particular aspect, a preferred particle: cell ratio is 1:5. In further aspects, the ratio of particles to cells can be varied depending on the day of stimulation. For example, in one aspect, the ratio of particles to cells is from 1:1 to 10:1 on the first day and additional particles are added to the cells every day or every other day thereafter for up to 10 days, at final ratios of from 1:1 to 1:10 (based on cell counts on the day of addition). In one particular aspect, the ratio of particles to cells is 1:1 on the first day of stimulation and adjusted to 1:5 on the third and fifth days of stimulation. In one aspect, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:5 on the third and fifth days of stimulation. In one aspect, the ratio of particles to cells is 2:1 on the first day of stimulation and adjusted to 1:10 on the third and fifth days of stimulation. In one aspect, particles are added on a daily or every other day basis to a final ratio of 1:1 on the first day, and 1:10 on the third and fifth days of stimulation. One of skill in the art will appreciate that a variety of other ratios may be suitable for use in the present invention. In particular, ratios will vary depending on particle size and on cell size and type. In one aspect, the most typical ratios for use are in the neighborhood of 1:1, 2:1 and 3:1 on the first day. 
     In further aspects, the cells, such as T cells, are combined with agent-coated beads, the beads and the cells are subsequently separated, and then the cells are cultured. In an alternative aspect, prior to culture, the agent-coated beads and cells are not separated but are cultured together. In a further aspect, the beads and cells are first concentrated by application of a force, such as a magnetic force, resulting in increased ligation of cell surface markers, thereby inducing cell stimulation. 
     By way of example, cell surface proteins may be ligated by allowing paramagnetic beads to which anti-CD3 and anti-CD28 are attached (3×28 beads) to contact the T cells. In one aspect the cells (for example, 10 4  to 10 9  T cells) and beads (for example, DYNABEADS® M-450 CD3/CD28 T paramagnetic beads at a ratio of 1:1) are combined in a buffer, for example PBS (without divalent cations such as, calcium and magnesium). Again, those of ordinary skill in the art can readily appreciate any cell concentration may be used. For example, the target cell may be very rare in the sample and comprise only 0.01% of the sample or the entire sample (i.e., 100%) may comprise the target cell of interest. Accordingly, any cell number is within the context of the present invention. In certain aspects, it may be desirable to significantly decrease the volume in which particles and cells are mixed together (i.e., increase the concentration of cells), to ensure maximum contact of cells and particles. For example, in one aspect, a concentration of about 10 billion cells/ml, 9 billion/ml, 8 billion/ml, 7 billion/ml, 6 billion/ml, 5 billion/ml, or 2 billion cells/ml is used. In one aspect, greater than 100 million cells/ml is used. In a further aspect, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet one aspect, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further aspects, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells. Such populations of cells may have therapeutic value and would be desirable to obtain in certain aspects. For example, using high concentration of cells allows more efficient selection of CD8+ T cells that normally have weaker CD28 expression. 
     In one embodiment, cells transduced with a nucleic acid encoding an anti-target CAR, e.g., an anti-target CAR described herein, are expanded, e.g., by a method described herein. In one embodiment, the cells are expanded in culture for a period of several hours (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 18, 21 hours) to about 14 days (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days). In one embodiment, the cells are expanded for a period of 4 to 9 days. In one embodiment, the cells are expanded for a period of 8 days or less, e.g., 7, 6 or 5 days. In one embodiment, the cells, e.g., an anti-target CAR cell described herein, are expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions. Potency can be defined, e.g., by various T cell functions, e.g. proliferation, target cell killing, cytokine production, activation, migration, or combinations thereof. In one embodiment, the cells, e.g., an anti-target CAR cell described herein, expanded for 5 days show at least a one, two, three or four fold increase in cells doublings upon antigen stimulation as compared to the same cells expanded in culture for 9 days under the same culture conditions. In one embodiment, the cells, e.g., the cells expressing an anti-target CAR described herein, are expanded in culture for 5 days, and the resulting cells exhibit higher proinflammatory cytokine production, e.g., IFN-γ and/or GM-CSF levels, as compared to the same cells expanded in culture for 9 days under the same culture conditions. In one embodiment, the cells, e.g., an anti-target CAR cell described herein, expanded for 5 days show at least a one, two, three, four, five, ten fold or more increase in pg/ml of proinflammatory cytokine production, e.g., IFN-γ and/or GM-CSF levels, as compared to the same cells expanded in culture for 9 days under the same culture conditions. 
     Several cycles of stimulation may also be desired such that culture time of T cells can be 60 days or more. Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 15, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGFβ, and TNF-α or any other additives for the growth of cells known to the skilled artisan. Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI 1640, AIM-V, DMEM, MEM, α-MEM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% CO 2 ). 
     In one embodiment, the cells are expanded in an appropriate media (e.g., media described herein) that includes one or more interleukin that result in at least a 200-fold (e.g., 200-fold, 250-fold, 300-fold, 350-fold) increase in cells over a 14 day expansion period, e.g., as measured by a method described herein such as flow cytometry. In one embodiment, the cells are expanded in the presence of IL-15 and/or IL-7 (e.g., IL-15 and IL-7). 
     In embodiments, methods described herein, e.g., anti-target CAR-expressing cell manufacturing methods, comprise removing T regulatory cells, e.g., CD25+ T cells, from a cell population, e.g., using an anti-CD25 antibody, or fragment thereof, or a CD25-binding ligand, IL-2. Methods of removing T regulatory cells, e.g., CD25+ T cells, from a cell population are described herein. In embodiments, the methods, e.g., manufacturing methods, further comprise contacting a cell population (e.g., a cell population in which T regulatory cells, such as CD25+ T cells, have been depleted; or a cell population that has previously contacted an anti-CD25 antibody, fragment thereof, or CD25-binding ligand) with IL-15 and/or IL-7. For example, the cell population (e.g., that has previously contacted an anti-CD25 antibody, fragment thereof, or CD25-binding ligand) is expanded in the presence of IL-15 and/or IL-7. 
     In some embodiments an anti-target CAR-expressing cell described herein is contacted with a composition comprising a interleukin-15 (IL-15) polypeptide, a interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of both a IL-15 polypeptide and a IL-15Ra polypeptide e.g., hetIL-15, during the manufacturing of the anti-target CAR-expressing cell, e.g., ex vivo. In embodiments, an anti-target CAR-expressing cell described herein is contacted with a composition comprising a IL-15 polypeptide during the manufacturing of the anti-target CAR-expressing cell, e.g., ex vivo. In embodiments, an anti-target CAR-expressing cell described herein is contacted with a composition comprising a combination of both a IL-15 polypeptide and a IL-15 Ra polypeptide during the manufacturing of the anti-target CAR-expressing cell, e.g., ex vivo. In embodiments, an anti-target CAR-expressing cell described herein is contacted with a composition comprising hetIL-15 during the manufacturing of the anti-target CAR-expressing cell, e.g., ex vivo. 
     In one embodiment the anti-target CAR-expressing cell described herein is contacted with a composition comprising hetIL-15 during ex vivo expansion. In an embodiment, the anti-target CAR-expressing cell described herein is contacted with a composition comprising an IL-15 polypeptide during ex vivo expansion. In an embodiment, the anti-target CAR-expressing cell described herein is contacted with a composition comprising both an IL-15 polypeptide and an IL-15Ra polypeptide during ex vivo expansion. In one embodiment the contacting results in the survival and proliferation of a lymphocyte subpopulation, e.g., CD8+ T cells. 
     T cells that have been exposed to varied stimulation times may exhibit different characteristics. For example, typical blood or apheresed peripheral blood mononuclear cell products have a helper T cell population (TH, CD4+) that is greater than the cytotoxic or suppressor T cell population (TC, CD8+). Ex vivo expansion of T cells by stimulating CD3 and CD28 receptors produces a population of T cells that prior to about days 8-9 consists predominately of TH cells, while after about days 8-9, the population of T cells comprises an increasingly greater population of TC cells. Accordingly, depending on the purpose of treatment, infusing a subject with a T cell population comprising predominately of TH cells may be advantageous. Similarly, if an antigen-specific subset of TC cells has been isolated it may be beneficial to expand this subset to a greater degree. 
     Further, in addition to CD4 and CD8 markers, other phenotypic markers vary significantly, but in large part, reproducibly during the course of the cell expansion process. Thus, such reproducibility enables the ability to tailor an activated T cell product for specific purposes. 
     Once an anti-target CAR described herein is constructed, various assays can be used to evaluate the activity of the molecule, such as but not limited to, the ability to expand T cells following antigen stimulation, sustain T cell expansion in the absence of re-stimulation, and anti-cancer activities in appropriate in vitro and animal models. Assays to evaluate the effects of a cars of the present invention are described in further detail below 
     Western blot analysis of anti-target CAR expression in primary T cells can be used to detect the presence of monomers and dimers. See, e.g., Milone et al., Molecular Therapy 17(8): 1453-1464 (2009). Very briefly, T cells (1:1 mixture of CD4+ and CD8+ T cells) expressing the CARs are expanded in vitro for more than 10 days followed by lysis and SDS-PAGE under reducing conditions. Anti-target CARs containing the full length TCR-cytoplasmic domain and the endogenous TCR-ζ chain are detected by western blotting using an antibody to the TCR-ζ chain. The same T cell subsets are used for SDS-PAGE analysis under non-reducing conditions to permit evaluation of covalent dimer formation. 
     In vitro expansion of anti-target CAR +  T cells following antigen stimulation can be measured by flow cytometry. For example, a mixture of CD4 +  and CD8 +  T cells are stimulated with αCD3/αCD28 aAPCs followed by transduction with lentiviral vectors expressing GFP under the control of the promoters to be analyzed. Exemplary promoters include the CMV IE gene, EF-1α, ubiquitin C, or phosphoglycerokinase (PGK) promoters. GFP fluorescence is evaluated on day 6 of culture in the CD4+ and/or CD8+ T cell subsets by flow cytometry. See, e.g., Milone et al., Molecular Therapy 17(8): 1453-1464 (2009). Alternatively, a mixture of CD4 +  and CD8 +  T cells are stimulated with αCD3/αCD28 coated magnetic beads on day 0, and transduced with anti-target CAR on day 1 using a bicistronic lentiviral vector expressing anti-target CAR along with eGFP using a 2A ribosomal skipping sequence. Cultures are re-stimulated with either a cancer associated antigen as described herein +  K562 cells (K562 expressing a cancer associated antigen as described herein), wild-type K562 cells (K562 wild type) or K562 cells expressing hCD32 and 4-1BBL in the presence of antiCD3 and anti-CD28 antibody (K562-BBL-3/28) following washing. Exogenous IL-2 is added to the cultures every other day at 100 IU/ml. GFP +  T cells are enumerated by flow cytometry using bead-based counting. See, e.g., Milone et al., Molecular Therapy 17(8): 1453-1464 (2009). 
     Sustained anti-target CAR +  T cell expansion in the absence of re-stimulation can also be measured. See, e.g., Milone et al., Molecular Therapy 17(8): 1453-1464 (2009). Briefly, mean T cell volume (fl) is measured on day 8 of culture using a Coulter Multisizer III particle counter, a Nexcelom Cellometer Vision or Millipore Scepter, following stimulation with αCD3/αCD28 coated magnetic beads on day 0, and transduction with the indicated anti-target CAR on day 1. 
     Animal models can also be used to measure anti-target CAR CART activity. For example, the xenograft model using a human cancer cell line as described in Example 1 can be used to measure anti-target CAR CART activity. 
     Dose dependent anti-target CAR treatment response can be evaluated. Exemplary methods used for evaluating CAR treatment response can be used to measure anti-target CAR treatment responses. See, e.g., Milone et al., Molecular Therapy 17(8): 1453-1464 (2009). For example, peripheral blood is obtained 35-70 days after establishing leukemia in mice injected on day 21 with CAR T cells, an equivalent number of mock-transduced T cells, or no T cells. Mice from each group are randomly bled for determination of peripheral blood a cancer associate antigen as described herein +  ALL blast counts and then killed on days 35 and 49. The remaining animals are evaluated on days 57 and 70. 
     Assessment of cell proliferation and cytokine production has been previously described, e.g., at Milone et al., Molecular Therapy 17(8): 1453-1464 (2009). Briefly, assessment of anti-target CAR-mediated proliferation is performed in microtiter plates by mixing washed T cells with K562 cells expressing a cancer associated antigen described herein (K19) or CD32 and CD137 (KT32-BBL) for a final T-cell:K562 ratio of 2:1. K562 cells are irradiated with gamma-radiation prior to use. Anti-CD3 (clone OKT3) and anti-CD28 (clone 9.3) monoclonal antibodies are added to cultures with KT32-BBL cells to serve as a positive control for stimulating T-cell proliferation since these signals support long-term CD8+ T cell expansion ex vivo. T cells are enumerated in cultures using CountBright™ fluorescent beads (Invitrogen, Carlsbad, Calif.) and flow cytometry as described by the manufacturer. CAR +  T cells are identified by GFP expression using T cells that are engineered with eGFP-2A linked anti-target CAR-expressing lentiviral vectors. For anti-target CAR+ T cells not expressing GFP, the anti-target CAR+ T cells are detected with biotinylated recombinant a cancer associate antigen as described herein protein and a secondary avidin-PE conjugate. CD4+ and CD8 +  expression on T cells are also simultaneously detected with specific monoclonal antibodies (BD Biosciences). Cytokine measurements are performed on supernatants collected 24 hours following re-stimulation using the human TH1/TH2 cytokine cytometric bead array kit (BD Biosciences, San Diego, Calif.) according the manufacturer&#39;s instructions. Fluorescence is assessed using a FACScalibur flow cytometer, and data is analyzed according to the manufacturer&#39;s instructions. 
     Cytotoxicity can be assessed by a standard 51Cr-release assay. See, e.g., Milone et al., Molecular Therapy 17(8): 1453-1464 (2009). Briefly, target cells (K562 lines and primary pro-B-ALL cells) are loaded with 51Cr (as NaCrO4, New England Nuclear, Boston, Mass.) at 37° C. for 2 hours with frequent agitation, washed twice in complete RPMI and plated into microtiter plates. Effector T cells are mixed with target cells in the wells in complete RPMI at varying ratios of effector cell:target cell (E:T). Additional wells containing media only (spontaneous release, SR) or a 1% solution of triton-X 100 detergent (total release, TR) are also prepared. After 4 hours of incubation at 37° C., supernatant from each well is harvested. Released 51Cr is then measured using a gamma particle counter (Packard Instrument Co., Waltham, Mass.). Each condition is performed in at least triplicate, and the percentage of lysis is calculated using the formula: % Lysis=(ER−SR)/(TR−SR), where ER represents the average 51Cr released for each experimental condition. 
     Imaging technologies can be used to evaluate specific trafficking and proliferation of anti-target CARs in tumor-bearing animal models. Such assays have been described for CARs, for example, in Barrett et al., Human Gene Therapy 22:1575-1586 (2011). Similar assays can be used to evaluate specific trafficking and proliferation of anti-target CARs in tumor-bearing animal models. Briefly, NOD/SCID/γc −/−  (NSG) mice are injected IV with Nalm-6 cells followed 7 days later with T cells 4 hour after electroporation with the CAR constructs. The T cells are stably transfected with a lentiviral construct to express firefly luciferase, and mice are imaged for bioluminescence. Alternatively, therapeutic efficacy and specificity of a single injection of CAR +  T cells in Nalm-6 xenograft model can be measured as the following: NSG mice are injected with Nalm-6 transduced to stably express firefly luciferase, followed by a single tail-vein injection of T cells electroporated with cars of the present invention 7 days later. Animals are imaged at various time points post injection. For example, photon-density heat maps of firefly luciferase positive leukemia in representative mice at day 5 (2 days before treatment) and day 8 (24 hr post CARP PBLs) can be generated. 
     Other assays, including those described in the Example section herein as well as those that are known in the art can also be used to evaluate the anti-target CARs described herein. 
     Therapeutic Application 
     The modified cells described herein may be included in a composition for therapy. In one aspect, the composition comprises a population of modified T cells comprising a nucleic acid sequence encoding an anti-target CAR. In yet another embodiment, the composition includes a modified T cell comprising an anti-target CAR that comprises a costimulatory domain described herein, e.g., that increases anti-tumor effect and T cell persistence. The composition may include a pharmaceutical composition and further include a pharmaceutically acceptable carrier. A therapeutically effective amount of the pharmaceutical composition comprising the modified cells may be administered. 
     In one aspect, the invention includes a method comprising administering a population of modified T cells to a subject in need thereof to treat a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed), wherein the modified T cells comprise a nucleic acid sequence encoding an anti-target CAR. In one embodiment, the disease associated with expression of a target CAR is a cancer, e.g., a cancer as described herein, or a non-cancerous condition, e.g., B cell aplasia. 
     In one aspect, the invention provides methods for treating a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed). 
     In one aspect, the present invention provides methods of treating a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed), e.g., a cancer, by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express an anti-target CAR described herein, wherein the cancer cells express a target CAR. In one embodiment, the target CAR is expressed on cancer cells. In one embodiment, the target CAR is not expressed, on normal cells. In one embodiment, the method further comprises selecting an anit-target CAR that binds a target CAR with an affinity that allows the anti-target CAR to bind and kill the cancer cells expressing the target CAR. In one embodiment, the selected anti-target CAR has an antigen binding domain that has a binding affinity KD of 10 −4  M to 10 −8  M, e.g., 10 −5  M to 10 −7  M, e.g., 10 −6  M or 10 −7  M, for the target CAR, e.g., for the extracellular domain of the target CAR, e.g., the antigen binding domain or hinge region of the target CAR. In one embodiment, the selected ligand of the anti-target CAR comprises an antibody molecule, e.g., an anti-idiotypic antibody, which has a binding affinity that is at least five-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold or 1,000-fold less than a reference antibody, e.g., an antibody described herein. 
     In one embodiment, the disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed) to be treated is ALL (acute lymphoblastic leukemia), CLL (chronic lymphocytic leukemia), DLBCL (diffuse large B-cell lymphoma), MCL (Mantle cell lymphoma, or MM (multiple myeloma). 
     In one embodiment, the present invention provides methods of treating a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed), e.g., a cancer by providing to the subject in need thereof immune effector cells (e.g., T cells, NK cells) that are engineered to express an anti-target CAR that binds to a target CAR, wherein the subject has experienced relapse and the relapsed cancer cells do not express the antigen bound by the target CAR (e.g., the relapsed cancer cells are negative for the target CAR antigen). In an embodiment, 
     a) the target CAR is a CD19CAR, the anti-target CAR binds to the CD19CAR, the subject had a CD19 expressing disease, and the relapse is a CD19-negative relapse; 
     b) the target CAR is a CD33 CAR, the anti-target CAR binds to the CD33CAR, the subject had a CD33 expressing disease, and the relapse is a CD33-negative relapse; 
     c) the target CAR is an EGFRvIIICAR, the anti-target CAR binds to the EGFRvIIICAR, the subject had a EGFRvIII expressing disease, and the relapse is a EGFRvIII-negative relapse; 
     d) the target CAR is a mesothelinCAR, the anti-target CAR binds to the mesothelinCAR, the subject had a mesothelin expressing disease, and the relapse is a mesothelin-negative relapse; 
     e) the target CAR is a BCMACAR, the anti-target CAR binds to the BCMACAR, the subject had a BCMA expressing disease, and the relapse is a BCMA-negative relapse; 
     f) the target CAR is a CD20CAR, the anti-target CAR binds to the CD20CAR, the subject had a CD20 expressing disease, and the relapse is a CD20-negative relapse; 
     g) the target CAR is a CD22CAR, the anti-target CAR binds to the CD22CAR, the subject had a CD22 expressing disease, and the relapse is a CD22-negative relapse; 
     h) the target CAR is a CD123CAR, the anti-target CAR binds to the CD123CAR, the subject had a CD123 expressing disease, and the relapse is a CD123-negative relapse; or 
     i) the target CAR is a CAR that binds to a tumor antigen described herein, the anti-target CAR binds to the target CAR, the subject had a disease expressing the tumor antigen bound by the target CAR, and the relapse is negative for expression of the tumor antigen bound by the target CAR. 
     In one aspect, the present invention relates to treatment of a subject in vivo using an PD1 CAR such that growth of a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed) is inhibited. A PD1 CAR may be used alone to inhibit the growth of a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed). Alternatively, PD1 CAR may be used in conjunction with an anti-target CARs, immunogenic agents, standard cancer treatments, or other antibodies. In one embodiment, the subject is treated with a PD1 CAR and an anti-target CAR described herein. In an embodiment, a PD1 CAR is used in conjunction with anti-target CAR, e.g., an anti-target CAR described herein, and a kinase inhibitor, e.g., a kinase inhibitor described herein. 
     In another aspect, a method of treating a subject, e.g., reducing or ameliorating, a hyperproliferative condition or disorder, e.g., a disease associated with expression of a target CAR (e.g., a disease in which a target CAR is expressed), e.g., a cancer, e.g., solid tumor, a soft tissue tumor, or a metastatic lesion, in a subject is provided. As used herein, the term “cancer” is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. Examples of solid tumors include malignancies, e.g., sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting liver, lung, breast, lymphoid, gastrointestinal (e.g., colon), genitourinary tract (e.g., renal, urothelial cells), prostate and pharynx. Adenocarcinomas include malignancies such as most colon cancers, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. In one embodiment, the cancer is a melanoma, e.g., an advanced stage melanoma. Metastatic lesions of the aforementioned cancers can also be treated or prevented using the methods and compositions of the invention. Examples of other cancers that can be treated include bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin Disease, non-Hodgkin lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi&#39;s sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers. Treatment of metastatic cancers, e.g., metastatic cancers that express PD-L1 (Iwai et al. (2005) Int. Immunol. 17:133-144) can be effected using the antibody molecules described herein. 
     Exemplary cancers whose growth can be inhibited include cancers typically responsive to immunotherapy. Non-limiting examples of cancers for treatment include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g. clear cell carcinoma), prostate cancer (e.g. hormone refractory prostate adenocarcinoma), breast cancer, colon cancer and lung cancer (e.g. non-small cell lung cancer). Additionally, refractory or recurrent malignancies can be treated using the molecules described herein. 
     In one aspect, the invention pertains to a vector comprising an anti-target CAR operably linked to promoter for expression in mammalian immune effector cells (e.g., T cells, NK cells). In one aspect, the invention provides a recombinant immune effector cell expressing an anti-target CAR of the present invention for use in treating a disease associated with expression of a target CAR. In one aspect, anti-target CAR-expressing cells of the invention are capable of contacting a cell, e.g., a cell expressing a target CAR, e.g., a cell from a disease associated with expression of the target CAR (e.g., a cancer) with at least one target CAR molecule expressed on its surface such that the anti-target CAR-expressing cell targets the cancer cell and growth of the cancer is inhibited. 
     In one aspect, the invention pertains to a method of inhibiting growth of a disease associated with expression of a target CAR, e.g., a cancer, comprising contacting the cancer cell with an anti-target CAR-expressing cell of the present invention such that the CART is activated in response to the target CAR antigen and targets the cancer cell expressing the target CAR, wherein the growth of the tumor associated with the target CAR is inhibited. 
     In one aspect, the invention pertains to a method of treating disease associated with expression of a target CAR, e.g., a cancer in a subject. The method comprises administering to the subject anti-target CAR-expressing cell of the present invention such that the cancer is treated in the subject. In one aspect, the cancer associated with expression of a target CAR as described herein is a hematological cancer. In one aspect, the hematological cancer is a leukemia or a lymphoma. In one aspect, a cancer associated with expression of target CAR as described herein includes cancers and malignancies including, but not limited to, e.g., one or more acute leukemias including but not limited to, e.g., B-cell acute Lymphoid Leukemia (“BALL”), T-cell acute Lymphoid Leukemia (“TALL”), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), Chronic Lymphoid Leukemia (CLL). Additional cancers or hematologic conditions associated with expression of a target CAR as described herein include, but are not limited to, e.g., B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt&#39;s lymphoma, diffuse large B cell lymphoma, Follicular lymphoma, Hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and “preleukemia” which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further a disease associated with expression of a target CAR as described herein expression include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions, immune-related disorders, e.g., B cell aplasia, or proliferative diseases associated with expression of a target CAR as described herein. 
     In some embodiments, a disease associated with expression of a target CAR, e.g., a cancer, that can be treated with anti-target CAR-expressing cell of the present invention is multiple myeloma. Multiple myeloma is a cancer of the blood, characterized by accumulation of a plasma cell clone in the bone marrow. Current therapies for multiple myeloma include, but are not limited to, treatment with lenalidomide, which is an analog of thalidomide. Lenalidomide has activities which include anti-tumor activity, angiogenesis inhibition, and immunomodulation. Generally, myeloma cells are thought to be negative for a cancer associate antigen as described herein expression by flow cytometry. Thus, in some embodiments, an anti-target CAR that binds to a CD19CAR, e.g., as described herein, may be used to target myeloma cells that do not express CD19. In some embodiments, anti-target CARS of the present invention therapy can be used in combination with one or more additional therapies, e.g., lenalidomide treatment. 
     The invention includes a type of cellular therapy where immune effector cells (e.g., T cells, NK cells) are genetically modified to express an anti-target CAR and the anti-target CAR-expressing T cell or NK cell is infused to a recipient in need thereof. The infused cell is able to kill cells associated with expression of a target CAR, e.g., tumor cells, in the recipient. Unlike antibody therapies, anti-target CAR-modified immune effector cells (e.g., T cells, NK cells) are able to replicate in vivo resulting in long-term persistence that can lead to sustained tumor control. In various aspects, the immune effector cells (e.g., T cells, NK cells) administered to the patient, or their progeny, persist in the patient for at least four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, thirteen months, fourteen month, fifteen months, sixteen months, seventeen months, eighteen months, nineteen months, twenty months, twenty-one months, twenty-two months, twenty-three months, two years, three years, four years, or five years after administration of the T cell or NK cell to the patient. 
     The invention also includes a type of cellular therapy where immune effector cells (e.g., T cells, NK cells) are modified, e.g., by in vitro transcribed RNA, to transiently express an anti-target CAR and the anti-target CAR T cell or NK cell is infused to a recipient in need thereof. The infused cell is able to kill cells associated with expression of a target CAR, e.g., tumor cells in the recipient. Thus, in various aspects, the immune effector cells (e.g., T cells, NK cells) administered to the patient, is present for less than one month, e.g., three weeks, two weeks, one week, after administration of the T cell or NK cell to the patient. 
     Without wishing to be bound by any particular theory, the anti-tumor immunity response elicited by the anti-target CAR-modified immune effector cells (e.g., T cells, NK cells) may be an active or a passive immune response, or alternatively may be due to a direct vs indirect immune response. In one aspect, the anti-target CAR transduced immune effector cells (e.g., T cells, NK cells) exhibit specific proinflammatory cytokine secretion and potent cytolytic activity in response to human cancer cells expressing the target CAR described herein, resist inhibition with a soluble cancer associate antigen as described herein, or mediate bystander killing and mediate regression of an established human tumor. 
     In one aspect, the fully-human anti-target CAR-modified immune effector cells (e.g., T cells, NK cells) of the invention may be a type of vaccine for ex vivo immunization and/or in vivo therapy in a mammal. In one aspect, the mammal is a human. 
     With respect to ex vivo immunization, at least one of the following occurs in vitro prior to administering the cell into a mammal: i) expansion of the cells, ii) introducing a nucleic acid encoding an anti-target CAR to the cells or iii) cryopreservation of the cells. 
     Ex vivo procedures are well known in the art and are discussed more fully below. Briefly, cells are isolated from a mammal (e.g., a human) and genetically modified (i.e., transduced or transfected in vitro) with a vector expressing an anti-target CAR disclosed herein. The anti-target CAR-modified cell can be administered to a mammalian recipient to provide a therapeutic benefit. The mammalian recipient may be a human and the anti-target CAR-modified cell can be autologous with respect to the recipient. Alternatively, the cells can be allogeneic, syngeneic or xenogeneic with respect to the recipient. 
     The procedure for ex vivo expansion of hematopoietic stem and progenitor cells is described in U.S. Pat. No. 5,199,942, incorporated herein by reference, can be applied to the cells of the present invention. Other suitable methods are known in the art, therefore the present invention is not limited to any particular method of ex vivo expansion of the cells. Briefly, ex vivo culture and expansion of immune effector cells (e.g., T cells, NK cells) comprises: (1) collecting CD34+ hematopoietic stem and progenitor cells from a mammal from peripheral blood harvest or bone marrow explants; and (2) expanding such cells ex vivo. In addition to the cellular growth factors described in U.S. Pat. No. 5,199,942, other factors such as flt3-L, IL-1, IL-3 and c-kit ligand, can be used for culturing and expansion of the cells. 
     In addition to using a cell-based vaccine in terms of ex vivo immunization, the present invention also provides compositions and methods for in vivo immunization to elicit an immune response directed against an antigen in a patient. 
     Generally, the cells activated and expanded as described herein may be utilized in the treatment and prevention of diseases that arise in individuals who are immunocompromised. In particular, the anti-target CAR-modified immune effector cells (e.g., T cells, NK cells) of the invention are used in the treatment of diseases, disorders and conditions associated with expression of a target CAR as described herein. In certain aspects, the cells of the invention are used in the treatment of patients at risk for developing diseases, disorders and conditions associated with expression of a target CAR as described herein. Thus, the present invention provides methods for the treatment of diseases, disorders and conditions associated with expression of a target CAR as described herein comprising administering to a subject in need thereof, a therapeutically effective amount of the anti-target CAR-modified immune effector cells (e.g., T cells, NK cells) of the invention. 
     In one aspect the anti-target CAR-expressing cells of the inventions may be used to treat a disease associated with expression of a target CAR, e.g., a proliferative disease such as a cancer or malignancy or is a precancerous condition such as a myelodysplasia, a myelodysplastic syndrome or a preleukemia. Further a disease associated with a target CAR expression as described herein expression include, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions, or proliferative diseases expressing a target CAR as described herein. Non-cancer related indications associated with expression of a target CAR herein include, but are not limited to, e.g., autoimmune disease, (e.g., lupus), inflammatory disorders (allergy and asthma), immune-related disorders, e.g., B cell aplasia, and transplantation. In an embodiment, the disease is B cell aplasia. 
     The anti-target CAR-modified immune effector cells (e.g., T cells, NK cells) of the present invention may be administered either alone, or as a pharmaceutical composition in combination with diluents and/or with other components such as IL-2 or other cytokines or cell populations. 
     Hematologic Cancer 
     Hematological cancer conditions are the types of cancer such as leukemia, lymphoma, and malignant lymphoproliferative conditions that affect blood, bone marrow and the lymphatic system. 
     Leukemia can be classified as acute leukemia and chronic leukemia. Acute leukemia can be further classified as acute myelogenous leukemia (AML) and acute lymphoid leukemia (ALL). Chronic leukemia includes chronic myelogenous leukemia (CML) and chronic lymphoid leukemia (CLL). Other related conditions include myelodysplastic syndromes (MDS, formerly known as “preleukemia”) which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells and risk of transformation to AML. 
     Lymphoma is a group of blood cell tumors that develop from lymphocytes. Exemplary lymphomas include non-Hodgkin lymphoma and Hodgkin lymphoma. 
     The present invention provides for compositions and methods for treating cancer. In one aspect, the cancer is a hematologic cancer including but is not limited to hematological cancer is a leukemia or a lymphoma. In one aspect, the anti-target CAR-expressing cells of the invention may be used to treat cancers and malignancies such as, but not limited to, e.g., acute leukemias including but not limited to, e.g., B-cell acute lymphoid leukemia (“BALL”), T-cell acute lymphoid leukemia (“TALL”), acute lymphoid leukemia (ALL); one or more chronic leukemias including but not limited to, e.g., chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL); additional hematologic cancers or hematologic conditions including, but not limited to, e.g., B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt&#39;s lymphoma, diffuse large B cell lymphoma, Follicular lymphoma, Hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and “preleukemia” which are a diverse collection of hematological conditions united by ineffective production (or dysplasia) of myeloid blood cells, and the like. Further a disease associated with a cancer associate antigen as described herein expression includes, but not limited to, e.g., atypical and/or non-classical cancers, malignancies, precancerous conditions or proliferative diseases expressing a cancer associate antigen as described herein. 
     The present invention also provides methods for inhibiting the proliferation or reducing a cancer associated antigen as described herein-expressing cell population, the methods comprising contacting a population of cells comprising a target CAR as described herein-expressing cell with an anti-target CAR-expressing T cell or NK cell of the invention that binds to the target CAR-expressing cell. In a specific aspect, the present invention provides methods for inhibiting the proliferation or reducing the population of cells expressing a target CAR, e.g., cancer cells, as described herein, the methods comprising contacting a target CAR-expressing cancer cell population with an anti-target CAR-expressing T cell or NK cell of the invention that binds to a target CAR-expressing cell. In one aspect, the present invention provides methods for inhibiting the proliferation or reducing the population of cells expressing a target CAR as described herein, the methods comprising contacting a target CAR-expressing cancer cell population with an anti-target CAR-expressing T cell or NK cell of the invention that binds to a target CAR-expressing cell. In certain aspects, an anti-target CAR-expressing T cell or NK cell of the invention reduces the quantity, number, amount or percentage of target CAR expressing cells, e.g., cancer cells by at least 25%, at least 30%, at least 40%, at least 50%, at least 65%, at least 75%, at least 85%, at least 95%, or at least 99% in a subject with or animal model for myeloid leukemia or another cancer associated with a target CAR described herein-expressing cells relative to a negative control. In one aspect, the subject is a human. 
     The present invention also provides methods for preventing, treating and/or managing a disease associated with expression of a target CAR-expressing cells (e.g., a hematologic cancer or atypical cancer expressing a cancer associated antigen as described herein), the methods comprising administering to a subject in need an anti-target CAR T cell or NK cell of the invention that binds to target CAR-expressing cell. In one aspect, the subject is a human. Non-limiting examples of disorders associated with a target CAR-expressing cells include autoimmune disorders (such as lupus), inflammatory disorders (such as allergies and asthma), immune related disorders such as B cell aplasia, and cancers (such as hematological cancers or atypical cancers expressing a target CAR as described herein). 
     The present invention also provides methods for preventing, treating and/or managing a disease associated with a target CAR as described herein-expressing cells, the methods comprising administering to a subject in need an anti-target CAR T cell or NK cell of the invention that binds to a target CAR-expressing cell. In one aspect, the subject is a human. 
     The present invention provides methods for treating relapse of cancer associated with target CAR-expressing cells, the methods comprising administering to a subject in need thereof an anti-target CAR T cell or NK cell of the invention that binds to a target CAR as described herein-expressing cell. In one aspect, the methods comprise administering to the subject in need thereof an effective amount of an anti-target CAR-expressing T cell or NK cell described herein that binds to a target CAR as described herein-expressing cell in combination with an effective amount of another therapy. 
     Combination Therapies 
     A CAR-expressing cell, e.g., an anti-target CAR expressing cell described herein, may be used in combination with other known agents and therapies. Administered “in combination”, as used herein, means that two (or more) different treatments are delivered to the subject during the course of the subject&#39;s affliction with the disorder, e.g., the two or more treatments are delivered after the subject has been diagnosed with the disorder and before the disorder has been cured or eliminated or treatment has ceased for other reasons. In some embodiments, the delivery of one treatment is still occurring when the delivery of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as “simultaneous” or “concurrent delivery”. In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatment is more effective because of combined administration. For example, the second treatment is more effective, e.g., an equivalent effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, than would be seen if the second treatment were administered in the absence of the first treatment, or the analogous situation is seen with the first treatment. In some embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive. The delivery can be such that an effect of the first treatment delivered is still detectable when the second is delivered. 
     A CAR-expressing cell, e.g., an anti-target CAR expressing cell described herein and the at least one additional therapeutic agent can be administered simultaneously, in the same or in separate compositions, or sequentially. For sequential administration, the CAR-expressing cell described herein can be administered first, and the additional agent can be administered second, or the order of administration can be reversed. 
     The anti-target CAR therapy and/or other therapeutic agents, procedures or modalities can be administered during periods of active disorder, or during a period of remission or less active disease. The anti-target CAR therapy can be administered before the other treatment, concurrently with the treatment, post-treatment, or during remission of the disorder. 
     When administered in combination, the anti-target CAR therapy and the additional agent (e.g., second or third agent), or all, can be administered in an amount or dose that is higher, lower or the same than the amount or dosage of each agent used individually, e.g., as a monotherapy. In certain embodiments, the administered amount or dosage of the anti-target CAR therapy, the additional agent (e.g., second or third agent), or all, is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50%) than the amount or dosage of each agent used individually, e.g., as a monotherapy. In other embodiments, the amount or dosage of the anti-target CAR therapy, the additional agent (e.g., second or third agent), or all, that results in a desired effect (e.g., treatment of cancer) is lower (e.g., at least 20%, at least 30%, at least 40%, or at least 50% lower) than the amount or dosage of each agent used individually, e.g., as a monotherapy, required to achieve the same therapeutic effect. 
     In certain embodiments of the methods or uses described herein, the anti-target CAR molecule is administered in combination with an agent that increases the efficacy of the immune effector cell, e.g., one or more of a protein phosphatase inhibitor, a kinase inhibitor, a cytokine, an inhibitor of an immune inhibitory molecule; or an agent that decreases the level or activity of a T REG  cell. 
     In certain embodiments of the methods or uses described herein, the protein phosphatase inhibitor is a SHP-1 inhibitor and/or an SHP-2 inhibitor. 
     In other embodiments of the methods or uses described herein, kinase inhibitor is chosen from one or more of a CDK4 inhibitor, a CDK4/6 inhibitor (e.g., palbociclib), a BTK inhibitor (e.g., ibrutinib or RN-486), an mTOR inhibitor (e.g., rapamycin or everolimus (RAD001)), an MNK inhibitor, or a dual P13K/mTOR inhibitor. In one embodiment, the BTK inhibitor does not reduce or inhibit the kinase activity of interleukin-2-inducible kinase (ITK). 
     In other embodiments of the methods or uses described herein, the agent that inhibits the immune inhibitory molecule comprises an antibody or antibody fragment, an inhibitory nucleic acid, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN) that inhibits the expression of the inhibitory molecule. 
     In other embodiments of the methods or uses described herein, the agent that decreases the level or activity of the T REG  cells is chosen from cyclophosphamide, anti-GITR antibody, CD25-depletion, or a combination thereof. 
     In certain embodiments of the methods or uses described herein, the immune inhibitory molecule is selected from the group consisting of PD1, PD-L1, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGF beta, CEACAM-1, CEACAM-3, and CEACAM-5. 
     In other embodiments, the agent that inhibits the inhibitory molecule comprises a first polypeptide comprising an inhibitory molecule or a fragment thereof and a second polypeptide that provides a positive signal to the cell, and wherein the first and second polypeptides are expressed on the anti-target CAR-containing immune cells, wherein (i) the first polypeptide comprises PD1, PD-L1, CTLA-4, TIM-3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGF beta, CEACAM-1, CEACAM-3, and CEACAM-5 or a fragment thereof; and/or (ii) the second polypeptide comprises an intracellular signaling domain comprising a primary signaling domain and/or a costimulatory signaling domain. In one embodiment, the primary signaling domain comprises a functional domain of CD3 zeta; and/or the costimulatory signaling domain comprises a functional domain of a protein selected from 41BB, CD27 and CD28. 
     In other embodiments, cytokine is chosen from IL-7, IL-15 or IL-21, or both. 
     In other embodiments, the immune effector cell comprising the anti-target CAR molecule and a second, e.g., any of the combination therapies disclosed herein (e.g., the agent that that increases the efficacy of the immune effector cell) are administered substantially simultaneously or sequentially. 
     In other embodiments, the immune cell comprising the anti-target CAR molecule is administered in combination with a molecule that targets GITR and/or modulates GITR function. In certain embodiments, the molecule targeting GITR and/or modulating GITR function is administered prior to the anti-target CAR-expressing cell or population of cells, or prior to apheresis. 
     In one embodiment, lymphocyte infusion, for example allogeneic lymphocyte infusion, is used in the treatment of the cancer, wherein the lymphocyte infusion comprises at least one anti-target CAR-expressing cell of the present invention. In one embodiment, autologous lymphocyte infusion is used in the treatment of the cancer, wherein the autologous lymphocyte infusion comprises at least one anti-target CAR-expressing cell described herein. 
     In one embodiment, the cell is a T cell and the T cell is diacylglycerol kinase (DGK) deficient. In one embodiment, the cell is a T cell and the T cell is Ikaros deficient. In one embodiment, the cell is a T cell and the T cell is both DGK and Ikaros deficient. 
     In one embodiment, the method includes administering a cell expressing the anti-target CAR moleculein combination with an agent which enhances the activity of a anti-target CAR-expressing cell, wherein the agent is a cytokine, e.g., IL-7, IL-15, IL-21, or a combination thereof. The cytokine can be delivered in combination with, e.g., simultaneously or shortly after, administration of the anti-target CAR-expressing cell. Alternatively, the cytokine can be delivered after a prolonged period of time after administration of the anti-target CAR-expressing cell, e.g., after assessment of the subject&#39;s response to the anti-target CAR-expressing cell. In one embodiment the cytokine is administered to the subject simultaneously (e.g., administered on the same day) with or shortly after administration (e.g., administered 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after administration) of the cell or population of cells of any of claims  61 - 80 . In other embodiments, the cytokine is administered to the subject after a prolonged period of time (e.g., at least 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, or more) after administration of the cell or population of cells of any of claims  61 - 80 , or after assessment of the subject&#39;s response to the cell. 
     In other embodiments, the cells expressing an anti-target CAR molecule are administered in combination with an agent that reduces or ameliorates one or more side effects associated with administration of a cell expressing a anti-target CAR molecule. Side effects associated with the anti-target CAR-expressing cell can be chosen from cytokine release syndrome (CRS) or hemophagocytic lymphohistiocytosis (HLH). 
     In embodiments of any of the aforesaid methods or uses, the cells expressing the anti-target CAR molecule are administered in combination with an agent that treats the disease associated with expression of target CAR, e.g., any of the second or third therapies disclosed herein. Additional exemplary combinations include one or more of the following. 
     In another embodiment, the cell expressing the anti-target CAR molecule, e.g., as described herein, can be administered in combination with another agent, e.g., a kinase inhibitor and/or checkpoint inhibitor described herein. In an embodiment, a cell expressing the anti-target CAR molecule can further express another agent, e.g., an agent which enhances the activity of an anti-target CAR-expressing cell. 
     For example, in one embodiment, the agent that enhances the activity of an anti-target CAR-expressing cell can be an agent which inhibits an inhibitory molecule (e.g., an immune inhibitor molecule). Examples of inhibitory molecules include PD1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta. 
     In one embodiment, the agent that inhibits the inhibitory molecule is an inhibitory nucleic acid is a dsRNA, a siRNA, or a shRNA. In embodiments, the inhibitory nucleic acid is linked to the nucleic acid that encodes a component of the anti-target CAR molecule. For example, the inhibitory molecule can be expressed on the anti-target CAR-expressing cell. 
     In another embodiment, the agent which inhibits an inhibitory molecule, e.g., is a molecule described herein, e.g., an agent that comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGF beta, or a fragment of any of these (e.g., at least a portion of the extracellular domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28, e.g., as described herein) and/or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of the extracellular domain of PD1), and a second polypeptide of an intracellular signaling domain described herein (e.g., a 4-1BB signaling domain described herein and/or a CD3 zeta signaling domain described herein). 
     In one embodiment, the anti-target CAR-expressing immune effector cell of the present invention, e.g., T cell or NK cell, is administered to a subject that has received a previous stem cell transplantation, e.g., autologous stem cell transplantation. 
     In one embodiment, the anti-target CAR-expressing immune effector cell of the present invention, e.g., T cell or NK cells, is administered to a subject that has received a previous dose of melphalan. 
     In one embodiment, the cell expressing an anti-target CAR molecule, e.g., an anti-target CAR molecule described herein, is administered in combination with an agent that increases the efficacy of a cell expressing an anti-target CAR molecule, e.g., an agent described herein. 
     In one embodiment, the cells expressing an anti-target CAR molecule are administered in combination with a low, immune enhancing dose of an mTOR inhibitor. While not wishing to be bound by theory, it is believed that treatment with a low, immune enhancing, dose (e.g., a dose that is insufficient to completely suppress the immune system but sufficient to improve immune function) is accompanied by a decrease in PD-1 positive T cells or an increase in PD-1 negative cells. PD-1 positive T cells, but not PD-1 negative T cells, can be exhausted by engagement with cells which express a PD-1 ligand, e.g., PD-L1 or PD-L2. 
     In an embodiment this approach can be used to optimize the performance of anti-target CAR cells described herein in the subject. While not wishing to be bound by theory, it is believed that, in an embodiment, the performance of endogenous, non-modified immune effector cells, e.g., T cells or NK cells, is improved. While not wishing to be bound by theory, it is believed that, in an embodiment, the performance of a target antigen anti-target CAR-expressing cell is improved. In other embodiments, cells, e.g., T cells or NK cells, which have, or will be engineered to express an anti-target CAR, can be treated ex vivo by contact with an amount of an mTOR inhibitor that increases the number of PD1 negative immune effector cells, e.g., T cells or increases the ratio of PD1 negative immune effector cells, e.g., T cells/PD1 positive immune effector cells, e.g., T cells. 
     In an embodiment, administration of a low, immune enhancing, dose of an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, or a catalytic inhibitor, is initiated prior to administration of an anti-target CAR expressing cell described herein, e.g., T cells or NK cells. In an embodiment, the anti-target CAR cells are administered after a sufficient time, or sufficient dosing, of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells or NK cells, or the ratio of PD1 negative immune effector cells, e.g., T cells/PD1 positive immune effector cells, e.g., T cells, has been, at least transiently, increased. 
     In an embodiment, the cell, e.g., T cell or NK cell, to be engineered to express an anti-target CAR, is harvested after a sufficient time, or after sufficient dosing of the low, immune enhancing, dose of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g., T cells/PD1 positive immune effector cells, e.g., T cells, in the subject or harvested from the subject has been, at least transiently, increased. 
     In one embodiment, the cell expressing an anti-target CAR molecule is administered in combination with an agent that reduces or ameliorates one or more side effect associated with administration of a cell expressing an anti-target CAR molecule, e.g., an agent described herein. 
     In one embodiment, the cell expressing an anti-target CAR molecule is administered in combination with an agent that treats the disease associated with a cancer associated antigen as described herein, e.g., an agent described herein. 
     In one embodiment, a cell expressing two or more anti-target CAR molecules, e.g., as described herein, is administered to a subject in need thereof to treat cancer. In one embodiment, a population of cells including an anti-target CAR expressing cell, e.g., as described herein, is administered to a subject in need thereof to treat cancer. 
     In one embodiment, the cell expressing an anti-target CAR molecule, is administered at a dose and/or dosing schedule described herein. 
     In one embodiment, the anti-target CAR molecule is introduced into immune effector cells (e.g., T cells, NK cells), e.g., using in vitro transcription, and the subject (e.g., human) receives an initial administration of cells comprising an anti-target CAR molecule and one or more subsequent administrations of cells comprising an anti-target CAR molecule wherein the one or more subsequent administrations are administered less than 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days after the previous administration. In one embodiment, more than one administration of cells comprising an anti-target CAR molecule are administered to the subject (e.g., human) per week, e.g., 2, 3, or 4 administrations of cells comprising an anti-target CAR molecule are administered per week. In one embodiment, the subject (e.g., human subject) receives more than one administration of cells comprising an anti-target CAR molecule per week (e.g., 2, 3 or 4 administrations per week) (also referred to herein as a cycle), followed by a week of no administration of cells comprising an anti-target CAR molecule and then one or more additional administration of cells comprising an anti-target CAR molecule (e.g., more than one administration of the cells comprising an anti-target CAR molecule per week) is administered to the subject. In another embodiment, the subject “(e.g., human subject)” receives more than one cycle of cells comprising an anti-target CAR molecule, and the time between each cycle is less than 10, 9, 8, 7, 6, 5, 4, or 3 days. In one embodiment, the cells comprising an anti-target CAR molecule are administered every other day for 3 administrations per week. In one embodiment, the cells comprising an anti-target CAR molecule are administered for at least two, three, four, five, six, seven, eight or more weeks. 
     In one embodiment, a population of cells described herein is administered. 
     In another aspect, the invention pertains to the isolated nucleic acid molecule encoding an anti-target CAR of the invention, the isolated polypeptide molecule of an anti-target CAR of the invention, the vector comprising an anti-target CAR of the invention, and the cell comprising an anti-target CAR of the invention for use as a medicament. 
     In another aspect, the invention pertains to a the isolated nucleic acid molecule encoding an anti-target CAR of the invention, the isolated polypeptide molecule of an anti-target CAR of the invention, the vector comprising an anti-target CAR of the invention, and the cell comprising a CAR of the invention for use in the treatment of a disease expressing a target CAR as described herein. 
     In another aspect, the invention pertains to a cell expressing an anti-target CAR molecule for use as a medicament in combination with a cytokine, e.g., IL-7, IL-15 and/or IL-21 as described herein. In another aspect, the invention pertains to a cytokine described herein for use as a medicament in combination with a cell expressing an anti-target CAR molecule described herein. 
     In another aspect, the invention pertains to a cell expressing an anti-target CAR molecule for use as a medicament in combination with a kinase inhibitor and/or a checkpoint inhibitor as described herein. In another aspect, the invention pertains to a kinase inhibitor and/or a checkpoint inhibitor described herein for use as a medicament in combination with a cell expressing an anti-target CAR molecule described herein. 
     In another aspect, the invention pertains to a cell expressing an anti-target CAR molecule for use in combination with a cytokine, e.g., IL-7, IL-15 and/or IL-21 as described herein, in the treatment of a disease expressing a target CAR targeted by the anti-target CAR. In another aspect, the invention pertains to a cytokine described herein for use in combination with a cell expressing an anti-target CAR molecule described herein, in the treatment of a disease expressing a target CAR targeted by the anti-target CAR. 
     In another aspect, the invention pertains to a cell expressing an anti-target CAR molecule for use in combination with a kinase inhibitor and/or a checkpoint inhibitor as described herein, in the treatment of a disease expressing a target CAR targeted by the anti-target CAR. In another aspect, the invention pertains to a kinase inhibitor and/or a checkpoint inhibitor described herein for use in combination with a cell expressing a anti-target CAR molecule described herein, in the treatment of a disease expressing target CAR targeted by the CAR. 
     In one embodiment of the methods or uses described herein, the anti-target CAR molecule is administered in combination with another agent. In one embodiment, the agent can be a kinase inhibitor, e.g., a CDK4/6 inhibitor, a BTK inhibitor, an mTOR inhibitor, a MNK inhibitor, or a dual PI3K/mTOR inhibitor, and combinations thereof. In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., a CDK4 inhibitor described herein, e.g., a CD4/6 inhibitor, such as, e.g., 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, hydrochloride (also referred to as palbociclib or PD0332991). In one embodiment, the kinase inhibitor is a BTK inhibitor, e.g., a BTK inhibitor described herein, such as, e.g., ibrutinib. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., an mTOR inhibitor described herein, such as, e.g., rapamycin, a rapamycin analog, OSI-027. The mTOR inhibitor can be, e.g., an mTORC1 inhibitor and/or an mTORC2 inhibitor, e.g., an mTORC1 inhibitor and/or mTORC2 inhibitor described herein. In one embodiment, the kinase inhibitor is a MNK inhibitor, e.g., a MNK inhibitor described herein, such as, e.g., 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-d] pyrimidine. The MNK inhibitor can be, e.g., a MNK1a, MNK1b, MNK2a and/or MNK2b inhibitor. The dual PI3K/mTOR inhibitor can be, e.g., PF-04695102. 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is a CDK4 inhibitor selected from aloisine A; flavopiridol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone; crizotinib (PF-02341066; 2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4-one, hydrochloride (P276-00); 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (RAF265); indisulam (E7070); roscovitine (CYC202); palbociclib (PD0332991); dinaciclib (SCH727965); N-[5-[[(5-tert-butyloxazol-2-yl)methyl]thin]thiazol-2-yl]piperidine-4-carboxamide (BMS 387032); 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d] [2]benzazepin-2-yl]amino]-benzoic acid (MLN8054); 5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-3-pyridinemethanamine (AG-024322); 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-(piperidin-4-yl)amide (AT7519); 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine (AZD5438); and XL281 (BMS908662). 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is a CDK4 inhibitor, e.g., palbociclib (PD0332991), and the palbociclib is administered at a dose of about 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg (e.g., 75 mg, 100 mg or 125 mg) daily for a period of time, e.g., daily for 14-21 days of a 28 day cycle, or daily for 7-12 days of a 21 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of palbociclib are administered. 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor selected from ibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. In one embodiment, the BTK inhibitor does not reduce or inhibit the kinase activity of interleukin-2-inducible kinase (ITK), and is selected from GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor, e.g., ibrutinib (PCI-32765), and the ibrutinib is administered at a dose of about 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg (e.g., 250 mg, 420 mg or 560 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of ibrutinib are administered. 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor that does not inhibit the kinase activity of ITK, e.g., RN-486, and RN-486 is administered at a dose of about 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg (e.g., 150 mg, 200 mg or 250 mg) daily for a period of time, e.g., daily a 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, or more cycles of RN-486 are administered. 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is an mTOR inhibitor selected from temsirolimus; ridaforolimus (1R,2R,4S)-4-[(2R)-2 [(1R,9S,12S,15R,16E,18R,19R,21R, 23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23, 29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0 4.9 ] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669; everolimus (RAD001); rapamycin (AY22989); simapimod; (5-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one (PF04691502); and N 2 -[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-aspartylL-serine- (SEQ ID NO: 112), inner salt (SF1126); and XL765. 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is an mTOR inhibitor, e.g., rapamycin, and the rapamycin is administered at a dose of about 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (e.g., 6 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of rapamycin are administered. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., everolimus and the everolimus is administered at a dose of about 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg (e.g., 10 mg) daily for a period of time, e.g., daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of everolimus are administered. 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is an MNK inhibitor selected from CGP052088; 4-amino-3-(p-fluorophenylamino)-pyrazolo [3,4-d] pyrimidine (CGP57380); cercosporamide; ETC-1780445-2; and 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-d] pyrimidine. 
     In one embodiment of the methods or uses described herein, the kinase inhibitor is a dual phosphatidylinositol 3-kinase (PI3K) and mTOR inhibitor selected from 2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido [2, 3-d]pyrimidin-7(8H)-one (PF-04691502); N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N′-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]urea (PF-05212384, PKI-587); 2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile (BEZ-235); apitolisib (GDC-0980, RG7422); 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GS K2126458); 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one Maleic acid (NVP-BGT226); 3-[4-(4-Morpholinylpyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl]phenol (PI-103); 5-(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine (VS-5584, SB2343); and N-[2-[(3,5-Dimethoxyphenyl)amino]quinoxalin-3-yl]-4-[(4-methyl-3-methoxyphenyl)carbonyl]aminophenylsulfonamide (XL765). 
     In one embodiment of the methods or uses described herein, an anti-target CAR expressing immune effector cell described herein is administered to a subject in combination with a protein tyrosine phosphatase inhibitor, e.g., a protein tyrosine phosphatase inhibitor described herein. In one embodiment, the protein tyrosine phosphatase inhibitor is an SHP-1 inhibitor, e.g., an SHP-1 inhibitor described herein, such as, e.g., sodium stibogluconate. In one embodiment, the protein tyrosine phosphatase inhibitor is an SHP-2 inhibitor. 
     In one embodiment of the methods or uses described herein, the anti-target CAR molecule is administered in combination with another agent, and the agent is a cytokine. The cytokine can be, e.g., IL-7, IL-15, IL-21, or a combination thereof. In another embodiment, the CAR molecule is administered in combination with a checkpoint inhibitor, e.g., a checkpoint inhibitor described herein. For example, in one embodiment, the check point inhibitor inhibits an inhibitory molecule selected from PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta. 
     In further aspects, an anti-target CAR-expressing cell described herein may be used in a treatment regimen in combination with surgery, chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludarabine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation. peptide vaccine, such as that described in Izumoto et al. 2008 J Neurosurg 108:963-971. 
     In one embodiment, am anti-target CAR-expressing cell described herein can be used in combination with a chemotherapeutic agent. Exemplary chemotherapeutic agents include an anthracycline (e.g., doxorubicin (e.g., liposomal doxorubicin)). a vinca alkaloid (e.g., vinblastine, vincristine, vindesine, vinorelbine), an alkylating agent (e.g., cyclophosphamide, decarbazine, melphalan, ifosfamide, temozolomide), an immune cell antibody (e.g., alemtuzamab, gemtuzumab, rituximab, ofatumumab, tositumomab, brentuximab), an antimetabolite (including, e.g., folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors (e.g., fludarabine)), an mTOR inhibitor, a TNFR glucocorticoid induced TNFR related protein (GITR) agonist, a proteasome inhibitor (e.g., aclacinomycin A, gliotoxin or bortezomib), an immunomodulator such as thalidomide or a thalidomide derivative (e.g., lenalidomide). 
     General Chemotherapeutic agents considered for use in combination therapies include anastrozole (Arimidex®), bicalutamide (Casodex®), bleomycin sulfate (Blenoxane®), busulfan (Myleran®), busulfan injection (Busulfex®), capecitabine (Xeloda®), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Paraplatin®), carmustine (BiCNU®), chlorambucil (Leukeran®), cisplatin (Platinol®), cladribine (Leustatin®), cyclophosphamide (Cytoxan® or Neosar®), cytarabine, cytosine arabinoside (Cytosar-U®), cytarabine liposome injection (DepoCyt®), dacarbazine (DTIC-Dome®), dactinomycin (Actinomycin D, Cosmegan), daunorubicin hydrochloride (Cerubidine®), daunorubicin citrate liposome injection (DaunoXome®), dexamethasone, docetaxel (Taxotere®), doxorubicin hydrochloride (Adriamycin®, Rubex®), etoposide (Vepesid®), fludarabine phosphate (Fludara®), 5-fluorouracil (Adrucil®, Efudex®), flutamide (Eulexin®), tezacitibine, Gemcitabine (difluorodeoxycitidine), hydroxyurea (Hydrea®), Idarubicin (Idamycin®), ifosfamide (IFEX®), irinotecan (Camptosar®), L-asparaginase (ELSPAR®), leucovorin calcium, melphalan (Alkeran®), 6-mercaptopurine (Purinethol®), methotrexate (Folex®), mitoxantrone (Novantrone®), mylotarg, paclitaxel (Taxol®), phoenix (Yttrium90/MX-DTPA), pentostatin, polifeprosan 20 with carmustine implant (Gliadel®), tamoxifen citrate (Nolvadex®), teniposide (Vumon®), 6-thioguanine, thiotepa, tirapazamine (Tirazone®), topotecan hydrochloride for injection (Hycamptin®), vinblastine (Velban®), vincristine (Oncovin®), and vinorelbine (Navelbine®). 
     Exemplary alkylating agents include, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes): uracil mustard (Aminouracil Mustard®, Chlorethaminacil®, Demethyldopan®, Desmethyldopan®, Haemanthamine®, Nordopan®, Uracil Nitrogen Mustard®, Uracillost®, Uracilmostaza®, Uramustin®, Uramustine®), chlormethine (Mustargen®), cyclophosphamide (Cytoxan®, Neosar®, Clafen®, Endoxan®, Procytox®, Revimmune™), ifosfamide (Mitoxana®), melphalan (Alkeran®), Chlorambucil (Leukeran®), pipobroman (Amedel®, Vercyte®), triethylenemelamine (Hemel®, Hexalen®, Hexastat®), triethylenethiophosphoramine, Temozolomide (Temodar®), thiotepa (Thioplex®), busulfan (Busilvex®, Myleran®), carmustine (BiCNU®), lomustine (CeeNU®), streptozocin (Zanosar®), and Dacarbazine (DTIC-Dome®). Additional exemplary alkylating agents include, without limitation, Oxaliplatin (Eloxatin®); Temozolomide (Temodar® and Temodal®); Dactinomycin (also known as actinomycin-D, Cosmegen®); Melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, Alkeran®); Altretamine (also known as hexamethylmelamine (HMM), Hexalen®); Carmustine (BiCNU®); Bendamustine (Treanda®); Busulfan (Busulfex® and Myleran®); Carboplatin (Paraplatin®); Lomustine (also known as CCNU, CeeNU®); Cisplatin (also known as CDDP, Platinol® and Platinol®-AQ); Chlorambucil (Leukeran®); Cyclophosphamide (Cytoxan® and Neosar®); Dacarbazine (also known as DTIC, DIC and imidazole carboxamide, DTIC-Dome®); Altretamine (also known as hexamethylmelamine (HMM), Hexalen®); Ifosfamide (Ifex®); Prednumustine; Procarbazine (Matulane®); Mechlorethamine (also known as nitrogen mustard, mustine and mechloroethamine hydrochloride, Mustargen®); Streptozocin (Zanosar®); Thiotepa (also known as thiophosphoamide, TESPA and TSPA, Thioplex®); Cyclophosphamide (Endoxan®, Cytoxan®, Neosar®, Procytox®, Revimmune®); and Bendamustine HCl (Treanda®). 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with fludarabine, cyclophosphamide, and/or rituximab. In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with fludarabine, cyclophosphamide, and rituximab (FCR). In embodiments, the subject has CLL. For example, the subject has a deletion in the short arm of chromosome 17 (del(17p), e.g., in a leukemic cell). In other examples, the subject does not have a del(17p). In embodiments, the subject comprises a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV H ) gene. In other embodiments, the subject does not comprise a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV H ) gene. In embodiments, the fludarabine is administered at a dosage of about 10-50 mg/m 2  (e.g., about 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, or 45-50 mg/m 2 ), e.g., intravenously. In embodiments, the cyclophosphamide is administered at a dosage of about 200-300 mg/m 2  (e.g., about 200-225, 225-250, 250-275, or 275-300 mg/m 2 ), e.g., intravenously. In embodiments, the rituximab is administered at a dosage of about 400-600 mg/m2 (e.g., 400-450, 450-500, 500-550, or 550-600 mg/m 2 ), e.g., intravenously. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with bendamustine and rituximab. In embodiments, the subject has CLL. For example, the subject has a deletion in the short arm of chromosome 17 (del(17p), e.g., in a leukemic cell). In other examples, the subject does not have a del(17p). In embodiments, the subject comprises a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV H ) gene. In other embodiments, the subject does not comprise a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV H ) gene. In embodiments, the bendamustine is administered at a dosage of about 70-110 mg/m2 (e.g., 70-80, 80-90, 90-100, or 100-110 mg/m2), e.g., intravenously. In embodiments, the rituximab is administered at a dosage of about 400-600 mg/m2 (e.g., 400-450, 450-500, 500-550, or 550-600 mg/m 2 ), e.g., intravenously. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with rituximab, cyclophosphamide, doxorubicine, vincristine, and/or a corticosteroid (e.g., prednisone). In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab, cyclophosphamide, doxorubicine, vincristine, and prednisone (R-CHOP). In embodiments, the subject has diffuse large B-cell lymphoma (DLBCL). In embodiments, the subject has nonbulky limited-stage DLBCL (e.g., comprises a tumor having a size/diameter of less than 7 cm). In embodiments, the subject is treated with radiation in combination with the R-CHOP. For example, the subject is administered R-CHOP (e.g., 1-6 cycles, e.g., 1, 2, 3, 4, 5, or 6 cycles of R-CHOP), followed by radiation. In some cases, the subject is administered R-CHOP (e.g., 1-6 cycles, e.g., 1, 2, 3, 4, 5, or 6 cycles of R-CHOP) following radiation. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and/or rituximab. In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R). In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with dose-adjusted EPOCH-R (DA-EPOCH-R). In embodiments, the subject has a B cell lymphoma, e.g., a Myc-rearranged aggressive B cell lymphoma. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with rituximab and/or lenalidomide. Lenalidomide ((RS)-3-(4-Amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione) is an immunomodulator. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab and lenalidomide. In embodiments, the subject has follicular lymphoma (FL) or mantle cell lymphoma (MCL). In embodiments, the subject has FL and has not previously been treated with a cancer therapy. In embodiments, lenalidomide is administered at a dosage of about 10-20 mg (e.g., 10-15 or 15-20 mg), e.g., daily. In embodiments, rituximab is administered at a dosage of about 350-550 mg/m 2  (e.g., 350-375, 375-400, 400-425, 425-450, 450-475, or 475-500 mg/m 2 ), e.g., intravenously. 
     Exemplary mTOR inhibitors include, e.g., temsirolimus; ridaforolimus (formally known as deferolimus, (1R,2R,4S)-4-[(2R)-2 [(1R,9S,12S,15R,16E,18R,19R,21R, 23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23, 29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0 4.9 ] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03/064383); everolimus (Afinitor® or RAD001); rapamycin (AY22989, Sirolimus®); simapimod (CAS 164301-51-3); emsirolimus, (5-{2,4-Bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido [2, 3-d]pyrimidin-7(8H)-one (PF04691502, CAS 1013101-36-4); and N 2 -[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-aspartylL-serine-(SEQ ID NO: 112), inner salt (SF1126, CAS 936487-67-1), and XL765. 
     Exemplary immunomodulators include, e.g., afutuzumab (available from Roche®); pegfilgrastim (Neulasta®); lenalidomide (CC-5013, Revlimid®); thalidomide (Thalomid®), actimid (CC4047); and IRX-2 (mixture of human cytokines including interleukin 1, interleukin 2, and interferon γ, CAS 951209-71-5, available from IRX Therapeutics). 
     Exemplary anthracyclines include, e.g., doxorubicin (Adriamycin® and Rubex®); bleomycin (Lenoxane®); daunorubicin (dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, Cerubidine®); daunorubicin liposomal (daunorubicin citrate liposome, DaunoXome®); mitoxantrone (DHAD, Novantrone®); epirubicin (Ellence™); idarubicin (Idamycin®, Idamycin PFS®); mitomycin C (Mutamycin®); geldanamycin; herbimycin; ravidomycin; and desacetylravidomycin. 
     Exemplary vinca alkaloids include, e.g., vinorelbine tartrate (Navelbine®), Vincristine (Oncovin®), and Vindesine (Eldisine®)); vinblastine (also known as vinblastine sulfate, vincaleukoblastine and VLB, Alkaban-AQ® and Velban®); and vinorelbine (Navelbine®). 
     Exemplary proteosome inhibitors include bortezomib (Velcade®); carfilzomib (PX-171-007, (S)-4-Methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-pentanamide); marizomib (NPI-0052); ixazomib citrate (MLN-9708); delanzomib (CEP-18770); and O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide (ONX-0912). 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with brentuximab. Brentuximab is an antibody-drug conjugate of anti-CD30 antibody and monomethyl auristatin E. In embodiments, the subject has Hodgkin&#39;s lymphoma (HL), e.g., relapsed or refractory HL. In embodiments, the subject comprises CD30+HL. In embodiments, the subject has undergone an autologous stem cell transplant (ASCT). In embodiments, the subject has not undergone an ASCT. In embodiments, brentuximab is administered at a dosage of about 1-3 mg/kg (e.g., about 1-1.5, 1.5-2, 2-2.5, or 2.5-3 mg/kg), e.g., intravenously, e.g., every 3 weeks. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with brentuximab and dacarbazine or in combination with brentuximab and bendamustine. Dacarbazine is an alkylating agent with a chemical name of 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide. Bendamustine is an alkylating agent with a chemical name of 445-[Bis(2-chloroethyl)aminol-1-methylbenzimidazol-2-yl]butanoic acid. In embodiments, the subject has Hodgkin&#39;s lymphoma (HL). In embodiments, the subject has not previously been treated with a cancer therapy. In embodiments, the subject is at least 60 years of age, e.g., 60, 65, 70, 75, 80, 85, or older. In embodiments, dacarbazine is administered at a dosage of about 300-450 mg/m 2  (e.g., about 300-325, 325-350, 350-375, 375-400, 400-425, or 425-450 mg/m 2 ), e.g., intravenously. In embodiments, bendamustine is administered at a dosage of about 75-125 mg/m2 (e.g., 75-100 or 100-125 mg/m 2 , e.g., about 90 mg/m 2 ), e.g., intravenously. In embodiments, brentuximab is administered at a dosage of about 1-3 mg/kg (e.g., about 1-1.5, 1.5-2, 2-2.5, or 2.5-3 mg/kg), e.g., intravenously, e.g., every 3 weeks. 
     In some embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with a CD20 inhibitor, e.g., an anti-CD20 antibody (e.g., an anti-CD20 mono- or bispecific antibody) or a fragment thereof. Exemplary anti-CD20 antibodies include but are not limited to rituximab, ofatumumab, ocrelizumab, veltuzumab, obinutuzumab, TRU-015 (Trubion Pharmaceuticals), ocaratuzumab, and Pro131921 (Genentech). See, e.g., Lim et al. Haematologica. 95.1(2010):135-43. 
     In some embodiments, the anti-CD20 antibody comprises rituximab. Rituximab is a chimeric mouse/human monoclonal antibody IgG1 kappa that binds to CD20 and causes cytolysis of a CD20 expressing cell, e.g., as described in www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s53111b1.pdf. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with rituximab. In embodiments, the subject has CLL or SLL. 
     In some embodiments, rituximab is administered intravenously, e.g., as an intravenous infusion. For example, each infusion provides about 500-2000 mg (e.g., about 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000, 1000-1100, 1100-1200, 1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800, 1800-1900, or 1900-2000 mg) of rituximab. In some embodiments, rituximab is administered at a dose of 150 mg/m 2  to 750 mg/m 2 , e.g., about 150-175 mg/m 2 , 175-200 mg/m 2 , 200-225 mg/m 2 , 225-250 mg/m 2 , 250-300 mg/m 2 , 300-325 mg/m 2 , 325-350 mg/m 2 , 350-375 mg/m 2 , 375-400 mg/m 2 , 400-425 mg/m 2 , 425-450 mg/m 2 , 450-475 mg/m 2 , 475-500 mg/m 2 , 500-525 mg/m 2 , 525-550 mg/m 2 , 550-575 mg/m 2 , 575-600 mg/m 2 , 600-625 mg/m 2 , 625-650 mg/m 2 , 650-675 mg/m 2 , or 675-700 mg/m 2 , where m 2  indicates the body surface area of the subject. In some embodiments, rituximab is administered at a dosing interval of at least 4 days, e.g., 4, 7, 14, 21, 28, 35 days, or more. For example, rituximab is administered at a dosing interval of at least 0.5 weeks, e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8 weeks, or more. In some embodiments, rituximab is administered at a dose and dosing interval described herein for a period of time, e.g., at least 2 weeks, e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 weeks, or greater. For example, rituximab is administered at a dose and dosing interval described herein for a total of at least 4 doses per treatment cycle (e.g., at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or more doses per treatment cycle). 
     In some embodiments, the anti-CD20 antibody comprises ofatumumab. Ofatumumab is an anti-CD20 IgG1κ human monoclonal antibody with a molecular weight of approximately 149 kDa. For example, ofatumumab is generated using transgenic mouse and hybridoma technology and is expressed and purified from a recombinant murine cell line (NSO). See, e.g., www.accessdata.fda.gov/drugsatfda_docs/label/2009/1253261b1.pdf; and Clinical Trial Identifier number NCT01363128, NCT01515176, NCT01626352, and NCT01397591. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with ofatumumab. In embodiments, the subject has CLL or SLL. 
     In some embodiments, ofatumumab is administered as an intravenous infusion. For example, each infusion provides about 150-3000 mg (e.g., about 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 500-550, 550-600, 600-650, 650-700, 700-750, 750-800, 800-850, 850-900, 900-950, 950-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800, 1800-2000, 2000-2200, 2200-2400, 2400-2600, 2600-2800, or 2800-3000 mg) of ofatumumab. In embodiments, ofatumumab is administered at a starting dosage of about 300 mg, followed by 2000 mg, e.g., for about 11 doses, e.g., for 24 weeks. In some embodiments, ofatumumab is administered at a dosing interval of at least 4 days, e.g., 4, 7, 14, 21, 28, 35 days, or more. For example, ofatumumab is administered at a dosing interval of at least 1 week, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 26, 28, 20, 22, 24, 26, 28, 30 weeks, or more. In some embodiments, ofatumumab is administered at a dose and dosing interval described herein for a period of time, e.g., at least 1 week, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 40, 50, 60 weeks or greater, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or greater, or 1, 2, 3, 4, 5 years or greater. For example, ofatumumab is administered at a dose and dosing interval described herein for a total of at least 2 doses per treatment cycle (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, or more doses per treatment cycle). 
     In some cases, the anti-CD20 antibody comprises ocrelizumab. Ocrelizumab is a humanized anti-CD20 monoclonal antibody, e.g., as described in Clinical Trials Identifier Nos. NCT00077870, NCT01412333, NCT00779220, NCT00673920, NCT01194570, and Kappos et al. Lancet. 19.378(2011):1779-87. 
     In some cases, the anti-CD20 antibody comprises veltuzumab. Veltuzumab is a humanized monoclonal antibody against CD20. See, e.g., Clinical Trial Identifier No. NCT00547066, NCT00546793, NCT01101581, and Goldenberg et al. Leuk Lymphoma. 51(5)(2010):747-55. 
     In some cases, the anti-CD20 antibody comprises GA101. GA101 (also called obinutuzumab or RO5072759) is a humanized and glyco-engineered anti-CD20 monoclonal antibody. See, e.g., Robak. Curr. Opin. Investig. Drugs. 10.6(2009):588-96; Clinical Trial Identifier Numbers: NCT01995669, NCT01889797, NCT02229422, and NCT01414205; and www.accessdata.fda.gov/drugsatfda_docs/label/2013/125486s0001b1.pdf. 
     In some cases, the anti-CD20 antibody comprises AME-133v. AME-133v (also called LY2469298 or ocaratuzumab) is a humanized IgG1 monoclonal antibody against CD20 with increased affinity for the FcγRIIIa receptor and an enhanced antibody dependent cellular cytotoxicity (ADCC) activity compared with rituximab. See, e.g., Robak et al. BioDrugs 25.1(2011):13-25; and Forero-Torres et al. Clin Cancer Res. 18.5(2012):1395-403. 
     In some cases, the anti-CD20 antibody comprises PRO131921. PRO131921 is a humanized anti-CD20 monoclonal antibody engineered to have better binding to FcγRIIIa and enhanced ADCC compared with rituximab. See, e.g., Robak et al. BioDrugs 25.1(2011):13-25; and Casulo et al. Clin Immunol. 154.1(2014):37-46; and Clinical Trial Identifier No. NCT00452127. 
     In some cases, the anti-CD20 antibody comprises TRU-015. TRU-015 is an anti-CD20 fusion protein derived from domains of an antibody against CD20. TRU-015 is smaller than monoclonal antibodies, but retains Fc-mediated effector functions. See, e.g., Robak et al. BioDrugs 25.1(2011):13-25. TRU-015 contains an anti-CD20 single-chain variable fragment (scFv) linked to human IgG1 hinge, CH2, and CH3 domains but lacks CH1 and CL domains. 
     In some embodiments, an anti-CD20 antibody described herein is conjugated or otherwise bound to a therapeutic agent, e.g., a chemotherapeutic agent (e.g., cytoxan, fludarabine, histone deacetylase inhibitor, demethylating agent, peptide vaccine, anti-tumor antibiotic, tyrosine kinase inhibitor, alkylating agent, anti-microtubule or anti-mitotic agent), anti-allergic agent, anti-nausea agent (or anti-emetic), pain reliever, or cytoprotective agent described herein. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with a B-cell lymphoma 2 (BCL-2) inhibitor (e.g., venetoclax, also called ABT-199 or GDC-0199) and/or rituximab. In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with venetoclax and rituximab. Venetoclax is a small molecule that inhibits the anti-apoptotic protein, BCL-2. The structure of venetoclax (4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide) is shown below. 
     
       
         
         
             
             
         
       
     
     In embodiments, the subject has CLL. In embodiments, the subject has relapsed CLL, e.g., the subject has previously been administered a cancer therapy. In embodiments, venetoclax is administered at a dosage of about 15-600 mg (e.g., 15-20, 20-50, 50-75, 75-100, 100-200, 200-300, 300-400, 400-500, or 500-600 mg), e.g., daily. In embodiments, rituximab is administered at a dosage of about 350-550 mg/m2 (e.g., 350-375, 375-400, 400-425, 425-450, 450-475, or 475-500 mg/m2), e.g., intravenously, e.g., monthly 
     In an embodiment, cells expressing an anti-target CAR described herein are administered to a subject in combination with a molecule that decreases the Treg cell population. Methods that decrease the number of (e.g., deplete) Treg cells are known in the art and include, e.g., CD25 depletion, cyclophosphamide administration, modulating GITR function. Without wishing to be bound by theory, it is believed that reducing the number of Treg cells in a subject prior to apheresis or prior to administration of an anti-target CAR-expressing cell described herein reduces the number of unwanted immune cells (e.g., Tregs) in the tumor microenvironment and reduces the subject&#39;s risk of relapse. In one embodiment, cells expressing an anti-target CAR described herein are administered to a subject in combination with a molecule targeting GITR and/or modulating GITR functions, such as a GITR agonist and/or a GITR antibody that depletes regulatory T cells (Tregs). In embodiments, cells expressing an anti-target CAR described herein are administered to a subject in combination with cyclophosphamide. In one embodiment, the GITR binding molecules and/or molecules modulating GITR functions (e.g., GITR agonist and/or Treg depleting GITR antibodies) are administered prior to administration of the CAR-expressing cell. For example, in one embodiment, the GITR agonist can be administered prior to apheresis of the cells. In embodiments, cyclophosphamide is administered to the subject prior to administration (e.g., infusion or re-infusion) of the anti-target CAR-expressing cell or prior to apheresis of the cells. In embodiments, cyclophosphamide and an anti-GITR antibody are administered to the subject prior to administration (e.g., infusion or re-infusion) of the anti-target CAR-expressing cell or prior to apheresis of the cells. In one embodiment, the subject has cancer (e.g., a solid cancer or a hematological cancer such as ALL or CLL). In an embodiment, the subject has CLL. In embodiments, the subject has ALL. In embodiments, the subject has a solid cancer, e.g., a solid cancer described herein. Exemplary GITR agonists include, e.g., GITR fusion proteins and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies) such as, e.g., a GITR fusion protein described in U.S. Pat. No. 6,111,090, European Patent No.: 090505B1, U.S. Pat. No. 8,586,023, PCT Publication Nos.: WO 2010/003118 and 2011/090754, or an anti-GITR antibody described, e.g., in U.S. Pat. No. 7,025,962, European Patent No.: 1947183B1, U.S. Pat. Nos. 7,812,135, 8,388,967, 8,591,886, European Patent No.: EP 1866339, PCT Publication No.: WO 2011/028683, PCT Publication No.: WO 2013/039954, PCT Publication No.: WO2005/007190, PCT Publication No.: WO 2007/133822, PCT Publication No.: WO2005/055808, PCT Publication No.: WO 99/40196, PCT Publication No.: WO 2001/03720, PCT Publication No.: WO99/20758, PCT Publication No.: WO2006/083289, PCT Publication No.: WO 2005/115451, U.S. Pat. No. 7,618,632, and PCT Publication No.: WO 2011/051726. 
     In one embodiment, an anti-target CAR expressing cell described herein is administered to a subject in combination with an mTOR inhibitor, e.g., an mTOR inhibitor described herein, e.g., a rapalog such as everolimus. In one embodiment, the mTOR inhibitor is administered prior to the anti-target CAR-expressing cell. For example, in one embodiment, the mTOR inhibitor can be administered prior to apheresis of the cells. In one embodiment, the subject has CLL. 
     In one embodiment, an anti-target CAR expressing cell described herein is administered to a subject in combination with a GITR agonist, e.g., a GITR agonist described herein. In one embodiment, the GITR agonist is administered prior to the anti-target CAR-expressing cell. For example, in one embodiment, the GITR agonist can be administered prior to apheresis of the cells. In one embodiment, the subject has CLL. 
     In one embodiment, an anti-target CAR-expressing cell described herein can be used in combination with a kinase inhibitor. In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., a CDK4 inhibitor described herein, e.g., a CD4/6 inhibitor, such as, e.g., 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, hydrochloride (also referred to as palbociclib or PD0332991). In one embodiment, the kinase inhibitor is a BTK inhibitor, e.g., a BTK inhibitor described herein, such as, e.g., ibrutinib. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., an mTOR inhibitor described herein, such as, e.g., rapamycin, a rapamycin analog, OSI-027. The mTOR inhibitor can be, e.g., an mTORC1 inhibitor and/or an mTORC2 inhibitor, e.g., an mTORC1 inhibitor and/or mTORC2 inhibitor described herein. In one embodiment, the kinase inhibitor is a MNK inhibitor, e.g., a MNK inhibitor described herein, such as, e.g., 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-d] pyrimidine. The MNK inhibitor can be, e.g., a MNK1a, MNK1b, MNK2a and/or MNK2b inhibitor. In one embodiment, the kinase inhibitor is a dual PI3K/mTOR inhibitor described herein, such as, e.g., PF-04695102. 
     In one embodiment, the kinase inhibitor is a CDK4 inhibitor selected from aloisine A; flavopiridol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone; crizotinib (PF-02341066; 2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4-one, hydrochloride (P276-00); 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (RAF265); indisulam (E7070); roscovitine (CYC202); palbociclib (PD0332991); dinaciclib (SCH727965); N-[5-[[(5-tert-butyloxazol-2-yl)methyl]thio]thiazol-2-yl]piperidine-4-carboxamide (BMS 387032); 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-benzoic acid (MLN8054); 5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-3-pyridinemethanamine (AG-024322); 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-(piperidin-4-yl)amide (AT7519); 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine (AZD5438); and XL281 (BMS908662). 
     In one embodiment, the kinase inhibitor is a CDK4 inhibitor, e.g., palbociclib (PD0332991), and the palbociclib is administered at a dose of about 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg (e.g., 75 mg, 100 mg or 125 mg) daily for a period of time, e.g., daily for 14-21 days of a 28 day cycle, or daily for 7-12 days of a 21 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of palbociclib are administered. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with a cyclin-dependent kinase (CDK) 4 or 6 inhibitor, e.g., a CDK4 inhibitor or a CDK6 inhibitor described herein. In embodiments, a CAR-expressing cell described herein is administered to a subject in combination with a CDK4/6 inhibitor (e.g., an inhibitor that targets both CDK4 and CDK6), e.g., a CDK4/6 inhibitor described herein. In an embodiment, the subject has MCL. MCL is an aggressive cancer that is poorly responsive to currently available therapies, i.e., essentially incurable. In many cases of MCL, cyclin D1 (a regulator of CDK4/6) is expressed (e.g., due to chromosomal translocation involving immunoglobulin and Cyclin D1 genes) in MCL cells. Thus, without being bound by theory, it is thought that MCL cells are highly sensitive to CDK4/6 inhibition with high specificity (i.e., minimal effect on normal immune cells). CDK4/6 inhibitors alone have had some efficacy in treating MCL, but have only achieved partial remission with a high relapse rate. An exemplary CDK4/6 inhibitor is LEE011 (also called ribociclib), the structure of which is shown below. 
     
       
         
         
             
             
         
       
     
     Without being bound by theory, it is believed that administration of an anti-target CAR-expressing cell described herein with a CDK4/6 inhibitor (e.g., LEE011 or other CDK4/6 inhibitor described herein) can achieve higher responsiveness, e.g., with higher remission rates and/or lower relapse rates, e.g., compared to a CDK4/6 inhibitor alone. 
     In one embodiment, the kinase inhibitor is a BTK inhibitor selected from ibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. In a preferred embodiment, the BTK inhibitor does not reduce or inhibit the kinase activity of interleukin-2-inducible kinase (ITK), and is selected from GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. 
     In one embodiment, the kinase inhibitor is a BTK inhibitor, e.g., ibrutinib (PCI-32765). In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with a BTK inhibitor (e.g., ibrutinib). In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with ibrutinib (also called PCI-32765). The structure of ibrutinib (1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one) is shown below. 
     
       
         
         
             
             
         
       
     
     In embodiments, the subject has CLL, mantle cell lymphoma (MCL), or small lymphocytic lymphoma (SLL). For example, the subject has a deletion in the short arm of chromosome 17 (del(17p), e.g., in a leukemic cell). In other examples, the subject does not have a del(17p). In embodiments, the subject has relapsed CLL or SLL, e.g., the subject has previously been administered a cancer therapy (e.g., previously been administered one, two, three, or four prior cancer therapies). In embodiments, the subject has refractory CLL or SLL. In other embodiments, the subject has follicular lymphoma, e.g., relapse or refractory follicular lymphoma. In some embodiments, ibrutinib is administered at a dosage of about 300-600 mg/day (e.g., about 300-350, 350-400, 400-450, 450-500, 500-550, or 550-600 mg/day, e.g., about 420 mg/day or about 560 mg/day), e.g., orally. In embodiments, the ibrutinib is administered at a dose of about 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg (e.g., 250 mg, 420 mg or 560 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of ibrutinib are administered. Without being bound by theory, it is thought that the addition of ibrutinib enhances the T cell proliferative response and may shift T cells from a T-helper-2 (Th2) to T-helper-1 (Th1) phenotype. Th1 and Th2 are phenotypes of helper T cells, with Th1 versus Th2 directing different immune response pathways. A Th1 phenotype is associated with proinflammatory responses, e.g., for killing cells, such as intracellular pathogens/viruses or cancerous cells, or perpetuating autoimmune responses. A Th2 phenotype is associated with eosinophil accumulation and anti-inflammatory responses. 
     In one embodiment, the kinase inhibitor is an mTOR inhibitor selected from temsirolimus; ridaforolimus (1R,2R,4S)-4-[(2R)-2 [(1R,9S,12S,15R,16E,18R,19R,21R, 23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23, 29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0 4.9 ] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669; everolimus (RAD001); rapamycin (AY22989); simapimod; (5-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one (PF04691502); and N 2 -[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-aspartylL-serine- (SEQ ID NO: 112), inner salt (SF1126); and XL765. 
     In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., rapamycin, and the rapamycin is administered at a dose of about 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (e.g., 6 mg) daily for a period of time, e.g., daily for 21 day cycle, or daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of rapamycin are administered. In one embodiment, the kinase inhibitor is an mTOR inhibitor, e.g., everolimus and the everolimus is administered at a dose of about 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg (e.g., 10 mg) daily for a period of time, e.g., daily for 28 day cycle. In one embodiment, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of everolimus are administered. 
     In one embodiment, the kinase inhibitor is an MNK inhibitor selected from CGP052088; 4-amino-3-(p-fluorophenylamino)-pyrazolo [3,4-d] pyrimidine (CGP57380); cercosporamide; ETC-1780445-2; and 4-amino-5-(4-fluoroanilino)-pyrazolo [3,4-d]pyrimidine. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with a phosphoinositide 3-kinase (PI3K) inhibitor (e.g., a PI3K inhibitor described herein, e.g., idelalisib or duvelisib) and/or rituximab. In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with idelalisib and rituximab. In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with duvelisib and rituximab. Idelalisib (also called GS-1101 or CAL-101; Gilead) is a small molecule that blocks the delta isoform of PI3K. The structure of idelalisib (5-Fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]-4(3H)-quinazolinone) is shown below. 
     
       
         
         
             
             
         
       
     
     Duvelisib (also called IPI-145; Infinity Pharmaceuticals and Abbvie) is a small molecule that blocks PI3K-δ,γ. The structure of duvelisib (8-Chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-1(2H)-isoquinolinone) is shown below. 
     
       
         
         
             
             
         
       
     
     In embodiments, the subject has CLL. In embodiments, the subject has relapsed CLL, e.g., the subject has previously been administered a cancer therapy (e.g., previously been administered an anti-CD20 antibody or previously been administered ibrutinib). For example, the subject has a deletion in the short arm of chromosome 17 (del(17p), e.g., in a leukemic cell). In other examples, the subject does not have a del(17p). In embodiments, the subject comprises a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV H ) gene. In other embodiments, the subject does not comprise a leukemic cell comprising a mutation in the immunoglobulin heavy-chain variable-region (IgV H ) gene. In embodiments, the subject has a deletion in the long arm of chromosome 11 (del(11q)). In other embodiments, the subject does not have a del(11q). In embodiments, idelalisib is administered at a dosage of about 100-400 mg (e.g., 100-125, 125-150, 150-175, 175-200, 200-225, 225-250, 250-275, 275-300, 325-350, 350-375, or 375-400 mg), e.g., BID. In embodiments, duvelisib is administered at a dosage of about 15-100 mg (e.g., about 15-25, 25-50, 50-75, or 75-100 mg), e.g., twice a day. In embodiments, rituximab is administered at a dosage of about 350-550 mg/m 2  (e.g., 350-375, 375-400, 400-425, 425-450, 450-475, or 475-500 mg/m 2 ), e.g., intravenously. 
     In one embodiment, the kinase inhibitor is a dual phosphatidylinositol 3-kinase (PI3K) and mTOR inhibitor selected from 2-Amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one (PF-04691502); N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]urea (PF-05212384, PKI-587); 2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile (BEZ-235); apitolisib (GDC-0980, RG7422); 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458); 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one Maleic acid (NVP-BGT226); 3-[4-(4-Morpholinylpyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl]phenol (PI-103); 5-(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine (VS-5584, SB2343); and N-[2-[(3,5-Dimethoxyphenyl)amino]quinoxalin-3-yl]-4-[(4-methyl-3-methoxyphenyl)carbonyl]aminophenylsulfonamide (XL765). 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with an anaplastic lymphoma kinase (ALK) inhibitor. Exemplary ALK kinases include but are not limited to crizotinib (Pfizer), ceritinib (Novartis), alectinib (Chugai), brigatinib (also called AP26113; Ariad), entrectinib (Ignyta), PF-06463922 (Pfizer), TSR-011 (Tesaro) (see, e.g., Clinical Trial Identifier No. NCT02048488), CEP-37440 (Teva), and X-396 (Xcovery). In some embodiments, the subject has a solid cancer, e.g., a solid cancer described herein, e.g., lung cancer. 
     The chemical name of crizotinib is 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl)pyrazol-4-yl)pyridin-2-amine. The chemical name of ceritinib is 5-Chloro-N 2 -[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N 4 -[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine. The chemical name of alectinib is 9-ethyl-6,6-dimethyl-8-(4-morpholinopiperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile. The chemical name of brigatinib is 5-Chloro-N 2 -{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl}-N 4 -[2-(dimethylphosphoryl)phenyl]-2,4-pyrimidinediamine. The chemical name of entrectinib is N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide. The chemical name of PF-06463922 is (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile. The chemical structure of CEP-37440 is (S)-2-((5-chloro-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide. The chemical name of X-396 is (R)-6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide. 
     Drugs that inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin). (Liu et al., Cell 66:807-815, 1991; Henderson et al., Immun 73:316-321, 1991; Bierer et al., Curr. Opin. Immun 5. 763-773, 1993) can also be used. In a further aspect, the cell compositions of the present invention may be administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, and/or antibodies such as OKT3 or CAMPATH. In one aspect, the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, in one embodiment, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain embodiments, following the transplant, subjects receive an infusion of the expanded immune cells of the present invention. In an additional embodiment, expanded cells are administered before or following surgery. 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with an indoleamine 2,3-dioxygenase (IDO) inhibitor. IDO is an enzyme that catalyzes the degradation of the amino acid, L-tryptophan, to kynurenine. Many cancers overexpress IDO, e.g., prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head, and lung cancer. pDCs, macrophages, and dendritic cells (DCs) can express IDO. Without being bound by theory, it is thought that a decrease in L-tryptophan (e.g., catalyzed by IDO) results in an immunosuppressive milieu by inducing T-cell anergy and apoptosis. Thus, without being bound by theory, it is thought that an IDO inhibitor can enhance the efficacy of an anti-target CAR-expressing cell described herein, e.g., by decreasing the suppression or death of an anti-target CAR-expressing immune cell. In embodiments, the subject has a solid tumor, e.g., a solid tumor described herein, e.g., prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head, or lung cancer. Exemplary inhibitors of IDO include but are not limited to 1-methyl-tryptophan, indoximod (NewLink Genetics) (see, e.g., Clinical Trial Identifier Nos. NCT01191216; NCT01792050), and INCB024360 (Incyte Corp.) (see, e.g., Clinical Trial Identifier Nos. NCT01604889; NCT01685255). 
     In embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with a modulator of myeloid-derived suppressor cells (MDSCs). MDSCs accumulate in the periphery and at the tumor site of many solid tumors. These cells suppress T cell responses, thereby hindering the efficacy of anti-target CAR-expressing cell therapy. Without being bound by theory, it is thought that administration of a MDSC modulator enhances the efficacy of an anti-target CAR-expressing cell described herein. In an embodiment, the subject has a solid tumor, e.g., a solid tumor described herein, e.g., glioblastoma. Exemplary modulators of MDSCs include but are not limited to MCS 110 and BLZ945. MCS 110 is a monoclonal antibody (mAb) against macrophage colony-stimulating factor (M-CSF). See, e.g., Clinical Trial Identifier No. NCT00757757. BLZ945 is a small molecule inhibitor of colony stimulating factor 1 receptor (CSF1R). See, e.g., Pyonteck et al. Nat. Med. 19(2013):1264-72. The structure of BLZ945 is shown below. 
     
       
         
         
             
             
         
       
     
     In some embodiments, an anti-target CAR-expressing cell described herein is administered to a subject in combination with a interleukin-15 (IL-15) polypeptide, a interleukin-15 receptor alpha (IL-15Ra) polypeptide, or a combination of both a IL-15 polypeptide and a IL-15Ra polypeptide e.g., hetIL-15 (Admune Therapeutics, LLC). hetIL-15 is a heterodimeric non-covalent complex of IL-15 and IL-15Ra. hetIL-15 is described in, e.g., U.S. Pat. No. 8,124,084, U.S. 2012/0177598, U.S. 2009/0082299, U.S. 2012/0141413, and U.S. 2011/0081311, incorporated herein by reference. In embodiments, het-IL-15 is administered subcutaneously. In embodiments, the subject has a cancer, e.g., solid cancer, e.g., melanoma or colon cancer. In embodiments, the subject has a metastatic cancer. 
     In one embodiment, the subject can be administered an agent which reduces or ameliorates a side effect associated with the administration of an anti-target CAR-expressing cell. Side effects associated with the administration of an anti-target CAR-expressing cell include, but are not limited to CRS, and hemophagocytic lymphohistiocytosis (HLH), also termed Macrophage Activation Syndrome (MAS). Symptoms of CRS include high fevers, nausea, transient hypotension, hypoxia, and the like. CRS may include clinical constitutional signs and symptoms such as fever, fatigue, anorexia, myalgias, arthalgias, nausea, vomiting, and headache. CRS may include clinical skin signs and symptoms such as rash. CRS may include clinical gastrointestinal signs and symptoms such as nausea, vomiting and diarrhea. CRS may include clinical respiratory signs and symptoms such as tachypnea and hypoxemia. CRS may include clinical cardiovascular signs and symptoms such as tachycardia, widened pulse pressure, hypotension, increased cardiac output (early) and potentially diminished cardiac output (late). CRS may include clinical coagulation signs and symptoms such as elevated d-dimer, hypofibrinogenemia with or without bleeding. CRS may include clinical renal signs and symptoms such as azotemia. CRS may include clinical hepatic signs and symptoms such as transaminitis and hyperbilirubinemia. CRS may include clinical neurologic signs and symptoms such as headache, mental status changes, confusion, delirium, word finding difficulty or frank aphasia, hallucinations, tremor, dymetria, altered gait, and seizures. 
     Accordingly, the methods described herein can comprise administering an anti-target CAR-expressing cell described herein to a subject and further administering one or more agents to manage elevated levels of a soluble factor resulting from treatment with a anti-target CAR-expressing cell. In one embodiment, the soluble factor elevated in the subject is one or more of IFN-γ, TNFα, IL-2 and IL-6. In an embodiment, the factor elevated in the subject is one or more of IL-1, GM-CSF, IL-10, IL-8, IL-5 and fraktalkine. Therefore, an agent administered to treat this side effect can be an agent that neutralizes one or more of these soluble factors. In one embodiment, the agent that neutralizes one or more of these soluble forms is an antibody or antigen binding fragment thereof. Examples of such agents include, but are not limited to a steroid (e.g., corticosteroid), an inhibitor of TNFα, and an inhibitor of IL-6. An example of a TNFα inhibitor is an anti-TNFα antibody molecule such as, infliximab, adalimumab, certolizumab pegol, and golimumab. Another example of a TNFα inhibitor is a fusion protein such as entanercept. Small molecule inhibitors of TNFα include, but are not limited to, xanthine derivatives (e.g. pentoxifylline) and bupropion. An example of an IL-6 inhibitor is an anti-IL-6 antibody molecule or an anti-IL-6 receptor antibody molecule such as tocilizumab (toc), sarilumab, elsilimomab, CNTO 328, ALD518/BMS-945429, CNTO 136, CPSI-2364, CDP6038, VX30, ARGX-109, FB301, and FM101. In one embodiment, the anti-IL-6 receptor antibody molecule is tocilizumab. An example of an IL-1R based inhibitor is anakinra. 
     In one embodiment, the subject can be administered an agent which enhances the activity of a anti-target CAR-expressing cell. For example, in one embodiment, the agent can be an agent which inhibits an inhibitory molecule. Inhibitory molecules, e.g., Programmed Death 1 (PD-1), can, in some embodiments, decrease the ability of a anti-target CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and TGF beta. Inhibition of an inhibitory molecule, e.g., by inhibition at the DNA, RNA or protein level, can optimize a anti-target CAR-expressing cell performance. In embodiments, an inhibitory nucleic acid, e.g., an inhibitory nucleic acid, e.g., a dsRNA, e.g., an siRNA or shRNA, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription-activator like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN), e.g., as described herein, can be used to inhibit expression of an inhibitory molecule in the anti-target CAR-expressing cell. In an embodiment the inhibitor is an shRNA. In an embodiment, the inhibitory molecule is inhibited within a anti-target CAR-expressing cell. In these embodiments, a dsRNA molecule that inhibits expression of the inhibitory molecule is linked to the nucleic acid that encodes a component, e.g., all of the components, of the anti-target CAR. In one embodiment, the inhibitor of an inhibitory signal can be, e.g., an antibody or antibody fragment that binds to an inhibitory molecule. For example, the agent can be an antibody or antibody fragment that binds to PD-1, PD-L1, PD-L2 or CTLA4 (e.g., ipilimumab (also referred to as MDX-010 and MDX-101, and marketed as Yervoy®; Bristol-Myers Squibb; Tremelimumab (IgG2 monoclonal antibody available from Pfizer, formerly known as ticilimumab, CP-675,206)). In an embodiment, the agent is an antibody or antibody fragment that binds to TIM3. In an embodiment, the agent is an antibody or antibody fragment that binds to CEACAM (CEACAM-1, CEACAM-3, and/or CEACAM-5). In an embodiment, the agent is an antibody or antibody fragment that binds to LAG3. 
     PD-1 is an inhibitory member of the CD28 family of receptors that also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells and myeloid cells (Agata et al. 1996 Int. Immunol 8:765-75). Two ligands for PD-1, PD-L1 and PD-L2 have been shown to downregulate T cell activation upon binding to PD-1 (Freeman et a. 2000 J Exp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094) Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1. Antibodies, antibody fragments, and other inhibitors of PD-1, PD-L1 and PD-L2 are available in the art and may be used combination with a cars of the present invention described herein. For example, nivolumab (also referred to as BMS-936558 or MDX1106; Bristol-Myers Squibb) is a fully human IgG4 monoclonal antibody which specifically blocks PD-1. Nivolumab (clone 5C4) and other human monoclonal antibodies that specifically bind to PD-1 are disclosed in U.S. Pat. No. 8,008,449 and WO2006/121168. Pidilizumab (CT-011; Cure Tech) is a humanized IgG1k monoclonal antibody that binds to PD-1. Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are disclosed in WO2009/101611. Pembrolizumab (formerly known as lambrolizumab, and also referred to as MK03475; Merck) is a humanized IgG4 monoclonal antibody that binds to PD-1. Pembrolizumab and other humanized anti-PD-1 antibodies are disclosed in U.S. Pat. No. 8,354,509 and WO2009/114335. MEDI4736 (Medimmune) is a human monoclonal antibody that binds to PDL1, and inhibits interaction of the ligand with PD1. MDPL3280A (Genentech/Roche) is a human Fc optimized IgG1 monoclonal antibody that binds to PD-L1. MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Pat. No. 7,943,743 and U.S Publication No.: 20120039906. Other anti-PD-L1 binding agents include YW243.55.570 (heavy and light chain variable regions are shown in SEQ ID NOs 20 and 21 in WO2010/077634) and MDX-1 105 (also referred to as BMS-936559, and, e.g., anti-PD-L1 binding agents disclosed in WO2007/005874). AMP-224 (B7-DCIg; Amplimmune; e.g., disclosed in WO2010/027827 and WO2011/066342), is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD-1 and B7-H1. Other anti-PD-1 antibodies include AMP 514 (Amplimmune), among others, e.g., anti-PD-1 antibodies disclosed in U.S. Pat. No. 8,609,089, US 2010028330, and/or US 20120114649. 
     TIM-3 (T cell immunoglobulin-3) also negatively regulates T cell function, particularly in IFN-g-secreting CD4+T helper 1 and CD8+T cytotoxic 1 cells, and plays a critical role in T cell exhaustion. Inhibition of the interaction between TIM3 and its ligands, e.g., galectin-9 (Ga19), phosphotidylserine (PS), and HMGB1, can increase immune response. Antibodies, antibody fragments, and other inhibitors of TIM3 and its ligands are available in the art and may be used combination with a CD19 CAR described herein. For example, antibodies, antibody fragments, small molecules, or peptide inhibitors that target TIM3 binds to the IgV domain of TIM3 to inhibit interaction with its ligands. Antibodies and peptides that inhibit TIM3 are disclosed in WO2013/006490 and US20100247521. Other anti-TIM3 antibodies include humanized versions of RMT3-23 (disclosed in Ngiow et al., 2011, Cancer Res, 71:3540-3551), and clone 8B.2C12 (disclosed in Monney et al., 2002, Nature, 415:536-541). Bi-specific antibodies that inhibit TIM3 and PD-1 are disclosed in US20130156774. 
     In other embodiments, the agent that enhances the activity of a anti-target CAR-expressing cell is a CEACAM inhibitor (e.g., CEACAM-1, CEACAM-3, and/or CEACAM-5 inhibitor). In one embodiment, the inhibitor of CEACAM is an anti-CEACAM antibody molecule. Exemplary anti-CEACAM-1 antibodies are described in WO 2010/125571, WO 2013/082366 WO 2014/059251 and WO 2014/022332, e.g., a monoclonal antibody 34B1, 26H7, and 5F4; or a recombinant form thereof, as described in, e.g., US 2004/0047858, U.S. Pat. No. 7,132,255 and WO 99/052552. In other embodiments, the anti-CEACAM antibody binds to CEACAM-5 as described in, e.g., Zheng et al.  PLoS One . Sep. 2, 2010; 5(9). pii: e12529 (DOI:10:1371/journal.pone.0021146), or crossreacts with CEACAM-1 and CEACAM-5 as described in, e.g., WO 2013/054331 and US 2014/0271618. 
     Without wishing to be bound by theory, carcinoembryonic antigen cell adhesion molecules (CEACAM), such as CEACAM-1 and CEACAM-5, are believed to mediate, at least in part, inhibition of an anti-tumor immune response (see e.g., Markel et al.  J Immunol . Mar. 15, 2002; 168(6):2803-10; Markel et al.  J Immunol . Nov. 1, 2006; 177(9):6062-71; Markel et al.  Immunology.  2009 February; 126(2):186-200; Markel et al.  Cancer Immunol Immunother.  2010 February; 59(2):215-30; Ortenberg et al.  Mol Cancer Ther.  2012 June; 11(6):1300-10; Stern et al.  J Immunol . Jun. 1, 2005; 174(11):6692-701; Zheng et al. PLoS One. Sep. 2, 2010; 5(9). pii: e12529). For example, CEACAM-1 has been described as a heterophilic ligand for TIM-3 and as playing a role in TIM-3-mediated T cell tolerance and exhaustion (see e.g., WO 2014/022332; Huang, et al. (2014)  Nature  doi:10.1038/nature13848). In embodiments, co-blockade of CEACAM-1 and TIM-3 has been shown to enhance an anti-tumor immune response in xenograft colorectal cancer models (see e.g., WO 2014/022332; Huang, et al. (2014), supra). In other embodiments, co-blockade of CEACAM-1 and PD-1 reduce T cell tolerance as described, e.g., in WO 2014/059251. Thus, CEACAM inhibitors can be used with the other immunomodulators described herein (e.g., anti-PD-1 and/or anti-TIM-3 inhibitors) to enhance an immune response against a cancer, e.g., a melanoma, a lung cancer (e.g., NSCLC), a bladder cancer, a colon cancer an ovarian cancer, and other cancers as described herein. 
     LAG-3 (lymphocyte activation gene-3 or CD223) is a cell surface molecule expressed on activated T cells and B cells that has been shown to play a role in CD8+ T cell exhaustion. Antibodies, antibody fragments, and other inhibitors of LAG-3 and its ligands are available in the art and may be used combination with a anti-target CAR described herein. For example, BMS-986016 (Bristol-Myers Squib) is a monoclonal antibody that targets LAG3. IMP701 (Immutep) is an antagonist LAG-3 antibody and IMP731 (Immutep and GlaxoSmithKline) is a depleting LAG-3 antibody. Other LAG-3 inhibitors include IMP321 (Immutep), which is a recombinant fusion protein of a soluble, portion of LAG3 and Ig that hinds to MHC class II molecules and activates antigen presenting cells (APC). Other antibodies are disclosed, e.g., in WO2010/019570. 
     In some embodiments, the agent which enhances the activity of a anti-target CAR-expressing cell can be, e.g., a fusion protein comprising a first domain and a second domain, wherein the first domain is an inhibitory molecule, or fragment thereof, and the second domain is a polypeptide that is associated with a positive signal, e.g., a polypeptide comprising an intracellular signaling domain as described herein. In some embodiments, the polypeptide that is associated with a positive signal can include a costimulatory domain of CD28, CD27, ICOS, e.g., an intracellular signaling domain of CD28, CD27 and/or ICOS, and/or a primary signaling domain, e.g., of CD3 zeta, e.g., described herein. In one embodiment, the fusion protein is expressed by the same cell that expressed the anti-target CAR. In another embodiment, the fusion protein is expressed by a cell, e.g., a T cell that does not express a CAR of the present invention. 
     In one embodiment, the agent which enhances activity of a anti-target CAR-expressing cell described herein is miR-17-92. 
     In one embodiment, the agent which enhances activity of a anti-target CAR-described herein is a cytokine. Cytokines have important functions related to T cell expansion, differentiation, survival, and homeostasis. Cytokines that can be administered to the subject receiving a anti-target CAR-expressing cell described herein include: IL-2, IL-4, IL-7, IL-9, IL-15, IL-18, and IL-21, or a combination thereof. In preferred embodiments, the cytokine administered is IL-7, IL-15, or IL-21, or a combination thereof. The cytokine can be administered once a day or more than once a day, e.g., twice a day, three times a day, or four times a day. The cytokine can be administered for more than one day, e.g. the cytokine is administered for 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or 4 weeks. For example, the cytokine is administered once a day for 7 days. 
     In embodiments, the cytokine is administered in combination with anti-target CAR-expressing T cells. The cytokine can be administered simultaneously or concurrently with the anti-target CAR-expressing T cells, e.g., administered on the same day. The cytokine may be prepared in the same pharmaceutical composition as the anti-target CAR-expressing T cells, or may be prepared in a separate pharmaceutical composition. Alternatively, the cytokine can be administered shortly after administration of the anti-target CAR-expressing T cells, e.g., 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after administration of the anti-target CAR-expressing T cells. In embodiments where the cytokine is administered in a dosing regimen that occurs over more than one day, the first day of the cytokine dosing regimen can be on the same day as administration with the anti-target CAR-expressing T cells, or the first day of the cytokine dosing regimen can be 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or 7 days after administration of the anti-target CAR-expressing T cells. In one embodiment, on the first day, the anti-target CAR-expressing T cells are administered to the subject, and on the second day, a cytokine is administered once a day for the next 7 days. In a preferred embodiment, the cytokine to be administered in combination with anti-target CAR-expressing T cells is IL-7, IL-15, or IL-21. 
     In other embodiments, the cytokine is administered a period of time after administration of anti-target CAR-expressing cells, e.g., at least 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 1 year or more after administration of anti-target CAR-expressing cells. In one embodiment, the cytokine is administered after assessment of the subject&#39;s response to the anti-target CAR-expressing cells. For example, the subject is administered anti-target CAR-expressing cells according to the dosage and regimens described herein. The response of the subject to anti-target CAR-expressing cell therapy is assessed at 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 1 year or more after administration of anti-target CAR-expressing cells, using any of the methods described herein, including inhibition of tumor growth, reduction of circulating tumor cells, or tumor regression. Subjects that do not exhibit a sufficient response to anti-target CAR-expressing cell therapy can be administered a cytokine. Administration of the cytokine to the subject that has sub-optimal response to the anti-target CAR-expressing cell therapy improves anti-target CAR-expressing cell efficacy or anti-cancer activity. In a preferred embodiment, the cytokine administered after administration of anti-target CAR-expressing cells is IL-7. 
     Combination with a Low Dose of an mTOR Inhibitor 
     In one embodiment, the cells expressing a anti-target CAR molecule, e.g., a anti-target CAR molecule described herein, are administered in combination with a low, immune enhancing dose of an mTOR inhibitor. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 90%, at least 10 but no more than 90%, at least 15, but no more than 90%, at least 20 but no more than 90%, at least 30 but no more than 90%, at least 40 but no more than 90%, at least 50 but no more than 90%, at least 60 but no more than 90%, or at least 70 but no more than 90%. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 80%, at least 10 but no more than 80%, at least 15, but no more than 80%, at least 20 but no more than 80%, at least 30 but no more than 80%, at least 40 but no more than 80%, at least 50 but no more than 80%, or at least 60 but no more than 80%. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 70%, at least 10 but no more than 70%, at least 15, but no more than 70%, at least 20 but no more than 70%, at least 30 but no more than 70%, at least 40 but no more than 70%, or at least 50 but no more than 70%. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 60%, at least 10 but no more than 60%, at least 15, but no more than 60%, at least 20 but no more than 60%, at least 30 but no more than 60%, or at least 40 but no more than 60%. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 50%, at least 10 but no more than 50%, at least 15, but no more than 50%, at least 20 but no more than 50%, at least 30 but no more than 50%, or at least 40 but no more than 50%. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 40%, at least 10 but no more than 40%, at least 15, but no more than 40%, at least 20 but no more than 40%, at least 30 but no more than 40%, or at least 35 but no more than 40%. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 5 but no more than 30%, at least 10 but no more than 30%, at least 15, but no more than 30%, at least 20 but no more than 30%, or at least 25 but no more than 30%. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 1, 2, 3, 4 or 5 but no more than 20%, at least 1, 2, 3, 4 or 5 but no more than 30%, at least 1, 2, 3, 4 or 5, but no more than 35, at least 1, 2, 3, 4 or 5 but no more than 40%, or at least 1, 2, 3, 4 or 5 but no more than 45%. 
     In an embodiment, a dose of an mTOR inhibitor is associated with, or provides, mTOR inhibition of at least 1, 2, 3, 4 or 5 but no more than 90%. 
     As is discussed herein, the extent of mTOR inhibition can be expressed as the extent of P70 S6 kinase inhibition, e.g., the extent of mTOR inhibition can be determined by the level of decrease in P70 S6 kinase activity, e.g., by the decrease in phosphorylation of a P70 S6 kinase substrate. The level of mTOR inhibition can be evaluated by a method described herein, e.g. by the Boulay assay, or measurement of phosphorylated S6 levels by western blot. 
     Exemplary MTOR Inhibitors 
     As used herein, the term “mTOR inhibitor” refers to a compound or ligand, or a pharmaceutically acceptable salt thereof, which inhibits the mTOR kinase in a cell. In an embodiment an mTOR inhibitor is an allosteric inhibitor. In an embodiment an mTOR inhibitor is a catalytic inhibitor. 
     Allosteric mTOR inhibitors include the neutral tricyclic compound rapamycin (sirolimus), rapamycin-related compounds, that is compounds having structural and functional similarity to rapamycin including, e.g., rapamycin derivatives, rapamycin analogs (also referred to as rapalogs) and other macrolide compounds that inhibit mTOR activity. 
     Rapamycin is a known macrolide antibiotic produced by  Streptomyces hygroscopicus  having the structure shown in Formula A. 
     
       
         
         
             
             
         
       
     
     See, e.g., McAlpine, J. B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S. L., et al., J. Am. Chem. Soc. (1991) 113: 7433; U.S. Pat. No. 3,929,992. There are various numbering schemes proposed for rapamycin. To avoid confusion, when specific rapamycin analogs are named herein, the names are given with reference to rapamycin using the numbering scheme of formula A. 
     Rapamycin analogs useful in the invention are, for example, O-substituted analogs in which the hydroxyl group on the cyclohexyl ring of rapamycin is replaced by OR 1  in which R 1  is hydroxyalkyl, hydroxyalkoxyalkyl, acylaminoalkyl, or aminoalkyl; e.g. RAD001, also known as, everolimus as described in U.S. Pat. No. 5,665,772 and WO94/09010 the contents of which are incorporated by reference. Other suitable rapamycin analogs include those substituted at the 26- or 28-position. The rapamycin analog may be an epimer of an analog mentioned above, particularly an epimer of an analog substituted in position 40, 28 or 26, and may optionally be further hydrogenated, e.g. as described in U.S. Pat. No. 6,015,815, WO95/14023 and WO99/15530 the contents of which are incorporated by reference, e.g. ABT578 also known as zotarolimus or a rapamycin analog described in U.S. Pat. No. 7,091,213, WO98/02441 and WO01/14387 the contents of which are incorporated by reference, e.g. AP23573 also known as ridaforolimus. 
     Examples of rapamycin analogs suitable for use in the present invention from U.S. Pat. No. 5,665,772 include, but are not limited to, 40-O-benzyl-rapamycin, 40-O-(4′-hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-dihydroxyethyl)]benzyl-rapamycin, 40-O-allyl-rapamycin, 40-O-[3′-(2,2-dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′E,4&#39;S)-40-O-(4′,5′-dihydroxypent-2′-en-1′-yl)-rapamycin, 40-O-(2-hydroxy)ethoxycarbonylmethyl-rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-(6-hydroxy)hexyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-dihydroxyprop-1-yl]-rapamycin, 40-O-(2-acetoxy)ethyl-rapamycin, 40-O-(2-nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(2-aminoethyl)-rapamycin, 40-O-(2-acetaminoethyl)-rapamycin, 40-O-(2-nicotinamidoethyl)-rapamycin, 40-O-(2-(N-methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-tolylsulfonamidoethyl)-rapamycin and 40 O-[2-(4′,5′-dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin. 
     Other rapamycin analogs useful in the present invention are analogs where the hydroxyl group on the cyclohexyl ring of rapamycin and/or the hydroxy group at the 28 position is replaced with an hydroxyester group are known, for example, rapamycin analogs found in U.S. RE44,768, e.g. temsirolimus. 
     Other rapamycin analogs useful in the preset invention include those wherein the methoxy group at the 16 position is replaced with another substituent, preferably (optionally hydroxy-substituted) alkynyloxy, benzyl, orthomethoxybenzyl or chlorobenzyl and/or wherein the mexthoxy group at the 39 position is deleted together with the 39 carbon so that the cyclohexyl ring of rapamycin becomes a cyclopentyl ring lacking the 39 position methyoxy group; e.g. as described in WO95/16691 and WO96/41807 the contents of which are incorporated by reference. The analogs can be further modified such that the hydroxy at the 40-position of rapamycin is alkylated and/or the 32-carbonyl is reduced. 
     Rapamycin analogs from WO95/16691 include, but are not limited to, 16-demthoxy-16-(pent-2-ynyl)oxy-rapamycin, 16-demthoxy-16-(but-2-ynyl)oxy-rapamycin, 16-demthoxy-16-(propargyl)oxy-rapamycin, 16-demethoxy-16-(4-hydroxy-but-2-ynyl)oxy-rapamycin, 16-demthoxy-16-benzyloxy-40-O-(2-hydroxyethyl)-rapamycin, 16-demthoxy-16-benzyloxy-rapamycin, 16-demethoxy-16-ortho-methoxybenzyl-rapamycin, 16-demethoxy-40-O-(2-methoxyethyl)-16-pent-2-ynyl)oxy-rapamycin, 39-demethoxy-40-desoxy-39-formyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-hydroxymethyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-carboxy-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-(4-methyl-piperazin-1-yl)carbonyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-(morpholin-4-yl)carbonyl-42-nor-rapamycin, 39-demethoxy-40-desoxy-39-[N-methyl, N-(2-pyridin-2-yl-ethyl)]carbamoyl-42-nor-rapamycin and 39-demethoxy-40-desoxy-39-(p-toluenesulfonylhydrazonomethyl)-42-nor-rapamycin. 
     Rapamycin analogs from WO96/41807 include, but are not limited to, 32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-rapamycin, 16-O-pent-2-ynyl-32-deoxo-40-O-(2-hydroxy-ethyl)-rapamycin, 16-O-pent-2-ynyl-32-(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin, 32(S)-dihydro-40-O-(2-methoxy)ethyl-rapamycin and 32(S)-dihydro-40-O-(2-hydroxyethyl)-rapamycin. 
     Another suitable rapamycin analog is umirolimus as described in US2005/0101624 the contents of which are incorporated by reference. 
     RAD001, otherwise known as everolimus (Afinitor®), has the chemical name (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(1R)-2-[(1 S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone 
     Further examples of allosteric mTOR inhibitors include sirolimus (rapamycin, AY-22989), 40-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin (also called temsirolimus or CCI-779) and ridaforolimus (AP-23573/MK-8669). Other examples of allosteric mTor inhibtors include zotarolimus (ABT578) and umirolimus. 
     Alternatively or additionally, catalytic, ATP-competitive mTOR inhibitors have been found to target the mTOR kinase domain directly and target both mTORC1 and mTORC2. These are also more effective inhibitors of mTORC1 than such allosteric mTOR inhibitors as rapamycin, because they modulate rapamycin-resistant mTORC1 outputs such as 4EBP1-T37/46 phosphorylation and cap-dependent translation. 
     Catalytic inhibitors include: BEZ235 or 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, or the monotosylate salt form. the synthesis of BEZ235 is described in WO2006/122806; CCG168 (otherwise known as AZD-8055, Chresta, C. M., et al., Cancer Res, 2010, 70(1), 288-298) which has the chemical name {5-[2,4-bis-((S)-3-methyl-morpholin-4-yl)-pyrido[2,3d]pyrimidin-7-yl]-2-methoxy-phenyl}-methanol; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide (WO09104019); 3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (WO10051043 and WO2013023184); A N-(3-(N-(3-((3,5-dimethoxyphenyl)amino) quinoxaline-2-yl) sulfamoyl)phenyl)-3-methoxy-4-methylbenzamide (WO07044729 and WO12006552); PKI-587 (Venkatesan, A. M., J. Med. Chem., 2010, 53, 2636-2645) which has the chemical name 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl]urea; GSK-2126458 (ACS Med. Chem. Lett., 2010, 1, 39-43) which has the chemical name 2,4-difluoro-N-{2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide; 5-(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine (WO10114484); (E)-N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide (WO12007926). 
     Further examples of catalytic mTOR inhibitors include 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one (WO2006/122806) and Ku-0063794 (Garcia-Martinez J M, et al., Biochem J., 2009, 421(1), 29-42. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).) WYE-354 is another example of a catalytic mTor inhibitor (Yu K, et al. (2009). Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin. Cancer Res. 69(15): 6232-6240). 
     mTOR inhibitors useful according to the present invention also include prodrugs, derivatives, pharmaceutically acceptable salts, or analogs thereof of any of the foregoing. 
     mTOR inhibitors, such as RAD001, may be formulated for delivery based on well-established methods in the art based on the particular dosages described herein. In particular, U.S. Pat. No. 6,004,973 (incorporated herein by reference) provides examples of formulations useable with the mTOR inhibitors described herein. 
     Evaluation of MTOR Inhibition 
     mTOR phosphorylates the kinase P70 S6, thereby activating P70 S6 kinase and allowing it to phosphorylate its substrate. The extent of mTOR inhibition can be expressed as the extent of P70 S6 kinase inhibition, e.g., the extent of mTOR inhibition can be determined by the level of decrease in P70 S6 kinase activity, e.g., by the decrease in phosphorylation of a P70 S6 kinase substrate. One can determine the level of mTOR inhibition, by measuring P70 S6 kinase activity (the ability of P70 S6 kinase to phosphorylate a substrate), in the absence of inhibitor, e.g., prior to administration of inhibitor, and in the presences of inhibitor, or after the administration of inhibitor. The level of inhibition of P70 S6 kinase gives the level of mTOR inhibition. Thus, if P70 S6 kinase is inhibited by 40%, mTOR activity, as measured by P70 S6 kinase activity, is inhibited by 40%. The extent or level of inhibition referred to herein is the average level of inhibition over the dosage interval. By way of example, if the inhibitor is given once per week, the level of inhibition is given by the average level of inhibition over that interval, namely a week. 
     Boulay et al.,  Cancer Res,  2004, 64:252-61, hereby incorporated by reference, teaches an assay that can be used to assess the level of mTOR inhibition (referred to herein as the Boulay assay). In an embodiment, the assay relies on the measurement of P70 S6 kinase activity from biological samples before and after administration of an mTOR inhibitor, e.g., RAD001. Samples can be taken at preselected times after treatment with an mTOR inhibitor, e.g., 24, 48, and 72 hours after treatment. Biological samples, e.g., from skin or peripheral blood mononuclear cells (PBMCs) can be used. Total protein extracts are prepared from the samples. P70 S6 kinase is isolated from the protein extracts by immunoprecipitation using an antibody that specifically recognizes the P70 S6 kinase. Activity of the isolated P70 S6 kinase can be measured in an in vitro kinase assay. The isolated kinase can be incubated with 40S ribosomal subunit substrates (which is an endogenous substrate of P70 S6 kinase) and gamma- 32 P under conditions that allow phosphorylation of the substrate. Then the reaction mixture can be resolved on an SDS-PAGE gel, and  32 P signal analyzed using a PhosphorImager. A  32 P signal corresponding to the size of the 40S ribosomal subunit indicates phosphorylated substrate and the activity of P70 S6 kinase. Increases and decreases in kinase activity can be calculated by quantifying the area and intensity of the  32 P signal of the phosphorylated substrate (e.g., using ImageQuant, Molecular Dynamics), assigning arbitrary unit values to the quantified signal, and comparing the values from after administration with values from before administration or with a reference value. For example, percent inhibition of kinase activity can be calculated with the following formula: 1-(value obtained after administration/value obtained before administration)×100. As described above, the extent or level of inhibition referred to herein is the average level of inhibition over the dosage interval. 
     Methods for the evaluation of kinase activity, e.g., P70 S6 kinase activity, are also provided in U.S. Pat. No. 7,727,950, hereby incorporated by reference. 
     The level of mTOR inhibition can also be evaluated by a change in the ration of PD1 negative to PD1 positive T cells. T cells from peripheral blood can be identified as PD1 negative or positive by art-known methods. 
     Low-Dose mTOR Inhibitors 
     Methods described herein use low, immune enhancing, dose mTOR inhibitors, doses of mTOR inhibitors, e.g., allosteric mTOR inhibitors, including rapalogs such as RAD001. In contrast, levels of inhibitor that fully or near fully inhibit the mTOR pathway are immunosuppressive and are used, e.g., to prevent organ transplant rejection. In addition, high doses of rapalogs that fully inhibit mTOR also inhibit tumor cell growth and are used to treat a variety of cancers (See, e.g., Antineoplastic effects of mammalian target of rapamycine inhibitors. Salvadori M. World J Transplant. Oct. 24, 2012; 2(5):74-83; Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Finn R S. Liver Cancer. 2012 November; 1(3-4):247-256; Emerging Signaling Pathways in Hepatocellular Carcinoma. Moeini A, Corneliá H, Villanueva A. Liver Cancer. 2012 September; 1(2):83-93; Targeted cancer therapy—Are the days of systemic chemotherapy numbered?Joo W D, Visintin I, Mor G. Maturitas. Sep. 20, 2013 ; Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR - TKIs and mTOR inhibitor . Santoni M, Berardi R, Amantini C, Burattini L, Santini D, Santoni G, Cascinu S. Int J Cancer. Oct. 2, 2013). 
     The present invention is based, at least in part, on the surprising finding that doses of mTOR inhibitors well below those used in current clinical settings had a superior effect in increasing an immune response in a subject and increasing the ratio of PD-1 negative T cells/PD-1 positive T cells. It was surprising that low doses of mTOR inhibitors, producing only partial inhibition of mTOR activity, were able to effectively improve immune responses in human subjects and increase the ratio of PD-1 negative T cells/PD-1 positive T cells. 
     Alternatively, or in addition, without wishing to be bound by any theory, it is believed that low, a low, immune enhancing, dose of an mTOR inhibitor can increase naive T cell numbers, e.g., at least transiently, e.g., as compared to a non-treated subject. Alternatively or additionally, again while not wishing to be bound by theory, it is believed that treatment with an mTOR inhibitor after a sufficient amount of time or sufficient dosing results in one or more of the following: 
     an increase in the expression of one or more of the following markers: CD62L high , CD127 high , CD27 + , and BCL2, e.g., on memory T cells, e.g., memory T cell precursors; 
     a decrease in the expression of KLRG1, e.g., on memory T cells, e.g., memory T cell precursors; and 
     an increase in the number of memory T cell precursors, e.g., cells with any one or combination of the following characteristics: increased CD62L high , increased CD127 high , increased CD27 + , decreased KLRG1, and increased BCL2; 
     and wherein any of the changes described above occurs, e.g., at least transiently, e.g., as compared to a non-treated subject (Araki, K et al. (2009)  Nature  460:108-112). Memory T cell precursors are memory T cells that are early in the differentiation program. For example, memory T cells have one or more of the following characteristics: increased CD62L high , increased CD127 high , increased CD27+, decreased KLRG1, and/or increased BCL2. 
     In an embodiment, the invention relates to a composition, or dosage form, of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., a rapalog, rapamycin, or RAD001, or a catalytic mTOR inhibitor, which, when administered on a selected dosing regimen, e.g., once daily or once weekly, is associated with: a level of mTOR inhibition that is not associated with complete, or significant immune suppression, but is associated with enhancement of the immune response. 
     An mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., a rapalog, rapamycin, or RAD001, or a catalytic mTOR inhibitor, can be provided in a sustained release formulation. Any of the compositions or unit dosage forms described herein can be provided in a sustained release formulation. In some embodiments, a sustained release formulation will have lower bioavailability than an immediate release formulation. E.g., in embodiments, to attain a similar therapeutic effect of an immediate release formulation a sustained release formulation will have from about 2 to about 5, about 2.5 to about 3.5, or about 3 times the amount of inhibitor provided in the immediate release formulation. 
     In an embodiment, immediate release forms, e.g., of RAD001, typically used for one administration per week, having 0.1 to 20, 0.5 to 10, 2.5 to 7.5, 3 to 6, or about 5, mgs per unit dosage form, are provided. For once per week administrations, these immediate release formulations correspond to sustained release forms, having, respectively, 0.3 to 60, 1.5 to 30, 7.5 to 22.5, 9 to 18, or about 15 mgs of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., rapamycin or RAD001. In embodiments both forms are administered on a once/week basis. 
     In an embodiment, immediate release forms, e.g., of RAD001, typically used for one administration per day, having 0.005 to 1.5, 0.01 to 1.5, 0.1 to 1.5, 0.2 to 1.5, 0.3 to 1.5, 0.4 to 1.5, 0.5 to 1.5, 0.6 to 1.5, 0.7 to 1.5, 0.8 to 1.5, 1.0 to 1.5, 0.3 to 0.6, or about 0.5 mgs per unit dosage form, are provided. For once per day administrations, these immediate release forms correspond to sustained release forms, having, respectively, 0.015 to 4.5, 0.03 to 4.5, 0.3 to 4.5, 0.6 to 4.5, 0.9 to 4.5, 1.2 to 4.5, 1.5 to 4.5, 1.8 to 4.5, 2.1 to 4.5, 2.4 to 4.5, 3.0 to 4.5, 0.9 to 1.8, or about 1.5 mgs of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., rapamycin or RAD001. For once per week administrations, these immediate release forms correspond to sustained release forms, having, respectively, 0.1 to 30, 0.2 to 30, 2 to 30, 4 to 30, 6 to 30, 8 to 30, 10 to 30, 1.2 to 30, 14 to 30, 16 to 30, 20 to 30, 6 to 12, or about 10 mgs of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., rapamycin or RAD001. 
     In an embodiment, immediate release forms, e.g., of RAD001, typically used for one administration per day, having 0.01 to 1.0 mgs per unit dosage form, are provided. For once per day administrations, these immediate release forms correspond to sustained release forms, having, respectively, 0.03 to 3 mgs of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., rapamycin or RAD001. For once per week administrations, these immediate release forms correspond to sustained release forms, having, respectively, 0.2 to 20 mgs of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., rapamycin or RAD001. 
     In an embodiment, immediate release forms, e.g., of RAD001, typically used for one administration per week, having 0.5 to 5.0 mgs per unit dosage form, are provided. For once per week administrations, these immediate release forms correspond to sustained release forms, having, respectively, 1.5 to 15 mgs of an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., rapamycin or RAD001. 
     As described above, one target of the mTOR pathway is the P70 S6 kinase. Thus, doses of mTOR inhibitors which are useful in the methods and compositions described herein are those which are sufficient to achieve no greater than 80% inhibition of P70 S6 kinase activity relative to the activity of the P70 S6 kinase in the absence of an mTOR inhibitor, e.g., as measured by an assay described herein, e.g., the Boulay assay. In a further aspect, the invention provides an amount of an mTOR inhibitor sufficient to achieve no greater than 38% inhibition of P70 S6 kinase activity relative to P70 S6 kinase activity in the absence of an mTOR inhibitor. 
     In one aspect the dose of mTOR inhibitor useful in the methods and compositions of the invention is sufficient to achieve, e.g., when administered to a human subject, 90+/−5% (i.e., 85-95%), 89+/−5%, 88+/−5%, 87+/−5%, 86+/−5%, 85+/−5%, 84+/−5%, 83+/−5%, 82+/−5%, 81+/−5%, 80+/−5%, 79+/−5%, 78+/−5%, 77+/−5%, 76+/−5%, 75+/−5%, 74+/−5%, 73+/−5%, 72+/−5%, 71+/−5%, 70+/−5%, 69+/−5%, 68+/−5%, 67+/−5%, 66+/−5%, 65+/−5%, 64+/−5%, 63+/−5%, 62+/−5%, 61+/−5%, 60+/−5%, 59+/−5%, 58+/−5%, 57+/−5%, 56+/−5%, 55+/−5%, 54+/−5%, 54+/−5%, 53+/−5%, 52+/−5%, 51+/−5%, 50+/−5%, 49+/−5%, 48+/−5%, 47+/−5%, 46+/−5%, 45+/−5%, 44+/−5%, 43+/−5%, 42+/−5%, 41+/−5%, 40+/−5%, 39+/−5%, 38+/−5%, 37+/−5%, 36+/−5%, 35+/−5%, 34+/−5%, 33+/−5%, 32+/−5%, 31+/−5%, 30+/−5%, 29+/−5%, 28+/−5%, 27+/−5%, 26+/−5%, 25+/−5%, 24+/−5%, 23+/−5%, 22+/−5%, 21+/−5%, 20+/−5%, 19+/−5%, 18+/−5%, 17+/−5%, 16+/−5%, 15+/−5%, 14+/−5%, 13+/−5%, 12+/−5%, 11+/−5%, or 10+/−5%, inhibition of P70 S6 kinase activity, e.g., as measured by an assay described herein, e.g., the Boulay assay. 
     P70 S6 kinase activity in a subject may be measured using methods known in the art, such as, for example, according to the methods described in U.S. Pat. No. 7,727,950, by immunoblot analysis of phosphoP70 S6K levels and/or phosphoP70 S6 levels or by in vitro kinase activity assays. 
     As used herein, the term “about” in reference to a dose of mTOR inhibitor refers to up to a +/−10% variability in the amount of mTOR inhibitor, but can include no variability around the stated dose. 
     In some embodiments, the invention provides methods comprising administering to a subject an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, at a dosage within a target trough level. In some embodiments, the trough level is significantly lower than trough levels associated with dosing regimens used in organ transplant and cancer patients. In an embodiment mTOR inhibitor, e.g., RAD001, or rapamycin, is administered to result in a trough level that is less than ½, ¼, 1/10, or 1/20 of the trough level that results in immunosuppression or an anticancer effect. In an embodiment mTOR inhibitor, e.g., RAD001, or rapamycin, is administered to result in a trough level that is less than ½, ¼, 1/10, or 1/20 of the trough level provided on the FDA approved packaging insert for use in immunosuppression or an anticancer indications. 
     In an embodiment a method disclosed herein comprises administering to a subject an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, at a dosage that provides a target trough level of 0.1 to 10 ng/ml, 0.1 to 5 ng/ml, 0.1 to 3 ng/ml, 0.1 to 2 ng/ml, or 0.1 to 1 ng/ml. 
     In an embodiment a method disclosed herein comprises administering to a subject an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, at a dosage that provides a target trough level of 0.2 to 10 ng/ml, 0.2 to 5 ng/ml, 0.2 to 3 ng/ml, 0.2 to 2 ng/ml, or 0.2 to 1 ng/ml. 
     In an embodiment a method disclosed herein comprises administering to a subject an mTOR inhibitor, e.g. an, allosteric inhibitor, e.g., RAD001, at a dosage that provides a target trough level of 0.3 to 10 ng/ml, 0.3 to 5 ng/ml, 0.3 to 3 ng/ml, 0.3 to 2 ng/ml, or 0.3 to 1 ng/ml. 
     In an embodiment a method disclosed herein comprises administering to a subject an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, at a dosage that provides a target trough level of 0.4 to 10 ng/ml, 0.4 to 5 ng/ml, 0.4 to 3 ng/ml, 0.4 to 2 ng/ml, or 0.4 to 1 ng/ml. 
     In an embodiment a method disclosed herein comprises administering to a subject an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, at a dosage that provides a target trough level of 0.5 to 10 ng/ml, 0.5 to 5 ng/ml, 0.5 to 3 ng/ml, 0.5 to 2 ng/ml, or 0.5 to 1 ng/ml. 
     In an embodiment a method disclosed herein comprises administering to a subject an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001, at a dosage that provides a target trough level of 1 to 10 ng/ml, 1 to 5 ng/ml, 1 to 3 ng/ml, or 1 to 2 ng/ml. 
     As used herein, the term “trough level” refers to the concentration of a drug in plasma just before the next dose, or the minimum drug concentration between two doses. 
     In some embodiments, a target trough level of RAD001 is in a range of between about 0.1 and 4.9 ng/ml. In an embodiment, the target trough level is below 3 ng/ml, e.g., is between 0.3 or less and 3 ng/ml. In an embodiment, the target trough level is below 3 ng/ml, e.g., is between 0.3 or less and 1 ng/ml. 
     In a further aspect, the invention can utilize an mTOR inhibitor other than RAD001 in an amount that is associated with a target trough level that is bioequivalent to the specified target trough level for RAD001. In an embodiment, the target trough level for an mTOR inhibitor other than RAD001, is a level that gives the same level of mTOR inhibition (e.g., as measured by a method described herein, e.g., the inhibition of P70 S6) as does a trough level of RAD001 described herein. 
     Pharmaceutical Compositions: mTOR Inhibitors 
     In one aspect, the present invention relates to pharmaceutical compositions comprising an mTOR inhibitor, e.g., an mTOR inhibitor as described herein, formulated for use in combination with CAR cells described herein. 
     In some embodiments, the mTOR inhibitor is formulated for administration in combination with an additional, e.g., as described herein. 
     In general, compounds of the invention will be administered in therapeutically effective amounts as described above via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. 
     The pharmaceutical formulations may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (e.g., an mTOR inhibitor or stabilized form of the compound (e.g., complex with a cyclodextrin derivative or other known complexation agent) is dissolved in a suitable solvent in the presence of one or more of the excipients described herein. The mTOR inhibitor is typically formulated into pharmaceutical dosage forms to provide an easily controllable dosage of the drug and to give the patient an elegant and easily handleable product. 
     Compounds of the invention can be administered as pharmaceutical compositions by any conventional route, in particular enterally, e.g., orally, e.g., in the form of tablets or capsules, or parenterally, e.g., in the form of injectable solutions or suspensions, topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form. Where an mTOR inhibitor is administered in combination with (either simultaneously with or separately from) another agent as described herein, in one aspect, both components can be administered by the same route (e.g., parenterally). Alternatively, another agent may be administered by a different route relative to the mTOR inhibitor. For example, an mTOR inhibitor may be administered orally and the other agent may be administered parenterally. 
     Sustained Release 
     mTOR inhibitors, e.g., allosteric mTOR inhibitors or catalytic mTOR inhibitors, disclosed herein can be provided as pharmaceutical formulations in form of oral solid dosage forms comprising an mTOR inhibitor disclosed herein, e.g., rapamycin or RAD001, which satisfy product stability requirements and/or have favorable pharmacokinetic properties over the immediate release (IR) tablets, such as reduced average plasma peak concentrations, reduced inter- and intra-patient variability in the extent of drug absorption and in the plasma peak concentration, reduced C max /C min  ratio and/or reduced food effects. Provided pharmaceutical formulations may allow for more precise dose adjustment and/or reduce frequency of adverse events thus providing safer treatments for patients with an mTOR inhibitor disclosed herein, e.g., rapamycin or RAD001. 
     In some embodiments, the present disclosure provides stable extended release formulations of an mTOR inhibitor disclosed herein, e.g., rapamycin or RAD001, which are multi-particulate systems and may have functional layers and coatings. 
     The term “extended release, multi-particulate formulation as used herein refers to a formulation which enables release of an mTOR inhibitor disclosed herein, e.g., rapamycin or RAD001, over an extended period of time e.g. over at least 1, 2, 3, 4, 5 or 6 hours. The extended release formulation may contain matrices and coatings made of special excipients, e.g., as described herein, which are formulated in a manner as to make the active ingredient available over an extended period of time following ingestion. 
     The term “extended release” can be interchangeably used with the terms “sustained release” (SR) or “prolonged release”. The term “extended release” relates to a pharmaceutical formulation that does not release active drug substance immediately after oral dosing but over an extended in accordance with the definition in the pharmacopoeias Ph. Eur. (7 th  edition) mongraph for tablets and capsules and USP general chapter &lt;1151&gt; for pharmaceutical dosage forms. The term “Immediate Release” (IR) as used herein refers to a pharmaceutical formulation which releases 85% of the active drug substance within less than 60 minutes in accordance with the definition of “Guidance for Industry: “Dissolution Testing of Immediate Release Solid Oral Dosage Forms” (FDA CDER, 1997). In some embodiments, the term “immediate release” means release of everolismus from tablets within the time of 30 minutes, e.g., as measured in the dissolution assay described herein. 
     Stable extended release formulations of an mTOR inhibitor disclosed herein, e.g., rapamycin or RAD001, can be characterized by an in-vitro release profile using assays known in the art, such as a dissolution assay as described herein: a dissolution vessel filled with 900 mL phosphate buffer pH 6.8 containing sodium dodecyl sulfate 0.2% at 37° C. and the dissolution is performed using a paddle method at 75 rpm according to USP by according to USP testing monograph 711, and Ph.Eur. testing monograph 2.9.3. respectively. 
     In some embodiments, stable extended release formulations of an mTOR inhibitor disclosed herein, e.g., rapamycin or RAD001, release the mTOR inhibitor in the in-vitro release assay according to following release specifications: 
     0.5 h: &lt;45%, or &lt;40, e.g., &lt;30% 
     1 h: 20-80%, e.g., 30-60% 
     2 h: &gt;50%, or &gt;70%, e.g., &gt;75% 
     3 h: &gt;60%, or &gt;65%, e.g., &gt;85%, e.g., &gt;90%. 
     In some embodiments, stable extended release formulations of an mTOR inhibitor disclosed herein, e.g., rapamycin or RAD001, release 50% of the mTOR inhibitor not earlier than 45, 60, 75, 90, 105 min or 120 min in the in-vitro dissolution assay. 
     Biopolymer Delivery Methods 
     In some embodiments, one or more CAR-expressing cells as disclosed herein can be administered or delivered to the subject via a biopolymer scaffold, e.g., a biopolymer implant. Biopolymer scaffolds can support or enhance the delivery, expansion, and/or dispersion of the CAR-expressing cells described herein. A biopolymer scaffold comprises a biocompatible (e.g., does not substantially induce an inflammatory or immune response) and/or a biodegradable polymer that can be naturally occurring or synthetic. 
     Examples of suitable biopolymers include, but are not limited to, agar, agarose, alginate, alginate/calcium phosphate cement (CPC), beta-galactosidase (β-GAL), (1, 2,3,4,6-pentaacetyl a-D-galactose), cellulose, chitin, chitosan, collagen, elastin, gelatin, hyaluronic acid collagen, hydroxyapatite, poly(3-hydroxybutyrate-co-3-hydroxy-hexanoate) (PHBHHx), poly(lactide), poly(caprolactone) (PCL), poly(lactide-co-glycolide) (PLG), polyethylene oxide (PEO), poly(lactic-co-glycolic acid) (PLGA), polypropylene oxide (PPO), polyvinyl alcohol) (PVA), silk, soy protein, and soy protein isolate, alone or in combination with any other polymer composition, in any concentration and in any ratio. The biopolymer can be augmented or modified with adhesion- or migration-promoting molecules, e.g., collagen-mimetic peptides that bind to the collagen receptor of lymphocytes, and/or stimulatory molecules to enhance the delivery, expansion, or function, e.g., anti-cancer activity, of the cells to be delivered. The biopolymer scaffold can be an injectable, e.g., a gel or a semi-solid, or a solid composition. 
     In some embodiments, CAR-expressing cells described herein are seeded onto the biopolymer scaffold prior to delivery to the subject. In embodiments, the biopolymer scaffold further comprises one or more additional therapeutic agents described herein (e.g., another CAR-expressing cell, an antibody, or a small molecule) or agents that enhance the activity of a CAR-expressing cell, e.g., incorporated or conjugated to the biopolymers of the scaffold. In embodiments, the biopolymer scaffold is injected, e.g., intratumorally, or surgically implanted at the tumor or within a proximity of the tumor sufficient to mediate an anti-tumor effect. Additional examples of biopolymer compositions and methods for their delivery are described in Stephan et al., Nature Biotechnology, 2015, 33:97-101; and WO2014/110591. 
     Pharmaceutical Compositions and Treatments 
     Pharmaceutical compositions of the present invention may comprise an anti-target CAR-expressing cell, e.g., a plurality of anti-target CAR-expressing cells, as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Compositions of the present invention are in one aspect formulated for intravenous administration. 
     Pharmaceutical compositions of the present invention may be administered in a manner appropriate to the disease to be treated (or prevented). The quantity and frequency of administration will be determined by such factors as the condition of the patient, and the type and severity of the patient&#39;s disease, although appropriate dosages may be determined by clinical trials. 
     In one embodiment, the pharmaceutical composition is substantially free of, e.g., there are no detectable levels of a contaminant, e.g., selected from the group consisting of endotoxin,  mycoplasma , replication competent lentivirus (RCL), p24, VSV-G nucleic acid, HIV gag, residual anti-CD3/anti-CD28 coated beads, mouse antibodies, pooled human serum, bovine serum albumin, bovine serum, culture media components, vector packaging cell or plasmid components, a bacterium and a fungus. In one embodiment, the bacterium is at least one selected from the group consisting of  Alcaligenes faecalis, Candida albicans, Escherichia coli, Haemophilus influenza, Neisseria meningitides, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumonia , and  Streptococcus pyogenes  group A. 
     When “an immunologically effective amount,” “an anti-tumor effective amount,” “a tumor-inhibiting effective amount,” or “therapeutic amount” is indicated, the precise amount of the compositions of the present invention to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject). It can generally be stated that a pharmaceutical composition comprising the immune effector cells (e.g., T cells, NK cells) described herein may be administered at a dosage of 10 4  to 10 9  cells/kg body weight, in some instances 10 5  to 10 6  cells/kg body weight, including all integer values within those ranges. T cell compositions may also be administered multiple times at these dosages. The cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). 
     In certain aspects, it may be desired to administer activated immune effector cells (e.g., T cells, NK cells) to a subject and then subsequently redraw blood (or have an apheresis performed), activate immune effector cells (e.g., T cells, NK cells) therefrom according to the present invention, and reinfuse the patient with these activated and expanded immune effector cells (e.g., T cells, NK cells). This process can be carried out multiple times every few weeks. In certain aspects, immune effector cells (e.g., T cells, NK cells) can be activated from blood draws of from 10 cc to 400 cc. In certain aspects, immune effector cells (e.g., T cells, NK cells) are activated from blood draws of 20 cc, 30 cc, 40 cc, 50 cc, 60 cc, 70 cc, 80 cc, 90 cc, or 100 cc. 
     The administration of the subject compositions may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient trans arterially, subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v.) injection, or intraperitoneally. In one aspect, the T cell compositions of the present invention are administered to a patient by intradermal or subcutaneous injection. In one aspect, the T cell compositions of the present invention are administered by i.v. injection. The compositions of immune effector cells (e.g., T cells, NK cells) may be injected directly into a tumor, lymph node, or site of infection. 
     In a particular exemplary aspect, subjects may undergo leukapheresis, wherein leukocytes are collected, enriched, or depleted ex vivo to select and/or isolate the cells of interest, e.g., T cells. These T cell isolates may be expanded by methods known in the art and treated such that one or more anti-target CAR constructs of the invention may be introduced, thereby creating a anti-target CAR T cell of the invention. Subjects in need thereof may subsequently undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain aspects, following or concurrent with the transplant, subjects receive an infusion of the expanded anti-target CAR T cells of the present invention. In an additional aspect, expanded cells are administered before or following surgery. 
     The dosage of the above treatments to be administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The scaling of dosages for human administration can be performed according to art-accepted practices. The dose for CAMPATH, for example, will generally be in the range 1 to about 100 mg for an adult patient, usually administered daily for a period between 1 and 30 days. The preferred daily dose is 1 to 10 mg per day although in some instances larger doses of up to 40 mg per day may be used (described in U.S. Pat. No. 6,120,766). 
     In one embodiment, the anti-target CAR is introduced into immune effector cells (e.g., T cells, NK cells), e.g., using in vitro transcription, and the subject (e.g., human) receives an initial administration of anti-target CAR immune effector cells (e.g., T cells, NK cells) of the invention, and one or more subsequent administrations of the anti-target CAR immune effector cells (e.g., T cells, NK cells) of the invention, wherein the one or more subsequent administrations are administered less than 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days after the previous administration. In one embodiment, more than one administration of the anti-target CAR immune effector cells (e.g., T cells, NK cells) of the invention are administered to the subject (e.g., human) per week, e.g., 2, 3, or 4 administrations of the anti-target CAR immune effector cells (e.g., T cells, NK cells) of the invention are administered per week. In one embodiment, the subject (e.g., human subject) receives more than one administration of the anti-target CAR immune effector cells (e.g., T cells, NK cells) per week (e.g., 2, 3 or 4 administrations per week) (also referred to herein as a cycle), followed by a week of no anti-target CAR immune effector cells (e.g., T cells, NK cells) administrations, and then one or more additional administration of the anti-target CAR immune effector cells (e.g., T cells, NK cells) (e.g., more than one administration of the anti-target CAR immune effector cells (e.g., T cells, NK cells) per week) is administered to the subject. In another embodiment, the subject (e.g., human subject) receives more than one cycle of anti-target CAR immune effector cells (e.g., T cells, NK cells), and the time between each cycle is less than 10, 9, 8, 7, 6, 5, 4, or 3 days. In one embodiment, the anti-target CAR immune effector cells (e.g., T cells, NK cells) are administered every other day for 3 administrations per week. In one embodiment, the anti-target CAR immune effector cells (e.g., T cells, NK cells) of the invention are administered for at least two, three, four, five, six, seven, eight or more weeks. 
     In one aspect, anti-target CAR-expressing cells of the present inventions are generated using lentiviral viral vectors, such as lentivirus. Cells, e.g., CARTs, generated that way will have stable anti-target CAR expression. 
     In one aspect, anti-target CAR-expressing cells, e.g., CARTs, are generated using a viral vector such as a gammaretroviral vector, e.g., a gammaretroviral vector described herein. CARTs generated using these vectors can have stable anti-target CAR expression. 
     In one aspect, CARTs transiently express anti-target CAR vectors for 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 days after transduction. Transient expression of anti-target CARs can be effected by RNA anti-target CAR vector delivery. In one aspect, the anti-target CAR RNA is transduced into the T cell by electroporation. 
     A potential issue that can arise in patients being treated using transiently expressing anti-target CAR immune effector cells (e.g., T cells, NK cells) (particularly with murine scFv bearing CARTs) is anaphylaxis after multiple treatments. 
     Without being bound by this theory, it is believed that such an anaphylactic response might be caused by a patient developing humoral anti-anti-target CAR response, i.e., anti-anti-target CAR antibodies having an anti-IgE isotype. It is thought that a patient&#39;s antibody producing cells undergo a class switch from IgG isotype (that does not cause anaphylaxis) to IgE isotype when there is a ten to fourteen day break in exposure to antigen. 
     If a patient is at high risk of generating an anti-anti-target CAR antibody response during the course of transient anti-target CAR therapy (such as those generated by RNA transductions), CART infusion breaks should not last more than ten to fourteen days. 
     EXAMPLES 
     The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein. 
     Example 1: A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells 
     Introduction 
     Anti-CD19 chimeric antigen receptor T cells (CART19, CTL019) have led to clinical responses in relapsing or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). With the approval of CTL019 for patients with B-ALL, increasing numbers of patients will be exposed to this therapy. A patient was reported who relapsed with CD19-negative, CAR19-expressing leukemia, likely due to inadvertent transduction of a leukemic cell with the CAR19 lentivirus during CTL019 manufacturing. The high expression of the CAR in leukemic cells and its absence from normal tissues make it a good engineered tumor target. Anti-CAR19 CAR T cells were therefore developed with the goal of specifically targeting CAR19+B-ALL. 
     Methods 
     Two anti-CAR19 CAR using an anti-CAR19 idiotype scFv (clone 136.20.1, original clone kind gift of Dr. Laurence Cooper) testing two light chain orientations for the scFv: light to heavy (L2H) and heavy to light (H2L) were designed. We cloned the constructs into our standard backbone containing the CD8 hinge and trans-membrane domains, 4-1BB costimulatory and CD3z signaling domain. The constructs were packaged into a lentiviral vector and used to transduce normal donor T cells. As target cells, we used ex-vivo expanded primary leukemic blasts from the CAR19+ relapsed patient (CHP-107), as well as a luciferized B-ALL cell line (NALM6) transduced with the full-length CAR19 used in our clinical studies. Of note, the expression of CAR19 in CD19+ NALM{circumflex over ( )} cells led to apparent loss of CD19 by flow cytometry. We tested CART function in vitro with luciferase-based killing assays, and in vivo in human xenograft models using NOD-SCID gamma chain deficient (NSG) mice. 
     Results 
     Both L2H and H2L anti-CAR19 CAR were efficiently expressed on T cells as detected by flow cytometry. In vitro CART-CAR19 efficiently killed CAR19+B-ALL (NALM6) (L2H orientation: p&lt;0.0001; H2L: p=0.0063) but not wild-type (WT) (p=NS). NALM6 ( FIG. 1A ). We compared the in vivo growth rate of CAR19+ NALM6 versus WT and did not observe any difference. Next, we tested our lead anti-CAR19 CART (L2H) in vivo. NSG mice were engrafted with either CAR19+ NALM6 (CD19-) or luciferase-positive relapsed CHP107 leukemia blasts (CAR19+, CD19-). At day 7 or 14 mice were randomized to receive no treatment, control T cells (UTD), CART19 or CART-CAR19 L2H. In both xenograft models, CART19 and UTD cells were not able to control disease progression. In contrast, CART-CAR19 L2H cells showed leukemia control in the CHP107R xenograft model ( FIG. 1B ). 
     CONCLUSIONS 
     The acquisition of CAR expression by leukemic cells during CART manufacturing is a rare event that can lead to loss of CD19 expression, and potential resistance to CD19-directed immunotherapy. However, the CAR becomes a tumor-specific antigen that can be targeted specifically without any off-target toxicity. Here we report for the first time, a proof-of-concept that the mechanism of immunoescape by leukemia can be used as a point of vulnerability. This finding also supports the use of anti-CAR19 CART as an “antidote” to CAR19 T cells for those patients who have been in deep leukemia remission for several years but still suffer B cell aplasia. 
     Example 2: Anti-CAR CART to Deplete CART19 
     This Example describes the use of anti-CAR CART cells to deplete CART19 expressing cells. Without wishing to be bound by theory, in some embodiments, CART19 cells can, e.g., target or kill cells expressing anti-CAR CART expressing cells. Accordingly, this experiment was designed to test the optimal ratio of anti-target CAR cells: target CAR cells. 
     Normal donor T cells were used to generate CART cells using standard protocols and lentivirus encoding the different constructs as described below. Cells were transduced with constructs expressing anti-CAR CART (clones c3025 (anti-CAR19 CAR H2L) or c3026 (anti-CAR19 CAR L2H)), CART19 (c2228; FMC63) or CART22 (c2270; m971). Transduction efficiencies were normalized by CAR expression. Cells expressing anti-CAR CART were labeled with CFSE, and cells expressing CART19 or CART22 were labeled with Cell tracker violet (CTV). The two CART expressing populations, e.g., anti-CAR CART population and CART19 population; or anti-CAR CART population and CART22 population, were co-cultured and relative killing was measured by flow cytometry. The cells were co-cultured at different ratios and the ratio of CFSE:CTV signal was assessed by flow cytometry at 24 and 48 hours as indicated in  FIGS. 2A-2D . 
     The data depicted in  FIGS. 2A-2D  show the importance of dosing of the anti-CAR CART as compared to CART19 expressing cells. The results demonstrate that, in some embodiments, a minimum ratio of 1:1 of anti-CAR-CART cells: target CART cells is required to allow anti-CAR CART cells to persist, e.g., prevail over, CART19 cells. 
     EQUIVALENTS 
     The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific aspects, it is apparent that other aspects and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such aspects and equivalent variations.